Document:

EX-10.2

 Exhibit 10.2   

 
  

 
 THIRD AMENDED AND RESTATED CREDIT
AGREEMENT 
 dated as of 

July 25, 2007, 
 as amended
and restated as of November 5, 2010, February 2, 2012, 
 and January 27, 2014 

among 
 CHS/COMMUNITY HEALTH
SYSTEMS, INC., 
 COMMUNITY HEALTH SYSTEMS, INC., 

THE LENDERS PARTY HERETO 
 and

 CREDIT SUISSE AG, 
 as
Administrative Agent and Collateral Agent 
  

 
 CREDIT SUISSE
SECURITIES (USA) LLC, 
 MERRILL LYNCH, PIERCE, FENNER & SMITH INCORPORATED, 

CITIGROUP GLOBAL MARKETS, INC., 

GOLDMAN SACHS BANK, USA, 
 J.P.
MORGAN SECURITIES LLC, 
 RBC CAPITAL MARKETS, LLC, 

SUNTRUST ROBINSON HUMPHREY, INC., 

UBS SECURITIES LLC 
 and 

WELLS FARGO SECURITIES, LLC, 
 as
Joint Bookrunners and Joint Lead Arrangers 
 BANK OF AMERICA, N.A., 

as Documentation Agent 
 THE BANK
OF TOKYO-MITSUBISHI UFJ, LTD., CREDIT AGRICOLE CORPORATE AND 
 INVESTMENT BANK, FIFTH THIRD BANK, DEUTSCHE BANK SECURITIES INC., 

SCOTIA CAPITAL (USA) INC., COMPASS BANK and SIEMENS FINANCIAL SERVICES, INC. 

as Co-Managers 
  

 
  

 Table of Contents 

 

							
	 	 	 	  	Page	 
	  
  

ARTICLE I
	 
 

  

	  
 Definitions

 
	 
   

	SECTION 1.01.	 	Defined Terms	  	 	3	  
	SECTION 1.02.	 	Terms Generally	  	 	46	  
	SECTION 1.03.	 	Pro Forma Calculations	  	 	47	  
	SECTION 1.04.	 	Classification of Loans and Borrowings	  	 	47	  
	  
 ARTICLE II
	 
   

	  
 The Credits

 
	 
   

	SECTION 2.01.	 	Commitments	  	 	49	  
	SECTION 2.02.	 	Loans	  	 	49	  
	SECTION 2.03.	 	Borrowing Procedure	  	 	52	  
	SECTION 2.04.	 	Evidence of Debt; Repayment of Loans	  	 	52	  
	SECTION 2.05.	 	Fees	  	 	53	  
	SECTION 2.06.	 	Interest on Loans	  	 	54	  
	SECTION 2.07.	 	Default Interest	  	 	54	  
	SECTION 2.08.	 	Alternate Rate of Interest	  	 	55	  
	SECTION 2.09.	 	Termination and Reduction of Commitments	  	 	55	  
	SECTION 2.10.	 	Conversion and Continuation of Borrowings	  	 	56	  
	SECTION 2.11.	 	Repayment of Term Borrowings	  	 	57	  
	SECTION 2.12.	 	Optional Prepayment	  	 	59	  
	SECTION 2.13.	 	Mandatory Prepayments	  	 	60	  
	SECTION 2.14.	 	Reserve Requirements; Change in Circumstances	  	 	62	  
	SECTION 2.15.	 	Change in Legality	  	 	63	  
	SECTION 2.16.	 	Indemnity	  	 	64	  
	SECTION 2.17.	 	Pro Rata Treatment	  	 	65	  
	SECTION 2.18.	 	Sharing of Setoffs	  	 	65	  
	SECTION 2.19.	 	Payments	  	 	65	  
	SECTION 2.20.	 	Taxes	  	 	66	  
	SECTION 2.21.	 	Assignment of Commitments Under Certain Circumstances; Duty to Mitigate	  	 	68	  
	SECTION 2.22.	 	Reserved	  	 	70	  
	SECTION 2.23.	 	Letters of Credit	  	 	70	  
	SECTION 2.24.	 	Incremental Term Loans	  	 	74	  
	SECTION 2.25.	 	Loan Modification Offers; Replacement Revolving Credit Facility	  	 	78	  
	SECTION 2.26.	 	Revolving Credit Commitment Increases	  	 	80	  
	SECTION 2.27.	 	Term Loan Pricing Protection	  	 	82	  

  
 i 

 Table of Contents 

(continued) 
  

							
	 	 	 	  	Page	 
	  
 ARTICLE III
	 
   

	  
 Representations and Warranties

 
	 
   

	SECTION 3.01.	 	Organization; Powers	  	 	83	  
	SECTION 3.02.	 	Authorization	  	 	83	  
	SECTION 3.03.	 	Enforceability	  	 	84	  
	SECTION 3.04.	 	Governmental Approvals	  	 	84	  
	SECTION 3.05.	 	Financial Statements	  	 	84	  
	SECTION 3.06.	 	No Material Adverse Change	  	 	85	  
	SECTION 3.07.	 	Title to Properties; Possession Under Leases	  	 	85	  
	SECTION 3.08.	 	Subsidiaries	  	 	85	  
	SECTION 3.09.	 	Litigation; Compliance with Laws	  	 	85	  
	SECTION 3.10.	 	Agreements	  	 	86	  
	SECTION 3.11.	 	Federal Reserve Regulations	  	 	86	  
	SECTION 3.12.	 	Investment Company Act	  	 	86	  
	SECTION 3.13.	 	Use of Proceeds	  	 	86	  
	SECTION 3.14.	 	Tax Returns	  	 	86	  
	SECTION 3.15.	 	No Material Misstatements	  	 	87	  
	SECTION 3.16.	 	Employee Benefit Plans	  	 	87	  
	SECTION 3.17.	 	Environmental Matters	  	 	87	  
	SECTION 3.18.	 	Insurance	  	 	88	  
	SECTION 3.19.	 	Security Documents	  	 	88	  
	SECTION 3.20.	 	Location of Real Property and Leased Premises	  	 	89	  
	SECTION 3.21.	 	Labor Matters	  	 	89	  
	SECTION 3.22.	 	Solvency	  	 	90	  
	SECTION 3.23.	 	Sanctioned Persons	  	 	91	  
	  
 ARTICLE IV
	 
   

	  
 Conditions of Lending

 
	 
   

	SECTION 4.01.	 	All Credit Events	  	 	91	  
	SECTION 4.02.	 	[Intentionally Omitted.]	  	 	92	  
	  
 ARTICLE V
	 
   

	  
 Affirmative Covenants

 
	 
   

	SECTION 5.01.	 	Existence; Compliance with Laws; Businesses and Properties	  	 	92	  
	SECTION 5.02.	 	Insurance	  	 	92	  
	SECTION 5.03.	 	Obligations and Taxes	  	 	93	  
	SECTION 5.04.	 	Financial Statements, Reports, etc	  	 	93	  

  
 ii 

 Table of Contents 

(continued) 
  

							
	 	 	 	  	Page	 
			
	SECTION 5.05.	 	Litigation and Other Notices	  	 	95	  
	SECTION 5.06.	 	Information Regarding Collateral	  	 	95	  
	SECTION 5.07.	 	Maintaining Records; Access to Properties and Inspections; Maintenance of Ratings	  	 	96	  
	SECTION 5.08.	 	Use of Proceeds	  	 	96	  
	SECTION 5.09.	 	Employee Benefits	  	 	96	  
	SECTION 5.10.	 	Compliance with Environmental Laws	  	 	97	  
	SECTION 5.11.	 	Preparation of Environmental Reports	  	 	97	  
	SECTION 5.12.	 	Further Assurances	  	 	97	  
	SECTION 5.13.	 	Proceeds of Certain Dispositions	  	 	98	  
	SECTION 5.14.	 	Operation of Facilities	  	 	99	  
	  
 ARTICLE VI
	 
   

	  
 Negative Covenants

 
	 
   

	SECTION 6.01.	 	Indebtedness	  	 	99	  
	SECTION 6.02.	 	Liens	  	 	103	  
	SECTION 6.03.	 	Sale and Lease-Back Transactions	  	 	106	  
	SECTION 6.04.	 	Investments, Loans and Advances	  	 	106	  
	SECTION 6.05.	 	Mergers, Consolidations, Sales of Assets and Acquisitions	  	 	111	  
	SECTION 6.06.	 	Restricted Payments; Restrictive Agreements	  	 	114	  
	SECTION 6.07.	 	Transactions with Affiliates	  	 	117	  
	SECTION 6.08.	 	Business of Parent, Borrower and Subsidiaries	  	 	118	  
	SECTION 6.09.	 	Other Indebtedness	  	 	118	  
	SECTION 6.10.	 	Practice Guarantees	  	 	119	  
	SECTION 6.11.	 	Capital Expenditures	  	 	119	  
	SECTION 6.12.	 	Interest Coverage Ratio	  	 	120	  
	SECTION 6.13.	 	Maximum Secured Net Leverage Ratio	  	 	120	  
	SECTION 6.14.	 	Fiscal Year	  	 	120	  
	  
 ARTICLE VII
	 
   

	  
 Events of Default
	 
   

	  
 ARTICLE VIII
	 
   

	  
 The Administrative Agent and the Collateral
Agent
	 
   

  
 iii 

 Table of Contents 

(continued) 
  

							
	 	 	 	  	Page	 
	  
 ARTICLE IX
	 
   

	  
 Miscellaneous

 
	 
   

	SECTION 9.01.	 	Notices	  	 	128	  
	SECTION 9.02.	 	Survival of Agreement	  	 	130	  
	SECTION 9.03.	 	Binding Effect	  	 	130	  
	SECTION 9.04.	 	Successors and Assigns	  	 	130	  
	SECTION 9.05.	 	Expenses; Indemnity	  	 	135	  
	SECTION 9.06.	 	Right of Setoff	  	 	136	  
	SECTION 9.07.	 	Applicable Law	  	 	137	  
	SECTION 9.08.	 	Waivers; Amendment	  	 	137	  
	SECTION 9.09.	 	Certain Releases of Guarantees and Security Interests	  	 	138	  
	SECTION 9.10.	 	Interest Rate Limitation	  	 	140	  
	SECTION 9.11.	 	Entire Agreement	  	 	140	  
	SECTION 9.12.	 	WAIVER OF JURY TRIAL	  	 	140	  
	SECTION 9.13.	 	Severability	  	 	141	  
	SECTION 9.14.	 	[Reserved]	  	 	141	  
	SECTION 9.15.	 	Headings	  	 	141	  
	SECTION 9.16.	 	Jurisdiction; Consent to Service of Process	  	 	141	  
	SECTION 9.17.	 	Confidentiality	  	 	142	  
	SECTION 9.18.	 	USA PATRIOT Act Notice	  	 	142	  
	SECTION 9.19.	 	Effect of Certain Inaccuracies	  	 	142	  
	SECTION 9.20.	 	Pari Passu Obligations and Other Junior Secured Debt	  	 	143	  

  
 iv 

 Table of Contents 

(continued) 
  

									
	 	 	 	  	 	    	 	  	Page
				
	SCHEDULES	  		    		  	
	Schedule 1.01(a)	  	-	    	Existing Letters of Credit	  	
	Schedule 1.01(b)	  	-	    	Subsidiary Guarantors	  	
	Schedule 1.01(c)	  	-	    	Mortgaged Property	  	
	Schedule 1.01(d)	  	-	    	Hospitals	  	
	Schedule 1.01(e)	  	-	    	Certain Permitted Joint Ventures	  	
	Schedule 1.01(f)	  	-	    	Certain Subsidiaries	  	
	Schedule 1.01(g)	  	-	    	Asset Sales	  	
	Schedule 2.01	  	-	    	Initial Lenders and Commitments	  	
	Schedule 3.08	  	-	    	Subsidiaries	  	
	Schedule 3.18	  	-	    	Insurance	  	
	Schedule 3.19(a)	  	-	    	UCC Filing Offices	  	
	Schedule 3.19(c)	  	-	    	Mortgage Filing Offices	  	
	Schedule 3.21	  	-	    	Collective Bargaining Agreements	  	
	Schedule 6.01	  	-	    	Existing Indebtedness	  	
	Schedule 6.02	  	-	    	Existing Liens	  	
	Schedule 6.04(h)	  	-	    	Certain Permitted Acquisitions	  	
	Schedule 6.05(b)	  	-	    	Certain Syndication Transactions	  	
	Schedule 6.07	  	-	    	Certain Affiliate Transactions	  	
				
	EXHIBITS	  		    		  	
					
	Exhibit A	 	-	  		    	Form of Administrative Questionnaire	  	
	Exhibit B	 	-	  		    	Form of Assignment and Acceptance	  	
	Exhibit C	 	-	  		    	Form of Borrowing Request	  	
	Exhibit D	 	-	  		    	Form of Mortgage	  	

  
 v 

 CREDIT AGREEMENT dated as of July 25, 2007, as amended and
restated as of November 5, 2010, February 2, 2012, and January 27, 2014, among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the “Borrower”), COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation
(“Parent”), the Lenders (as defined in Article I), and CREDIT SUISSE AG, as administrative agent (in such capacity, the “Administrative Agent”) and as collateral agent (in such capacity, the
“Collateral Agent”) for the Lenders. 
 PRELIMINARY STATEMENT 

The Borrower, Parent, the lenders party thereto and Credit Suisse AG (formerly known as Credit Suisse), as administrative
agent and collateral agent, have previously entered into a Credit Agreement dated as of July 25, 2007 (the “Original Credit Agreement”). 

On the First Restatement Effective Date, (a) certain Original Funded Term Loans and Original Delayed Draw Term Loans were
converted to Extended Term Loans (each as defined in the Existing Credit Agreement) pursuant to the First Amendment and Restatement Agreement (such term and each other capitalized term used and not otherwise defined in this Preliminary Statement
having the meaning assigned thereto in Article I) , and all other Original Funded Term Loans and Original Delayed Draw Term Loans were redesignated as Non-Extended Funded Term Loans or Non-Extended Delayed Draw Term Loans (each as defined in the
Existing Credit Agreement), as applicable, and (b) the Original Credit Agreement was amended and restated in the form attached as Exhibit A to the First Amendment and Restatement Agreement (as so amended and restated, the “First
Amended and Restated Credit Agreement”). 
 On the Second Restatement Effective Date, (a) certain
Non-Extended Funded Term Loans and Non-Extended Delayed Draw Term Loans were converted to Extended Term Loans (each as defined in the Existing Credit Agreement) pursuant to the Second Amendment and Restatement Agreement and (b) the First
Amended and Restated Credit Agreement was amended and restated in the form attached as Exhibit A to the Second Amendment and Restatement Agreement (the “Existing Credit Agreement”). 

On the First Incremental Term Loan Assumption Agreement Date, the Borrower incurred Incremental Term Loans in an aggregate
principal amount of $750,000,000 (the “First Incremental Term Loans”). 
 On the Third Restatement
Effective Date, the Existing Credit Agreement was amended and restated in the form of this Agreement, and in connection therewith: 

(a) the Borrower borrowed 2019 Term A Loans in an aggregate principal amount of $1,000,000,000; 

 
 2
 
  

 (b) the Borrower borrowed 2017 Term E Loans in an aggregate
principal amount of $171,146,550.47; 
 (c) the Borrower borrowed 2021 Term D Loans in an aggregate
principal amount of $2,925,000,000; 
 (d) certain Extended Term Loans were converted to 2021 Term D Loans
and certain Extended Term Loans were converted to 2017 Term E Loans, in each case pursuant to the Third Amendment and Restatement Agreement; 

(e) the Borrower prepaid in full all the First Incremental Term Loans, all the Non-Extended Term Loans (as
defined in the Existing Credit Agreement) and all the Extended Term Loans (as defined in the Existing Credit Agreement) that were not converted into either 2021 Term D Loans or 2017 Term E Loans on the Third Restatement Effective Date; and 

(f) all the Revolving Credit Commitments (as defined in the Existing Credit Agreement) were terminated and
replacement Revolving Credit Commitments were established under this Agreement in an aggregate principal amount of $1,000,000,000. 

In addition, on the Third Restatement Effective Date, (i) the Borrower acquired all the outstanding capital stock (the
“Permitted HMA Transaction”) of Health Management Associates, Inc. (“HMA”) pursuant to the Agreement and Plan of Merger, dated as of July 29, 2013 (together with all exhibits, annexes, schedules
and other disclosure letters thereto, collectively, as amended through the date hereof, the “HMA Merger Agreement”), by and among FWCT-2 Acquisition Corporation, a Delaware corporation and a direct subsidiary of the Borrower
(“Merger Sub”), Parent and HMA, pursuant to which upon the consummation of the merger provided for thereunder, Merger Sub merged with and into HMA, with HMA surviving such merger and immediately thereafter becoming a wholly
owned Subsidiary and a Subsidiary Guarantor, (ii) the Borrower incurred (A) senior secured notes (the “2021 Notes”) issued in a Rule 144A placement that yielded $1,000,000,000 in gross cash proceeds and
(B) senior unsecured notes (the “2022 Notes” and, together with the 2021 Notes, the “New Notes”) issued in a Rule 144A placement that yielded $3,000,000,000 in gross cash proceeds, and
(iii) the Borrower consummated the HMA Refinancing. 
 The proceeds of the 2019 Term A Loans and the 2021 Term D Loans
and the 2017 Term E Loans made on the Third Restatement Effective Date were used solely to pay a portion of the HMA Acquisition Costs. The proceeds of the Revolving Loans will be used solely for working capital and other general corporate purposes,
including permitted investments and Capital Expenditures and to repay Indebtedness. Letters of Credit will be used for general corporate purposes of the Borrower and the Subsidiaries. 

 
 3
 
  

 Accordingly, the parties hereto agree as follows: 

ARTICLE I 
 Definitions 

SECTION 1.01. Defined Terms. As used in this Agreement, the following terms shall have the meanings specified
below: 
 “2017 Term E Borrowing” shall mean a Borrowing consisting of 2017 Term E Loans of the same
Type and, in the case of a Eurodollar Loan, having the same Interest Period. 
 “2017 Term E
Commitment” shall have the meaning assigned to such term in the Third Amendment and Restatement Agreement. The initial aggregate amount of the 2017 Term E Commitments was $171,146,550.47. 

“2017 Term E Loan” shall mean, collectively, (a) each Extended Term Loan (as defined in the
Existing Credit Agreement) that was converted to a 2017 Term E Loan pursuant to Section 3(d)(i) of the Third Amendment and Restatement Agreement and (b) Loans made pursuant to Section 3(b)(ii) of the Third Amendment and Restatement
Agreement. For the avoidance of doubt, the Loans described in the foregoing clauses (a) and (b) shall constitute a single Class of Loans for all purposes under this Agreement. 

“2017 Term E Loan Lender” shall mean, at any time, any Lender that has a 2017 Term E Loan at such
time. 
 “2017 Term E Loan Repayment Date” shall have the meaning assigned to such term in Section
2.11(a)(iii). 
 “2017 Term E Maturity Date” shall mean January 25, 2017. 

“2018 Notes” shall mean the Borrower’s 5.125% Senior Secured Notes due 2018. 

“2019 Notes” shall mean the Borrower’s 8% Senior Notes due 2019. 

“2019 Term A Borrowing” shall mean a Borrowing consisting of 2019 Term A Loans of the same Type and,
in the case of a Eurodollar Loan, having the same Interest Period. 
 “2019 Term A Commitment” shall
have the meaning assigned to such term in the Third Amendment and Restatement Agreement. The initial aggregate amount of the 2019 Term A Commitments was $1,000,000,000. 

“2019 Term A Lender” shall mean, at any time, any Lender that has a 2019 Term A Commitment or a 2019
Term A Loan at such time. 
 “2019 Term A Loan Repayment Date” shall have the meaning assigned to
such term in Section 2.11(a)(iv). 

 
 4
 
  

 “2019 Term A Loans” shall mean Loans made pursuant to
Section 3(a) of the Third Amendment and Restatement Agreement. 
 “2019 Term A Maturity Date”
shall mean January 27, 2019; provided that the 2019 Term A Maturity Date shall instead be (a) October 26, 2016, if, on such date, the Maturity Trigger has occurred with respect to the 2017 Term E Loans, or (b) May 16,
2018, if, on such date, the Maturity Trigger has occurred with respect to the 2018 Notes; provided further, that, in each case, if any such day is not a Business Day, the 2019 Term A Maturity Date shall be the Business Day immediately
preceding such day. 
 “2020 Notes” shall mean the Borrower’s 7.125% Senior Notes due 2020.

 “2021 Notes” shall have the meaning assigned to such term in the Preliminary Statement. 

“2021 Term D Borrowing” shall mean a Borrowing consisting of 2021 Term D Loans of the same Type and,
in the case of a Eurodollar Loan, having the same Interest Period. 
 “2021 Term D Commitment” shall
have the meaning assigned to such term in the Third Amendment and Restatement Agreement. The initial aggregate amount of the 2021 Term D Commitments was $2,925,000,000. 

“2021 Term D Lender” shall mean, at any time, any Lender that has a 2021 Term D Commitment or a 2021
Term D Loan at such time. 
 “2021 Term D Loan Repayment Date” shall have the meaning assigned to
such term in Section 2.11(a)(v). 
 “2021 Term D Loans” means, collectively, (a) each Extended
Term Loan (as defined in the Existing Credit Agreement) that was converted to a 2021 Term D Loan pursuant to Section 3(d)(i) of the Third Amendment and Restatement Agreement and (b) Loans made pursuant to Section 3(b)(i) of the Third
Amendment and Restatement Agreement. For the avoidance of doubt, the Loans described in the foregoing clauses (a) and (b) shall constitute a single Class of Loans for all purposes under this Agreement. 

“2021 Term D Maturity Date” shall mean January 27, 2021; provided that the 2021 Term D
Maturity Date shall instead be (a) October 26, 2016, if, on such date, the Maturity Trigger has occurred with respect to the 2017 Term E Loans, (b) May 16, 2018, if, on such date, the Maturity Trigger has occurred with respect to
the 2018 Notes, (c) August 16, 2019, if, on such date, the Maturity Trigger has occurred with respect to the 2019 Notes or (d) April 15, 2020, if, on such date, the Maturity Trigger has occurred with respect to the 2020 Notes;
provided further, that, in each case, if any such day is not a Business Day, the 2021 Term D Maturity Date shall be the Business Day immediately preceding such day. 

“2022 Notes” shall have the meaning assigned to such term in the Preliminary Statement. 

 
 5
 
  

 “ABR”, when used in reference to any Loan or
Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are bearing interest at a rate determined by reference to the Alternate Base Rate. 

“Accepting Lenders” shall have the meaning assigned to such term in Section 2.25(a). 

“Adjusted LIBO Rate” shall mean, with respect to any Eurodollar Borrowing for any Interest Period, an
interest rate per annum equal to the product of (a) the LIBO Rate in effect for such Interest Period and (b) Statutory Reserves. 

“Administrative Agent Fees” shall have the meaning assigned to such term in Section 2.05(b). 

“Administrative Questionnaire” shall mean an Administrative Questionnaire in the form of Exhibit A, or
such other form as may be supplied from time to time by the Administrative Agent. 
 “Affected
Class” shall have the meaning assigned to such term in Section 2.25(a). 

“Affiliate” shall mean, when used with respect to a specified person, another person that directly, or
indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the person specified; provided, however, that, for purposes of Section 6.07, the term “Affiliate” shall also include
any person that directly or indirectly owns 10% or more of any class of Equity Interests of the person specified. 

“Aggregate Revolving Credit Exposure” shall mean the aggregate amount of the Lenders’ Revolving
Credit Exposures. 
 “Alternate Base Rate” shall mean, for any day, a rate per annum equal to the
greatest of (a) the Prime Rate in effect on such day, (b) the Federal Funds Effective Rate in effect on such day plus 1/2 of 1% and (c) the Adjusted LIBO Rate on such day for a three month Interest Period commencing on the second
Business Day after such day plus 1%; provided that in no event shall the Alternate Base Rate be less than, in the case of 2021 Term D Loans, 2.00%. If the Administrative Agent shall have determined (which determination shall be conclusive
absent manifest error) that it is unable to ascertain the Federal Funds Effective Rate or the Adjusted LIBO Rate for any reason, including the inability or failure of the Administrative Agent to obtain sufficient quotations in accordance with the
terms of the definition of Federal Funds Effective Rate, the Alternate Base Rate shall be determined without regard to clause (b) or (c), as applicable, of the preceding sentence until the circumstances giving rise to such inability no longer
exist. Any change in the Alternate Base Rate due to a change in the Prime Rate, the Federal Funds Effective Rate or the Adjusted LIBO Rate shall be effective on the effective date of such change in the Prime Rate, the Federal Funds Effective Rate or
the Adjusted LIBO Rate, as the case may be. 

 
 6
 
  

 “Alternative Incremental Facility Indebtedness” shall
mean any Indebtedness which (a) is in the form of one or more series of senior or junior secured notes or senior unsecured notes or senior or junior secured bridge loans or senior unsecured bridge loans or junior secured loans, (b) is
issued, incurred, created, assumed or guaranteed by any Loan Party, (c) is not an obligation of, or otherwise Guaranteed by, any Subsidiary of Parent that is not a Loan Party, (d) to the extent the same is secured, is not secured by any
Lien on any asset of Parent, the Borrower or any Subsidiary other than any asset constituting Collateral, (e) to the extent the same is secured, is subject to a Pari Passu Intercreditor Agreement (or, in the case of junior secured notes, junior
secured bridge loans or junior secured loans, a Junior Lien Intercreditor Agreement), (f) matures on or after, and requires no scheduled payments of principal prior to, the Latest Term Loan Maturity Date in effect at the time such Indebtedness
is incurred (which, in the case of bridge loans, shall be determined by reference to the loans or notes into which such bridge loans are converted at maturity) (other than pursuant to customary offers to purchase upon a change of control, payments
required to prevent any such Indebtedness from being treated as an “applicable high yield discount obligation” within the meaning of Section 163(i)(1) of the Code, asset sale or event of loss and customary acceleration rights after an
event of default), unless 100% of the Net Cash Proceeds thereof are used to prepay or repay outstanding Term Loans, in which case such Indebtedness shall mature on or after the latest maturity date of the Term Loans so prepaid or repaid and
(g) contains no financial maintenance covenants. 
 “Amendment Effective Date” shall mean
August 3, 2012. 
 “Amendment No. 2 Effective Date” shall mean November 27, 2012.

 “Amendment No. 3 Effective Date” shall mean August 12, 2013. 

“Applicable Percentage” shall mean, for any day, (a) (i) with respect to any Eurodollar 2019
Term A Loan, ABR 2019 Term A Loan, Eurodollar Revolving Loan or ABR Revolving Loan, the applicable percentage set forth below under the caption “Eurodollar Spread—2019 Term A Loans”, “ABR Spread—2019 Term A Loans”,
“Eurodollar Spread—Revolving Loans” or “ABR Spread—Revolving Loans”, as the case may be, and (ii) with respect to the Revolving Credit Commitment Fee, the applicable rate set forth below under the caption
“Revolving Credit Commitment Fee Rate”, in each case based upon the Secured Net Leverage Ratio as of the relevant date of determination, (b) with respect to any Eurodollar 2021 Term D Loan or ABR 2021 Term D Loan, 3.25% per annum
and 2.25% per annum, respectively, and (c) with respect to any Eurodollar 2017 Term E Loan and ABR 2017 Term E Loan, 3.25% per annum and 2.25% per annum, respectively. 

 
 7
 
  

											
	
Secured
 Net

Leverage
 Ratio

 
	 	
Eurodollar
Spread--
 2019 Term
A
Loans
	 	 ABR

Spread—
 2019
Term
 A Loans
	 	
Eurodollar
Spread--
Revolving
 Loans
	 	 ABR

Spread--
Revolving
 Loans
	 	
Revolving
 Credit
Commitment

Fee Rate

	     Category
1  
  
 3 4.00 to 1.00

 
	 	2.75%	 	1.75%	 	2.75%	 	1.75%	 	0.50%
	     Category
2  
  
 3 3.50 to 1.00

and
 < 4.00 to 1.00

 
	 	2.50%	 	1.50%	 	2.50%	 	1.50%	 	0.50%
	     Category
3  
  
 3 3.00 to 1.00

and
 < 3.50 to 1.00

 
	 	2.25%	 	1.25%	 	2.25%	 	1.25%	 	0.50%
	     Category
4  
  
 < 3.00 to 1.00

 
	 	2.00%	 	1.00%	 	2.00%	 	1.00%	 	0.375%

 Each change in the Applicable Percentage resulting from a change in the Secured Net Leverage Ratio shall be
effective with respect to all applicable Loans and Letters of Credit outstanding on and after the date of delivery to the Administrative Agent of the financial statements and certificates required by Section 5.04(a) or (b) and
Section 5.04(c), respectively, indicating such change until the date immediately preceding the next date of delivery of such financial statements and certificates indicating another such change. Notwithstanding the foregoing, from and after the
Third Restatement Effective Date, the Secured Net Leverage Ratio shall be deemed to be in Category 1 for purposes of determining the Applicable Percentage until the end of the first full fiscal quarter following the Third Restatement Effective
Date (at which time, subject to the immediately succeeding sentence, the Secured Net Leverage Ratio shall be determined on the basis of the financial statements and certificates most recently delivered pursuant to Section 5.04(a) or
(b) and Section 5.04(c), respectively, prior to such date, and the Applicable Percentage resulting from such Secured Net Leverage Ratio shall be effective until any such change is required pursuant to the immediately preceding sentence).
Notwithstanding the foregoing, for any day prior to the Third Restatement Effective Date, the Applicable Percentage with respect to 2017 Term E Loans and 2021 Term D Loans will be determined in accordance with the provisions of the Existing Credit
Agreement. In addition, at any time during which the Borrower has failed to deliver the financial statements and certificates required by Section 5.04(a) or (b) and Section 5.04(c), respectively (until the time of the delivery
thereof), the Secured Net Leverage Ratio shall be deemed to be in Category 1 for purposes of determining the Applicable Percentage. 

“Approved Fund” shall mean any person (other than a natural person) that is engaged in making,
purchasing, holding or investing in commercial loans and similar extensions of credit in the ordinary course of its activities and that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an
Affiliate of an entity that administers or manages a Lender. 

 
 8
 
  

 “Arrangers” shall mean Credit Suisse Securities (USA)
LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated, Citigroup Global Markets, Inc., Goldman Sachs Bank, USA, J.P. Morgan Securities LLC, RBC Capital Markets, LLC, Suntrust Robinson Humphrey, Inc., UBS Securities LLC and Wells Fargo
Securities, LLC. 
 “Asset Sale” shall mean the sale, transfer or other disposition (by way of
merger, casualty, condemnation or otherwise) by Parent, the Borrower or any of the Subsidiaries to any person other than the Borrower or any Subsidiary Guarantor of (a) any Equity Interests of any of the Subsidiaries (other than directors’
qualifying shares) or (b) any other assets of Parent, the Borrower or any of the Subsidiaries, other than: 

(i) inventory, damaged, obsolete or worn out assets, scrap, surplus and Permitted Investments, in each case disposed of
in the ordinary course of business; 
 (ii) donations of assets by the Borrower or any Subsidiary (whether of real or
personal property (including cash and Equity Interests)) to state or local municipalities (or other Governmental Authorities), nonprofit organizations, foundations, charities or similar entities of the Borrower’s or such Subsidiary’s
choice, with an aggregate fair market value not to exceed $50,000,000 in any fiscal year of Parent; 

(iii) dispositions by any Subsidiary that is not a Subsidiary Guarantor to the Borrower or any other Subsidiary; 

(iv) sales or other dispositions of (x) Receivables of the Borrower or any of the Subsidiaries that are more than 180
days past due or are written-off at the time of such sale or disposition or (y) any Receivables of the Borrower or any of the Subsidiaries that are self-pay accounts receivable and that are reasonably determined by the Borrower to be unable to
be paid in full within 150 days of the related service date, provided that the face value of all such Receivables sold or disposed of on or after the Third Restatement Effective Date does not exceed $200,000,000;

 (v) sales or other dispositions of property (including like-kind exchanges) to the extent that (x) such property is
exchanged for credit against the purchase price of similar or replacement property or (y) the proceeds of such sale or disposition are applied to the purchase price of such property, provided that, if the property so sold or exchanged
constituted Collateral, then the property so received shall also constitute Collateral; 
 (vi) leases or sub-leases of any
real property or personal property in the ordinary course of business; 
 (vii) dispositions of investments in joint
ventures to the extent required by, or made pursuant to, customary buy/sell arrangements between the joint venture parties set forth in the joint venture arrangements and similar binding arrangements; 

(viii) licensings and sublicensings of intellectual property of the Borrower or any Subsidiary in the ordinary course of
business; 

 
 9
 
  

 (ix) sales, transfers, leases or other dispositions of property in the
ordinary course of business consisting of the abandonment of intellectual property rights which, in the reasonable good faith determination of the Borrower, are not material to the conduct of the business of Parent, the Borrower and the
Subsidiaries; 
 (x) the contribution or other transfer of property (including Equity Interests) to any Spinout Subsidiary
in connection with a Spinout Transaction; 
 (xi) dispositions of Equity Interests of any Subsidiary as contemplated by
clause (b) of the definition of Permitted Joint Venture; 
 (xii) dispositions consisting of the granting of Liens
permitted by Section 6.02; 
 (xiii) any sale, transfer or other disposition or series of related sales, transfers or
other dispositions having a value not in excess of $25,000,000; and 
 (xiv) any sale, transfer or other disposition of any
property or asset described on Schedule 1.01(g). 
 “Assignment and Acceptance” shall mean an
assignment and acceptance entered into by a Lender and an assignee, and accepted by the Administrative Agent, in the form of Exhibit B or such other form as shall be approved by the Administrative Agent. 

“Available Amount” shall mean, as at any date of determination, an amount (if positive) equal to
(a) for each fiscal year of Parent commencing with the fiscal year ending December 31, 2010 for which Excess Cash Flow shall have been positive, the Excess Cash Flow for such years that is retained by the Borrower after application of
Section 2.13(c), minus (b) the aggregate amount of all Restricted Payments made in reliance on Section 6.06(a)(vii) prior to such date, minus (c) the aggregate amount paid in reliance on Section 6.09(b)(iv)
prior to such date, minus (d) the aggregate amount of all investments made in reliance on Section 6.04(y)(i) prior to such date. 

“Available Declined Proceeds Amount” shall mean, as at any date of determination, an amount (if
positive) equal to (a) the aggregate amount of Declined Proceeds retained by the Borrower after the Third Restatement Effective Date, minus (b) the aggregate amount paid in reliance on Section 6.09(b)(v) prior to such date,
minus (c) the aggregate amount of all investments made in reliance on Section 6.04(y)(ii) prior to such date. 

“Board” shall mean the Board of Governors of the Federal Reserve System of the United States of
America. 
 “Borrower Materials” shall have the meaning assigned to such term in Section 9.01.

 
 10
 
  

 “Borrowing” shall mean Loans of the same Class and
Type made, converted or continued on the same date and, in the case of Eurodollar Loans, as to which a single Interest Period is in effect. 

“Borrowing Request” shall mean a request by the Borrower in accordance with the terms of
Section 2.03 and substantially in the form of Exhibit C, or such other form as shall be approved by the Administrative Agent. 

“Business Day” shall mean any day other than a Saturday, Sunday or day on which banks in New York City
are authorized or required by law to close; provided, however, that when used in connection with a Eurodollar Loan, the term “Business Day” shall also exclude any day on which banks are not open for dealings in
dollar deposits in the London interbank market. 
 “CapEx Pull-Forward Amount” shall have the
meaning assigned to such term in Section 6.11. 
 “Capital Expenditures” shall mean, for any
period, the additions to property, plant and equipment and other capital expenditures of Parent, the Borrower and its consolidated subsidiaries (including all amounts expended or capitalized under Capital Lease Obligations, but excluding any amount
representing capitalized interest) that are (or should be) set forth in a consolidated statement of cash flows of Parent for such period prepared in accordance with GAAP, but excluding in each case any such expenditure (i) made with insurance
proceeds, condemnation awards or damage recovery proceeds, (ii) made with the proceeds of the issuance of Equity Interests, (iii) to the extent such expenditure is made with proceeds that would have constituted Net Cash Proceeds under
clause (a) of the definition of the term “Net Cash Proceeds” (but for the application of the second proviso to such clause (a)), (iv) to the extent of the credit against the gross purchase price of newly acquired equipment
granted by the seller of such newly acquired equipment for other equipment that is simultaneously traded-in at the time of purchase of such newly acquired equipment, (v) is accounted for as a capital expenditure pursuant to GAAP but that
actually is paid for by a third party (excluding Parent, the Borrower or any Subsidiary) and for which none of Parent, the Borrower or any Subsidiary has provided or is required to provide or incur, directly or indirectly, any consideration or
obligation to such third party or any other person (whether before, during or after such period) or (vi) constituting the purchase price of the Permitted HMA Transaction, any Permitted Acquisition or any investment permitted under Sections
6.04(a), 6.04(i), 6.04(j), 6.04(k) or 6.04(x), 6.04(y) or 6.04(z). 
 “Capital Lease Obligations” of
any person shall mean the obligations of such person to pay rent or other amounts under any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations are required to be
classified and accounted for as capital leases on a balance sheet of such person under GAAP (excluding any lease that would be required to be so classified as a result of a change in GAAP after the First Restatement Effective Date), and the amount
of such obligations shall be the capitalized amount thereof determined in accordance with GAAP. 

 
 11
 
  

 “Captive Insurance Subsidiary” shall mean a
Subsidiary established for the purpose of insuring the healthcare businesses or Facilities owned or operated by the Borrower or any of the Subsidiaries, any joint venture of the Borrower or any of the Subsidiaries or any physician or other personnel
employed by or on the medical staff of any such business or Facility. 
 “Cash Management
Obligations” shall mean the obligations owed by Parent, the Borrower or any Subsidiary to the Administrative Agent, any Arranger, any Lender or an Affiliate of any of the foregoing in respect of any overdraft protections, netting
services and similar arrangements arising from treasury, depository and cash management services, any automated clearing house transfers of funds or any credit card or similar services, in each case in the ordinary course of business. 

A “Change in Control” shall be deemed to have occurred if (a) any “person” or
“group” (within the meaning of Rule 13d-5 of the Securities Exchange Act of 1934 as in effect on the Closing Date), shall own, directly or indirectly, beneficially or of record, shares
representing more than 40% of the aggregate ordinary voting power represented by the issued and outstanding capital stock of Parent (other than a transaction following which holders of securities that represented 100% of such aggregate ordinary
voting power represented by the issued and outstanding capital stock of Parent immediately prior to such transaction (or other securities into which such securities are converted as part of such transaction) own, directly or indirectly, shares
representing at least a majority of the aggregate ordinary voting power represented by the issued and outstanding capital stock of the surviving Person in such transaction immediately after such transaction), (b) a majority of the seats (other
than vacant seats) on the board of directors of Parent shall at any time be occupied by persons who were neither (i) nominated by the board of directors of Parent nor (ii) appointed by directors so nominated, (c) any change in control
(or similar event, however denominated) with respect to Parent, the Borrower or any Subsidiary shall occur under and as defined in any indenture or agreement in respect of Material Indebtedness to which Parent, the Borrower or any Subsidiary is a
party (other than, (x) under any indenture or agreement in respect of Material Indebtedness assumed in connection with a Permitted Acquisition, any change in control triggered by the Permitted Acquisition pursuant to which such Indebtedness was
assumed or (y) under any HMA Indenture), or (d) Parent shall cease to directly own, beneficially and of record, 100% of the issued and outstanding Equity Interests of the Borrower. Notwithstanding anything in this Agreement to the
contrary, a “Change of Control” shall not occur in connection with the consummation of the Permitted HMA Transaction on the Third Restatement Effective Date. 

“Change in Law” shall mean (a) the adoption of any law, rule or regulation after the Closing
Date, (b) any change in any law, rule or regulation or in the interpretation or application thereof by any Governmental Authority after the Closing Date or (c) compliance by any Lender or the Issuing Bank (or, for purposes of
Section 2.14, by any lending office of such Lender or by such Lender’s or Issuing Bank’s holding company, if any) with any policy, guideline or directive (whether or not having the force of law) of any Governmental Authority made or
issued after the Closing Date. 

 
 12
 
  

 “Class”, when used in reference to any Loan or
Borrowing, refers to whether such Loan, or the Loans comprising such Borrowing, are Revolving Loans, 2019 Term A Loans, 2017 Term E Loans, 2021 Term D Loans or Other Term Loans and, when used in reference to any Commitment, refers to whether such
Commitment is a Revolving Credit Commitment, a 2019 Term A Commitment, a 2021 Term D Commitment or any Incremental Term Loan Commitment. 

“Closing Date” shall mean July 25, 2007. 

“Code” shall mean the Internal Revenue Code of 1986, as amended from time to time. 

“Collateral” shall mean all the “Collateral” as defined in any Security Document and shall
also include the Mortgaged Properties. 
 “Commitment” shall mean, with respect to any Lender, such
Lender’s Revolving Credit Commitment, Term Loan Commitment and Incremental Term Loan Commitment. 

“Commitment Fees” shall mean the Revolving Credit Commitment Fees. 

“Confidential Information Memorandum” shall mean the Confidential Information Memorandum of the
Borrower dated January 2014. 
 “Consolidated EBITDA” shall mean, for any period, Consolidated Net
Income for such period plus (a) without duplication and (except in the case of clause (a)(x) and clause (a)(xiii) below) to the extent deducted (and not added back) in determining such Consolidated Net Income, the sum of 

(i) interest expense (net of interest income), including amortization and write offs of debt discount and debt issuance
costs and commissions, discounts and other fees and charges associated with (x) letters of credit, (y) obtaining or unwinding Hedging Agreements or (z) surety bonds for financing activities, in each case for such period, 

(ii) provision for taxes based on income, profits or capital and franchise taxes, including Federal, foreign, state,
franchise, excise and similar taxes and foreign withholding taxes paid or accrued during such period, including any penalties and interest relating to any tax examinations for such period, 

(iii) depreciation and amortization expenses including acceleration thereof and including the amortization of the
increase in inventory resulting from the application of Statement of Financial Accounting Standards No. 141 (“FASB 141”) for transactions contemplated hereby, including Permitted Acquisitions, for such period, 

(iv) non-cash compensation expenses arising from the sale of Equity Interests, the granting of options to purchase Equity
Interests, the granting of appreciation rights in respect of Equity Interests and similar arrangements for such period, 

 
 13
 
  

 (v) the excess of the expense in respect of post-retirement benefits
and post-employment benefits accrued under Statement of Financial Accounting Standards No. 106 (“FASB 106”) and Statement of Financial Accounting Standards No. 112 (“FASB 112”) over the cash expense in respect of such
post-retirement benefits and post-employment benefits for such period, 
 (vi) minority interest (to the extent
distributions are not required to be made and are not made in respect thereof), 
 (vii) upfront fees or charges
arising from any Permitted Receivables Transaction for such period, and any other amounts for such period comparable to or in the nature of interest under any Permitted Receivables Transaction, and losses on dispositions of Receivables and related
assets in connection with any Permitted Receivables Transaction for such period, 
 (viii) fees and expenses for such
period incurred or paid in connection with the Transactions, 
 (ix) to the extent covered by insurance and actually
reimbursed, or, so long as the Borrower has made a determination that such amount is reasonably likely to be reimbursed by the insurer and only to the extent that such amount is (A) not denied by the applicable carrier in writing within
180 days and (B) in fact reimbursed within 365 days of the date of the relevant event (with a deduction for any amount so added back to the extent not so reimbursed within such 365 days), expenses with respect to liability or casualty
events, 
 (x) proceeds of received business interruption insurance, 

(xi) any fees and expenses incurred during such period in connection with any acquisition, investment, recapitalization,
asset disposition, issuance or repayment of debt, issuance of Equity Interests, Permitted Receivables Transaction, refinancing transaction or amendment or other modification of any debt instrument (in each case, including any such transaction
consummated prior to the Closing Date and any such transaction undertaken but not completed), 
 (xii) any
(w) severance costs, relocation costs, integration and facilities opening costs, signing costs, retention or completion bonuses and transition costs incurred during such period, (x) cash restructuring related or nonrecurring cash merger
costs and expenses incurred during such period as a result of any acquisition, investment, recapitalization, or asset disposition permitted hereunder, (y) other nonrecurring cash losses and charges for such period and (z) cash payments
made during such period in respect of litigation that was pending against the Borrower, Triad or any of their subsidiaries, or any Acquired Entity or other obligations (contingent or otherwise) of the Borrower, Triad or any of their subsidiaries or
any Acquired Entity, in each case prior to the Closing Date (or, with respect to an Acquired Entity, the closing date of the relevant Permitted Acquisition) and for which a liability would not be, in accordance with GAAP, recognized on Parent’s
consolidated balance sheet as of the Closing Date (or, with respect to an Acquired Entity, the closing date of the relevant Permitted Acquisition), 

 
 14
 
  

 (xiii) the amount of cost savings, operating improvements and synergies
projected by the Borrower in good faith and certified by a Responsible Officer of the Borrower in writing to the Administrative Agent expected to result from actions in connection with the Permitted HMA Transaction and either taken or expected to be
taken during such period (which cost savings, operating improvements and synergies shall be calculated on a pro forma basis as though they had been realized on the first day of such period), net of the amount of actual benefits realized during such
period from such actions to the extent already included in Consolidated Net Income for such period; provided that (A) a Responsible Officer of the Borrower shall have certified to the Administrative Agent that (x) such cost savings,
operating improvements and synergies are projected in good faith and are reasonably identifiable, reasonably supportable and reasonably anticipated to result from such actions and (y) such actions have been taken or are expected to be taken and
the benefits resulting therefrom are anticipated by the Borrower to be realized within twelve months, and (B) the aggregate amount added back pursuant to this clause (xiii) in any such period shall not exceed $250,000,000, and 

(xiv) other non-cash charges for such period (other than the write down of current assets, unless such assets are acquired
pursuant to a Permitted Acquisition or the Permitted HMA Transaction, in which case any such write down shall (A) occur on or before the first anniversary of the date on which the applicable Permitted Acquisition or the Permitted HMA
Transaction, as the case may be, was consummated and (B) result from (1) a change in accounting policies or (2) a revision in the estimated value of such assets), and minus 

(b) without duplication, (i) non-recurring gains and (ii) all cash payments made during such period on account
of reserves, restructuring charges and other non-cash charges added to Consolidated Net Income pursuant to clause (a)(xiv) (other than any such non-cash charges that if originally paid in cash and so not taken as non-cash charges would have been
added to Consolidated Net Income above pursuant to clause (a)(xii)) in a previous period. 
 For purposes of determining
Consolidated EBITDA under this Agreement, Consolidated EBITDA for the fiscal quarters ended December 31, 2012, March, 31, 2013, June 30, 2013 and September 30, 2013 shall be deemed to be $741,000,000, $718,000,000,
$617,000,000 and $627,000,000, respectively (which amounts, for the avoidance of doubt shall be subject, without duplication, to add-backs and adjustments pursuant to this definition and shall give effect to calculations made on a pro forma basis in
accordance with Section 1.03 that in each case may become applicable due to actions taken on or after the Third Restatement Effective Date after giving effect to the consummation of the Permitted HMA Transaction). 

“Consolidated Interest Expense” shall mean, for any period, the sum of (a) the interest expense
paid in cash (including imputed interest expense in respect of Capital Lease Obligations and Synthetic Lease Obligations) of Parent, the Borrower and the 

 
 15
 
  

 
Subsidiaries for such period, net of interest income, determined on a consolidated basis in accordance with GAAP and (b) the dividends paid in cash during such period by Parent, the Borrower
and the Subsidiaries on a consolidated basis in respect of Disqualified Stock, but excluding, however, to the extent otherwise included therein, (i) fees and expenses associated with the consummation of the Transactions and the Permitted HMA
Transaction, (ii) annual agency fees paid to the Administrative Agent, (iii) costs associated with obtaining or unwinding any Hedging Agreements, (iv) fees and expenses associated with any investment permitted pursuant to
Section 6.04, issuances of Equity Interests or Indebtedness, Permitted Receivables Transactions or amendments of any Indebtedness (whether or not consummated), (v) penalties and interest relating to Taxes and (vi) all non-recurring
cash interest expense consisting of liquidated damages for failure to timely comply with registration rights obligations and financing fees. For purposes of the foregoing, interest expense shall be determined after giving effect to any net payments
made or received by Parent, the Borrower or any Subsidiary with respect to interest rate Hedging Agreements. 

“Consolidated Net Income” shall mean, for any period, the net income or loss ((i) excluding
extraordinary gains and losses, and gains and losses arising from the proposed or actual disposition of material assets and (ii) excluding the cumulative effect of changes in accounting principles) of Parent, the Borrower and the Subsidiaries
for such period determined on a consolidated basis in accordance with GAAP; provided that there shall be excluded the income of any Subsidiary to the extent that the declaration or payment of dividends or similar distributions by the
Subsidiary of that income is not at the time permitted by operation of the terms of its charter or any agreement, instrument, judgment, decree, statute, rule or governmental regulation applicable to such Subsidiary. Notwithstanding the foregoing,
the amount of any cash dividends paid by any Unrestricted Subsidiary and received by Parent, the Borrower or the Subsidiaries during any such period shall be included, without duplication, in the calculation of Consolidated Net Income for such
period. There shall be excluded from Consolidated Net Income for any period (i) gains and losses, including unrealized gains and losses, for such period attributable to (v) the early extinguishment of Indebtedness, (w) discontinued
operations, (x) facilities to be closed within one year of the date of recognition of such gain or loss, (y) obtaining or unwinding Hedging Agreements and (z) except as provided above, interests in Unrestricted Subsidiaries,
(ii) all deferred financing costs written off or amortized and premiums paid or other expenses incurred directly in connection with any extinguishment of Indebtedness and any net gain (loss) from any write-off or forgiveness of Indebtedness,
(iii) any (w) severance costs, relocation costs, integration and facilities opening costs, signing costs, retention or completion bonuses and transition costs made during such period in cash or reserves taken in connection with the
Permitted HMA Transaction, (x) cash payments made or reserves taken during such period in respect of litigation that was pending against HMA or any of its subsidiaries prior to the Third Restatement Effective Date, (y) charges resulting
from the termination of certain contracts in connection with the Permitted HMA Transaction and (z) costs and expenses incurred in connection with the sale, transfer or other disposition of the hospitals set forth on Schedule 1.01(g), in each
case to the extent such costs, expenses, payments, reserves or charges would otherwise be deducted in the determination of Consolidated Net Income, provided that any reversal of a reserve excluded from Consolidated Net Income

 
 16
 
  

 
in a prior period shall also be excluded from Consolidated Net Income, (iv) CVR Payments made during such period to the extent deducted in the determination of Consolidated Net Income and
(v) the effects of purchase accounting adjustments to inventory, property, equipment and intangible assets and deferred revenue in component amounts required or permitted by GAAP, as a result of the Transactions, the Permitted HMA Transaction,
any Permitted Acquisition or acquisition consummated before the Closing Date, or the amortization or write-off of any amounts thereof. 

“Contractual Obligation” shall mean, as to any person, any provision of any security issued by such
person or of any agreement, instrument or undertaking to which such person is a party or by which it or any of the property owned by it is bound. 

“Control” shall mean the possession, directly or indirectly, of the power to direct or cause the
direction of the management or policies of a person, whether through the ownership of voting securities, by contract or otherwise, and the terms “Controlling” and “Controlled” shall have meanings
correlative thereto. 
 “Credit Event” shall have the meaning assigned to such term in
Section 4.01. 
 “Credit Facilities” shall mean the revolving credit, letter of credit and term
loan facilities provided for by this Agreement. 
 “Current Assets” shall mean, at any time, the
consolidated current assets (other than cash, cash equivalents and Permitted Investments and current and deferred tax assets) of Parent, the Borrower and the Subsidiaries. 

“Current Liabilities” shall mean, at any time, the consolidated current liabilities of Parent, the
Borrower and the Subsidiaries at such time, but excluding, without duplication, (a) the current portion of any long-term Indebtedness, (b) current accrued and deferred income taxes and accrued
interest and (c) outstanding Revolving Loans. 
 “CVR Payments” shall have the meaning assigned
to such term in the definition of Indebtedness. 
 “Declined Proceeds” shall have the meaning
assigned to such term in Section 2.13(f). 
 “Default” shall mean any event or condition which upon
notice, lapse of time or both would constitute an Event of Default. 
 “Defaulting Lender” shall
mean any Lender that (a) defaults in its obligation to make any Loan or fulfill any obligation required to be made or fulfilled by it hereunder in the case of any funding requirement within two Business Days of the date such Loans were required
to be funded hereunder, unless such Lender notifies the Administrative Agent and the Borrower in writing that such failure is the result of such Lender’s good faith determination that one or more conditions precedent to funding (which
conditions precedent, together with the applicable default, if any, shall be specifically identified in such writing) has not been satisfied, (b) has notified the Administrative Agent or any 

 
 17
 
  

 
Loan Party in writing that it does not intend to satisfy any such obligations or (c) has become the subject of a bankruptcy or insolvency proceeding, or has had a receiver, conservator,
trustee, custodian, administrator, assignee for the benefit of creditors or similar Person charged with the reorganization or liquidation of its business, appointed for it, or has taken any action in furtherance of, or indicating its consent to,
approval of or acquiescence in any such proceeding or appointment or has a parent company that has become the subject of a bankruptcy or insolvency proceeding, or has had a receiver, conservator, trustee, custodian, administrator, assignee for the
benefit of creditors or similar Person charged with the reorganization or liquidation of its business, appointed for it, or has taken any action in furtherance of, or indicating its consent to, approval of or acquiescence in any such proceeding or
appointment; provided that if a Lender would be a “Defaulting Lender” solely by reason of events relating to a parent company of such Lender or solely because a Governmental Authority has been appointed as receiver, conservator,
trustee or custodian for such Lender, such Lender shall not be a “Defaulting Lender” if and for so long as such Lender confirms in writing, upon request by the Administrative Agent, that it will continue to comply with its obligations to
make Loans and fulfill all other obligations required to be made and fulfilled by it hereunder. 
 “Designated
Non-Cash Consideration” shall mean the fair market value (as determined in good faith by the Borrower) of non-cash consideration received by the Borrower or one of its Subsidiaries in connection with an Asset Sale that is so designated
as Designated Non-Cash Consideration pursuant to an officer’s certificate, setting forth the basis of such valuation, less the amount of cash or cash equivalents (including Permitted Investments) received in connection with a subsequent
payment, redemption, retirement, sale or other disposition of such Designated Non-Cash Consideration. A particular item of Designated Non-Cash Consideration will no longer be considered to be outstanding when and to the extent it has been paid,
redeemed or otherwise retired or sold or otherwise disposed of in compliance with Section 6.05(b). 

“Disqualified Stock” shall mean any Equity Interest that, by its terms (or by the terms of any
security into which it is convertible or for which it is exchangeable), or upon the happening of any event, (a) matures (excluding any maturity as the result of an optional redemption by the issuer thereof) or is mandatorily redeemable,
pursuant to a sinking fund obligation or otherwise (except (i) as a result of a change of control or asset sale so long as any rights of the holders thereof upon the occurrence of a change of control or asset sale shall be subject to the prior
repayment in full of the Loans and all other Obligations that are accrued and payable and the termination of the Commitments or (ii) pursuant to any put option with respect to any Equity Interests of a Permitted Syndication Subsidiary granted
in favor of any Permitted Syndication Transaction Partner), or is redeemable at the option of the holder thereof, in whole or in part, or requires the payment of any cash dividend or any other scheduled payment constituting a return of capital in
cash (other than, in the case of Equity Interests of a Subsidiary issued to a Permitted Syndication Transaction Partner or held by a Subsidiary Guarantor, periodic distributions of available cash (determined in good faith by the Borrower)), in each
case at any time on or prior to the first anniversary of the Latest Term Loan Maturity Date in effect at the time such Equity Interest is issued, or (b) is convertible into or exchangeable (unless at the sole option of the issuer thereof) for
(i) Indebtedness or (ii) 

 
 18
 
  

 
any Equity Interest referred to in clause (a) above, in each case at any time prior to the first anniversary of the Latest Term Loan Maturity Date in effect at the time such Equity Interest
is issued. 
 “dollars” or “$” shall mean lawful money of the United States
of America. 
 “Domestic Subsidiaries” shall mean all Subsidiaries incorporated or organized under
the laws of the United States of America, any State thereof or the District of Columbia. 
 “Effective
Yield” shall mean, as of any date of determination with respect to any term loan, the sum of (i) the higher of (A) the “Adjusted LIBO rate” on such date for a deposit in dollars with a maturity of one month and
(B) the “LIBOR floor”, if any, with respect thereto as of such date, (ii) the interest rate margin as of such date, (with such interest rate margin to be determined by reference to the “Adjusted LIBOR rate”) and
(iii) the amount of original issue discount and upfront fees thereon (converted to yield assuming a four-year average life and without any present value discount but excluding any arrangement, structuring, syndication, commitment or other fees
in connection therewith that are not shared with all providers of such financing). 
 “Eligible
Assignee” shall mean any commercial bank, insurance company, investment or mutual fund or other entity (but not any natural person) that is an “accredited investor” (as defined in Regulation D under the Securities Act of 1933,
as amended) that extends credit or invests in bank loans as one of its businesses; provided that neither the Borrower nor any of its Affiliates shall be an Eligible Assignee. 

“Environmental Laws” shall mean all former, current and future Federal, state, local and foreign laws
(including common law), treaties, regulations, rules, ordinances, codes, decrees, judgments, directives, orders (including consent orders), and legally binding agreements in each case, relating to protection of the environment, natural resources,
occupational health and safety or Hazardous Materials. 
 “Environmental Liability” shall mean all
liabilities, obligations, damages, losses, claims, actions, suits, judgments, orders, fines, penalties, fees, expenses and costs (including administrative oversight costs, natural resource damages and remediation costs), whether contingent or
otherwise, arising out of or relating to (a) compliance or non-compliance with any Environmental Law, (b) the generation, use, handling, transportation, storage, treatment, recycling, arrangement for
disposal, or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the presence or Release of any Hazardous Materials or (e) any contract, agreement or other consensual arrangement pursuant to which
liability is assumed or imposed with respect to any of the foregoing. 
 “Equity
Interests” shall mean shares of capital stock, partnership interests, membership interests in a limited liability company, beneficial interests in a trust or other equity interests in any person, and any option,
warrant or other right entitling the holder thereof to purchase or otherwise acquire any such equity interest. 

 
 19
 
  

 “ERISA” shall mean the Employee Retirement Income
Security Act of 1974, as the same may be amended from time to time. 
 “ERISA Affiliate” shall mean
any trade or business (whether or not incorporated) that, together with the Borrower, is treated as a single employer under Section 414(b) or (c) of the Code, or, solely for purposes of Section 302 of ERISA and Section 412 of the
Code, is treated as a single employer under Section 414 of the Code. 
 “ERISA Event” shall
mean (a) any “reportable event”, as defined in Section 4043 of ERISA or the regulations issued thereunder, with respect to a Plan (other than an event for which the 30-day notice period is waived), (b) a failure by any Plan
to meet the minimum funding standards (within the meaning of Section 412 of the Code or Section 302 of ERISA) applicable to such Plan, in each case whether or not waived, (c) the filing pursuant to Section 412(c) of the Code or
Section 302(c) of ERISA, of an application for a waiver of the minimum funding standard with respect to any Plan, (d) a determination that any Plan is, or is expected to be, in “at-risk” status (as defined in
Section 303(i)(4) of ERISA or Section 430(i)(4) of the Code), (e) the incurrence by Parent or any of its ERISA Affiliates of any liability under Title IV of ERISA with respect to the termination of any Plan or the withdrawal or
partial withdrawal of the Borrower or any of its ERISA Affiliates from any Plan or Multiemployer Plan, (f) the receipt by Parent or any of its ERISA Affiliates from the PBGC or a plan administrator of any notice relating to the intention to
terminate any Plan or Plans or to appoint a trustee to administer any Plan, (g) the receipt by Parent or any of its ERISA Affiliates of any notice, or the receipt by any Multiemployer Plan from Parent or any of its ERISA Affiliates of any
notice, concerning the imposition of Withdrawal Liability or a determination that a Multiemployer Plan is, or is expected to be, insolvent or in reorganization, within the meaning of Title IV of ERISA or in endangered or critical status, within
the meaning of Section 432 of the Code or Section 305 of ERISA, (h) the occurrence of a “prohibited transaction” with respect to which the Borrower or any of the Subsidiaries is a “disqualified person” (within the
meaning of Section 4975 of the Code) or with respect to which the Borrower or any such Subsidiary could otherwise be liable or (i) any other event or condition with respect to a Plan or Multiemployer Plan that could result in liability of
the Borrower or any Subsidiary. 
 “Eurodollar” when used in reference to any Loan or Borrowing,
refers to whether such Loan, or the Loans comprising such Borrowing, are bearing interest at a rate determined by reference to the Adjusted LIBO Rate. 

“Event of Default” shall have the meaning assigned to such term in Article VII. 

“Excess Cash Flow” shall mean, for any fiscal year of Parent, the excess of (a) the sum, without
duplication, of (i) Consolidated Net Income for such fiscal year, (ii) an amount equal to the amount of all non-cash charges or losses to the extent deducted in arriving at such Consolidated Net Income, (iii) an amount equal to the
provision for Taxes based on income, profits or capital of Parent, the Borrower and the Subsidiaries, including Federal, foreign, state, franchise, excise and similar taxes and foreign withholding taxes paid or accrued during such period to the
extent deducted in 

 
 20
 
  

 
arriving at such Consolidated Net Income, (iv) [reserved], (v) reductions to noncash working capital of Parent, the Borrower and the Subsidiaries for such fiscal year (i.e., the
decrease, if any, in Current Assets minus Current Liabilities from the beginning to the end of such fiscal year, excluding decreases resulting from the Permitted HMA Transaction or any Permitted Acquisition or disposition occurring during such
fiscal year) and (vi) an amount equal to all anticipated payments deducted from Excess Cash Flow pursuant to clause (b)(vi) in any prior period that the Borrower has determined will not be made, or that were not made during the applicable four
fiscal quarter period, and that have not previously been added back to Excess Cash Flow pursuant to this clause (a)(vi) over (b) the sum, without duplication, of (i) the amount of any Taxes (including penalties and interest) payable in
cash by Parent, the Borrower and the Subsidiaries with respect to such fiscal year, (ii) Capital Expenditures made in cash during such fiscal year, except to the extent financed with the proceeds of Indebtedness (other than Revolving Loans),
equity issuances, casualty proceeds or condemnation proceeds to the extent such proceeds would not be included in Consolidated Net Income, (iii) permanent repayments of Indebtedness (other than mandatory prepayments of Loans under
Section 2.13 and Voluntary Prepayments) made in cash by Parent, the Borrower and the Subsidiaries during such fiscal year, but only to the extent that the Indebtedness so prepaid by its terms cannot be reborrowed or redrawn and such prepayments
do not occur in connection with a refinancing of all or any portion of such Indebtedness, (iv) payments by Parent, the Borrower and the Subsidiaries during such fiscal year in respect of long-term liabilities of Parent, the Borrower and the
Subsidiaries other than Indebtedness, (v) the aggregate amount of cash consideration paid by Parent, the Borrower and the Subsidiaries (on a consolidated basis) in connection with Permitted Acquisitions or other investments permitted pursuant
to Section 6.04 (other than Section 6.04(b)), except to the extent any such Permitted Acquisition or investment is financed with the proceeds of Indebtedness (other than Revolving Loans) or equity issuances, to the extent such proceeds
would not be included in Consolidated Net Income, (vi) the aggregate amount of cash consideration required to be paid by Parent, the Borrower and the Subsidiaries (on a consolidated basis) in the subsequent first four fiscal quarters following
such fiscal year pursuant to binding contracts related to Permitted Acquisitions and Capital Expenditures entered into during such fiscal year, (vii) the aggregate amount of any premium, make-whole or penalty payments actually paid in cash by
Parent, the Borrower or the Subsidiaries during such period that are required to be made in connection with any prepayment of Indebtedness to the extent not deducted in determining Consolidated Net Income for such fiscal year, (viii) cash
expenditures in respect of Hedging Agreements to the extent not deducted in determining Consolidated Net Income for such fiscal year, (ix) additions to noncash working capital for such fiscal year (i.e., the increase, if any, in Current
Assets minus Current Liabilities from the beginning to the end of such fiscal year, excluding increases resulting from any Permitted Acquisition or disposition occurring during such fiscal year or the Permitted HMA Transaction), (x) an amount
equal to the amount of all non-cash credits or gains to the extent included in arriving at such Consolidated Net Income and the amount related to items that were added to or not deducted from net income or loss in calculating Consolidated Net Income
to the extent such items represented a cash payment or cash expenditure (which had not reduced Excess Cash Flow in a prior fiscal year) and (xi) the aggregate amount of cash expenditures paid by Parent, the Borrower and the

 
 21
 
  

 
Subsidiaries (on a consolidated basis) pursuant to Section 6.06(iii), (v) and (ix) (except to the extent any such cash expenditure is financed with the proceeds of Indebtedness
(other than Revolving Loans) or equity issuances, to the extent such proceeds would not be included in Consolidated Net Income); provided that in no event shall the calculation of Excess Cash Flow include any insurance proceeds or proceeds of
any condemnation, taking or similar occurrence. 
 “Excluded Taxes” shall mean, with respect to the
Administrative Agent, any Lender, the Issuing Bank or any other recipient of any payment to be made by or on account of any obligation of the Borrower hereunder, (a) income or franchise taxes imposed on (or measured by) its net income by the
United States of America, or by the jurisdiction under the laws of which such recipient is organized or in which its principal office is located or, in the case of any Lender, in which its applicable lending office is located, (b) any branch
profits taxes imposed by the United States of America or any similar tax imposed by any other jurisdiction described in clause (a) above and (c) in the case of the Administrative Agent or a Foreign Lender (other than an assignee pursuant
to a request by the Borrower under Section 2.21(a)), any withholding tax that is imposed on amounts payable to such Administrative Agent or Foreign Lender as a result of any law in effect (including FATCA) at the time such Administrative Agent
or Foreign Lender becomes a party to this Agreement (or designates a new lending office) or is attributable to such Administrative Agent or Foreign Lender’s failure to comply with Section 2.20(e), except to the extent that such
Administrative Agent or Foreign Lender (or its assignor, if any) was entitled, at the time of designation of a new lending office (or assignment), to receive additional amounts from the Borrower with respect to such withholding tax pursuant to
Section 2.20(a). 
 “Existing Credit Agreement” shall have the meaning assigned to such term in the
Preliminary Statement. 
 “Existing Letter of Credit” shall mean each Letter of Credit
(a) previously issued for the account of HMA that was outstanding on the Third Restatement Effective Date and is listed on Schedule 1.01(a) or (b) that was issued for the account of the Borrower under the Existing Credit Agreement.

 “Extended OID” shall have the meaning assigned to such term in Section 2.27. 

“Facility” shall mean any Hospital, outpatient clinic, long-term care facility, ambulatory center,
nursing home or rehabilitation center and related medical office building or other facility owned or used by the Borrower or any Subsidiary in connection with their respective business. 

“FATCA” shall mean Sections 1471 through 1474 of the Code, as of the date of this Agreement, and
any regulations or official interpretations thereof issued after the date of this Agreement. 
 “Federal Funds
Effective Rate” shall mean, for any day, the weighted average of the rates on overnight Federal funds transactions with members of the Federal Reserve 

 
 22
 
  

 
System arranged by Federal funds brokers, as published on the next succeeding Business Day by the Federal Reserve Bank of New York, or, if such rate is not so published for any day that is a
Business Day, the average of the quotations for the day for such transactions received by the Administrative Agent from three Federal funds brokers of recognized standing selected by it. 

“Fee Letter” shall mean the Fee Letter dated March 16, 2007, among Parent, Credit Suisse
Securities (USA) LLC, the Administrative Agent, Wachovia Capital Markets LLC, Wachovia Bank, National Association and Wachovia Investment Holdings, LLC. 

“Fees” shall mean the Commitment Fees, the Administrative Agent Fees, the L/C Participation Fees and
the Issuing Bank Fees. 
 “Financial Officer” of any person shall mean the chief financial officer,
principal accounting officer, treasurer or controller of such person. 
 “First Amended and Restated Credit
Agreement” shall have the meaning assigned to such term in the Preliminary Statement. 
 “First
Amendment and Restatement Agreement” shall mean the Amendment and Restatement Agreement dated as of November 5, 2010, among Parent, the Borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and the
Administrative Agent. 
 “First Incremental Term Loan Assumption Agreement Date” shall mean
March 6, 2012. 
 “First Incremental Term Loans” shall have the meaning assigned to such term
in the Preliminary Statement. 
 “First Restatement Effective Date” shall mean November 5,
2010. 
 “Foreign Lender” shall mean any Lender that is organized under the laws of a jurisdiction
other than that in which the Borrower is located. For purposes of this definition, the United States of America, each State thereof and the District of Columbia shall be deemed to constitute a single jurisdiction. 

“Foreign Subsidiary” shall mean any Subsidiary that is not a Domestic Subsidiary. 

“GAAP” shall mean United States generally accepted accounting principles. 

“Governmental Authority” shall mean any Federal, state, local or foreign court or governmental agency,
authority, instrumentality or regulatory body. 
 “Granting Lender” shall have the meaning assigned
to such term in Section 9.04(i). 

 
 23
 
  

 “Guarantee” of or by any person shall mean any
obligation, contingent or otherwise, of such person guaranteeing or having the economic effect of guaranteeing any Indebtedness of any other person (the “primary obligor”) in any manner, whether directly or indirectly, and
including any obligation of such person, direct or indirect, (a) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or to purchase (or to advance or supply funds for the purchase of) any security
for the payment of such Indebtedness, (b) to purchase or lease property, securities or services for the purpose of assuring the owner of such Indebtedness of the payment of such Indebtedness or (c) to maintain working capital, equity
capital or any other financial statement condition or liquidity of the primary obligor so as to enable the primary obligor to pay such Indebtedness; provided, however, that the term “Guarantee” shall not include
(i) endorsements for collection or deposit in the ordinary course of business or (ii) Practice Guarantees. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount (based on the maximum
reasonably anticipated net liability in respect thereof as determined by the Borrower in good faith) of the primary obligation or portion thereof in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably
anticipated net liability in respect thereof (assuming such person is required to perform thereunder) as determined by the Borrower in good faith. 

“Guarantee and Collateral Agreement” shall mean the Guarantee and Collateral Agreement, dated as of
July 25, 2007, as amended and restated as of November 5, 2010, among the Borrower, Parent, the Subsidiaries party thereto and the Collateral Agent for the benefit of the Secured Parties. 

“Guarantors” shall mean Parent and the Subsidiary Guarantors. 

“Hazardous Materials” shall mean (a) any petroleum products or byproducts and all other
hydrocarbons, coal ash, radon gas, asbestos and asbestos-containing materials, urea formaldehyde foam insulation, polychlorinated biphenyls, chlorofluorocarbons and all other ozone-depleting substances, medical, biological and animal wastes and
(b) without limitation of the foregoing, any other chemical, material, substance or waste that is prohibited, limited or regulated by or pursuant to any Environmental Law. 

“Health Care Associates” shall have the meaning assigned to such term in Section 6.04(e). 

“Hedging Agreement” shall mean any interest rate protection agreement, foreign currency exchange
agreement, commodity price protection agreement or other interest or currency exchange rate or commodity price hedging arrangement. 

“HMA” shall have the meaning assigned to such term in the Preliminary Statement. 

“HMA Acquisition Costs” shall mean those amounts incurred (i) to pay the consideration required to be
paid by the Borrower on the Third Restatement Effective Date pursuant to the HMA Merger Agreement, (ii) to pay the fees and expenses incurred 

 
 24
 
  

 
in connection with the Permitted HMA Transaction, the issuance of the New Notes, the HMA Refinancing, the payment of the HMA Acquisition Costs, the amendment and restatement of the Existing
Credit Agreement in the form hereof and the other transactions contemplated by the Third Amendment and Restatement Agreement and (iii) to pay for the HMA Refinancing. 

“HMA Indentures” shall mean each of the Indenture, dated as of April 21, 2006, between HMA and
U.S. Bank National Association pertaining to HMA’s 6.125% Senior Notes due 2016, the Indenture, dated as of May 21, 2008, between HMA and U.S. Bank, National Association pertaining to HMA’s 3.75% Convertible Senior Subordinated Notes
due 2028, and the Indenture, dated as of November 18, 2011, among HMA, each of the subsidiary guarantors party thereto and U.S. Bank, National Association pertaining to HMA’s 7.375% Senior Notes due 2020, in each case as the same may be
amended, restated, substituted, replaced, refinanced, supplemented or otherwise modified from time to time. 

“HMA Merger Agreement” shall have the meaning assigned to such term in the Preliminary Statement. 

“HMA Refinancing” shall mean (i) the prepayment in full of all the First Incremental Term Loans,
all the Non-Extended Term Loans and all the Extended Term Loans (each as defined in the Existing Credit Agreement) that are not converted to either 2021 Term D Loans or 2017 Term E Loans on the Third Restatement Effective Date, the termination of
all the Revolving Credit Commitments (as defined in the Existing Credit Agreement), the repayment of all outstanding Revolving Loans (as defined in the Existing Credit Agreement) and the establishment of replacement Revolving Credit Commitments in
an aggregate principal amount of $1,000,000,000 and the payment of all fees, interest and other amounts due and payable pursuant to the Existing Credit Agreement or this Agreement on or prior to the Third Restatement Effective Date, including, to
the extent invoiced, reimbursement or payment of all out of pocket expenses required to be reimbursed or paid by the Borrower under the Third Amendment and Restatement Agreement and (ii) the repayment of certain Indebtedness of HMA. 

“Hospital” shall mean each hospital now or hereafter owned, leased or operated by the Borrower or any
of the Subsidiaries or in which the Borrower or any of the Subsidiaries owns an equity interest. Set forth on Schedule 1.01(d) is a list of all Hospitals in existence on the Second Restatement Effective Date owned or used by the Borrower and the
Subsidiaries. 
 “Increasing Revolving Credit Lender” shall have the meaning assigned to such term
in Section 2.26(a). 
 “Incremental Acquisition Revolving Credit Commitment Increase” shall
mean a Revolving Credit Commitment Increase designated as an “Incremental Acquisition Revolving Credit Commitment Increase” by the Borrower, the Administrative Agent and the applicable Increasing Revolving Credit Lenders in the applicable
Revolving Credit Commitment Increase Amendment, the effectiveness of which is conditioned upon the 

 
 25
 
  

 
consummation of a Permitted Acquisition (including the refinancing of Indebtedness in connection therewith (to the extent required in connection with such Permitted Acquisition) and the payment
of related fees and expenses). 
 “Incremental Acquisition Term Loan” shall mean an Incremental Term
Loan designated as an “Incremental Acquisition Term Loan” by the Borrower, the Administrative Agent and the applicable Incremental Term Lenders in the applicable Incremental Term Loan Assumption Agreement, the making of which is
conditioned upon the consummation of, and the proceeds of which will be used to finance, a Permitted Acquisition (including the refinancing of Indebtedness in connection therewith and the payment of related fees and expenses). 

“Incremental Amount” shall mean, at any time, the excess, if any, of (a) the greater of
(x) $1,500,000,000 and (y) an amount equal to the maximum principal amount of Indebtedness that, if fully drawn at such time, would not cause the Secured Net Leverage Ratio to exceed 4.00:1.00 (calculated on a pro forma basis in accordance
with Section 1.03 after giving effect to the incurrence of such Indebtedness and without giving effect to any cash proceeds thereof, but including the application of such proceeds) over (b) the sum of (i) the aggregate amount of all
Incremental Term Loan Commitments established after the Third Restatement Effective Date and prior to such time pursuant to Section 2.24 (whether in respect of Other Term Loans, Other Term A Loans or otherwise), (ii) the aggregate amount
of all Revolving Credit Commitment Increases established after the Third Restatement Effective Date and prior to such time pursuant to Section 2.26, (iii) the aggregate amount of all revolving credit commitments established after the Third
Restatement Effective Date and prior to such time in accordance with Section 6.01(r) and (iv) the aggregate principal amount of Indebtedness incurred pursuant to Section 6.01(w) after the Third Restatement Effective Date and prior to
such time; provided, however, that, to the extent the proceeds of any Incremental Term Loans or any Alternative Incremental Facility Indebtedness are used concurrently with the incurrence thereof to prepay then-outstanding Term Loans,
the establishment of such Incremental Term Loan Commitments or the incurrence of such Alternative Incremental Facility Indebtedness, as the case may be, shall not reduce the Incremental Amount. In furtherance of and not limiting the foregoing, the
aggregate amount of all Incremental Term Loan Commitments established after the Third Restatement Effective Date pursuant to Section 2.24 in respect of Other Term A Loans shall not exceed an amount equal to the sum of (A) the greater of
(x) $750,000,000 and (y) an amount equal to 50% of Consolidated EBITDA for the most recent period of four fiscal quarters for which financial statements have been delivered pursuant to Section 5.04(a) or (b) (calculated on a pro
forma basis in accordance with Section 1.03) and (B) the aggregate principal amount of Other Term A Loans incurred after the Third Restatement Effective Date to the extent the proceeds of such Other Term A Loans are used concurrently with
the incurrence thereof to prepay then-outstanding 2019 Term A Loans or Other Term A Loans. 
 “Incremental Term
Borrowing” shall mean a Borrowing comprised of Incremental Term Loans. 

 
 26
 
  

 “Incremental Term Lender” shall mean a Lender with an
Incremental Term Loan Commitment or an outstanding Incremental Term Loan. 
 “Incremental Term Loan Assumption
Agreement” shall mean an Incremental Term Loan Assumption Agreement among, and in form and substance reasonably satisfactory to, the Borrower, the Administrative Agent and one or more Incremental Term Lenders. 

“Incremental Term Loan Commitment” shall mean the commitment of any Lender, established pursuant to
Section 2.24, to make Incremental Term Loans to the Borrower. 
 “Incremental Term Loan Maturity
Date” shall mean the final maturity date of any Incremental Term Loan, as set forth in the applicable Incremental Term Loan Assumption Agreement. 

“Incremental Term Loan Repayment Dates” shall mean the dates scheduled for the repayment of principal
of any Incremental Term Loan, as set forth in the applicable Incremental Term Loan Assumption Agreement. 

“Incremental Term Loans” shall mean Term Loans made by one or more Lenders to the Borrower pursuant to
Section 2.01(c). Incremental Term Loans may be made in the form of additional 2021 Term D Loans or, to the extent permitted by Section 2.24 and provided for in the relevant Incremental Term Loan Assumption Agreement, Other Term Loans. 

“Indebtedness” of any person shall mean, without duplication, (a) all obligations of such person
for borrowed money or with respect to deposits or advances of any kind (other than customer deposits and interest payable thereon in the ordinary course of business), (b) all obligations of such person evidenced by bonds, debentures, notes or
similar instruments, (c) all obligations of such person under conditional sale or other title retention agreements relating to property or assets purchased by such person, (d) all obligations of such person issued or assumed as the
deferred purchase price of property or services (excluding trade accounts payable and accrued obligations incurred in the ordinary course of business and deferred payment for services to employees or former employees incurred in the ordinary course
of business and payable in accordance with customary practices and other deferred compensation arrangements), (e) all Indebtedness of others secured by (or for which the holder of such Indebtedness has an existing right, contingent or
otherwise, to be secured by) any Lien on property owned or acquired by such person, whether or not the obligations secured thereby have been assumed, (f) all Guarantees by such person of Indebtedness of others, (g) all Capital Lease
Obligations and Synthetic Lease Obligations of such person, (h) all obligations of such person as an account party in respect of letters of credit, (i) all obligations of such person in respect of bankers’ acceptances, (j) all
obligations of such person pursuant to any Permitted Receivables Transaction and (k) the aggregate liquidation preference of all outstanding Disqualified Stock issued by such person; provided that in all cases (v) contingent value
rights issued in connection with the Permitted HMA Transaction (any payments made 

 
 27
 
  

 
pursuant to such contingent value rights being referred to herein as the “CVR Payments”), (w) Practice Guarantees, (x) earnouts, unless not paid after becoming
due and payable, and working capital adjustments under acquisition or disposition agreements, (y) deferred or prepaid revenue and (z) purchase price holdbacks in respect of a portion of the purchase price of an asset to satisfy warranty or
other unperformed obligations of the respective seller, shall be excluded from the definition of “Indebtedness”. The Indebtedness of any person shall include the Indebtedness of any partnership in which such person is a general partner.

 “Indemnified Taxes” shall mean Taxes other than Excluded Taxes. 

“Interest Coverage Ratio” shall mean, for any period, the ratio of (a) Consolidated EBITDA for
such period to (b) Consolidated Interest Expense for such period. 
 “Interest Payment Date”
shall mean (a) with respect to any ABR Loan, the last Business Day of each March, June, September and December, and (b) with respect to any Eurodollar Loan, the last day of the Interest Period applicable to the Borrowing of which such Loan
is a part and, in the case of a Eurodollar Borrowing with an Interest Period of more than three months’ duration, each day that would have been an Interest Payment Date had successive Interest Periods of three months’ duration been
applicable to such Borrowing. 
 “Interest Period” shall mean, with respect to any Eurodollar
Borrowing, the period commencing on the date of such Borrowing and ending on the numerically corresponding day (or, if there is no numerically corresponding day, on the last day) in the calendar month that is 1, 2, 3 or 6 months
thereafter or, with the consent of each applicable Lender, 12 months thereafter, as the Borrower may elect; provided, however, that if any Interest Period would end on a day other than a Business Day, such Interest Period shall be
extended to the next succeeding Business Day unless such next succeeding Business Day would fall in the next calendar month, in which case such Interest Period shall end on the next preceding Business Day. Interest shall accrue from and including
the first day of an Interest Period to but excluding the last day of such Interest Period. For purposes hereof, the date of a Borrowing initially shall be the date on which such Borrowing is made and thereafter shall be the effective date of the
most recent conversion or continuation of such Borrowing. 
 “Issuing Bank” shall mean, as the
context may require, except as provided in the last sentence of Section 2.23(a), (a) Wells Fargo Bank, N.A., acting through any of its Affiliates or branches, in its capacity as an issuer of Letters of Credit hereunder, (b) with
respect to each Existing Letter of Credit, the Lender that issued such Existing Letter of Credit, and (c) any other Lender that may become an Issuing Bank pursuant to Section 2.23(i) or 2.23(k), with respect to Letters of Credit issued by
such Lender. The Issuing Bank may, in its discretion, arrange for one or more Letters of Credit to be issued by Affiliates or branches of the Issuing Bank, in which case the term “Issuing Bank” shall include any such Affiliate or branch
with respect to Letters of Credit issued by such Affiliate or branch. 

 
 28
 
  

 “Issuing Bank Fees” shall have the meaning assigned
to such term in Section 2.05(c). 
 “Junior Lien Intercreditor Agreement” shall mean any
intercreditor agreement, collateral trust agreement or similar agreement governing the relative priorities of the holders of the Obligations and Other Senior Secured Debt, on the one hand, and the holders of Other Junior Secured Debt, on the other
hand, provided that such agreement (a) provides for such Indebtedness to be secured by Liens on the Collateral having junior priority to the Liens securing the Obligations and (b) is otherwise on terms reasonably acceptable to the
Administrative Agent and the Borrower. 
 “Latest Term Loan Maturity Date” shall mean, at any date
of determination, the latest maturity date applicable to any Term Loans or Term Loan Commitment hereunder at such time. 

“L/C Commitment” shall mean the commitment of the Issuing Bank to issue Letters of Credit pursuant to
Section 2.23. 
 “L/C Disbursement” shall mean a payment or disbursement made by the Issuing
Bank pursuant to a Letter of Credit. 
 “L/C Exposure” shall mean at any time the sum of
(a) the aggregate undrawn amount of all outstanding Letters of Credit at such time and (b) the aggregate amount of all L/C Disbursements that have not yet been reimbursed by or on behalf of the Borrower at such time. The L/C Exposure of
any Revolving Credit Lender at any time shall equal its Pro Rata Percentage of the aggregate L/C Exposure at such time. 

“L/C Participation Fee” shall have the meaning assigned to such term in Section 2.05(c). 

“Lenders” shall mean (a) the persons listed on Schedule 2.01 (other than any such person
that has ceased to be a party hereto pursuant to an Assignment and Acceptance) and (b) any person that has become a party hereto pursuant to an Assignment and Acceptance or a Revolving Accession Agreement. 

“Letter of Credit” shall mean any letter of credit issued pursuant to Section 2.23 and any
Existing Letter of Credit. 
 “Leverage Ratio” shall mean, on any date, the ratio of Total Debt on
such date to Consolidated EBITDA for the period of four consecutive fiscal quarters most recently ended on or prior to such date for which financial statements have been delivered (or were required to be delivered) pursuant to Section 5.04(a)
or (b). In any period of four consecutive fiscal quarters in which any Permitted Acquisition, the Permitted HMA Transaction or any Significant Asset Sale occurs, the Leverage Ratio shall be determined on a pro forma basis in accordance with
Section 1.03. 
 “LIBO Rate” shall mean, with respect to any Eurodollar Borrowing for any
Interest Period, the rate per annum determined by the Administrative Agent at 

 
 29
 
  

 
approximately 11:00 a.m. (London time) on the date that is two Business Days prior to the commencement of such Interest Period by reference to the British Bankers’ Association Interest
Settlement Rates (or to any replacement publicly available market convention therefor selected by the Administrative Agent) for deposits in dollars (as set forth by any service selected by the Administrative Agent that has been nominated by the
British Bankers’ Association or any successor thereof as an authorized information vendor for the purpose of displaying such rates) for a period equal to such Interest Period; provided that in no event shall the LIBO Rate be less than,
in the case of 2021 Term D Loans, 1.00%; provided further that, to the extent that an interest rate is not ascertainable pursuant to the foregoing provisions of this definition, the “LIBO Rate” shall be the interest rate per annum
determined by the Administrative Agent to be the average of the rates per annum at which deposits in dollars are offered for such relevant Interest Period to major banks in the London interbank market in London, England by the Administrative Agent
at approximately 11:00 a.m. (London time) on the date that is two Business Days prior to the beginning of such Interest Period. 

“Lien” shall mean, with respect to any asset, (a) any mortgage, deed of trust, lien, pledge,
encumbrance, charge or security interest in or on such asset and (b) the interest of a vendor or a lessor under any conditional sale agreement, capital lease or title retention agreement (or any financing lease having substantially the same
economic effect as any of the foregoing) relating to such asset. For the avoidance of doubt, the term “Lien” shall not be deemed to include any license of intellectual property. 

“Loan Documents” shall mean this Agreement, the First Amendment and Restatement Agreement, the Second
Amendment and Restatement Agreement, the Third Amendment and Restatement Agreement, the Letters of Credit, the Security Documents, each Incremental Term Loan Assumption Agreement, any Pari Passu Intercreditor Agreement, any Junior Lien Intercreditor
Agreement, any Loan Modification Agreement, any Revolving Accession Agreement, any Revolving Credit Commitment Increase Amendment and the promissory notes, if any, executed and delivered pursuant to Section 2.04(e). 

“Loan Modification Agreement” shall mean a Loan Modification Agreement in form and substance
reasonably satisfactory to the Administrative Agent and the Borrower, among the Borrower, the other Loan Parties, one or more Accepting Lenders and the Administrative Agent. 

“Loan Modification Offer” shall have the meaning specified in Section 2.25(a). 

“Loan Parties” shall mean Parent, the Borrower and the Guarantors. 

“Loans” shall mean the Revolving Loans and the Term Loans. 

“Margin Stock” shall have the meaning assigned to such term in Regulation U. 

“Material Adverse Effect” shall mean (a) a materially adverse effect on the business, assets,
operations, financial condition or operating results of the Borrower and the Subsidiaries, taken as a whole, (b) a material impairment of the ability of the Loan 

 
 30
 
  

 
Parties, taken as a whole, to perform their obligations under the Loan Document to which they are or will be a party or (c) a material impairment of the rights and remedies of or benefits
available to the Lenders under the Loan Documents. 
 “Material Indebtedness” shall mean
Indebtedness (other than the Loans and Letters of Credit and intercompany loans), or obligations in respect of one or more Hedging Agreements, of any one or more of Parent, the Borrower or any Subsidiary in an aggregate principal amount exceeding
$125,000,000. For purposes of determining Material Indebtedness, the “principal amount” of the obligations of Parent, the Borrower or any Subsidiary in respect of any Hedging Agreement at any time shall be the maximum aggregate amount
(giving effect to any netting agreements) that Parent, the Borrower or such Subsidiary would be required to pay if such Hedging Agreement were terminated at such time. 

“Material Subsidiary” shall mean any Subsidiary other than any (a) Permitted Joint Venture
Subsidiary, (b) Permitted Syndication Subsidiary, (c) Securitization Subsidiary, (d) Foreign Subsidiary, (e) Captive Insurance Subsidiary or (f) Non-Significant Subsidiary. 

“Maturity Trigger” shall mean, and shall be deemed to have occurred if, on any applicable date of
determination with respect to the 2017 Term E Loans, the 2018 Notes, the 2019 Notes or the 2020 Notes, as the case may be, the aggregate principal amount of outstanding 2017 Term E Loans, 2018 Notes, 2019 Notes or 2020 Notes with respect to which
the Maturity Trigger is being tested is greater than or equal to $125,000,000. For purposes of determining whether a Maturity Trigger has occurred (a) with respect to the Revolving Credit Maturity Date or the 2019 Term A Maturity Date, any
refinancing (“Refinanced Indebtedness”) of 2017 Term E Loans, 2018 Notes, 2019 Notes or 2020 Notes shall be deemed to continue to be, as applicable, 2017 Term E Loans, 2018 Notes, 2019 Notes or 2020 Notes, if such Refinanced
Indebtedness has a maturity date prior to the date that is ninety-one (91) days after the date that is five years after the Third Restatement Effective Date, or (b) with respect to the 2021 Term D Maturity Date, Refinanced Indebtedness
shall be deemed to continue to be, as applicable, 2017 Term E Loans, 2018 Notes, 2019 Notes or 2020 Notes, if such Refinanced Indebtedness has a maturity date prior to the date that is ninety-one (91) days after the date that is seven years
after the Third Restatement Effective Date. 
 “Moody’s” shall mean Moody’s Investors
Service, Inc., or any successor thereto. 
 “Mortgaged Properties” shall mean, initially, the owned
real properties of the Loan Parties specified on Schedule 1.01(c), and shall include each other parcel of real property and improvements thereto with respect to which a Mortgage is granted pursuant to Section 5.12. 

“Mortgages” shall mean the mortgages, deeds of trust, assignments of leases and rents, modifications
and other security documents delivered pursuant to clause (i) of Section 4.02(g) of the Original Credit Agreement, Section 6(g) of the First Amendment and Restatement Agreement or Section 7(b) or 7(c) of the Third Amendment and

 
 31
 
  

 
Restatement Agreement or pursuant to Section 5.12 of the Original Credit Agreement, the First Amended and Restated Credit Agreement, the Existing Credit Agreement or this Agreement, each
substantially in the form of Exhibit D. 
 “Multiemployer Plan” shall mean a multiemployer plan
as defined in Section 4001(a)(3) of ERISA. 
 “Net Cash Proceeds” shall mean (a) with
respect to any Asset Sale (other than Receivables sold in a Permitted Receivables Transaction), the aggregate cash proceeds received in respect of such Asset Sale, and any cash payments received in respect of promissory notes or other non-cash
consideration delivered in respect of such Asset Sale, net of (without duplication) (i) the reasonable expenses (including legal fees and brokers’ and underwriters’ commissions paid to third parties which are not Subsidiaries or
Affiliates of Parent) incurred in effecting such Asset Sale, (ii) any taxes reasonably attributable to such Asset Sale and, in the case of an Asset Sale in a foreign jurisdiction, any taxes reasonably attributable to the repatriation of the
proceeds of such Asset Sale reasonably estimated by the Borrower to be actually payable, (iii) any amounts payable to a Governmental Authority triggered as a result of any such Asset Sale, (iv) any Indebtedness or Contractual Obligation of
Parent, the Borrower and the Subsidiaries (other than the Loans, other Obligations and any Other Senior Secured Debt) required to be paid or retained in connection with such Asset Sale and (v) the aggregate amount of reserves required in the
reasonable judgment of the Borrower or the applicable Subsidiary to be maintained on the books of the Borrower or such Subsidiary in order to pay contingent liabilities with respect to such Asset Sale (so long as amounts deducted from aggregate
proceeds pursuant to this clause (v) and not actually paid by the Borrower or any of the Subsidiaries in liquidation of such contingent liabilities shall be deemed to be Net Cash Proceeds received at such time as such contingent liabilities
shall cease to be obligations of the Borrower or any of the Subsidiaries); provided, however, that if (x) the Borrower intends to reinvest such proceeds in assets of a kind then used or usable in the business of the Borrower and
the Subsidiaries or in Permitted Acquisitions or other investments permitted pursuant to Section 6.04 (other than Section 6.04(b)) within 15 months of receipt of such proceeds and (y) no Default or Event of Default shall have
occurred and shall be continuing at the time of such receipt, such proceeds (but not to exceed $1,000,000,000 in the aggregate in the case of all such Asset Sales occurring after the Third Restatement Effective Date) shall not constitute Net Cash
Proceeds except to the extent not so used at the end of such 15-month period, at which time such proceeds shall be deemed to be Net Cash Proceeds; provided further that if during such 15-month period Parent, the Borrower or a Subsidiary
enters into a written agreement committing it to so apply all or a portion of such proceeds, such 15-month period will be extended with respect to the amount of proceeds for an additional six months, at which time such proceeds shall be deemed to be
Net Cash Proceeds; (b) with respect to any issuance or incurrence of Indebtedness (other than Indebtedness incurred pursuant to any Receivables Transaction), the cash proceeds thereof, net of all taxes and customary fees, commissions, costs and
other expenses incurred in connection therewith; and (c) with respect to any sale of Receivables in a Receivables Transaction, the initial cash proceeds thereof (and any subsequent cash proceeds therefrom to the extent resulting from an
increase in the Receivables Transaction Amount above the highest previous Receivables Transaction Amount balance), in each case received by the applicable originators net of all taxes and customary fees, commissions, costs and other expenses
incurred in connection therewith. 

 
 32
 
  

 “New Notes” shall have the meaning assigned to such
term in the Preliminary Statement. 
 “New Loan Margin” shall have the meaning assigned to such term
in Section 2.27. 
 “New Term Loan” shall mean any Pari Passu Debt in the form of term loans secured
by Liens on the Collateral having the same priority as the Liens securing the Term Loans (but excluding, for the avoidance of doubt, any Incremental Term Loans), made to Parent or any of its subsidiaries, the proceeds of which will be used to
finance, in whole or in part, one or more Permitted Acquisitions. 
 “New Term Loan OID” shall have
the meaning assigned to such term in Section 2.27. 
 “New Term Loan Yield Differential” shall have
the meaning assigned to such term in Section 2.27. 
 “Non-Significant Subsidiary” shall mean at any
time, any Subsidiary (a) which at such time has total assets book value (including the total assets book value of any subsidiaries of such Subsidiary), or for which the Borrower or any of the Subsidiaries shall have paid (including the
assumption of Indebtedness) in connection with the acquisition of Equity Interests or the total assets of such Subsidiary, less than $10,000,000 or (b) which does not and will not itself or through its subsidiaries own a Hospital or an interest
in a Hospital or manage or operate a Hospital and which is listed on Schedule 1.01(d) hereto (or on any updates to such Schedule subsequently furnished by the Borrower to the Administrative Agent) as a “Non-Significant Subsidiary”,
provided that the total assets of all Non-Significant Subsidiaries at any time does not exceed 5.0% of the total assets of Parent, the Borrower and the Subsidiaries on a consolidated basis. 

“Notice of Increase” shall have the meaning assigned to such term in Section 2.26(a). 

“Obligations” shall mean all obligations defined as “Bank Loan Obligations” in the Guarantee
and Collateral Agreement and the other Security Documents. 
 “Original Credit Agreement” shall have
the meaning assigned to such term in the Preliminary Statement. 
 “Other Junior Secured Debt” shall
mean Indebtedness secured by Liens on the Collateral having a priority junior to that of the Liens securing the Obligations. 

 
 33
 
  

 “Other Senior Secured Debt” shall mean Pari Passu
Debt and Alternative Incremental Facility Indebtedness, in each case secured by Liens on the Collateral having the same priority as the Liens securing the Obligations. 

“Other Taxes” shall mean any and all present or future stamp or documentary taxes or any other excise
or property taxes, charges or similar levies arising from any payment made under any Loan Document or from the execution, delivery or enforcement of, or otherwise with respect to, any Loan Document. 

“Other Term A Loans” shall mean Other Term Loans (a) which amortize at a rate per annum of not
less than 5.00% in each period of four consecutive fiscal quarters commencing on or after the funding of such Other Term Loans and ending on or prior to the applicable Incremental Term Loan Maturity Date and (b) which have a weighted average
life to maturity, when incurred, of five years or less. 
 “Other Term Loans” shall have the meaning
assigned to such term in Section 2.24(a). 
 “Pari Passu Debt” shall mean Indebtedness which
(a) is issued, incurred, created, assumed or guaranteed by any Loan Party, (b) is not an obligation of, or otherwise Guaranteed by, any Subsidiary of Parent that is not a Loan Party, (c) is not secured by any Lien on any asset of
Parent, the Borrower or any Subsidiary other than any asset constituting Collateral, (d) does not amortize at a rate per annum in excess of 1.00% during any period of four consecutive fiscal quarters commencing on or after the date such Pari
Passu Debt is incurred by any Loan Party, (e) is subject to a Pari Passu Intercreditor Agreement and (f) is issued, incurred, created or assumed (i) to finance, or otherwise in connection with, a Permitted Acquisition, (ii) in
order to extend, renew, refinance or replace existing Pari Passu Debt, provided that (A) the principal amount of such Pari Passu Debt is not increased (except by an amount not to exceed (1) the amount of unpaid accrued interest and
premium on the existing Pari Passu Debt so extended, renewed, refinanced or replaced, plus (2) other reasonable amounts paid and fees and expenses incurred in connection with such extension, renewal, refinancing or replacement) and
(B) neither the final maturity nor the weighted average life to maturity of such Pari Passu Debt is decreased thereby or (iii) in order to obtain Net Cash Proceeds, 100% of which (if not used in the manner set forth in the foregoing
clauses (i) and (ii)) are used by the Borrower, not later than the fifth Business Day following the receipt thereof, to prepay outstanding Term Loans in the manner set forth in Section 2.13(g). 

“Pari Passu Debt Obligations” shall have the meaning assigned to such term in the Guarantee and
Collateral Agreement. 
 “Pari Passu Intercreditor Agreement” shall mean any intercreditor
agreement, collateral trust agreement or similar agreement governing the relative priorities of the holders of the Obligations, on the one hand, and the holders of the Pari Passu Debt Obligations, on the other hand, provided that such agreement
(a) contains terms that are not less favorable to the holders of the Obligations than to the holders of the Pari Passu Debt Obligations, (b) provides for the Pari Passu Debt Obligations to be secured by Liens

 
 34
 
  

 
on the Collateral having the same priority as, or junior priority to, the Liens securing the Obligations and (c) is otherwise on terms reasonably acceptable to the Administrative Agent and
the Borrower. 
 “PBGC” shall mean the Pension Benefit Guaranty Corporation referred to and defined
in ERISA and any successor entity performing similar functions. 
 “Pension Act” shall mean the
Pension Protection Act of 2006, as amended from time to time. 
 “Permitted Acquisition” shall have
the meaning assigned to such term in Section 6.04(h). 
 “Permitted Additional Debt” of any
Loan Party shall mean any unsecured Indebtedness of such Loan Party or an unsecured or subordinated Guarantee of or by such Loan Party, in each case which (a) matures on or after, and requires no scheduled payments of principal prior to, the
date that is ninety-one (91) days after the Latest Term Loan Maturity Date in effect at the time such Indebtedness is incurred (which, in the case of bridge loans, shall be determined by reference to the loans or notes into which such bridge
loans are converted at maturity) (other than pursuant to customary offers to purchase upon a change of control, payments required to prevent any such Indebtedness from being treated as an “applicable high yield discount obligation” within
the meaning of Section 163(i)(1) of the Code, asset sale or event of loss and customary acceleration rights after an event of default), (b) contains no financial maintenance covenants unless such financial maintenance covenants are added
to this Agreement for the benefit of the Lenders hereunder and (c) to the extent the same is subordinated to any Indebtedness, is subordinate or junior in right of payment to the Obligations, pursuant to a written agreement on terms customary
for similar Indebtedness at the time of issuance. 
 “Permitted Amendments” shall have the meaning
assigned to such term in Section 2.25(c). 
 “Permitted Capital Expenditure Amount” shall have
the meaning assigned to such term in Section 6.11. 
 “Permitted HMA Transaction” shall have
the meaning assigned to such term in the Preliminary Statement. 
 “Permitted Interest Transfer”
shall mean a sale, issuance or other transfer of securities of a Subsidiary or of assets of any Subsidiary to a new Subsidiary, or sale, issuance or transfer of securities of a Subsidiary to another person if after such sale, issuance or other
transfer, such Subsidiary shall meet the applicable requirements of the definition of “Permitted Joint Venture Subsidiary”, “Non-Significant Subsidiary” or “Permitted Syndication Subsidiary”; provided that
(a) the aggregate fair market value (determined at the time of and after giving effect to any Permitted Interest Transfer) of all Permitted Interest Transfers made to, or in connection with the establishment of, a Permitted Joint Venture shall
not exceed $1,000,000,000 and (b) at the time of and after giving effect to any Permitted Interest Transfer the total book value of the assets, 

 
 35
 
  

 
calculated as of the date of the applicable Permitted Interest Transfer, of all Subsidiaries (other than Loan Parties) that become Permitted Joint Venture Subsidiaries or Permitted Syndication
Subsidiaries after the Closing Date as a result of a Permitted Interest Transfer made after the Closing Date shall not exceed (i) 10% of the total book value of the assets of Parent, the Borrower and the Subsidiaries on a consolidated basis,
calculated as of the date of the applicable Permitted Interest Transfer, in the case of Permitted Joint Venture Subsidiaries, and (ii) 10% of the total book value of the assets of Parent, the Borrower and the Subsidiaries on a consolidated
basis, calculated as of the date of the applicable Permitted Interest Transfer, in the case of Permitted Syndication Subsidiaries. 

“Permitted Investments” shall mean: 

(a) direct obligations of, or obligations the principal of and interest on which are unconditionally guaranteed by, the
United States of America (or by any agency thereof to the extent such obligations are backed by the full faith and credit of the United States of America), in each case maturing within one year from the date of acquisition thereof; 

(b) investments in commercial paper maturing within 270 days from the date of acquisition thereof and having, at such
date of acquisition, the highest credit rating obtainable from S&P or from Moody’s; 
 (c) investments in
certificates of deposit, banker’s acceptances and time deposits maturing within one year from the date of acquisition thereof issued or guaranteed by or placed with, and money market deposit accounts issued or offered by, the Administrative
Agent or any domestic office of any commercial bank organized under the laws of the United States of America or any State thereof that has a combined capital and surplus and undivided profits of not less than $500,000,000; 

(d) fully collateralized repurchase agreements with a term of not more than 30 days for securities described in
clause (a) above and entered into with a financial institution satisfying the criteria of clause (c) above; 

(e) investments in “money market funds” within the meaning of Rule 2a-7 of the Investment Company Act of 1940,
as amended, substantially all of whose assets are invested in investments of the type described in clauses (a) through (d) above; and 

(f) other short-term investments utilized by Foreign Subsidiaries in accordance with normal investment practices for cash
management in investments of a type analogous to the foregoing. 
 “Permitted Joint Venture
Subsidiary” shall mean a partially owned Subsidiary pursuant to which the Borrower or such Subsidiary conducts a Permitted Joint Venture. 

“Permitted Joint Ventures” shall mean (a) acquisitions (by merger, purchase, lease (including any
lease that contains upfront payments or buy out options) or otherwise), not constituting Permitted Acquisitions, by Parent, the Borrower or any of the Subsidiaries of interests in any of the assets of, or shares of the capital stock of or other
Equity Interests in, a person or division or line of business of any person engaged in the 

 
 36
 
  

 
same business as the Borrower and the Subsidiaries or in a related business, (b) sales, issuances or other transfers of securities of a Subsidiary to a Person other than a Loan Party if
after such sale, issuance or other transfer, such Subsidiary shall meet the applicable requirements of the definition of “Permitted Joint Venture Subsidiary” or (c) other investments in and loans and advances to Permitted Joint
Venture Subsidiaries; provided that (x) no Default or Event of Default shall have occurred and be continuing and (y) except for the Permitted Joint Ventures listed on Schedule 1.01(e), to the extent the aggregate value of the
investments, loans and advances made by Parent, the Borrower and the Subsidiaries in (including assets transferred to) any Permitted Joint Venture, in each case, measured as of the date of each such investment, loan or advance (net of any repayments
or return of capital in respect thereof actually received in cash by Parent, the Borrower or the Subsidiaries (net of applicable Taxes) after the Closing Date) (the “Net Investment Amount”), when added to the aggregate Net
Investment Amounts of all Permitted Joint Ventures consummated after the Third Restatement Effective Date, would exceed $1,000,000,000, the Secured Net Leverage Ratio Condition would be satisfied. 

“Permitted Real Estate Indebtedness” shall have the meaning assigned to such term in Section 6.01(f).

 “Permitted Receivables Transaction” shall have the meaning assigned to such term in Section
6.05(b). 
 “Permitted Syndication Subsidiary” shall mean a partially owned Subsidiary of the
Borrower which, after giving effect to a Permitted Syndication Transaction, owns, leases or operates the Hospital which is the subject of such Permitted Syndication Transaction. 

“Permitted Syndication Transaction” shall have the meaning assigned to such term in Section 6.05(b).

 “Permitted Syndication Transaction Partner” shall mean one or more persons (other than Parent,
the Borrower or any Subsidiary) that owns a minority interest in a Permitted Syndication Subsidiary. 

“person” shall mean any natural person, corporation, business trust, joint venture, association,
company, limited liability company, partnership, Governmental Authority or other entity. 
 “Plan”
shall mean any employee pension benefit plan (other than a Multiemployer Plan) subject to the provisions of Title IV of ERISA or Section 412 of the Code or Section 302 of ERISA, sponsored, maintained or contributed to by the Borrower
or any ERISA Affiliate. 
 “Platform” shall have the meaning assigned to such term in Section 9.01.

 “Practice Guarantees” shall mean admitting physician practice guarantees pursuant to which
Parent, the Borrower or any of the Subsidiaries guarantees to pay an 

 
 37
 
  

 
admitting physician on the medical staff of a Hospital the difference between such admitting physician’s monthly net revenue from professional fees and a minimum monthly guaranteed amount.

 “Prime Rate” shall mean the rate of interest per annum determined from time to time by Credit
Suisse AG as its prime rate in effect at its principal office in New York City and notified to the Borrower. 

“Pro Rata Percentage” of any Revolving Credit Lender at any time shall mean the percentage of the
Total Revolving Credit Commitment represented by such Lender’s Revolving Credit Commitment. In the event the Revolving Credit Commitments shall have expired or been terminated, the Pro Rata Percentages shall be determined on the basis of the
Revolving Credit Commitments most recently in effect, giving effect to any subsequent assignments. 
 “Public
Lender” shall have the meaning assigned to such term in Section 9.01. 
 “Qualified Capital
Stock” of any person shall mean any Equity Interest of such person that is not Disqualified Stock. 

“Receivables” shall mean a right to receive payment arising from a sale or lease of goods or the
performance of services by a person pursuant to an arrangement with another person by which such other person is obligated to pay for goods or services under terms that permit the purchase of such goods and services on credit, and all proceeds
thereof and rights (contractual or other) and collateral related thereto, and shall include, in any event, any items of property that would be classified as accounts receivable on the balance sheet of the Borrower or any of the Subsidiaries prepared
in accordance with GAAP or an “account”, “chattel paper”, an “instrument”, a “general intangible” or a “payment intangible” under the Uniform Commercial Code as in effect in the State of New York and
any “supporting obligations” or “proceeds” (as so defined) of any such items. 
 “Receivables
Transaction” shall mean, with respect to the Borrower and/or any of the Subsidiaries, any transaction or series of transactions of sales, factoring or securitizations involving Receivables pursuant to which the Borrower or any
Subsidiary may sell, convey or otherwise transfer to a Securitization Subsidiary or any other Person, and may grant a corresponding security interest in, any Receivables (whether now existing or arising in the future) of the Borrower or any
Subsidiary, and any assets related thereto including collateral securing such Receivables, contracts and all Guarantees or other obligations in respect of such Receivables, the proceeds of such Receivables and other assets which are customarily
transferred, or in respect of which security interests are customarily granted, in connection with sales, factoring or securitizations involving Receivables. 

“Receivables Transaction Amount” shall mean (a) in the case of any Receivables securitization
(but excluding any sale or factoring of Receivables), the amount of obligations outstanding under the legal documents entered into as part of such 

 
 38
 
  

 
Receivables securitization on any date of determination that would be characterized as principal if such Receivables securitization were structured as a secured lending transaction rather than as
a purchase and (b) in the case of any sale or factoring of Receivables, the cash purchase price paid by the buyer in connection with its purchase of Receivables (including any bills of exchange) less the amount of collections received in
respect of such Receivables and paid to such buyer, excluding any amounts applied to purchase fees or discount or in the nature of interest, in each case as determined in good faith and in a consistent and commercially reasonable manner by the
Borrower (provided that if such method of calculation is not applicable to such sale or factoring of Receivables, the amount of Receivables Transaction Amount associated therewith shall be determined in a manner mutually acceptable to the
Borrower and the Administrative Agent). 
 “Received Exercise Proceeds Amount” shall mean, as at any
date of determination, an amount equal to (a) the aggregate net cash proceeds received by the Borrower in respect of any issuance of Equity Interests to employees or directors after the Closing Date, including payments in connection with the
exercise of stock options, minus (b) the aggregate amount of all Restricted Payments made in reliance on Section 6.06(a)(viii) prior to such date. 

“Reference Margin” shall have the meaning assigned to such term in Section 2.27. 

“Refinancing Incremental Term Loans” shall mean any Incremental Term Loans incurred pursuant to
Section 2.24, all of the proceeds of which are used concurrently with the incurrence thereof to prepay then-outstanding Term Loans. 

“Register” shall have the meaning assigned to such term in Section 9.04(d). 

“Regulation T” shall mean Regulation T of the Board as from time to time in effect and all
official rulings and interpretations thereunder or thereof. 
 “Regulation U” shall mean
Regulation U of the Board as from time to time in effect and all official rulings and interpretations thereunder or thereof. 

“Regulation X” shall mean Regulation X of the Board as from time to time in effect and all
official rulings and interpretations thereunder or thereof. 
 “Related Fund” shall mean, with
respect to any Lender that is a fund or commingled investment vehicle that invests in bank loans, any other fund that invests in bank loans and is managed or advised by the same investment advisor as such Lender or by an Affiliate of such investment
advisor. 
 “Related Parties” shall mean, with respect to any specified person, such person’s
Affiliates and the respective directors, trustees, officers, employees, agents and advisors of such person and such person’s Affiliates. 

 
 39
 
  

 “Release” shall mean any release, spill, emission,
leaking, dumping, injection, pouring, deposit, disposal, discharge, dispersal, leaching or migration into or through the environment or within or upon any building, structure, facility or fixture. 

“Repayment Date” shall mean a 2017 Term E Loan Repayment Date, a 2019 Term A Loan Repayment Date, a
2021 Term D Loan Repayment Date or an Incremental Term Loan Repayment Date. 
 “Replacement Capital
Expenditures” shall mean Capital Expenditures on or after the Closing Date made in connection with (i) the replacement of a Hospital as required by the agreements pursuant to which such Hospital, or the entity owning such Hospital,
was acquired by the Borrower or any of the Subsidiaries from a third-party, whether pursuant to such agreement existing as of the Closing Date or entered into thereafter or (ii) the replacement of the Hospitals (owned, leased or operated by the
Borrower or any of the Subsidiaries or in which the Borrower or any of the Subsidiaries owns an Equity Interest as of the Closing Date) in Birmingham, Alabama and Barstow, California. 

“Replacement Revolving Credit Facility” shall have the meaning assigned to such term in
Section 2.25(d). 
 “Required Covenant Lenders” shall mean, at any time, Lenders having 2019
Term A Loans, Other Term A Loans, Revolving Loans, L/C Exposure and unused Revolving Credit Commitments representing more than 50% of the sum of all 2019 Term A Loans, Other Term A Loans, Revolving Loans, L/C Exposure and unused Revolving Credit
Commitments at such time; provided that the Revolving Loans, L/C Exposure and unused Revolving Credit Commitments of any Defaulting Lender shall be disregarded in the determination of the Required Covenant Lenders at any time. 

“Required Lenders” shall mean, at any time, Lenders having Loans, L/C Exposure and unused Revolving
Credit Commitments and Term Loan Commitments representing more than 50% of the sum of all Loans outstanding, L/C Exposure, unused Revolving Credit Commitments and Term Loan Commitments at such time; provided that the Revolving Loans, L/C
Exposure and unused Revolving Credit Commitments of any Defaulting Lender shall be disregarded in the determination of the Required Lenders at any time. 

“Responsible Officer” of any person shall mean any executive officer, executive vice president or
Financial Officer of such person and any other officer or similar official thereof responsible for the administration of the obligations of such person in respect of this Agreement. 

“Restricted Indebtedness” shall mean Indebtedness of Parent, the Borrower or any Subsidiary, the
payment, prepayment, repurchase or defeasance of which is restricted under Section 6.09(b). 
 “Restricted
Payment” shall mean any dividend or other distribution (whether in cash, securities or other property (other than Qualified Capital Stock of the person making such dividend or distribution)) with respect to any Equity Interests in
Parent, the 

 
 40
 
  

 
Borrower or any Subsidiary, or any payment (whether in cash, securities or other property (other than Qualified Capital Stock of the person making such dividend or distribution)), including any
sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any Equity Interests in Parent, the Borrower or any Subsidiary (other than, in each case, capital contributions to, or
the purchase of Equity Interests in, any Subsidiary). 
 “Revolving Accession Agreement” shall have
the meaning assigned to such term in Section 2.26(a). 
 “Revolving Credit Borrowing” shall
mean a Borrowing comprised of Revolving Loans. 
 “Revolving Credit Commitment” shall mean, with
respect to each Lender, the commitment of such Lender to make Revolving Loans hereunder (and to acquire participations in Letters of Credit as provided for herein) as set forth on Schedule III to the Third Amendment and Restatement Agreement,
or in the Assignment and Acceptance pursuant to which such Lender assumed its Revolving Credit Commitment, as applicable, as the same may be (a) reduced from time to time pursuant to Section 2.09, (b) increased from time to time
pursuant to Section 2.26 and (c) reduced or increased from time to time pursuant to assignments by or to such Lender pursuant to Section 9.04. 

“Revolving Credit Commitment Fee” shall have the meaning assigned to such term in
Section 2.05(a). 
 “Revolving Credit Commitment Fee Rate” shall have the meaning assigned to
such term in the definition of the term “Applicable Percentage”. 
 “Revolving Credit Commitment
Increase” shall have the meaning assigned to such term in Section 2.26(a). 
 “Revolving Credit
Commitment Increase Amendment” shall have the meaning assigned to such term in Section 2.26(a). 

“Revolving Credit Exposure” shall mean, with respect to any Lender at any time, the aggregate
principal amount at such time of all outstanding Revolving Loans of such Lender, plus the aggregate amount at such time of such Lender’s L/C Exposure. 

“Revolving Credit Lender” shall mean a Lender with a Revolving Credit Commitment or an outstanding
Revolving Loan. 
 “Revolving Credit Maturity Date” shall mean January 27, 2019;
provided that the Revolving Credit Maturity Date shall instead be (a) October 26, 2016, if, on such date, the Maturity Trigger has occurred with respect to the 2017 Term E Loans, or (b) May 16, 2018, if, on such date, the
Maturity Trigger has occurred with respect to the 2018 Notes; provided further, that, in each case, if any such day is not a Business Day, the Revolving Credit Maturity Date shall be the Business Day immediately preceding such day. 

 
 41
 
  

 “Revolving Loans” shall mean the revolving loans made
by the Lenders to the Borrower pursuant to Section 2.01(b). 
 “S&P” shall mean
Standard & Poor’s Ratings Service, or any successor thereto. 
 “SEC” shall mean the
U.S. Securities and Exchange Commission or any Governmental Authority succeeding to any or all of its functions. 

“Second Amendment and Restatement Agreement” shall mean the Second Amendment and Restatement Agreement
dated as of the Second Restatement Effective Date among Parent, the Borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and the Administrative Agent. 

“Second Restatement Effective Date” shall mean February 2, 2012. 

“Secured Net Leverage Ratio” shall mean, on any date, the ratio of (a) (i) Total Secured
Debt minus (ii) the aggregate amount of unrestricted cash, cash equivalents and Permitted Investments that is included on the consolidated balance sheet of Parent, the Borrower and the Subsidiaries on such date, to (b) Consolidated EBITDA
for the period of four consecutive fiscal quarters most recently ended on or prior to such date for which financial statements have been delivered (or were required to be delivered) pursuant to Section 5.04(a) or (b). In any period of four
consecutive fiscal quarters in which any Permitted Acquisition, the Permitted HMA Transaction or any Significant Asset Sale occurs, the Secured Net Leverage Ratio shall be determined on a pro forma basis in accordance with Section 1.03. 

“Secured Net Leverage Ratio Condition” shall mean, on any date, after giving pro forma effect to any
Specified Transaction to occur on such date as contemplated by Section 1.03, that the Secured Net Leverage Ratio shall not be greater than 4.00 to 1.0. 

“Secured Parties” shall have the meaning assigned to such term in the Guarantee and Collateral
Agreement. 
 “Securitization Subsidiary” shall mean any special purpose Subsidiary that acquires
Receivables generated by the Borrower or any of the Subsidiaries and that engages in no operations or activities other than those related to a Permitted Receivables Transaction. 

“Security Documents” shall mean the Mortgages, the Guarantee and Collateral Agreement and each of the
security agreements, mortgages and other instruments and documents executed and delivered pursuant to any of the foregoing or pursuant to Section 5.12 or 9.20. 

“Senior Note Indenture” shall mean each indenture under which Senior Notes are issued, as the same may
be amended, restated, substituted, replaced, refinanced, supplemented or otherwise modified from time to time in accordance with Section 6.01(a). 

 
 42
 
  

 “Senior Notes” shall mean the 2018 Notes, the 2019
Notes, the 2020 Notes, the 2021 Notes and the 2022 Notes, in each case, as the same may be amended, restated, substituted, replaced, refinanced, supplemented or otherwise modified from time to time in accordance with Section 6.01(a). 

“Shared Collateral Agent” shall have the meaning assigned to such term in Section 9.20. 

“Significant Asset Sale” shall mean the sale, transfer, lease or other disposition by Parent, the
Borrower or any Subsidiary to any person other than the Borrower or a Subsidiary Guarantor of all or substantially all of the assets of, or a majority of the Equity Interests in, a person, or a division or line of business or other business unit of
a person. 
 “SPC” shall have the meaning assigned to such term in Section 9.04(i). 

“Specified Representations” shall mean the representations and warranties made in Sections 3.01,
3.02(a) and (b)(i)(A) and (B) (with respect to the Loan Documents), 3.03, 3.11, 3.12, 3.19, 3.22 and 3.23. 

“Specified Transaction” shall mean (a) the consummation of a Permitted Acquisition or other
acquisition permitted pursuant to Section 6.04, (b) the investment in a Permitted Joint Venture or an Unrestricted Subsidiary, (c) the consummation of the Permitted HMA Transaction or (d) the incurrence or assumption of
Indebtedness pursuant to Section 6.01(m) or (v) and the use of proceeds thereof. 
 “Spinout
Subsidiary” shall mean an Unrestricted Subsidiary that is formed for the purpose of acquiring property of Parent, the Borrower or any Subsidiary in connection with a Spinout Transaction. 

“Spinout Transaction” shall mean, collectively, any series or combination of contributions,
distributions and/or other transfers by Parent, the Borrower and/or any Subsidiary of property (including Equity Interests) owned by it to any Spinout Subsidiary (or to a Subsidiary in contemplation of the further contribution, distribution or other
transfer of such property to any Spinout Subsidiary) and the ultimate distribution of the Equity Interests of an Ultimate Spinout Subsidiary to the equity holders of Parent; provided that (i) the aggregate Consolidated EBITDA
attributable to all such property (including Equity Interests) so contributed, distributed or transferred (determined for each such contribution, distribution or other transfer at the time thereof and for the period of four consecutive fiscal
quarters most recently ended on or prior to the date of the relevant contribution, distribution or other transfer for which financial statements have been delivered (or were required to be delivered) pursuant to Section 5.04(a) or (b)) shall
not exceed in the aggregate for all such contributions, distributions and other transfers 15.0% of Consolidated EBITDA of Parent, the Borrower and the Subsidiaries for such period and (ii) after giving effect to such Spinout Transaction and the
repayment of any Indebtedness in connection therewith, the Secured Net Leverage Ratio calculated on a pro forma basis shall not exceed the lesser of (x) 3.75 to 1.00 and (y) the Secured Net Leverage Ratio immediately prior to giving effect
to such Spinout Transaction. 

 
 43
 
  

 “Statutory Reserves” shall mean a fraction (expressed
as a decimal), the numerator of which is the number one and the denominator of which is the number one minus the aggregate of the maximum reserve percentages (including any marginal, special, emergency or supplemental reserves) expressed as a
decimal established by the Board and any other banking authority, domestic or foreign, to which the Administrative Agent or any Lender (including any branch, Affiliate or other fronting office making or holding a Loan) is subject for Eurocurrency
Liabilities (as defined in Regulation D of the Board). Eurodollar Loans shall be deemed to constitute Eurocurrency Liabilities (as defined in Regulation D of the Board) and to be subject to such reserve requirements without benefit of or
credit for proration, exemptions or offsets that may be available from time to time to any Lender under such Regulation D. Statutory Reserves shall be adjusted automatically on and as of the effective date of any change in any reserve
percentage. 
 “subsidiary” shall mean, as to any person, a corporation, partnership or other entity
of which Equity Interests having ordinary voting power (other than Equity Interests having such power only by reason of the happening of a contingency) to elect a majority of the board of directors or other managers of such corporation, partnership
or other entity are at the time owned, directly or indirectly, or the management of which is otherwise Controlled, directly or indirectly, or both, by such person. 

“Subsidiary” shall mean any subsidiary of the Borrower; provided, however, that
Unrestricted Subsidiaries shall be deemed not to be Subsidiaries for any purpose of this Agreement or the other Loan Documents. 

“Subsidiary Guarantor” shall mean each Subsidiary listed on Schedule 1.01(b), and each other
Subsidiary that is or becomes a party to the Guarantee and Collateral Agreement pursuant to Section 5.12 (it being understood and agreed that no (i) Foreign Subsidiary, (ii) Non-Significant Subsidiary, (iii) Permitted Syndication
Subsidiary, (iv) Securitization Subsidiary, (v) Captive Insurance Subsidiary, (vi) Permitted Joint Venture Subsidiary or (vii) Subsidiary listed on Schedule 1.01(f), shall, in any case, be required to enter into the Guarantee and
Collateral Agreement pursuant to Section 5.12, unless the Borrower elects to make any such Permitted Joint Venture Subsidiary a Subsidiary Guarantor). 

“Syndication Proceeds” shall have the meaning assigned to such term in Section 6.05(b). 

“Syndication Transaction” shall mean a transaction (or series of transactions) whereby the Borrower or
a Subsidiary sells, transfers or otherwise disposes of part, but not all, of its interest in a Subsidiary that owns, leases or operates a Hospital to one or more third parties or of its interest in a Hospital to a partially owned Subsidiary. 

“Synthetic Lease” shall mean, as to any person, any lease (including leases that may be terminated by
the lessee at any time) of any property (whether real, personal or mixed) (a) that is accounted for as an operating lease under GAAP and (b) in respect of which the lessee retains or obtains ownership of the property so leased for U.S.
federal income tax purposes, other than any such lease under which such person is the lessor. 

 
 44
 
  

 “Synthetic Lease Obligations” shall mean, as to any
person, an amount equal to the capitalized amount of the remaining lease payments under any Synthetic Lease that would appear on a balance sheet of such person in accordance with GAAP if such obligations were accounted for as Capital Lease
Obligations. 
 “Synthetic Purchase Agreement” shall mean any swap, derivative or other agreement or
combination of agreements pursuant to which Parent, the Borrower or any Subsidiary is or may become obligated to make (a) any payment in connection with a purchase by any third party from a person other than Parent, the Borrower or any
Subsidiary of any Equity Interest or Restricted Indebtedness or (b) any payment (other than on account of a permitted purchase by it of any Equity Interest or Restricted Indebtedness) the amount of which is determined by reference to the price
or value at any time of any Equity Interest or Restricted Indebtedness; provided that no phantom stock or similar plan providing for payments only to current or former directors, officers or employees of Parent, the Borrower or the
Subsidiaries (or to their heirs and estates) shall be deemed to be a Synthetic Purchase Agreement. 

“Taxes” shall mean any and all present or future taxes, levies, imposts, duties, deductions, charges
or withholdings imposed by any Governmental Authority. 
 “Term Borrowing” shall mean a Borrowing
comprised of 2019 Term A Loans, 2017 Term E Loans, 2021 Term D Loans or Incremental Term Loans. 
 “Term
Lender” shall mean a Lender with a Term Loan Commitment or an outstanding Term Loan. 
 “Term Loan
Commitments” shall mean the 2019 Term A Commitments, the 2017 Term E Commitments and the 2021 Term D Commitments. Unless the context shall otherwise require, the term “Term Loan Commitments” shall include the
Incremental Term Loan Commitments. 
 “Term Loans” shall mean the 2019 Term A Loans, the 2017 Term E
Loans and the 2021 Term D Loans. Unless the context shall otherwise require, the term “Term Loans” shall include any Incremental Term Loans. 

“Third Amendment and Restatement Agreement” shall mean the Third Amendment and Restatement Agreement
dated as of the date hereof among Parent, the Borrower, the Subsidiary Guarantors party thereto, the Lenders party thereto and the Administrative Agent. 

“Third Restatement Effective Date” shall have the meaning assigned to such term in the Third Amendment
and Restatement Agreement. 
 “Total Assets” shall mean, as of any date, the total consolidated
assets of Parent and its Subsidiaries on a consolidated basis, as shown on the most recent consolidated balance sheet of Parent and its Subsidiaries, determined on a pro forma basis in accordance with Section 1.03. 

 
 45
 
  

 “Total Debt” shall mean, at any time, (a) the
total Indebtedness of Parent, the Borrower and the Subsidiaries at such time (excluding (i) Indebtedness of the type described in clause (h) of the definition of such term or under performance or surety bonds, in each case except to the
extent of any unreimbursed drawings thereunder and (ii) Indebtedness of the type described in clauses (c), (d), (e), (i), (j) and (k) of the definition of such term) minus (b) the aggregate amount of unrestricted cash, cash
equivalents and Permitted Investments that is included on the consolidated balance sheet of Parent, the Borrower and the Subsidiaries at such time. 

“Total Revolving Credit Commitment” shall mean, at any time, the aggregate amount of the Revolving
Credit Commitments, as in effect at such time. As of the Third Restatement Effective Date, the Total Revolving Credit Commitment is $1,000,000,000. 

“Total Secured Debt” shall mean, at any time the total Indebtedness of Parent, the Borrower and the
Subsidiaries at such time (excluding (i) Indebtedness of the type described in clause (h) of the definition of such term or under performance or surety bonds, in each case except to the extent of any unreimbursed drawings thereunder and
(ii) Indebtedness of the type described in clauses (c), (d), (e), (i), (j) and (k) of the definition of such term) that is secured by Liens on any property or asset of Parent, the Borrower and the Subsidiaries at such time. 

“Transactions” shall have the meaning assigned to such term in the Original Credit Agreement. 

“Triad” shall mean Triad Healthcare Corporation (f/k/a Triad Hospitals, Inc.), a Delaware corporation
and a wholly owned Subsidiary of the Borrower. 
 “Type”, when used in respect of any Loan or
Borrowing, shall refer to the Rate by reference to which interest on such Loan or on the Loans comprising such Borrowing is determined. For purposes hereof, the term “Rate” shall mean the Adjusted LIBO Rate and the Alternate
Base Rate. 
 “Ultimate Spinout Subsidiary” shall mean a Spinout Subsidiary or other Subsidiary the
Equity Interests of which are (or are intended to be, as the context may require) distributed to the equity holders of Parent. 

“Unrestricted Subsidiary” shall mean any Subsidiary organized or acquired directly or indirectly by
Parent after the Closing Date that Parent designates as an “Unrestricted Subsidiary” by written notice to the Administrative Agent. No Unrestricted Subsidiary may own any Equity Interests of a Subsidiary; provided that, so long as
no Default or Event of Default shall have occurred and be continuing or would result therefrom, Parent may redesignate any Unrestricted Subsidiary as a “Subsidiary” by written notice to the Administrative Agent and by complying with the
applicable provisions of Section 5.12. 

 
 46
 
  

 “USA PATRIOT Act” shall mean The Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Title III of Pub. L. No. 107-56 (signed into law October 26, 2001)). 

“Voluntary Prepayment” shall mean a prepayment of principal of Term Loans pursuant to
Section 2.12 in any year to the extent that such prepayment reduces the scheduled installments of principal due in respect of Term Loans in any subsequent year. 

“wholly owned Subsidiary” of any person shall mean a subsidiary of such person of which securities
(except for directors’ qualifying shares) or other ownership interests representing 100% of the Equity Interests are, at the time any determination is being made, owned, Controlled or held by such person or one or more wholly owned Subsidiaries
of such person or by such person and one or more wholly owned Subsidiaries of such person. 
 “Withdrawal
Liability” shall mean liability to a Multiemployer Plan as a result of a complete or partial withdrawal from such Multiemployer Plan, as such terms are defined in Part I of Subtitle E of Title IV of ERISA. 

“Withholding Agent” shall mean any Loan Party or the Administrative Agent. 

SECTION 1.02.  Terms Generally.   The definitions in Section 1.01 shall apply
equally to both the singular and plural forms of the terms defined. Whenever the context may require, any pronoun shall include the corresponding masculine, feminine and neuter forms. The words “include”, “includes” and
“including” shall be deemed to be followed by the phrase “without limitation”. The word “will” shall be construed to have the same meaning and effect as the word “shall”; and the words “asset” and
“property” shall be construed as having the same meaning and effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights. All references herein to Articles,
Sections, Exhibits and Schedules shall be deemed references to Articles and Sections of, and Exhibits and Schedules to, this Agreement unless the context shall otherwise require. Except as otherwise expressly provided herein, (a) any reference
in this Agreement to any Loan Document shall mean such document as amended, restated, supplemented or otherwise modified from time to time and (b) all terms of an accounting or financial nature shall be construed in accordance with GAAP, as in
effect from time to time; provided, however, that if the Borrower notifies the Administrative Agent that the Borrower wishes to amend any covenant in Article VI or any related definition to eliminate the effect of any change in
GAAP occurring after the date of this Agreement on the operation of such covenant (or if the Administrative Agent notifies the Borrower that the Required Lenders wish to amend Article VI or any related definition for such purpose), then the
Borrower’s compliance with such covenant shall at all times be determined on the basis of GAAP in effect immediately before the relevant change in GAAP became effective, until either such notice is withdrawn or such covenant is amended in a
manner satisfactory to the Borrower and the Required Lenders. 

 
 47
 
  

 SECTION 1.03.  Pro Forma
Calculations.   With respect to any period of four consecutive fiscal quarters during which the Permitted HMA Transaction or any Permitted Acquisition, other acquisition permitted pursuant to Section 6.04,
Significant Asset Sale or Spinout Transaction occurs, each of the Leverage Ratio and the Secured Net Leverage Ratio, and, without duplication, Consolidated EBITDA (other than for purposes of determining the Interest Coverage Ratio) and Total Assets,
shall, for all purposes set forth herein, be calculated with respect to such period on a pro forma basis after giving effect to such Permitted Acquisition, acquisition, Significant Asset Sale, the Permitted HMA Transaction or Spinout Transaction
(and any related repayment of Indebtedness) (including, without duplication, (a) all pro forma adjustments permitted or required by Article 11 of Regulation S-X under the Securities Act of 1933, as amended, (b) pro forma adjustments
for designation of any Subsidiary as an Unrestricted Subsidiary and any Unrestricted Subsidiary as a Subsidiary in accordance with the definition of “Unrestricted Subsidiary” (a “Subsidiary Designation”), and
(c) except in the case of the Permitted HMA Transaction, pro forma adjustments for cost savings and synergies (net of continuing associated expenses) to the extent such cost savings and synergies are reasonably identifiable, reasonably
supportable, are expected to have a continuing impact and have been realized or are reasonably expected to be realized within 12 months following any such Permitted Acquisition or acquisition (which cost savings and synergies shall be calculated on
a pro forma basis as though they had been realized on the first day of such period); provided that at the election of Parent, such pro forma adjustment shall not be required to be determined for any Permitted Acquisition or other acquisition
if the aggregate consideration paid in connection with such acquisition is less than $100,000,000; provided further that all such adjustments shall be set forth in a reasonably detailed certificate of a Financial Officer of Parent), assuming,
for purposes of making such calculations, the Permitted HMA Transaction or such Permitted Acquisition, Subsidiary Designation, acquisition permitted pursuant to Section 6.04, Significant Asset Sale or Spinout Transaction (and related repayment
of Indebtedness), and any other Permitted Acquisitions, Significant Asset Sales and Spinout Transactions (and related repayment of Indebtedness) that have been consummated during the period, had been consummated on the first day of such period;
provided, further, that the aggregate amount added to or included in Consolidated EBITDA above in respect of synergies for any period of four consecutive fiscal quarters shall not exceed an amount equal to 10% of Consolidated EBITDA,
calculated on a pro forma basis in accordance with this Section 1.03 after giving effect to such addition and any other prior additions in respect of such period pursuant to this Section 1.03. In addition, solely for purposes of
determining whether a Specified Transaction is permitted hereunder (including whether such Specified Transaction would result in a Default or Event of Default and whether the Secured Net Leverage Ratio Condition would be met), the Secured Net
Leverage Ratio shall be calculated on a pro forma basis as provided in the preceding sentence. 
 SECTION
1.04.  Classification of Loans and Borrowings.   For purposes of this Agreement, Loans may be classified and referred to by Class (e.g., a “Revolving Loan”) or by Type (e.g., a
“Eurodollar Loan”) or by Class and Type (e.g., a “Eurodollar Revolving Loan”). Borrowings also may be classified and referred to by Class (e.g., a “Revolving Borrowing”) or by Type (e.g., a
“Eurodollar Borrowing”) or by Class and Type (e.g., a “Eurodollar Revolving Borrowing”). 

 
 48
 
  

 SECTION 1.05.  Excluded Swap
Obligations.   (a) Notwithstanding any provision of this Agreement or any other Loan Document, no Guarantee by any Loan Party under any Loan Document shall include a Guarantee of any Obligation that, as to such
Loan Party, is an Excluded Swap Obligation and no Collateral provided by any Loan Party shall secure any Obligation that, as to such Loan Party, is an Excluded Swap Obligation. In the event that any payment is made by, or any collection is realized
from, any Loan Party as to which any Obligations are Excluded Swap Obligations, or from any Collateral provided by such Loan Party, the proceeds thereof shall be applied to pay the Obligations of such Loan Party as otherwise provided herein without
giving effect to such Excluded Swap Obligations and each reference in this Agreement or any other Loan Document to the ratable application of such amounts as among the Obligations or any specified portion of the Obligations that would otherwise
include such Excluded Swap Obligations shall be deemed so to provide. 
 (b)   The following terms shall for
purposes of this Section 1.05 have the meanings set forth below: 
 “Commodity Exchange Act”
means the Commodity Exchange Act (7 U.S. C. § et seq.), as amended from time to time, and any successor statute. 

“Excluded Swap Obligation” means, with respect to Guarantor, any Swap Obligation if, and to the
extent that, the Guarantee by such Guarantor of, or the grant by such Guarantor of a security interest to secure, such Swap Obligation (or any Guarantee thereof) is or becomes illegal under the Commodity Exchange Act or any rule, regulation or order
of the Commodity Futures Trading Commission (or the application or official interpretation of any thereof) by virtue of such Guarantor’s failure for any reason to constitute an “eligible contract participant” as defined in the
Commodity Exchange Act at the time the Guarantee of such Guarantor becomes effective with respect to such related Swap Obligation. 

“Qualified ECP Guarantor” means, in respect of any Swap Obligation, each Guarantor that has total
assets exceeding $10,000,000 or that otherwise constitutes an “eligible contract participant” under the Commodity Exchange Act or any regulations promulgated thereunder at the time such Swap Obligation is incurred (including as a result of
any agreement in the Guarantee and Collateral Agreement or any other Guarantee or other support agreement in respect of the obligations of such Subsidiary Guarantor by the Borrower or another Person that constitutes an “eligible contract
participant”). 
 “Swap Obligation” means, with respect to any Guarantor, any obligation to
pay or perform under any agreement, contract or transaction that constitutes a “swap” within the meaning of Section 1a(47) of the Commodity Exchange Act. 

 
 49
 
  

 ARTICLE II 

The Credits 

SECTION 2.01.  Commitments. 

(a)  Term Loans.  The Borrower and the Term Lenders acknowledge (i) the making
of 2019 Term A Loans, 2017 Term E Loans and 2021 Term D Loans on the Third Restatement Effective Date pursuant to the Third Amendment and Restatement Agreement and (ii) the conversion on the Third Restatement Effective Date pursuant to the
Third Amendment and Restatement Agreement of certain Extended Term Loans (as defined in the Existing Credit Agreement) to 2021 Term D Loans and certain Extended Term Loans (as defined in the Existing Credit Agreement) to 2017 Term E Loans. Amounts
paid or prepaid in respect of Term Loans may not be reborrowed. 
 (b)  The Revolving Credit
Commitments.  Subject to the terms and conditions and relying upon the representations and warranties herein set forth, each Revolving Credit Lender agrees, severally and not jointly, to make Revolving Loans to the Borrower, at any
time and from time to time after the Third Restatement Effective Date, and until the earlier of the Revolving Credit Maturity Date and the termination of the Revolving Credit Commitment of such Lender in accordance with the terms hereof, in an
aggregate principal amount at any time outstanding that will not result in such Lender’s Revolving Credit Exposure exceeding such Lender’s Revolving Credit Commitment. Within the limits set forth in the preceding sentence and subject
to the terms, conditions and limitations set forth herein, the Borrower may borrow, pay or prepay and reborrow Revolving Loans. 

(c)  The Incremental Term Loan Commitments.  Subject to the terms and conditions
and relying upon the representations and warranties set forth herein and in the applicable Incremental Term Loan Assumption Agreement, each Lender having an Incremental Term Loan Commitment agrees, severally and not jointly, to make Incremental Term
Loans to the Borrower, in an aggregate principal amount not to exceed its Incremental Term Loan Commitment. Amounts paid or prepaid in respect of Incremental Term Loans may not be reborrowed. 

SECTION 2.02.  Loans.   (a)  Each Loan shall be made as part of a Borrowing
consisting of Loans made by the Lenders ratably in accordance with their applicable Commitments; provided, however, that the failure of any Lender to make any Loan shall not in itself relieve any other Lender of its obligation to lend
hereunder (it being understood, however, that no Lender shall be responsible for the failure of any other Lender to make any Loan required to be made by such other Lender). Except for Loans deemed made pursuant to Section 2.02(f), the Loans
comprising any Borrowing shall be in an aggregate principal amount that is (i) an integral multiple of $1,000,000 and not less than $3,000,000 (except, with respect to any Incremental Term Borrowing, to the extent otherwise provided in the
related Incremental Term Loan Assumption Agreement) or (ii) equal to the remaining available balance of the applicable Commitments. 

 
 50
 
  

 (b)  Subject to Sections 2.02(f), 2.08 and
2.15, each Borrowing shall be comprised entirely of ABR Loans or Eurodollar Loans as the Borrower may request pursuant to Section 2.03. Each Lender may at its option make any Eurodollar Loan by causing any domestic or foreign branch or
Affiliate of such Lender to make such Loan; provided that any exercise of such option shall not affect the obligation of the Borrower to repay such Loan in accordance with the terms of this Agreement. Borrowings of more than one Type may be
outstanding at the same time; provided, however, that the Borrower shall not be entitled to request any Borrowing that, if made, would result in more than fifteen Eurodollar Borrowings outstanding hereunder at any time. For
purposes of the foregoing, Borrowings having different Interest Periods, regardless of whether they commence on the same date, shall be considered separate Borrowings. 

(c)  Except with respect to Loans made pursuant to Section 2.02(f), each Lender shall make each
Loan to be made by it hereunder on the proposed date thereof by wire transfer of immediately available funds to such account in New York City as the Administrative Agent may designate not later than 1:00 p.m., New York City time, and the
Administrative Agent shall promptly credit the amounts so received to an account designated by the Borrower in the applicable Borrowing Request or, if a Borrowing shall not occur on such date because any condition precedent herein specified shall
not have been met, return the amounts so received to the respective Lenders. 
 (d)  Unless the
Administrative Agent shall have received notice from a Lender prior to the date of any Borrowing that such Lender will not make available to the Administrative Agent such Lender’s portion of such Borrowing, the Administrative Agent may assume
that such Lender has made such portion available to the Administrative Agent on the date of such Borrowing in accordance with paragraph (c) above and the Administrative Agent may, in reliance upon such assumption, make available to the Borrower
on such date a corresponding amount. If the Administrative Agent shall have so made funds available then, to the extent that such Lender shall not have made such portion available to the Administrative Agent, such Lender agrees to repay to the
Administrative Agent forthwith on demand such corresponding amount together with interest thereon, for each day from the date such amount is made available to the Borrower to but excluding the date such amount is repaid to the Administrative Agent
at a rate determined by the Administrative Agent to represent its cost of overnight or short-term funds (which determination shall be conclusive absent manifest error). If such Lender shall not repay to the
Administrative Agent such corresponding amount within three Business Days after demand by the Administrative Agent, then the Administrative Agent shall be entitled to recover such amount with interest thereon at the rate per annum equal to the
interest rate applicable at the time to the Loans comprising such Borrowing, on demand, from the Borrower. If such Lender shall repay to the Administrative Agent such corresponding amount, such amount shall constitute such Lender’s Loan as part
of such Borrowing for purposes of this Agreement. 

 
 51
 
  

 (e)  Notwithstanding any other provision of this
Agreement, the Borrower shall not be entitled to request any Revolving Credit Borrowing if the Interest Period requested with respect thereto would end after the Revolving Credit Maturity Date. 

(f)  If the Issuing Bank shall not have received from the Borrower the payment required to be made
by Section 2.23(e) within the time specified in such Section, the Issuing Bank will promptly notify the Administrative Agent of the L/C Disbursement and the Administrative Agent will promptly notify each Revolving Credit Lender of such L/C
Disbursement and its Pro Rata Percentage thereof. Each Revolving Credit Lender shall pay by wire transfer of immediately available funds to the Administrative Agent not later than 2:00 p.m., New York City time, on such date (or, if such Revolving
Credit Lender shall have received such notice later than 12:00 (noon), New York City time, on any day, not later than 10:00 a.m., New York City time, on the immediately following Business Day), an amount equal to such Lender’s Pro Rata
Percentage of such L/C Disbursement (it being understood that (i) if the conditions precedent to borrowing set forth in Sections 4.01(b) and (c) have been satisfied, such amount shall be deemed to constitute an ABR Revolving Loan of
such Lender and, to the extent of such payment, the obligations of the Borrower in respect of such L/C Disbursement shall be discharged and replaced with the resulting ABR Revolving Credit Borrowing, and (ii) if such conditions precedent to
borrowing have not been satisfied, then any such amount paid by any Revolving Credit Lender shall not constitute a Loan and shall not relieve the Borrower from its obligation to reimburse such L/C Disbursement), and the Administrative Agent will
promptly pay to the Issuing Bank amounts so received by it from the Revolving Credit Lenders. The Administrative Agent will promptly pay to the Issuing Bank any amounts received by it from the Borrower pursuant to Section 2.23(e) prior to the
time that any Revolving Credit Lender makes any payment pursuant to this paragraph (f); any such amounts received by the Administrative Agent thereafter will be promptly remitted by the Administrative Agent to the Revolving Credit Lenders that shall
have made such payments and to the Issuing Bank, as their interests may appear. If any Revolving Credit Lender shall not have made its Pro Rata Percentage of such L/C Disbursement available to the Administrative Agent as provided above, such Lender
and the Borrower severally agree to pay interest on such amount, for each day from and including the date such amount is required to be paid in accordance with this paragraph to but excluding the date such amount is paid, to the Administrative Agent
for the account of the Issuing Bank at (i) in the case of the Borrower, a rate per annum equal to the interest rate applicable to Revolving Loans pursuant to Section 2.06(a), and (ii) in the case of such Lender, for the first such
day, the Federal Funds Effective Rate, and for each day thereafter, the Alternate Base Rate. 

 
 52
 
  

 SECTION 2.03.  Borrowing
Procedure.   In order to request a Borrowing (other than a deemed Borrowing pursuant to Section 2.02(f), as to which this Section 2.03 shall not apply), the Borrower shall notify the Administrative Agent of such
request by telephone (a) in the case of a Eurodollar Borrowing, not later than 12:00 (noon), New York City time, three Business Days before a proposed Borrowing, and (b) in the case of an ABR Borrowing, not later than 11:00 a.m.,
New York City time, on the day of a proposed Borrowing; provided that the request for the initial Borrowings of 2019 Term A Loans, 2017 Term E Loans and 2021 Term D Loans on the Third Restatement Effective Date may be made not later than
the time specified therefor by the Administrative Agent. Each such telephonic Borrowing Request shall be irrevocable, and shall be confirmed promptly by hand delivery or fax to the Administrative Agent of a written Borrowing Request and shall
specify the following information: (i) whether the Borrowing then being requested is to be a 2019 Term A Borrowing, a 2017 Term E Loan Borrowing, a 2021 Term D Borrowing, an Incremental Term Borrowing or a Revolving Credit Borrowing, and
whether such Borrowing is to be a Eurodollar Borrowing or an ABR Borrowing; (ii) the date of such Borrowing (which shall be a Business Day); (iii) the number and location of the account to which funds are to be disbursed; (iv) the
amount of such Borrowing; and (v) if such Borrowing is to be a Eurodollar Borrowing, the Interest Period with respect thereto; provided, however, that, notwithstanding any contrary specification in any Borrowing Request, each
requested Borrowing shall comply with the requirements set forth in Section 2.02. If no election as to the Type of Borrowing is specified in any such notice, then the requested Borrowing shall be an ABR Borrowing. If no Interest Period with
respect to any Eurodollar Borrowing is specified in any such notice, then the Borrower shall be deemed to have selected an Interest Period of one month’s duration. The Administrative Agent shall promptly advise the applicable Lenders of any
notice given pursuant to this Section 2.03 (and the contents thereof), and of each Lender’s portion of the requested Borrowing. 

SECTION 2.04.  Evidence of Debt; Repayment of Loans.    (a)  The Borrower hereby
unconditionally promises to pay to the Administrative Agent for the account of each Lender (i) the principal amount of each Term Loan of such Lender as provided in Section 2.11 and (ii) the then unpaid principal amount of each
Revolving Loan of such Lender on the Revolving Credit Maturity Date. 
 (b)  Each Lender shall
maintain in accordance with its usual practice an account or accounts evidencing the indebtedness of the Borrower to such Lender resulting from each Loan made by such Lender from time to time, including the amounts of principal and interest payable
and paid to such Lender from time to time under this Agreement. 
 (c)  The Administrative Agent
shall maintain accounts in which it will record (i) the amount of each Loan made hereunder, the Class and Type thereof and, if applicable, the Interest Period applicable thereto, (ii) the amount of any principal or interest due and payable
or to become due and payable from the Borrower to each Lender hereunder and (iii) the amount of any sum received by the Administrative Agent hereunder from the Borrower or any Guarantor and each Lender’s share thereof. 

 
 53
 
  

 (d)  The entries made in the accounts maintained
pursuant to paragraphs (b) and (c) above shall be prima facie evidence of the existence and amounts of the obligations therein recorded; provided, however, that the failure of any Lender or the Administrative Agent to
maintain such accounts or any error therein shall not in any manner affect the obligations of the Borrower to repay the Loans in accordance with their terms. 

(e)  Any Lender may request that Loans made by it hereunder be evidenced by a promissory note. In
such event, the Borrower shall execute and deliver to such Lender a promissory note payable to such Lender and its registered assigns and in a form and substance reasonably acceptable to the Administrative Agent and the Borrower. Notwithstanding any
other provision of this Agreement, in the event any Lender shall request and receive such a promissory note, the interests represented by such note shall at all times (including after any assignment of all or part of such interests pursuant to
Section 9.04) be represented by one or more promissory notes payable to the payee named therein or its registered assigns. 

SECTION 2.05.  Fees.   (a)  The Borrower agrees to pay to each Revolving
Credit Lender, through the Administrative Agent, on the last Business Day of March, June, September and December in each year and on each date on which any Revolving Credit Commitment of such Lender shall expire or be terminated as provided herein,
a commitment fee (a “Revolving Credit Commitment Fee”) equal to the Revolving Credit Commitment Fee Rate per annum on the daily unused amount of the Revolving Credit Commitment of such Lender during the preceding quarter (or
other period ending with the Revolving Credit Maturity Date or the date on which the Revolving Credit Commitments of such Lender shall expire or be terminated). All Commitment Fees shall be computed on the basis of the actual number of days elapsed
in a year of 360 days. 
 (b)  The Borrower agrees to pay to the Administrative Agent, for its own
account, the administrative fees set forth in the Fee Letter at the times and in the amounts specified therein (the “Administrative Agent Fees”). 

(c)  The Borrower agrees to pay (i) to each Revolving Credit Lender, through the Administrative
Agent, on the last Business Day of March, June, September and December of each year and on the date on which the Revolving Credit Commitment of such Lender shall be terminated as provided herein, a fee (an “L/C Participation
Fee”) calculated on such Lender’s Pro Rata Percentage of the daily aggregate L/C Exposure (excluding the portion thereof attributable to unreimbursed L/C Disbursements) during the preceding quarter (or shorter period ending with
the Revolving Credit Maturity Date or the date on which all Letters of Credit have been canceled or have expired and the Revolving Credit Commitments of all Lenders shall have been terminated) at a rate per annum equal to the Applicable Percentage
from time to time used to determine the interest rate on Revolving Credit Borrowings comprised of Eurodollar Loans pursuant to Section 2.06, and (ii) to the Issuing Bank with respect to each Letter of Credit the standard fronting, issuance and
drawing fees specified from time to 

 
 54
 
  

 
time by the Issuing Bank (the “Issuing Bank Fees”); provided that each such fronting fee charged from time to time shall not exceed 0.25% per annum of the
aggregate undrawn face amount of the then outstanding Letters of Credit. All L/C Participation Fees and Issuing Bank Fees shall be computed on the basis of the actual number of days elapsed in a year of 360 days. 

(d)  All Fees shall be paid on the dates due, in immediately available funds, to the Administrative
Agent for distribution, if and as appropriate, among the Lenders, except that the Issuing Bank Fees shall be paid directly to the Issuing Bank. Once paid, none of the Fees shall be refundable under any circumstances. 

SECTION 2.06.  Interest on
Loans.        (a)  Subject to the provisions of Section 2.07, the Loans comprising each ABR Borrowing shall bear interest (computed on the basis of the actual number of days elapsed
over a year of 365 or 366 days, as the case may be, when the Alternate Base Rate is determined by reference to the Prime Rate and over a year of 360 days at all other times and calculated from and including the date of such Borrowing to
but excluding the date of repayment thereof) at a rate per annum equal to the Alternate Base Rate plus the Applicable Percentage in effect from time to time. 

(b)  Subject to the provisions of Section 2.07, the Loans comprising each Eurodollar Borrowing
shall bear interest (computed on the basis of the actual number of days elapsed over a year of 360 days) at a rate per annum equal to the Adjusted LIBO Rate for the Interest Period in effect for such Borrowing plus the Applicable Percentage in
effect from time to time. 
 (c)  Interest on each Loan shall be payable on the Interest Payment
Dates applicable to such Loan except as otherwise provided in this Agreement. The applicable Alternate Base Rate or Adjusted LIBO Rate for each Interest Period or day within an Interest Period, as the case may be, shall be determined by the
Administrative Agent, and such determination shall be conclusive absent manifest error. 
 SECTION
2.07.  Default Interest.  If the Borrower shall default in the payment of any principal of or interest on any Loan or any other amount due hereunder, by acceleration or otherwise, or under any other Loan Document,
then, until such defaulted amount shall have been paid in full, to the extent permitted by law, such defaulted amount shall bear interest (after as well as before judgment), payable on demand, (a) in the case of principal, at the rate otherwise
applicable to such Loan pursuant to Section 2.06 plus 2.00% per annum and (b) in all other cases, at a rate per annum (computed on the basis of the actual number of days elapsed over a year of 365 or 366 days, as the case may be, when
determined by reference to the Prime Rate and over a year of 360 days at all other times) equal to the rate that would be applicable to an ABR Loan of the applicable Class plus 2.00% per annum. 

 
 55
 
  

 SECTION 2.08.  Alternate Rate of
Interest.  In the event, and on each occasion, that on the day two Business Days prior to the commencement of any Interest Period for a Eurodollar Borrowing the Administrative Agent shall have determined that dollar deposits in the
principal amounts of the Loans comprising such Borrowing are not generally available in the London interbank market, or that the rates at which such dollar deposits are being offered will not adequately and fairly reflect the cost to any Lender of
making or maintaining its Eurodollar Loan during such Interest Period, or that reasonable means do not exist for ascertaining the Adjusted LIBO Rate, the Administrative Agent shall, as soon as practicable thereafter, give written or fax notice of
such determination to the Borrower and the Lenders. In the event of any such determination, until the Administrative Agent shall have advised the Borrower and the Lenders that the circumstances giving rise to such notice no longer exist, any request
by the Borrower for a Eurodollar Borrowing pursuant to Section 2.03 or 2.10 shall be deemed to be a request for an ABR Borrowing. Each determination by the Administrative Agent under this Section 2.08 shall be conclusive absent
manifest error. 
 SECTION 2.09.  Termination and Reduction of
Commitments.      (a)  The Incremental Term Loan Commitments shall terminate as provided in the related Incremental Term Loan Assumption Agreement. The 2019 Term A Commitment of each 2019 Term A
Lender, the 2017 Term E Commitment of each 2017 Term E Lender and the 2021 Term D Commitment of each 2021 Term D Lender shall, in each case, terminate in accordance with the Third Amendment and Restatement Agreement. The Revolving Credit Commitments
shall automatically terminate on the Revolving Credit Maturity Date. The L/C Commitment shall automatically terminate on the earlier to occur of (i) the termination of the Revolving Credit Commitments and (ii) the date 10 Business Days
prior to the Revolving Credit Maturity Date. 
 (b)  Upon at least three Business Days’ prior
written or fax notice to the Administrative Agent, the Borrower may at any time in whole permanently terminate, or from time to time in part permanently reduce, the Revolving Credit Commitments; provided, however, that (i) each
partial reduction of the Revolving Credit Commitments shall be in an integral multiple of $1,000,000 and in a minimum amount of $3,000,000, and (ii) the Total Revolving Credit Commitment shall not be reduced to an amount that is less than the
Aggregate Revolving Credit Exposure at the time. Each notice delivered by the Borrower pursuant to this Section 2.09 shall be irrevocable; provided that a notice of termination of the Revolving Credit Commitments delivered by the
Borrower may state that such notice is conditioned upon the effectiveness of other credit facilities, indentures or similar agreements or any other event, in which case such notice may be revoked by the Borrower (by notice to the Administrative
Agent on or prior to the specified effective date) if such condition is not satisfied. 

(c)  Each reduction in the Revolving Credit Commitments hereunder shall be made ratably among the
Lenders in accordance with their respective applicable Commitments. The Borrower shall pay to the Administrative Agent for the account of the applicable Lenders, on the date of each termination or reduction, the Commitment Fees on the amount of the
Commitments so terminated or reduced accrued to but excluding the date of such termination or reduction. 

 
 56
 
  

 SECTION 2.10.  Conversion and Continuation of
Borrowings.   The Borrower shall have the right at any time upon prior irrevocable notice to the Administrative Agent (a) not later than 11:00 a.m., New York City time, on the date of conversion, to convert any
Eurodollar Borrowing into an ABR Borrowing, (b) not later than 12:00 (noon), New York City time, three Business Days prior to conversion or continuation, to convert any ABR Borrowing into a Eurodollar Borrowing or to continue any
Eurodollar Borrowing as a Eurodollar Borrowing for an additional Interest Period, and (c) not later than 12:00 (noon), New York City time, three Business Days prior to conversion, to convert the Interest Period with respect to any
Eurodollar Borrowing to another permissible Interest Period, subject in each case to the following: 

(i)  each conversion or continuation shall be made pro rata among the Lenders in accordance with the
respective principal amounts of the Loans comprising the converted or continued Borrowing; 

(ii)  if less than all the outstanding principal amount of any Borrowing shall be converted or
continued, then each resulting Borrowing shall satisfy the limitations specified in Sections 2.02(a) and 2.02(b) regarding the principal amount and maximum number of Borrowings of the relevant Type; 

(iii)  each conversion shall be effected by each Lender and the Administrative Agent by recording
for the account of such Lender the new Loan of such Lender resulting from such conversion and reducing the Loan (or portion thereof) of such Lender being converted by an equivalent principal amount; accrued interest on any Eurodollar Loan (or
portion thereof) being converted shall be paid by the Borrower at the time of conversion; 

(iv)  if any Eurodollar Borrowing is converted at a time other than the end of the Interest Period
applicable thereto, the Borrower shall pay, upon demand, any amounts due to the Lenders pursuant to Section 2.16; 

(v)  any portion of a Borrowing of any Loans maturing or required to be repaid in less than one
month may not be converted into or continued as a Eurodollar Borrowing; 
 (vi)  any portion of a
Eurodollar Borrowing that cannot be converted into or continued as a Eurodollar Borrowing by reason of the immediately preceding clause shall be automatically converted at the end of the Interest Period in effect for such Borrowing into an
ABR Borrowing; 
 (vii)  no Interest Period may be selected for any Eurodollar Term Borrowing
that would end later than a Repayment Date occurring on or after the first day of such Interest Period if, after giving effect to such selection, the aggregate outstanding amount of (A) the Eurodollar Term Borrowings comprised of 2017 Term E
Loans, 2019 Term A Loans, 2021 Term D Loans or Other Term 

 
 57
 
  

 
Loans, as applicable, with Interest Periods ending on or prior to such Repayment Date and (B) the ABR Term Borrowings comprised of 2017 Term E Loans, 2019 Term A Loans, 2021 Term D
Loans or Other Term Loans, as applicable, would not be at least equal to the principal amount of Term Borrowings to be paid on such Repayment Date; and 

(viii)  upon notice to the Borrower from the Administrative Agent given at the request of the
Required Lenders, after the occurrence and during the continuance of a Default or Event of Default, no outstanding Loan may be converted into, or continued as, a Eurodollar Loan. 

Each notice pursuant to this Section 2.10 shall be irrevocable and shall refer to this Agreement and specify (i) the
identity and amount of the Borrowing that the Borrower requests be converted or continued, (ii) whether such Borrowing is to be converted to or continued as a Eurodollar Borrowing or an ABR Borrowing, (iii) if such notice requests a
conversion, the date of such conversion (which shall be a Business Day) and (iv) if such Borrowing is to be converted to or continued as a Eurodollar Borrowing, the Interest Period with respect thereto. If no Interest Period is specified in any
such notice with respect to any conversion to or continuation as a Eurodollar Borrowing, then, the Borrower shall be deemed to have selected an Interest Period of one month’s duration. The Administrative Agent shall advise the Lenders of any
notice given pursuant to this Section 2.10 and of each Lender’s portion of any converted or continued Borrowing. If the Borrower shall not have given notice in accordance with this Section 2.10 to continue any Borrowing into a
subsequent Interest Period (and shall not otherwise have given notice in accordance with this Section 2.10 to convert such Borrowing), such Borrowing shall, at the end of the Interest Period applicable thereto (unless repaid pursuant to the
terms hereof), automatically be continued into an ABR Borrowing. 
 SECTION 2.11.  Repayment of Term
Borrowings.  (a)  (i) [reserved]. 
 (ii) [reserved]. 

(iii)  The Borrower shall pay to the Administrative Agent, for the account of the 2017 Term E Loan Lenders,
(A) on the last Business Day of each March, June, September and December, commencing with the last Business Day of March 2012 (each such date being called an “2017 Term E Loan Repayment Date”), a principal amount of the
2017 Term E Loans (as adjusted from time to time pursuant to Sections 2.12, 2.13(g) and 2.24(d)) equal to 0.25% of the aggregate principal amount of all 2017 Term E Loans outstanding on the Third Restatement Effective Date and (B) on the
2017 Term E Maturity Date, the aggregate principal amount of all 2017 Term E Loans outstanding on such date, together in each case with accrued and unpaid interest on the principal amount to be paid to but excluding the date of such payment. 

(iv) The Borrower shall pay to the Administrative Agent, for the account of the 2019 Term A Lenders on each date set
forth below (each such date being called a “2019 Term A Loan Repayment Date”), or if any such date is not a Business Day, on the next 

 
 58
 
  

 
preceding Business Day, a principal amount of the 2019 Term A Loans (as adjusted from time to time pursuant to Sections 2.12, 2.13(g) and 2.24(d)) equal to (x) the aggregate principal amount
of the 2019 Term A Loans outstanding on the Third Restatement Effective Date multiplied by (y) the percentage set forth below opposite such date, with the balance payable in full on the 2019 Term A Maturity Date (all such payments shall be
accompanied by accrued and unpaid interest on the principal amount to be paid to but excluding the date of such payment): 
  

			
	 Date
	  	 Amount

	 June 30, 2014
	  	1 2⁄3%
	 September 30, 2014
	  	1 2⁄3%
	 December 31, 2014
	  	1 2⁄3%
	 March 31, 2015
	  	2.50%
	 June 30, 2015
	  	2.50%
	 September 30, 2015
	  	2.50%
	 December 31, 2015
	  	2.50%
	 March 31, 2016
	  	2.50%
	 June 30, 2016
	  	2.50%
	 September 30, 2016
	  	2.50%
	 December 31, 2016
	  	2.50%
	 March 31, 2017
	  	3.75%
	 June 30, 2017
	  	3.75%
	 September 30, 2017
	  	3.75%
	 December 31, 2017
	  	3.75%
	 March 31, 2018
	  	15.0%
	 June 30, 2018
	  	15.0%
	 September 30, 2018
	  	15.0%

  
 (v)  The
Borrower shall pay to the Administrative Agent, for the account of the 2021 Term D Lenders, (A) on the last Business Day of each March, June, September and December, commencing with the last Business Day of March 2014 (each such date being
called a “2021 Term D Loan Repayment Date”), a principal amount of the 2021 Term D Loans (as adjusted from time to time pursuant to Sections 2.12, 2.13(g) and 2.24(d)) equal to 0.25% of the aggregate principal amount of
all 2021 Term D Loans outstanding on the Third Restatement Effective Date and (B) on the 2021 Term D Maturity Date, the aggregate principal amount of all 2021 Term D Loans outstanding on such date, together in each case with accrued and unpaid
interest on the principal amount to be paid to but excluding the date of such payment. 
 (vi)  The Borrower shall
pay to the Administrative Agent, for the account of the Incremental Term Lenders in respect of Incremental Term Loans incurred after the Third Restatement Effective Date, on each Incremental Term Loan Repayment Date, a principal amount of the Other
Term Loans (as adjusted from time to time pursuant to Sections 2.12, 2.13(g) and 2.24(d)) equal to the amount set forth for such date in the applicable Incremental Term Loan Assumption Agreement, together in each case with accrued and unpaid
interest on the principal amount to be paid to but excluding the date of such payment. 

 
 59
 
  

 (b) To the extent not previously paid, (i) all 2017 Term E Loans shall
be due and payable on the 2017 Term E Maturity Date, (ii) all 2019 Term A Loans shall be due and payable on the 2019 Term A Maturity Date, (iii) all 2021 Term D Loans shall be due and payable on the 2021 Term D Maturity Date and
(iv) all Other Term Loans shall be due and payable on the Incremental Term Loan Maturity Date applicable thereto, in each case together with accrued and unpaid interest on the principal amount to be paid to but excluding the date of payment.

 (c) All repayments pursuant to this Section 2.11 shall be subject to Section 2.16, but shall otherwise be
without premium or penalty. 
 SECTION 2.12.  Optional
Prepayment.   (a)  Subject to paragraph (d) below, the Borrower shall have the right at any time and from time to time to prepay any Borrowing, in whole or in part, upon at least three Business Days’ prior
written or fax notice (or telephone notice promptly confirmed by written or fax notice) in the case of Eurodollar Loans, or written or fax notice (or telephone notice promptly confirmed by written or fax notice) at least one Business Day prior to
the date of prepayment in the case of ABR Loans, to the Administrative Agent before 11:00 a.m., New York City time; provided, however, that each partial prepayment shall be in an amount that is an integral multiple of $1,000,000 and
not less than $3,000,000. 
 (b)  Optional prepayments of Term Loans shall be applied as directed
by the Borrower, and if no such direction is provided, pro rata against the remaining scheduled installments of principal due in respect of the Term Loans to be prepaid under Section 2.11. 

(c)  Each notice of prepayment shall specify the prepayment date and the principal amount of each
Borrowing (or portion thereof) to be prepaid, shall be irrevocable and shall commit the Borrower to prepay such Borrowing by the amount stated therein on the date stated therein; provided that a notice of prepayment may state that such notice
is conditioned upon the effectiveness of other credit facilities, indentures or similar agreements or any other event, in which case such notice may be revoked by the Borrower (by notice to the Administrative Agent on or prior to the specified
effective date) if such condition is not satisfied. All prepayments under this Section 2.12 shall be subject to Section 2.16 but otherwise without premium or penalty, except as expressly provided in Section 2.12(d). All prepayments
under this Section 2.12 (other than prepayments of ABR Revolving Loans that are not made in connection with the termination or permanent reduction of the Revolving Credit Commitments) shall be accompanied by accrued and unpaid interest on the
principal amount to be prepaid to but excluding the date of payment. 
 (d)  If, prior to the date
that is six months after the Third Restatement Effective Date, (i) all or any portion of the 2021 Term D Loans or the 2017 Term 

 
 60
 
  

 
E Loans are prepaid out of the proceeds of a substantially concurrent issuance or incurrence of secured term loans and the Effective Yield of such secured term loan financing is less than the
Effective Yield of the 2021 Term D Loans or the 2017 Term E Loans, as applicable, or (ii) a 2021 Term D Lender or 2017 Term E Lender must assign its 2021 Term D Loans or 2017 Term E Loans pursuant to Section 2.21 as a result of its failure
to consent to an amendment that would reduce the Effective Yield then in effect with respect to such 2021 Term D Loans or 2017 Term E Loans, as applicable, then in each case the aggregate principal amount so prepaid or assigned will be subject to a
fee payable by the Borrower, in each case equal to 1.0% of the principal amount thereof; provided that this Section 2.12(d) shall not apply to any prepayment of the 2021 Term D Loans or the 2017 Term E Loans upon the occurrence of a
Change in Control. 
 SECTION 2.13.  Mandatory Prepayments.  (a)  In the event
of any termination of all the Revolving Credit Commitments, the Borrower shall, on the date of such termination, repay or prepay all its outstanding Revolving Credit Borrowings and replace or cause to be canceled (or make other arrangements
satisfactory to the Administrative Agent and the Issuing Bank with respect to) all outstanding Letters of Credit. If, after giving effect to any partial reduction of the Revolving Credit Commitments or at any other time, the Aggregate Revolving
Credit Exposure would exceed the Total Revolving Credit Commitment, then the Borrower shall, on the date of such reduction or at such other time, repay or prepay Revolving Credit Borrowings and, after the Revolving Credit Borrowings shall have been
repaid or prepaid in full, replace or cause to be canceled (or make other arrangements satisfactory to the Administrative Agent and the Issuing Bank with respect to) Letters of Credit in an amount sufficient to eliminate such excess. 

(b)  Not later than the fifth Business Day after the earlier of (i) the receipt of aggregate
Net Cash Proceeds in respect of Asset Sales (other than, for the avoidance of doubt, sales of Receivables in a Permitted Receivables Transaction) in excess of $50,000,000 and (ii) the first anniversary of the Borrower’s most recent
prepayment pursuant to this Section 2.13(b), the Borrower shall apply 100% of the Net Cash Proceeds in excess of $50,000,000 for any fiscal year so received (and not yet used to prepay Term Loans pursuant to this Section 2.13(b)) to prepay
outstanding Term Loans in accordance with Section 2.13(g); provided that the Borrower may use a portion of such Net Cash Proceeds to prepay or repurchase Other Senior Secured Debt to the extent any applicable credit agreement, indenture
or other agreement governing such Other Senior Secured Debt requires the Borrower to prepay or make an offer to purchase such Other Senior Secured Debt with the proceeds of such Asset Sale, in each case in an amount not to exceed the product of
(A) the amount of such Net Cash Proceeds and (B) a fraction, the numerator of which is the outstanding principal amount of such Other Senior Secured Debt and the denominator of which is the sum of the outstanding principal amount of such
Other Senior Secured Debt and the outstanding principal amount of Term Loans. 
 (c)  No later
than 95 days after the end of each fiscal year of the Borrower, the Borrower shall prepay outstanding Term Loans in accordance with 

 
 61
 
  

 
Section 2.13(g) in an aggregate principal amount equal to (x) 50% of Excess Cash Flow for the fiscal year then ended minus (y) Voluntary Prepayments made during such fiscal
year; provided that such percentage shall be reduced to 25% if the Leverage Ratio as of the end of such fiscal year was less than 4.50 to 1.00 but equal to or greater than 3.50 to 1.00 and such percentage shall be reduced to zero (i.e., no
payments shall be required pursuant to this Section 2.13(c)) if the Leverage Ratio as of the end of such fiscal year was less than 3.50 to 1.00. 

(d)  In the event that Parent or any of its subsidiaries shall receive Net Cash Proceeds from the
issuance or incurrence of Indebtedness for money borrowed (other than any cash proceeds from the issuance of Indebtedness for money borrowed permitted pursuant to Section 6.01), the Borrower shall, substantially simultaneously with (and in any
event not later than the fifth Business Day next following) the receipt of such Net Cash Proceeds by Parent or such subsidiary, apply an amount equal to 100% of such Net Cash Proceeds to prepay outstanding Term Loans in accordance with
Section 2.13(g). 
 (e)  [Intentionally Omitted]. 

(f)  Notwithstanding the foregoing, any Term Lender may elect, by written notice delivered to the
Administrative Agent not later than 5:00 p.m. New York City time one Business Day after the date of such Lender’s receipt of notice regarding such prepayment (or, if different, at the time and in the manner otherwise specified by the
Administrative Agent in such notice of prepayment), to decline all (but not less than all) of any mandatory prepayment of its Term Loans pursuant to this Section 2.13 (such declined amounts, the “Declined Proceeds”). To
the extent Term Lenders elect to decline their pro rata shares of such Declined Proceeds, such remaining Declined Proceeds may be retained by the Borrower. 

(g)  Mandatory prepayments of outstanding Term Loans under this Agreement shall be allocated pro
rata among the 2017 Term E Loans, the 2019 Term A Loans, the 2021 Term D Loans and the Other Term Loans and first applied in order of maturity of the scheduled installments of principal due in respect of the 2017 Term E Loans, the 2019 Term A Loans,
the 2021 Term D Loans and the Other Term Loans under Sections 2.11(a), (iii), (iv), (v) and (vi) for the first eight installments following such mandatory prepayment (commencing with the first such scheduled installment pursuant to
Sections 2.11(a), (iii), (iv), (v) and (vi)) and, if applicable, thereafter applied pro rata against the remaining scheduled installments of principal due in respect of the 2017 Term E Loans, the 2019 Term A Loans, the 2021 Term D Loans
and the Other Term Loans under Sections 2.11(a)(iii), (iv), (v) and (vi), respectively. The amount of any mandatory prepayment in respect of Term Loans of any Class shall be applied first to Term Loans of such Class that are ABR Loans to
the full extent thereof before application to Term Loans of such Class that are Eurodollar Loans, in a manner that minimizes the amount of any payments required to be made by the Borrower pursuant to Section 2.16. Notwithstanding the foregoing

 
 62
 
  

 
provisions of this Section 2.13(g), the proceeds of any Pari Passu Debt shall not be required to be applied to prepay 2019 Term A Loans or 2021 Term D Loans until the 2017 Term E Loans have
been repaid in full and until such time any such proceeds shall be allocated to the payment of Term Loans in accordance with the foregoing provisions of this Section 2.13(g) as if no such 2019 Term A Loans and 2021 Term D Loans were
outstanding. From and after the time that the 2017 Term E Loans are no longer outstanding, the proceeds of any Pari Passu Debt shall be applied in accordance with this Section 2.13(g) without giving effect to the prior sentence of this
Section 2.13(g). 
 (h)  The Borrower shall deliver to the Administrative Agent, at the time
of each prepayment required under this Section 2.13(b), (c) or (d), as applicable, (i) a certificate signed by a Financial Officer of the Borrower setting forth in reasonable detail the calculation of the amount of such prepayment and
(ii) to the extent practicable, at least two days prior written notice of such prepayment. Each notice of prepayment shall specify the prepayment date, the Type of each Loan being prepaid and the principal amount of each Loan (or portion
thereof) to be prepaid. All prepayments of Borrowings under this Section 2.13 shall be subject to Section 2.16, but shall otherwise be without premium or penalty, and shall be accompanied by accrued and unpaid interest on the principal
amount to be prepaid to but excluding the date of payment (which interest amounts shall reduce the amount of Net Cash Proceeds required to be applied to prepay the Loans). 

SECTION 2.14.  Reserve Requirements; Change in
Circumstances.        (a)  Notwithstanding any other provision of this Agreement, if any Change in Law shall impose, modify or deem applicable any reserve, special deposit or similar
requirement against assets of, deposits with or for the account of or credit extended by any Lender or the Issuing Bank (except any such reserve requirement which is reflected in the Adjusted LIBO Rate) or shall impose on such Lender or the Issuing
Bank or the London interbank market any other condition affecting this Agreement or Eurodollar Loans made by such Lender or any Letter of Credit or participation therein, and the result of any of the foregoing shall be to increase the cost to such
Lender or the Issuing Bank of making or maintaining any Eurodollar Loan or increase the cost to any Lender of issuing or maintaining any Letter of Credit or purchasing or maintaining a participation therein or to reduce the amount of any sum
received or receivable by such Lender or the Issuing Bank hereunder (whether of principal, interest or otherwise) by an amount deemed by such Lender or the Issuing Bank to be material, then the Borrower will pay to such Lender or the Issuing Bank,
as the case may be, from time to time such additional amount or amounts as will compensate such Lender or the Issuing Bank, as the case may be, for such additional costs incurred or reduction suffered. 

(b)  If any Lender or the Issuing Bank shall have determined that any Change in Law regarding
capital adequacy or liquidity has or would have the effect of reducing the rate of return on such Lender’s or the Issuing Bank’s capital or on the capital of such Lender’s or the Issuing Bank’s holding company, if any, as a
consequence of this Agreement or the Loans made or participations 

 
 63
 
  

 
in Letters of Credit purchased by such Lender pursuant hereto or the Letters of Credit issued by the Issuing Bank pursuant hereto to a level below that which such Lender or the Issuing Bank or
such Lender’s or the Issuing Bank’s holding company could have achieved but for such Change in Law (taking into consideration such Lender’s or the Issuing Bank’s policies and the policies of such Lender’s or the Issuing
Bank’s holding company with respect to capital adequacy or liquidity) by an amount deemed by such Lender or the Issuing Bank to be material, then from time to time the Borrower shall pay to such Lender or the Issuing Bank, as the case may be,
such additional amount or amounts as will compensate such Lender or the Issuing Bank or such Lender’s or the Issuing Bank’s holding company for any such reduction suffered. 

(c)  A certificate of a Lender or the Issuing Bank setting forth the amount or amounts necessary to
compensate such Lender or the Issuing Bank or its holding company, as applicable, as specified in paragraph (a) or (b) above shall be delivered to the Borrower and shall be conclusive absent manifest error. The Borrower shall pay such
Lender or the Issuing Bank the amount shown as due on any such certificate delivered by it within 30 days after its receipt of the same. 

(d)  Failure or delay on the part of any Lender or the Issuing Bank to demand compensation for any
increased costs or reduction in amounts received or receivable or reduction in return on capital shall not constitute a waiver of such Lender’s or the Issuing Bank’s right to demand such compensation; provided that the Borrower
shall not be under any obligation to compensate any Lender or the Issuing Bank under paragraph (a) or (b) above with respect to increased costs or reductions with respect to any period prior to the date that is 120 days prior to such
request if such Lender or the Issuing Bank knew or could reasonably have been expected to know of the circumstances giving rise to such increased costs or reductions and of the fact that such circumstances would result in a claim for increased
compensation by reason of such increased costs or reductions; provided further that the foregoing limitation shall not apply to any increased costs or reductions arising out of the retroactive application of any Change in Law within such
120-day period. The protection of this Section shall be available to each Lender and the Issuing Bank regardless of any possible contention of the invalidity or inapplicability of the Change in Law that shall have occurred or been imposed. 

SECTION 2.15.  Change in Legality.  (a)  Notwithstanding any other provision of
this Agreement, if any Change in Law shall make it unlawful for any Lender to make or maintain any Eurodollar Loan or to give effect to its obligations as contemplated hereby with respect to any Eurodollar Loan, then, by written notice to the
Borrower and to the Administrative Agent: 
 (i) such Lender may declare that Eurodollar Loans will not
thereafter (for the duration of such unlawfulness) be made by such Lender hereunder (or be continued for additional Interest Periods) and ABR Loans will not thereafter (for such duration) be converted into

 
 64
 
  

 
Eurodollar Loans, whereupon any request for a Eurodollar Borrowing (or to convert an ABR Borrowing to a Eurodollar Borrowing or to continue a Eurodollar Borrowing for an additional Interest
Period) shall, as to such Lender only, be deemed a request for an ABR Loan (or a request to continue an ABR Loan as such for an additional Interest Period or to convert a Eurodollar Loan into an ABR Loan, as the case may be), unless such declaration
shall be subsequently withdrawn; and 
 (ii) such Lender may require that all outstanding Eurodollar Loans
made by it be converted to ABR Loans, in which event all such Eurodollar Loans shall be automatically converted to ABR Loans as of the effective date of such notice as provided in paragraph (b) below. 

In the event any Lender shall exercise its rights under (i) or (ii) above, all payments and prepayments of principal that would
otherwise have been applied to repay the Eurodollar Loans that would have been made by such Lender or the converted Eurodollar Loans of such Lender shall instead be applied to repay the ABR Loans made by such Lender in lieu of, or resulting from the
conversion of, such Eurodollar Loans. 
 (b)  For purposes of this Section 2.15, a notice to
the Borrower by any Lender shall be effective as to each Eurodollar Loan made by such Lender, if lawful, on the last day of the Interest Period then applicable to such Eurodollar Loan; in all other cases such notice shall be effective on the date of
receipt by the Borrower. 
 SECTION 2.16.  Indemnity.   The Borrower shall indemnify
each Lender against any loss or expense (but not against any lost profits) that such Lender may sustain or incur as a consequence of (a) any event, other than a default by such Lender in the performance of its obligations hereunder, which
results in (i) such Lender receiving or being deemed to receive any amount on account of the principal of any Eurodollar Loan prior to the end of the Interest Period in effect therefor, (ii) the conversion of any Eurodollar Loan to an ABR
Loan, or the conversion of the Interest Period with respect to any Eurodollar Loan, in each case other than on the last day of the Interest Period in effect therefor, or (iii) any Eurodollar Loan to be made by such Lender (including any
Eurodollar Loan to be made pursuant to a conversion or continuation under Section 2.10) not being made after notice of such Loan shall have been given by the Borrower hereunder (any of the events referred to in this clause (a) being called
a “Breakage Event”) or (b) any default in the making of any payment or prepayment of any Eurodollar Loan required to be made hereunder. In the case of any Breakage Event, such loss shall include an amount equal to the
excess, as reasonably determined by such Lender, of (i) its cost of obtaining funds for the Eurodollar Loan that is the subject of such Breakage Event for the period from the date of such Breakage Event to the last day of the Interest Period in
effect (or that would have been in effect) for such Loan over (ii) the amount of interest likely to be realized by such Lender in redeploying the funds released or not utilized by reason of such Breakage Event for such period. A certificate of
any Lender setting forth any amount or amounts which such Lender is entitled to receive pursuant to this Section 2.16 shall be delivered to the Borrower and shall be conclusive absent manifest error. 

 
 65
 
  

 SECTION 2.17.  Pro Rata
Treatment.   Except as required under Section 2.13(f) or 2.15, each Borrowing, each payment or prepayment of principal of any Borrowing, each payment of interest on the Loans, each payment of the Commitment Fees, each
reduction of the Term Loan Commitments or the Revolving Credit Commitments and each conversion of any Borrowing to or continuation of any Borrowing as a Borrowing of any Type shall be allocated pro rata among the Lenders in accordance with their
respective applicable Commitments (or, if such Commitments shall have expired or been terminated, in accordance with the respective principal amounts of their outstanding Loans). Each Lender agrees that in computing such Lender’s portion of any
Borrowing to be made hereunder, the Administrative Agent may, in its discretion, round each Lender’s percentage of such Borrowing to the next higher or lower whole dollar amount. 

SECTION 2.18.  Sharing of Setoffs.   Each Lender agrees that if it shall, through the
exercise of a right of banker’s lien, setoff or counterclaim against the Borrower or any other Loan Party, or pursuant to a secured claim under Section 506 of Title 11 of the United States Code or other security or interest arising
from, or in lieu of, such secured claim, received by such Lender under any applicable bankruptcy, insolvency or other similar law or otherwise, or by any other means (excluding means expressly contemplated elsewhere in this Agreement), obtain
payment (voluntary or involuntary) in respect of any Loan or Loans or L/C Disbursement as a result of which the unpaid principal portion of its Loans and participations in L/C Disbursements shall be proportionately less than the unpaid principal
portion of the Loans and participations in L/C Disbursements of any other Lender, it shall be deemed simultaneously to have purchased from such other Lender at face value, and shall promptly pay to such other Lender the purchase price for, a
participation in the Loans and L/C Exposure of such other Lender, so that the aggregate unpaid principal amount of the Loans and L/C Exposure and participations in Loans and L/C Exposure held by each Lender shall be in the same proportion to the
aggregate unpaid principal amount of all Loans and L/C Exposure then outstanding as the principal amount of its Loans and L/C Exposure prior to such exercise of banker’s lien, setoff or counterclaim or other event was to the principal amount of
all Loans and L/C Exposure outstanding prior to such exercise of banker’s lien, setoff or counterclaim or other event; provided, however, that if any such purchase or purchases or adjustments shall be made pursuant to this
Section 2.18 and the payment giving rise thereto shall thereafter be recovered, such purchase or purchases or adjustments shall be rescinded to the extent of such recovery and the purchase price or prices or adjustment restored without
interest. The Borrower and Parent expressly consent to the foregoing arrangements and agree that any Lender holding a participation in a Loan or L/C Disbursement deemed to have been so purchased may exercise any and all rights of banker’s lien,
setoff or counterclaim with respect to any and all moneys owing by the Borrower and Parent to such Lender by reason thereof as fully as if such Lender had made a Loan directly to the Borrower in the amount of such participation. 

SECTION 2.19.  Payments.        (a)  The Borrower
shall make each payment (including principal of or interest on any Borrowing or any L/C Disbursement or any 

 
 66
 
  

 
Fees or other amounts) hereunder and under any other Loan Document not later than 1:00 p.m., New York City time, on the date when due in immediately available dollars, without setoff,
defense or counterclaim. Each such payment (other than Issuing Bank Fees, which shall be paid directly to the Issuing Bank) shall be made to the Administrative Agent at its offices at Eleven Madison Avenue, New York, NY 10010. The Administrative
Agent shall promptly distribute to each Lender any payments received by the Administrative Agent on behalf of such Lender. 

(b)  Except as otherwise expressly provided herein, whenever any payment (including principal of or
interest on any Borrowing or any Fees or other amounts) hereunder or under any other Loan Document shall become due, or otherwise would occur, on a day that is not a Business Day, such payment may be made on the next succeeding Business Day, and
such extension of time shall in such case be included in the computation of interest or Fees, if applicable. 

(c)  Unless the Administrative Agent shall have received notice from the Borrower prior to the date
on which any payment is due to the Administrative Agent for the account of the Lenders or the Issuing Bank hereunder that the Borrower will not make such payment, the Administrative Agent may assume that the Borrower has made such payment on such
date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the Issuing Bank, as the case may be, the amount due. In such event, if the Borrower does not in fact make such payment, then each of the Lenders or
the Issuing Bank, as the case may be, severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to such Lender, and to pay interest thereon, for each day from and including the date such amount is
distributed to it to but excluding the date of payment to the Administrative Agent, at a rate determined by the Administrative Agent to represent its cost of overnight or short-term funds (which determination shall be conclusive absent manifest
error). 
 SECTION 2.20.  Taxes.   (a)  Any and all payments by or on
account of any obligation of the Borrower or any other Loan Party hereunder or under any other Loan Document shall be made free and clear of and without deduction for any Indemnified Taxes or Other Taxes; provided that, if the Borrower or any
other Loan Party shall be required to deduct any Indemnified Taxes or Other Taxes from such payments, then (i) the sum payable shall be increased as necessary so that after making all required deductions (including deductions applicable to
additional sums payable under this Section) the Administrative Agent, Lender or Issuing Bank (as the case may be) receives an amount equal to the sum it would have received had no such deductions been made, (ii) the Borrower or such Loan Party
shall make such deductions and (iii) the Borrower or such Loan Party shall pay the full amount deducted to the relevant Governmental Authority in accordance with applicable law. 

(b)  In addition, the Borrower shall pay any Other Taxes to the relevant Governmental Authority in
accordance with applicable law. 

 
 67
 
  

 (c)  The Borrower shall indemnify the
Administrative Agent, each Lender and the Issuing Bank, within 10 days after written demand therefor, for the full amount of any Indemnified Taxes or Other Taxes paid by the Administrative Agent, such Lender or the Issuing Bank, as the case may be,
on or with respect to any payment by or on account of any obligation of the Borrower or any other Loan Party hereunder or under any other Loan Document (including Indemnified Taxes or Other Taxes imposed or asserted on or attributable to amounts
payable under this Section) and any penalties, interest and reasonable expenses arising therefrom or with respect thereto; provided that the Borrower shall not be obligated to so indemnify any Lender, the Administrative Agent or the Issuing
Bank in respect of interest or penalties attributable to any Indemnified Taxes or Other Taxes to the extent that such interest or penalties resulted solely from the gross negligence or willful misconduct of the Administrative Agent or such Lender or
the Issuing Bank. A certificate as to the amount of such payment or liability delivered to the Borrower by a Lender or the Issuing Bank, or by the Administrative Agent on behalf of itself, a Lender or the Issuing Bank, shall be conclusive absent
manifest error. 
 (d)  As soon as practicable after any payment of Indemnified Taxes or Other
Taxes by the Borrower or any other Loan Party to a Governmental Authority, the Borrower shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of
the return reporting such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent. 

(e)  (i) Any Foreign Lender that is entitled to an exemption from or reduction of withholding
tax under the law of the jurisdiction in which the Borrower is located, or any treaty to which such jurisdiction is a party, with respect to payments under this Agreement shall deliver to the Borrower (with a copy to the Administrative Agent), at
the time or times prescribed by applicable law, such properly completed and executed documentation prescribed by applicable law or reasonably requested by the Borrower as will permit such payments to be made without withholding or at a reduced rate.

 (ii) If a payment made to a Lender or Issuing Bank under this Agreement or any Loan Document would be subject to U.S.
Federal withholding Tax imposed by FATCA if such Lender or Issuing Bank were to fail to comply with the applicable reporting requirements of FATCA (including those contained in Section 1471(b) or 1472((b) of the Code, as applicable), such
Lender or Issuing Bank shall deliver to the Withholding Agent, at the time or times prescribed by law and at such other time or times reasonably requested by the Withholding Agent, such documentation prescribed by applicable law (including as
prescribed by Section 1471(b)(3)(C)(i) of the Code) and such additional documentation reasonably requested by the Withholding Agent as may be necessary for the Withholding Agent to comply with its obligations under FATCA, to determine that such
Lender or Issuing Bank has complied with such Lender or Issuing Bank’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. 

 
 68
 
  

 (f)  Each Lender shall severally indemnify the
Administrative Agent, within 10 days after demand therefor, for (i) any Indemnified Taxes attributable to such Lender (but only to the extent that the Borrower has not already indemnified the Administrative Agent for such Indemnified Taxes and
without limiting the obligation of the Borrower to do so) and (ii) any Excluded Taxes attributable to such Lender, in each case, that are payable or paid by the Administrative Agent in connection with any Loan Document, and any reasonable
expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority; provided, that this paragraph (f) shall not create any additional
obligation of the Borrower hereunder. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender hereby authorizes the Administrative Agent
to set off and apply any and all amounts at any time owing to such Lender under any Loan Document or otherwise payable by the Administrative Agent to the Lender from any other source against any amount due to the Administrative Agent under this
paragraph (f). 
 SECTION 2.21.   Assignment of Commitments Under Certain Circumstances; Duty to
Mitigate.   (a)  In the event (i) any Lender or the Issuing Bank delivers a certificate requesting compensation pursuant to Section 2.14, (ii) any Lender or the Issuing Bank delivers a notice described in
Section 2.15, (iii) the Borrower is required to pay any additional amount to any Lender or the Issuing Bank or any Governmental Authority on account of any Lender or the Issuing Bank pursuant to Section 2.20, (iv) any Lender
refuses to consent to any amendment, waiver or other modification of any Loan Document requested by the Borrower that requires the consent of a greater percentage of the Lenders than the Required Lenders and such amendment, waiver or other
modification is consented to by the Required Lenders, (v) any Lender refuses to consent to any Loan Modification Offer, and such Loan Modification Offer is consented to by Lenders holding a majority in interest of the Affected Class or
(vi) any Lender becomes a Defaulting Lender, then, in each case, the Borrower may, at its sole expense and effort (including with respect to the processing and recordation fee referred to in Section 9.04(b)), upon notice to such Lender or
the Issuing Bank, as the case may be, and the Administrative Agent, require such Lender or the Issuing Bank to transfer and assign, without recourse (in accordance with and subject to the restrictions contained in Section 9.04), all of its
interests, rights and obligations under this Agreement (or, in the case of clause (iv), (v) or (vi) above, all of its interests, rights and obligations with respect to the Class of Loans or Commitments that is the subject of the related
consent, amendment, waiver or other modification or in respect of which such Lender is a Defaulting Lender, as the case may be) to an Eligible Assignee that shall assume such assigned obligations and, with respect to clause (iv) or
(v) above, shall consent to such requested amendment, waiver or other modification of any Loan Document (which Eligible Assignee may be another Lender, if a Lender accepts such assignment); provided that (x) such assignment shall
not conflict with any law, rule or regulation or order of any court or other Governmental Authority having jurisdiction, (y) the Borrower shall have received the prior written consent of the Administrative Agent (and, if a Revolving Credit
Commitment is being assigned, of the Issuing Bank), which consents shall not 

 
 69
 
  

 
unreasonably be withheld or delayed, and (z) the Borrower or such Eligible Assignee shall have paid to the affected Lender or the Issuing Bank in immediately available funds an amount equal
to the sum of the principal of and interest accrued to the date of such payment on the outstanding Loans or L/C Disbursements of such Lender or the Issuing Bank, respectively, plus all Fees (except, in the case of a Defaulting Lender, any Fees not
required to be paid to such Defaulting Lender pursuant to the express provisions of this Agreement) and other amounts accrued for the account of such Lender or the Issuing Bank hereunder with respect thereto (including any amounts under
Sections 2.14 and 2.16); provided further that, if prior to any such transfer and assignment the circumstances or event that resulted in such Lender’s or the Issuing Bank’s claim for compensation under Section 2.14, notice
under Section 2.15 or the amounts paid pursuant to Section 2.20, as the case may be, cease to cause such Lender or the Issuing Bank to suffer increased costs or reductions in amounts received or receivable or reduction in return on
capital, or cease to have the consequences specified in Section 2.15, or cease to result in amounts being payable under Section 2.20, as the case may be (including as a result of any action taken by such Lender or the Issuing Bank pursuant
to paragraph (b) below), or if such Lender or the Issuing Bank shall waive its right to claim further compensation under Section 2.14 in respect of such circumstances or event or shall withdraw its notice under Section 2.15 or shall
waive its right to further payments under Section 2.20 in respect of such circumstances or event or shall consent to the proposed amendment, waiver, consent or other modification or shall cease to be a Defaulting Lender, as the case may be,
then such Lender or the Issuing Bank shall not thereafter be required to make any such transfer and assignment hereunder. Each Lender hereby grants to the Administrative Agent an irrevocable power of attorney (which power is coupled with an
interest) to execute and deliver, on behalf of such Lender as assignor, any Assignment and Acceptance necessary to effectuate any assignment of such Lender’s interests hereunder in the circumstances contemplated by this Section 2.21(a).

 (b)  If (i) any Lender or the Issuing Bank shall request compensation under
Section 2.14, (ii) any Lender or the Issuing Bank delivers a notice described in Section 2.15 or (iii) the Borrower is required to pay any additional amount to any Lender or the Issuing Bank or any Governmental Authority on
account of any Lender or the Issuing Bank, pursuant to Section 2.20, then such Lender or the Issuing Bank shall use reasonable efforts (which shall not require such Lender or the Issuing Bank to incur an unreimbursed loss or unreimbursed cost
or expense or otherwise take any action inconsistent with its internal policies or legal or regulatory restrictions or suffer any disadvantage or burden deemed by it to be significant) (x) to file any certificate or document reasonably
requested in writing by the Borrower or (y) to assign its rights and delegate and transfer its obligations hereunder to another of its offices, branches or affiliates, if such filing or assignment would reduce its claims for compensation under
Section 2.14 or enable it to withdraw its notice pursuant to Section 2.15 or would reduce amounts payable pursuant to Section 2.20, as the case may be, in the future. The Borrower hereby agrees to pay all reasonable costs and expenses
incurred by any Lender or the Issuing Bank in connection with any such filing or assignment, delegation and transfer. 

 
 70
 
  

 SECTION 2.22.   Reserved. 

SECTION 2.23.  Letters of
Credit.      (a)  General.    Subject to the terms and conditions herein set forth, the Borrower may request the issuance of a Letter of Credit for its own account or for the
account of any of the Subsidiaries (in which case the Borrower and such Subsidiary shall be co-applicants with respect to such Letter of Credit), in a form reasonably acceptable to the Administrative Agent and the Issuing Bank, at any time and from
time to time while the L/C Commitment remains in effect. This Section shall not be construed to impose an obligation upon the Issuing Bank to issue any Letter of Credit that is inconsistent with the terms and conditions of this Agreement.
Notwithstanding anything to the contrary contained in this Section 2.23 or elsewhere in this Agreement, (i) in the event that a Revolving Credit Lender is a Defaulting Lender, no Issuing Bank shall be required to issue any Letter of Credit
unless such Issuing Bank has entered into arrangements reasonably satisfactory to it and the Borrower to eliminate such Issuing Bank’s risk with respect to the participation in Letters of Credit by all such Defaulting Lenders, including by cash
collateralizing each such Defaulting Lender’s Pro Rata Percentage of the applicable L/C Exposure, and (ii) if agreed to between the Borrower and any Issuing Bank in writing, the obligation of such Issuing Bank (and its Affiliates) to
issue, extend or renew any Letters of Credit under this Agreement may be terminated (in whole or in part) as provided therein. 

(b)  Notice of Issuance, Amendment, Renewal, Extension; Certain
Conditions.    In order to request the issuance of a Letter of Credit (or to amend, renew or extend an existing Letter of Credit), the Borrower shall hand deliver or fax to the Issuing Bank and the Administrative Agent
(reasonably in advance of the requested date of issuance, amendment, renewal or extension) a notice requesting the issuance of a Letter of Credit, or identifying the Letter of Credit to be amended, renewed or extended, the date of issuance,
amendment, renewal or extension, the date on which such Letter of Credit is to expire (which shall comply with paragraph (c) below), the amount of such Letter of Credit, the name and address of the beneficiary thereof and such other information
as shall be necessary to prepare such Letter of Credit. A Letter of Credit shall be issued, amended, renewed or extended only if, and upon issuance, amendment, renewal or extension of each Letter of Credit the Borrower shall be deemed to represent
and warrant that, after giving effect to such issuance, amendment, renewal or extension (i) the L/C Exposure shall not exceed $150,000,000 and (ii) the Aggregate Revolving Credit Exposure shall not exceed the Total Revolving Credit
Commitment. 
 (c)  Expiration Date.    Each Letter of Credit
shall expire at the close of business on the earlier of the date one year after the date of the issuance of such Letter of Credit and the date that is five Business Days prior to the Revolving Credit Maturity Date, unless such Letter of Credit
expires by its terms on an earlier date; provided, however, that a Letter of Credit may, upon the request of the Borrower, include a provision whereby such Letter of Credit shall be renewed automatically for additional consecutive
periods of 12 months or less (but not beyond the date that is five Business Days prior to the Revolving Credit 

 
 71
 
  

 
Maturity Date) unless the Issuing Bank notifies the beneficiary thereof at least 30 days (or such longer period as may be specified in such Letter of Credit) prior to the then-applicable
expiration date that such Letter of Credit will not be renewed. 

(d)  Participations.  By the issuance of a Letter of Credit and without any
further action on the part of the Issuing Bank or the Lenders, the Issuing Bank hereby grants to each Revolving Credit Lender, and each such Lender hereby acquires from the Issuing Bank, a participation in such Letter of Credit equal to such
Lender’s Pro Rata Percentage of the aggregate amount available to be drawn under such Letter of Credit, effective upon the issuance of such Letter of Credit or, in the case of the Existing Letters of Credit, effective upon the Third Restatement
Effective Date. In consideration and in furtherance of the foregoing, each Revolving Credit Lender hereby absolutely and unconditionally agrees to pay to the Administrative Agent, for the account of the Issuing Bank, such Lender’s Pro Rata
Percentage of each L/C Disbursement made by the Issuing Bank and not reimbursed by the Borrower (or, if applicable, another party pursuant to its obligations under any other Loan Document) forthwith on the date due as provided in
Section 2.02(f). Each Revolving Credit Lender acknowledges and agrees that its obligation to acquire participations pursuant to this paragraph in respect of Letters of Credit is absolute and unconditional and shall not be affected by any
circumstance whatsoever, including the occurrence and continuance of a Default or an Event of Default, and that each such payment shall be made without any offset, abatement, withholding or reduction whatsoever. 

(e)  Reimbursement.      If the Issuing Bank shall make
any L/C Disbursement in respect of a Letter of Credit, the Borrower shall pay to the Administrative Agent an amount equal to such L/C Disbursement not later than 1:00 p.m., New York City time, on the immediately following Business Day after the
Issuing Bank notifies the Borrower thereof. 
 (f)  Obligations
Absolute.    The Borrower’s obligations to reimburse L/C Disbursements as provided in paragraph (e) above shall be absolute, unconditional and irrevocable, and shall be performed strictly in accordance with the
terms of this Agreement, under any and all circumstances whatsoever, and irrespective of: 
 (i) any lack
of validity or enforceability of any Letter of Credit or any Loan Document, or any term or provision therein; 

(ii) any amendment or waiver of or any consent to departure from all or any of the provisions of any Letter
of Credit or any Loan Document; 
 (iii) the existence of any claim, setoff, defense or other right that
the Borrower, any other party guaranteeing, or otherwise obligated with, 

 
 72
 
  

 
the Borrower, any Subsidiary or other Affiliate thereof or any other person may at any time have against the beneficiary under any Letter of Credit, the Issuing Bank, the Administrative Agent or
any Lender or any other person, whether in connection with this Agreement, any other Loan Document or any other related or unrelated agreement or transaction; 

(iv) any draft or other document presented under a Letter of Credit proving to be forged, fraudulent, invalid
or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; 
 (v)
payment by the Issuing Bank under a Letter of Credit against presentation of a draft or other document that does not comply with the terms of such Letter of Credit; and 

(vi) any other act or omission to act or delay of any kind of the Issuing Bank, the Lenders, the
Administrative Agent or any other person or any other event or circumstance whatsoever, whether or not similar to any of the foregoing, that might, but for the provisions of this Section, constitute a legal or equitable discharge of the
Borrower’s obligations hereunder. 
 Without limiting the generality of the foregoing, it is expressly understood and
agreed that the absolute and unconditional obligation of the Borrower hereunder to reimburse L/C Disbursements will not be excused by the gross negligence or willful misconduct of the Issuing Bank. However, the foregoing shall not be construed to
excuse the Issuing Bank from liability to the Borrower to the extent of any direct damages (as opposed to consequential damages, claims in respect of which are hereby waived by the Borrower to the extent permitted by applicable law) suffered by the
Borrower that are caused by the Issuing Bank’s gross negligence, bad faith or willful misconduct in determining whether drafts and other documents presented under a Letter of Credit comply with the terms thereof. It is further understood and
agreed that the Issuing Bank may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary and, in making any payment under any Letter of
Credit (i) the Issuing Bank’s exclusive reliance on the documents presented to it under such Letter of Credit as to any and all matters set forth therein, including reliance on the amount of any draft presented under such Letter of Credit,
whether or not the amount due to the beneficiary thereunder equals the amount of such draft and whether or not any document presented pursuant to such Letter of Credit proves to be insufficient in any respect, if such document on its face appears to
be in order, and whether or not any other statement or any other document presented pursuant to such Letter of Credit proves to be forged or invalid or any statement therein proves to be inaccurate or untrue in any respect whatsoever and
(ii) any noncompliance in any immaterial respect of the documents presented under such Letter of Credit with the terms thereof shall, in each case, be deemed not to constitute gross negligence or willful misconduct of the Issuing Bank. 

 
 73
 
  

 (g)  Disbursement
Procedures.      The Issuing Bank shall, promptly following its receipt thereof, examine all documents purporting to represent a demand for payment under a Letter of Credit. The Issuing Bank shall as promptly as
possible give telephonic notification, confirmed by fax, to the Administrative Agent and the Borrower of such demand for payment and whether the Issuing Bank has made or will make an L/C Disbursement thereunder; provided that any failure to
give or delay in giving such notice shall not relieve the Borrower of its obligation to reimburse the Issuing Bank and the Revolving Credit Lenders with respect to any such L/C Disbursement. 

(h)  Interim Interest.      If the Issuing Bank shall
make any L/C Disbursement in respect of a Letter of Credit, then, unless the Borrower shall reimburse such L/C Disbursement in full on such date, the unpaid amount thereof shall bear interest for the account of the Issuing Bank, for each day from
and including the date of such L/C Disbursement, to but excluding the earlier of the date of payment by the Borrower or the date on which interest shall commence to accrue thereon as provided in Section 2.02(f), at the rate per annum that would
apply to such amount if such amount were an ABR Revolving Loan. 
 (i)  Resignation or
Removal of the Issuing Bank.  The Issuing Bank may resign at any time by giving 30 days’ prior written notice to the Administrative Agent, the Lenders and the Borrower, and may be removed at any time by the Borrower by notice
to the Issuing Bank, the Administrative Agent and the Lenders. Upon the acceptance of any appointment as the Issuing Bank hereunder by a Lender that shall agree to serve as successor Issuing Bank, such successor shall succeed to and become vested
with all the interests, rights and obligations of the retiring Issuing Bank. At the time such removal or resignation shall become effective, the Borrower shall pay all accrued and unpaid fees pursuant to Section 2.05(c)(ii). The acceptance of
any appointment as the Issuing Bank hereunder by a successor Lender shall be evidenced by an agreement entered into by such successor, in a form satisfactory to the Borrower and the Administrative Agent, and, from and after the effective date of
such agreement, (i) such successor Lender shall have all the rights and obligations of the previous Issuing Bank under this Agreement and the other Loan Documents and (ii) references herein and in the other Loan Documents to the term
“Issuing Bank” shall be deemed to refer to such successor or to any previous Issuing Bank, or to such successor and all previous Issuing Banks, as the context shall require. After the resignation or removal of the Issuing Bank hereunder,
the retiring Issuing Bank shall remain a party hereto and shall continue to have all the rights and obligations of an Issuing Bank under this Agreement and the other Loan Documents with respect to Letters of Credit issued by it prior to such
resignation or removal, but shall not be required to issue additional Letters of Credit. 

(j)  Cash Collateralization.    If any Event of Default shall
occur and be continuing, the Borrower shall, on the Business Day it receives notice from the Administrative Agent or the Required Lenders (or, if the maturity of the Loans 

 
 74
 
  

 
has been accelerated, Revolving Credit Lenders holding participations in outstanding Letters of Credit representing greater than 50% of the aggregate undrawn amount of all outstanding Letters of
Credit) thereof and of the amount to be deposited, deposit in an account with the Collateral Agent, for the benefit of the Revolving Credit Lenders, an amount in cash equal to the L/C Exposure as of such date. Such deposit shall be held by the
Collateral Agent as collateral for the payment and performance of the Obligations. The Collateral Agent shall have exclusive dominion and control, including the exclusive right of withdrawal, over such account. Other than any interest earned on the
investment of such deposits in Permitted Investments, which investments shall be made at the option and sole discretion of the Collateral Agent, such deposits shall not bear interest. Interest or profits, if any, on such investments shall accumulate
in such account. Moneys in such account shall (i) automatically be applied by the Administrative Agent to reimburse the Issuing Bank for L/C Disbursements for which it has not been reimbursed, (ii) be held for the satisfaction of the
reimbursement obligations of the Borrower for the L/C Exposure at such time and (iii) if the maturity of the Loans has been accelerated (but subject to the consent of Revolving Credit Lenders holding participations in outstanding Letters of
Credit representing greater than 50% of the aggregate undrawn amount of all outstanding Letters of Credit), be applied to satisfy the Obligations. If the Borrower is required to provide an amount of cash collateral hereunder as a result of the
occurrence of an Event of Default, such amount (to the extent not applied as aforesaid) shall be returned to the Borrower within three Business Days after all Events of Default have been cured or waived. Notwithstanding the foregoing, following the
incurrence by the Borrower or any Subsidiary of any Other Senior Secured Debt, the treatment and application of any amounts provided by the Borrower as cash collateral hereunder shall be subject to the terms and provisions of any applicable Pari
Passu Intercreditor Agreement and, in the event of any conflict between the terms of such Pari Passu Intercreditor Agreement and the terms of this paragraph (j), the terms of such Pari Passu Intercreditor Agreement shall govern. 

(k)  Additional Issuing Banks.  The Borrower may, at any time and from time
to time with the consent of the Administrative Agent (which consent shall not be unreasonably withheld or delayed) and such Lender, designate one or more additional Lenders to act as an issuing bank under the terms of this Agreement. Any Lender
designated as an issuing bank pursuant to this paragraph (k) shall be deemed to be an “Issuing Bank” (in addition to being a Lender) in respect of Letters of Credit issued or to be issued by such Lender, and, with respect to such
Letters of Credit, such term shall thereafter apply to the other Issuing Bank and such Lender. 
 SECTION
2.24.  Incremental Term Loans.    (a)  The Borrower may, by written notice to the Administrative Agent from time to time, request Incremental Term Loan Commitments in an amount not to exceed the
Incremental Amount from one or more Incremental Term Lenders, which may include any existing Lender; provided that each Incremental Term Lender, if not already a Lender hereunder or Affiliate of a Lender or an

 
 75
 
  

 
Approved Fund, shall be subject to the approval of the Administrative Agent (which approval shall not be unreasonably withheld or delayed). Such notice shall set forth (i) the amount of the
Incremental Term Loan Commitments being requested (which shall be in minimum increments of $1,000,000 and a minimum amount of $25,000,000 or such lesser amount equal to the remaining Incremental Amount), (ii) the date on which such Incremental
Term Loan Commitments are requested to become effective, and (iii) whether such Incremental Term Loan Commitments are commitments to make additional 2021 Term D Loans or commitments to make term loans with terms different from the 2021 Term D
Loans, including Other Term A Loans (“Other Term Loans”). 
 (b)  The
Borrower and each Incremental Term Lender shall execute and deliver to the Administrative Agent an Incremental Term Loan Assumption Agreement and such other documentation as the Administrative Agent shall reasonably specify to evidence the
Incremental Term Loan Commitment of each Incremental Term Lender. Each Incremental Term Loan Assumption Agreement shall specify the terms of the Incremental Term Loans to be made thereunder; provided that, without the prior written consent of
the Required Lenders, (i) the final maturity date of any Other Term Loans (other than any Other Term A Loans) shall be no earlier than the Latest Term Loan Maturity Date in effect at the time the Incremental Term Loan Commitments with respect
to such Other Term Loans become effective (or, in the case of Other Term Loans all of the proceeds of which will be used to repay existing Term Loans (other than Other Term A Loans), the latest maturity date of such refinanced Term Loans),
(ii) the average life to maturity of the Other Term Loans (other than any Other Term A Loans) shall be no shorter than the then remaining average life to maturity of any other Class of Loans (or, in the case of Other Term Loans all of the
proceeds of which will be used to repay existing Term Loans (other than Other Term A Loans), the then remaining average life to maturity of such refinanced Term Loans), (iii) if the initial yield (excluding upfront or arrangement or similar
fees payable to the arranger, if any, of such loan) on such Other Term Loans (as determined by the Administrative Agent to be equal to the sum of (x) the margin above the Adjusted LIBO Rate on such Other Term Loans (the “Other Term
Loan Margin”) (which shall be increased by the amount that any “LIBOR floor” applicable to such Other Term Loans on the date such Other Term Loans are made would exceed the Adjusted LIBO Rate that would be in effect for a
three-month Interest Period commencing on such date) and (y) if such Other Term Loans are initially made at a discount or the Lenders making the same (as opposed to the arranger, if any, thereof) receive a fee directly or indirectly from
Parent, the Borrower or any Subsidiary for doing so (the amount of such discount or fee, expressed as a percentage of the Other Term Loans, being referred to herein as “OID”), the amount of such OID divided by the lesser of
(A) the average life to maturity of such Other Term Loans and (B) four) exceeds by more than 50 basis points the sum of (1) the margin applicable for Eurodollar Term Loans of any Class (other than Other Term A Loans and any other
Class of Term Loans that does not elect to be subject to this clause (iii) in its Incremental Term Loan Assumption Agreement or Loan Modification Agreement) (which margin shall be the sum of the Applicable Percentage for Eurodollar Term Loans

 
 76
 
  

 
of such Class (determined, solely for purposes of this Section 2.24, by reference to the Secured Net Leverage Ratio and the Total Leverage Ratio, as and to the extent applicable, in each
case calculated on a pro forma basis after giving effect to any Specified Transaction to which such Other Term Loans relate and any Indebtedness incurred or expected to be incurred in connection therewith) (such margin, the “Other Term
Loan Reference Margin”) increased by the amount that any “LIBOR floor” applicable to such Eurodollar Term Loans on such date would exceed the Adjusted LIBO Rate that would be in effect for a three-month Interest Period
commencing on such date) plus (2) the OID (if any) initially paid in respect of such Term Loans (for any Class of Term Loans, the applicable amount of such excess above 50 basis points being referred to herein as the “Yield
Differential”) then (I) the Applicable Percentage then in effect for such Class of Term Loans shall automatically be increased to the Other Term Loan Reference Margin plus the applicable Yield Differential (or, in the case
of that portion, if any, of the Yield Differential resulting from the “LIBOR floor” applicable to such Other Term Loans being greater than that applicable to such Class of Term Loans on the date such Other Term Loans are made, by first
increasing or (if no “LIBOR floor” is applicable to such Class of Term Loans at such time) by adding a “LIBOR floor” with respect to such portion of the Yield Differential), (II) each interest rate margin with respect to such
Class of Term Loans set forth in the definition of Applicable Percentage shall be increased by the Yield Differential (or, in the case of that portion, if any, of the Yield Differential resulting from the “LIBOR floor” applicable to such
Other Term Loans being greater than that applicable to such Class of Term Loans on the date such Other Term Loans are made, by first increasing or (if no “LIBOR floor” is applicable to such Class of Term Loans at such time) by adding a
“LIBOR floor” with respect to such portion of the Yield Differential) and (III) the Applicable Percentage for such Class of Term Loans will thereafter be determined in accordance with the definition of Applicable Percentage as so amended
and by reference to the Secured Net Leverage Ratio or Leverage Ratio, as the case may be and to the extent applicable; provided that in the event that the Applicable Percentage with respect to any such Class of Term Loans would be subject to
any decrease as a result of any change in the Secured Net Leverage Ratio or the Leverage Ratio, as the case may be and to the extent applicable, the amount of any such decrease in the Applicable Percentage with respect to such Class of Term Loans
shall not exceed the amount of any corresponding decrease, if any, in the Other Term Loan Margin as a result of such changes in the Secured Net Leverage Ratio and the Total Leverage Ratio, as the case may be and to the extent applicable, in each
case effective upon the incurrence of such Other Term Loans and (iv) if the initial yield (excluding upfront or arrangement or similar fees payable to the arranger, if any, of such loan) on any Other Term A Loans (other than any Other Term A
Loans that do not elect to be subject to this Section 2.24(b)(iv) in its Incremental Term Loan Assumption Agreement or Loan Modification Agreement) (as determined by the Administrative Agent on the same basis as the initial yield for Other Term
Loans is determined pursuant to clause (iii) above) exceeds by more than 50 basis points the then-applicable yield 

 
 77
 
  

 
(as determined by the Administrative Agent on the same basis as the then-applicable yield for existing Term Loans is determined pursuant to clause (iii) above) for the 2019 Term A Loans or
any Class of Other Term A Loans (for the 2019 Term A Loans or any such Class of Other Term A Loans, the applicable amount of such excess above 50 basis points being referred to herein as the “TLA Yield Differential”) then
(I) the Applicable Percentage then in effect for the 2019 Term A Loans and each other Class of Other Term A Loans shall automatically be increased to the Other Term Loan Reference Margin applicable thereto plus the applicable TLA Yield
Differential (or, in the case of that portion, if any, of the TLA Yield Differential resulting from the “LIBOR floor” applicable to such new Other Term A Loans being greater than that applicable to the 2019 Term A Loans or such Class of
Other Term A Loans on the date such new Other Term A Loans are made, by first increasing or (if no “LIBOR floor” is applicable to the 2019 Term A Loans or such existing Class of Other Term A Loans at such time) by adding a “LIBOR
floor” with respect to such portion of the TLA Yield Differential), (II) each interest rate margin with respect to the 2019 Term A Loans or such existing Class of Other Term A Loans set forth in any table in the definition of Applicable
Percentage, if any, shall be increased by the TLA Yield Differential (or, in the case of that portion, if any, of the TLA Yield Differential resulting from the “LIBOR floor” applicable to such new Other Term A Loans being greater than that
applicable to the 2019 Term A Loans or such existing Class of Other Term A Loans on the date such new Other Term A Loans are made, by first increasing or (if no “LIBOR floor” is applicable to the 2019 Term A Loans or such existing Class of
Other Term A Loans at such time) by adding a “LIBOR floor” with respect to such portion of the TLA Yield Differential) and (III) the Applicable Percentage for the 2019 Term A Loans or such existing Class of Other Term A Loans will
thereafter be determined in accordance with the definition of Applicable Percentage as so amended and by reference to the Secured Net Leverage Ratio or Leverage Ratio, as the case may be and to the extent applicable; provided that in the
event that the Applicable Percentage with respect to the 2019 Term A Loans or any such Class of existing Other Term A Loans would be subject to any decrease as a result of any change in the Secured Net Leverage Ratio or the Leverage Ratio, as the
case may be and to the extent applicable, the amount of any such decrease in the Applicable Percentage with respect to the 2019 Term A Loans or such Class of existing Other Term A Loans shall not exceed the amount of any corresponding decrease, if
any, in the Other Term Loan Margin as a result of such changes in the Secured Net Leverage Ratio and the Total Leverage Ratio, as the case may be and to the extent applicable, in each case effective upon the incurrence of such new Other Term A
Loans. The Administrative Agent shall promptly notify each Lender as to the effectiveness of each Incremental Term Loan Assumption Agreement. Each of the parties hereto hereby agrees that, upon the effectiveness of any Incremental Term Loan
Assumption Agreement, this Agreement shall be deemed amended to the extent (but only to the extent) necessary to reflect the existence and terms of the Incremental Term Loan Commitment and the Incremental Term Loans evidenced thereby. 

 
 78
 
  

 (c)  Notwithstanding the foregoing, no Incremental
Term Loan Commitment shall become effective under this Section 2.24 unless (i) on the date of such effectiveness, the applicable conditions set forth in paragraphs (b) and (c) of Section 4.01 shall be satisfied and the
Administrative Agent shall have received a certificate to that effect dated such date and executed by a Financial Officer of the Borrower and (ii) except as otherwise specified in the applicable Incremental Term Loan Assumption Agreement, the
Administrative Agent shall have received legal opinions, board resolutions and other closing certificates reasonably requested by the Administrative Agent and consistent with those delivered on the Closing Date under Section 4.02 of the
Original Credit Agreement. 
 (d)  Each of the parties hereto hereby agrees that the
Administrative Agent may, in consultation with the Borrower, take any and all action as may be reasonably necessary to ensure that all Incremental Term Loans (other than Other Term Loans), when originally made, are included in each Borrowing of
outstanding 2021 Term D Loans on a pro rata basis. This may be accomplished by requiring each outstanding Eurodollar 2021 Term D Term Loan Borrowing to be converted into an ABR Term Borrowing on the date of each Incremental Term Loan, or by
allocating a portion of each Incremental Term Loan to each outstanding Eurodollar 2021 Term D Loan Borrowing on a pro rata basis. Any conversion of Eurodollar Term Loans to ABR Term Loans required by the preceding sentence shall be subject to
Section 2.16. If any Incremental Term Loan is to be allocated to an existing Interest Period for a Eurodollar Term Borrowing, then the interest rate thereon for such Interest Period and the other economic consequences thereof shall be as set
forth in the applicable Incremental Term Loan Assumption Agreement. In addition, to the extent any Incremental Term Loans are not Other Term Loans, the scheduled amortization payments under Section 2.11(a)(v) required to be made after the
making of such Incremental Term Loans shall be ratably increased by the aggregate principal amount of such Incremental Term Loans. 

SECTION 2.25.  Loan Modification Offers; Replacement Revolving Credit
Facility.    (a)  The Borrower may, by written notice to the Administrative Agent from time to time, make one or more offers (each, a “Loan Modification Offer”) to all the Lenders of one
or more Classes of Loans and/or Commitments (each Class subject to such a Loan Modification Offer, an “Affected Class”) to make one or more Permitted Amendments pursuant to procedures reasonably specified by the
Administrative Agent and reasonably acceptable to the Borrower. Such notice shall set forth (i) the terms and conditions of the requested Permitted Amendment and (ii) the date on which such Permitted Amendment is requested to become
effective. Permitted Amendments shall become effective only with respect to the Loans and/or Commitments of the Lenders of the Affected Class that accept the applicable Loan Modification Offer (such Lenders, the “Accepting
Lenders”) and, in the case of any Accepting Lender, only with respect to such Lender’s Loans and/or Commitments of such Affected Class as to which such Lender’s acceptance has been made. 

 
 79
 
  

 (b)  The Borrower and each Accepting Lender shall
execute and deliver to the Administrative Agent a Loan Modification Agreement and such other documentation as the Administrative Agent shall reasonably specify to evidence the acceptance of the Permitted Amendments and the terms and conditions
thereof. The Administrative Agent shall promptly notify each Lender as to the effectiveness of each Loan Modification Agreement. Each of the parties hereto hereby agrees that, upon the effectiveness of any Loan Modification Agreement, this Agreement
shall be deemed amended to the extent (but only to the extent) necessary to reflect the existence and terms of the Permitted Amendment evidenced thereby and only with respect to the applicable Loans and/or Commitments of the Accepting Lenders of the
Affected Class, including any amendments necessary to treat the applicable Loans and/or Commitments of the Accepting Lenders of the Affected Class as a new “Class” of loans and/or commitments hereunder. Notwithstanding the foregoing, no
Permitted Amendment shall become effective unless the Administrative Agent, to the extent reasonably requested by the Administrative Agent, shall have received legal opinions, board resolutions, officer’s and secretary’s certificates and
other documentation consistent with those delivered on the First Restatement Effective Date under the First Amendment and Restatement Agreement. 

(c)  “Permitted Amendments” means any or all of the following: (i) an
extension of the final maturity date and/or amortization applicable to the applicable Loans and/or Commitments of the Accepting Lenders, (ii) a change in the Applicable Percentage with respect to the applicable Loans and/or Commitments of the
Accepting Lenders, (iii) a change in the Fees payable to (or the inclusion of additional fees to be payable to) the Accepting Lenders, (iv) changes to any prepayment premiums with respect to the applicable Loans and Commitments,
(v) such amendments to this Agreement and the other Loan Documents as shall be appropriate, in the reasonable judgment of the Administrative Agent, to provide the rights and benefits of this Agreement and other Loan Documents to each new
“Class” of loans and/or commitments resulting therefrom and (vi) additional amendments to the terms of this Agreement applicable to the applicable Loans and/or Commitments of the Accepting Lenders that are less favorable to such
Accepting Lenders than the terms of this Agreement prior to giving effect to such Permitted Amendments and that are reasonably acceptable to the Administrative Agent; provided, that, if any such Permitted Amendment shall create a new Class of
Revolving Credit Commitments, (A) the allocation of the participation exposure with respect to any then-existing or subsequently issued or made Letter of Credit as between the commitments of such new “Class” and the Commitments of the
then-existing Revolving Credit Lenders shall be made on a ratable basis as between the commitments of such new “Class” and the Commitments of the then-existing Revolving Credit Lenders and (B) the L/C Commitment may not be extended
without the prior written consent of the Issuing Bank. 
 (d)  Notwithstanding anything to the
contrary contained herein, this Agreement may be amended with the written consent of the Administrative 

 
 80
 
  

 
Agent, the Borrower and the Lenders providing the relevant Replacement Revolving Credit Facility (as defined below) to effect the refinancing of all the Revolving Credit Commitments with a
replacement facility under this Agreement (a “Replacement Revolving Credit Facility”); provided that (a) the aggregate amount of commitments under such Replacement Revolving Facility Commitments shall not exceed
the aggregate amount of the replaced Revolving Credit Commitments and (b) the maturity date of such Replacement Revolving Credit Facility shall not be earlier than the latest Revolving Credit Maturity Date at the time of such replacement. Each
of the parties hereto hereby agrees that, upon the effectiveness of any Replacement Revolving Credit Facility, this Agreement shall be deemed amended to the extent (but only to the extent) necessary to reflect the existence and terms of the
Replacement Revolving Credit Facility evidenced thereby. Notwithstanding the foregoing, (i) no Replacement Revolving Credit Facility shall become effective unless the Administrative Agent, to the extent reasonably requested by the
Administrative Agent, shall have received legal opinions, board resolutions, officer’s and secretary’s certificates and other documentation consistent with those delivered on the First Restatement Effective Date under the First Amendment
and Restatement Agreement and (ii) the Issuing Bank shall not be obligated to continue to issue Letters of Credit, respectively, under the Replacement Revolving Credit Facility except to the extent it agrees in writing to do so at or prior to
the effectiveness of the Replacement Revolving Credit Facility. Without limiting the foregoing, in the event that the initial Replacement Revolving Credit Facility is in an aggregate principal amount less than the aggregate principal amount of the
Revolving Credit Commitments being replaced, this Agreement may be further amended with the written consent of the Administrative Agent, the Borrower and the Lenders providing the relevant additional commitments under the Replacement Revolving
Credit Facility (and subject to the same limitations and requirements provided above in this paragraph (d)) to include additional commitments under the Replacement Revolving Credit Facility that will not cause the aggregate amount of the commitments
thereunder to exceed the aggregate amount of the replaced Revolving Credit Commitments. 
 SECTION
2.26.  Revolving Credit Commitment Increases.    (a)  The Borrower may from time to time, by written notice (a “Notice of Increase”) to the Administrative Agent (which
shall promptly deliver a copy to each of the Revolving Credit Lenders), request that new Revolving Credit Commitments of any Class be extended or existing Revolving Credit Commitments of any Class be increased by one or more financial institutions,
which may include any Revolving Credit Lender (any such financial institution, an “Increasing Revolving Credit Lender”) (any such extension or increase, a “Revolving Credit Commitment Increase”);
provided that (i) the terms of the Revolving Credit Commitments under the Revolving Credit Commitment Increase shall be identical to the existing Revolving Credit Commitments of the applicable Class, except for any upfront fees paid to
Increasing Revolving Credit Lenders; (ii) at the time of effectiveness of any Revolving Credit Commitment Increase effected pursuant to this paragraph (A) the amount of such Revolving Credit Commitment Increase shall not exceed the
Incremental Amount and (B) the aggregate amount of Revolving Credit Commitment 

 
 81
 
  

 
Increases effected pursuant to this paragraph shall not exceed the greater of (x) $750,000,000 and (y) an amount equal to 50% of Consolidated EBITDA for the most recently ended
four-quarter period for which financial statements have been delivered in accordance with Section 5.04(a) or (b); (iii) each Revolving Credit Commitment Increase shall be in an aggregate principal amount of not less than $25,000,000,
except to the extent necessary to utilize the remaining unused amount of increase permitted under this Section 2.26(a); (iv) prior to any such Revolving Credit Commitment Increase, except as otherwise specified in the applicable Revolving
Accession Agreement, the Administrative Agent shall have received legal opinions, board resolutions and other closing certificates reasonably requested by the Administrative Agent and consistent with those delivered on the Closing Date under
Section 4.02 of the Original Credit Agreement and (v) at the time of each such Revolving Credit Commitment Increase request and immediately after giving effect to the effectiveness of each such Revolving Credit Commitment Increase, the
applicable conditions set forth in paragraphs (b) and (c) of Section 4.01 shall be satisfied and the Administrative Agent shall have received certificates to that effect dated such dates and executed by a Financial Officer of the
Borrower. Such Notice of Increase shall set forth the amount of the requested Revolving Credit Commitment Increase and the date on which such Revolving Credit Commitment Increase is requested to become effective. The Borrower may arrange for one or
more Revolving Credit Lenders or one or more other financial institutions to act as Increasing Revolving Credit Lenders with respect to the proposed Revolving Credit Commitment Increase; provided that each Increasing Revolving Credit Lender
shall be subject to the approval of the Administrative Agent, each Issuing Bank (which approvals shall not be unreasonably withheld, conditioned or delayed) and each Increasing Revolving Credit Lender shall become a party to this Agreement by
completing and delivering to the Administrative Agent a duly executed accession agreement in a form reasonably satisfactory to the Administrative Agent and the Borrower (a “Revolving Accession Agreement”). Revolving Credit
Commitment Increases shall become effective on the date specified in the Notice of Increase delivered pursuant to this paragraph (but not prior to, for any Increasing Revolving Credit Lender that is not already a Revolving Credit Lender, execution
and delivery by such Increasing Revolving Credit Lender of a Revolving Accession Agreement). Upon the effectiveness of any Revolving Accession Agreement to which any Increasing Revolving Credit Lender is a party, such Increasing Revolving Credit
Lender shall thereafter be deemed to be a party to this Agreement and shall be entitled to all rights, benefits and privileges, and subject to all obligations, of a Revolving Credit Lender hereunder. 

(b)  Each of the parties hereto hereby agrees that, upon the effectiveness of any Revolving Credit
Commitment Increase, this Agreement may be amended (such amendment, a “Revolving Credit Commitment Increase Amendment”) without the consent of any Lender to the extent (but only to the extent) necessary to reflect the
existence and terms of the Revolving Credit Commitment Increase evidenced thereby. Upon the effectiveness of each Revolving Credit Commitment Increase pursuant to this Section 2.26, (i) each Revolving Credit Lender immediately prior to
such increase will automatically and without further act be deemed to have assigned to each Increasing Revolving Credit Lender providing a portion of such Revolving Credit Commitment Increase, and each

 
 82
 
  

 
such Increasing Revolving Credit Lender will automatically and without further act be deemed to have assumed, a portion of such Revolving Credit Lender’s participations hereunder in
outstanding Letters of Credit such that, after giving effect to such Revolving Credit Commitment Increase and each such deemed assignment and assumption of participations, the percentage of the aggregate outstanding participations hereunder in
Letters of Credit held by each Revolving Credit Lender (including each such Increasing Revolving Credit Lender) will equal such Lender’s Pro Rata Percentage and (ii) if, on the date of such Revolving Credit Commitment Increase, there are
any Revolving Loans outstanding, such Revolving Loans shall on or prior to the effectiveness of such Revolving Credit Commitment Increase be prepaid from the proceeds of additional Revolving Loans made hereunder (reflecting such Revolving Credit
Commitment Increase), which prepayment shall be accompanied by accrued interest on the Revolving Loans being prepaid and any costs incurred by any Lender in accordance with Section 2.12. The Administrative Agent and the Lenders hereby agree
that the minimum borrowing, pro rata borrowing and pro rata payment requirements contained elsewhere in this Agreement shall not apply to the transactions effected pursuant to the immediately preceding sentence. 

SECTION 2.27.  Term Loan Pricing Protection.    From and after the Third
Restatement Effective Date, if the initial yield on any New Term Loans incurred on or after such date (as determined by the Administrative Agent and to be equal to the sum of (x) the margin above the adjusted LIBO or eurocurrency rate on such
New Term Loans (the “New Loan Margin”) (which shall be increased by the amount that any “LIBOR floor” applicable to such New Term Loans on the date such New Term Loans are made would exceed the adjusted LIBO or
eurocurrency rate that would be in effect for a three-month Interest Period commencing on such date) and (y) if such New Term Loans are initially made at a discount or the lenders making the same (as opposed to the arrangers, if any, thereof)
receive a fee directly or indirectly from Parent, the Borrower or any subsidiary of Parent for doing so (the amount of such discount or fee, expressed as a percentage of the New Term Loans, being referred to herein as “New Term Loan
OID”), the amount of such New Term Loan OID divided by the lesser of (A) the average life to maturity of such New Term Loans and (B) four) exceeds by more than 50 basis points the sum of (1) the margin applicable to the
Eurodollar 2017 Term E Term Loans or the Eurodollar 2021 Term D Loans (which margin shall be the sum of the Applicable Percentage for 2017 Term E Term Loans or the 2021 Term D Loans (such margin, the “Reference Margin”)
increased by the amount that any “LIBOR floor” applicable to such Eurodollar 2017 Term E Term Loans or such Eurodollar 2021 Term D Loans on such date would exceed the Adjusted LIBO Rate that would be in effect for a three-month Interest
Period commencing on such date) plus (2) if such 2017 Term E Term Loans or 2021 Term D Loans were initially made at a discount or the Lenders making the same (as opposed to the arranger, if any, thereof) received a fee directly or
indirectly from Parent, the Borrower or any Subsidiary for doing so (the amount of such discount or fee, expressed as a percentage of the 2017 Term E Term Loans or the 2021 Term D Loans and calculated on a weighted average basis, being referred to
herein as “Extended OID”), the amount of such Extended OID divided by four (such excess above 50 basis points being referred to herein as the “New Term Loan Yield Differential”) then (i) the

 
 83
 
  

 
Applicable Percentage then in effect for such 2017 Term E Term Loans or 2021 Term D Loans shall automatically be increased to the Reference Margin plus the applicable New Term Loan Yield
Differential (or, in the case of that portion, if any, of the New Term Loan Yield Differential resulting from the “LIBOR floor” applicable to such New Term Loans being greater than that applicable to such 2017 Term E Term Loans or 2021
Term D Loans on the date such New Term Loans are made, by first increasing or (if no “LIBOR floor” is applicable to such 2017 Term E Term Loans or 2021 Term D Loans at such time) by adding a “LIBOR floor” with respect to such
portion of the New Term Loan Yield Differential), (ii) each interest rate margin with respect to the 2017 Term E Loans or the 2021 Term D Loans set forth in the definition of Applicable Percentage shall be increased by the New Term Loan Yield
Differential (or, in the case of that portion, if any, of the New Term Loan Yield Differential resulting from the “LIBOR floor” applicable to such New Term Loans being greater than that applicable to such 2017 Term E Loans or the 2021 Term
D Loans on the date such New Term Loans are made, by first increasing or (if no “LIBOR floor” is applicable to such 2017 Term E Loans or such 2021 Term D Loans at such time) by adding a “LIBOR floor” with respect to such portion
of the New Term Loan Yield Differential) and (iii) the Applicable Percentage for the 2017 Term E Term Loans or the 2021 Term D Loans will thereafter be determined in accordance with the definition of Applicable Percentage as so amended. 

ARTICLE III 
 Representations and
Warranties 
 Each of Parent and the Borrower represents and warrants to the Administrative Agent, the Collateral Agent, the
Issuing Bank and each of the Lenders that: 
 SECTION 3.01.  Organization;
Powers.    Each of the Loan Parties (a) is duly organized, validly existing and in good standing under the laws of the jurisdiction of its organization, except, with respect to Loan Parties other than Parent or the
Borrower, to the extent that the failure of such Loan Parties to be in good standing could not reasonably be expected to have a Material Adverse Effect, (b) has all requisite power and authority to own its property and assets and to carry on
its business as now conducted and as proposed to be conducted, except to the extent that the failure to possess such power and authority could not reasonably be expected to result in a Material Adverse Effect, (c) is qualified to do business
in, and is in good standing in, every jurisdiction where such qualification is required, except where the failure so to qualify could not reasonably be expected to result in a Material Adverse Effect, and (d) has the power and authority to
execute, deliver and perform its obligations under each of the Loan Documents and each other agreement or instrument contemplated thereby to which it is or will be a party and, in the case of the Borrower, to borrow hereunder. 

SECTION 3.02.  Authorization.  The execution, delivery and performance by the Loan Parties
of the Loan Documents to which they are a party and the making of the Borrowings hereunder (a) have been duly authorized by all requisite corporate and, if required, stockholder action and (b) will not (i) violate (A) any
provision of law, statute, rule or regulation, or of the certificate or articles of incorporation or other constitutive 

 
 84
 
  

 
documents or by-laws of Parent, the Borrower or any Subsidiary, (B) any order of any Governmental Authority or (C) any provision of any indenture, agreement or other instrument to which
Parent, the Borrower or any Subsidiary is a party or by which any of them or any of their property is or may be bound, except as could not reasonably be expected to result in a Material Adverse Effect, (ii) be in conflict with, result in a
breach of or constitute (alone or with notice or lapse of time or both) a default under, or give rise to any right to accelerate or to require the prepayment, repurchase or redemption of any obligation under any such indenture, agreement or other
instrument, except as could not reasonably be expected to result in a Material Adverse Effect or (iii) result in the creation or imposition of any Lien upon or with respect to any property or assets now owned or hereafter acquired by Parent,
the Borrower or any Subsidiary (other than any Lien created hereunder or under the Security Documents or permitted pursuant to Section 6.02). 

SECTION 3.03.  Enforceability.      The Third Amendment and Restatement
Agreement has been duly executed and delivered by Parent and the Borrower and constitutes, and this Agreement and each other Loan Document constitutes, a legal, valid and binding obligation of such Loan Party enforceable against such Loan Party in
accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization, moratorium, or similar laws affecting creditors’ rights generally and by general principles of equity (regardless of
whether enforcement is sought in a proceeding in equity or at law). 
 SECTION 3.04.  Governmental
Approvals.    No action, consent or approval of, registration or filing with or any other action by any Governmental Authority is or will be required in connection with the execution, delivery and performance by the Loan
Parties of the Loan Documents to which they are a party and the making of the Borrowings hereunder, except for (a) the filing of Uniform Commercial Code financing statements and filings with the United States Patent and Trademark Office and the
United States Copyright Office, (b) recordation of Mortgages and other filings and recordings in respect of Liens created pursuant to the Security Documents, (c) such as have been made or obtained and are in full force and effect and
(d) such actions, consents, approvals, registrations or filings which the failure to obtain or make could not reasonably be expected to result in a Material Adverse Effect. 

SECTION 3.05.  Financial Statements.    Parent has heretofore furnished to the
Lenders its consolidated balance sheets and related statements of income, stockholders’ equity and cash flows of Parent as of and for the 2012 fiscal year, audited by and accompanied by the opinion of Deloitte & Touche LLP, independent
public accountant, and (ii) as of and for each 2013 fiscal quarter of Parent (other than the fourth fiscal quarter) thereafter ended at least 45 days prior to the Third Restatement Effective Date. Such financial statements present fairly
in all material respects the financial condition and results of operations and cash flows of Parent and its consolidated subsidiaries as of such dates and for such periods. Such balance sheets and the notes thereto disclose all material liabilities,
direct or contingent, of Parent and its consolidated subsidiaries as of the dates thereof in accordance with GAAP in all material respects. Such financial statements were prepared in accordance with GAAP applied on a consistent basis in all material
respects, subject, in the case of unaudited financial statements, to year-end audit adjustments and the absence of footnotes. 

 
 85
 
  

 SECTION 3.06.  No Material Adverse
Change.    No event, change or condition has occurred that has had, or could reasonably be expected to have, a material adverse effect on the business, assets, operations, financial condition or operating results of
Parent, the Borrower and the Subsidiaries, taken as a whole, since December 31, 2012. 
 SECTION
3.07.  Title to Properties; Possession Under Leases.    (a)  Each of Parent, the Borrower and the Subsidiaries has good and marketable title to, or valid leasehold interests in, or a right to
use, all its properties and assets (including all Mortgaged Property), except for minor defects in title that do not interfere with its ability to conduct its business as currently conducted or to utilize such properties and assets for their
intended purposes and except where the failure to have such title or other interest could not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect. All such material properties and assets are free and clear of
Liens, other than Liens expressly permitted by Section 6.02. 
 (b)  As of the Third
Restatement Effective Date, neither Parent nor the Borrower has received any notice of, nor has any knowledge of, any pending or contemplated material condemnation proceeding affecting the Mortgaged Properties in any material respect or any sale or
disposition thereof in lieu of condemnation. 
 (c)  As of the Third Restatement Effective Date,
none of Parent, the Borrower or any of the Subsidiaries is obligated under any right of first refusal, option or other contractual right to sell, assign or otherwise dispose of any Mortgaged Property or any material interest therein, except for
customary rights of first refusal granted to the prior owners of such Mortgaged Property or their Affiliates. 
 SECTION
3.08.  Subsidiaries.      Schedule 3.08 sets forth as of the Third Restatement Effective Date a list of all Subsidiaries and the percentage ownership interest of Parent or the Borrower
therein. The shares of capital stock or other ownership interests so indicated on Schedule 3.08 are, in the case of corporations, fully paid and non-assessable and are owned by Parent or the Borrower, directly or indirectly, free and clear of
all Liens (other than Liens created under the Security Documents or permitted pursuant to Section 6.02). 
 SECTION
3.09.  Litigation; Compliance with Laws.    (a)  Except as disclosed in the periodic and other reports, proxy statements and other materials filed by Parent, the Borrower or any Subsidiary with
the SEC prior to the Third Restatement Effective Date, there are no actions, suits or proceedings at law or in equity or by or before any Governmental Authority now pending or, to the knowledge of Parent or the Borrower through receipt of written
notice or proceeding, threatened against or affecting Parent or the Borrower or any Subsidiary or any business, property or rights of any such person as to which there is a reasonable possibility of an adverse determination and that, if adversely
determined, could reasonably be expected, individually or in the aggregate, to result in a Material Adverse Effect. 

 
 86
 
  

 (b)  None of Parent, the Borrower or any of the
Subsidiaries or any of their respective material properties or assets is in violation of, nor will the continued operation of their material properties and assets as currently conducted violate, any law, rule or regulation (including any
occupational safety and health, health care, pension, certificate of need, Medicare, Medicaid, insurance fraud or similar law, zoning, building, Environmental Law, ordinance, code or approval or any building permits) or any restrictions of record or
agreements affecting the Mortgaged Property, or is in default with respect to any judgment, writ, injunction, decree or order of any Governmental Authority, where such violation or default could reasonably be expected to result in a Material Adverse
Effect. 
 SECTION 3.10.  Agreements.    None of Parent, the Borrower or any of
the Subsidiaries is in default in any manner under any provision of any indenture or other agreement or instrument evidencing Indebtedness, or any other material agreement or instrument to which it is a party or by which it or any of its properties
or assets are or may be bound, where such default could reasonably be expected to result in a Material Adverse Effect. 

SECTION 3.11.  Federal Reserve Regulations.      (a)  None of
Parent, the Borrower or any of the Subsidiaries is engaged principally, or as one of its important activities, in the business of extending credit for the purpose of buying or carrying Margin Stock. 

(b)  No part of the proceeds of any Loan or any Letter of Credit will be used, whether directly or
indirectly, and whether immediately, incidentally or ultimately, for any purpose that entails a violation of, or that is inconsistent with, the provisions of the Regulations of the Board, including Regulation T, U or X. 

SECTION 3.12.  Investment Company Act.  None of Parent, the Borrower or any Subsidiary
is an “investment company” as defined in, or subject to regulation under, the Investment Company Act of 1940. 

SECTION 3.13.  Use of Proceeds.  The Borrower will (a) use the proceeds of the Loans
and will request the issuance of Letters of Credit only for the purposes specified in the Preliminary Statement to this Agreement and (b) use the proceeds of Incremental Term Loans only for the purposes specified in the applicable Incremental
Term Loan Assumption Agreement. 
 SECTION 3.14.  Tax Returns.  Each of Parent, the
Borrower and the Subsidiaries has filed or caused to be filed, or has timely requested an extension to file or has received an approved extension to file, all Federal, state, local and foreign tax returns or materials that to the Borrower’s
best knowledge are required to have been filed by it and has paid or caused to be paid all taxes due and payable by it and all assessments received by it, except taxes that are being contested in good faith by appropriate proceedings and for

 
 87
 
  

 
which Parent, the Borrower or such Subsidiary, as applicable, shall have set aside on its books reserves in accordance with GAAP and except any such filings or taxes, fees or charges, the failure
of which to make or pay, could not reasonably be expected to have a Material Adverse Effect. 
 SECTION
3.15.  No Material Misstatements.      None of (a) the Confidential Information Memorandum or (b) any other written information, report, financial statement, exhibit or schedule (other
than estimates and information of a general economic or general industry nature) heretofore or contemporaneously furnished by or on behalf of Parent or the Borrower to the Administrative Agent or any Lender in connection with the negotiation of any
Loan Document or included therein or delivered pursuant thereto, when furnished and taken as a whole, contained, contains or will contain any material misstatement of fact or omitted, omits or will omit to state any material fact necessary to make
the statements therein, in the light of the circumstances under which they were, are or will be made, not materially misleading in light of the circumstances under which such statements were made; provided that to the extent any such
information, report, financial statement, exhibit or schedule was based upon or constitutes a forecast or projection, each of Parent and the Borrower represents only that it acted in good faith and utilized assumptions that each of Parent and the
Borrower believed to be reasonable at the time made. 
 SECTION 3.16.  Employee Benefit
Plans.  Each of the Borrower and its ERISA Affiliates is in compliance in all material respects with the applicable provisions of ERISA and the Code and the regulations and published interpretations thereunder. No ERISA Event has
occurred or is reasonably expected to occur that, when taken together with all other such ERISA Events, could reasonably be expected to result in a Material Adverse Effect. The present value of all benefit liabilities under each Plan (based on the
assumptions used for purposes of Statement of Financial Accounting Standards Board Accounting Standards Codification Topic 715) did not, as of the last annual valuation date applicable thereto, exceed the fair market value of the assets of such Plan
in such amount that could reasonably be expected to result in a Material Adverse Effect, and the present value of all benefit liabilities of all underfunded Plans (based on the assumptions used for purposes of Financial Accounting Standards Board
Accounting Standards Codification Topic 715) did not, as of the last annual valuation dates applicable thereto, exceed the fair market value of the assets of all such underfunded Plans in such amount that could reasonably be expected to result in a
Material Adverse Effect. 
 SECTION 3.17.  Environmental Matters.    Except with
respect to any matters that, individually or in the aggregate, could not reasonably be expected to result in a Material Adverse Effect, none of Parent, the Borrower or any of the Subsidiaries (i) has failed to comply with any Environmental Law
or to obtain, maintain or comply with any permit, license or other approval required under any Environmental Law, (ii) has become subject to any Environmental Liability, (iii) has received notice of any claim with respect to any
Environmental Liability or (iv) knows of any basis for any Environmental Liability. 

 
 88
 
  

 SECTION 3.18.  Insurance.  Schedule 3.18
sets forth a true, complete and correct description, in all material respects, of all insurance maintained by Parent or the Borrower for itself or the Subsidiaries as of the Third Restatement Effective Date. As of the Third Restatement Effective
Date, such insurance is in full force and effect and all premiums have been duly paid. Parent, the Borrower and the Subsidiaries have insurance in such amounts and covering such risks and liabilities as are in accordance with normal industry
practice. 
 SECTION 3.19.  Security
Documents.      (a)  The Guarantee and Collateral Agreement creates in favor of the Collateral Agent, for the ratable benefit of the Secured Parties, a legal, valid and enforceable security interest in
the Collateral (as defined in the Guarantee and Collateral Agreement) and the proceeds thereof, subject to the effects of bankruptcy, insolvency or similar laws affecting creditors’ rights generally and general equitable principles, and
(i) with respect to all Pledged Collateral (as defined in the Guarantee and Collateral Agreement) previously delivered to and in possession of the Collateral Agent, the Lien created under the Guarantee and Collateral Agreement constitutes, or
in the case of Pledged Collateral to be delivered to the Collateral Agent in the future will constitute, a fully perfected first priority Lien on, and security interest in, all right, title and interest of the Loan Parties in such Pledged Collateral
as to which perfection may be obtained by such actions, in each case prior and superior in right to any other person (other than the rights of persons pursuant to (x) Liens permitted by Section 6.02(z) and (y) Liens permitted by
Section 6.02 having priority by operation of law), and (ii) with the previous filing of financing statements in the offices specified on Schedule 3.19(a), the Lien created under the Guarantee and Collateral Agreement constitutes, or in the
case of financing statements in appropriate form to be filed in the offices specified on Schedule 3.19(a) (as such schedule may be updated from time to time; provided, that such schedules shall be deemed to be updated when the Borrower
provides the relevant information in accordance with the Guarantee and Collateral Agreement), the Lien created under the Guarantee and Collateral Agreement will constitute, a fully perfected Lien on, and security interest in, all right, title and
interest of the Loan Parties in such Collateral (other than Intellectual Property, as defined in the Guarantee and Collateral Agreement) as to which perfection may be obtained by such filings, in each case prior and superior in right to any other
person, other than with respect to Liens expressly permitted by Section 6.02. 
 (b)  The
Guarantee and Collateral Agreement (or a short form security agreement in form and substance reasonably satisfactory to the Borrower and the Collateral Agent), together with the filings made pursuant to the Guarantee and Collateral Agreement
currently on file with the United States Patent and Trademark Office and the United States Copyright Office and the financing statements currently on file in the offices specified on Schedule 3.19(a), constitutes, or in the case of financing
statements in appropriate form to be filed in the offices specified on Schedule 3.19(a) (as such schedule may be updated from time to time; provided that such schedules shall be deemed to be updated when the Borrower provides the relevant
information in accordance with the Guarantee and Collateral Agreement), will constitute, a fully perfected Lien on, and security interest in, all right, title and interest of the Loan Parties in the 

 
 89
 
  

 
Intellectual Property (as defined in the Guarantee and Collateral Agreement) in which a security interest may be perfected by filing security agreements in the United States and its territories
and possessions, in each case prior and superior in right to any other person other than with respect to Liens permitted pursuant to Section 6.02 (it being understood that subsequent recordings in the United States Patent and Trademark Office
and the United States Copyright Office may be necessary to perfect a Lien on registered trademarks and patents, trademark and patent applications and registered copyrights acquired by the Loan Parties after the Closing Date). 

(c)  The Mortgages are effective to create in favor of the Collateral Agent, for the ratable benefit
of the Secured Parties a legal, valid and enforceable Lien on all of the Loan Parties’ right, title and interest in and to the Mortgaged Property thereunder and the proceeds thereof, and the Mortgages constitute a fully perfected Lien on, and
security interest in, all right, title and interest of the Loan Parties in such Mortgaged Property and the proceeds thereof, in each case prior and superior in right to any other person, other than with respect to the rights of persons pursuant to
Liens expressly permitted by Section 6.02. 
 SECTION 3.20.  Location of Real Property and Leased
Premises.  (a)  Schedule 1.01(d) lists completely and correctly as of the Third Restatement Effective Date all Hospitals owned by Parent, the Borrower and the Subsidiaries and the addresses thereof. The Borrower and
the Subsidiaries own in fee all the real property set forth on Schedule 1.01(d). 

(b)  Schedule 1.01(d) lists completely and correctly as of the Third Restatement Effective Date
all Hospitals leased by Parent, the Borrower and the Subsidiaries and the addresses thereof. The Borrower and the Subsidiaries have valid leases in all the material real property set forth on Schedule 1.01(d). 

SECTION 3.21.  Labor Matters.  Except as set forth on Schedule 3.21, as of the Third
Restatement Effective Date, there are no strikes, lockouts or slowdowns against Parent, the Borrower or any Subsidiary pending or, to the knowledge of Parent or the Borrower by delivery of written notice or proceeding, threatened. The consummation
of the Transactions or the Permitted HMA Transaction will not give rise to any right of termination or right of renegotiation on the part of any union under any collective bargaining agreement to which Parent, the Borrower or any Subsidiary is
bound. Except as set forth on Schedule 3.21, as of the Third Restatement Effective Date, none of Parent, the Borrower or any Subsidiary is a party to any collective bargaining agreement or other labor contract applicable to persons employed by it at
any Facility. 

 
 90
 
  

 SECTION
3.22.  Solvency.     After giving effect to the consummation of the Subject Transactions, (i) each of the Fair Value and the Present Fair Salable Value of the assets of Parent and its
Subsidiaries taken as a whole exceed their Stated Liabilities and Identified Contingent Liabilities; (ii) Parent and its Subsidiaries taken as a whole do not have Unreasonably Small Capital; and (iii) Parent and its Subsidiaries taken as a
whole can pay their Stated Liabilities and Identified Contingent Liabilities as they mature. For purposes of this Section 3.22, the following terms shall have the meanings specified: 

“Subject Transactions” shall mean the consummation of the Permitted HMA Transaction
and the other transactions to occur on the Third Restatement Effective Date (including the execution and delivery of the Third Restatement Agreement and the effectiveness of this Agreement, the making of the Loans to be made on the Third Restatement
Effective Date and the use of proceeds of such Loans on the Third Restatement Effective Date. 

“Fair Value” shall mean the amount at which the assets (both tangible and intangible),
in their entirety, of Parent and its Subsidiaries taken as a whole would change hands between a willing buyer and a willing seller, within a commercially reasonable period of time, each having reasonable knowledge of the relevant facts, with neither
being under any compulsion to act. 
 “Present Fair Salable Value” shall mean the
amount that could be obtained by an independent willing seller from an independent willing buyer if the assets (both tangible and intangible) of Parent and its Subsidiaries taken as a whole are sold on a going concern basis with reasonable
promptness in an arm’s-length transaction under present conditions for the sale of comparable business enterprises insofar as such conditions can be reasonably evaluated. 

“Stated Liabilities” shall mean the recorded liabilities (including contingent
liabilities that would be recorded in accordance with GAAP) of Parent and its Subsidiaries taken as a whole, as of the date hereof after giving effect to the consummation of Subject Transactions, determined in accordance with GAAP consistently
applied. 
 “Identified Contingent Liabilities” shall mean the maximum estimated
amount of liabilities reasonably likely to result from pending litigation, asserted claims and assessments, guaranties, uninsured risks and other contingent liabilities of Parent and its Subsidiaries taken as a whole after giving effect to the
Subject Transactions (including all fees and expenses related thereto but exclusive of such contingent liabilities to the extent reflected in Stated Liabilities), as identified and explained in terms of their nature and estimated magnitude by
responsible officers of Parent. 
 “Do not have Unreasonably Small Capital” shall
mean Parent and its Subsidiaries taken as a whole after giving effect to the Subject Transactions have sufficient capital to ensure that it is a going concern. 

“Can pay their Stated Liabilities and Identified Contingent Liabilities as they
mature” shall mean Parent and its Subsidiaries taken as a whole after giving effect to the Subject Transactions have sufficient assets and cash flow to pay their respective Stated Liabilities and Identified Contingent Liabilities as
those liabilities mature or (in the case of contingent liabilities) otherwise become payable. 

 
 91
 
  

 SECTION 3.23.  Sanctioned
Persons.    None of Parent, the Borrower, or any Subsidiary or any Unrestricted Subsidiary nor, to the knowledge of the Borrower, any director, officer, agent, employee or Affiliate of Parent, the Borrower, any Subsidiary
or any Unrestricted Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”) and each is currently in compliance with all rules and
regulations promulgated by OFAC; and the Borrower will not directly or indirectly use the proceeds of the Loans or the Letters of Credit or otherwise make available such proceeds to any person, for the purpose of financing the activities of any
person currently subject to any U.S. sanctions administered by OFAC. 
 ARTICLE IV 

Conditions of Lending 

The obligations of the Lenders to make Loans and of the Issuing Bank to issue Letters of Credit hereunder are subject to the
satisfaction of the following conditions: 
 SECTION 4.01.  All Credit Events.  On the
date of each Borrowing (other than a conversion or a continuation of a Borrowing), including on the date of each issuance of or increase to a Letter of Credit (each such event being called a “Credit Event”): 

(a)  The Administrative Agent shall have received a notice of such Borrowing as required by
Section 2.03 (or such notice shall have been deemed given in accordance with Section 2.02) or, in the case of the issuance of or increase to a Letter of Credit, the Issuing Bank and the Administrative Agent shall have received a notice
requesting the issuance of or increase to such Letter of Credit as required by Section 2.23(b). 

(b)  (i)  In the case of an Incremental Acquisition Term Loan or Incremental Acquisition
Revolving Credit Commitment Increase, the Specified Representations, and (ii) in all other cases, the representations and warranties set forth in Article III and in each other Loan Document shall be true and correct in all material
respects on and as of the date of such Credit Event with the same effect as though made on and as of such date, except to the extent such representations and warranties expressly relate to an earlier date. 

(c)  Except in the case of any Incremental Acquisition Term Loan or Incremental Acquisition
Revolving Credit Commitment Increase, at the time of and immediately after such Credit Event, no Default or Event of Default shall have occurred and be continuing. 

Each Credit Event shall be deemed to constitute a representation and warranty by the Borrower and Parent on the date of such
Credit Event as to the applicable matters specified in paragraphs (b) and (c) of this Section 4.01. 

 
 92
 
  

 SECTION 4.02.  [Intentionally Omitted.] 

ARTICLE V 
 Affirmative Covenants

 Each of Parent and the Borrower covenants and agrees with each Lender that so long as this Agreement shall remain in
effect and until the Commitments have been terminated and the principal of and interest on each Loan, all Fees and all other expenses or amounts payable under any Loan Document shall have been paid in full and all Letters of Credit have been
canceled or have expired and all amounts drawn thereunder have been reimbursed in full or other arrangements acceptable to the Issuing Bank and the Administrative Agent have been made with respect thereto, unless the Required Lenders shall otherwise
consent in writing, each of Parent and the Borrower will, and will cause (i) in the case of Sections 5.01 and 5.02, each of the Material Subsidiaries, and (ii) in the case of Sections 5.03 through 5.15, each of the Subsidiaries to: 

SECTION 5.01.  Existence; Compliance with Laws; Businesses and
Properties.  (a)  Do or cause to be done all things necessary to preserve, renew and keep in full force and effect its legal existence, except as otherwise expressly permitted under Section 6.05. 

(b)  (i)  Do or cause to be done all things necessary to obtain, preserve, renew, extend
and keep in full force and effect the rights, licenses, permits, franchises and authorizations, material to the conduct of its business, except as could not reasonably be expected to have a Material Adverse Effect; (ii) comply in all material
respects with all applicable laws, rules, regulations and decrees and orders of any Governmental Authority, whether now in effect or hereafter enacted, except as could not reasonably be expected to have a Material Adverse Effect; and (iii) at
all times maintain and preserve all tangible property material to the conduct of such business and keep such property in good repair, working order and condition (subject to ordinary wear and tear, casualty and condemnation) and from time to time
make, or cause to be made, all needful and proper repairs, renewals, additions, improvements and replacements thereto necessary in order that the business carried on in connection therewith may be properly conducted at all times, except as could not
reasonably be expected to have a Material Adverse Effect. 
 SECTION
5.02.  Insurance.    (a)  Maintain with financially sound and reputable insurers insurance, to such extent and against such risks, including fire and other risks insured against by extended
coverage, as is customary with companies in the same or similar businesses operating in the same or similar locations, including hospital liability (which shall include general liability, medical professional liability, contractual liability and
druggists’ liability), workers’ compensation, employers’ liability, automobile liability and physical damage coverage, environmental impairment liability, all risk property, business interruption, fidelity and crime insurance and
public liability insurance against claims for personal injury or death or property damage occurring upon, in, about or in connection with the use of any properties owned, occupied or controlled by it; provided 

 
 93
 
  

 
that the Borrower may implement programs of self insurance in the ordinary course of business and in accordance with industry standards for a company of similar size so long as reserves are
maintained in accordance with GAAP for the liabilities associated therewith. 
 (b)  Cause all
casualty and property policies covering any Collateral to name the Collateral Agent as loss payee or mortgagee, and/or additional insured, and each provider of any such insurance shall agree, by endorsement upon such policies issued by it, that it
will give the Administrative Agent 30 days prior written notice before any such policy or policies shall be altered or canceled. 

(c)  If at any time the area in which the Premises (as defined in the Mortgages) are located is
designated a “flood hazard area” in any Flood Insurance Rate Map published by the Federal Emergency Management Agency (or any successor agency), obtain flood insurance in such total amount as the Administrative Agent, the Collateral Agent
or the Required Lenders may from time to time require, and otherwise comply with the National Flood Insurance Program as set forth in the Flood Disaster Protection Act of 1973, as it may be amended from time to time. 

SECTION 5.03.  Obligations and Taxes.  Pay and discharge promptly when due all taxes,
assessments and governmental charges or levies imposed upon it or upon its income or profits or in respect of its property, before the same shall become delinquent, as well as all lawful claims for labor, materials and supplies or otherwise that, if
unpaid, could reasonably be expected to give rise to a Lien upon such properties or any part thereof; provided, however, that such payment and discharge shall not be required with respect to any such tax, assessment, charge, levy or
claim so long as (i) the validity or amount thereof shall be contested in good faith by appropriate proceedings and the Borrower shall have set aside on its books adequate reserves with respect thereto in accordance with GAAP or (ii) the
failure to pay and discharge such tax, assessment, charge, levy or claim could not reasonably be expected to have a Material Adverse Effect. 

SECTION 5.04.  Financial Statements, Reports, etc.    In the case of Parent,
furnish to the Administrative Agent, which shall furnish to each Lender: 
 (a)  within
90 days after the end of each fiscal year, its consolidated balance sheet and related statements of income, stockholders’ equity and cash flows showing the financial condition of Parent and its consolidated subsidiaries as of the close of
such fiscal year and the results of its operations and the operations of such subsidiaries during such year, together with comparative figures for the immediately preceding fiscal year, all audited by Deloitte & Touche LLP or other
independent public accountants of recognized national standing and accompanied by an opinion of such accountants (which opinion shall be without a “going concern” or like qualification or exception or any qualification or exception as to
the scope of such audit) to the effect that such consolidated financial statements fairly present in all material respects the financial condition and results of operations of Parent and its consolidated subsidiaries on a consolidated basis in
accordance with GAAP; 

 
 94
 
  

 (b)  within 50 days after the end of each of
the first three fiscal quarters of each fiscal year, its consolidated balance sheet and related statements of income, stockholders’ equity and cash flows showing the financial condition of Parent and its consolidated subsidiaries as of the
close of such fiscal quarter and the results of its operations and the operations of such subsidiaries during such fiscal quarter and the then elapsed portion of the fiscal year, and comparative figures for the same periods in the immediately
preceding fiscal year all certified by one of its Financial Officers as fairly presenting in all material respects the financial condition and results of operations of Parent and its consolidated subsidiaries on a consolidated basis in accordance
with GAAP, subject to normal year-end audit adjustments; 
 (c)  concurrently with any delivery of
financial statements under paragraph (a) or (b) above, a certificate of a Financial Officer of the Borrower (i) certifying that no Event of Default or Default has occurred or, if such an Event of Default or Default has occurred,
specifying the nature and extent thereof and any corrective action taken or proposed to be taken with respect thereto, (ii) setting forth computations in reasonable detail satisfactory to the Administrative Agent demonstrating compliance with
the covenants contained in Sections 6.11 (in the case of the financial statements delivered under paragraph (a) only), 6.12 and 6.13 and, with respect to any Permitted Acquisition consummated during the preceding quarter for total consideration
in excess of $100,000,000, 6.04(h), (iii) setting forth the identity and value of any Hospital acquired in fee by Parent or any Subsidiary during the preceding quarter and not previously identified to the Administrative Agent if the fair market
value thereof is in excess of $10,000,000 and (iv) setting forth computations in reasonable detail satisfactory to the Administrative Agent of the Secured Net Leverage Ratio and the Leverage Ratio and, in the case of a certificate delivered
with the financial statements required by paragraph (a) above, setting forth Parent’s calculation of Excess Cash Flow; 

(d)  within 120 days after the beginning of each fiscal year of Parent, a detailed consolidated
budget for such fiscal year (including a projected consolidated balance sheet and related statements of projected operations and cash flows as of the end of and for such fiscal year and setting forth the assumptions used for purposes of preparing
such budget) and, promptly when available, any significant revisions of such budget; 

(e)  promptly after the same become publicly available, copies of all periodic and other reports,
proxy statements and other materials filed by Parent, the Borrower or any Subsidiary with the SEC, or with any national securities exchange, or distributed to its shareholders, as the case may be; 

 
 95
 
  

 (f) promptly after the request by any Lender (made through
the Administrative Agent), all documentation and other information that such Lender reasonably requests in order to comply with its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations,
including the USA PATRIOT Act; 
 (g) promptly after the request by the Administrative Agent or any Lender,
copies of (i) any documents described in Section 101(k)(1) of ERISA that the Borrower or any of its ERISA Affiliates may request with respect to any Multiemployer Plan and (ii) any notices described in Section 101(l)(1) of ERISA
that the Borrower or any of its ERISA Affiliates may request with respect to any Multiemployer Plan; provided that if the Borrower or any of its ERISA Affiliates has not requested such documents or notices from the administrator or sponsor of
the applicable Multiemployer Plan, the Borrower or the applicable ERISA Affiliate shall promptly make a request for such documents or notices from such administrator or sponsor and shall provide copies of such documents and notices promptly after
receipt thereof; 
 (h) promptly, from time to time, such other information regarding the operations,
business affairs and financial condition of Parent, the Borrower or any Subsidiary, or compliance with the terms of any Loan Document, as the Administrative Agent may reasonably request (on behalf of itself or any Lender); and 

(i) substantially contemporaneously with each designation of a Subsidiary as an “Unrestricted
Subsidiary” and each redesignation of an Unrestricted Subsidiary as a “Subsidiary”, provide written notice of such designation or redesignation, as applicable, to the Administrative Agent (who shall promptly notify the Lenders). 

SECTION 5.05. Litigation and Other Notices.    Furnish to the Administrative Agent prompt
written notice of the following: 
 (a) any Event of Default or Default, specifying the nature and extent
thereof and the corrective action (if any) taken or proposed to be taken with respect thereto; 
 (b) the
filing or commencement of, or any threat or notice of intention of any person to file or commence, any action, suit or proceeding, whether at law or in equity or by or before any Governmental Authority, against Parent, the Borrower or any Subsidiary
that could reasonably be expected to result in a Material Adverse Effect; and 
 (c) any event or occurrence
that has resulted in, or could reasonably be expected to result in, a Material Adverse Effect. 
 SECTION 5.06.
Information Regarding Collateral.          Furnish to the Administrative Agent prompt written notice of any change (i) in any Loan Party’s

 
 96
 
  

 
corporate name, (ii) in any Loan Party’s jurisdiction of organization or formation, (iii) in any Loan Party’s identity or corporate structure or (iv) in any Loan
Party’s Federal Taxpayer Identification Number. Parent and the Borrower agree not to effect or permit any change referred to in the preceding sentence unless all filings have been made under the Uniform Commercial Code or otherwise that are
required in order for the Collateral Agent to continue at all times following such change to have a valid, legal and perfected security interest in all the Collateral. Parent and the Borrower also agree promptly to notify the Administrative Agent if
any material portion of the Collateral is damaged or destroyed. 
 SECTION 5.07. Maintaining Records; Access to
Properties and Inspections; Maintenance of Ratings. (a) Keep books of record and account in which full, true and correct entries in all material respects are made of all dealings and transactions in relation to its business and
activities which permit financial statements to be prepared in conformity with GAAP and all requirements of law. Each Loan Party will, and will cause each of its subsidiaries to, permit any representatives designated by the Administrative Agent or
the Required Lenders to visit and inspect the financial records and the properties of such person at reasonable times and as often as reasonably requested upon reasonable notice and to make extracts from and copies of such financial records (in each
case excluding patient medical records and any other material which is confidential pursuant to any laws, rules, regulations and decrees and orders of any Governmental Authority) and permit any representatives designated by the Administrative Agent
or the Required Lenders to discuss the affairs, finances and condition of such person with the officers thereof and independent accountants therefor (with a senior officer of the Borrower present); provided that, excluding any such visits and
inspections during the continuation of an Event of Default, only one such visit during any fiscal year shall be at the Borrower’s expense. 

(b) In the case of Parent and the Borrower, use commercially reasonable efforts to cause the Credit Facilities
to be continuously rated by S&P and Moody’s, and to maintain a corporate rating from S&P and a corporate family rating from Moody’s, in each case in respect of Parent. 

SECTION 5.08. Use of Proceeds. Use the proceeds of the Loans and request the issuance of Letters of Credit only
for the purposes specified in the Preliminary Statement to this Agreement. 
 SECTION 5.09. Employee Benefits.
(a) Comply in all material respects with the applicable provisions of ERISA and the Code, except as would not reasonably be expected to have a Material Adverse Effect, and (b) furnish to the Administrative Agent as soon as possible after,
and in any event within ten days after any Responsible Officer of Parent, the Borrower or any ERISA Affiliate knows or has reason to know that, any ERISA Event has occurred that, alone or together with any other ERISA Event could reasonably be
expected to result in liability of the Borrower or any ERISA Affiliate in an aggregate amount exceeding $10,000,000, a statement of a Financial Officer of Parent or the Borrower setting forth details as to such ERISA Event and the action, if any,
that Parent or the Borrower proposes to take with respect thereto. 

 
 97
 
  

 SECTION 5.10. Compliance with Environmental
Laws.   Comply and cause all lessees and other persons occupying its properties to comply, in all material respects with all Environmental Laws applicable to its operations and properties; obtain and renew all material
environmental permits necessary for its operations and properties; and promptly conduct any remedial action in accordance with Environmental Laws; provided, however, that none of Parent, the Borrower or any Subsidiary shall be required
to undertake any remedial action required by Environmental Laws to the extent that its obligation to do so is being contested in good faith and by proper proceedings and appropriate reserves are being maintained with respect to such circumstances in
accordance with GAAP. 
 SECTION 5.11. Preparation of Environmental Reports.   If a Default
caused by reason of a breach of Section 3.17 or Section 5.10 shall have occurred and be continuing for more than 20 days without Parent, the Borrower or any Subsidiary commencing activities reasonably likely to cure such Default, at
the written request of the Required Lenders through the Administrative Agent, the Borrower shall provide to the Lenders within 45 days after receipt of such request, at the expense of the Loan Parties, environmental site assessment reports
(Phase I, Phase II and/or compliance audits) regarding the matters which are the subject of such Default prepared by an environmental consulting firm reasonably acceptable to the Administrative Agent and indicating the compliance matter and/or the
presence or absence of Hazardous Materials and the estimated cost of any compliance or remedial action in connection with such Default. 

SECTION 5.12. Further Assurances.   Execute any and all further documents, financing statements,
agreements and instruments, and take all further action (including filing Uniform Commercial Code and other financing statements, mortgages and deeds of trust) that may be required under applicable law, or that the Required Lenders, the
Administrative Agent or the Collateral Agent may reasonably request, in order to effectuate the transactions contemplated by the Loan Documents and in order to grant, preserve, protect and perfect the validity and first priority of the security
interests created or intended to be created by the Security Documents. The Borrower will cause any subsequently acquired or organized Material Subsidiary (or any Subsidiary that becomes a Material Subsidiary) to become a Loan Party by executing the
Guarantee and Collateral Agreement and each applicable Security Document in favor of the Collateral Agent. The Borrower may, in its discretion, elect to cause a Permitted Joint Venture Subsidiary to become a Loan Party by complying with the
foregoing sentence. In addition, except with respect to which, in the reasonable judgment of the Administrative Agent (confirmed in writing by written notice to the Borrower), the cost or other consequences (including any Tax consequence) of doing
so shall be excessive in view of the benefits to be obtained by the Lenders therefrom and subject to applicable limitations set forth in the Security Documents, from time to time, the Borrower will, at its cost and expense, promptly secure the
Obligations by pledging or creating, or causing to be pledged or created, perfected security interests with respect to such of its assets and properties as the Administrative Agent or the Required Lenders shall designate (it being understood that it
is the intent of the parties that the Obligations shall be secured by substantially all the assets of Parent, the Borrower and the Subsidiary Guarantors (including properties acquired subsequent to the Closing Date), except this Section 5.12
shall not require Parent, the Borrower or any Subsidiary Guarantor to (a) pledge (i) more than 65% of the 

 
 98
 
  

 
outstanding voting Equity Interests in any Foreign Subsidiary, (ii) any Equity Interest in any Non-Significant Subsidiary or (iii) any Equity Interest in any Permitted Syndication
Subsidiary, any Securitization Subsidiary or any Permitted Joint Venture Subsidiary to the extent the pledge of the Equity Interest in such Subsidiary is prohibited by any applicable Contractual Obligation or requirement of law, or (b) grant
security interests in any asset that (i) would result in the violation of the enforceable anti-assignment provision of any contract, or would be prohibited by or would violate applicable law or contractual provisions (including any right of
first refusal) or would otherwise result in termination or any forfeiture under any contract, (ii) is a vehicle or other asset subject to certificate of title, (iii) require perfection through control agreements (including, to the extent
required in the relevant jurisdiction for deposit accounts and investment property), (iv) are minority Equity Interests, (v) are leasehold interests or (vi) is permitted to be so excluded under the Guarantee and Collateral Agreement.
Such security interests and Liens will be created under the Security Documents and other security agreements, mortgages, deeds of trust and other instruments and documents in form and substance reasonably satisfactory to the Collateral Agent, and
the Borrower shall deliver or cause to be delivered to the Lenders all such instruments and documents (including legal opinions, title insurance policies and lien searches) as the Collateral Agent shall reasonably request to evidence compliance with
this Section. Any requirement to mortgage real property that is acquired after the Closing Date pursuant to this Section 5.12 shall be limited to real property owned in fee by a Loan Party that (i) has a fair market value equal to or
exceeding $10,000,000, (ii) is not subject to a Lien permitted under Section 6.02(c), (n) or (s) (for so long as such Lien exists), and (iii) the Borrower does not intend to sell within six months of the acquisition thereof
pursuant to clause (i) or (x) of Section 6.05(b) or such longer period permitted by the Collateral Agent. No appraisals, environmental reports or surveys shall be required to be obtained in connection with any mortgage of real
property pursuant to this Section 5.12. The Borrower agrees to provide such evidence as the Collateral Agent shall reasonably request as to the perfection and priority status of each such security interest and Lien. 

SECTION 5.13.  Proceeds of Certain Dispositions.  If, as a result of the receipt of any cash
proceeds by Parent, the Borrower or any Subsidiary in connection with any sale, transfer, lease or other disposition of any asset the Borrower would be required by the terms of any Senior Note Indenture or the documentation governing any other
Material Indebtedness that is unsecured or secured by Liens junior to the Liens securing the Obligations to make an offer to purchase any of the Indebtedness thereunder, then, prior to the first day on which the Borrower would be required to
commence such an offer to purchase, (i) prepay Loans in accordance with Section 2.12 or 2.13, provided that the Borrower may use a portion of such cash proceeds to prepay or repurchase Other Senior Secured Debt to the extent any
applicable credit agreement, indenture or other agreement governing such Other Senior Secured Debt requires the Borrower to prepay or make an offer to purchase such Other Senior Secured Debt with such cash proceeds, in each case in an amount not to
exceed the product of (A) the amount of such cash proceeds and (B) a fraction, the numerator of which is the outstanding principal amount of such Other Senior Secured Debt and the denominator of which is the sum of the outstanding
principal amount of such Other Senior Secured Debt and the outstanding principal amount of Term Loans, or (ii) acquire assets or make investments in a manner that is permitted hereby, in each case in a manner that will eliminate any such
requirement to make such an offer to purchase. 

 
 99
 
  

 SECTION 5.14.  Operation of
Facilities.  Use commercially reasonable efforts to operate, and cause the Subsidiaries to operate, the Facilities owned, leased or operated by Parent, the Borrower or any of the Subsidiaries now or in the future in a manner
believed by the Borrower to be consistent with prevailing health care industry standards in the locations where the Facilities exist from time to time, except to the extent failure to do so would not have a Material Adverse Effect. 

ARTICLE VI 
 Negative Covenants

 Each of Parent and the Borrower covenants and agrees with each Lender that, so long as this Agreement shall remain in
effect and until the Commitments have been terminated and the principal of and interest on each Loan, all Fees and all other expenses or amounts payable under any Loan Document have been paid in full and all Letters of Credit have been cancelled or
have expired and all amounts drawn thereunder have been reimbursed in full or other arrangements acceptable to the Issuing Bank and the Administrative Agent have been made with respect thereto, unless the Required Lenders shall otherwise consent in
writing, neither Parent nor the Borrower will, nor will they cause or permit any of the Subsidiaries to: 
 SECTION 6.01.
Indebtedness.    Incur, create, assume or permit to exist any Indebtedness, except: 

(a) Indebtedness existing on the Third Restatement Effective Date and set forth in Schedule 6.01 and any
extensions, renewals, refinancings or replacements of such Indebtedness to the extent the principal amount of such Indebtedness is not increased (except by an amount equal to the unpaid accrued interest and premium thereon plus other reasonable
amounts paid and fees and expenses incurred in connection with such extension, renewal, refinancing or replacement), neither the final maturity nor the weighted average life to maturity of such Indebtedness is decreased, such Indebtedness, if
subordinated to the Obligations, remains so subordinated on terms no less favorable to the Lenders, and the obligors thereof, if not the original obligors in respect of such Indebtedness, are Loan Parties; 

(b) Indebtedness created hereunder and under the other Loan Documents; 

(c) intercompany Indebtedness of Parent, the Borrower and the Subsidiaries to the extent permitted by
Section 6.04(c); 
 (d) Indebtedness of the Borrower or any Subsidiary incurred to finance the
acquisition, construction or improvement of any fixed or capital assets, and extensions, renewals, refinancings and replacements of any such Indebtedness that do not increase the outstanding principal amount thereof (except by an

 
 100
 
  

 
amount equal to the unpaid accrued interest and premium thereon plus other reasonable amounts paid and fees and expenses incurred in connection with such extension, renewal, refinancing or
replacement); provided that (i) such Indebtedness is incurred prior to or within 270 days after such acquisition or the completion of such construction or improvement and (ii) the aggregate principal amount of Indebtedness permitted
by this Section 6.01(d), when combined with the aggregate principal amount of all Capital Lease Obligations and Synthetic Lease Obligations incurred pursuant to Section 6.01(e), shall not exceed $500,000,000 at any time outstanding; 

(e) Capital Lease Obligations and Synthetic Lease Obligations in an aggregate principal amount, when combined
with the aggregate principal amount of all Indebtedness incurred pursuant to Section 6.01(d), not in excess of $500,000,000 at any time outstanding; 

(f) Indebtedness (including Capital Lease Obligations) of any Subsidiary secured by one or more Facilities
owned or leased by such Subsidiary, and extensions, renewals, refinancings and replacements of any such Indebtedness that do not increase the outstanding principal amount thereof (except by an amount equal to the unpaid accrued interest and premium
thereon plus other reasonable amounts paid and fees and expenses incurred in connection with such extension, renewal, refinancing or replacement); provided that (i) when incurred, such Indebtedness shall not exceed the fair market value
of the Facilities securing the same and (ii) the aggregate principal amount of all such Indebtedness incurred pursuant to this Section 6.01(f) shall not exceed $500,000,000 at any time outstanding (such Indebtedness meeting the criteria of
this Section 6.01(f) being referred to herein as “Permitted Real Estate Indebtedness”); 

(g) Indebtedness under performance bonds, bid bonds, appeal bonds, surety bonds and completion guarantees and
similar obligations, or with respect to workers’ compensation claims, in each case incurred in the ordinary course of business, including those incurred to secure health, safety and environmental obligations in the ordinary course of business;

 (h) [reserved]; 

(i) Indebtedness in respect of Hedging Agreements permitted by Section 6.04(g); 

(j) Cash Management Obligations; 

(k) Indebtedness incurred by Foreign Subsidiaries in an aggregate principal amount not exceeding $75,000,000
at any time outstanding; 
 (l) Indebtedness pursuant to any Permitted Receivables Transaction incurred in
accordance with Section 6.05(b); 

 
 101
 
  

 (m) Indebtedness incurred to finance, or assumed in
connection with, one or more Permitted Acquisitions or the Permitted HMA Transaction, and any extensions, renewals, refinancings or replacements of such Indebtedness to the extent the principal amount of such Indebtedness is not increased (except by
an amount equal to the unpaid accrued interest and premium thereon plus other reasonable amounts paid and fees and expenses incurred in connection with such extension, renewal, refinancing or replacement plus unused committed amounts), neither the
final maturity nor the weighted average life to maturity of such Indebtedness is decreased, such Indebtedness, if subordinated to the Obligations, remains so subordinated on terms no less favorable to the Lenders, and the obligors thereof, if not
the original obligors in respect of such Indebtedness, are Loan Parties; 
 (n) Indebtedness owed to a
seller in a Permitted Acquisition or any other acquisition permitted under Section 6.04, or a Permitted Joint Venture or to a buyer in a disposition permitted under Section 6.05 that (i) relates to post-closing adjustments with
respect to accounts receivable, accounts payable, net worth and/or similar items or earnouts or (ii) relates to indemnities granted to the seller or buyer in such transactions; 

(o) Permitted Additional Debt, provided that, at the time of incurrence of such Permitted Additional
Debt, and after giving pro forma effect thereto and to the use of the proceeds thereof, the Interest Coverage Ratio (as such term and its component definitions are defined on the Third Restatement Effective Date) shall not be less than (i) at
any time on or prior to December 31, 2016, 2.00 to 1.0 or (ii) at any time thereafter, 2.25 to 1.0; 

(p) Indebtedness in the nature of letters of credit (other than Letters of Credit issued pursuant to this
Agreement) issued for the account of Parent, the Borrower or any Subsidiary (and related reimbursement obligations) not to exceed an aggregate face amount of $100,000,000; 

(q) without duplication of any other Indebtedness, non-cash accruals of interest, accretion or amortization of
original issue discount and/or pay-in-kind interest on Indebtedness otherwise permitted hereunder; 
 (r)
from and after the latest Revolving Credit Maturity Date (including the final maturity date of any Replacement Revolving Credit Facility), Indebtedness to finance the general needs of the Borrower and the Subsidiaries incurred after such latest
Revolving Credit Maturity Date in an aggregate principal amount not to exceed, when taken together with the aggregate principal amount of all other outstanding Indebtedness incurred in reliance on this paragraph (r), $1,500,000,000 at any time
outstanding, provided that the Borrower shall have (i) repaid all Revolving Loans and reimbursed, if any, all L/C Disbursements and made arrangements acceptable to the Issuing Bank and the Administrative Agent with respect to any
outstanding Letters of Credit and (ii) paid all related fees and expenses, each in accordance with the terms of this Agreement; 

 
 102
 
  

 (s) Indebtedness consisting of obligations to pay insurance
premiums; 
 (t) except as otherwise expressly provided herein, Guarantees by Parent, the Borrower or the
Subsidiaries of Indebtedness of Parent, the Borrower and the Subsidiaries permitted to be incurred hereunder; 

(u) other Indebtedness incurred after the Third Restatement Effective Date of the Borrower or the Subsidiaries
in an aggregate principal amount not exceeding $1,000,000,000 at any time outstanding; 
 (v) (x) Pari
Passu Debt, provided that, either (i) at the time of incurrence of such Pari Passu Debt, and after giving effect thereto and to the use of the proceeds thereof, (A) no Default or Event of Default shall have occurred and be
continuing and (B) the Secured Net Leverage Ratio Condition shall be satisfied or (ii) not later than the fifth Business Day following the incurrence thereof, 100% of the Net Cash Proceeds thereof are used by the Borrower to prepay Term
Loans in the manner set forth in Section 2.13(g) and (y) Pari Passu Debt or Permitted Additional Debt that refinances or replaces any existing Pari Passu Debt; provided that the principal amount of such Pari Passu Debt is not
increased (except by an amount not to exceed (1) the amount of unpaid accrued interest and premium on the existing Pari Passu Debt so refinanced or replaced, plus (2) other reasonable amounts paid and fees and expenses incurred in
connection with such refinancing or replacement plus unused commitments); 
 (w) (i) Alternative
Incremental Facility Indebtedness; provided that (x) at the time of incurrence of such Alternative Incremental Facility Indebtedness the principal amount of such Alternative Incremental Facility Indebtedness does not exceed the
Incremental Amount and (y) either (A) at the time of incurrence of such Alternative Incremental Facility Indebtedness, and after giving effect thereto and to the use of the proceeds thereof, no Default or Event of Default shall have
occurred and be continuing, (B) 100% of the Net Cash Proceeds thereof are used within five Business Days of the incurrence thereof to prepay then-outstanding Term Loans pursuant to Section 2.12 or (C) such Indebtedness is incurred in
connection with a Permitted Acquisition; and (ii) any extensions, renewals, refinancings and replacements of Indebtedness permitted to be incurred pursuant to this Section 6.01(w) (the Indebtedness being extended, renewed, refinanced or
replaced being referred to herein as the “Refinanced Indebtedness”; and the Indebtedness incurred under this subclause (ii) being referred to herein as “Permitted Refinancing Indebtedness”);
provided that (x) the principal amount of the Permitted Refinancing Indebtedness is not increased (except by an amount equal to the accrued interest and premium on, or other amounts paid, and fees and expenses incurred, in connection
with such extension, renewal, refinancing or replacement plus any unused commitments) and (y) the Permitted Refinancing Indebtedness complies with clauses (a) through (g) of the definition of the term “Alternative Incremental
Facility Indebtedness”; and 

 
 103
 
  

 (x) (1) Other Junior Secured Debt of Loan Parties,
provided that, at the time of incurrence of such Other Junior Secured Debt, (A) after giving effect thereto and to the use of the proceeds thereof, no Default or Event of Default shall have occurred and be continuing and (B) after
giving pro forma effect thereto and to the use of the proceeds thereof, the Secured Net Leverage Ratio shall not be greater than 4.25 to 1.0, and (2) Other Junior Secured Debt of Loan Parties that refinances or replaces any existing Other
Junior Secured Debt of Loan Parties; provided that the principal amount of such Other Junior Secured Debt is not increased (except by an amount not to exceed (x) the amount of unpaid accrued interest and premium on the existing Other
Junior Secured Debt so refinanced or replaced, plus (y) other reasonable amounts paid and fees and expenses incurred in connection with such refinancing or replacement plus unused commitments). 

SECTION 6.02. Liens. Create, incur, assume or permit to exist any Lien on any property or assets (including
Equity Interests or other securities of any person, including the Borrower or any Subsidiary) now owned or hereafter acquired by it or on any income or revenues or rights in respect of any thereof, except: 

(a) Liens on property or assets of the Borrower and the Subsidiaries existing on the Third Restatement
Effective Date and set forth in Schedule 6.02; provided that such Liens shall secure only those obligations which they secured on the Third Restatement Effective Date and extensions, renewals and replacements thereof permitted hereunder;

 (b) any Lien created under the Loan Documents; 

(c) any Lien existing on any property or asset prior to the acquisition thereof by the Borrower or any
Subsidiary or existing on any property or assets of any person that becomes a Subsidiary after the Closing Date prior to the time such person becomes a Subsidiary, as the case may be; provided that (i) such Lien is not created in
contemplation of or in connection with such acquisition or such person becoming a Subsidiary, (ii) such Lien does not apply to any other property or assets of Parent, the Borrower or any Subsidiary (other than affixed or incorporated into the
property covered by such Lien) and (iii) such Lien secures only those obligations which it secures on the date of such acquisition or the date such person becomes a Subsidiary, as the case may be, and any extensions, renewals, refinancings or
replacements of such obligations; 
 (d) Liens, assessments or governmental charges or claims for taxes not
yet delinquent or which are not required to be paid pursuant to Section 5.03; 
 (e) carriers’,
warehousemen’s, mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business and securing obligations that are not delinquent or which are not required to be paid under Section 5.03;

 
 104
 
  

 (f) Liens incurred and pledges and deposits made in the
ordinary course of business in connection with any self-retention or self-insurance, or with respect to workmen’s compensation, unemployment insurance, general liability, medical malpractice, professional liability or property insurance and
other social security laws or regulations; 
 (g) deposits to secure the performance of bids, trade
contracts (other than for Indebtedness), leases (other than Capital Lease Obligations), statutory obligations, surety and appeal bonds, government contracts, performance bonds and other obligations of a like nature incurred in the ordinary course of
business; 
 (h) zoning restrictions, easements, rights-of-way, rights of first refusal, restrictions on use
of real property, minor defects or irregularities in title and other similar charges or encumbrances which, in the aggregate, do not interfere in any material respect with the business of the Borrower and the Subsidiaries, taken as a whole; 

(i) zoning, building codes and other land use laws, regulations and ordinances regulating the use or occupancy
of real property or the activities conducted thereon which are imposed by any Governmental Authority having jurisdiction over such real property which are not violated by the current use or occupancy of such real property or the operation of the
business of the Borrower or any of the Subsidiaries or any violation of which would not have a Material Adverse Effect; 

(j) ground leases in respect of real property on which Facilities owned or leased by the Borrower or any of
the Subsidiaries are located; 
 (k) any interest or title of a lessor or secured by a lessor’s
interest under any lease permitted hereunder; 
 (l) leases or subleases granted to others not interfering
in any material respect with the business of the Borrower and the Subsidiaries, taken as a whole; 
 (m)
Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods; 

(n) Liens securing Indebtedness to finance the acquisition, construction or improvement of fixed or capital
assets; provided that (i) such security interests secure Indebtedness permitted by Section 6.01, (ii) such security interests are incurred, and the Indebtedness secured thereby is created, within 270 days after such
acquisition, construction or improvement, and (iii) such security interests do not apply to any other property or assets of the Borrower or any Subsidiary, except for accessions to the property financed with the proceeds of such Indebtedness
and the proceeds and the products thereof; provided that individual financings of equipment provided by one lender may be cross-collateralized to other financings of equipment provided by such lender secured by a Lien permissibly incurred
pursuant to this Section 6.02(n); 

 
 105
 
  

 (o) Liens arising out of judgments or awards that do not
constitute an Event of Default under paragraph (i) of Article VII; 
 (p) Liens pursuant to
Receivables Transactions incurred in accordance with Section 6.05(b), including Liens on the assets of any Securitization Subsidiary created pursuant to a Receivables Transaction and Liens incurred by the Borrower and the Subsidiaries on
Receivables to secure obligations owing by them in respect of any such Receivables Transaction, provided that any Receivables not transferred to a Securitization Subsidiary in connection with such Receivables Transaction to the extent
constituting intercompany indebtedness required to be pledged pursuant to the Guarantee and Collateral Agreement shall be and remain subject to the perfected first priority Lien and security interest granted to the Collateral Agent in favor of the
Lenders in accordance with the Guarantee and Collateral Agreement; 
 (q) Liens on assets of Foreign
Subsidiaries; provided that (i) such Liens do not extend to, or encumber, assets that constitute Collateral or the Equity Interests of the Borrower or any of the Domestic Subsidiaries, and (ii) such Liens extending to the assets of
any Foreign Subsidiary secure only Indebtedness incurred by such Foreign Subsidiary pursuant to Section 6.01(k); 

(r) Liens (i) of a collecting bank arising under Section 4-210 of the Uniform Commercial Code on
items in the course of collection, (ii) attaching to commodity trading accounts or other commodities brokerage accounts incurred in the ordinary course of business; and (iii) in favor of a banking institution arising as a matter of law
encumbering deposits (including the right of set off); 
 (s) Liens on one or more Facilities owned or
leased by any Subsidiary to secure Permitted Real Estate Indebtedness incurred by such Subsidiary pursuant to Section 6.01(f); 

(t) Liens that are contractual rights of set-off (i) relating to the establishment of depository
relations with banks not given in connection with the issuance of Indebtedness, (ii) relating to pooled deposit or sweep accounts of Parent, the Borrower or any Subsidiary to permit satisfaction of overdraft or similar obligations incurred in
the ordinary course of business of Parent, the Borrower and the Subsidiaries or (iii) relating to purchase orders and other agreements entered into with customers of Parent, the Borrower or any Subsidiary in the ordinary course of business;

 (u) Liens arising out of conditional sale, title retention, consignment or similar arrangements for the
sale or purchase of goods entered into by the Borrower or any of the Subsidiaries in the ordinary course of business permitted hereunder; 

 
 106
 
  

 (v) Liens solely on any cash earnest money deposits made by
Parent, the Borrower or any of the Subsidiaries in connection with any letter of intent or purchase agreement permitted hereunder; 

(w) Liens securing insurance premiums financing arrangements, provided that such Liens are limited to
the applicable unearned insurance premiums; 
 (x) other Liens that do not, individually or in the
aggregate, secure obligations in excess of $300,000,000 at any one time; 
 (y) Liens on the Collateral
which (i) secure Indebtedness incurred pursuant to Section 6.01(r) and (ii) have the same priority as, or junior priority to, the Liens securing the Obligations; 

(z) Liens on the Collateral which (i) secure Pari Passu Debt Obligations and/or Alternative Incremental
Facility Indebtedness and (ii) have the same priority as, or junior priority to, the Liens securing the Obligations; 

(aa) Liens on the Collateral which (i) secure Indebtedness incurred pursuant to Section 6.01(m) if,
at the time of the incurrence or assumption thereof, the Secured Net Leverage Ratio Condition is met, (ii) have the same priority as, or junior priority to, the Liens securing the Obligations and (iii) are subject to the Pari Passu
Intercreditor Agreement or a Junior Lien Intercreditor Agreement; and 
 (bb) Liens on the Collateral which
(i) secure Other Junior Secured Debt incurred pursuant to Section 6.01(x) that is not secured by any asset other than Collateral that secures the Obligations, (ii) have junior priority to the Liens securing the Obligations and
(iii) are subject to a Junior Lien Intercreditor Agreement. 
 SECTION 6.03.  Sale and Lease-Back
Transactions.         Enter into any arrangement, directly or indirectly, with any person whereby it shall sell or transfer any property, real or personal, used or useful in its business, whether
now owned or hereafter acquired, and thereafter rent or lease such property or other property which it intends to use for substantially the same purpose or purposes as the property being sold or transferred unless (a) the sale or transfer of
such property is permitted by Section 6.05 and (b) any Capital Lease Obligations, Synthetic Lease Obligations, Permitted Real Estate Indebtedness or Liens arising in connection therewith are permitted by Sections 6.01 and 6.02, as the case
may be. 
 SECTION 6.04.  Investments, Loans and Advances.   Purchase, hold or
acquire any Equity Interests, evidences of indebtedness or other securities of, make or permit to exist any loans or advances to, or make or permit to exist any investment or any other interest in, any other person, except: 

(a) (i)  investments by Parent, the Borrower and the Subsidiaries existing on the Closing Date in
the Borrower and the Subsidiaries, (ii) additional investments by Parent, the Borrower and the Subsidiaries in the Borrower and the 

 
 107
 
  

 
Subsidiaries and any Unrestricted Subsidiaries and (iii) additional investments by Parent, the Borrower and the Subsidiaries in Permitted Joint Ventures (subject to the limitations on such
investments referred to in the definition of the term “Permitted Joint Ventures”); provided that (x) any Equity Interests held by a Loan Party shall be pledged to the extent required by Section 5.12 and the Guarantee and
Collateral Agreement and (y) any such investments made pursuant to clause (ii) above made by a Loan Party to a Subsidiary that is not a Loan Party, or made by Parent, the Borrower or any Subsidiary to an Unrestricted Subsidiary, may only
be made if (A) no Default or Event of Default shall have occurred and be continuing and (B) the aggregate amount of all such investments made by Loan Parties in Subsidiaries that are not Loan Parties, or by Parent, the Borrower or any
Subsidiary in an Unrestricted Subsidiary and outstanding at any time (without regard to any write-downs or write-offs thereof, and valued net in the case of intercompany loans and transferred liabilities) shall not exceed $500,000,000 after the
Third Restatement Effective Date plus the amount of dividends, distributions and other returns of capital actually received in cash by any Loan Party with respect to any such investments; for purposes of the foregoing, if the Borrower designates a
Subsidiary as an Unrestricted Subsidiary in accordance with the definition of the term “Unrestricted Subsidiary”, the Borrower will be deemed to have made an investment at that time in the resulting Unrestricted Subsidiary in an aggregate
amount equal to the fair market value of the net assets of such Unrestricted Subsidiary; 
 (b) Permitted
Investments; 
 (c) (i) loans or advances in respect of intercompany accounts attributable to the
operation of the Borrower’s cash management system (including with respect to intercompany self-insurance arrangements), (ii) loans or advances made by the Borrower or any of the Subsidiaries to a Permitted Syndication Subsidiary for
working capital needs evidenced by a promissory note that is pledged to the Collateral Agent so long as such loans or advances constitute Indebtedness of the primary obligor that is not subordinate to any other Indebtedness of such obligor, and
(iii) loans or advances made by Parent to the Borrower or any Subsidiary, the Borrower to Parent or any Subsidiary and by any Subsidiary to Parent, the Borrower or any other Subsidiary; provided, however, that (x) any such
loans and advances made by a Loan Party that are evidenced by a promissory note shall be pledged to the Collateral Agent for the ratable benefit of the Secured Parties pursuant to the Guarantee and Collateral Agreement (and any such loans and
advances made by a Loan Party to a Subsidiary that is not a Loan Party shall be so evidenced and pledged) and (y) any such loan or advance made by a Loan Party to a Subsidiary that is not a Loan Party or by Parent, the Borrower or any
Subsidiary to an Unrestricted Subsidiary shall be subject to the requirements and limitations described in clause (y) of the first proviso to Section 6.04(a), except to the extent that (1) such loan or advance shall be secured by a
fully perfected, first-priority Lien on substantially all of the assets of the recipient of such loan or advance and its subsidiaries (in each case of a type that would have constituted Collateral if such recipient were party to the applicable
Security Documents) and (2) such Lien is collaterally assigned to the Collateral Agent for the benefit of the Secured Parties, all on terms reasonably satisfactory to the Collateral Agent; 

 
 108
 
  

 (d) investments received in connection with the bankruptcy or
reorganization of, or settlement of delinquent accounts and disputes with, customers and suppliers, in each case in the ordinary course of business; 

(e) the Borrower and the Subsidiaries may make loans and advances in the ordinary course of business to their
respective employees, officers, consultants and agents (including payroll advances, travel and entertainment advances and relocation loans in the ordinary course of business to employees, officers and agents of the Borrower or any such Subsidiary
(or to any physician or other health care professional associated with or agreeing to become associated with Parent, the Borrower or any Subsidiary or any Hospital owned or leased or operated by the Borrower or any Subsidiary (“Health
Care Associates”))); 
 (f) Guarantees to third parties made in the ordinary course of business
in connection with the relocation of employees or agents of Health Care Associates of the Borrower or any of the Subsidiaries; 

(g) the Borrower and the Subsidiaries may enter into Hedging Agreements that are not speculative in nature;

 (h) the Borrower or any Subsidiary may acquire (including by any lease that contains upfront payments
and/or buyout options) all or substantially all the assets of a person or line of business of such person, or directly acquire and beneficially own (and retain the right to vote) more than 50% of the aggregate ordinary voting power and aggregate
equity value represented by the outstanding capital stock or other Equity Interests of any acquired or newly formed corporation or other entity that acquires or leases such person, division or line of business (referred to herein as the
“Acquired Entity”); provided that (i) as of the consummation thereof, such acquisition shall have been approved by the board of directors of the Acquired Entity; (ii) the Acquired Entity shall be in a
similar, related, incidental or complementary line of business as that of the Borrower and the Subsidiaries as conducted during the current and most recent calendar year; and (iii) at the time of such transaction
(A) [Reserved], (B) if the total consideration paid in connection with such acquisition and any other acquisitions pursuant to this Section 6.04(h) after the Third Restatement Effective Date (including any Indebtedness of the
Acquired Entity that is assumed by the Borrower or any Subsidiary following such acquisition and any payments following such acquisition pursuant to earn-out provisions or similar obligations) shall exceed $500,000,000 in the aggregate
(excluding the total consideration paid in respect of Permitted Acquisitions listed on Schedule 6.04(h) and consideration consisting of, or funded with the proceeds of, Qualified Capital Stock and excluding any acquisition for total
consideration of no more that $150,000,000), then the Borrower would be in compliance with the covenant set forth in Section 6.13 on the last day of the most recently ended fiscal quarter for which financial

 
 109
 
  

 
statements have been or were required to be delivered, after giving pro forma effect to such transaction and to any other event occurring after such period as to which pro forma recalculation is
appropriate (including any other transaction described in this Section 6.04(h) occurring after such period) as if such transaction had occurred as of the first day of such period, (C) [Reserved], (D) the Borrower shall comply, and
shall cause the Acquired Entity to comply, with the applicable provisions of Section 5.12 and the Security Documents within a period after consummation of such transaction agreed to by the Administrative Agent (other than, in each case, any
Captive Insurance Subsidiary or Securitization Subsidiary), and (E) the aggregate consideration paid in connection with all such acquisitions of Acquired Entities that become Foreign Subsidiaries (or, in the case of an acquisition of assets,
such assets are not directly acquired by Loan Parties), shall not exceed $300,000,000 (any acquisition of an Acquired Entity meeting all the applicable criteria of this Section 6.04(h) being referred to herein as a “Permitted
Acquisition”); 
 (i) Permitted Joint Ventures; 

(j) investments in a Permitted Syndication Subsidiary in connection with a Permitted Syndication Transaction
made pursuant to Section 6.05(b); 
 (k) investments in any Securitization Subsidiary or other person
as required pursuant to the terms and conditions of any Permitted Receivables Transaction made pursuant to Section 6.05(b); 

(l) the Borrower or any of the Subsidiaries may acquire and hold Receivables owing to it or Parent, if created
or acquired in the ordinary course of business and payable or dischargeable in accordance with customary trade terms; 

(m) investments to the extent that payment for such investments is made with issuances of or the cash proceeds
from the issuance of Equity Interests of Parent; 
 (n) extensions of trade credit and purchases of
equipment and inventory in the ordinary course of business; 
 (o) loans and advances to Parent in lieu of,
and not in excess of the amount of, dividends to the extent permitted to be made to Parent in accordance with Section 6.06; 

(p) investments in the ordinary course of business consisting of endorsements for collection or deposit and
customary trade arrangements with customers consistent with past practices; 
 (q) investments by Parent,
the Borrower and the Subsidiaries in any Captive Insurance Subsidiary in an aggregate amount not to exceed 150% of the minimum amount of capital required under the laws of the jurisdiction in which such Captive Insurance Subsidiary is formed (plus
any excess capital generated as 

 
 110
 
  

 
a result of any such prior investment that would result in an unfavorable tax or reimbursement impact if distributed), and other investments in any Captive Insurance Subsidiary to cover
reasonable general corporate and overhead expenses of such Captive Insurance Subsidiary; 
 (r) investments
by any Captive Insurance Subsidiary; 
 (s) investments in any Captive Insurance Subsidiary in connection
with a push down by the Borrower of insurance reserves; 
 (t) investments held by a person (including by
way of acquisition, merger or consolidation) after the Closing Date otherwise in accordance with this Section 6.04 to the extent that such investments were not made in contemplation of or in connection with such acquisition, merger or
consolidation and were in existence on the date of such acquisition, merger or consolidation; 
 (u)
investments in minority interests existing on the Closing Date; 
 (v) the contribution or other transfer of
property to any Spinout Subsidiary in connection with a Spinout Transaction and investments received in connection with a Spinout Transaction; 

(w) investments representing the non-cash portion of the consideration received for an Asset Sale or other
asset disposition permitted under Section 6.05; 
 (x) investments entered into in order to consummate
the Permitted HMA Transaction or held as a result of the consummation of the HMA Permitted Transaction; 

(y) (i) investments made using the Available Amount or (ii) investments made using the Available
Declined Proceeds Amount; and 
 (z) in addition to investments permitted by paragraphs (a) through
(y) above, additional investments, loans and advances by the Borrower and the Subsidiaries so long as the aggregate outstanding amount of investments, loans and advances pursuant to this paragraph (z) (determined without regard to any
write-downs or write-offs of such investments, loans and advances) does not exceed $200,000,000 plus the amount of dividends, distributions and other returns of capital actually received in cash by any Loan Party or any of its Subsidiaries in
respect of investments made in reliance on this paragraph (z) in the aggregate at any time. 
 It is understood and
agreed that, in the event that any investment is made by the Borrower or any Subsidiary in any person through substantially concurrent interim transfers of any amount through one or more other Subsidiaries, then such other substantially concurrent
interim transfers shall be disregarded for purposes of this Section 6.04. 

 
 111
 
  

 SECTION 6.05. Mergers, Consolidations, Sales of Assets and
Acquisitions. (a)  Merge into or consolidate with any other person, or permit any other person to merge into or consolidate with it, or sell, transfer, lease or otherwise dispose of (in one transaction or in a series of
transactions) all or substantially all the assets (whether now owned or hereafter acquired) of the Borrower or less than all the Equity Interests of any Subsidiary (other than pursuant to any Permitted Interest Transfer, any Permitted Joint Venture
or transfers of Equity Interests of any Subsidiary to a Loan Party or by a Subsidiary that is not a Subsidiary Guarantor to any Subsidiary or transfers of Equity Interests of a Subsidiary that remains a Subsidiary Guarantor after giving effect to
such transfer), or purchase or otherwise acquire (in one transaction or a series of transactions) all or substantially all of the assets of any other person, except that (i) the Borrower and any Subsidiary may purchase and sell inventory in the
ordinary course of business and (ii) if at the time thereof and immediately after giving effect thereto no Event of Default or Default shall have occurred and be continuing, (w) Parent or the Borrower may merge with any other Person (other
than Parent and the Borrower); provided that (1) Parent or the Borrower, as applicable, shall be the continuing and surviving Person or the continuing or surviving Person shall expressly assume the obligations of Parent or Borrower, as
applicable, including all of the obligations under this Agreement and the other Loan Documents, in a manner reasonably acceptable to the Administrative Agent, and (2) Parent and the Borrower or such continuing or surviving Person, as
applicable, remains organized under the laws of the United States, any state thereof or the District of Columbia, (x) any wholly owned Subsidiary may merge into the Borrower in a transaction in which the Borrower is the surviving corporation,
(y) any Subsidiary may merge into or consolidate with any other Subsidiary in a transaction in which the surviving entity is a Subsidiary (provided that (A) if any party to any such transaction is a Loan Party, the surviving entity
of such transaction shall be a Loan Party and (B) to the extent any person other than the Borrower or a wholly owned Subsidiary receives any consideration in connection therewith, then such transaction shall be considered as an investment under
the applicable paragraph of Section 6.04) and (z) the Borrower and the Subsidiaries may make Permitted Acquisitions or any other investment, loan or advance permitted pursuant to Section 6.04 (including by merger), and may enter into
Permitted Joint Ventures. 
 (b) Make any Asset Sale otherwise permitted under paragraph (a) above unless such Asset
Sale is: 
 (i) for consideration that is at least equal to the fair market value of the assets being sold,
transferred, leased or disposed of; provided that for any disposition of assets with a fair market value of more than $50,000,000, at least 75% of such consideration is cash, cash equivalents or Permitted Investments; 

(ii) a Receivables Transaction, provided that (w) the material terms and conditions and the
structure of such Receivables Transaction have been approved by the Administrative Agent (such approval not to be unreasonably withheld or delayed), (x) any Liens granted in connection with such Receivables Transaction shall comply with the
terms of Section 6.02(p), 

 
 112
 
  

 
(y) the aggregate Receivables Transaction Amount outstanding at any time in respect of all Receivables Transactions does not exceed $3,000,000,000 and (z) to the extent Parent or any of
its subsidiaries shall receive aggregate Net Cash Proceeds in excess of $700,000,000 from the consummation of Receivables Transactions after the Third Restatement Effective Date, the Borrower shall, substantially simultaneously with (and in any
event not later than the fifth Business Day next following) the receipt of such Net Cash Proceeds by Parent or such subsidiary, apply an amount equal to 100% of the amount of such Net Cash Proceeds so in excess of $700,000,000 to prepay
then-outstanding Indebtedness (other than Indebtedness in respect of revolving extensions of credit, except to the extent that any such prepayment is accompanied by a permanent reduction in related commitments) (any Receivables Transaction meeting
all the criteria of this Section 6.05(b)(ii) being referred to herein as a “Permitted Receivables Transaction”); 

(iii) a Syndication Transaction, provided that the aggregate amount or value of the consideration
received by any Permitted Syndication Subsidiary and/or the Borrower and the other Subsidiaries from third parties in connection with such Syndication Transaction (or series of Syndication Transactions), except for the Syndication Transactions
listed on Schedule 6.05(b) (the “Syndication Proceeds”), when added to the aggregate Syndication Proceeds from all previous Permitted Syndications on or after the Closing Date does not exceed $200,000,000 (any Syndication
Transaction meeting the criteria of this Section 6.05(b)(iii) being referred to herein as a “Permitted Syndication Transaction”); 

(iv) any Permitted Interest Transfer; 

(v) for the sale or other disposition consummated by the Borrower or any of the Subsidiaries after the
Closing Date of assets constituting a subsidiary or business unit or units of the Borrower or the Subsidiaries (including a Facility) or the interest of the Borrower or the Subsidiaries therein, provided that (i) such sale or other
disposition shall be made for fair value on an arm’s-length basis and (ii) the consideration received for such sale or other disposition constitutes or would constitute a Permitted Acquisition, Permitted Joint Venture or Permitted
Syndication Subsidiary in accordance with the definition thereof; 
 (vi) the Borrower and the Subsidiaries
may abandon, allow to lapse or otherwise dispose of intangible property that the Borrower or such Subsidiary shall determine in its reasonable business judgment is immaterial to the conduct of its business; 

(vii) forgiveness of any loans or advances made pursuant to Section 6.04(e); 

 
 113
 
  

 (viii) transfers of property subject to casualty or a
condemnation proceeding; 
 (ix) Restricted Payments permitted pursuant to Section 6.06; 

(x) [reserved]; or 

(xi) any investment, loan or advance permitted pursuant to Section 6.04. 

For the purposes of Section 6.05(b)(i), the following will be deemed to be cash: 

(i) the assumption by the transferee of Indebtedness or other liabilities contingent or otherwise of the
Borrower or a Subsidiary (other than subordinated Indebtedness of the Borrower or a Guarantor) and the release of the Borrower or such Subsidiary from all liability on such Indebtedness or other liability in connection with such Asset Sale; 

(ii) securities, notes or other obligations received by the Borrower or any Subsidiary of the Borrower from
the transferee that are converted by the Borrower or such Subsidiary into cash or cash equivalents (including Permitted Investments) within 180 days following the closing of such Asset Sale; 

(iii) Indebtedness of any Subsidiary that is no longer a Subsidiary as a result of such Asset Sale, to the
extent that the Borrower and each other Subsidiary are released from any Guarantee of payment of such Indebtedness in connection with such Asset Sale; 

(iv) consideration consisting of Indebtedness of the Borrower (other than subordinated Indebtedness) received
after the Third Amendment Effective Date from Persons who are not the Borrower or any Subsidiary; and 

(v) any Designated Non-Cash Consideration received by the Borrower or any Subsidiary in such Asset Sale
having an aggregate fair market value, taken together with all other Designated Non-Cash Consideration received pursuant to this covenant that is at that time outstanding, not to exceed the greater of $800,000,000 and 3.0% of Total Assets (with the
fair market value of each item of Designated Non-Cash Consideration being measured at the time received and without giving effect to subsequent changes in value). 

 
 114
 
  

 SECTION 6.06.  Restricted Payments; Restrictive
Agreements.   (a)  Declare or make, directly or indirectly, any Restricted Payment (including pursuant to any Synthetic Purchase Agreement); provided, however, that 

(i) any Subsidiary may declare and pay dividends or make other distributions ratably to its equity holders;

 (ii) Parent, the Borrower or any Subsidiary may distribute the Equity Interests of a Spinout Subsidiary
pursuant to a Spinout Transaction; 
 (iii) so long as no Event of Default or Default shall have occurred
and be continuing or would result therefrom, the Borrower may, or the Borrower may make distributions to Parent so that Parent may, repurchase its Equity Interests owned by current or former employees, directors or consultants of Parent, the
Borrower or the Subsidiaries or make payments to employees, directors or consultants of Parent, the Borrower or the Subsidiaries in connection with the exercise of stock options, stock appreciation rights or similar equity incentives or equity based
incentives pursuant to management incentive plans in an aggregate amount not to exceed $60,000,000 in any fiscal year; 

(iv) the Borrower may make Restricted Payments to Parent (A) (x) to the extent necessary to pay
general corporate and overhead expenses incurred by Parent in the ordinary course of business (including legal, accounting and similar expenses) and expenses necessary to maintain its status as a publicly held corporation, and (y) in an amount
necessary to pay the Tax liabilities of Parent or (B) consisting of (1) costs (including all professional fees and expenses) incurred by Parent in connection with reporting obligations under or otherwise incurred in connection with
compliance with applicable laws, rules or regulations of any governmental, regulatory or self-regulatory body or stock exchange, the Senior Notes, the Loan Documents or any other agreement or instrument relating to Indebtedness of the Borrower or
any Subsidiary, customary indemnification obligations of Parent owing to directors, officers, employees or other Persons under its charter or by-laws or pursuant to written agreements with any such Person to the extent relating to the Borrower and
its Subsidiaries, (2) obligations of Parent in respect of director and officer insurance (including premiums therefor) to the extent relating to the Borrower and its Subsidiaries, (3) expenses incurred by Parent in connection with any
public offering or other sale of Equity Interests or Indebtedness: (x) where the net proceeds of such offering or sale are intended to be received by or contributed to the Borrower or a Subsidiary, (y) in a pro-rated amount of such
expenses in proportion to the amount of such net proceeds intended to be so received or contributed, or (z) otherwise on an interim basis prior to completion of such offering so long as Parent shall cause the amount of such expenses to be
repaid to the Borrower or the relevant Subsidiary out of the proceeds of such offering promptly if completed; provided, however, that all Restricted Payments made to Parent pursuant to this clause (iv) are used by Parent for the
purposes specified herein within 20 days of the receipt thereof; 

 
 115
 
  

 (v) in addition to Restricted Payments permitted by clauses
(i) through (iv) above, so long as no Event of Default or Default shall have occurred and be continuing or would result therefrom, the Borrower may make other Restricted Payments, and Parent may make Restricted Payments, in an aggregate
amount from and after the Third Restatement Effective Date not to exceed $200,000,000 less the amount of payments made from and after the Third Restatement Effective Date pursuant to Section 6.09(b)(i); 

(vi) the Borrower may net shares under employee benefits plans to settle option price payments owed by
employees and directors with respect thereto and to settle employees’ and directors’ Federal, state and income tax liabilities (if any) related thereto; 

(vii) so long as (A) no Event of Default or Default shall have occurred and be continuing or would
result therefrom and (B) at the time of and after giving effect thereto, the Secured Net Leverage Ratio shall not be greater than 3.5 to 1.0, the Borrower may make other Restricted Payments, and Parent may make Restricted Payments, in an amount
not to exceed the Available Amount at the time such Restricted Payment is made; 
 (viii) so long as no
Event of Default or Default shall have occurred and be continuing or would result therefrom, the Borrower may, or the Borrower may make distributions to Parent so that Parent may, (A) repurchase any of its Equity Interests, or (B) make
payments to employees, directors or consultants of Parent, the Borrower or the Subsidiaries in connection with the exercise of stock options, stock appreciation rights or similar equity incentives or equity based incentives pursuant to management
incentive plans, in each case in an aggregate amount not to exceed the Received Exercise Proceeds Amount at the time such Restricted Payment is made; 

(ix) so long as no Event of Default or Default shall have occurred and be continuing or would result
therefrom, the Borrower may make other Restricted Payments, and Parent may make Restricted Payments, in an aggregate amount not to exceed $25,000,000 in any fiscal year, beginning with the fiscal year ending December 31, 2013; 

(x) Parent, Borrower or any Subsidiary may make a payment of any dividend or distribution within 60 days
after the date of declaration thereof, if at the date of declaration such payment would have complied with the provisions of this Agreement; 

 
 116
 
  

 (xi) Parent, Borrower or any Subsidiary may make a purchase,
repurchase, redemption, defeasance or other acquisition or retirement of preferred Equity Interests made by exchange (including any such exchange pursuant to the exercise of a conversion right or privilege in connection with which cash is paid in
lieu of the issuance of fractional shares) for, or out of the proceeds of the substantially concurrent sale of, preferred Equity Interests of the Borrower or Parent (other than Disqualified Stock and other than preferred Equity Interests sold to a
Subsidiary) or a substantially concurrent contribution to the equity (other than through the issuance of Disqualified Stock or by preferred Equity Interests sold to any Subsidiary) of the Borrower or Parent; 

(xii) the Borrower may make payments or loans, advances, dividends or distributions to Parent to make
payments to holders of Equity Interests of Parent in lieu of the issuance of fractional shares of such Equity Interests, provided, however, that any such payment, loan, advance, dividend or distribution shall not be for the purpose of evading
any limitation of this covenant or otherwise to facilitate any dividend or other return of capital to the holders of such Equity Interests (as determined in good faith by the board of directors of the Borrower); 

(xiii) Parent, the Borrower or any Subsidiary may make purchases, repurchases, redemptions, defeasances or
other acquisitions or retirements of Equity Interests deemed to occur upon the exercise of stock options, warrants or other rights in respect thereof if such Equity Interests represent a portion of the exercise price thereof; and 

(xiv) Parent, the Borrower or any Subsidiary may pay dividends or other distributions of Equity Interests of,
or Indebtedness owed to Parent, the Borrower or a Subsidiary by, Unrestricted Subsidiaries (unless the Unrestricted Subsidiary’s principal asset is cash or cash equivalents (including Permitted Investments)). 

(b) Enter into, incur or permit to exist any agreement or other arrangement that prohibits, restricts or imposes any condition
upon (i) the ability of Parent, the Borrower or any Subsidiary (other than any Permitted Joint Venture Subsidiary) to create, incur or permit to exist any Lien upon any of its property or assets to secure the Obligations, or (ii) the
ability of any Subsidiary (other than any Permitted Joint Venture Subsidiary) to pay dividends or other distributions with respect to any of its Equity Interests or to make or repay loans or advances to the Borrower or any Subsidiary Guarantor or to
Guarantee Indebtedness of the Borrower or any Subsidiary Guarantor; provided (x) that the foregoing shall not apply to restrictions and conditions (A) imposed by law or by any Loan Document or any Senior Note Indenture,
(B) contained in agreements relating to the sale of a Subsidiary or other assets pending such sale, provided such restrictions and conditions apply only to the Subsidiary or assets that are to be sold and such sale is permitted
hereunder, (C) imposed on any Foreign Subsidiary by the terms of any Indebtedness of such Foreign Subsidiary permitted to be incurred hereunder, (D) imposed 

 
 117
 
  

 
pursuant to other Indebtedness incurred pursuant to Section 6.01 with such encumbrances and restrictions that, taken as a whole, are not more restrictive than the terms hereof,
(E) contained in any agreement relating to a Permitted Receivables Transaction if such restrictions or encumbrances apply only to the relevant Permitted Receivables Transaction and are required pursuant to the terms and conditions of such
Permitted Receivables Transaction, (F) on Permitted Joint Ventures or other joint ventures permitted under Section 6.04 and Permitted Syndication Subsidiaries imposed by the terms of the agreements governing the same, (G) applicable
to an Acquired Entity at the time such Acquired Entity became a Subsidiary, so long as such restriction or encumbrance was not created in contemplation of or in connection with such Acquired Entity becoming a Subsidiary and apply only to such
Acquired Entity and (H) imposed by any credit agreement, indenture or other agreement governing Pari Passu Debt or Alternative Incremental Facility Indebtedness, so long as such restrictions and conditions are not less favorable to the Lenders
than to the holders of such Pari Passu Debt or such Alternative Incremental Facility Indebtedness, as the case may be; and (y) clause (i) of the foregoing shall not apply to restrictions or conditions (A) that are customary provisions
in leases and other contracts restricting the assignment thereof and any right of first refusal and (B) imposed by any agreement relating to secured Indebtedness permitted by this Agreement if such restrictions or conditions apply only to the
property or assets securing such Indebtedness. 
 For the avoidance of doubt, any transaction permitted pursuant to this Section 6.06
to be made or consummated by the Borrower (other than Section 6.06(a)(iv)) shall be permitted to be made or consummated by Parent. 

SECTION 6.07. Transactions with Affiliates.      Except for (a) transactions
between or among Parent and its Subsidiaries or described on Schedule 6.07 and (b) the contribution or other transfer by Parent, the Borrower or any Subsidiary of property owned by it to any Spinout Subsidiary pursuant to a Spinout
Transaction and transition services agreements, tax sharing agreements, intellectual property sharing agreements, real estate matter and employee matter agreements, indemnification and insurance agreements and other similar agreements among Parent,
the Borrower, any Subsidiary and a Spinout Subsidiary entered into in connection with a Spinout Transaction, sell or transfer any property or assets to, or purchase or acquire any property or assets from, or otherwise engage in any other
transactions with, any of its Affiliates, except (i) the Borrower or any Subsidiary may engage in any of the foregoing transactions on terms and conditions not less favorable to the Borrower or such Subsidiary than could be obtained on an
arm’s-length basis from unrelated third parties, (ii) Parent, the Borrower and the Subsidiaries may make (x) investments, loans and advances and (y) Restricted Payments, permitted by Section 6.04 and Section 6.06,
respectively, (iii) the Borrower may engage in Receivables Transactions, (iv) any issuance of Equity Interests otherwise permitted hereunder, (v) any issuance of Equity Interests, or other payments, awards or grants in cash,
securities or otherwise pursuant to, or the funding of, employment arrangements, stock options and stock ownership plans, or indemnities provided on behalf of employees or directors and approved by the board of directors or senior management of
Parent and (vi) the payment of reasonable fees to directors of Parent, the Borrower and the Subsidiaries who are not employees of Parent, the Borrower or the Subsidiaries. 

 
 118
 
  

 SECTION 6.08. Business of Parent, Borrower and
Subsidiaries.  Engage at any time in any business or business activity other than the business currently conducted by it and business activities reasonably similar, incidental or complementary thereto and reasonable extensions
thereof. 
 SECTION 6.09. Other Indebtedness.      (a)  Permit any
waiver, supplement, modification or amendment of any Senior Note Indenture or any waiver, supplement, modification or amendment of any indenture, instrument or agreement pursuant to which any subordinated Material Indebtedness of Parent, the
Borrower or any of the Subsidiaries is outstanding if the effect of such waiver, supplement, modification or amendment would materially increase the obligations of the obligor (except as permitted by this Agreement) or confer additional material
rights on the holder of such Indebtedness in a manner adverse to the Lenders. 
 (b)    Make any
distribution, whether in cash, property, securities or a combination thereof, other than regular scheduled payments of principal and interest as and when due (to the extent not prohibited by applicable subordination provisions), in respect of, or
pay, or commit to pay, or directly or indirectly (including pursuant to any Synthetic Purchase Agreement) redeem, repurchase, retire or otherwise acquire for consideration, or set apart any sum for the aforesaid purposes, any subordinated
Indebtedness (other than intercompany Indebtedness); provided, however, that, so long as no Default or Event of Default shall have occurred and be continuing at the date of such redemption, repurchase, retirement or other acquisition
for consideration, or would result therefrom, Parent, the Borrower or any Subsidiary may redeem, repurchase, retire or otherwise acquire for consideration (i) (i) from and after the Third Restatement Effective Date, subordinated Indebtedness
for an aggregate price not in excess of (A) $300,000,000 less (B) the amount of Restricted Payments made from and after the Third Restatement Effective Date pursuant to clause (v) of Section 6.06(a), (ii) subordinated
Indebtedness with the proceeds of or in exchange for (A) subordinated Indebtedness that is permitted pursuant to Section 6.01 and is subordinated on terms not materially less advantageous to the Lenders than those of the Indebtedness being
redeemed, repurchased, retired or otherwise acquired for consideration or (B) the issuance of Equity Interests, (iv) subordinated Indebtedness so long as (A) the amount paid in respect thereof does not exceed the Available Amount at
the time paid and (B) at the time of and after giving effect thereto, the Secured Net Leverage Ratio shall not be greater than 4.0 to 1.0, or (v) subordinated Indebtedness so long as (A) the amount paid in respect thereof does not
exceed the Available Declined Proceeds Amount at the time paid and (B) at the time of and after giving effect thereto, the Secured Net Leverage Ratio shall not be greater than 4.0 to 1.0. 

(c)    Nothing in this Section 6.09 shall limit or otherwise prohibit the making (and any payment in
connection therewith) of any “Change of Control Offer” under any HMA Indenture in connection with the Permitted HMA Transaction or in accordance with clause (f) of Article VII. 

 
 119
 
  

 SECTION 6.10.  Practice
Guarantees.     Enter into Practice Guarantees with a term of 30 months or longer in an aggregate amount in excess of $300,000,000 in effect at any time with respect to all such Practice Guarantees. 

SECTION 6.11.  Capital Expenditures.    Permit the aggregate amount of Capital
Expenditures (other than Replacement Capital Expenditures) made by Parent, the Borrower and the Subsidiaries in any period set forth below to exceed the greater of (a) 7.5% of consolidated net revenues of Parent, the Borrower and the
Subsidiaries for the immediately preceding fiscal year (as set forth in the financial statements delivered pursuant to Section 5.04(a) with respect to such fiscal year) and (b) $1,100,000,000 (such greater amount, the “Permitted
Capital Expenditure Amount”): 
 In any year in which a Permitted Acquisition occurs, the Permitted Capital
Expenditure Amount in respect of such fiscal year shall be increased (but not decreased) by an amount equal to 7.5% of the net revenues generated by the Acquired Entity acquired during the preceding fiscal year of such Acquired Entity (pro rated
based on the number of days remaining in such fiscal year). In addition, to the extent any portion of the Permitted Capital Expenditure Amount for any fiscal year (as the same may have been increased pursuant to the preceding sentence) is not fully
expended during such fiscal year, then 50% of the amount not so expended may be carried forward to and used in succeeding fiscal years. In addition, for any fiscal year, the amount of Capital Expenditures that would otherwise be permitted in such
fiscal year pursuant to this Section 6.11 may be increased by an amount not to exceed 50% of the Permitted Capital Expenditure Amount for the immediately succeeding fiscal year (the “CapEx Pull-Forward Amount”). The
actual CapEx Pull-Forward Amount in respect of any such fiscal year shall reduce, on a dollar-for-dollar basis, the amount of Capital Expenditures that would have been permitted to be made in the immediately succeeding fiscal year. In addition, for
any fiscal year, the amount of Capital Expenditures that would otherwise be permitted in such fiscal year pursuant to this Section 6.11 may be increased by an amount not to exceed $400,000,000 if, at the time of such expenditure, both before
and after giving pro forma effect thereto, (x) no Default or Event of Default shall have occurred and be continuing and (y) the Leverage Ratio is less than 4.50 to 1.00. 

The provisions of this Section 6.11 are solely for the benefit of the Revolving Credit Lenders, the 2019 Term A Lenders
and any Lenders having Other Term A Loans and, notwithstanding the provisions of Section 9.08, the Required Covenant Lenders may (i) amend or otherwise modify Section 6.11 or, solely for purposes of Section 6.11, the defined
terms used, directly or indirectly, therein, or (ii) waive any non-compliance with Section 6.11 or any Event of Default resulting from such non-compliance, in each case without the consent of any other Lenders. 

 
 120
 
  

 SECTION 6.12.  Interest Coverage Ratio. Permit the
Interest Coverage Ratio for any period of four consecutive fiscal quarters, in each case taken as one accounting period, ending during any period set forth below to be less than the ratio set forth opposite such period below: 

 

					
	 Period
	 	 Ratio
	 	  
			
	 December 31, 2013 through December 31, 2016
	 	2.00 to 1.00	 	
	 Thereafter
	 	2.25 to 1.00	 	

 The provisions of this Section 6.12 are solely for the benefit of the Revolving Credit Lenders, the 2019 Term A Lenders
and any Lenders having Other Term A Loans and, notwithstanding the provisions of Section 9.08, the Required Covenant Lenders may (i) amend or otherwise modify Section 6.12 or, solely for purposes of Section 6.12, the defined
terms used, directly or indirectly, therein, or (ii) waive any non-compliance with Section 6.12 or any Event of Default resulting from such non-compliance, in each case without the consent of any other Lenders. 

SECTION 6.13.  Maximum Secured Net Leverage Ratio.   Permit the Secured Net
Leverage Ratio as of the last day of any fiscal quarter ending during a period set forth below to be greater than the ratio set forth opposite such period below: 
  

					
	 Period
	 	 Ratio
	 	  
			
	 December 31, 2013 through December 31, 2015
	 	4.50 to 1.00	 	
	 January 1, 2016 through December 31, 2016
	 	4.25 to 1.00	 	
	 Thereafter
	 	4.00 to 1.00	 	

 The provisions of this Section 6.13 are solely for the benefit of the Revolving Credit Lenders, the 2019 Term A Lenders
and any Lenders having Other Term A Loans and, notwithstanding the provisions of Section 9.08, the Required Covenant Lenders may (i) amend or otherwise modify Section 6.13 or, solely for purposes of Section 6.13, the defined
terms used, directly or indirectly, therein, or (ii) waive any non-compliance with Section 6.13 or any Event of Default resulting from such non-compliance, in each case without the consent of any other Lenders. 

SECTION 6.14.  Fiscal Year.   With respect to Parent and the Borrower, change their
fiscal year-end to a date other than December 31. 
 ARTICLE VII 

Events of Default 

In case of the happening of any of the following events (“Events of Default”): 

(a) any representation, warranty or statement made or deemed made by any Loan Party herein or in any other
Loan Document or any certificate delivered or required to be delivered pursuant hereto or thereto shall prove to be untrue in any material respect on the date as of which it was made or deemed made; 

 
 121
 
  

 (b) default shall be made in the payment of any principal of
any Loan or the reimbursement with respect to any L/C Disbursement when and as the same shall become due and payable, whether at the due date thereof or at a date fixed for prepayment thereof or by acceleration thereof or otherwise; 

(c) default shall be made in the payment of any interest on any Loan or any Fee or L/C Disbursement or any
other amount (other than an amount referred to in (b) above) due under any Loan Document, when and as the same shall become due and payable, and such default shall continue unremedied for a period of five Business Days; 

(d) (i) default shall be made in the due observance or performance by Parent, the Borrower or any
Subsidiary of any covenant, condition or agreement contained in Section 5.01(a) (with respect to Parent and the Borrower only), 5.05(a) or 5.08 or in Article VI (other than Section 6.11, Section 6.12 or Section 6.13);
(ii) solely for the benefit of the Revolving Credit Lenders, 2019 Term A Lenders and Lenders holding Other Term A Loans, default shall be made in the due observance or performance by Parent, the Borrower or any Subsidiary of any covenant,
condition or agreement contained in Section 6.11, Section 6.12 or Section 6.13; or (iii) an Event of Default shall have occurred under paragraph (d)(ii) and the Required Covenant Lenders shall have terminated any Revolving Credit
Commitments or shall have accelerated any Loans; 
 (e) default shall be made in the due observance or
performance by Parent, the Borrower or any Subsidiary of any covenant or agreement contained in any Loan Document (other than those specified in (b), (c) or (d) above) and such default shall continue unremedied for a period of 30 days
after notice thereof from the Administrative Agent or any Lender to the Borrower; 
 (f) (i) Parent,
the Borrower or any Subsidiary shall fail to pay any principal, interest or other amount due in respect of any Material Indebtedness, when and as the same shall become due and payable (after giving effect to any grace period) or (ii) any other
event or condition occurs that results in any Material Indebtedness (other than any Material Indebtedness of any Securitization Subsidiary) becoming due prior to its scheduled maturity or that enables or permits (after giving effect to any grace
period) the holder or holders of any Material Indebtedness or any trustee or agent on its or their behalf to cause any Material Indebtedness to become due, or to require the prepayment, repurchase, redemption or defeasance thereof, prior to its
scheduled maturity or that results in the termination or permits any counterparty to terminate any Hedging Agreement the obligations under which constitute Material Indebtedness; provided that (A) this clause (ii) shall not apply to
secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Indebtedness, and (B) for the avoidance of doubt, a requirement to make a mandatory offer to repurchase under the terms
of any Indebtedness of any person acquired by the Borrower or any of its Subsidiaries pursuant to any Permitted Acquisition or the Permitted HMA Transaction (including Indebtedness under any 

 
 122
 
  

 
HMA Indenture) as a result of a “change of control” (or equivalent term) shall not constitute a Default or an Event of Default under this clause (ii) so long as (I) on or
prior to the date the events constituting such “change of control” (or equivalent term) occur, either (1) the terms of such Indebtedness have been amended to eliminate the requirement to make such offer or (2) such Indebtedness
has been defeased or discharged so that such requirement shall no longer apply (and, in the event such “change of control” is subject to a requirement that a specific credit ratings event or similar condition subsequent occur, no Event of
Default shall exist pursuant to this paragraph (ii) until such time as the specific credit ratings event or similar condition subsequent has also occurred resulting in the obligor under such Indebtedness to become unconditionally obligated to
make such offer) or (II) (x) the sum of (1) the aggregate amount of unrestricted cash, cash equivalents and Permitted Investments held by Parent, the Borrower and the Subsidiaries plus any available debt financing commitments from any
Revolving Lender or any Affiliate of a Revolving Lender or any other financial institution of nationally recognized standing available to the Borrower or its Subsidiaries for purposes of refinancing such Indebtedness is at least equal to the
aggregate amount that would be required to repay such Indebtedness pursuant to any required “change of control offer” (or equivalent term) pursuant to the terms of such Indebtedness at all times prior to the expiration of the rights of the
holders of such Indebtedness to require the repurchase or repayment of such Indebtedness as a result of such acquisition and (y) the Borrower or the applicable Subsidiary complies with the provisions of such Indebtedness that are applicable as a
result of such acquisition (including by consummating any required “change of control offer” (or equivalent term) for such Indebtedness); provided further that this clause (f) shall not apply if such failure is remedied or waived by
the holders of such Indebtedness prior to any termination of the Commitments or acceleration of the Loans pursuant to this Article VII; 

(g) an involuntary proceeding shall be commenced or an involuntary petition shall be filed in a court of
competent jurisdiction seeking (i) relief in respect of Parent, the Borrower or any Subsidiary (other than a Non-Significant Subsidiary within the meaning of clause (a) of the definition thereof), or of a substantial part of the property
or assets of Parent, the Borrower or a Subsidiary (other than a Non-Significant Subsidiary within the meaning of clause (a) of the definition thereof), under Title 11 of the United States Code, as now constituted or hereafter amended, or
any other Federal, state or foreign bankruptcy, insolvency, receivership or similar law, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for Parent, the Borrower or any Subsidiary (other
than a Non-Significant Subsidiary within the meaning of clause (a) of the definition thereof) or for a substantial part of the property or assets of Parent, the Borrower or a Subsidiary or (iii) the winding-up or liquidation of Parent, the
Borrower or any Subsidiary (other than a Non-Significant Subsidiary within the meaning of clause (a) of the definition thereof); and such proceeding or petition shall continue undismissed for 60 days or an order or decree approving or
ordering any of the foregoing shall be entered; 

 
 123
 
  

 (h) Parent, the Borrower or any Subsidiary (other than a
Non-Significant Subsidiary within the meaning of clause (a) of the definition thereof) shall (i) voluntarily commence any proceeding or file any petition seeking relief under Title 11 of the United States Code, as now constituted or
hereafter amended, or any other Federal, state or foreign bankruptcy, insolvency, receivership or similar law, (ii) consent to the institution of any proceeding or the filing of any petition described in (g) above, (iii) apply for or
consent to the appointment of a receiver, trustee, custodian, sequestrator, conservator or similar official for Parent, the Borrower or any Subsidiary (other than a Non-Significant Subsidiary within the meaning of clause (a) of the definition
thereof) or for a substantial part of the property or assets of Parent, the Borrower or any Subsidiary (other than a Non-Significant Subsidiary within the meaning of clause (a) of the definition thereof), (iv) file an answer admitting the
material allegations of a petition filed against it in any such proceeding, (v) make a general assignment for the benefit of creditors, (vi) become unable, admit in writing its inability or fail generally to pay its debts as they become
due or (vii) take any corporate action for the purpose of effecting any of the foregoing; 
 (i) one or
more judgments shall be rendered against Parent, the Borrower, any Subsidiary or any combination thereof (not paid or fully covered by insurance) and the same shall remain undischarged for a period of 30 consecutive days during which execution
shall not be effectively stayed, or any action shall be legally taken by a judgment creditor to levy upon assets or properties of Parent, the Borrower or any Subsidiary to enforce any such judgment and such judgment is for the payment of money in an
aggregate amount in excess of $125,000,000; 
 (j) an ERISA Event shall have occurred that, in the opinion
of the Required Lenders, when taken together with all other such ERISA Events, could reasonably be expected to result in a Material Adverse Effect; 

(k) any Guarantee under the Guarantee and Collateral Agreement for any reason shall cease to be in full force
and effect (other than in accordance with its terms), or any Guarantor shall deny in writing that it has any further liability under the Guarantee and Collateral Agreement (other than as a result of the discharge of such Guarantor in accordance with
the terms of the Loan Documents); 
 (l) any security interest purported to be created by any Security
Document with respect to any Collateral with an aggregate fair market value in excess of $125,000,000 shall cease to be, or shall be asserted by the Borrower or any other Loan Party not to be, a valid, perfected (subject to the qualifications set
forth in Section 3.19(a)), first priority (except as otherwise expressly provided in this Agreement or such Security Document) security interest in the securities, assets or properties covered thereby, except to the extent that any such loss of
perfection or priority results from the failure of the Collateral Agent to maintain possession of certificates representing securities pledged under the Guarantee and Collateral Agreement or any other act or omission by the Collateral Agent and
except to the extent that such loss is covered by a lender’s title insurance policy and the related insurer does not deny that such loss is covered by such title insurance policy; 

 
 124
 
  

 (m) the Indebtedness under any subordinated Indebtedness of
Parent, the Borrower or any Subsidiary constituting Material Indebtedness shall cease (or any Loan Party or an Affiliate of any Loan Party shall so assert), for any reason, to be validly subordinated to the Obligations as provided in the agreements
evidencing such subordinated Indebtedness; 
 (n) there shall have occurred a Change in Control; 

(o) on any date, any Pari Passu Debt that at the time would constitute Material Indebtedness and that has a
final stated maturity date within 91 days of such date, shall remain outstanding; 
 (p) so long as any
Other Senior Secured Debt is outstanding, any Pari Passu Intercreditor Agreement shall cease to be effective or cease to be legally valid and binding, or otherwise not be effective to create the rights and obligations purported to be created
thereunder, unless the same (i) results directly from the action or inaction of the Collateral Agent or (ii) is not materially adverse to the Lenders; or 

(q) so long as any Other Junior Secured Debt is outstanding, any Junior Lien Intercreditor Agreement shall
cease to be effective or cease to be legally valid and binding, or otherwise not be effective to create the rights and obligations purported to be created thereunder, unless the same (i) results directly from the action or inaction of the
Collateral Agent or (ii) is not materially adverse to the Lenders; 
 then, and in every such event (other than an
event with respect to Parent or the Borrower described in paragraph (g) or (h) above or an event described in paragraph (d)(ii) above), and at any time thereafter during the continuance of such event, the Administrative Agent, at the
request of the Required Lenders shall, by notice to the Borrower, take either or both of the following actions, at the same or different times: (i) terminate forthwith the Commitments and (ii) declare the Loans then outstanding to be
forthwith due and payable in whole or in part, whereupon the principal of the Loans so declared to be due and payable, together with accrued interest thereon and any unpaid accrued Fees and all other liabilities of the Borrower accrued hereunder and
under any other Loan Document, shall become forthwith due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived by the Borrower, anything contained herein or in any other Loan
Document to the contrary notwithstanding; in any event with respect to Parent or the Borrower described in paragraph (g) or (h) above, the Commitments shall automatically terminate and the principal of the Loans then outstanding, together
with accrued interest thereon and any unpaid accrued Fees and all other liabilities of the Borrower accrued hereunder and under any other Loan Document, shall automatically become due and payable, without presentment, demand, protest or any other
notice of any kind, all of 

 
 125
 
  

 
which are hereby expressly waived by the Borrower, anything contained herein or in any other Loan Document to the contrary notwithstanding; and in any such event described in paragraph (d)(ii)
above, and at any time thereafter during the continuance of such event, the Administrative Agent, at the request of the Required Covenant Lenders shall, by notice to the Borrower, take either or both of the following actions, at the same or
different times: (i) terminate forthwith the Revolving Credit Commitments and (ii) declare the 2019 Term A Loans, Other Term A Loans and Revolving Loans then outstanding to be forthwith due and payable in whole or in part, whereupon
the principal of such Loans so declared to be due and payable, together with accrued interest thereon and any unpaid accrued Fees and all other liabilities of the Borrower accrued hereunder and under any other Loan Document in respect of the
Revolving Credit Commitments or such Loans, shall become forthwith due and payable, without presentment, demand, protest or any other notice of any kind, all of which are hereby expressly waived by the Borrower, anything contained herein or in any
other Loan Document to the contrary notwithstanding. 
 Notwithstanding anything to the contrary contained in this Article
VII, upon the request of the Borrower made in writing to the Administrative Agent, in the event of any Event of Default under any covenant set forth in Section 6.12 or 6.13 and until the expiration of the tenth Business Day after the date on
which financial statements are required to be delivered with respect to the applicable fiscal quarter hereunder, Parent may issue Qualified Capital Stock and elect to treat all or any portion of the net cash proceeds thereof as having increased
Consolidated EBITDA with respect to such applicable quarter solely for the purpose of determining actual and pro forma compliance with Sections 6.12 and 6.13 at the end of such applicable quarter and applicable subsequent periods and for purposes of
determining whether the Secured Net Leverage Ratio Condition has been satisfied and not for any other purpose of this Agreement (including determining the Applicable Percentage); provided that (a) such proceeds (i) are actually
received by Parent and contributed to the Borrower no later than ten days after the date on which financial statements are required to be delivered with respect to such fiscal quarter hereunder and (ii) do not exceed the aggregate amount
necessary to cause Parent to be in compliance with the covenants under Sections 6.12 or 6.13 for any applicable period and (b) in each period of four fiscal quarters, there shall be at least two fiscal quarters in which no such right to cure
permitted by this paragraph is utilized. 
 ARTICLE VIII 

The Administrative Agent and the Collateral Agent 

Each of the Lenders and the Issuing Bank hereby irrevocably appoints the Administrative Agent and the Collateral Agent (for
purposes of this Article VIII, the Administrative Agent and the Collateral Agent are referred to collectively as the “Agents”) its agent and authorizes the Agents to take such actions on its behalf and to exercise such powers
as are delegated to such Agent by the terms of the Loan Documents, together with such actions and powers as are reasonably incidental thereto. Without limiting the generality of the foregoing, the Agents are hereby expressly authorized to execute
any and all documents (including releases) with respect to the Collateral and the rights of the Secured Parties with respect thereto, as contemplated by and in accordance with the provisions of this Agreement and the Security Documents. 

 
 126
 
  

 The bank serving as the Administrative Agent and/or the Collateral Agent
hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not an Agent, and such bank and its Affiliates may accept deposits from, lend money to and generally engage
in any kind of business with Parent, the Borrower or any Subsidiary or other Affiliate thereof as if it were not an Agent hereunder. 

Neither Agent shall have any duties or obligations except those expressly set forth in the Loan Documents. Without limiting
the generality of the foregoing, (a) neither Agent shall be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing, (b) neither Agent shall have any duty to take any discretionary
action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby that such Agent is instructed in writing to exercise by the Required Lenders (or such other number or percentage of the Lenders as
shall be necessary under the circumstances as provided in Section 9.08), and (c) except as expressly set forth in the Loan Documents, neither Agent shall have any duty to disclose, nor shall it be liable for the failure to disclose, any
information relating to Parent, the Borrower or any of the Subsidiaries that is communicated to or obtained by the bank serving as Administrative Agent and/or Collateral Agent or any of its Affiliates in any capacity. Neither Agent shall be liable
for any action taken or not taken by it with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary under the circumstances as provided in Section 9.08) or in the absence
of its own gross negligence or willful misconduct. Neither Agent shall be deemed to have knowledge of any Default unless and until written notice thereof is given to such Agent by Parent, the Borrower or a Lender, and neither Agent shall be
responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or representation made in or in connection with any Loan Document, (ii) the contents of any certificate, report or other document delivered
thereunder or in connection therewith, (iii) the performance or observance of any of the covenants, agreements or other terms or conditions set forth in any Loan Document, (iv) the validity, enforceability, effectiveness or genuineness of
any Loan Document or any other agreement, instrument or document, or (v) the satisfaction of any condition set forth in Article IV or elsewhere in any Loan Document, other than to confirm receipt of items expressly required to be delivered to
such Agent. 
 Each Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice,
request, certificate, consent, statement, instrument, document or other writing believed by it to be genuine and to have been signed or sent by the proper person. Each Agent may also rely upon any statement made to it orally or by telephone and
believed by it to have been made by the proper person, and shall not incur any liability for relying thereon. Each Agent may consult with legal counsel (who may be counsel for the Borrower), independent accountants and other experts selected by it,
and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. 

 
 127
 
  

 Each Agent may perform any and all its duties and exercise its rights and
powers by or through any one or more sub-agents appointed by it. Each Agent and any such sub-agent may perform any and all its duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of
the preceding paragraphs shall apply to any such sub-agent and to the Related Parties of each Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the Credit Facilities as well as
activities as Agent. 
 Subject to the appointment and acceptance of a successor Agent as provided below, either Agent may
resign at any time by notifying the Lenders, the Issuing Bank and the Borrower. Upon any such resignation, the Required Lenders shall have the right, with the consent (not to be unreasonably withheld or delayed) of the Borrower, to appoint a
successor; provided that during the existence and continuation of an Event of Default pursuant to paragraph (b), (c), (g) or (h) of Article VII, no consent of the Borrower shall be required. If no successor shall have been so
appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring Agent gives notice of its resignation, then the retirement of the retiring Agent shall become effective on such 30th day and the
retiring Agent may (but shall not have any obligation to do so), on behalf of the Lenders and the Issuing Bank, appoint a successor Agent which shall be a bank with an office in New York, New York, having a combined capital and surplus of at least
$1,000,000,000, or an Affiliate of any such bank and, so long as no Event of Default pursuant to paragraph (b), (c), (g) or (h) of Article VII shall have occurred and be continuing, reasonably acceptable to the Borrower. Upon the
acceptance of its appointment as Agent hereunder by a successor, such successor shall succeed to and become vested with all the rights, powers, privileges and duties of the retiring Agent, and the retiring Agent shall be discharged from its duties
and obligations hereunder. The fees payable by the Borrower to a successor Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Borrower and such successor. After an Agent’s resignation hereunder, the
provisions of this Article and Section 9.05 shall continue in effect for the benefit of such retiring Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them while acting
as Agent. 
 Each Lender acknowledges that it has, independently and without reliance upon the Agents or any other Lender
and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the Agents or any
other Lender and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement or any other Loan Document, any related
agreement or any document furnished hereunder or thereunder. 

 
 128
 
  

 ARTICLE IX 

Miscellaneous 

SECTION 9.01.  Notices.   Notices and other communications provided for herein shall be
in writing and shall be delivered by hand or overnight courier service, mailed by certified or registered mail or sent by fax, as follows: 

(a)   if to the Borrower or Parent, to it at Community Health Systems, Inc., 4000 Meridian Boulevard, Franklin,
Tennessee 37067, Attention of the Chief Financial Officer (Fax No. (615) 373-9704); 
 (b)   if to the
Administrative Agent, to Credit Suisse AG, Eleven Madison Avenue, New York, NY 10010, Attention of Agency Group (Fax No. (212) 322-2291), Email: agency.loanops@credit-suisse.com; and 

(c)   if to a Lender, to it at its address (or fax number) set forth on Schedule 2.01 or in the Assignment and
Acceptance pursuant to which such Lender shall have become a party hereto. 
 All notices and other communications given to
any party hereto in accordance with the provisions of this Agreement shall be deemed to have been given on the date of receipt if delivered by hand or overnight courier service or sent by fax or on the date five Business Days after dispatch by
certified or registered mail if mailed, in each case delivered, sent or mailed (properly addressed) to such party as provided in this Section 9.01 or in accordance with the latest unrevoked direction from such party given in accordance with
this Section 9.01. As agreed to among Parent, the Borrower, the Administrative Agent and the applicable Lenders from time to time, notices and other communications may also be delivered by e-mail to the e-mail address of a representative of the
applicable person provided from time to time by such person. 
 Parent and the Borrower hereby acknowledge that (a) the
Administrative Agent will make available to the Lenders and the Issuing Bank materials and/or information provided by or on behalf of the Borrower hereunder (collectively, the “Borrower Materials”) by posting the Borrower
Materials on Intralinks or another similar electronic system (the “Platform”) and (b) certain of the Lenders may be “public-side” Lenders (i.e., Lenders that do not wish to receive material non-public
information with respect to each Borrower or its securities) (each, a “Public Lender”). Parent and the Borrower hereby agree that (i) all Borrower Materials that are to be made available to Public Lenders shall be
clearly and conspicuously marked “PUBLIC” which, at a minimum, shall mean that the word “PUBLIC” shall appear prominently on the first page thereof; (ii) by marking Borrower Materials “PUBLIC,” the Borrower shall
be deemed to have authorized the Administrative Agent and the Lenders to treat such Borrower Materials as not containing any material non-public information with respect to Parent and the Borrower or its securities for purposes of foreign, United
States Federal and state securities laws (provided, however, that to the extent such Borrower Materials constitute Information, they shall be treated as set forth in Section 9.17); (iii) all Borrower Materials

 
 129
 
  

 
marked “PUBLIC” are permitted to be made available through a portion of the Platform designated as “Public Investor” and (iv) the Administrative Agent shall be entitled
to treat any Borrower Materials that are not marked “PUBLIC” as being suitable only for posting on a portion of the Platform not marked as “Public Investor”. Notwithstanding the foregoing, the following Borrower Materials shall
be marked “PUBLIC”, unless Parent or the Borrower notifies the Administrative Agent promptly that any such document contains material non-public information: (A) the Loan Documents, (B) any notification of changes in the terms of
the Credit Facilities and (C) all information delivered pursuant to Section 5.04(a), (b) and (c). 
 Each
Public Lender agrees to cause at least one individual at or on behalf of such Public Lender to at all times have selected the “Private Side Information” or similar designation on the content declaration screen of the Platform in order to
enable such Public Lender or its delegate, in accordance with such Public Lender’s compliance procedures and applicable law, including foreign, United States Federal and state securities laws, to make reference to Communications that are not
made available through the “Public Side Information” portion of the Platform and that may contain material non-public information with respect to Parent or the Borrower or its securities for purposes of foreign, United States Federal or
state securities laws. 
 THE PLATFORM IS PROVIDED “AS IS” AND “AS AVAILABLE”. NEITHER THE
ADMINISTRATIVE AGENT NOR ANY OF ITS RELATED PARTIES WARRANTS THE ACCURACY OR COMPLETENESS OF THE COMMUNICATIONS OR THE ADEQUACY OF THE PLATFORM AND EACH EXPRESSLY DISCLAIMS LIABILITY FOR ERRORS OR OMISSIONS IN THE COMMUNICATIONS. NO WARRANTY OF ANY
KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS IS MADE BY THE ADMINISTRATIVE AGENT OR ANY OF ITS
RELATED PARTIES IN CONNECTION WITH THE COMMUNICATIONS OR THE PLATFORM. IN NO EVENT SHALL THE ADMINISTRATIVE AGENT OR ANY OF ITS RELATED PARTIES HAVE ANY LIABILITY TO ANY LOAN PARTY, ANY LENDER OR ANY OTHER PERSON FOR DAMAGES OF ANY KIND, WHETHER OR
NOT BASED ON STRICT LIABILITY AND INCLUDING DIRECT OR INDIRECT, SPECIAL, INCIDENTAL OR CONSEQUENTIAL DAMAGES, LOSSES OR EXPENSES (WHETHER IN TORT, CONTRACT OR OTHERWISE) ARISING OUT OF ANY LOAN PARTY’S OR THE ADMINISTRATIVE AGENT’S
TRANSMISSION OF COMMUNICATIONS THROUGH THE INTERNET, EXCEPT TO THE EXTENT THE LIABILITY OF ANY SUCH PERSON IS FOUND IN A FINAL RULING BY A COURT OF COMPETENT JURISDICTION TO HAVE RESULTED PRIMARILY FROM SUCH PERSON’S GROSS NEGLIGENCE OR WILLFUL
MISCONDUCT. 
 The Administrative Agent agrees that the receipt of the Communications by the Administrative Agent at its
e-mail address set forth above shall constitute effective delivery of the Communications to the Administrative Agent for purposes of the Loan Documents. Each Lender agrees that receipt of notice to it (as provided in the next

 
 130
 
  

 
sentence) specifying that the Communications have been posted to the Platform shall constitute effective delivery of the Communications to such Lender for purposes of the Loan Documents. Each
Lender agrees to notify the Administrative Agent in writing (including by electronic communication) from time to time of such Lender’s e-mail address to which the foregoing notice may be sent by electronic transmission and that the foregoing
notice may be sent to such e-mail address. 
 Nothing herein shall prejudice the right of the Administrative Agent or any
Lender to give any notice or other communication pursuant to any Loan Document in any other manner specified in such Loan Document. 

SECTION 9.02.  Survival of Agreement.        All covenants,
agreements, representations and warranties made by the Borrower or Parent herein and in the certificates or other instruments prepared or delivered in connection with or pursuant to this Agreement or any other Loan Document shall be considered to
have been relied upon by the Lenders and the Issuing Bank and shall survive the making by the Lenders of the Loans and the issuance of Letters of Credit by the Issuing Bank, regardless of any investigation made by the Lenders or the Issuing Bank or
on their behalf, and shall continue in full force and effect as long as the principal of or any accrued interest on any Loan or any Fee or any other amount payable under this Agreement or any other Loan Document is outstanding and unpaid or any
Letter of Credit is outstanding and so long as the Commitments have not been terminated. The provisions of Sections 2.14, 2.16, 2.20, 9.05 and 9.18 shall remain operative and in full force and effect regardless of the expiration of the term of this
Agreement, the consummation of the transactions contemplated hereby, the repayment of any of the Loans, the expiration of the Commitments, the expiration of any Letter of Credit, the invalidity or unenforceability of any term or provision of this
Agreement or any other Loan Document, or any investigation made by or on behalf of the Administrative Agent, the Collateral Agent, any Lender or the Issuing Bank. 

SECTION 9.03.  Binding Effect.     This Agreement shall become effective as
provided in the Third Amendment and Restatement Agreement. 
 SECTION 9.04.  Successors and
Assigns.   (a) Whenever in this Agreement any of the parties hereto is referred to, such reference shall be deemed to include the permitted successors and assigns of such party; and all covenants, promises and agreements
by or on behalf of the Borrower, Parent, the Administrative Agent, the Collateral Agent, the Issuing Bank or the Lenders that are contained in this Agreement shall bind and inure to the benefit of their respective successors and assigns. 

(b)   Each Lender may assign to one or more Eligible Assignees all or a portion of its interests, rights and
obligations under this Agreement (including all or a portion of its Commitment and the Loans at the time owing to it), with notice to the Borrower and the prior written consent of the Administrative Agent (not to be unreasonably withheld or
delayed); provided, however, that (i) in the case of an assignment of a Revolving Credit Commitment, each of the Borrower, the Issuing Bank must also give its prior written consent to such assignment (which consent shall not be
unreasonably withheld or 

 
 131
 
  

 
delayed) (provided, that the consent of the Borrower shall not be required to any such assignment made to another Lender or an Affiliate of a Lender or after the occurrence and during the
continuance of any Event of Default referred to in paragraph (b), (c), (g) or (h) of Article VII), (ii) the amount of the Commitment or Loans of the assigning Lender subject to each such assignment (determined as of the date the
Assignment and Acceptance with respect to such assignment is delivered to the Administrative Agent) shall be not less than (x) $1,000,000 (with respect to an assignment of Term Loans) and (y) $5,000,000 (with respect to an assignment of
Revolving Credit Commitments or Revolving Loans) (or, in any case, if less, the entire remaining amount of such Lender’s Commitment or Loans of the relevant Class), (iii) the parties to each such assignment shall execute and deliver to the
Administrative Agent an Assignment and Acceptance via an electronic settlement system acceptable to the Administrative Agent (or, if previously agreed with the Administrative Agent, manually), and shall pay to the Administrative Agent a processing
and recordation fee of $3,500 (which fee may be waived or reduced in the sole discretion of the Administrative Agent and will not apply in the case of an assignment by a Lender to an Approved Fund that is managed by such Lender or an Affiliate of
such Lender or by an entity or an Affiliate of an entity that adminsters or manages such Lender), and (iv) the assignee, if it shall not be a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire and all applicable
tax forms. Upon acceptance and recording pursuant to paragraph (e) of this Section 9.04, from and after the effective date specified in each Assignment and Acceptance, (A) the assignee thereunder shall be a party hereto and, to the
extent of the interest assigned by such Assignment and Acceptance, have the rights and obligations of a Lender under this Agreement and (B) the assigning Lender thereunder shall, to the extent of the interest assigned by such Assignment and
Acceptance, be released from its obligations under this Agreement (and, in the case of an Assignment and Acceptance covering all or the remaining portion of an assigning Lender’s rights and obligations under this Agreement, such Lender shall
cease to be a party hereto but shall continue to be entitled to the benefits of Sections 2.14, 2.16, 2.20 and 9.05, as well as to any Fees accrued for its account and not yet paid). 

(c)   By executing and delivering an Assignment and Acceptance, the assigning Lender thereunder and the
assignee thereunder shall be deemed to confirm to and agree with each other and the other parties hereto as follows: (i) such assigning Lender warrants that it is the legal and beneficial owner of the interest being assigned thereby free
and clear of any adverse claim and that its Term Loan Commitment and Revolving Credit Commitment, are as set forth in such Assignment and Acceptance; (ii) except as set forth in (i) above, such assigning Lender makes no representation or
warranty and assumes no responsibility with respect to any statements, warranties or representations made in or in connection with this Agreement, or the execution, legality, validity, enforceability, genuineness, sufficiency or value of this
Agreement, any other Loan Document or any other instrument or document furnished pursuant hereto, or the financial condition of the Borrower or any Subsidiary or the performance or observance by the Borrower or any Subsidiary of any of its
obligations under this Agreement, any other Loan Document or any other instrument or document furnished pursuant hereto; (iii) such assignee represents and warrants that it is an Eligible Assignee and is legally authorized to enter into such
Assignment and Acceptance; (iv) such assignee confirms 

 
 132
 
  

 
that it has received a copy of this Agreement, together with copies of the most recent financial statements referred to in Section 3.05 or delivered pursuant to Section 5.04 and such
other documents and information as it has deemed appropriate to make its own credit analysis and decision to enter into such Assignment and Acceptance; (v) such assignee will independently and without reliance upon the Administrative Agent, the
Collateral Agent, such assigning Lender or any other Lender and based on such documents and information as it shall deem appropriate at the time, continue to make its own credit decisions in taking or not taking action under this Agreement;
(vi) such assignee appoints and authorizes the Administrative Agent and the Collateral Agent to take such action as agent on its behalf and to exercise such powers under this Agreement as are delegated to the Administrative Agent and the
Collateral Agent, respectively, by the terms hereof, together with such powers as are reasonably incidental thereto; and (vii) such assignee agrees that it will perform in accordance with their terms all the obligations which by the terms of
this Agreement are required to be performed by it as a Lender. 
 (d)   The Administrative Agent, acting for
this purpose as an agent of the Borrower, shall maintain at one of its offices in The City of New York a copy of each Assignment and Acceptance delivered to it and a register for the recordation of the names and addresses of the Lenders, and the
Commitment of, and principal amount of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be conclusive and the Borrower, the Administrative
Agent, the Issuing Bank, the Collateral Agent and the Lenders may treat each person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary.
The Register shall be available for inspection by the Borrower, the Issuing Bank, the Collateral Agent and any Lender, at any reasonable time and from time to time upon reasonable prior notice. 

(e)   Upon its receipt of, and consent to, a duly completed Assignment and Acceptance executed by an assigning
Lender and an assignee, an Administrative Questionnaire completed in respect of the assignee (unless the assignee shall already be a Lender hereunder), the processing and recordation fee referred to in paragraph (b) above, if applicable, and
the written consent of the Administrative Agent and, if required, the Borrower and the Issuing Bank to such assignment and any applicable tax forms, the Administrative Agent shall promptly (i) accept such Assignment and Acceptance and
(ii) record the information contained therein in the Register. No assignment shall be effective unless it has been recorded in the Register as provided in this paragraph (e). 

(f)   Each Lender may without the consent of the Borrower, the Issuing Bank or the Administrative Agent sell
participations to one or more banks or other persons in all or a portion of its rights and obligations under this Agreement (including all or a portion of its Commitment and the Loans owing to it); provided, however, that (i) such
Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations, (iii) the participating banks or other persons
shall be entitled to the benefit of the cost protection provisions contained in Sections 2.14, 2.16 and 2.20 to the same extent as if 

 
 133
 
  

 
they were Lenders (but, with respect to any particular participant, to no greater extent than the Lender that sold the participation to such participant) and (iv) the Borrower, the
Administrative Agent, the Issuing Bank and the Lenders shall continue to deal solely and directly with such Lender in connection with such Lender’s rights and obligations under this Agreement, and such Lender shall retain the sole right to
enforce the obligations of the Borrower relating to the Loans or L/C Disbursements and to approve any amendment, modification or waiver of any provision of this Agreement (other than amendments, modifications or waivers decreasing any fees payable
to such participating bank or person hereunder or the amount of principal of or the rate at which interest is payable on the Loans in which such participating bank or person has an interest, extending any scheduled principal payment date or date
fixed for the payment of interest on the Loans in which such participating bank or person has an interest, increasing or extending the Commitments in which such participating bank or person has an interest or releasing any Subsidiary Guarantor
(other than pursuant to the terms thereof or in connection with the sale of such Subsidiary Guarantor in a transaction permitted by Section 6.05) or all or substantially all of the Collateral). 

(g)   Any Lender or participant may, in connection with any assignment or participation or proposed assignment
or participation pursuant to this Section 9.04, disclose to the assignee or participant or proposed assignee or participant any information relating to the Borrower furnished to such Lender by or on behalf of the Borrower; provided that,
prior to any such disclosure of information designated by the Borrower as confidential, each such assignee or participant or proposed assignee or participant shall execute an agreement whereby such assignee or participant shall agree (subject to
customary exceptions) to preserve the confidentiality of such confidential information on terms no less restrictive than those applicable to the Lenders pursuant to Section 9.17. 

(h)   Any Lender may at any time assign all or any portion of its rights under this Agreement to secure
extensions of credit to such Lender or in support of obligations owed by such Lender; provided that no such assignment shall release a Lender from any of its obligations hereunder or substitute any such assignee for such Lender as a party
hereto. 
 (i)   Notwithstanding anything to the contrary contained herein, any Lender (a
“Granting Lender”) may grant to a special purpose funding vehicle (an “SPC”), identified as such in writing from time to time by the Granting Lender to the Administrative Agent and the Borrower, the
option to provide to the Borrower all or any part of any Loan that such Granting Lender would otherwise be obligated to make to the Borrower pursuant to this Agreement; provided that (i) nothing herein shall constitute a commitment
by any SPC to make any Loan and (ii) if an SPC elects not to exercise such option or otherwise fails to provide all or any part of such Loan, the Granting Lender shall be obligated to make such Loan pursuant to the terms hereof. The making of a
Loan by an SPC hereunder shall utilize the Commitment of the Granting Lender to the same extent, and as if, such Loan were made by such Granting Lender. Each party hereto hereby agrees that no SPC shall be liable for any indemnity or similar payment
obligation under this Agreement (all liability for which shall remain with the Granting Lender). In furtherance of the foregoing, each party hereto hereby agrees (which agreement shall 

 
 134
 
  

 
survive the termination of this Agreement) that, prior to the date that is one year and one day after the payment in full of all outstanding commercial paper or other senior indebtedness of any
SPC, it will not institute against, or join any other person in instituting against, such SPC any bankruptcy, reorganization, arrangement, insolvency or liquidation proceedings under the laws of the United States or any State thereof. In addition,
notwithstanding anything to the contrary contained in this Section 9.04, any SPC may (i) with notice to, but without the prior written consent of, the Borrower and the Administrative Agent and without paying any processing fee therefor,
assign all or a portion of its interests in any Loans to the Granting Lender or to any financial institutions (consented to by the Borrower and Administrative Agent) providing liquidity and/or credit support to or for the account of such SPC to
support the funding or maintenance of Loans and (ii) disclose on a confidential basis any non-public information relating to its Loans to any investor, potential investor, rating agency, commercial paper dealer, collateral manager, servicer or
provider of any surety, guarantee or credit or liquidity enhancement to such SPC. 
 (j)   Neither Parent nor
the Borrower shall assign or delegate any of its rights or duties hereunder without the prior written consent of the Administrative Agent, the Issuing Bank and each Lender, and any attempted assignment without such consent shall be null and void.

 (k)   In the event that any Revolving Credit Lender shall become a Defaulting Lender or S&P,
Moody’s and Thompson’s BankWatch (or InsuranceWatch Ratings Service, in the case of Lenders that are insurance companies (or Best’s Insurance Reports, if such insurance company is not rated by Insurance Watch Ratings Service)) shall,
after the date that any Lender becomes a Revolving Credit Lender, downgrade the long-term certificate of deposit ratings of such Lender, and the resulting ratings shall be below BBB-, Baa3 and C (or BB, in the
case of a Lender that is an insurance company (or B, in the case of an insurance company not rated by InsuranceWatch Ratings Service)) (or, with respect to any Revolving Credit Lender that is not rated by any such ratings service or provider, the
Issuing Bank shall have reasonably determined that there has occurred a material adverse change in the financial condition of any such Lender, or a material impairment of the ability of any such Lender to perform its obligations hereunder, as
compared to such condition or ability as of the date that any such Lender became a Revolving Credit Lender) then the Issuing Bank shall have the right, but not the obligation, at its own expense, upon notice to such Lender and the Administrative
Agent, to replace such Lender with an assignee (in accordance with and subject to the restrictions contained in paragraph (b) above), and such Lender hereby agrees to transfer and assign without recourse (in accordance with and subject to the
restrictions contained in paragraph (b) above) all its interests, rights and obligations in respect of its Revolving Credit Commitment to such assignee; provided, however, that (i) no such assignment shall conflict with any
law, rule and regulation or order of any Governmental Authority and (ii) the Issuing Bank or such assignee, as the case may be, shall pay to such Lender in immediately available funds on the date of such assignment the principal of and interest
accrued to the date of payment on the Loans made by such Lender hereunder and all other amounts accrued for such Lender’s account or owed to it hereunder. 

 
 135
 
  

 SECTION 9.05.  Expenses;
Indemnity.     (a) The Borrower and Parent agree, jointly and severally, to pay all reasonable out-of-pocket expenses incurred by the Administrative Agent, the Collateral Agent, each Arranger and each Issuing
Bank in connection with the syndication of the Credit Facilities and the preparation and administration of this Agreement and the other Loan Documents or in connection with any amendments, modifications or waivers of the provisions hereof or thereof
(whether or not the transactions hereby or thereby contemplated shall be consummated) or incurred by the Administrative Agent, the Collateral Agent, any Arranger, any Issuing Bank or any Lender in connection with the enforcement or protection of its
rights in connection with this Agreement and the other Loan Documents or in connection with the Loans made or Letters of Credit issued hereunder, including the fees, charges and disbursements of Cravath, Swaine & Moore LLP, counsel for the
Administrative Agent and the Collateral Agent, and, in connection with any such enforcement or protection, the fees, charges and disbursements of one counsel in each relevant jurisdiction (and any such additional counsel, if necessary, as a result
of actual or potential conflicts of interest) for the Administrative Agent, the Collateral Agent, the Arrangers, the Issuing Banks and the Lenders. 

(b)   The Borrower and Parent agree, jointly and severally, to indemnify the Administrative Agent, the
Collateral Agent, each Lender, each Arranger, each Issuing Bank and each Related Party of any of the foregoing persons (each such person being called an “Indemnitee”) against, and to hold each Indemnitee harmless from, any
and all actual losses, claims, damages, liabilities, penalties and related reasonable out-of-pocket expenses, including reasonable fees, charges and disbursements of one counsel in each relevant jurisdiction (and any such additional counsel, if
necessary, as a result of actual or potential conflicts of interest) for all Indemnitees, incurred by or asserted against any Indemnitee arising out of, in any way connected with, or as a result of (i) the execution or delivery of this
Agreement or any other Loan Document or any agreement or instrument contemplated thereby, the performance by the parties thereto of their respective obligations thereunder or the consummation of the Transactions, the Permitted HMA Transaction or any
related transaction and the other transactions contemplated thereby (including the syndication of the Credit Facilities), (ii) the use of the proceeds of the Loans or issuance of Letters of Credit, (iii) any claim, litigation,
investigation or proceeding relating to any of the foregoing, whether or not any Indemnitee is a party thereto (and regardless of whether such matter is initiated by a third party or by the Borrower, any other Loan Party or any of their respective
Affiliates), or (iv) any actual or alleged presence or Release of Hazardous Materials on any property currently or formerly owned or operated by the Borrower or any of the Subsidiaries, or any Environmental Liability related in any way to the
Borrower or the Subsidiaries; provided that such indemnity shall not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities, penalties or related expenses (x) are determined by a court of
competent jurisdiction by final judgment to have resulted primarily from (1) the gross negligence, bad faith or willful misconduct of such Indemnitee or (2) a material breach of the obligations under this Agreement of such Indemnitee or
any of such Indemnitee’s Affiliates or of any of its or their respective officers, directors, employees, agents, advisors or other representatives of the foregoing under this Agreement (as determined by a court of competent jurisdiction in a
final and nonappealable decision) or (y) result from 

 
 136
 
  

 
any proceeding (other than a proceeding against a party hereto acting pursuant to this Agreement or in its capacity as such or of any of its Affiliates or its or their respective officers,
directors, employees, agents, advisors and other representatives and the successors of each of the foregoing) solely between or among Indemnitees not arising from any act or omission of a Loan Party. 

(c)   To the extent that Parent and the Borrower fail to pay any amount required to be paid by them to the
Administrative Agent, the Collateral Agent, any Arranger or any Issuing Bank under paragraph (a) or (b) of this Section, each Lender severally agrees to pay to the Administrative Agent, the Collateral Agent, such Arranger or such Issuing
Bank, as the case may be, such Lender’s pro rata share (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount; provided that the unreimbursed expense or indemnified loss,
claim, damage, liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent, the Collateral Agent, such Arranger or such Issuing Bank in its capacity as such. For purposes hereof, a Lender’s
“pro rata share” shall be determined based upon its share of the sum of the Aggregate Revolving Credit Exposure, outstanding Term Loans and unused Commitments at the time. 

(d)   To the extent permitted by applicable law, neither Parent nor the Borrower nor any Indemnitee shall
assert, and each hereby waives, any claim against any Indemnitee or Parent and the Borrower and each of their respective Affiliates, as applicable, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to
direct or actual damages) arising out of, in connection with, or as a result of, this Agreement or any agreement or instrument contemplated hereby, the Transactions, any Loan or Letter of Credit or the use of the proceeds thereof. 

(e)   The provisions of this Section 9.05 shall remain operative and in full force and effect regardless
of the expiration of the term of this Agreement, the consummation of the transactions contemplated hereby, the repayment of any of the Loans, the expiration of the Commitments, the expiration of any Letter of Credit, the invalidity or
unenforceability of any term or provision of this Agreement or any other Loan Document, or any investigation made by or on behalf of the Administrative Agent, the Collateral Agent, any Lender, any Arranger or any Issuing Bank. All amounts due under
this Section 9.05 shall be payable, within 30 days of written demand therefor with a reasonably detailed summary of the amounts claimed. 

SECTION 9.06.  Right of Setoff.   If an Event of Default shall have occurred and be
continuing, each Lender or an Affiliate of such Lender is hereby authorized at any time and from time to time, except to the extent prohibited by law, to set off and apply any and all deposits (general or special, time or demand, provisional or
final) at any time held and other indebtedness at any time owing by such Lender or an Affiliate of such Lender to or for the credit or the account of the Borrower or Parent against any of and all the obligations of the Borrower or Parent now or
hereafter existing under this Agreement and other Loan Documents held by such Lender, provided that at such time such obligations are due or payable. The rights of each Lender and Affiliates of such Lender under this Section 9.06 are in
addition to other rights and remedies (including other rights of setoff) which such Lender or an Affiliate of such Lender may have. 

 
 137
 
  

 SECTION 9.07.  Applicable
Law.    THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS (OTHER THAN LETTERS OF CREDIT AND AS EXPRESSLY SET FORTH IN OTHER LOAN DOCUMENTS) SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAWS OF THE STATE OF NEW
YORK. EACH LETTER OF CREDIT SHALL BE GOVERNED BY, AND SHALL BE CONSTRUED IN ACCORDANCE WITH, THE LAWS OR RULES DESIGNATED IN SUCH LETTER OF CREDIT, OR IF NO SUCH LAWS OR RULES ARE DESIGNATED, THE UNIFORM CUSTOMS AND PRACTICE FOR DOCUMENTARY CREDITS
MOST RECENTLY PUBLISHED AND IN EFFECT, ON THE DATE SUCH LETTER OF CREDIT WAS ISSUED, BY THE INTERNATIONAL CHAMBER OF COMMERCE (THE “UNIFORM CUSTOMS”) AND, AS TO MATTERS NOT GOVERNED BY THE UNIFORM CUSTOMS, THE LAWS OF THE STATE OF NEW
YORK. 
 SECTION 9.08.  Waivers; Amendment.        (a) No
failure or delay of the Administrative Agent, the Collateral Agent, any Lender or the Issuing Bank in exercising any power or right hereunder or under any other Loan Document shall operate as a waiver thereof, nor shall any single or partial
exercise of any such right or power, or any abandonment or discontinuance of steps to enforce such a right or power, preclude any other or further exercise thereof or the exercise of any other right or power. The rights and remedies of the
Administrative Agent, the Collateral Agent, the Issuing Bank and the Lenders hereunder and under the other Loan Documents are cumulative and are not exclusive of any rights or remedies that they would otherwise have. No waiver of any provision of
this Agreement or any other Loan Document or consent to any departure by the Borrower or any other Loan Party therefrom shall in any event be effective unless the same shall be permitted by paragraph (b) below, and then such waiver or consent
shall be effective only in the specific instance and for the purpose for which given. No notice or demand on the Borrower or Parent in any case shall entitle the Borrower or Parent to any other or further notice or demand in similar or other
circumstances. 
 (b)   Neither this Agreement nor any provision hereof, may be waived, amended or modified
except pursuant to an agreement or agreements in writing entered into by the Borrower, Parent and the Required Lenders; provided, however, that no such agreement shall (i) decrease the principal amount of, or extend the
maturity of or any scheduled principal payment date or date for the payment of any interest on any Loan or any date for reimbursement of an L/C Disbursement, or waive or excuse any such payment or any part thereof, or decrease the rate of interest
on any Loan or L/C Disbursement, without the prior written consent of each Lender directly adversely affected thereby, (ii) increase or extend the Commitment or decrease or extend the date for payment of any Fees of any Lender without the
prior written consent of such Lender, (iii) amend or modify the pro rata requirements of Section 2.17, the provisions of Section 9.04(j) or the provisions of this Section or release all or substantially all of the value of the
Subsidiary Guarantors (other than pursuant to the terms hereof or thereof or in connection with the sale of such Subsidiary Guarantor in a transaction permitted by Section 6.05) or all or substantially all

 
 138
 
  

 
of the Collateral, without the prior written consent of each Lender, (iv) change the provisions of any Loan Document in a manner that by its terms adversely affects the rights in
respect of payments due to Lenders holding Loans of one Class differently from the rights of Lenders holding Loans of any other Class without the prior written consent of Lenders holding a majority in interest of the outstanding Loans and unused
Commitments of each adversely affected Class, (v) modify the protections afforded to an SPC pursuant to the provisions of Section 9.04(i) without the written consent of such SPC or (vi) reduce the percentage contained in the
definition of the term “Required Lenders” without the prior written consent of each Lender (it being understood that with the consent of the Required Lenders, additional extensions of credit pursuant to this Agreement may be included in
the determination of the Required Lenders on substantially the same basis as the Term Loan Commitments and Revolving Credit Commitments on the date hereof); provided further that (A) no such agreement shall amend, modify or otherwise
affect the rights or duties of the Administrative Agent, the Collateral Agent or the Issuing Bank hereunder or under any other Loan Document without the prior written consent of the Administrative Agent, the Collateral Agent or the Issuing Bank;
(B) the Borrower and the Administrative Agent may amend or supplement this Agreement and any other Loan Documents, without the consent of any Lender, in order to (x) cure ambiguities, omissions, mistakes or defects, (y) cause this
Agreement and the other Loan Documents to be consistent with the Guarantee and Collateral Agreement and other similar documents or (z) cause the Guarantee and Collateral Agreement or other document to comply with local Law on the advice of
local counsel; and (C) Section 6.11, Section 6.12, Section 6.13 and paragraph (d)(ii) of Article VII may be amended, waived or otherwise modified by the agreement of the Borrower and the Required Covenant Lenders, but shall not
be amended, waived or otherwise modified without the approval of the Required Covenant Lenders. 
 SECTION
9.09.  Certain Releases of Guarantees and Security Interests.    (a) Subject to the terms of any Pari Passu Intercreditor Agreement, upon the closing of any Asset Sale consisting of the sale, transfer
or other disposition of all of the Equity Interests of any Subsidiary Guarantor permitted pursuant to Section 6.05, (i) the obligations of such Subsidiary Guarantor pursuant to the Guarantee and Collateral Agreement shall automatically be
discharged and released without any further action by the Administrative Agent or any Lender, and (ii) the Administrative Agent and the Lenders will, upon the request and at the sole expense of the Borrower, execute and deliver any instrument
or other document in a form acceptable to the Administrative Agent which may reasonably be required to evidence such discharge and release, all without representation, recourse or warranty. 

(b)  Subject to the terms of any Pari Passu Intercreditor Agreement, upon the closing of any Asset
Sale consisting of the sale, transfer or other disposition of Equity Interests of any Subsidiary Guarantor or any other Subsidiary of the Borrower permitted pursuant to Section 6.05, (i) the Collateral Agent shall release to the Borrower,
without representation, warranty or recourse, express or implied, the pledged Equity Interests of such Subsidiary Guarantor or other Subsidiary, as applicable, held by it, (ii) the Collateral Agent shall release its security interest in all
Collateral of such Subsidiary, including any Mortgages, 

 
 139
 
  

 
and (iii) the Collateral Agent will, upon the request and at the sole expense of the Borrower, execute and deliver any instrument or other document in a form acceptable to the Collateral
Agent which may reasonably be required to evidence such release. 
 (c)  Subject to the terms of
any Pari Passu Intercreditor Agreement, upon consummation by the Borrower or any Subsidiary of a Permitted Interest Transfer or designation of an Unrestricted Subsidiary in accordance with the terms hereof, (i) the Collateral Agent shall
release to the Borrower, without representation, warranty or recourse, express or implied, those Equity Interests of the Subsidiary that are the subject of such Permitted Interest Transfer or designation in accordance with clauses (i) and
(ii) of Section 9.09(b) and shall release any pledged note theretofore pledged to the extent such note is being discharged in connection with such Permitted Interest Transfer or designation, and (ii) if such Subsidiary whose shares
are the subject of such Permitted Interest Transfer or designation is a Subsidiary Guarantor, the obligations of such Subsidiary under its Guarantee shall automatically be discharged and released in accordance with clauses (i) and (ii) of
Section 9.09(a) and any Lien granted by such Subsidiary under the Loan Documents shall automatically be discharged and released. 

(d)  Subject to the terms of any Pari Passu Intercreditor Agreement, the Collateral Agent will, upon
the request and at the sole expense of the Borrower, execute and deliver any instrument or other document in a form acceptable to the Collateral Agent which may be reasonably be required to discharge and release, all without representation, recourse
or warranty, any Lien on any Collateral granted to or held by the Collateral Agent under any Loan Document (i) upon termination of the Commitments and payment in full of the principal and interest on each Loan, all Fees and all other expenses
or amounts payable under any Loan Document and cancellation or expiration of all Letters of Credit and reimbursement of all amounts drawn thereunder in full (or other arrangements having been entered into with respect thereto acceptable to the
Issuing Bank and the Administrative Agent), (ii) that is sold, transferred or otherwise disposed of or to be sold, transferred or otherwise disposed of as part of or in connection with any sale, transfer or other disposition permitted hereunder
to a Person other than the Borrower or any Subsidiary Guarantor, and upon consummation by the Borrower or any Subsidiary of any such sale, transfer or other disposition, any Lien granted by the Borrower or such Subsidiary under the Loan Documents on
such Collateral shall automatically be discharged and released, and (iii) the Administrative Agent and the Lenders will, upon the request and at the sole expense of the Borrower, execute and deliver any instrument or other document in a form
acceptable to the Administrative Agent which may reasonably be required to evidence such discharge and release, all without representation, recourse or warranty. 

(e)  Subject to the terms of any Pari Passu Intercreditor Agreement, upon notification by the
Borrower to the Collateral Agent that a Subsidiary Guarantor 

 
 140
 
  

 
is a Non-Significant Subsidiary, and would not be required to become a Guarantor in accordance with the terms hereof, the Collateral Agent shall release the obligations of such Subsidiary under
its Guarantee and shall release and discharge any Lien granted by such Subsidiary Guarantor under the Loan Documents in accordance with clauses (i) and (ii) of Section 9.09(a). 

SECTION 9.10.  Interest Rate Limitation.   Notwithstanding anything herein to the
contrary, if at any time the interest rate applicable to any Loan or participation in any L/C Disbursement, together with all fees, charges and other amounts which are treated as interest on such Loan or participation in such L/C Disbursement under
applicable law (collectively the “Charges”), shall exceed the maximum lawful rate (the “Maximum Rate”) which may be contracted for, charged, taken, received or reserved by the Lender holding such Loan
or participation in accordance with applicable law, the rate of interest payable in respect of such Loan or participation hereunder, together with all Charges payable in respect thereof, shall be limited to the Maximum Rate and, to the extent
lawful, the interest and Charges that would have been payable in respect of such Loan or participation but were not payable as a result of the operation of this Section 9.10 shall be cumulated and the interest and Charges payable to such Lender
in respect of other Loans or participations or periods shall be increased (but not above the Maximum Rate therefor) until such cumulated amount, together with interest thereon at the Federal Funds Effective Rate to the date of repayment, shall have
been received by such Lender. 
 SECTION 9.11.  Entire Agreement.    This
Agreement, the Fee Letter and the other Loan Documents constitute the entire contract between the parties relative to the subject matter hereof. Any other previous agreement among the parties with respect to the subject matter hereof is superseded
by this Agreement and the other Loan Documents. Nothing in this Agreement or in the other Loan Documents, expressed or implied, is intended to confer upon any person (other than the parties hereto and thereto, their respective successors and assigns
permitted hereunder (including any Affiliate of the Issuing Bank that issues any Letter of Credit) and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent, the Collateral Agent, the Issuing Bank and
the Lenders) any rights, remedies, obligations or liabilities under or by reason of this Agreement or the other Loan Documents. 

SECTION 9.12.  WAIVER OF JURY TRIAL.     EACH PARTY HERETO HEREBY WAIVES, TO
THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OF THE OTHER LOAN DOCUMENTS. EACH PARTY
HERETO (A) CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND
(B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS, AS APPLICABLE, BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION 9.12. 

 
 141
 
  

 SECTION 9.13.  Severability.   In the
event any one or more of the provisions contained in this Agreement or in any other Loan Document should be held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein
and therein shall not in any way be affected or impaired thereby (it being understood that the invalidity of a particular provision in a particular jurisdiction shall not in and of itself affect the validity of such provision in any other
jurisdiction). The parties shall endeavor in good-faith negotiations to replace the invalid, illegal or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the invalid, illegal or
unenforceable provisions. 
 SECTION 9.14.  [Reserved]. 

SECTION 9.15.  Headings.     Article and Section headings and the Table of
Contents used herein are for convenience of reference only, are not part of this Agreement and are not to affect the construction of, or to be taken into consideration in interpreting, this Agreement. 

SECTION 9.16.  Jurisdiction; Consent to Service of Process.  (a) Each of
Parent and the Borrower hereby irrevocably and unconditionally submits, for itself and its property, to the exclusive jurisdiction of any New York State court or Federal court of the United States of America sitting in New York City, and
any appellate court from any thereof, in any action or proceeding arising out of or relating to this Agreement or the other Loan Documents, or for recognition or enforcement of any judgment, and each of the parties hereto hereby irrevocably and
unconditionally agrees that all claims in respect of any such action or proceeding may be heard and determined in such New York State or, to the extent permitted by law, in such Federal court. Each of the parties hereto agrees that a final
judgment in any such action or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. Nothing in this Agreement shall affect any right that the Administrative Agent,
the Collateral Agent, the Issuing Bank or any Lender may otherwise have to bring any action or proceeding relating to this Agreement or the other Loan Documents against the Borrower, Parent or their respective properties in the courts of any
jurisdiction. 
 (b)   Each of Parent and the Borrower hereby irrevocably and unconditionally waives, to the
fullest extent it may legally and effectively do so, any objection which it may now or hereafter have to the laying of venue of any suit, action or proceeding arising out of or relating to this Agreement or the other Loan Documents in any
New York State or Federal court. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by law, the defense of an inconvenient forum to the maintenance of such action or proceeding in any such court. 

(c)   Each party to this Agreement irrevocably consents to service of process in the manner provided for
notices in Section 9.01. Nothing in this Agreement will affect the right of any party to this Agreement to serve process in any other manner permitted by law. 

 
 142
 
  

 SECTION
9.17.  Confidentiality.     Each of the Administrative Agent, the Collateral Agent, the Issuing Bank and the Lenders agrees to maintain the confidentiality of the Information (as defined below),
except that Information may be disclosed (a) to its and its Affiliates’ officers, directors, employees and agents, including accountants, legal counsel, numbering, administration and settlement service providers, and other advisors (it
being understood that the persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to the extent requested by any regulatory authority or
quasi-regulatory authority (such as the National Association of Insurance Commissioners), (c) to the extent required by applicable laws or regulations or by any subpoena or similar legal process, (d) in connection with the exercise of any
remedies hereunder or under the other Loan Documents or any suit, action or proceeding relating to the enforcement of its rights hereunder or thereunder, (e) subject to an agreement containing provisions substantially the same as those of this
Section 9.17, to (i) any actual or prospective assignee of or participant in any of its rights or obligations under this Agreement and the other Loan Documents or (ii) any actual or prospective counterparty (or its advisors) to any
swap or derivative transaction relating to the Borrower or any Subsidiary or any of their respective obligations, (f) with the consent of the Borrower or (g) to the extent such Information becomes publicly available other than as a result
of a breach of this Section 9.17. For the purposes of this Section, “Information” shall mean all information received from the Borrower or Parent and related to the Borrower or Parent or their business, other than any
such information that was available to the Administrative Agent, the Collateral Agent, the Issuing Bank or any Lender on a nonconfidential basis prior to its disclosure by the Borrower or Parent; provided that any Lender, the Administrative
Agent, the Collateral Agent or the Issuing Bank shall give Parent prior notice of any disclosure pursuant to clause (c) to the extent permissible. Any person required to maintain the confidentiality of Information as provided in this
Section 9.17 shall be considered to have complied with its obligation to do so if such person has exercised the same degree of care to maintain the confidentiality of such Information as such person would accord its own confidential
information. 
 SECTION 9.18.  USA PATRIOT Act
Notice.        Each Lender and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies Parent and the Borrower that pursuant to the requirements of the USA PATRIOT Act, it
is required to obtain, verify and record information that identifies Parent and the Borrower, which information includes the name and address of Parent and the Borrower and other information that will allow such Lender or the Administrative Agent,
as applicable, to identify Parent and the Borrower in accordance with the USA PATRIOT Act. 
 SECTION
9.19.  Effect of Certain Inaccuracies.  In the event that any financial statement or certificate delivered pursuant to Section 5.04(a) or (b) and Section 5.04(c), respectively, is inaccurate within
one year after delivery thereof, and such inaccuracy, if corrected, would have led to the application of a higher Applicable Percentage or a higher Commitment Fee for any period (an “Applicable Period”) than the Applicable
Percentage 

 
 143
 
  

 
or Commitment Fee applied for such Applicable Period, then (i) the Borrower shall promptly deliver to the Administrative Agent a corrected financial statement and a corrected compliance
certificate for such Applicable Period, (ii) the Applicable Percentage and the Commitment Fee shall be determined based on the corrected compliance certificate for such Applicable Period, and (iii) the Borrower shall promptly pay to the
Administrative Agent (for the accounts of the applicable Lenders during the Applicable Period or their successors and assigns) the accrued additional interest or additional Commitment Fees (or both) owing as a result of such increased Applicable
Percentage or Commitment Fee for such Applicable Period. This Section 9.19 shall not limit the rights of the Administrative Agent or the Lenders with respect to Section 2.07 or Article VII. 

SECTION 9.20.  Pari Passu Obligations and Other Junior Secured Debt.   (a) Each
Lender and each Issuing Bank acknowledges that Pari Passu Debt Obligations and Other Junior Secured Debt may be secured by Liens on the Collateral having the same priority as, or junior priority to, the Liens securing the Obligations and hereby
consents thereto. 
 (b)   In connection with the incurrence by the Borrower or any Subsidiary of Pari Passu
Debt, Alternative Incremental Facility Indebtedness and/or Other Junior Secured Debt, each Lender and each Issuing Bank (i) acknowledges that, at the request of the Borrower, each of the Administrative Agent and/or the Collateral Agent shall
enter into one or more Pari Passu Intercreditor Agreements or Junior Lien Intercreditor Agreements, (ii) authorizes and directs each Agent to execute and deliver any Pari Passu Intercreditor Agreement or Junior Lien Intercreditor Agreement and
any documents relating thereto, in each case on behalf of such Lender or Issuing Bank and without any further consent, authorization or other action by such Lender or Issuing Bank, (iii) authorizes and directs each Agent to act as its
representative under, and in connection with, any Pari Passu Intercreditor Agreement or Junior Lien Intercreditor Agreement, (iv) acknowledges that any Pari Passu Intercreditor Agreement may contain provisions that permit or require the Liens
securing the Obligations and the Pari Passu Debt Obligations to be granted in favor of a single collateral agent trustee, which may not be the Administrative Agent or the Collateral Agent (a “Shared Collateral Agent”),
(v) acknowledges that any Pari Passu Intercreditor Agreement may provide that the holders of a majority in aggregate principal amount of Obligations and Pari Passu Debt Obligations, voting as a single class, may direct the Shared Collateral
Agent with respect to enforcement or the actions concerning the Collateral, and (vi) agrees that, upon the execution and delivery thereof, it will be bound by the provisions of any Pari Passu Intercreditor Agreement or Junior Lien Intercreditor
Agreement as if it were a signatory thereto and will take no actions contrary to the provisions thereof. Each Lender and each Issuing Bank further authorizes and directs each Agent to enter into such amendments, supplements or other modifications to
any Pari Passu Intercreditor Agreement or Junior Lien Intercreditor Agreement as are reasonably acceptable to the Administrative Agent in order to (A) enable any extension, renewal, refinancing, replacement or additional incurrence of any Loans
or any Pari Passu Debt, Alternative Incremental Facility Indebtedness or Other Junior Secured Debt permitted under this Agreement and (B) provide for the Pari Passu Debt Obligations or Other Junior Secured Debt thereunder to

 
 144
 
  

 
be secured by Liens on the Collateral having, as applicable, the same priority as, or junior priority to, the Liens on the Collateral securing the Obligations, in each case on behalf of such
Lender or such Issuing Bank and without any further consent, authorization or other action by such Lender or such Issuing Bank. 

(c)   Each Lender and each Issuing Bank (i) acknowledges that, at the request of the Borrower, each of the
Administrative Agent and the Collateral Agent shall, to the extent required by the terms of (or in order to implement the provisions of) any Pari Passu Intercreditor Agreement, delegate, assign and/or transfer any or all of its rights, duties,
remedies, powers or obligations with respect to the Collateral to a Shared Collateral Agent and (ii) hereby consents to any such delegation, assignment or transfer. The exculpatory provisions of Article VIII shall apply to any Shared Collateral
Agent and to the Related Parties thereof, and shall apply to their respective activities in connection with the Collateral and with any Pari Passu Intercreditor Agreement or any other Loan Documents. 

(d)   Each Lender and each Issuing Bank (i) acknowledges that, at the request of the Borrower, each of the
Administrative Agent and/or the Collateral Agent shall (A) amend, substitute, supplement or otherwise modify the Guarantee and Collateral Agreement, (B) amend, substitute, replace, supplement or otherwise modify any other Security
Document, (C) enter into additional Security Documents and (D) take such further actions as are reasonably incidental to the foregoing, in each case as are reasonably acceptable to the Administrative Agent and the Collateral Agent in order
to (1) enable the Borrower or any Subsidiary to incur Pari Passu Debt, Alternative Incremental Facility Indebtedness and/or Other Junior Secured Debt otherwise permitted to be incurred hereunder, (2) provide for any Pari Passu Debt
Obligations thereunder to be secured, in accordance with the terms of any Pari Passu Intercreditor Agreement, by Liens on the Collateral having the same priority as, or junior priority to, the Liens on the Collateral securing the Obligations and
(3) provide for any Other Junior Secured Debt thereunder to be secured, in accordance with the terms of any Junior Lien Intercreditor Agreement, by Liens on the Collateral having junior priority to the Liens on the Collateral securing the
Obligations, (ii) authorizes and directs each Agent to execute and deliver any such amendments, supplements, agreements and other documents, in each case on behalf of such Lender or Issuing Bank and without any further consent, authorization or
other action by such Lender or Issuing Bank and (iii) agrees that, upon the execution and delivery thereof, it will be bound by the provisions of such amendments, supplements, agreements and other documents as if it were a signatory thereto and
will take no actions contrary to the provisions thereof. 
 (e)   Without limiting the foregoing, no Secured
Party shall have any right individually to realize upon any of the Collateral or to enforce any Guarantee of the Obligations, it being understood and agreed that all powers, rights and remedies under the Loan Documents may be exercised solely by the
Agents on behalf of the Secured Parties in accordance with the terms thereof (subject, in the case of the Collateral, to the provisions of any Pari Passu Intercreditor Agreement and any Junior Lien Intercreditor Agreement). In the event of a
foreclosure by the Collateral Agent or any Shared Collateral Agent on any of the Collateral pursuant to a public or private sale or other 

 
 145
 
  

 
disposition, any Lender may be the purchaser of any or all of such Collateral at any such sale or other disposition, and such Collateral Agent or Shared Collateral Agent, as agent for and
representative of the Secured Parties (but not any Lender or Lenders in its or their respective individual capacities) shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the
Collateral sold at any such sale, to use and apply any of the Obligations as a credit on account of the purchase price for any Collateral payable by such Collateral Agent or Shared Collateral Agent on behalf of the Secured Parties at such sale or
other disposition. Each Secured Party, whether or not a party hereto, will be deemed, by its acceptance of the benefits of the Collateral and of the Guarantees of the Obligations provided under the Loan Documents, to have agreed to the foregoing
provisions. The provisions of this paragraph are for the sole benefit of the Lenders and shall not afford any right to, or constitute a defense available to, any Loan Party. 

SECTION 9.21.  No Fiduciary Relationship.   Each of Parent and the Borrower, on behalf
of itself and its subsidiaries, agrees that in connection with all aspects of the transactions contemplated hereby and any communications in connection therewith, Parent, the Borrower, the other Subsidiaries and their Affiliates, on the one hand,
and the Administrative Agent, the Collateral Agent, the Lenders, the Issuing Banks and their Affiliates, on the other hand, will have a business relationship that does not create, by implication or otherwise, any fiduciary duty on the part of the
Administrative Agent, the Collateral Agent, the Lenders, the Issuing Banks or their Affiliates, and no such duty will be deemed to have arisen in connection with any such transactions or communications. The Administrative Agent, the Collateral
Agent, the Arrangers, the Lenders, the Issuing Banks and their Affiliates may be engaged, for their own accounts or the accounts of customers, in a broad range of transactions that involve interests that differ from those of Parent, the Borrower and
their Affiliates, and none of the Administrative Agent, the Collateral Agent, the Arrangers, the Lenders, the Issuing Banks and their Affiliates has any obligation to disclose any of such interests to Parent, the Borrower or any of their Affiliates.
To the fullest extent permitted by law, each of Parent and the Borrower hereby waives and releases any claims that it or any of its Affiliates may have against the Administrative Agent, the Collateral Agent, the Arrangers, the Lenders, the Issuing
Banks and their Affiliates with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby. 

 DISCLOSURE SCHEDULE 

to 
 THIRD AMENDED AND RESTATED
CREDIT AGREEMENT 
 dated as of 

July 25, 2007, 
 as amended
and restated as of November 5, 2010, February 2, 2012 and January 27, 2014 
 among 

CHS/COMMUNITY HEALTH SYSTEMS, INC., 

COMMUNITY HEALTH SYSTEMS, INC., 

THE LENDERS PARTY HERETO 
 and

 CREDIT SUISSE AG, 
 as
Administrative Agent and Collateral Agent 
 CREDIT SUISSE SECURITIES (USA) LLC 

as Sole Bookrunner and Sole Lead Arranger 

 Reference is hereby made to that certain Credit Agreement, dated as of
July 25, 2007, as amended and restated as of November 5, 2010, February 2, 2012 and January 27, 2014 (the “Agreement”), by and among CHS/COMMUNITY HEALTH SYSTEMS, INC., a Delaware corporation (the
“Borrower”), COMMUNITY HEALTH SYSTEMS INC., a Delaware corporation (the “Parent”), the Lenders (as defined in Article I) and CREDIT SUISSE AG, as administrative agent (in such capacity, the “Administrative
Agent”) and as collateral agent (in such capacity, the “Collateral Agent”) for the Lenders. This Disclosure Schedule (this “Disclosure Schedule”) has been prepared and delivered in accordance with the
Agreement. 
 References to schedule numbers in the headings of this Disclosure Schedule relate to the corresponding
sections of the Agreement. Inclusion of any matter or item in any schedule of this Disclosure Schedule shall be deemed disclosure of such matter or item in another schedule of this Disclosure Schedule if and only if it is readily apparent from the
description of such matter or item that it applies to such other schedule. Inclusion of any matter or item in this Disclosure Schedule does not imply that such matter or item would, under the provisions of the Agreement, have to be included in any
schedule of this Disclosure Schedule or that such matter or term is otherwise material. In addition, matters disclosed in any section of this Disclosure Schedule are not necessarily limited to matters required by the Agreement to be disclosed in
this Disclosure Schedule, and any such additional matters are set forth for informational purposes only and do not necessarily include other matters of a similar nature. In no event shall the listing of such agreements or other matters in the
Disclosure Schedule be deemed or interpreted to broaden or otherwise amplify the Borrower’s representations and warranties or covenants contained in the Agreement. 

Terms defined in this Agreement and not otherwise defined in the Disclosure Schedule are used herein as in the Agreement. 

 INDEX OF SCHEDULES 

 

					
	Schedule 1.01(a)	  	-	  	Existing Letters of Credit
	Schedule 1.01(b)	  	-	  	Subsidiary Guarantors
	Schedule 1.01(c)	  	-	  	Mortgaged Property
	Schedule 1.01(d)	  	-	  	Hospitals
	Schedule 1.01(e)	  	-	  	Certain Permitted Joint Ventures
	Schedule 1.01(f)	  	-	  	Certain Subsidiaries
	Schedule 3.08	  	-	  	Subsidiaries
	Schedule 3.19(a) 	  	-	  	UCC Filing Offices
	Schedule 6.01	  	-	  	Existing Indebtedness
	Schedule 6.05(b)	  	-	  	Certain Syndication Transactions
	Schedule 6.07	  	-	  	Certain Affiliate Transactions

 Schedule 1.01 (a) 

Existing Letters of Credit 

1.         Irrevocable Letter of Credit outstanding as of the date hereof under the Existing Credit Agreement.

  

											
	LC Number	    	   Beneficiary	  	Maturity  	 	  	Gross Amount 	 
	
	 CHS Existing Letters of Credit:
	   

	SM413504	    	 Louisiana Patient’s Compensation
	  	 	07/20/14   	  	  	 	$125,000.00	  
	SM416221	    	 City of McCaysville
	  	 	03/19/14   	  	  	 	357,730.00	  
	SM200963	    	 The Doctors Company
	  	 	11/22/14   	  	  	 	100,000.00	  
	SM201505	    	 Secretary US Department of Education
	  	 	12/31/14   	  	  	 	183,000.00	  
	SM209374	    	 Secretary/US Department of Education
	  	 	07/27/14   	  	  	 	486,000.00	  
	SM203959	    	 Continental Casualty Company
	  	 	07/03/14   	  	  	 	8,000,000.00	  
	SM227363W	    	 Employers Insurance of Wausau
	  	 	09/13/14   	  	  	 	100,000.00	  
	SM227374W        	    	 Louisiana Patient Compensation Fund
	  	 	08/25/14   	  	  	 	125,000.00	  
	SM227430W	    	 Department of Health and Human
	  	 	10/19/14   	  	  	 	460,500.00	  
	SM227439W	    	 Arkansas Insurance Department
	  	 	12/05/14   	  	  	 	100,000.00	  
	SM227442W	    	 Matanuska Electric Association
	  	 	03/07/14   	  	  	 	124,000.00	  
	SM227444W	    	 Arkansas Department of Workforce Services
	  	 	12/05/14   	  	  	 	100,000.00	  
	SM227446W	    	 Health Care Indemnity, Inc
	  	 	12/31/14   	  	  	 	2,800,000.00	  
	SM227456W	    	 Texas HCP Holding, L.P.
	  	 	03/30/14   	  	  	 	361,463.94	  
	SM228411W	    	 MPT of Cheraw, LLC; MPT of Bennettsville, LLC and MPT of Hillsboro, LP
	  	 	10/29/14   	  	  	 	4,179,942.00	  
	SM235994W	    	 Constellation NewEnergy
	  	 	11/10/14   	  	  	 	1,720,000.00	  
	IS0003107	    	 State of Nevada
	  	 	09/28/14   	  	  	 	100,000.00	  
			
	 HMA Existing Letters of Credit:
	  				  			
	IS 0012611	    	 Powell-Clinch Utilities
	  	 	6/12/2014  	  	  	 	10,000.00 	  
	IS0008090	    	 Florida Power & Light
	  	 	12/15/2014	  	  	 	1,875,220.00 	  
	IS0008098	    	 BancFirst
	  	 	12/15/2014	  	  	 	2,500,000.00 	  
	IS0008100	    	 Georgia Power & Light
	  	 	12/15/2014	  	  	 	200,000.00 	  
	IS0008111	    	 Carolina Power & Light
	  	 	12/15/2014	  	  	 	100,000.00 	  
	IS0008113	    	 Tullahoma Utilities Board
	  	 	12/15/2014	  	  	 	188,000.00 	  
	IS0008114	    	 Central Florida Gas Company
	  	 	12/15/2014	  	  	 	7,650.00 	  
	IS0008115	    	 Noll Drive Assoc LP c/o Property Management
	  	 	12/15/2014	  	  	 	250,000.00 	  
	IS0008135	    	 Florida Power Corp
	  	 	12/15/2014	  	  	 	196,895.00 	  
	IS0008136	    	 Entergy MS, Inc.
	  	 	12/15/2014	  	  	 	7,000.00 	  
	IS0008138	    	 2125 Noll Drive Assoc. LP c/o Property Management
	  	 	12/15/2014	  	  	 	250,000.00 	  
	IS0008226	    	 Liberty Mutual Insurance Company
	  	 	12/15/2014	  	  	 	50,700,000.00 	  
	IS0009749	    	 Carolina Power & Light Company
	  	 	2/2/2015    	  	  	 	15,500.00 	  
	IS0012559	    	 Citizens Gas Utility; District of Scott&MorganCity
	  	 	6/11/2014  	  	  	 	5,000.00 	  
	IS0012560	    	 State Volunteer Mutual Insurance Company
	  	 	6/11/2014  	  	  	 	150,000.00 	  
	IS0012561	    	 Lafollete Utilities Board
	  	 	6/12/2014  	  	  	 	100,000.00 	  
	IS0012562	    	 Appalachian Electric Cooperative
	  	 	6/12/2014  	  	  	 	72,000.00 	  
	IS0012570	    	 Newport Utilities
	  	 	10/15/2014	  	  	 	74,000.00 	  
	IS0012577	    	 Knoxville Utility Board
	  	 	6/12/2014  	  	  	 	1,300,000.00 	  
	IS0012613	    	 Enterprise FM Trust
	  	 	6/12/2014  	  	  	 	18,000.00 	  

  
 4 

											
	IS0012617	    	 LCUB
	  	 	6/12/2014  	  	  	 	100,000.00 	  
	IS0013057	    	 OG&E
	  	 	7/2/2014    	  	  	 	379,660.00 	  
	IS0076585U	    	 OG&E
	  	 	9/4/2014    	  	  	 	12,935.00 	  
	SM205605W          	    	 Withlacoochee River Electric Cooperative
	  	 	10/31/2014	  	  	 	150,000.00 	  
	SM412786	    	 City Electric System

Utility Board of the City of Key West
	  	 	5/19/2014  	  	  	 	97,500.00 	  
	S510122	    	 Pacific Employers Company and Insurance

North America and Cigna Insurance Company
	  	 	10/1/2014  	  	  	 	700,000.00 	  
			
	 Total (CHS and HMA):
	  				  	 	$78,881,995.94	  

  
 All CHS and HMA Existing Letters of Credit are issued by Well Fargo Bank, National Association. 

  
 5 

 Schedule 1.01(b) 

Subsidiary Guarantors 
  

	 	1.	Abilene Hospital, LLC 

	 	2.	Abilene Merger, LLC 

	 	3.	Affinity Health Systems, LLC 

	 	4.	Affinity Hospital, LLC 

	 	5.	Anna Hospital Corporation 

	 	6.	Berwick Hospital Company, LLC 

	 	7.	Big Bend Hospital Corporation 

	 	8.	Big Spring Hospital Corporation 

	 	9.	Birmingham Holdings, LLC 

	 	10.	Birmingham Holdings II, LLC 

	 	11.	Blue Island Hospital Company, LLC 

	 	12.	Blue Island Illinois Holdings, LLC 

	 	13.	Bluefield Holdings, LLC 

	 	14.	Bluefield Hospital Company, LLC 

	 	15.	Bluffton Health System LLC 

	 	16.	Brownsville Hospital Corporation 

	 	17.	Brownwood Hospital, L.P. 

	 	18.	Brownwood Medical Center, LLC 

	 	19.	Bullhead City Hospital Corporation 

	 	20.	Bullhead City Hospital Investment Corporation 

	 	21.	Carlsbad Medical Center, LLC 

	 	22.	Centre Hospital Corporation 

	 	23.	CHHS Holdings, LLC 

	 	24.	CHS Kentucky Holdings, LLC 

	 	25.	CHS Pennsylvania Holdings, LLC 

	 	26.	CHS Virginia Holdings, LLC 

	 	27.	CHS Washington Holdings, LLC 

	 	28.	Clarksville Holdings, LLC 

	 	29.	Clarksville Holdings II, LLC 

	 	30.	Cleveland Hospital Corporation 

	 	31.	Cleveland Tennessee Hospital Company, LLC 

	 	32.	Clinton Hospital Corporation 

	 	33.	Coatesville Hospital Corporation 

	 	34.	College Station Hospital, L.P. 

	 	35.	College Station Medical Center, LLC 

	 	36.	College Station Merger, LLC 

	 	37.	Community GP Corp. 

	 	38.	Community Health Investment Company, LLC 

	 	39.	Community LP Corp. 

	 	40.	CP Hospital GP, LLC 

	 	41.	CPLP, LLC 

	 	42.	Crestwood Hospital LP, LLC 

	 	43.	Crestwood Hospital, LLC 

	 	44.	CSMC, LLC 

  
 6 

	 	45.	CSRA Holdings, LLC 

	 	46.	Deaconess Holdings, LLC 

	 	47.	Deaconess Hospital Holdings, LLC 

	 	48.	Deming Hospital Corporation 

	 	49.	Desert Hospital Holdings, LLC 

	 	50.	Detar Hospital, LLC 

	 	51.	DHSC, LLC  

	 	52.	DHFW Holdings, LLC 

	 	53.	Dukes Health System, LLC 

	 	54.	Dyersburg Hospital Corporation 

	 	55.	Emporia Hospital Corporation 

	 	56.	Evanston Hospital Corporation 

	 	57.	Fallbrook Hospital Corporation 

	 	58.	Foley Hospital Corporation 

	 	59.	Forrest City Arkansas Hospital Company, LLC 

	 	60.	Forrest City Hospital Corporation 

	 	61.	Fort Payne Hospital Corporation 

	 	62.	Frankfort Health Partner, Inc. 

	 	63.	Franklin Hospital Corporation 

	 	64.	Gadsden Regional Medical Center, LLC 

	 	65.	Galesburg Hospital Corporation 

	 	66.	Granbury Hospital Corporation 

	 	67.	Granite City Hospital Corporation 

	 	68.	Granite City Illinois Hospital Company, LLC 

	 	69.	Greenville Hospital Corporation 

	 	70.	GRMC Holdings, LLC 

	 	71.	Hallmark Healthcare Company, LLC 

	 	72.	Hobbs Medco, LLC 

	 	73.	Hospital of Barstow, Inc. 

	 	74.	Hospital of Fulton, Inc. 

	 	75.	Hospital of Louisa, Inc. 

	 	76.	Hospital of Morristown, Inc. 

	 	77.	Jackson Hospital Corporation (KY) 

	 	78.	Jackson Hospital Corporation (TN) 

	 	79.	Jourdanton Hospital Corporation 

	 	80.	Kay County Hospital Corporation 

	 	81.	Kay County Oklahoma Hospital Company, LLC 

	 	82.	Kirksville Hospital Company, LLC 

	 	83.	Lakeway Hospital Corporation 

	 	84.	Lancaster Hospital Corporation 

	 	85.	Las Cruces Medical Center, LLC 

	 	86.	Lea Regional Hospital, LLC 

	 	87.	Lexington Hospital Corporation 

	 	88.	Longview Clinic Operations Company, LLC 

	 	89.	Longview Medical Center, L.P. 

	 	90.	Longview Merger, LLC 

  
 7 

	 	91.	LRH, LLC 

	 	92.	Lutheran Health Network of Indiana, LLC 

	 	93.	Marion Hospital Corporation 

	 	94.	Martin Hospital Corporation 

	 	95.	Massillon Community Health System LLC 

	 	96.	Massillon Health System LLC 

	 	97.	Massillon Holdings, LLC 

	 	98.	McKenzie Tennessee Hospital Company, LLC 

	 	99.	McNairy Hospital Corporation 

	 	100.	   MCSA, L.L.C. 

	 	101.	   Medical Center of Brownwood, LLC 

	 	102.	   Merger Legacy Holdings, LLC 

	 	103.	   MMC of Nevada, LLC 

	 	104.	   Moberly Hospital Company, LLC 

	 	105.	   MWMC Holdings, LLC 

	 	106.	   Nanticoke Hospital Company, LLC 

	 	107.	   National Healthcare of Leesville, Inc. 

	 	108.	   National Healthcare of Mt. Vernon, Inc. 

	 	109.	   National Healthcare of Newport, Inc. 

	 	110.	   Navarro Hospital, L.P. 

	 	111.	   Navarro Regional, LLC 

	 	112.	   NC-DSH, LLC 

	 	113.	   Northampton Hospital Company, LLC 

	 	114.	   Northwest Hospital, LLC 

	 	115.	   Northwest Arkansas Hospitals, LLC 

	 	116.	   NOV Holdings, LLC 

	 	117.	   NRH, LLC 

	 	118.	   Oak Hill Hospital Corporation 

	 	119.	   Oro Valley Hospital, LLC 

	 	120.	   Palmer-Wasilla Health System, LLC 

	 	121.	   Payson Hospital Corporation 

	 	122.	   Peckville Hospital Company, LLC 

	 	123.	   Pennsylvania Hospital Company, LLC 

	 	124.	   Phillips Hospital Corporation 

	 	125.	   Phoenixville Hospital Company, LLC 

	 	126.	   Pottstown Hospital Company, LLC 

	 	127.	   QHG Georgia Holdings, Inc. 

	 	128.	   QHG Georgia Holdings II, LLC 

	 	129.	   QHG Georgia, LP 

	 	130.	   QHG of Bluffton Company, LLC 

	 	131.	   QHG of Clinton County, Inc. 

	 	132.	   QHG of Enterprise, Inc. 

	 	133.	   QHG of Forrest County, Inc. 

	 	134.	   QHG of Fort Wayne Company, LLC 

	 	135.	   QHG of Hattiesburg, Inc. 

	 	136.	   QHG of Massillon, Inc. 

  
 8 

	 	137.	   QHG of South Carolina, Inc. 

	 	138.	   QHG of Spartanburg, Inc. 

	 	139.	   QHG of Springdale, Inc. 

	 	140.	   QHG of Warsaw Company, LLC 

	 	141.	   Quorum Health Resources, LLC 

	 	142.	   Red Bud Hospital Corporation 

	 	143.	   Red Bud Illinois Hospital Company, LLC 

	 	144.	   Regional Hospital of Longview, LLC 

	 	145.	   River Region Medical Corporation 

	 	146.	   Roswell Hospital Corporation 

	 	147.	   Ruston Hospital Corporation 

	 	148.	   Ruston Louisiana Hospital Company, LLC 

	 	149.	   SACMC, LLC 

	 	150.	   Salem Hospital Corporation 

	 	151.	   San Angelo Community Medical Center, LLC 

	 	152.	   San Angelo Medical, LLC 

	 	153.	   San Miguel Hospital Corporation 

	 	154.	   Scranton Holdings, LLC 

	 	155.	   Scranton Hospital Company, LLC 

	 	156.	   Scranton Quincy Holdings, LLC 

	 	157.	   Scranton Quincy Hospital Company, LLC 

	 	158.	   Shelbyville Hospital Corporation 

	 	159.	   Siloam Springs Arkansas Hospital Company, LLC 

	 	160.	   Siloam Springs Holdings, LLC 

	 	161.	   Southern Texas Medical Center, LLC 

	 	162.	   Spokane Valley Washington Hospital Company, LLC 

	 	163.	   Spokane Washington Hospital Company, LLC 

	 	164.	   Tennyson Holdings, LLC 

	 	165.	   Tooele Hospital Corporation 

	 	166.	   Tomball Texas Holdings, LLC 

	 	167.	   Tomball Texas Hospital Company, LLC 

	 	168.	   Triad Healthcare Corporation 

	 	169.	   Triad Holdings III, LLC 

	 	170.	   Triad Holdings IV, LLC 

	 	171.	   Triad Holdings V, LLC 

	 	172.	   Triad Nevada Holdings, LLC 

	 	173.	   Triad of Alabama, LLC 

	 	174.	   Triad of Oregon, LLC 

	 	175.	   Triad-ARMC, LLC 

	 	176.	   Triad-El Dorado, Inc. 

	 	177.	   Triad-Navarro Regional Hospital Subsidiary, LLC 

	 	178.	   Tunkhannock Hospital Company, LLC 

	 	179.	   VHC Medical, LLC 

	 	180.	   Vicksburg Healthcare, LLC 

	 	181.	   Victoria Hospital, LLC 

	 	182.	   Victoria of Texas, L.P. 

  
 9 

	 	183.	   Virginia Hospital Company, LLC 

	 	184.	   Warren Ohio Hospital Company, LLC 

	 	185.	   Warren Ohio Rehab Hospital Company, LLC 

	 	186.	   Watsonville Hospital Corporation 

	 	187.	   Waukegan Hospital Corporation 

	 	188.	   Waukegan Illinois Hospital Company, LLC 

	 	189.	   Weatherford Hospital Corporation 

	 	190.	   Weatherford Texas Hospital Company, LLC 

	 	191.	   Webb Hospital Corporation 

	 	192.	   Webb Hospital Holdings, LLC 

	 	193.	   Wesley Health System LLC 

	 	194.	   West Grove Hospital Company, LLC 

	 	195.	   WHMC, LLC 

	 	196.	   Wilkes-Barre Behavioral Hospital Company, LLC 

	 	197.	   Wilkes-Barre Holdings, LLC 

	 	198.	   Wilkes-Barre Hospital Company, LLC 

	 	199.	   Williamston Hospital Corporation 

	 	200.	   Women & Children’s Hospital, LLC 

	 	201.	   Woodland Heights Medical Center, LLC 

	 	202.	   Woodward Health System, LLC 

	 	203.	   York Pennsylvania Holdings, LLC 

	 	204.	   York Pennsylvania Hospital Company, LLC 

	 	205.	   Youngstown Ohio Hospital Company, LLC 

	 	206.	   Amory HMA, LLC 

	 	207.	   Bartow HMA, LLC 

	 	208.	   Biloxi H.M.A., LLC 

	 	209.	   Brandon HMA, LLC 

	 	210.	   Brevard HMA Holdings, LLC 

	 	211.	   Brevard HMA Hospitals, LLC 

	 	212.	   Campbell County HMA, LLC 

	 	213.	   Carlisle HMA, LLC 

	 	214.	   Carolinas JV Holdings General, LLC 

	 	215.	   Carolinas JV Holdings, L.P. 

	 	216.	   Central Florida HMA Holdings, LLC 

	 	217.	   Central States HMA Holdings, LLC 

	 	218.	   Chester HMA, LLC 

	 	219.	   Citrus HMA, LLC 

	 	220.	   Clarksdale HMA, LLC 

	 	221.	   Cocke County HMA, LLC 

	 	222.	   Florida HMA Holdings, LLC 

	 	223.	   Fort Smith HMA, LLC 

	 	224.	   Hamlet H.M.A., LLC 

	 	225.	   Health Management Associates, Inc. 

	 	226.	   Health Management Associates, LP 

	 	227.	   Health Management General Partner, LLC 

	 	228.	   HMA Fentress County General Hospital, LLC 

  
 10 

	 	229.	   HMA Hospitals Holdings, LP 

	 	230.	   HMA Santa Rosa Medical Center, LLC 

	 	231.	   Hospital Management Associates, LLC 

	 	232.	   Jackson HMA, LLC 

	 	233.	   Jefferson County HMA, LLC 

	 	234.	   Kennett HMA, LLC 

	 	235.	   Key West HMA, LLC 

	 	236.	   Knoxville HMA Holdings, LLC 

	 	237.	   Lehigh HMA, LLC 

	 	238.	   Lone Star HMA, L.P. 

	 	239.	   Madison HMA, LLC 

	 	240.	   Melbourne HMA, LLC 

	 	241.	   Mesquite HMA General, LLC 

	 	242.	   Metro Knoxville HMA, LLC 

	 	243.	   Mississippi HMA Holdings I, LLC 

	 	244.	   Mississippi HMA Holdings II, LLC 

	 	245.	   Monroe HMA, LLC 

	 	246.	   Naples HMA, LLC 

	 	247.	   Poplar Bluff Regional Medical Center, LLC 

	 	248.	   Port Charlotte HMA, LLC 

	 	249.	   Punta Gorda HMA, LLC 

	 	250.	   River Oaks Hospital, LLC 

	 	251.	   Rockledge HMA, LLC 

	 	252.	   ROH, LLC 

	 	253.	   Sebastian Hospital, LLC 

	 	254.	   Sebring Hospital Management Associates, LLC 

	 	255.	   Southeast HMA Holdings, LLC 

	 	256.	   Southwest Florida HMA Holdings, LLC 

	 	257.	   Statesville HMA, LLC 

	 	258.	   VAN BUREN H.M.A., LLC 

	 	259.	   Venice HMA, LLC 

	 	260.	   Winder HMA, LLC 

	 	261.	   Yakima HMA, LLC 

  
 11 

 Schedule 1.01(c) 

Mortgaged Property 
  

			
	
              Hospital Name/Address (County)

 
	  	
              Corporate Owner

	 DeKalb Regional Medical Center

200 Medical Center Drive
 P.O. Box 680778

Fort Payne, AL  35968  (Dekalb)
  
	  	Fort Payne Hospital Corporation (AL)
	 Flowers Hospital

4370 West Main Street
 Dothan,
AL  36305  (Houston)
  
	  	Triad of Alabama, LLC (DE)
	 Gadsden Regional Medical Center

1007 Goodyear Avenue
 Gadsden,
AL  35903  (Etowah)
  
	  	Gadsden Regional Medical Center, LLC (DE)
	 Medical Center Enterprise

400 North Edwards St.
 Enterprise,
AL  36330  (Coffee)
  
	  	QHG of Enterprise, Inc. (AL)
	 Northwest Hospital

6200 N. LaCholla Blvd.
 Tucson, AZ 85755  (Pima)

 
	  	Northwest Hospital, LLC (DE)
	 Northwest Hospital Oro Valley

1551 E. Tangerine Rd.
 Oro Valley, AZ 85755 (Pima)

 
	  	Oro Valley Hospital, LLC (DE)
	 Watsonville Community Hospital

75 Neilson Street
 Watsonville,
CA  95076  (Santa Cruz)
  
	  	Watsonville Hospital Corporation (DE)
	 Galesburg Cottage Hospital

695 N. Kellogg St.
 Galesburg,
IL  61401  (Knox)
  
	  	Galesburg Hospital Corporation (IL)
	 Gateway Regional Medical Center

2100 Madison Avenue
 Granite City,
IL  62040  (Madison)
  
	  	Granite City Illinois Hospital Company, LLC (IL)
	 Heartland Regional Medical Center

3333 West DeYoung
 Marion,
IL  62959  (Williamson)
  
	  	Marion Hospital Corporation (IL)
	 Vista Medical Center (includes East and West)

1324 N. Sheridan Road
 Waukegan,
IL  60085  (Lake)
  
	  	Waukegan Illinois Hospital Company, LLC (IL)
	 Bluffton Regional Medical Center

303 South Main Street
 Bluffton,
IN  46714  (Wells)
  
	  	Bluffton Health System LLC (DE)

  
 12 

			
	
              Hospital Name/Address (County)

 
	  	
              Corporate Owner

	 Dukes Memorial Hospital

275 W. 12th Street
 Peru,
IN  46970  (Miami)
  
	  	Dukes Health System, LLC (DE)
	 Women and Children’s Hospital

4200 Nelson Road
 Lake Charles,
LA  70605  (Calcasieu)
  
	  	Women and Children’s Hospital, LLC (DE)
	 River Region Health System

2100 Highway 61 North/1111 N.
 Frontage Road

Vicksburg, MS  39183  (Warren)
  
	  	Vicksburg Healthcare, LLC (DE)
	 Wesley Medical Center

5001 Hardy Street
 Hattiesburg, MS 39402  (Lamar)

 
	  	Wesley Health System LLC (DE)
	 Moberly Regional Medical Center

1515 Union Avenue
 Moberly,
MO  65270  (Randolph)
  
	  	Moberly Hospital Company, LLC (DE)
	 Mesa View Regional Hospital

1299 Bertha Howe Avenue
 Mesquite,
NV  89027  (Clark)
  
	  	MMC of Nevada, LLC (DE)
	 The Memorial Hospital of Salem County

310 Woodstown Road
 Salem,
NJ  08079  (Salem)
  
	  	Salem Hospital Corporation (NJ)
	 Alta Vista Regional Hospital

104 Legion Drive
 Las Vegas, NM  87701  (San
Miguel)
  
	  	San Miguel Hospital Corporation (NM)
	 Carlsbad Medical Center

2430 West Pierce
 Carlsbad,
NM  88220  (Eddy)
  
	  	Carlsbad Medical Center, LLC (DE)
	 Eastern New Mexico Medical Center

405 West Country Club Road
 Roswell,
NM  88201  (Chaves)
  
	  	Roswell Hospital Corporation (NM)
	 Lea Regional Medical Center

5419 N. Lovington Highway
 Hobbs,
NM  88240  (Lea)
  
	  	Lea Regional Hospital, LLC (DE)
	 MountainView Regional Medical Center

4311 East Lohman Avenue
 Las Cruces,
NM  88011  (Dona Ana)
  
	  	Las Cruces Medical Center, LLC (DE)
	 Affinity Medical Center

875 Eighth Street NE
 Massillon,
OH  44646  (Stark)
  
	  	DHSC, LLC (DE)

  
 13 

			
	
              Hospital Name/Address (County)

 
	  	
              Corporate Owner

	 Hillside Rehabilitation Hospital

8747 Squires Lane NE
 Warren,
OH  44484  (Trumbull)
  
	  	Warren Ohio Rehab Hospital Company, LLC (DE)
	 Northside Medical Center

500 Gypsy Lane
 Youngstown,
OH  44501  (Trumbull and Mahoning)
  
	  	Youngstown Ohio Hospital Company, LLC (DE)
	 Trumbull Memorial Hospital

1350 East Market Street
 Warren,
OH  44482  (Trumbull)
  
	  	Warren Ohio Hospital Company, LLC (DE)
	 Ponca City Medical Center

1900 North 14th Street
 Ponca City,
OK  74601  (Kay)
  
	  	Kay County Oklahoma Hospital Company, LLC (OK)
	 Berwick Hospital Center

701 East 16th Street
 Berwick,
PA  18603  (Columbia)
  
	  	Berwick Hospital Company, LLC (DE)
	 Brandywine Hospital

201 Reeceville Rd.
 Coatesville,
PA  19320  (Chester)
  
	  	Coatesville Hospital Corporation (PA)
	 Easton Hospital

250 South 21st Street
 Easton,
PA  18042-3892  (Northampton)
  
	  	Northampton Hospital Company, LLC (DE)
	 Jennersville Regional Hospital

1015 West Baltimore Pike
 West Grove,
PA  19390  (Chester)
  
	  	West Grove Hospital Company, LLC (DE)
	 Lock Haven Hospital

24 Cree Drive
 Lock Haven,
PA  17745-2699  (Washington)
  
	  	Clinton Hospital Corporation (PA)
	 Moses Taylor Hospital

700 Quincy Avenue
 Scranton, PA 18510-1798 (Lackawanna)

 
	  	Scranton Quincy Hospital Company, LLC (DE)
	 Phoenixville Hospital

140 Nutt Road
 Phoenixville,
PA  19460  (Chester)
  
	  	Phoenixville Hospital Company, LLC (DE)
	 Pottstown Memorial Medical Center

1600 East High Street
 Pottstown,
PA  19464  (Montgomery)
  
	  	Pottstown Hospital Company, LLC (DE)
	 Regional Hospital of Scranton

746 Jefferson Avenue
 Scranton, PA  18510
(Lackawanna)
  
	  	Scranton Hospital Company, LLC (DE)

  
 14 

			
	
              Hospital Name/Address (County)

 
	  	
              Corporate Owner

	 Tyler Memorial Hospital

5950 SR6
 Tunkhannock, PA 18657 (Wyoming)

 
	  	Tunkhannock Hospital Company, LLC (DE)
	 Wilkes-Barre General Hospital

575 North River Street
 Wilkes-Barre,
PA  18764  (Luzerne and Wyoming)
  
	  	 Wilkes-Barre
Hospital Company, LLC (DE)
 Wilkes-Barre Behavioral Hospital Company, LLC (DE)

	 Carolinas Hospital System

805 Pamplico Highway
 Florence,
SC  29505  (Florence)
  
	  	QHG of South Carolina, Inc. (SC)
	 Marion Regional Hospital

2829 East Highway 76
 Mullins,
SC  29574  (Marion and Horry)
  
	  	QHG of South Carolina, Inc. (SC)
	 Springs Memorial Hospital

800 W. Meeting Street
 Lancaster,
SC  29720  (Lancaster)
  
	  	Lancaster Hospital Corporation (DE)
	 Dyersburg Regional Medical Center

400 E. Tickle Street
 Dyersburg,
TN  38024  (Dyer)
  
	  	Dyersburg Hospital Corporation (TN)
	 Lakeway Regional Hospital

726 McFarland Street
 Morristown,
TN  37814  (Hamblen)
  
	  	Hospital of Morristown, Inc. (TN)
	 SkyRidge Medical Center (includes Cleveland)

2305 Chambliss Avenue NW
 Cleveland,
TN  37320  (Bradley)
  
	  	National Healthcare of Cleveland, Inc. (TN)
	 Volunteer Community Hospital

161 Mt. Pelia Road
 Martin,
TN  38237  (Weakley)
  
	  	Martin Hospital Corporation (TN)
	 College Station Medical Center

1604 Rock Prairie Rd.
 College Station,
TX  77845  (Brazos)
  
	  	College Station Hospital, L.P. (DE)
	 DeTar Hospital Navarro

506 E. San Antonio Street
 Victoria,
TX  77901  (Victoria)
  
	  	Victoria of Texas, L.P. (DE)
	 DeTar Hospital North

101 Medical Drive
 Victoria,
TX  77904  (Victoria)
  
	  	Victoria of Texas, L.P. (DE)
	 Scenic Mountain Medical Center

1601 West Eleventh Place
 Big Spring,
TX  79720  (Howard)
  
	  	Big Spring Hospital Corporation (TX)

  
 15 

			
	
              Hospital Name/Address (County)

 
	  	
              Corporate Owner

 

	 South Texas Regional Medical Center

1905 Highway 97 E
 Jourdanton,
TX  78026  (Atascosa)
  
	  	Jourdanton Hospital Corporation (TX)
	 Tomball Regional Medical Center

605 Holderrieth Blvd.
 Tomball, TX  77375 (Harris)1
  
	  	Tomball Texas Hospital Company, LLC (DE)
	 Mountain West Medical Center

2055 N. Main St.
 Tooele,
UT  84074-2794  (Tooele)
  
	  	Tooele Hospital Corporation (UT)
	 Southern Virginia Regional Medical Center

727 North Main Street
 Emporia,
VA  23847  (Greensville)
  
	  	Emporia Hospital Corporation (VA)
	 Southampton Memorial Hospital

100 Fairview Drive
 Franklin,
VA  23851  (Southampton)
  
	  	Franklin Hospital Corporation (VA)
	 Deaconess Medical Center

800 West Fifth Avenue
 Spokane,
WA  99204  (Spokane)
  
	  	Spokane Washington Hospital Company, LLC (DE)
	 Valley Hospital and Medical Center

12606 East Mission
 Spokane Valley,
WA  99216  (Spokane)
  
	  	Spokane Valley Washington Hospital Company (DE)
	 Bluefield Regional Medical Center

500 Cherry Street
 Bluefield, WV  24701 (Mercer)

 
	  	Bluefield Hospital Company, LLC (DE)
	 MetroSouth Medical Center

12935 So. Gregory Street
 Blue Island, IL  60406
(Cook)
	  	Blue Island Hospital Company, LLC
	 Memorial Hospital 2

325 S. Belmont St.
 York, PA 17405 (York)
	  	York Pennsylvania Hospital Company, LLC (DE)
	 Mullins Nursing Center

518 S. Main Street
 Mullins, SC 29574 (Marion)3
	  	QHG of South Carolina, Inc. (SC)
	 1605 Loucks Road

York, PA 17403 (York)
	  	York Pennsylvania Hospital Company, LLC (DE)
	 Trinity Medical Center

800 Montclair Road
 Birmingham, AL 35213 (Jefferson)
	  	Affinity Hospital, LLC (DE)

  
  

1          Including the property at 13700 Medical
Complex Dr., Tomball, TX 77375. 

2          Including the properties at 1788-92 Third
Ave., York, PA 17403 and 1750 Fifth Ave., York, PA 17403. 

3          This property was mortgaged as part of the
mortgage on Marion Regional Hospital and is not required to be mortgaged pursuant to the Third Restated Credit Agreement. 

  
 16 

			
	
              Hospital Name/Address (County)

 
	  	
              Corporate Owner

 

	 Medical Center of South Arkansas

700 W. Grove Street El Dorado,
 AR 71730 (Union)
	  	MCSA, LLC (AR)
	 Western Arizona Regional

Medical Center
 2735 Silver Creek Road

Bullhead City, AZ 86442 (Mohave)
	  	Bullhead City Hospital Corporation (AZ)
	 Barstow Community Hospital

820 East Mountain View St.
 Barstow, CA 92311 (San
Bernardino)
	  	Hospital of Barstow, Inc. (DE)
	 Longview Regional Medical Center

2901 N. Fourth Street
 Longview, TX 75605 (Gregg)
	  	Longview Medical Center, L.P. (DE)
	 Northwest Medical Center – Springdale

609 W. Maple Ave.
 Springdale, AR 72764 (Washington)
	  	Northwest Arkansas Hospitals, LLC (DE)
	 Willow Creek Women’s Hospital

4301 Greathouse Springs Rd.
 Johnson, AR 72741
(Washington)
	  	Northwest Arkansas Hospitals, LLC (DE)
	 Northwest Medical Center - Bentonville

3000 Medical Center Pkwy.
 Bentonville, AR  72712

(Benton)
	  	Northwest Arkansas Hospitals, LLC (DE)
	 13.342 acres

Birmingham, AL (Jefferson)4
	  	Affinity Hospital, LLC (DE)

  
  

 

4          As of the Third Restatement Effective Date,
this property has not yet been mortgaged. 

  
 17 

 Real property to be mortgaged pursuant to Section 7(c) of the Third Amendment and Restatement Agreement, within
180 days after the Third Restatement Effective Date (or such later date as the Administrative Agent in its sole discretion may permit): 
  

			
	
              Hospital Name/Address (County)

 
	  	
              Corporate Owner

 

	 Gilmore Memorial Regional Medical Center (Wellness Center, Offices)

1105 Earl Frye Blvd.
 Amory, MS 38821 (Monroe)
	  	Amory HMA, LLC (MS)
	 Bartow Regional Medical Center

2200 Osprey Blvd.
 Bartow, FL 33830 (Polk)
	  	Bartow HMA, LLC
	 Carlisle Regional Medical Center

361 Alexander Spring Road
 Carlisle, PA 17015
(Cumberland )
	  	Carlisle HMA, LLC
	 Newport Medical Center

435 Second St.
 Newport, TN 37821 (Cocke )
	  	Cocke County HMA, LLC
	 Seven Rivers Regional Medical Center

6201 N. Suncoast Blvd.
 Crystal River, FL 34428 (Citrus)
	  	Citrus HMA, LLC
	 Sparks Health System (Fitness Center, Ambulatory Surgery Center and Cogeneration
Building)
 1001 Towson Ave.
 Fort Smith, AR 72901
(Sebastian)
	  	Fort Smith HMA, LLC
	 Sandhills Regional Medical Center

1000 West Hamlet Ave.
 Hamlet, NC 28345 (Richmond)
	  	Hamlet H.M.A., LLC
	 Dallas Regional Medical Center

1011 North Galloway
 Mesquite, TX 75149 (Dallas)
	  	Lone Star HMA, L.P.
	 Madison River Oaks Medical Center

161 River Oaks Dr.
 Canton, MS 39046 (Madison)
	  	Madison HMA, LLC
	 Wuesthoff Medical Center - Melbourne

250 N. Wickham Rd.
 Melbourne, FL 32934 (Brevard)
	  	Melbourne HMA, LLC
	 Physicians Regional Medical Center (lands ground leased to third parties improved by
MOBs)
 900 East Oak Hill Ave.
 Knoxville, TN 37917
(Knox)
	  	Metro Knoxville HMA, LLC
	 Turkey Creek Medical Center (lands ground leased to third parties improved by MOBs)

10820 Parkside Dr.
 Knoxville, TN 37934 (Knox)
	  	Metro Knoxville HMA, LLC
	 North Knoxville Medical Center (Fitness Center, lands ground leased to third party
improved by MOB, ancillary buildings)
 7565 Dannaher Dr.

Knoxville, TN 37849 (Knox)
	  	Metro Knoxville HMA, LLC

  
 18 

			
	
              Hospital Name/Address (County)

 
	  	
              Corporate Owner

 

	 Clearview Regional Medical Center & ancillary buildings

2151 West Spring St.
 Monroe, GA 30655 (Monroe)
	  	Monroe HMA, LLC
	 Physicians Regional Medical Center (Pine Ridge)

6101 Pine Ridge Rd.
 Naples, FL 34119 (Collier)
	  	Naples HMA, LLC
	 Physicians Regional Medical Center (Collier Blvd. and MOB)

8300 Collier Blvd.
 Naples, FL 34114 (Collier)
	  	Naples HMA, LLC
	 Poplar Bluff Regional Medical Center

3100 Oak Grove Road
 Poplar Bluff, MO 63901

(Butler)
	  	Poplar Bluff Regional Medical Center, LLC
	 Peace River Regional Medical Center (MOBs, Offices)

2500 Harbor Blvd.
 Port Charlotte, FL 33952 (Charlotte)
	  	Port Charlotte HMA, LLC
	 Charlotte Regional Medical Center

809 E. Marion Ave
 Punta Gorda, FL 33950 (Charlotte)
	  	Punta Gorda HMA, LLC
	 Riverside Behavioral Center

733 E. Olympia Ave.,
 Punta Gorda, FL 33950 (Charlotte)
	  	Punta Gorda HMA, LLC
	 River Oaks Hospital

1030 River Oaks Dr.
 Flowood, MS 39232 (Rankin)
	  	River Oaks Hospital, LLC
	 Wuesthoff Medical Center – Rockledge (several office buildings)

110 Longwood Ave.
 Rockledge, FL 32955 (Brevard )
	  	Rockledge HMA, LLC
	 Woman’s Hospital and ancillary buildings

1026 N. Flowood Dr.
 Flowood, MS 39232 (Rankin)
	  	ROH, LLC
	 Sebastian River Medical Center

13695 US Highway 1
 Sebastian, FL 32976 (Indian River)
	  	Sebastian Hospital, LLC
	 Davis Regional Medical Center

218 Old Mocksville Rd.
 Statesville, NC 28625 (Iredell)
	  	Statesville HMA, LLC
	 Venice Regional Medical Center & Parking Garage

540 The Rialto
 Venice, FL 34285 (Sarasota)
	  	Venice HMA, LLC
	 Yakima Regional Medical & Cardiac Center

110 S. 9th Ave.
 Yakima, WA 98902 (Yakima)
	  	Yakima HMA, LLC

  
 19 

 Schedule 1.01(d) 

Hospitals 

 

 Abilene, Texas 

Abilene Regional Medical Center 
 6250 Highway 83/84 

Abilene, TX  79606 
 (Taylor) 

ARMC, L.P.(DE) 
 Massillon, Ohio 

Affinity Medical Center 
 875 Eighth Street, N.E. 

(P.O. Box 805) 
 Massillon, OH  44648 

(Stark) 
 DHSC, LLC (DE) 

Las Vegas, New Mexico 
 Alta Vista Regional Hospital 

104 Legion Drive 
 Las Vegas, NM  87701 

(San Miguel) 
 San Miguel Hospital Corporation (NM) 

Barstow, California 
 Barstow Community Hospital 

555 South 7th Street 
 Barstow, CA  92311 

(San Bernadino) 
 Hospital of Barstow, Inc. (DE) 

Berwick, Pennsylvania 
 Berwick Hospital Center 

701 East 16th Street 
 Berwick, PA  18603 

(Columbia) 
 Berwick Hospital Company, LLC (DE) 

Alpine, Texas 
 Big Bend Regional Medical Center 

2600 Highway 118 North 
 Alpine, TX  79830 

(Brewster) 
 Big Bend Hospital Corporation (TX)

 Bluefield, West Virginia 

Bluefield Regional Medical Center 
 500 Cherry St. 

Bluefield, WV 24701 
 (Mercer) 

Bluefield Hospital Company, LLC (DE) 
 Bluffton, Indiana

 Bluffton Regional Medical Center 
 303 S. Main Street

 Bluffton, IN  46714 
 (Wells) 

Bluffton Health System LLC (DE) 
 Coatesville, Pennsylvania

 Brandywine Hospital 
 201 Reeceville Rd. 

Coatesville, PA  19320 
 (Chester) 

Coatesville Hospital Corporation (PA) 
 Brownwood, Texas

 Brownwood Regional Medical Center 
 1501 Burnet Drive

 (P.O. Box 760 / zip 76804) 
 Brownwood, TX  76801

 (Brown) 
 Brownwood Hospital L.P. (DE) 

Leesville, Louisiana 
 Byrd Regional Hospital 

1020 Fertitta Blvd. 
 Leesville, LA  71446 

(Vernon Parish) 
 National Healthcare of Leesville, Inc. (DE) 

Carlsbad, New Mexico 
 Carlsbad Medical Center 

2430 W. Pierce 
 Carlsbad, NM  88220 

(Eddy) 
 Carlsbad Medical Center, LLC (DE)

 

  
 20 

 Florence, South Carolina 

Carolinas Hospital System 
 805 Pamplico Hwy 

Florence, SC  29505 
 (Florence) 

QHG of South Carolina, Inc (SC) 
 Cedar Park, Texas 

Cedar Park Regional Medical Center 
 1401 Medical Parkway 

Cedar Park, TX  78613 
 (Williamson) 

Cedar Park Health System, L.P. (DE) 
 Centre, Alabama 

Cherokee Medical Center 
 400 Northwood Drive 

Centre, AL  35960 
 (Centre) 

Centre Hospital Corporation (AL) 
 Cheraw, South Carolina

 Chesterfield General Hospital 
 Highway 9 West (P.O. Box
151) 
 Cheraw, SC  29520 
 (Chesterfield) 

Chesterfield/Marlboro, L.P. (DE) 
 Philadelphia, Pennsylvania

 Chestnut Hill Hospital 
 8835 Germantown Avenue 

Philadelphia, PA  19118 
 (Montgomery) 

CHHS Hospital Company, LLC (DE) 
 College Station, Texas

 College Station Medical Center 
 (P.O. Box 10000 / zip
77842) 
 College Station, TX  77845 
 (Brazos) 

College Station Hospital, LP (DE) 
 Huntsville, Alabama

 Crestwood Medical Center 
 One Hospital Drive SW 

Huntsville, AL  35801 
 (Madison) 

Crestwood Healthcare, L.P. (DE)

 Mt. Vernon, Illinois 

Crossroads Community Hospital 
 #8 Doctor’s Park Road 

Mt. Vernon, IL  62864 
 (Jefferson) 

National Healthcare of Mt. Vernon, Inc. (DE) 
 Oklahoma City,
Oklahoma 
 Deaconess Hospital 
 5501 N. Portland Avenue

 Oklahoma City, OK  73112-2099 
 (Oklahoma) 

Deaconess Health System, LLC (DE) 
 Spokane, Washington

 Deaconess Hospital 
 800 W. 5th Avenue 

Spokane, WA  99204 
 (Spokane) 

Spokane Washington Hospital Company, LLC (DE) 
 Fort Payne,
Alabama 
 DeKalb Regional Medical Center 
 200 Medical
Center Drive 
 P. O. Box 680778 
 Fort Payne,
AL  35968 
 (DeKalb) 
 Fort Payne Hospital
Corporation (AL) 
 Victoria, Texas 
 DeTar Hospital
North 
 101 Medical Drive 
 Victoria, TX  77904 

(Victoria) 
 Victoria of Texas, L.P. (DE) 

Victoria, Texas 
 DeTar Hospital Navarro 

506 E. San Antonio Street 
 Victoria, TX  77901 

(Victoria) 
 Victoria of Texas, L.P. (DE) 

Peru, Indiana 
 Dukes Memorial Hospital 

275 West 12th Street 
 Peru, IN  46970-1698 

(Miami) 
 Dukes Health System, LLC (DE)

 

  
 21 

 Fort Wayne, Indiana 

Dupont Hospital 
 2520 E. Dupont Road 

Fort Wayne, IN  46825 
 (Allen) 

Dupont Hospital, LLC (DE) 
 Dyersburg, Tennessee 

Dyersburg Regional Medical Center 
 400 Tickle Street 

Dyersburg, TN  38024 
 (Dyer) 

Dyersburg Hospital Corporation (TN) 
 Roswell, New Mexico

 Eastern New Mexico Medical Center 
 405 West Country Club
Road 
 Roswell, NM  88201 
 (Chaves) 

Roswell Hospital Corporation (NM) 
 Easton, Pennsylvania

 Easton Hospital 
 250 South 21st Street 

Easton, PA  18042-3892 
 (Northampton) 

Northampton Hospital Company, LLC (DE) 
 Evanston, Wyoming

 Evanston Regional Hospital 
 190 Arrowhead Drive 

Evanston, WY  82930 
 (Uinta) 

Evanston Hospital Corporation (WY) 
 Fallbrook, California

 Fallbrook Hospital 
 624 East Elder 

Fallbrook, CA  92028 
 (San Diego) 

Fallbrook Hospital Corporation (DE) 
 Blue Ridge, Georgia

 Fannin Regional Hospital 
 2855 Old Highway 5, North 

Blue Ridge, GA  30513 
 (Fannin) 

Blue Ridge Georgia Hospital Company, LLC (DE)

 Dothan, Alabama 

Flowers Hospital 
 4370 West Main Street 

Dothan, AL  36305 
 (Houston) 

Triad of Alabama, LLC (DE) 
 Forrest City, Arkansas 

Forrest City Medical Center 
 1601 Newcastle Road 

Forrest City, AR  72336 
 (Saint Francis) 

Forrest City Arkansas Hospital Company, LLC (AR) 
 Gadsden,
Alabama 
 Gadsden Regional Medical Center 
 1007 Goodyear
Avenue 
 Gadsden, AL  35903 
 (Etowah) 

Gadsden Regional Medical Center, LLC (DE) 
 Galesburg,
Illinois 
 Galesburg Cottage Hospital 
 695 N. Kellogg St.

 Galesburg, IL  61401 
 (Knox) 

Galesburg Hospital Corporation (IL) 
 Clarksville, Tennessee

 Gateway Medical Center 
 651 Dunlop Lane 

PO Box 31629 
 Clarksville, TN  37040 

(Montgomery) 
 Clarksville Health System, G.P. (DE) 

Granite City, Illinois 
 Gateway Regional Medical Center

 2100 Madison Avenue 
 Granite City, IL  62040 

(Madison) 
 Granite City Illinois Hospital Company, LLC (IL)

 

  
 22 

 Ronceverte, West Virginia 

Greenbrier Valley Medical Center 
 202 Maplewood Avenue 

(P.O. Box 497) 
 Ronceverte, WV  24970 

(Greenbrier) 
 Greenbrier VMC, LLC (DE) 

Newport, Arkansas 
 Harris Hospital 

1205 McLain 
 Newport, AR  72112 

(Jackson) 
 National Healthcare of Newport, Inc. (DE) 

Brownsville, Tennessee 
 Haywood Park Community Hospital

 2545 N. Washington Ave. 
 Brownsville, TN  38012

 (Haywood) 
 Brownsville Hospital Corporation (TN) 

Marion, Illinois 
 Heartland Regional Medical Center 

3333 West DeYoung 
 Marion, IL  62959 

(Williamson) 
 Marion Hospital Corporation (IL) 

Helena, Arkansas 
 Helena Regional Medical Center 

1801 Martin Luther King Drive / PO Box 788 
 Helena,
AR  72342 
 (Phillips) 
 Phillips Hospital
Corporation (AR) 
 Lexington, Tennessee 
 Henderson
County Community Hospital 
 200 West Church St. 
 Lexington,
TN  38351 
 (Henderson) 
 Lexington Hospital
Corporation (TN) 
 Shelbyville, Tennessee 
 Heritage
Medical Center 
 2835 Hwy. 23IN 
 Shelbyville,
TN  37160 
 (Bedford) 
 Shelbyville Hospital
Corporation (TN) 

 Hillsboro, Texas 

Hill Regional Hospital 
 101 Circle Drive 

Hillsboro, TX  76645 
 (Hill) 

NHCI of Hillsboro, Inc. (TX) 
 West Grove, Pennsylvania

 Jennersville Regional Hospital 
 1015 West Baltimore Pike

 West Grove, PA.  19390 
 (Chester) 

West Grove Hospital Company, LLC (DE) 
 Jackson, Kentucky

 Kentucky River Medical Center 
 540 Jetts Drive 

Jackson, KY  41339 
 Breathitt) 

Jackson Hospital Corporation (KY) 
 Warsaw, Indiana 

Kosciusko Community Hospital 
 2101 East DuBois Drive 

Warsaw, IN  46580 
 (Kosciusko) 

Warsaw Health System, LLC (DE) 
 Greenville, Alabama 

L.V. Stabler Memorial Hospital 
 29 L.V. Stabler Drive 

Greenville, AL  36037 
 (Butler) 

Greenville Hospital Corporation (AL) 
 Granbury, Texas

 Lake Granbury Medical Center 
 1310 Paluxy Road 

Granbury, TX  76048 
 (Hood) 

Granbury Hospital Corporation (TX) 
 Lake Wales, Florida

 Lake Wales Medical Center 
 410 South 11th Street 

Lake Wales, FL  33853 
 (Polk) 

Lake Wales Hospital Corporation (FL) 

 

  
 23 

 Morristown, Tennessee 

Lakeway Regional Hospital 
 726 McFarland Street 

Morristown, TN  37814 
 (Hamblen) 

Hospital of Morristown, Inc. (TN) 
 Laredo, Texas 

Laredo Medical Center 
 1700 East Saunders 

Laredo, TX  78041 
 (Webb) 

Laredo Texas Hospital Company, L.P. (TX) 
 Hobbs, New Mexico

 Lea Regional Medical Center 
 5419 N. Lovington Hwy 

(P.O. Box 3000) 
 Hobbs, NM  88240 

(Lea) 
 Lea Regional Hospital, LLC (DE) 

Lock Haven, Pennsylvania 
 Lock Haven Hospital 

24 Cree Drive 
 Lock Haven, PA  17745-2699 

(Washington) 
 Clinton Hospital Corporation (PA) 

Longview, Texas 
 Longview Regional Medical Center 

2901 N. Fourth Street 
 (P.O. Box 14000 / zip 75607) 

Longview, TX  75605 
 (Gregg) 

Longview Medical Center, L.P. (DE) 
 Fort Wayne, Indiana

 Lutheran Hospital 
 7950 W. Jefferson Blvd. 

Fort Wayne, IN  46804 
 (Allen) 

IOM Health System, L.P. (IN) 
 McKenzie, Tennessee 

McKenzie Regional Hospital 
 161 Hospital Dr. 

McKenzie, TN  38201 
 (Carroll) 

McKenzie Tennessee Hospital Company, LLC (DE)

 Springfield, Oregon 

McKenzie-Willamette Medical Center 
 1460 G Street 

Springfield, OR  97477 
 (Lane) 

McKenzie-Willamette Regional Medical 
 Center Associates, LLC (DE)

 Selmer, Tennessee 
 McNairy Regional Hospital 

705 Poplar Ave. 
 Selmer, TN  38375 

(McNairy) 
 McNairy Hospital Corporation (TN) 

Mullins, SC 
 Marion Regional Hospital 

2829 East Hwy 76 
 Mullins, SC 29574 

(Marion) 
 QHG of South Carolina, Inc (SC) 

Bennettsville, South Carolina 
 Marlboro Park Hospital

 1138 Cheraw Hwy (P.O. Box 738) 
 Bennettsville,
SC  29512 
 (Marlboro) 
 Chesterfield/Marlboro, L.P.
(DE) 
 Williamston, North Carolina 
 Martin General
Hospital 
 310 S. McCaskey Road 
 Williamston,
NC  27892 
 (Martin) 
 Williamston Hospital
Corporation (NC) 
 Spartanburg, South Carolina 
 Mary
Black Health System 
 1700 Skylyn Drive 
 Spartanburg,
SC  29307 
 (Spartanburg) 
 Mary Black Health System,
LLC (DE) 
 Palmer, Alaska 
 Mat-Su Regional Medical
Center 
 2500 S. Woodworth Loop (P.O. Box 1687) 
 Palmer,
AK  99645 
 (Matanuska-Susitna Borough) 
 Mat-Su
Valley Medical Center, LLC (AK) 

 

  
 24 

 Enterprise, Alabama 

Medical Center Enterprise 
 400 North Edwards Street 

Enterprise, AL  36330 
 (Coffee) 

QHG of Enterprise, Inc. (AL) 
 El Dorado, Arkansas 

Medical Center of South Arkansas 
 700 W. Grove Street 

El Dorado, AR  71730 
 (Union) 

MCSA, LLC (AR) 
 Salem, New Jersey 

The Memorial Hospital of Salem County 
 310 Woodstown Road 

Salem, NJ  08079 
 (Salem) 

Salem Hospital Corporation (NJ) 
 Mesquite, Nevada 

Mesa View Regional Hospital 
 1299 Bertha Howe Avenue 

(P.O. Box 3540 / zip 89024-3540) 
 Mesquite, NV  89027

 (Clark) 
 MMC of Nevada, LLC (DE) 

Peckville, Pennsylvania 
 Mid-Valley Hospital 

1400 Main Street 
 Peckville, PA 18542 

(Lackawanna) 
 Peckville Hospital Company, LLC (De) 

Deming, New Mexico 
 Mimbres Memorial Hospital 

900 W. Ash Street 
 Deming, NM  88030 

(Luna) 
 Deming Hospital Corporation (NM) 

Moberly, Missouri 
 Moberly Regional Medical Center 

1515 Union Avenue 
 Moberly, MO   65270 

(Randolph) 
 Moberly Hospital Company, LLC (DE)

 Scranton, Pennsylvania 

Moses Taylor Hospital 
 700 Quincy Avenue 

Scranton, PA 18510 
 (Lackawanna) 

Scranton Quincy Hospital Company, LLC (DE) 
 Tooele, Utah

 Mountain West Medical Center 
 2055 N. Main 

Tooele, UT  84074-2794 
 (Tooele) 

Tooele Hospital Corporation (UT) 
 Las Cruces, New Mexico

 MountainView Regional Medical Center 
 4311 East Lohman
Avenue 
 Las Cruces, NM  88011 
 (Dona Ana) 

Las Cruces Medical Center, LLC (DE) 
 Corsicana, Texas

 Navarro Regional Hospital 
 3201 W. Highway 22 

Corsicana, TX  75110 
 (Navarro) 

Navarro Hospital, L.P. (DE) 
 Crestview, Florida 

North Okaloosa Medical Center 
 151 Redstone Avenue, S.E. 

Crestview, FL  32539-6026 
 (Okaloosa) 

Crestview Hospital Corporation (FL) 
 Kirksville, Missouri

 Northeast Regional Medical Center 
 315 S. Osteopathy

 Kirksville, MO  63501 
 (Adair) 

Kirksville Missouri Hospital Company, LLC (MO) 
 Ruston,
Louisiana 
 Northern Louisiana Medical Center 
 401 East
Vaughn Avenue 
 Ruston, LA  71270 
 (Lincoln Parish)

 Ruston Louisiana Hospital Company, LLC (DE)

 

  
 25 

 Youngstown, Ohio 

Northside Medical Center 
 500 Gypsy Lane 

Youngstown, OH 
 (Mahoning) 

Youngstown Ohio Hospital Company, LLC (DE) 
 Tucson, Arizona

 Northwest Medical Center 
 6200 N. LaCholla Blvd. 

Tucson, AZ  85741 
 (Pima) 

Northwest Hospital, LLC (DE) 
 Bentonville, Arkansas 

Northwest Medical Center - Bentonville 
 3000 Medical Center Pkwy.

 Bentonville, AR  72712 
 (Benton) 

Northwest Arkansas Hospitals, LLC (DE) 
 Springdale, Arkansas

 Northwest Medical Center - Springdale 
 609 W. Maple 

Springdale, AR  72764 
 (Washington and Benton) 

Northwest Arkansas Hospitals, LLC (DE) 
 Oro Valley, Arizona

 Oro Valley Hospital 
 1551 E. Tangerine Road 

Oro Valley, AZ  85755 
 (Pima) 

Oro Valley Hospital, LLC (DE) 
 Fort Wayne, IN 

The Orthopedic Hospital of Lutheran Health Network 
 700 Broadway

 Fort Wayne, IN 46802 
 (Allen) 

Lutheran Musculoskeletal Center, LLC (DE) 
 Fulton, Kentucky

 Parkway Regional Hospital 
 2000 Holiday Lane (P.O. Box
866) 
 Fulton, KY  42041 
 (Fulton) 

Hospital of Fulton, Inc. (KY)

 Payson, Arizona 

Payson Regional Medical Center 
 807 South Ponderosa 

Payson, AZ  85541 
 (Gila) 

Payson Hospital Corporation (AZ) 
 Phoenixville, Pennsylvania

 Phoenixville Hospital 
 140 Nutt Road 

Phoenixville, PA  19460 
 (Chester) 

Phoenixville Hospital Company, LLC (DE) 
 Oak Hill, West
Virginia 
 Plateau Medical Center 
 430 Main Street 

Oak Hill, WV  25901 
 (Fayette) 

Oak Hill Hospital Corporation (WV) 
 Ponca City, Oklahoma

 Ponca City Medical Center 
 1900 North 14th Street 

Ponca City, OK  74601 
 (Kay and Osage) 

Kay County Oklahoma Hospital Company, LLC (OK) 
 Valparaiso,
Indiana 
 Porter Hospital 
 814 LaPorte Avenue 

Valparaiso, IN  46383 
 (Porter) 

Porter Hospital, LLC (DE) 
 Pottstown, Pennsylvania 

Pottstown Memorial Medical Center 
 1600 East High Street 

Pottstown, PA  19464 
 (Montgomery) 

Pottstown Hospital Company, LLC (DE) 
 Red Bud, Illinois

 Red Bud Regional Hospital 
 325 Spring Street 

Red Bud, IL  62278 
 (Randolph) 

Red Bud Illinois Hospital Company, LLC (IL)

 

  
 26 

 Jackson, Tennessee 

Regional Hospital of Jackson 
 367 Hospital Blvd. 

Jackson, TN  38305 
 (Madison) 

Jackson, Tennessee Hospital Company, LLC (TN) 
 Scranton,
Pennsylvania 
 Regional Hospital of Scranton 
 746
Jefferson Ave. 
 Scranton, PA 18510 
 (Lackawanna) 

Scranton Hospital Company, LLC (DE) 
 Vicksburg, Mississippi

 River Region Health System 
 2100 Highway 61 North 

Vicksburg, MS  39183 
 (Warren) 

Vicksburg Healthcare, LLC (DE) 
 San Angelo, Texas 

San Angelo Community Medical Center 
 3501 Knickerbocker Road 

San Angelo, TX  76904 
 (Tom Green) 

San Angelo Hospital, L.P. (DE) 
 Big Spring, Texas 

Scenic Mountain Medical Center 
 1601 West Eleventh Place 

Big Spring, TX  79720 
 (Howard) 

Big Spring Hospital Corporation (TX) 
 Siloam Springs, AR

 Siloam Springs Memorial Hospital 
 205 E. Jefferson
Street 
 Siloam Springs, AR  72761 
 (Benton) 

Siloam Springs Arkansas Hospital Company, LLC (DE) 

Cleveland, Tennessee 
 SkyRidge Medical Center 

2305 Chambliss Avenue 
 Cleveland, TN  37311 

(Bradley) 
 Cleveland Tennessee Hospital Company, LLC (DE)

 Foley, Alabama 

South Baldwin Regional Medical Center 
 1613 North McKenzie Street

 Foley, AL  36535 
 (Baldwin) 

Foley Hospital Corporation (AL) 
 Jourdanton, Texas 

South Texas Regional Medical Center 
 1905 Highway 97 E 

Jourdanton, TX  78026 
 (Atascosa) 

Jourdanton Hospital Corporation (TX) 
 Franklin, Virginia

 Southampton Memorial Hospital 
 100 Fairview Drive 

Franklin, VA  23851 
 (Franklin) 

Franklin Hospital Corporation (VA) 
 Emporia, Virginia

 Southern Virginia Regional Medical Center 
 727 North
Main Street 
 Emporia, VA  23847 
 (Emporia) 

Emporia Hospital Corporation (VA) 
 Petersburg, Virginia

 Southside Regional Medical Center 
 200 Medical Park
Blvd. 
 Petersburg, VA  23805 
 (Petersburg) 

Petersburg Hospital Company, LLC (VA) 
 Nanticoke,
Pennsylvania 
 Special Care Hospital 
 128 W. Washington
Street 
 Nanticoke, PA 18634 
 (Luzerne) 

Nanticoke Hospital Company, LLC (DE) 
 Lancaster, South
Carolina 
 Springs Memorial Hospital 
 800 W. Meeting
Street 
 Lancaster, SC  29720 
 (Lancaster) 

Lancaster Hospital Corporation (DE) 

 

  
 27 

 Fort Wayne, Indiana 

St. Joseph Hospital 
 700 Broadway 

Fort Wayne, IN  46802 
 (Allen) 

St. Joseph Health System, LLC (DE) 
 Sunbury, Pennsylvania

 Sunbury Community Hospital 
 350 N. Eleventh Street (P.
O. Box 737) 
 Sunbury, PA  17801 
 (Northumberland)

 Sunbury Hospital Company, LLC (DE) 
 Louisa, Kentucky

 Three Rivers Medical Center 
 2483 Highway 644 (P.O. Box
769) 
 Louisa, KY  41230 
 (Lawrence) 

Hospital of Louisa, Inc. (KY) 
 Tomball, Texas 

Tomball Regional Medical Center 
 605 Holderrieth 

Tomball, TX 77375 
 (Harris) 

Tomball Texas Hospital Company, LLC (DE) 
 Augusta, Georgia

 Trinity Hospital of Augusta 
 2260 Wrightsboro Road 

Augusta, GA  30904 
 (Richmond) 

Augusta Hospital, LLC (DE) 
 Birmingham, Alabama 

Trinity Medical Center 
 800 Montclair Road 

Birmingham, AL  35213 
 (Jefferson) 

Affinity Hospital, LLC (DE) 
 Warren, Ohio 

Trumbull Memorial Hospital 
 1350 E. Market St. 

Warren, OH 
 (Trumbull) 

Warren Ohio Hospital Company, LLC (DE)

 Tunkhannock, Pennsylvania 

Tyler Memorial Hospital 
 880 SR 6 West 

Tunkhannock, PA  18657 
 (Wyoming) 

Tunkhannock Hospital Company, LLC (DE) 
 Anna, Illinois

 Union County Hospital 
 517 North Main 

Anna, IL 62906 
 (Union) 

Anna Hospital Corporation (IL) 
 Spokane Valley, Washington

 Valley Hospital 
 12606 East Mission Avenue 

Spokane Valley, WA  99216 
 (Spokane) 

Spokane Valley Washington Hospital Company, LLC (DE) 

Waukegan, Illinois 
 Vista Medical Center 

1324 N. Sheridan Road 
 Waukegan, IL  60085 

(Lake County) 
 Waukegan Illinois Hospital Company, LLC (IL) 

Martin, Tennessee 
 Volunteer Community Hospital 

161 Mt. Pelia Road 
 Martin, TN  38237 

(Weakley) 
 Martin Hospital Corporation (TN) 

Watsonville, California 
 Watsonville Community Hospital

 75 Nielson Street 
 Watsonville, CA  95076 

(Santa Cruz) 
 Watsonville Hospital Corporation (DE) 

Weatherford, Texas 
 Weatherford Regional Medical Center

 713 E. Anderson Street 
 Weatherford, TX  76086

 (Parker) 
 Weatherford Texas Hospital Company, LLC (TX)

 

  
 28 

 Hattiesburg, Mississippi 

Wesley Medical Center 
 5001 Hardy Street 

Hattiesburg, MS  39402 
 (Forrest) 

Wesley Health System LLC (DE) 
 Bullhead City, Arizona

 Western Arizona Regional Medical Center 
 2735 Silver
Creek Road 
 Bullhead City, AZ  86442 
 (Mohave) 

Bullhead City Hospital Corporation (AZ) 
 Johnson, Arkansas

 Willow Creek Women’s Hospital 
 4301 Greathouse
Springs Rd. 
 (P.O. Box 544) 
 Johnson, AR  72741

 (Washington) 
 Northwest Arkansas Hospitals, LLC (DE) 

Wilkes - Barre, Pennsylvania 
 Wilkes-Barre General
Hospital 
 575 North River Street 
 Wilkes-Barre, PA 18764-0001

 (Luzerne) 
 Wilkes-Barre Hospital Company, LLC (DE) 

Lake Charles, Louisiana 
 Women & Children’s
Hospital 
 4200 Nelson Road 
 Lake Charles, LA  70605

 (Calcasieu) 
 Women & Children’s Hospital, LLC
(DE) 
 Lufkin, Texas 
 Woodland Heights Medical Center

 505 S. John Redditt Drive 
 (P.O. Box 150610 / zip 75915)

 Lufkin, TX  75904 
 (Angelina) 

Piney Woods Healthcare System, L.P. (DE) 
 Woodward, Oklahoma

 Woodward Regional Hospital 
 900 17th Street 

Woodward, OK  73801 
 (Woodward) 

Woodward Health System, LLC (DE)

 Blue Island, Illinois 

MetroSouth Medical Center 
 12935 Gregory Street 

Blue Island, IL  60406 
 (Cook) 

Blue Island Hospital Company, LLC (DE) 
 York, Pennsylvania

 Memorial Hospital 
 325 S. Belmont St 

York, PA  17405 
 (York) 

York Pennsylvania Hospital Company, LLC (DE)

 

  
 29 

 Amory, Mississippi 

Gilmore Memorial Reg Medical Center 
 1105 Earl Frye Blvd 

Amory, MS  38821 
 (Monroe) 

Amory HMA, LLC 
 Anniston, Alabama 

Stringfellow Memorial Hospital 
 301 East 18th Street 

Anniston, AL  36207 
 (Calhoun) 

Anniston HMA, LLC 
 Bartow, Florida 

Bartow Regional Medical Center 
 2200 Osprey Boulevard 

PO Box 1050 
 Bartow, FL  33831 

(Polk) 
 Bartow HMA, LLC 

Batesville, Mississippi 
 Tri Lakes Medical Center 

303 Medical Center Drive 
 Batesville, MS  38606 

(Panola) 
 Alliance Health Partners, LLC 

Biloxi, Mississippi 
 Biloxi Regional Medical Center 

150 Reynoir Street 
 Biloxi, MS  39530 

(Harrison) 
 Biloxi HMA, LLC 

Blackwell, Oklahoma 
 INTEGRIS Blackwell Regional Hospital

 710 South 13th Street 
 Blackwell, OK  74631 

(Kay) 
 Blackwell HMA, LLC 

Brandon, Mississippi 
 Crossgates River Oaks Hospital 

350 Crossgates Boulevard 
 Brandon, MS  39042 

(Rankin) 
 Brandon HMA, LLC

 Brooksville, Florida 

Brooksville Regional Hospital 
 17240 Cortez Blvd. 

Brooksville, FL  34601 
 (Hernando) 

Hernando HMA, LLC 
 Canton, Mississippi 

Madison River Oaks Medical Center 
 161 River Oaks Drive 

PO Box 1607 (zip 39046-1607) 
 Canton, MS  39046 

(Madison) 
 Madison HMA, LLC 

Carlisle, Pennsylvania 
 Carlisle Regional Medical Center

 361 Alexander Spring Rd. 
 Carlisle, PA  17015 

(Cumberland) 
 Carlisle HMA, LLC 

Chester, South Carolina 
 Chester Regional Medical Center

 One Medical Park Drive 
 Chester, SC  29706 

(Chester) 
 Chester HMA, LLC 

Clarksdale, Mississippi 
 Northwest Mississippi Regional
Medical Center 
 1970 Hospital Drive 
 Clarksdale,
MS  38614 
 (Clarksdale) 
 Clarksdale HMA, LLC 

Clinton,, Oklahoma 
 INTEGRIS Clinton Regional Hospital

 100 North 30th Street 
 Clinton, OK 73601 

(Custer) 
 Clinton HMA, LLC 

Crystal River, Florida 
 Seven Rivers Regional Medical
Center 
 6201 N. Suncoast Blvd. 
 Crystal River,
FL  34428-671 
 (Citrus) 
 Citrus HMA, LLC

 

  
 30 

 Dale City, Florida 

Pasco Regional Medical Center 
 13100 Fort King Road 

Dade City, FL  33525-5294 
 (Prince William) 

Pasco Regional Medical Center, LLC 
 Dallas, Texas 

Dallas Regional Medical Center 
 1011 North Galloway 

Mesquite, TX  75149 
 (Dallas) 

Lone Star HMA, LP 
 Durant, Oklahoma 

Medical Center of SE Oklahoma 
 1800 University Boulevard 

Durant, OK  74701 
 (Bryan) 

Durant HMA, LLC 
 Flowood, Mississippi 

River Oaks Hospital 
 1030 River Oaks Drive 

Flowood, MS  39232 
 (Rankin) 

River Oaks Hospital, LLC 
 Flowood, Mississippi 

Woman’s Hospital 
 1026 N. Flowood Drive 

PO Box 4546 (Jackson, MS  39296-4546) 
 Flowood,
MS  39232 
 (Rankin) 
 ROH, LLC 

Fort Smith, Arizona 
 Sparks Health System 

PO Box 2406 (1001 Towson Ave.) 
 Fort Smith, AR  72902

 (Sebastian) 
 Fort Smith HMA, LLC 

Gadsden, Alabama 
 Riverview Regional Medical Center 

600 South 3rd Street 
 PO Box 268 (zip 35999) 

Gadsden, AL  35901 
 (Etowah) 

Riverview Regional Medical Center, LLC

 Haines City, Florida 

Heart of Florida Regional Medical Center 
 40100 US Highway 27

 Davenport, FL  33837-5906 
 (Polk) 

Haines City HMA, LLC 
 Hamlet, North Carolina 

Sandhills Regional Medical Center 
 1000 West Hamlet Avenue 

Hamlet, NC  28345 
 (Richmond) 

Hamlet HMA, LLC 
 Harstville, South Carolina 

Carolina Pines Regional Medical Center 
 1304 W. Bobo Newsom Hwy

 Hartsville, SC  29550 
 (Darlington) 

Hartsville HMA, LLC 
 Jackson, Mississippi 

Central Mississippi Medical Center 
 1850 Chadwick Drive 

Jackson, MS  39204 
 (Jackso) 

Jackson HMA, LLC 
 Jamestown, Tennessee 

Jamestown Regional Medical Center 
 436 Central Avenue West 

Jamestown, TN  38556 
 (Fentress) 

HMA Fentress County General Hospital, LLC 
 Jefferson City,
Tennessee 
 Jefferson Memorial Hospital 
 110 Hospital
Drive 
 Jefferson City, TN  37760 
 (Jefferson) 

Jefferson County HMA, LLC 
 Kennett, Missouri 

Physicians Regional Medical Center 
 900 E. Oak Hill Ave. 

Knoxville, TN  37917 
 (Dunkin) 

Kennett HMA, LLC 
 Key West, Florida 

Lower Keys Medical Center 
 5900 College Rd. 

Key West, FL 33040 
 (Monroe) 

Key West HMA, LLC 

 

  
 31 

 
 Knoxville, Tennessee 

Physicians Regional Medical Center 
 900 E. Oak Hill Ave. 

Knoxville, TN  37917 
 (Knox) 

Metro Knoxville HMA, LLC 
 Knoxville, Tennessee 

Turkey Creek Medical Center 
 10820 Parkside Drive 

Knoxville, TN  37934 
 (Knox) 

Metro Knoxville HMA, LLC 
 Knoxville, Tennessee 

North Knoxville Medical Center 
 7565 Dannaher Drive 

Powell, TN  37849 
 (Knox) 

Metro Knoxville HMA, LLC 
 LaFollette, Tennessee 

LaFollette Medical Center 
 923 East Central Ave. 

LaFollette, TN  37766 
 (Campbell) 

Campbell County HMA, LLC 
 Lake City, Florida 

Shands Lake Shore Regional Medical Center 
 368NE Franklin St.

 Lake City, FL 32055-3088 
 (Columbia) 

Lake Shore HMA, LLC 
 Lancaster, Pennsylvania 

Lancaster Regional Medical Center 
 250 College Avenue 

PO Box 3434 (zip 17604-3434) 
 Lancaster, PA 17603 

(Lancaster) 
 Rose City HMA, LLC 

Lebanon, Tennessee 
 University Medical Center 

1411 W. Baddour Parkway 
 Lebanon, TN  7087-2513 

(Wilson) 
 Lebanon HMA, LLC

 Lebanon, Tennessee 

McFarland Specialty Hospital 
 500 Park Avenue 

Lebanon, TN 37087-3721 
 (Wilson) 

Lebanon HMA, LLC 
 Lehigh Acres, Florida 

Lehigh Regional Medical Center 
 1500 Lee Boulevard 

Lehigh Acres, FL  33936 
 (Lee) 

Lehigh HMA, LLC 
 Lititz, Pennsylvania 

Heart of Lancaster Regional Medical Center 
 1500 Highlands Drive

 Lititz, PA 17543 
 (Lancaster) 

Lancaster HMA, LLC 
 Live Oak, Florida 

Shands Live Oak Regional Medical Center 
 1100 11th Street SW 

Live Oak, FL 32060 
 (Suwannee) 

Live Oak HMA, LLC 
 Madill, Oklahoma 

INTEGRIS Marshall County Medical Center 
 901 S. 5th Ave. 

Madill, OK 73446 
 (Marshall) 

Marshall County HMA, LLC 
 Melbourne, Florida 

Wuesthoff Medical Center-Melbourne 
 250 N. Wickham Road 

Melbourne, FL 32935 
 (Brevard) 

Melbourne HMA, LLC 
 Midwest City, Oklahoma 

Midwest Regional Medical Center 
 2825 Parklawn Drive 

Midwest City, OK  73110-4221 
 (Oklahoma) 

Midwest Regional Medical Center, LLC 

 

  
 32 

 
 Milton, Florida 

Santa Rosa Medical Center 
 6002 Berryhill Rd. 

Milton, FL  32570 
 (Santa Rosa) 

HMA Santa Rosa Medical Center, LLC 
 Monroe, Georgia 

Clearview Regional Medical Center 
 2151 West Spring Street 

PO Box 1346 (zip 30655-1346) 
 Monroe, GA  30655 

(Walton) 
 Monroe HMA, LLC 

Mooresville, North Carolina 
 Lake Norman Regional Medical
Center 
 171 Fairview Road 
 Mooresville, NC 28117 

(Iredell) 
 Mooresville Hospital Management Associates, LLC 

Naples, Florida 
 Physicians Regional Medical Center 

6101 Pine Ridge Rd. 
 Naples, FL 34119 

(Collier) 
 Naples HMA, LLC 

Naples, Florida 
 Physicians Regional Medical Center 

8300 Collier Blvd. 
 Naples, FL 34114 

(Collier) 
 Naples HMA, LLC 

Natchez, Mississippi 
 Natchez Community Hospital 

129 Jefferson Davis Boulevard 
 Natchez, MS 39120 

(Adams) 
 Natchez Community Hospital, LLC 

Newport, Tennessee 
 Newport Medical Center 

435 Second Street 
 Newport, TN  7821 

(Cocke) 
 Cocke County HMA, LLC

 Paintsville, Kentucky 

Paul B. Hall Regional Medical Center 
 625 James S. Trimble Blvd.

 Paintsville, KY 41240 
 (Johnson) 

Paintsville Hospital Company, LLC 
 Poplar Bluff, Missouri

 Poplar Bluff Regional Medical Center 
 3100 Oak Grove
Road 
 Poplar Bluff, MO 63901 
 (Butler) 

Poplar Bluff Regional Medical Center, LLC 
 Port Charlotte,
Florida 
 Peace River Regional Medical Center 
 2500 Harbor
Boulevard 
 Port Charlotte, FL 33952 
 (Charlotte) 

Port Charlotte HMA, LLC 
 Pryor, Oklahoma 

INTEGRIS Mayes County Medical Center 
 111 North Bailey 

Pryor, OK 74361 
 (Mayes) 

Mayes County HMA, LLC 
 Punta Gorda, Florida 

Charlotte Regional Medical Center 
 809 East Marion Avenue 

Punta Gorda, FL 33950-3898 
 (Charlotte) 

Punta Gorda HMA, LLC 
 Rockledge, Florida 

Wuesthoff Medical Center-Rockledge 
 110 Longwood Avenue 

Rockledge, FL 32955 
 (Brevard) 

Rockledge HMA, LLC 
 Sebastian, Florida 

Sebastian River Medical Center 
 13695 US Highway 1 

PO Box 780838 
 Sebastian, FL 32958 

(Indian River) 
 Sebastian Hospital, LLC

 

  
 33 

 
 Sebring, Florida 

Highlands Regional Medical Center 
 3600 South Highlands Avenue

 PO Drawer 2066 
 Sebring, FL 33870 

(Highlands) 
 Sebring Hospital Management Associates, LLC 

Seminole, Oklahoma 
 INTEGRIS Seminole Medical Center 

2401 Wrangler Boulevard 
 Seminole, OK 74868 

(Seminole) 
 Seminole HMA, LLC 

Spring Hill, Florida 
 Spring Hill Regional Hospital 

10461 Quality Drive 
 Spring Hill, FL  34609 

(Hernando) 
 Hernando HMA, LLC 

St. Cloud, Florida 
 St. Cloud Regional Medical Center

 2906 17th Street 
 St. Cloud, FL  34769 

(Osceola) 
 OsceolaSC, LLC 

St. Petersburg, Florida 
 Bayfront Medical Center 

701 6th Street South 
 St. Petersburg, FL  33701 

(Pinellas) 
 Bayfront HMA Medical Center, LLC 

Starke, Florida 
 Shands Starke Regional Medical Center

 922 E. Call Street 
 Starke, FL  32091 

(Bradford) 
 Starke HMA, LLC 

Statesboro, Georgia 
 East Georgia Regional Medical Center

 1499 Fair Road 
 Statesboro, GA  30458 

(Bulloch) 
 East Georgia Regional Medical Center, LLC

 Statesville, North Carolina 

Davis Regional Medical Center 
 218 Old Mocksville Road 

Statesville, NC  28625 
 (Iredell) 

Statesville HMA, LLC 
 Toppenish, Washington 

Toppenish Community Hospital 
 502 W. 4th 

Toppenish, WA  98948 
 (Yakima) 

Yakima HMA, LLC 
 Tullahoma, Tennessee 

Harton Regional Medical Center 
 1801 N. Jackson St. 

Tullahoma, TN  37388-2201 
 (Coffee and Franklin) 

Tullahoma HMA, LLC 
 Van Buren, Arkansas 

Summit Medical Center 
 E. Main & South 20th Street 

PO Box 409 (zip 72957) 
 Van Buren, AR  72956 

(Van Buren) 
 Van Buren HMA, LLC 

Venice, Florida 
 Venice Regional Medical Center 

540 The Rialto 
 Venice, FL  34285 

(Sarasota) 
 Venice HMA, LLC 

Williamson, West Virginia 
 Williamson Memorial Hospital

 859 Alderson Street 
 PO Box 1980 

Williamson, WV  25661 
 (Mingo) 

Williamson Memorial Hospital, LLC 
 Winder, Georgia 

Barrow Regional Medical Center 
 316 North Broad Street 

Winder, GA  30680-2150 
 (Barrow) 

Winder HMA, LLC 
 Yakima, Washington 

Yakima Regional Medical & Cardiac Center 
 110 S. 9th
Avenue 
 Yakima, WA  98902 
 (Yakima) 

Yakima HMA, LLC 

 

  
 34 

 Schedule 1.01(e) 

Certain Permitted Joint Ventures 

1.   Alliance Health Partners, LLC 

2.   Anniston HMA, LLC 

3.   Bayfront HMA Healthcare Holdings, LLC 

4.   Carolina Holdings, LLC 

5.   Durant H.M.A., LLC 

6.   East Georgia Regional Medical Center, LLC 

7.   Haines City HMA, LLC 

8.   Hartsville HMA, LLC 

9.   Hernando HMA, LLC 

10. Integris HMA, LLC 
 11. Lake
Shore HMA, LLC 
 12. Lancaster HMA, LLC 

13. Lebanon HMA, LLC 
 14. Live
Oak HMA, LLC 
 15. Midwest Regional Medical Center, LLC 

16. Mooresville HMA Investors, LLC 

17. Mooresville Hospital Management Associates, LLC 

18. Natchez Community Hospital, LLC 

19. OsceolaSC, LLC 
 20.
Paintsville Hospital Company, LLC 
 21. Pasco Regional Medical Center, LLC 

22. Riverview Regional Medical Center, LLC 

23. Rose City HMA, LLC 
 24.
Starke HMA, LLC 
 25. Tullahoma HMA, LLC 

26. Williamson Memorial Hospital, LLC 

  
 35 

 Schedule 1.01(f) 

Certain Subsidiaries 
 None.

  
 36 

 Schedule 3.08 

Subsidiaries 
  

			
	Legal Entity	  	  Percentage Owned  
	 5300 Grand
Limited Partnership
	  	91%
	 A Woman’s
Place, LLC
	  	100%
	 Abilene Clinic
Asset Holding Company, LLC
	  	100%
	 Abilene
Hospital, LLC
	  	100%
	 Abilene
Merger, LLC
	  	100%
	 Affinity
Health Systems, LLC
	  	100%
	 Affinity
Hospital, LLC
	  	100%
	 Affinity
Orthopedic Services, LLC
	  	100%
	 Affinity
Physician Services, LLC
	  	100%
	 Affinity
Skilled Nursing, LLC
	  	100%
	 Alaska
Physician Services, LLC
	  	100%
	 Alice
Hospital, LLC
	  	100%
	 Ambulance
Services of Dyersburg, Inc.
	  	100%
	 Ambulance
Services of Forrest City, LLC
	  	100%
	 Ambulance
Services of Lexington, Inc.
	  	100%
	 Ambulance
Services of McKenzie, Inc.
	  	100%
	 Ambulance
Services of McNairy, Inc.
	  	100%
	 Ambulance
Services of Tooele, LLC
	  	100%
	 American
Health Facilities Development, LLC
	  	100%
	 Anesthesiology
Group of Hattiesburg, LLC
	  	100%
	 Angelo
Community Healthcare Services, Inc.
	  	100%
	 Anna Clinic
Corp.
	  	100%
	 Anna Home Care
Services, LLC
	  	100%
	 Anna Hospital
Corporation
	  	100%
	 APS Medical,
LLC
	  	100%
	 Arizona ASC
Management, Inc.
	  	100%
	 Arizona DH,
LLC
	  	100%
	 Arizona Medco,
LLC
	  	100%
	 ARMC,
LP
	  	87.57%
	 Arusha,
LLC
	  	71%
	 ASC JV
Holdings, LLC
	  	100%
	 Augusta Health
System, LLC
	  	88.72%
	 Augusta Home
Care Services, LLC
	  	100%
	 Augusta
Hospital, LLC
	  	88.72%
	 Augusta
Physician Services, LLC
	  	100%
	 Barberton
Health System, LLC
	  	100%
	 Barberton
Physician Services, LLC
	  	100%
	 Barstow
Healthcare Management, Inc.
	  	100%
	 Barstow
Primary Care Clinic
	  	0% (100% control)
	 Beauco,
LLC
	  	100%
	 Beaumont
Medical Center, L.P.
	  	100%

  
 37 

			
	 Beaumont Regional, LLC
	  	100%
	 Berwick Clinic
Company, LLC
	  	100%
	 Berwick Clinic
Corp.
	  	100%
	 Berwick Home
Care Services, LLC
	  	100%
	 Berwick Home
Health Private Care, Inc.
	  	100%
	 Berwick
Hospital Company, LLC
	  	100%
	 BH Trans
Company, LLC
	  	100%
	 Big Bend Home
Care Services, LLC
	  	100%
	 Big Bend
Hospital Corporation
	  	100%
	 Big Spring
Hospital Corporation
	  	100%
	 Birmingham
Holdings, LLC
	  	100%
	 Birmingham
Holdings II, LLC
	  	100%
	 Birmingham
Home Care Services, LLC
	  	100%
	 Bluefield
Holdings, LLC
	  	100%
	 Bluefield
Hospital Company, LLC
	  	100%
	 Blue Island
Clinic Company, LLC
	  	100%
	 Blue Island
HBP Medical Group, LLC
	  	100%
	 Blue Island
Home Care Services, LLC
	  	100%
	 Blue Island
Hospital Company, LLC
	  	100%
	 Blue Island
Illinois Holdings, LLC
	  	100%
	 Blue Ridge
Georgia Hospital Company, LLC
	  	98.21%
	 Bluffton
Health System LLC
	  	100%
	 Bluffton
Physician Services, LLC
	  	100%
	 Brandywine
Hospital Malpractice Assistance Fund, Inc.
	  	100%
	 Brazos Valley
of Texas, L.P.
	  	100%
	 Brazos Valley
Surgical Center, LLC
	  	100%
	 Broken Arrow
Medical Group, LLC
	  	100%
	 Brooklyn
Medical Associates, LLC
	  	100%
	 Brownsville
Clinic Corp.
	  	100%
	 Brownsville
Hospital Corporation
	  	100%
	 Brownwood
Asset Holding Company, LLC
	  	100%
	 Brownwood
Hospital, L.P.
	  	100%
	 Brownwood
Medical Center, LLC
	  	100%
	 Bullhead City
Clinic Corp.
	  	100%
	 Bullhead City
Hospital Corporation
	  	100%
	 Bullhead City
Hospital Investment Corporation
	  	100%
	 Bullhead City
Imaging Corporation
	  	100%
	 Byrd Medical
Clinic, Inc.
	  	100%
	 Cardiology
Associates of Spokane, LLC
	  	100%
	 Cardiology
Associates of Tri-cities, LLC
	  	100%
	 Carlsbad
Medical Center, LLC
	  	100%
	 Carolina
Surgery Center, LLC
	  	52.74%
	 Carolinas
Internal Medicine, LLC
	  	100%
	 Carolinas
Medical Alliance, Inc.
	  	100%
	 Carolinas
OB/GYN Medical Group, LLC
	  	100%

  
 38 

			
	 Cedar Park Clinic Asset Holding Company, LLC
	  	100%
	 Cedar Park
Health System, L.P.
	  	80%
	 Center for
Adult Healthcare, LLC
	  	100%
	 Central
Alabama Physician Services, Inc.
	  	100%
	 Centre Clinic
Corp.
	  	100%
	 Centre HBP
Services, LLC
	  	100%
	 Centre Home
Care Corporation
	  	100%
	 Centre
Hospital Corporation
	  	100%
	 Centre RHC
Corp.
	  	100%
	 Chaves County
New Mexico Hospital Company, LLC
	  	100%
	 Chesterfield
Clinic Corp.
	  	100%
	
Chesterfield/Marlboro, L.P.
	  	100%
	 Chestnut Hill
Clinic Company, LLC
	  	85%
	 Chestnut Hill
Health System, LLC
	  	85%
	 CHHS ALF
Company, LLC
	  	85%
	 CHHS
Development Company, LLC
	  	85%
	 CHHS Holdings,
LLC
	  	100%
	 CHHS Hospital
Company, LLC
	  	85%
	 CHHS Rehab
Company, LLC
	  	85%
	 CHS Kentucky
Holdings, LLC
	  	100%
	 CHS
Pennsylvania Holdings, LLC
	  	100%
	 CHS PSO,
LLC
	  	100%
	 CHS
Receivables Funding, LLC
	  	100%
	 CHS Realty
Holdings I, Inc.
	  	100%
	 CHS Realty
Holdings II, Inc.
	  	100%
	 CHS Realty
Holdings Joint Venture
	  	100%
	 CHS Utah
Holdings, LLC
	  	100%
	 CHS Virginia
Holdings, LLC
	  	100%
	 CHS Washington
Holdings, LLC
	  	100%
	 CHS/Community
Health Systems, Inc.
	  	100%
	 CHSPSC
Leasing, Inc.
	  	100%
	 Claremore
Anesthesia, LLC
	  	100%
	 Claremore
Internal Medicine, LLC
	  	100%
	 Claremore
Physicians, LLC
	  	100%
	 Claremore
Regional Hospital, LLC
	  	100%
	 Clarksville
Endoscopy Center, LLC
	  	80%
	 Clarksville
Health System, G.P.
	  	80%
	 Clarksville
Holdings, LLC
	  	100%
	 Clarksville
Holdings II, LLC
	  	100%
	 Clarksville
Home Care Services, LLC
	  	80%
	 Clarksville
Physician Services, G.P.
	  	80%
	 Cleveland Home
Care Services, LLC
	  	100%
	 Cleveland
Hospital Corporation
	  	100%
	 Cleveland
Medical Clinic, Inc.
	  	100%
	 Cleveland PHO,
Inc.
	  	100%

  
 39 

			
	 Cleveland Tennessee Hospital Company, LLC
	  	100%
	 Clinton County
Health System, LLC
	  	100%
	 Clinton
Hospital Corporation
	  	100%
	 Coastal Health
Partners
	  	0% (100% control)
	 Coatesville
Cardiology Clinic, LLC
	  	100%
	 Coatesville
Clinic Company, LLC
	  	100%
	 Coatesville
Hospital Corporation
	  	100%
	 C-OK,
LLC
	  	100%
	 College
Station Clinic Asset Holding Company, LLC
	  	100%
	 College
Station Hospital, L.P.
	  	100%
	 College
Station Medical Center, LLC
	  	100%
	 College
Station Merger, LLC
	  	100%
	 College
Station RHC Company, LLC
	  	100%
	 Commonwealth
Health Physician Network, LLC
	  	100%
	 Community GP
Corp.
	  	100%
	 Community
Health Care Partners, Inc.
	  	100%
	 Community
Health Investment Company, LLC
	  	100%
	 Community
Health Network, Inc.
	  	100%
	 Community
Health Physicians Operations Holding Company, LLC
	  	100%
	 Community
Health Systems Foundation
	  	100%
	 Community
Health Systems Professional Services Corporation
	  	100%
	 Community
Health Systems Professional Services Corporation Political Action Committee
	  	100%
	 Community
Health United Home Care, LLC
	  	100%
	 Community
Insurance Group SPC, LTD.
	  	100%
	 Community LP
Corp.
	  	100%
	 Community
Network Solutions, LLC
	  	100%
	 Coronado
Medical, LLC
	  	100%
	 Cottage Home
Options, L.L.C.
	  	100%
	 Coventry
Clinic Company, LLC
	  	100%
	 CP Hospital
GP, LLC
	  	100%
	 CPLP,
LLC
	  	100%
	 Credentialing
Verification Services, LLC
	  	100%
	 Crestview
Hospital Corporation
	  	96.99%
	 Crestview
Professional Condominiums Association, Inc.
	  	64.4%
	 Crestview
Surgery Center, L.P.
	  	100%
	 Crestwood
Healthcare, L.P.
	  	95.07%
	 Crestwood
Hospital LP, LLC
	  	100%
	 Crestwood
Hospital, LLC
	  	100%
	 Crestwood
Physician Services, LLC
	  	100%
	 Crestwood
Surgery Center, LLC
	  	90.29%
	 Crossroads
Home Care Services, LLC
	  	100%
	 Crossroads
Physician Corp.
	  	100%
	 CSMC,
LLC
	  	100%
	 CSRA Holdings,
LLC
	  	100%

  
 40 

			
	 Dallas Phy Service, LLC
	  	100%
	 Dallas
Physician Practice, L.P.
	  	100%
	 Day Surgery,
Inc.
	  	100%
	 Deaconess
Health System, LLC
	  	99.24%
	 Deaconess
Holdings, LLC
	  	100%
	 Deaconess
Hospital Holdings, LLC
	  	100%
	 Deaconess
Metropolitan Physicians, LLC
	  	100%
	 Deaconess
Physician Services, LLC
	  	100%
	 Deming Clinic
Corporation
	  	100%
	 Deming Home
Care Services, LLC
	  	100%
	 Deming
Hospital Corporation
	  	100%
	 Deming Nursing
Home Company, LLC
	  	100%
	 Desert
Hospital Holdings, LLC
	  	100%
	 Detar
Hospital, LLC
	  	100%
	 DFW Physerv,
LLC
	  	100%
	 DH Cardiology,
LLC
	  	100%
	 DHFW Holdings,
LLC
	  	100%
	 DHSC,
LLC
	  	100%
	 Diagnostic
Imaging Management of Brandywine Valley, LLC
	  	100%
	 Doctors
Hospital Physician Services, LLC
	  	100%
	 Doctors of
Laredo, LLC
	  	100%
	 Dothan HBP
Services, LLC
	  	100%
	 Dukes Health
System, LLC
	  	100%
	 Dukes
Physician Services, LLC
	  	100%
	 Dupont
Hospital, LLC
	  	72.03%
	 Dyersburg
Clinic Corp.
	  	100%
	 Dyersburg HBP
Medical Group, LLC
	  	100%
	 Dyersburg Home
Care Services, LLC
	  	100%
	 Dyersburg
Hospital Corporation
	  	100%
	 E.D. Clinics,
LLC
	  	100%
	 East Tennessee
Clinic Corp.
	  	100%
	 East Tennessee
Health Systems, Inc.
	  	100%
	 Easton
Hospital Malpractice Assistance Fund, Inc.
	  	100%
	 Edge Medical
Clinic, Inc.
	  	100%
	 Edwardsville
Ambulatory Surgery Center, L.L.C.
	  	68.44%
	 El Dorado Home
Care Services, LLC
	  	100%
	 El Dorado
Surgery Center, L.P.
	  	58.7%
	 EL MED,
LLC
	  	100%
	 Eligibility
Screening Services, LLC
	  	100%
	 Empire Health
Services
	  	100%
	 Emporia Clinic
Corp.
	  	100%
	 Emporia Home
Care Services, LLC
	  	100%
	 Emporia
Hospital Corporation
	  	100%
	 Enterprise
Clinic, LLC
	  	100%
	 Eufaula Clinic
Corp.
	  	100%

  
 41 

			
	 Eufaula Hospital Corporation
	  	100%
	 Evanston
Clinic Corp.
	  	100%
	 Evanston
Hospital Corporation
	  	100%
	 Fallbrook
Healthcare Partners
	  	0% (100% control)
	 Fallbrook Home
Care Services, LLC
	  	100%
	 Fallbrook
Hospital Corporation
	  	100%
	 Family Home
Care, Inc.
	  	100%
	 Fannin
Regional Orthopaedic Center, Inc.
	  	100%
	 First Choice
Health Network, Inc.
	  	8.33%
	 Florence Home
Care Services, LLC
	  	100%
	 Foley Clinic
Corp.
	  	100%
	 Foley Home
Health Corporation
	  	100%
	 Foley Hospital
Corporation
	  	100%
	 Forrest City
Arkansas Hospital Company, LLC
	  	100%
	 Forrest City
Clinic Company, LLC
	  	100%
	 Forrest City
Hospital Corporation
	  	100%
	 Fort Payne
Clinic Corp.
	  	100%
	 Fort Payne
Home Care Corporation
	  	100%
	 Fort Payne
Hospital Corporation
	  	100%
	 Fort Payne RHC
Corp.
	  	100%
	 Frankfort
Health Partner, Inc.
	  	100%
	 Franklin
Clinic Corp.
	  	100%
	 Franklin Home
Care Services, LLC
	  	100%
	 Franklin
Hospital Corporation
	  	100%
	 Fulton Home
Care Services, LLC
	  	100%
	 FWCT-2
Acquisition Corporation
	  	100%
	 FWCT-2 Escrow
Corporation
	  	100%
	 Gadsden Home
Care Services, LLC
	  	100%
	 Gadsden
Regional Medical Center, LLC
	  	100%
	 Gadsden
Regional Physician Group Practice, LLC
	  	100%
	 Gadsden
Regional Primary Care, LLC
	  	100%
	 Galesburg Home
Care Corporation
	  	100%
	 Galesburg
Hospital Corporation
	  	100%
	 Galesburg
In-Home Assistance, Inc.
	  	100%
	 Galesburg
Professional Services, LLC
	  	100%
	 Gateway
Malpractice Assistance Fund, Inc.
	  	100%
	 Gateway
Medical Services, Inc.
	  	100%
	 Granbury
Clinic Asset Holding Company, LLC
	  	100%
	 Granbury
Hospital Corporation
	  	100%
	 Granbury Texas
Hospital Investment Corporation
	  	100%
	 Granite City
ASC Investment Company, LLC
	  	100%
	 Granite City
Clinic Corp.
	  	100%
	 Granite City
HBP Corp.
	  	100%
	 Granite City
Home Care Services, LLC
	  	100%
	 Granite City
Hospital Corporation
	  	100%

  
 42 

			
	 Granite City Illinois Hospital Company, LLC
	  	100%
	 Granite City
Orthopedic Physicians Company, LLC
	  	100%
	 Granite City
Physicians Corp.
	  	100%
	 GRB Real
Estate, LLC
	  	100%
	 Greenbrier
Valley Anesthesia, LLC
	  	100%
	 Greenbrier
Valley Emergency Physicians, LLC
	  	100%
	 Greenbrier
VMC, LLC
	  	96%
	 Greenville
Clinic Corp.
	  	100%
	 Greenville
Hospital Corporation
	  	100%
	 GRMC Holdings,
LLC
	  	100%
	 Gulf Coast
Hospital, L.P.
	  	100%
	 Gulf Coast
Medical Center, LLC
	  	100%
	 Hallmark
Healthcare Company, LLC
	  	100%
	 Harris Managed
Services, Inc.
	  	100%
	 Harris Medical
Clinics, Inc.
	  	100%
	 Hattiesburg
ASC-GP, LLC
	  	100%
	 Hattiesburg
Home Care Services, LLC
	  	100%
	 Haven Clinton
Medical Associates, LLC
	  	100%
	 Healthcare of
Forsyth County, Inc.
	  	100%
	 Healthwest
Holdings, Inc.
	  	100%
	 Heartland
Malpractice Assistance Fund, Inc.
	  	100%
	 Heartland
Regional Health System, LLC
	  	100%
	 Heartland
Rural Healthcare, LLC
	  	100%
	 Helena Home
Care Services, LLC
	  	100%
	 Hidden Valley
Medical Center, Inc.
	  	100%
	 Highland
Health Systems, Inc.
	  	100%
	 Hill Regional
Clinic Corp.
	  	100%
	 Hill Regional
Medical Group
	  	100%
	 Hobbs Medco,
LLC
	  	100%
	 Hobbs
Physician Practice, LLC
	  	100%
	 Hood Medical
Group
	  	100%
	 Hood Medical
Services, Inc.
	  	100%
	 Hospital of
Barstow, Inc.
	  	100%
	 Hospital of
Fulton, Inc.
	  	100%
	 Hospital of
Louisa, Inc.
	  	100%
	 Hospital of
Morristown, Inc.
	  	100%
	 Hot Springs
Outpatient Surgery Center, G.P.
	  	100%
	 HTI Tucson
Rehabilitation, Inc.
	  	100%
	 Humble Texas
Home Care Corporation
	  	100%
	 Huntington
Associates
	  	100%
	 INACTCO,
Inc.
	  	100%
	 In-Home
Assistance, L.L.C.
	  	100%
	 In-Home
Medical Equipment Supplies and Services, Inc.
	  	100%
	 Innovative
Recoveries, LLC
	  	100%
	 Intermountain
Medical Group, Inc.
	  	100%

  
 43 

			
	 IOM Health System, L.P.
	  	86.3%
	 Jackson Home
Care Services, LLC
	  	100%
	 Jackson
Hospital Corporation (KY)
	  	100%
	 Jackson
Hospital Corporation (TN)
	  	100%
	 Jackson
Physician Corp.
	  	100%
	 Jackson,
Tennessee Hospital Company, LLC
	  	96.94%
	 Jennersville
Family Medicine, LLC
	  	100%
	 Jennersville
Regional Hospital Malpractice Assistance Fund, Inc.
	  	100%
	 Jourdanton
Clinic Asset Holding Company, LLC
	  	100%
	 Jourdanton
Home Care Services, LLC
	  	100%
	 Jourdanton
Hospital Corporation
	  	100%
	 Kay County
Clinic Company, LLC
	  	100%
	 Kay County
Hospital Corporation
	  	100%
	 Kay County
Oklahoma Hospital Company, LLC
	  	100%
	 Kentucky River
HBP, LLC
	  	100%
	 Kentucky River
Physician Corporation
	  	100%
	 King City
Physician Company, LLC
	  	100%
	 Kirksville
Academic Medicine, LLC
	  	100%
	 Kirksville
Clinic Corp.
	  	100%
	 Kirksville
Hospital Company, LLC
	  	100%
	 Kirksville
Missouri Hospital Company, LLC
	  	88.10%
	 Kirksville
Physical Therapy Services, LLC
	  	100%
	 Knox Clinic
Corp.
	  	100%
	 Kosciusko
Medical Group, LLC
	  	100%
	 Lake Area
Physician Services, LLC
	  	100%
	 Lake Area
Surgicare, A Partnership in Commendam
	  	85.75%
	 Lake Wales
Clinic Corp.
	  	100%
	 Lake Wales
Hospital Corporation
	  	95.71%
	 Lake Wales
Hospital Investment Corporation
	  	95.71%
	 Lake Wales
Imaging Center, LLC
	  	100%
	 Lakeland Home
Care Services, LLC
	  	100%
	 Lakeway
Hospital Corporation
	  	100%
	 Lancaster
Clinic Corp.
	  	100%
	 Lancaster Home
Care Services, LLC
	  	100%
	 Lancaster
Hospital Corporation
	  	100%
	 Lancaster
Imaging Center, LLC
	  	100%
	 Laredo Clinic
Asset Holding Company, LLC
	  	100%
	 Laredo Texas
Hospital Company, L.P.
	  	95%
	 Las Cruces
ASC-GP, LLC
	  	100%
	 Las Cruces
Home Care Services, LLC
	  	100%
	 Las Cruces
Medical Center, LLC
	  	100%
	 Las Cruces
Physician Services, LLC
	  	100%
	 Las Cruces
Surgery Center, L.P.
	  	77.88%
	 Lea Regional
Hospital, LLC
	  	100%
	 Lexington
Clinic Corp.
	  	100%

  
 44 

			
	 Lexington Family Physicians, LLC
	  	100%
	 Lexington Home
Care Services, LLC
	  	100%
	 Lexington
Hospital Corporation
	  	100%
	 Lindenhurst
Illinois Hospital Company, LLC
	  	100%
	 Lindenhurst
Surgery Center, LLC
	  	51%
	 Lock Haven
Clinic Company, LLC
	  	100%
	 Lock Haven
Home Care Services, LLC
	  	100%
	 Logan Hospital
Corporation
	  	100%
	 Logan, West
Virginia Hospital Company, LLC
	  	100%
	 Longview
Clinic Operations Company, LLC
	  	100%
	 Longview
Medical Center, L.P.
	  	73.98%
	 Longview
Merger, LLC
	  	100%
	 Longview
Outpatient Physical Therapy, LLC
	  	100%
	 Louisa Home
Care Services, LLC
	  	100%
	 LRH,
LLC
	  	100%
	 LS
Psychiatric, LLC
	  	100%
	 Lufkin Clinic
Asset Holding Company, LLC
	  	100%
	 Lutheran
Health Network CBO, LLC
	  	100%
	 Lutheran
Health Network Investors, LLC
	  	86.3%
	 Lutheran
Health Network of Indiana, LLC
	  	100%
	 Lutheran
Medical Group, LLC
	  	100%
	 Lutheran
Musculoskeletal Center, LLC
	  	60%
	 Lutheran/TRMA
Network, LLC
	  	50%
	 Madison Clinic
Corp.
	  	100%
	 Madison
Hospital, LLC
	  	100%
	 Marion
Hospital Corporation
	  	100%
	 Marion
Physician Services, LLC
	  	100%
	 Marlboro
Clinic Corp.
	  	100%
	 Martin Clinic
Corp.
	  	100%
	 Martin
Hospital Corporation
	  	100%
	 Martins Ferry
Clinic Company, LLC
	  	100%
	 Martins Ferry
Hospital Company, LLC
	  	100%
	 Mary Black
Health System LLC
	  	98.3%
	 Mary Black
Medical Office Building Limited Partnership
	  	98.3%
	 Mary Black MOB
II, L.P.
	  	98.3%
	 Mary Black
Orthopedic Group, LLC
	  	100%
	 Mary Black
Physician Services, LLC
	  	100%
	 Mary Black
Physicians Group, LLC
	  	100%
	 Massillon
Community Health System LLC
	  	100%
	 Massillon
Health System, LLC
	  	100%
	 Massillon
Holdings, LLC
	  	100%
	 Massillon
Physician Services, LLC
	  	100%
	 Mat-Su
Regional ASC GP, LLC
	  	100%
	 Mat-Su
Regional Surgery Center, L.P.
	  	100%
	 Mat-Su Valley
II, LLC
	  	75%

  
 45 

			
	 Mat-Su Valley III, LLC
	  	75%
	 Mat-Su Valley
Medical Center, LLC
	  	74.52%
	 McKenna Court
Homes, LLC
	  	100%
	 McKenzie
Clinic Corp.
	  	100%
	 McKenzie
Physician Services, LLC
	  	100%
	 McKenzie
Tennessee Hospital Company, LLC
	  	100%
	
McKenzie-Willamette Regional Medical Center Associates, LLC
	  	92.24%
	 McNairy Clinic
Corp.
	  	100%
	 McNairy
Hospital Corporation
	  	100%
	 MCSA,
L.L.C.
	  	100%
	 Medical Center
at Terrell, LLC
	  	100%
	 Medical Center
of Brownwood, LLC
	  	100%
	 Medical Center
of Sherman, LLC
	  	100%
	 Medical
Holdings, Inc.
	  	100%
	 MEDSTAT,
LLC
	  	100%
	 Memorial
Hospital of Salem Malpractice Assistance Fund, Inc.
	  	100%
	 Memorial
Management, Inc.
	  	100%
	 Merger Legacy
Holdings, LLC
	  	100%
	 Mesa View
Physical Rehabilitation, LLC
	  	50%
	 Mesa View PT,
LLC
	  	100%
	 Mesquite
Clinic Management Company, LLC
	  	100%
	 MHS Ambulatory
Surgery Center, Inc.
	  	100%
	 Mid-Plains,
LLC
	  	100%
	 Minot Health
Services, Inc.
	  	100%
	 MMC of Nevada,
LLC
	  	100%
	 Moberly HBP
Medical Group, LLC
	  	100%
	 Moberly
Hospital Company, LLC
	  	100%
	 Moberly
Medical Clinics, Inc.
	  	100%
	 Moberly
Physicians Corp.
	  	100%
	 Mohave Imaging
Center, LLC
	  	100%
	 Morristown
Clinic Corp.
	  	100%
	 Morristown
Professional Centers, Inc.
	  	100%
	 Morristown
Surgery Center, LLC
	  	100%
	 MWMC Holdings,
LLC
	  	100%
	 Nanticoke
Hospital Company, LLC
	  	100%
	 National
Healthcare of England Arkansas, Inc.
	  	100%
	 National
Healthcare of Holmes County, Inc.
	  	100%
	 National
Healthcare of Leesville, Inc.
	  	100%
	 National
Healthcare of Mt. Vernon, Inc.
	  	100%
	 National
Healthcare of Newport, Inc.
	  	100%
	 Navarro
Hospital, L.P.
	  	100%
	 Navarro
Regional, LLC
	  	100%
	 NC-CSH,
Inc.
	  	100%
	 NC-DSH,
LLC
	  	100%
	 Newport Home
Care Services, LLC
	  	100%

  
 46 

			
	 NHCI of Hillsboro, Inc.
	  	100%
	 North Okaloosa
Clinic Corp.
	  	100%
	 North Okaloosa
Home Health Corp.
	  	100%
	 North Okaloosa
Medical Corp.
	  	96.99%
	 North Okaloosa
Surgery Venture Corp.
	  	100%
	 Northampton
Cardiology Clinic, LLC
	  	100%
	 Northampton
Clinic Company, LLC
	  	100%
	 Northampton
Endoscopy Center, LLC
	  	51%
	 Northampton
Home Care, LLC
	  	100%
	 Northampton
Hospital Company, LLC
	  	100%
	 Northampton
Physician Services Corp.
	  	100%
	 Northampton
Urgent Care, LLC
	  	100%
	 Northeast
Medical Center, L.P.
	  	100%
	 Northern
Indiana Oncology Center of Porter Memorial Hospital, LLC
	  	95.2%
	 Northwest
Allied Physicians, LLC
	  	100%
	 Northwest
Arkansas Employees, LLC
	  	100%
	 Northwest
Arkansas Hospitals, LLC
	  	100%
	 Northwest
Benton County Physician Services, LLC
	  	100%
	 Northwest
Cardiology, LLC
	  	100%
	 Northwest
Hospital, LLC
	  	100%
	 Northwest
Indiana Health System, LLC
	  	91.16%
	 Northwest
Marana Hospital, LLC
	  	100%
	 Northwest
Medical Center CT/MRI at Marana, LLC
	  	100%
	 Northwest
Physicians, LLC
	  	100%
	 Northwest
Rancho Vistoso Imaging Services, LLC
	  	100%
	 Northwest
Tucson ASC-GP, LLC
	  	100%
	 NOV Holdings,
LLC
	  	100%
	 NRH,
LLC
	  	100%
	 Oak Hill
Clinic Corp.
	  	100%
	 Oak Hill
Hospital Corporation
	  	100%
	 OHANI,
LLC
	  	100%
	 Oklahoma City
ASC-GP, LLC
	  	100%
	 Oklahoma City
Home Care Services, LLC
	  	100%
	 Olive Branch
Clinic Corp.
	  	100%
	 Olive Branch
Hospital, Inc.
	  	100%
	 Open MRI of
Wharton, LLP
	  	100%
	 Oro Valley
Hospital, LLC
	  	100%
	 Pacific Group
ASC, Inc.
	  	100%
	 Pacific
Physicians Services, LLC
	  	100%
	 Pain
Management Joint Venture, LLP
	  	50%
	 Palm Drive
Hospital, L.P.
	  	100%
	 Palm Drive
Medical Center, LLC
	  	100%
	 Palmer-Wasilla
Health System, LLC
	  	100%
	 Palmetto
Tri-County Medical Specialists, LLC
	  	100%
	 Palmetto
Women’s Care, LLC
	  	100%

  
 47 

			
	 Pampa Medical Center, LLC
	  	100%
	 Panhandle
Medical Center, LLC
	  	100%
	 Panhandle
Surgical Hospital, L.P.
	  	100%
	 Parkway
Regional Medical Clinic, Inc.
	  	100%
	 Payson
Healthcare Management, Inc.
	  	100%
	 Payson Home
Care Services, LLC
	  	100%
	 Payson
Hospital Corporation
	  	100%
	 PDMC,
LLC
	  	100%
	 Peckville
Hospital Company, LLC
	  	100%
	 Pecos Valley
of New Mexico, LLC
	  	100%
	 Peerless
Healthcare, LLC
	  	100%
	 Pennsylvania
Hospital Company, LLC
	  	100%
	 Petersburg
Clinic Company, LLC
	  	100%
	 Petersburg
Home Care Services, LLC
	  	100%
	 Petersburg
Hospital Company, LLC
	  	99.29%
	 Phillips &
Coker OB-GYN, LLC
	  	100%
	 Phillips
Clinic Corp.
	  	100%
	 Phillips
Hospital Corporation
	  	100%
	 Phoenix
Surgical, LLC
	  	100%
	 Phoenixville
Clinic Company, LLC
	  	100%
	 Phoenixville
Hospital Company, LLC
	  	100%
	 Phoenixville
Hospital Malpractice Assistance Fund, Inc.
	  	100%
	 Phoenixville
Orthopedic Specialists, LLC
	  	100%
	 Phoenixville
Specialty Clinics, LLC
	  	100%
	 Physician
Practice Support, Inc.
	  	100%
	 Piney Woods
Healthcare System, L.P.
	  	93.57%
	 Plymouth
Hospital Corporation
	  	100%
	 Polk Medical
Services, Inc.
	  	100%
	 Ponca City
Home Care Services, Inc.
	  	100%
	 Porter Health
Services, LLC
	  	100%
	 Porter
Hospital, LLC
	  	91.16%
	 Porter
Physician Services, LLC
	  	100%
	 Pottstown
Clinic Company, LLC
	  	100%
	 Pottstown Home
Care Services, LLC
	  	100%
	 Pottstown
Hospital Company, LLC
	  	100%
	 Pottstown
Hospital Corporation
	  	100%
	 Pottstown
Imaging Company, LLC
	  	100%
	 Pottstown
Memorial Ambulance Company, LLC
	  	100%
	 Pottstown
Memorial Malpractice Assistance Fund, Inc.
	  	100%
	 Pottstown
Professional Services Company, LLC
	  	100%
	 PremierCare of
Arkansas, LLC
	  	79.6%
	 PremierCare of
Northwest Arkansas, LLC
	  	79.6%
	 Premier Care
Super PHO, LLC
	  	100%
	 Procure
Solutions, LLC
	  	100%
	 Professional
Account Services Inc.
	  	100%

  
 48 

			
	 QHG Georgia Holdings, Inc.
	  	100%
	 QHG Georgia
Holdings II, LLC
	  	100%
	 QHG Georgia,
L.P.
	  	100%
	 QHG of
Barberton, Inc.
	  	100%
	 QHG of
Bluffton Company, LLC
	  	100%
	 QHG of Clinton
County, Inc.
	  	100%
	 QHG of
Enterprise, Inc.
	  	100%
	 QHG of Forrest
County, Inc.
	  	100%
	 QHG of Fort
Wayne Company, LLC
	  	100%
	 QHG of
Hattiesburg, Inc.
	  	100%
	 QHG of
Kenmare, Inc.
	  	100%
	 QHG of Lake
City, Inc.
	  	100%
	 QHG of
Massillon, Inc.
	  	100%
	 QHG of Minot,
Inc.
	  	100%
	 QHG of Ohio,
Inc.
	  	100%
	 QHG of South
Carolina, Inc.
	  	100%
	 QHG of
Spartanburg, Inc.
	  	100%
	 QHG of
Springdale, Inc.
	  	100%
	 QHG of Texas,
Inc.
	  	100%
	 QHG of Warsaw
Company, LLC
	  	100%
	 QHR Healthcare
Affiliates, LLC
	  	100%
	 QHR Intensive
Resources, LLC
	  	100%
	 QHR
International, LLC
	  	100%
	 QHR Naples
ASC, LLC
	  	100%
	 Quorum ELF,
Inc.
	  	100%
	 Quorum Health
Resources, LLC
	  	100%
	 Quorum Health
Services, Inc.
	  	100%
	 Quorum
Purchasing Advantage, LLC
	  	100%
	 Quorum
Solutions, LLC
	  	100%
	 Red Bud Clinic
Corp.
	  	100%
	 Red Bud Home
Care Services, LLC
	  	100%
	 Red Bud
Hospital Corporation
	  	100%
	 Red Bud
Illinois Hospital Company, LLC
	  	100%
	 Red Bud
Physician Group, LLC
	  	100%
	 Regional
Cancer Treatment Center, Ltd.
	  	24.35%
	 Regional
Employee Assistance Program
	  	100%
	 Regional
Hospital of Longview, LLC
	  	100%
	 Regional
Surgical Services, LLC
	  	82.1%
	 Rehab Hospital
of Fort Wayne General Partnership
	  	86.3%
	 Revenue Cycle
Service Center, LLC
	  	100%
	 River Region
Medical Corporation
	  	100%
	 River to River
Heart Group, LLC
	  	100%
	 Rockwood
Clinic, P.S.
	  	50%
	 Rockwood
Clinic Real Estate Holdings, LLC
	  	100%
	 Ronceverte
Physician Group, LLC
	  	100%

  
 49 

			
	 Roswell Clinic Corp.
	  	100%
	 Roswell
Community Hospital Investment Corporation
	  	100%
	 Roswell
Hospital Corporation
	  	100%
	 Russell County
Clinic Corp.
	  	100%
	 Russell County
Medical Center, Inc.
	  	100%
	 Ruston Clinic
Company, LLC
	  	100%
	 Ruston
Hospital Corporation
	  	100%
	 Ruston
Louisiana Hospital Company, LLC
	  	100%
	 SACMC,
LLC
	  	100%
	 Salem Clinic
Corp.
	  	100%
	 Salem Home
Care Services, LLC
	  	100%
	 Salem Hospital
Corporation
	  	100%
	 Salem Medical
Professionals, P.C.
	  	0% (100% control)
	 Samaritan
Surgicenters of Arizona II, LLC
	  	100%
	 San Angelo
Community Medical Center, LLC
	  	100%
	 San Angelo
Hospital, L.P.
	  	94.76%
	 San Angelo
Medical, LLC
	  	100%
	 San Leandro,
LLC
	  	100%
	 San Leandro
Hospital, L.P.
	  	100%
	 San Leandro
Medical Center, LLC
	  	100%
	 San Miguel
Clinic Corp.
	  	100%
	 San Miguel
Hospital Corporation
	  	100%
	 Scenic Managed
Services, Inc.
	  	100%
	 Schuylkill
Internal Medicine Associates, LLC
	  	100%
	 Scranton
Cardiovascular Physician Services, LLC
	  	100%
	 Scranton
Clinic Company, LLC
	  	100%
	 Scranton
Emergency Physician Services, LLC
	  	100%
	 Scranton GP
Holdings, LLC
	  	100%
	 Scranton
Holdings, LLC
	  	100%
	 Scranton Home
Care Services, LLC
	  	100%
	 Scranton
Hospital Company, LLC
	  	100%
	 Scranton
Hospitalist Physician Services, LLC
	  	100%
	 Sebastopol,
LLC
	  	100%
	 Scranton
Quincy Ambulance, LLC
	  	100%
	 Scranton
Quincy Clinic Company, LLC
	  	100%
	 Scranton
Quincy Holdings, LLC
	  	100%
	 Scranton
Quincy Home Care Services, LLC
	  	100%
	 Scranton
Quincy Hospital Company, LLC
	  	100%
	 Scranton
Quincy QRFS, LLC
	  	100%
	 Senior Circle
Association
	  	100%
	 SEPA
Integrated Providers Alliance, LLC
	  	100%
	 Sharon Clinic
Company, LLC
	  	100%
	 Sharon Home
Care Services, LLC
	  	100%
	 Sharon
Pennsylvania Holdings, LLC
	  	100%
	 Sharon
Pennsylvania Hospital Company, LLC
	  	100%

  
 50 

			
	 Shelby Alabama Real Estate, LLC
	  	100%
	 Shelbyville
Clinic Corp.
	  	100%
	 Shelbyville
Home Care Services, LLC
	  	100%
	 Shelbyville
Hospital Corporation
	  	100%
	 Sherman
Hospital, L.P.
	  	100%
	 Sherman
Medical Center, LLC
	  	100%
	 Siloam Springs
Arkansas Hospital Company, LLC
	  	100%
	 Siloam Springs
Clinic Company, LLC
	  	100%
	 Siloam Springs
Holdings, LLC
	  	100%
	 Silver Creek
MRI, LLC
	  	100%
	 SJ Home Care,
LLC
	  	100%
	 SkyRidge
Clinical Associates, LLC
	  	100%
	 SLH,
LLC
	  	100%
	 SMMC Medical
Group
	  	100%
	 Software Sales
Corp.
	  	100%
	 South Alabama
Managed Care Contracting, Inc.
	  	100%
	 South Alabama
Medical Management Services, Inc.
	  	100%
	 South Alabama
Physician Services, Inc.
	  	100%
	 South Arkansas
Clinic, LLC
	  	100%
	 South Arkansas
Physician Services, LLC
	  	100%
	 South Tulsa
Medical Group, LLC
	  	100%
	 SouthCrest
Anesthesia Group, LLC
	  	100%
	 SouthCrest
Medical Group, LLC
	  	100%
	 SouthCrest,
L.L.C.
	  	100%
	 Southeast
Alabama Maternity Center, LLC
	  	50.78%
	 Southern
Chester County Medical Building I
	  	56%
	 Southern
Chester County Medical Building II
	  	63%
	 Southern
Illinois Medical Care Associates, LLC
	  	100%
	 Southern Texas
Medical Center, LLC
	  	100%
	 Southside
Physician Network, LLC
	  	100%
	 Spokane Home
Care Services, LLC
	  	100%
	 Spokane Valley
Washington Hospital Company, LLC
	  	100%
	 Spokane
Washington Hospital Company, LLC
	  	100%
	 Springdale
Home Care Services, LLC
	  	100%
	 Springfield
Oregon Holdings, LLC
	  	100%
	 Sprocket
Medical Management, LLC
	  	100%
	 SS ParentCo.,
LLC
	  	100%
	 St. Joseph
Health System, LLC
	  	86.3%
	 St. Joseph
Medical Group, Inc.
	  	100%
	 Sunbury Clinic
Company, LLC
	  	100%
	 Sunbury
Hospital Company, LLC
	  	73.26%
	 Surgery Center
of Salem County, L.L.C.
	  	90.9%
	 Surgical
Center of Amarillo, LLC
	  	100%
	 Surgical
Center of Carlsbad, LLC
	  	100%
	 Surgicare of
Independence, Inc.
	  	100%

  
 51 

			
	 Surgicare of San Leandro, Inc.
	  	100%
	 Surgicare of
Sherman, Inc.
	  	100%
	 Surgicare of
Victoria, Inc.
	  	100%
	 Surgicare of
Victoria, Ltd.
	  	100%
	 Surgicare
Outpatient Center of Lake Charles, Inc.
	  	100%
	 Surgicenter of
Johnson County, Inc.
	  	100%
	 Surgicenters
of America, Inc.
	  	100%
	 SVRMC-HBP,
LLC
	  	100%
	 Tennyson
Holdings, LLC
	  	100%
	 Terrell
Hospital, L.P.
	  	100%
	 Terrell
Medical Center, LLC
	  	100%
	 The Sleep
Disorder Center of Wyoming Valley, LLC
	  	100%
	 The Vicksburg
Clinic, LLC
	  	100%
	 Three Rivers
Medical Clinics, Inc.
	  	100%
	 Timberland
Medical Group
	  	100%
	 Tomball
Ambulatory Surgery Center, L.P.
	  	52%
	 Tomball Clinic
Asset Holding Company, LLC
	  	100%
	 Tomball
Equipment Leasing Company, LLC
	  	41%
	 Tomball Texas
Equipment Ventures, LLC
	  	100%
	 Tomball Texas
Holdings, LLC
	  	100%
	 Tomball Texas
Home Care Services, LLC
	  	100%
	 Tomball Texas
Hospital Company, LLC
	  	100%
	 Tomball Texas
Ventures, LLC
	  	100%
	 Tooele Clinic
Corp.
	  	100%
	 Tooele Home
Care Services, LLC
	  	100%
	 Tooele
Hospital Corporation
	  	100%
	 Triad
Corporate Services, Limited Partnership
	  	100%
	 Triad CSGP,
LLC
	  	100%
	 Triad CSLP,
LLC
	  	100%
	 Triad
Healthcare Corporation
	  	100%
	 Triad
Healthcare System of Phoenix, L.P.
	  	100%
	 Triad Holdings
III, LLC
	  	100%
	 Triad Holdings
IV, LLC
	  	100%
	 Triad Holdings
V, LLC
	  	100%
	 Triad Holdings
VI, Inc.
	  	100%
	 Triad Indiana
Holdings, LLC
	  	86.3%
	 Triad Nevada
Holdings, LLC
	  	100%
	 Triad of
Alabama, LLC
	  	100%
	 Triad of
Arizona (L.P.), Inc.
	  	100%
	 Triad of
Oregon, LLC
	  	100%
	 Triad of
Phoenix, Inc.
	  	100%
	 Triad RC,
Inc.
	  	100%
	 Triad-Arizona
I, Inc.
	  	100%
	 Triad-ARMC,
LLC
	  	100%
	 Triad-Denton
Hospital GP, LLC
	  	100%

  
 52 

			
	 Triad-Denton Hospital, L.P.
	  	100%
	 Triad-El
Dorado, Inc.
	  	100%
	 Triad-Navarro
Regional Hospital Subsidiary, LLC
	  	100%
	 Triad-South
Tulsa Hospital Company, Inc.
	  	100%
	 Tri-Irish,
Inc.
	  	100%
	 Tri-World,
LLC
	  	100%
	 TROSCO,
LLC
	  	100%
	 Troy Hospital
Corporation
	  	100%
	 Tunkhannock
Clinic Company, LLC
	  	100%
	 Tunkhannock
Hospital Company, LLC
	  	100%
	 Tunkhannock
Hospital Physician Services, LLC
	  	100%
	 Tuscora Park
Medical Specialists, LLC
	  	100%
	 ValleyCare
Cardiology Group, LLC
	  	100%
	 VHC Holdings,
LLC
	  	100%
	 VHC Medical,
LLC
	  	100%
	 Vicksburg
Healthcare, LLC
	  	100%
	 Vicksburg
Surgical Center, LLC
	  	100%
	 Victoria
Clinic Asset Holding Company, LLC
	  	100%
	 Victoria
Hospital, LLC
	  	100%
	 Victoria of
Texas, L.P.
	  	100%
	 Victoria Texas
Home Care Services, LLC
	  	100%
	 Village
Medical Center Associates, LLC
	  	100%
	 Virginia Care
Company, LLC
	  	100%
	 Virginia
Hospital Company, LLC
	  	100%
	 WA-SPOK DH
CRNA, LLC
	  	100%
	 WA-SPOK DH
Urgent Care, LLC
	  	100%
	 WA-SPOK Kidney
Care, LLC
	  	100%
	 WA-SPOK
Medical Care, LLC
	  	100%
	 WA-SPOK
Primary Care, LLC
	  	100%
	 WA-SPOK
Pulmonary & Critical Care, LLC
	  	100%
	 WA-SPOK VH
CRNA, LLC
	  	100%
	 WA-SPOK VH
Urgent Care, LLC
	  	100%
	 Warren Ohio
Hospital Company, LLC
	  	100%
	 Warren Ohio
Physician Services, LLC
	  	100%
	 Warren Ohio
Rehab Hospital Company, LLC
	  	100%
	 Warsaw Health
System, LLC
	  	99.08%
	 Washington
Clinic Corp.
	  	100%
	 Washington
Hospital Corporation
	  	100%
	 Washington
Physician Corp.
	  	100%
	 Watsonville
Hospital Corporation
	  	100%
	 Waukegan
Clinic Corp.
	  	100%
	 Waukegan
Hospice Corp.
	  	100%
	 Waukegan
Hospital Corporation
	  	100%
	 Waukegan
Illinois Hospital Company, LLC
	  	100%
	 Weatherford
Home Care Services, LLC
	  	100%

  
 53 

			
	 Weatherford Hospital Corporation
	  	100%
	 Weatherford
Texas Hospital Company, LLC
	  	100%
	 Webb County
Texas Home Care Services, LLC
	  	100%
	 Webb Hospital
Corporation
	  	100%
	 Webb Hospital
Holdings, LLC
	  	100%
	 Wesley Health
System LLC
	  	100%
	 Wesley
HealthTrust, Inc.
	  	100%
	 Wesley
Physician Services, LLC
	  	100%
	 West Anaheim
Medical Center, LLC
	  	100%
	 West Anaheim,
LLC
	  	100%
	 West Grove
Clinic Company, LLC
	  	100%
	 West Grove
Family Practice, LLC
	  	100%
	 West Grove
Home Care, LLC
	  	100%
	 West Grove
Hospital Company, LLC
	  	100%
	 Western
Arizona Regional Home Health and Hospice, Inc.
	  	100%
	 Western
Reserve Health Education, Inc.
	  	100%
	 Wharton Medco,
LLC
	  	100%
	 Wheeling HBP
Clinic Company, LLC
	  	100%
	 Wheeling West
Virginia Clinic Company, LLC
	  	100%
	 Wheeling West
Virginia Hospital Company, LLC
	  	100%
	 WHMC,
LLC
	  	100%
	 Wichita Falls
Texas Home Care Corporation
	  	100%
	 Wichita Falls
Texas Private Duty Corporation
	  	100%
	 Wilkes-Barre
Academic Medicine, LLC
	  	100%
	 Wilkes-Barre
Behavioral Hospital Company, LLC
	  	100%
	 Wilkes-Barre
Behavioral Ventures, LLC
	  	100%
	 Wilkes-Barre
Clinic Company, LLC
	  	100%
	 Wilkes-Barre
Community Residential Unit, LLC
	  	100%
	 Wilkes-Barre
Holdings, LLC
	  	100%
	 Wilkes-Barre
Home Care Services, LLC
	  	100%
	 Wilkes-Barre
Hospital Company, LLC
	  	100%
	 Wilkes-Barre
Intermountain Clinic, LLC
	  	100%
	 Wilkes-Barre
Personal Care Services, LLC
	  	100%
	 Wilkes-Barre
Skilled Nursing Services, LLC
	  	100%
	 Willamette
Community Medical Group, LLC
	  	100%
	 Williamston
Clinic Corp.
	  	100%
	 Williamston
HBP Services, LLC
	  	100%
	 Williamston
Hospital Corporation
	  	100%
	 Wiregrass
Clinic, LLC
	  	100%
	 Women &
Children’s Hospital, LLC
	  	100%
	 Women’s
Health Partners, LLC
	  	100%
	 Woodland
Heights Medical Center, LLC
	  	100%
	 Woodward
Clinic Company, LLC
	  	100%
	 Woodward
Health System, LLC
	  	100%
	 Woodward Home
Care Services, LLC
	  	100%

  
 54 

			
	 York Anesthesiology Physician Services, LLC
	  	100%
	 York Clinic
Company, LLC
	  	100%
	 York Home Care
Services, LLC
	  	100%
	 York Pathology
Physician Services, LLC
	  	100%
	 York
Pennsylvania Holdings, LLC
	  	100%
	 York
Pennsylvania Hospital Company, LLC
	  	100%
	 Youngstown
Home Care Services, LLC
	  	100%
	 Youngstown
Ohio Hospital Company, LLC
	  	100%
	 Youngstown
Ohio Laboratory Services Company, LLC
	  	100%
	 Youngstown
Ohio Outpatient Services Company, LLC
	  	100%
	 Youngstown
Ohio Physician Services Company, LLC
	  	100%
	 Youngstown
Ohio PSC, LLC
	  	100%
	 Zinni,
Ltd.
	  	0% (100% control)

  
 55 

 HMA Entities: 
  

			
	 Alabama HMA Physician Management, LLC
	  	100%
	 Alliance
Health Partners, LLC
	  	90.58%
	 Amory HMA
Physician Management, LLC
	  	100%
	 Amory HMA,
LLC
	  	100%
	 Anniston HMA,
LLC
	  	86.99%
	 Arkansas HMA
Regional Service Center, LLC
	  	100%
	 Augusta HMA
Physician Management, Inc.
	  	100%
	 Augusta HMA,
Inc.
	  	100%
	 Barrow Health
Ventures, Inc.
	  	51%
	 Bartow HMA
Physician Management, LLC
	  	100%
	 Bartow HMA,
LLC
	  	100%
	 Batesville HMA
Development, LLC
	  	100%
	 Batesville HMA
Medical Group, LLC
	  	100%
	 Bayfront HMA
Convenient Care, LLC
	  	100%
	 Bayfront HMA
Healthcare Holdings, LLC
	  	80%
	 Bayfront HMA
Home Health, LLC
	  	100%
	 Bayfront HMA
Investments, LLC
	  	100%
	 Bayfront HMA
Medical Center, LLC
	  	100%
	 Bayfront HMA
Physician Management, LLC
	  	100%
	 Bayfront HMA
Real Estate Holdings, LLC
	  	100%
	 Bayfront HMA
Wellness Center, LLC
	  	100%
	 Biloxi H.M.A.,
LLC
	  	100%
	 Biloxi HMA
Physician Management, LLC
	  	100%
	 Blackwell HMA,
LLC
	  	100%
	 Blackwell
HMPN, LLC
	  	100%
	 Brandon HMA,
LLC
	  	100%
	 Brevard HMA
ALF, LLC
	  	100%
	 Brevard HMA
APO, LLC
	  	100%
	 Brevard HMA
ASC, LLC
	  	100%
	 Brevard HMA
Diagnostic Imaging, LLC
	  	100%
	 Brevard HMA
HME, LLC
	  	100%
	 Brevard HMA
Holdings, LLC
	  	100%
	 Brevard HMA
Home Health, LLC
	  	100%
	 Brevard HMA
Hospice, LLC
	  	100%
	 Brevard HMA
Hospitals, LLC
	  	100%
	 Brevard HMA
Investment Properties, LLC
	  	100%
	 Brevard HMA
Nursing Home, LLC
	  	100%
	 Brooksville
HMA Physician Management, LLC
	  	100%
	 Campbell
County HMA, LLC
	  	100%
	 Canton HMA,
LLC
	  	100%
	 Carlisle HMA,
LLC
	  	100%
	 Carlisle HMA
Physician Management, LLC
	  	100%
	 Carlisle HMA
Surgery Center, LLC
	  	100%

  
 56 

			
	 Carlisle Medical Group, LLC
	  	100%
	 Carolinas
Holdings, LLC
	  	100%
	 Carolinas JV
Holdings General , LLC
	  	100%
	 Carolinas JV
Holdings, L.P.
	  	99%
	 Central
Florida HMA Holdings, LLC
	  	99%
	 Central Polk,
LLC
	  	100%
	 Central States
HMA Holdings, LLC
	  	99%
	 Chester HMA,
LLC
	  	100%
	 Chester HMA
Physician Management, LLC
	  	100%
	 Chester
Medical Group, LLC
	  	100%
	 Chester PPM,
LLC
	  	100%
	 Citrus HMA,
LLC
	  	100%
	 Clarksdale
HMA, LLC
	  	100%
	 Clarksdale HMA
Physician Management, LLC
	  	100%
	 Click to Care,
LLC
	  	100%
	 Clinton HMA,
LLC
	  	100%
	 Clinton HMPN,
LLC
	  	100%
	 Cocke County
HMA, LLC
	  	100%
	 Coffee
Hospital Management Associates, Inc.
	  	100%
	 Collier
Boulevard HMA Physician Management, LLC
	  	100%
	 Collier HMA
Facility Based Physician Management, LLC
	  	100%
	 Collier HMA
Neurological Vascular Medical Group, LLC
	  	100%
	 Collier HMA
Physician Management, LLC
	  	100%
	 Crossgates HMA
Medical Group, LLC
	  	100%
	 Crystal River
HMA Physician Management, LLC
	  	100%
	 Durant H.M.A.,
LLC
	  	100%
	 Durant HMA
Home Health, LLC
	  	100%
	 Durant HMA
Physician Management, LLC
	  	100%
	 Durant HMA
Surgical Center, LLC
	  	100%
	 East Georgia
HMA Physician Management, LLC
	  	100%
	 East Georgia
Regional Medical Center, LLC
	  	89.26%
	 EverRad HMA
Holdings, LLC
	  	100%
	 Florida
Endoscopy and Surgery Center, LLC
	  	70%
	 Florida HMA
Holdings, LLC
	  	99%
	 Florida HMA
Regional Service Center, LLC
	  	100%
	 Florida HMA
Urgent Care, LLC
	  	100%
	 Flowood River
Oaks HMA Medical Group, LLC
	  	100%
	 Fort Smith
HMA, LLC
	  	100%
	 Fort Smith HMA
Home Health, LLC
	  	100%
	 Fort Smith HMA
PBC Management, LLC
	  	100%
	 Fort Smith HMA
Physician Management, LLC
	  	100%
	 Gadsden HMA
Physician Management, LLC
	  	100%
	 Gaffney
H.M.A., LLC
	  	100%
	 Gaffney HMA
Physician Management, LLC
	  	100%
	 Gaffney PPM,
LLC
	  	100%

  
 57 

			
	 Georgia HMA Physician Management, LLC
	  	100%
	 Green Clinic,
LLC
	  	100%
	 Gulf Coast HMA
Physician Management, LLC
	  	100%
	 Gulf Oaks
Therapeutic Day School, LLC
	  	100%
	 Haines City
HMA, LLC
	  	97.86%
	 Haines City
HMA Physician Management, LLC
	  	100%
	 Haines City
HMA Urgent Care, LLC
	  	100%
	 Hamlet H.M.A.,
LLC
	  	100%
	 Hamlet HMA
Physician Management, LLC
	  	100%
	 Hamlet HMA
PPM, LLC
	  	100%
	 Hamlet PPM,
LLC
	  	100%
	 Harrison HMA,
LLC
	  	100%
	 Harrison HMA
Physician Management, LLC
	  	100%
	 Hartsville
ENT, LLC
	  	100%
	 Hartsville
HMA, LLC
	  	98.36%
	 Hartsville HMA
Physician Management, LLC
	  	100%
	 Hartsville
Medical Group, LLC
	  	100%
	 Hartsville
PPM, LLC
	  	100%
	 Health
Management Associates, LP
	  	100%
	 Health
Management Associates, Inc.
	  	100%
	 Fed PAC,
LLC
	  	100%
	 Health
Management Associates, LP
	  	100%
	 Health
Management General Partner, LLC
	  	100%
	 Health
Management General Partner I, LLC
	  	100%
	 Health
Management Information Technology, LLC
	  	100%
	 Health
Management Intellectual Properties, LLC
	  	100%
	 Health
Management Physician Associates, LLC
	  	100%
	 Hernando HMA,
LLC
	  	97.16%
	 Hernando HMA
Ancillary, LLC
	  	100%
	 HMA ASC
Holdings, LLC
	  	100%
	 HMA ASCOA
Holdings, LLC
	  	100%
	 HMA-ASCOA
Investments, LLC
	  	51%
	 HMA Bayflite
Services, LLC
	  	100%
	 HMA Blue Chip
Holdings, LLC
	  	100%
	 HMA Blue Chip
Investments, LLC
	  	51%
	 HMA CAT,
LLC
	  	100%
	 HMA Employee
Disaster Relief Fund, Inc.
	  	100%
	 HMA Fentress
County General Hospital, LLC
	  	100%
	 HMA
Foundation, Inc.
	  	100%
	 HMA Hospitals
Holdings, LP
	  	100%
	 HMA Lake
Shore, Inc.
	  	100%
	 HMA Leasing,
LLC
	  	100%
	 HMA MRI,
LLC
	  	100%
	 HMA Oklahoma
Clearing Service, LLC
	  	100%
	 HMA Physician
Practice Management, LLC
	  	100%

  
 58 

			
	 HMA Professional Services Group, LP
	  	99%
	 HMA Regent
Holdings, LLC
	  	100%
	 HMA Santa Rosa
Medical Center, LLC
	  	100%
	 HMA Services
GP, LLC(
	  	100%
	 HMA SunCrest
Holdings, LLC
	  	100%
	 Hospital
Management Associates, LLC
	  	100%
	 Hospital
Management Services of Florida, LP
	  	100%
	 ICSE Leasing
Corp.
	  	100%
	 Innovations
Surgery Center, LLC
	  	100%
	 Insurance
Company of the Southeast, Ltd.
	  	100%
	 Integris
Blackwell Home Health & Hospice, LLC
	  	100%
	 Integris
Clinton Home Health & Hospice, LLC
	  	100%
	 Integris HMA,
LLC
	  	80%
	 Jackson HMA,
LLC
	  	100%
	 Jackson HMA
North Medical Office Building, LLC
	  	100%
	 Jamestown HMA
Leasing, LLC
	  	100%
	 Jamestown HMA
Physician Management, LLC
	  	100%
	 Jasper Medical
Group, LLC
	  	100%
	 Jefferson
County HMA, LLC
	  	100%
	 Kennett HMA,
LLC
	  	100%
	 Kennett HMA
Physician Management, LLC
	  	100%
	 Keystone HMA
Property Management, LLC
	  	100%
	 Key West HMA,
LLC
	  	100%
	 Key West HMA
Physician Management, LLC
	  	100%
	 Knoxville HMA
Cardiology PPM, LLC
	  	100%
	 Knoxville HMA
Development, LLC
	  	100%
	 Knoxville HMA
Family Services, LLC
	  	100%
	 Knoxville HMA
Holdings, LLC
	  	100%
	 Knoxville HMA
Homecare DME & Hospice, LLC
	  	100%
	 Knoxville HMA
JV Holdings, LLC
	  	100%
	 Knoxville HMA
Mission Services, LLC
	  	100%
	 Knoxville HMA
Physician Management, LLC
	  	100%
	 Knoxville HMA
Wellness Center, LLC
	  	100%
	 Lake Shore
HMA, LLC
	  	60%
	 Lake Shore HMA
Medical Group, LLC
	  	100%
	 Lancaster HMA,
LLC
	  	98.73%
	 Lake Shore
HMA, LLC
	  	60%
	 Lake Shore HMA
Medical Group, LLC
	  	100%
	 Lancaster HMA,
LLC
	  	98.73%
	 Lancaster HMA
Physician Management, LLC
	  	100%
	 Lancaster
Medical Group, LLC
	  	100%
	 Lancaster
Medical Group HMA, LLC
	  	100%
	 Lancaster
Outpatient Imaging, LLC
	  	100%
	 Lebanon HMA,
LLC
	  	98.27%
	 Lebanon HMA
Leasing, LLC
	  	100%

  
 59 

			
	 Lebanon HMA Physician Management, LLC
	  	100%
	 Lebanon HMA
Surgery Center, LLC
	  	100%
	 Lehigh HMA,
LLC
	  	100%
	 Lehigh HMA
Physician Management, LLC
	  	100%
	 Little Rock
HMA, Inc.
	  	100%
	 Live Oak HMA,
LLC
	  	60%
	 Live Oak HMA
Medical Group, LLC
	  	100%
	 Lone Star HMA,
L.P.
	  	100%
	 Lone Star HMA
Physician Management, Inc.
	  	100%
	 Louisburg
H.M.A, LLC
	  	100%
	 Louisburg HMA
Physician Management, LLC
	  	100%
	 Louisburg PPM,
LLC
	  	100%
	 Madison
HMA,LLC
	  	100%
	 Madison HMA
Physician Management, LLC
	  	100%
	 Marathon
H.M.A., LLC
	  	100%
	 Marathon HMA
Medical Group, LLC
	  	100%
	 Marshall
County HMA, LLC
	  	100%
	 Marshall
County HMPN, LLC
	  	100%
	 Mayes County
HMA, LLC
	  	100%
	 Mayes County
HMA Home Health, LLC
	  	100%
	 Mayes County
HMPN, LLC
	  	100%
	 Melbourne HMA,
LLC
	  	100%
	 Melbourne HMA
Medical Group, LLC
	  	100%
	 Meridian HMA
Clinic Management, LLC
	  	100%
	 Meridian HMA,
LLC
	  	100%
	 Meridian HMA
Nursing Home, LLC
	  	100%
	 Mesquite HMA
General, LLC
	  	100%
	 Metro
Knoxville HMA, LLC
	  	100%
	 Midwest City
HMA Physician Management, LLC
	  	100%
	 Midwest HMA
Home Health, LLC
	  	100%
	 Midwest
Regional Medical Center, LLC
	  	98.60%
	 Mississippi
Health Management Medical Education Fund, LLC
	  	100%
	 Mississippi
HMA DME, LLC
	  	100%
	 Mississippi
HMA Holdings I, LLC
	  	99%
	 Mississippi
HMA Holdings II, LLC
	  	99%
	 Mississippi
HMA Hospitalists, LLC
	  	100%
	 Mississippi
HMA Regional Service Center, LLC
	  	100%
	 Mississippi
HMA Urgent Care, LLC
	  	100%
	 Mississippi
HMA Ventures, LLC
	  	100%
	 Monroe
Diagnostic Testing Centers, LLC
	  	100%
	 Monroe HMA,
LLC
	  	100%
	 Monroe HMA
Physician Management, LLC
	  	100%
	 Mooresville
HMA Investors, LLC
	  	98.63%
	 Mooresville
HMA Physician Management, LLC
	  	100%
	 Mooresville
Hospital Management Associates, LLC
	  	100%

  
 60 

			
	 Mooresville PPM, LLC
	  	100%
	 Munroe HMA
HMPN, LLC
	  	100%
	 Munroe HMA
Holdings, LLC
	  	100%
	 Munroe HMA
Hospital, LLC
	  	100%
	 Munroe HMA
Investments, LLC
	  	100%
	 Munroe HMA
Physician Health Partners, LLC
	  	100%
	 Naples HMA,
LLC
	  	100%
	 Natchez
Community Hospital, LLC
	  	83%
	 Natchez HMA
Physician Management, LLC
	  	100%
	 North Carolina
HMA Regional Service Center, LLC
	  	100%
	 North Port
HMA, LLC
	  	100%
	 Oklahoma HMA
Urgent Care, LLC
	  	100%
	 OsceolaSC,
LLC
	  	80%
	 Osler HMA
Medical Group, LLC
	  	100%
	 Oviedo HMA,
LLC
	  	100%
	 Paintsville
HMA Physician Management, LLC
	  	100%
	 Paintsville
Hospital Company, LLC
	  	97.02%
	 Pasco Hernando
HMA Physician Management, LLC
	  	100%
	 Pasco Regional
Medical Center, LLC
	  	90.81%
	 PBEC HMA,
Inc.
	  	100%
	 Peace River
HMA Nursing Center, LLC
	  	100%
	 Personal Home
Health Care, LLC
	  	100%
	 Physicians
Regional Marco Island, LLC
	  	100%
	 Poinciana HMA,
LLC
	  	100%
	 Poplar Bluff
Regional Medical Center, LLC
	  	100%
	 Poplar Bluff
HMA Physician Management, LLC
	  	100%
	 Port Charlotte
HMA, LLC
	  	100%
	 Port Charlotte
HMA Physician Management, LLC
	  	100%
	 Preferred
Nurse Staffing, LLC
	  	100%
	 Punta Gorda
HMA, LLC
	  	100%
	 Punta Gorda
HMA Physician Management, LLC
	  	100%
	 Rankin
Cardiology Center, LLC
	  	100%
	 River Oaks
Hospital, LLC
	  	100%
	 River Oaks
Management Company, LLC
	  	100%
	 River Oaks
Medical Office Building, LLC
	  	100%
	 Riverpark
Community Cath Lab, LLC
	  	100%
	 Riverview
Regional Medical Center, LLC
	  	88.51%
	 Rockledge HMA,
LLC
	  	100%
	 Rockledge HMA
Convenient Care, LLC
	  	100%
	 Rockledge HMA
Medical Group, LLC
	  	100%
	 Rockledge HMA
Urgent Care, LLC
	  	100%
	 ROH,
LLC
	  	100%
	 Rose City HMA,
LLC
	  	89.90%
	 Rose City HMA
Medical Group, LLC
	  	100%
	 Santa Rosa HMA
Physician Management, LLC
	  	100%

  
 61 

			
	 Santa Rosa HMA Urgent Care, LLC
	  	100%
	 Scott County
HMA, LLC
	  	100%
	 Sebastian HMA
Physician Management, LLC
	  	100%
	 Sebastian
Hospital, LLC
	  	100%
	 Sebring HMA
Physician Management, LLC
	  	100%
	 Sebring
Hospital Management Associates, LLC
	  	100%
	 Seminole HMA,
LLC
	  	100%
	 Seminole HMPN,
LLC
	  	100%
	 Southeast HMA
Holdings, LLC
	  	99%
	 Southwest
Florida HMA Holdings, LLC
	  	99%
	 Southwest
Physicians Risk Retention Group, Inc.
	  	51%
	 Sparks
PremierCare, L.L.C.
	  	100%
	 Spring Hill
HMA Medical Group, LLC
	  	100%
	 Spring Hill
HMA Physician Management, LLC
	  	100%
	 St. Cloud HMA
Physician Management, LLC
	  	100%
	 St. Cloud
Physician Management, LLC
	  	100%
	 St.
Mary’s Ambulatory Surgery Center, LLC
	  	100%
	 Starke HMA,
LLC
	  	60%
	 Starke HMA
Medical Group, LLC
	  	100%
	 Statesboro HMA
Medical Group, LLC
	  	100%
	 Statesboro HMA
Physician Management, LLC
	  	100%
	 Statesville
HMA, LLC
	  	100%
	 Statesville
HMA Medical Group, LLC
	  	100%
	 Statesville
HMA Physician Management, LLC
	  	100%
	 Statesville
PPM, LLC
	  	100%
	 Sumter HMA,
LLC
	  	100%
	 Surgery Center
of Midwest City, LLC
	  	65.7680%
	 Tennessee HMA
Holdings, LP
	  	99%
	 Tennessee HMA
Regional Service Center, LLC
	  	100%
	 The Surgery
Center, LLC
	  	100%
	 The Surgery
Center at Durant, LLC
	  	100%
	 Tullahoma HMA,
LLC
	  	94.27%
	 Tullahoma HMA
Leasing, LLC
	  	100%
	 Tullahoma HMA
Physician Management, LLC
	  	100%
	 Van Buren
H.M.A., LLC
	  	100%
	 Van Buren HMA
Central Business Office, LLC
	  	100%
	 Venice HMA,
LLC
	  	100%
	 Vicksburg HMA
Physician Management, LLC
	  	100%
	 Wauchula HMA
Physician Management, LLC
	  	100%
	 Williamson HMA
Physician Management, LLC
	  	100%
	 Williamson
Memorial Hospital, LLC
	  	95.84%
	 Winder HMA,
LLC
	  	100%
	 Women’s
Health Specialists of Carlisle, LLC
	  	100%
	 Yakima HMA,
LLC
	  	100%
	 Yakima HMA
Home Health, LLC
	  	100%
	 Yakima HMA
Physician Management, LLC
	  	100%

  
 62 

 Schedules 3.19(a) 

UCC Filing Offices 
  

							
	  	  	Entity Name	 	
Jurisdiction
 of

Formation
	  	Filing Office
	1.	  	Centre Hospital Corporation	 	Alabama	  	Secretary of State of the State of Alabama
	2.	  	Foley Hospital Corporation	 	Alabama	  	Secretary of State of the State of Alabama
	3.	  	Fort Payne Hospital Corporation	 	Alabama	  	Secretary of State of the State of Alabama
	4.	  	Greenville Hospital Corporation	 	Alabama	  	Secretary of State of the State of Alabama
	5.	  	QHG of Enterprise, Inc.	 	Alabama	  	Secretary of State of the State of Alabama
	6.	  	Bullhead City Hospital Corporation	 	Arizona	  	Secretary of State of the State of Arizona
	7.	  	Payson Hospital Corporation	 	Arizona	  	Secretary of State of the State of Arizona
	8.	  	Forrest City Arkansas Hospital Company, LLC	 	Arkansas	  	Secretary of State of the State of Arkansas
	9.	  	Forrest City Hospital Corporation	 	Arkansas	  	Secretary of State of the State of Arkansas
	10.	  	MCSA, L.L.C.	 	Arkansas	  	Secretary of State of the State of Arkansas
	11.	  	Phillips Hospital Corporation	 	Arkansas	  	Secretary of State of the State of Arkansas
	12.	  	QHG of Springdale, Inc.	 	Arkansas	  	Secretary of State of the State of Arkansas
	13.   	  	Triad-El Dorado, Inc.	 	Arkansas	  	Secretary of State of the State of Arkansas
	14.	  	Abilene Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	15.	  	Abilene Merger, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	16.	  	Affinity Health Systems, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	17.	  	Affinity Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	18.	  	Berwick Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	19.	  	Birmingham Holdings II, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	20.	  	Birmingham Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	21.	  	Blue Island Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	22.	  	Blue Island Illinois Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	23.	  	Bluefield Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	24.	  	Bluefield Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	25.	  	Bluffton Health System LLC	 	Delaware	  	Secretary of State of the State of Delaware
	26.	  	Brownwood Hospital, L.P.	 	Delaware	  	Secretary of State of the State of Delaware
	27.	  	Brownwood Medical Center, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	28.	  	Bullhead City Hospital Investment Corporation	 	Delaware	  	Secretary of State of the State of Delaware
	29.	  	Carlsbad Medical Center, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	30.	  	CHS/Community Health Systems, Inc.	 	Delaware	  	Secretary of State of the State of Delaware
	31.	  	CHHS Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware

  
 63 

							
	32.	  	CHS Kentucky Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	33.	  	CHS Pennsylvania Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	34.	  	CHS Virginia Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	35.	  	CHS Washington Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	36.	  	Clarksville Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	37.	  	Clarksville Holdings II, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	38.	  	Cleveland Tennessee Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	39.	  	College Station Hospital, L.P.	 	Delaware	  	Secretary of State of the State of Delaware
	40.	  	College Station Medical Center, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	41.	  	College Station Merger, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	42.	  	Community GP Corp.	 	Delaware	  	Secretary of State of the State of Delaware
	43.	  	Community Health Investment Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	44.	  	Community Health Systems, Inc.	 	Delaware	  	Secretary of State of the State of Delaware
	45.	  	Community LP Corp.	 	Delaware	  	Secretary of State of the State of Delaware
	46.	  	CP Hospital GP, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	47.	  	CPLP, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	48.	  	Crestwood Hospital LP, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	49.	  	Crestwood Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	50.	  	CSMC, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	51.	  	CSRA Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	52.	  	Deaconess Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	53.	  	Deaconess Hospital Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	54.	  	Desert Hospital Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	55.	  	Detar Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	56.	  	DHFW Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	57.	  	DHSC, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	58.	  	Dukes Health System, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	59.	  	Fallbrook Hospital Corporation	 	Delaware	  	Secretary of State of the State of Delaware
	60.	  	Gadsden Regional Medical Center, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	61.	  	GRMC Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	62.	  	Hallmark Healthcare Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	63.	  	Hobbs Medco, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	64.	  	Hospital of Barstow, Inc.	 	Delaware	  	Secretary of State of the State of Delaware
	65.	  	Kirksville Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	66.   	  	Lancaster Hospital Corporation	 	Delaware	  	Secretary of State of the State of Delaware
	67.	  	Las Cruces Medical Center, LLC	 	Delaware	  	Secretary of State of the State of Delaware

  
 64 

							
	68.	  	Lea Regional Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	69.	  	Longview Clinic Operations Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	70.	  	Longview Medical Center, L.P.	 	Delaware	  	Secretary of State of the State of Delaware
	71.	  	Longview Merger, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	72.	  	LRH, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	73.	  	Lutheran Health Network of Indiana, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	74.	  	Massillon Community Health System LLC	 	Delaware	  	Secretary of State of the State of Delaware
	75.	  	Massillon Health System LLC	 	Delaware	  	Secretary of State of the State of Delaware
	76.	  	Massillon Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	77.	  	McKenzie Tennessee Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	78.	  	Medical Center of Brownwood, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	79.	  	Merger Legacy Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	80.	  	MMC of Nevada, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	81.	  	Moberly Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	82.	  	MWMC Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	83.	  	Nanticoke Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	84.	  	National Healthcare of Leesville, Inc.	 	Delaware	  	Secretary of State of the State of Delaware
	85.	  	National Healthcare of Mt. Vernon, Inc.	 	Delaware	  	Secretary of State of the State of Delaware
	86.	  	National Healthcare of Newport, Inc.	 	Delaware	  	Secretary of State of the State of Delaware
	87.	  	Navarro Hospital, L.P.	 	Delaware	  	Secretary of State of the State of Delaware
	88.	  	Navarro Regional, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	89.	  	Northampton Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	90.	  	Northwest Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	91.	  	Northwest Arkansas Hospitals, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	92.	  	NOV Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	93.	  	NRH, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	94.	  	Oro Valley Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	95.	  	Palmer-Wasilla Health System, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	96.	  	Peckville Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	97.	  	Pennsylvania Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	98.	  	Phoenixville Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	99.	  	Pottstown Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	100. 	  	QHG Georgia Holdings II, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	101.	  	QHG of Bluffton Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	102.	  	QHG of Fort Wayne Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	103.	  	QHG of Warsaw Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	104.	  	Quorum Health Resources, LLC	 	Delaware	  	Secretary of State of the State of Delaware

  
 65 

							
	105.	  	Regional Hospital of Longview, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	106.	  	Ruston Hospital Corporation	 	Delaware	  	Secretary of State of the State of Delaware
	107.	  	Ruston Louisiana Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	108.	  	SACMC, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	109.	  	San Angelo Community Medical Center, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	110.	  	San Angelo Medical, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	111.	  	Scranton Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	112.	  	Scranton Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	113.	  	Scranton Quincy Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	114.	  	Scranton Quincy Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	115.	  	Siloam Springs Arkansas Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	116.	  	Siloam Springs Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	117.	  	Southern Texas Medical Center, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	118.	  	Spokane Valley Washington Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	119. 	  	Spokane Washington Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	120.	  	Tennyson Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	121.	  	Tomball Texas Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	122.	  	Tomball Texas Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	123.	  	Triad Healthcare Corporation	 	Delaware	  	Secretary of State of the State of Delaware
	124.	  	Triad Holdings III, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	125.	  	Triad Holdings IV, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	126.	  	Triad Holdings V, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	127.	  	Triad Nevada Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	128.	  	Triad of Alabama, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	129.	  	Triad of Oregon, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	130.	  	Triad-ARMC, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	131.	  	Triad-Navarro Regional Hospital Subsidiary, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	132.	  	Tunkhannock Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	133.	  	VHC Medical, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	134.	  	Vicksburg Healthcare, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	135.	  	Victoria Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	136.	  	Victoria of Texas, L.P.	 	Delaware	  	Secretary of State of the State of Delaware
	137.	  	Warren Ohio Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	138.	  	Warren Ohio Rehab Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware

  
 66 

							
	139. 	  	Watsonville Hospital Corporation	 	Delaware	  	Secretary of State of the State of Delaware
	140.	  	Webb Hospital Corporation	 	Delaware	  	Secretary of State of the State of Delaware
	141.	  	Webb Hospital Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	142.	  	Wesley Health System LLC	 	Delaware	  	Secretary of State of the State of Delaware
	143.	  	West Grove Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	144.	  	WHMC, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	145.	  	Wilkes-Barre Behavioral Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	146.	  	Wilkes-Barre Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	147.	  	Wilkes-Barre Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	148.	  	Women & Children’s Hospital, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	149.	  	Woodland Heights Medical Center, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	150.	  	Woodward Health System, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	151.	  	York Pennsylvania Holdings, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	152.	  	Youngstown Ohio Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	153.	  	York Pennsylvania Hospital Company, LLC	 	Delaware	  	Secretary of State of the State of Delaware
	154.	  	QHG Georgia Holdings, Inc.	 	Georgia	  	Office of the Clerk of any Superior Court
	155.	  	QHG Georgia, LP	 	Georgia	  	Office of the Clerk of any Superior Court
	156.	  	Anna Hospital Corporation	 	Illinois	  	Secretary of State of the State of Illinois
	157.	  	Galesburg Hospital Corporation	 	Illinois	  	Secretary of State of the State of Illinois
	158.	  	Granite City Hospital Corporation	 	Illinois	  	Secretary of State of the State of Illinois
	159.	  	Granite City Illinois Hospital Company, LLC	 	Illinois	  	Secretary of State of the State of Illinois
	160.	  	Marion Hospital Corporation	 	Illinois	  	Secretary of State of the State of Illinois
	161.	  	Red Bud Hospital Corporation	 	Illinois	  	Secretary of State of the State of Illinois
	162.	  	Red Bud Illinois Hospital Company, LLC	 	Illinois	  	Secretary of State of the State of Illinois
	163.	  	Waukegan Hospital Corporation	 	Illinois	  	Secretary of State of the State of Illinois
	164.	  	Waukegan Illinois Hospital Company, LLC	 	Illinois	  	Secretary of State of the State of Illinois
	165.	  	Frankfort Health Partner, Inc.	 	Indiana	  	Secretary of State of the State of Indiana
	166.	  	QHG of Clinton County, Inc.	 	Indiana	  	Secretary of State of the State of Indiana
	167.	  	Hospital of Fulton, Inc.	 	Kentucky	  	Secretary of State of the State of Kentucky
	168.	  	Hospital of Louisa, Inc.	 	Kentucky	  	Secretary of State of the State of Kentucky
	169.	  	Jackson Hospital Corporation	 	Kentucky	  	Secretary of State of the State of Kentucky
	170.	  	QHG of Forrest County, Inc.	 	Mississippi	  	Secretary of State of the State of Mississippi
	171.	  	QHG of Hattiesburg, Inc.	 	Mississippi	  	Secretary of State of the State of Mississippi
	172.	  	River Region Medical Corporation	 	Mississippi	  	Secretary of State of the State of Mississippi
	173.	  	NC-DSH, LLC	 	Nevada	  	Secretary of State of the State of Nevada

  
 67 

							
	174. 	  	Salem Hospital Corporation	 	New Jersey	  	New Jersey Department of Treasury/Division of Revenue
	175.	  	Deming Hospital Corporation	 	New Mexico	  	Secretary of State of the State of New Mexico
	176.	  	Roswell Hospital Corporation	 	New Mexico	  	Secretary of State of the State of New Mexico
	177.	  	San Miguel Hospital Corporation	 	New Mexico	  	Secretary of State of the State of New Mexico
	178.	  	Williamston Hospital Corporation	 	North Carolina	  	Secretary of State of the State of North Carolina
	179.	  	QHG of Massillon, Inc.	 	Ohio	  	Secretary of State of the State of Ohio
	180.	  	Kay County Hospital Corporation	 	Oklahoma	  	Secretary of State of the State of Oklahoma
	181.	  	Kay County Oklahoma Hospital Company, LLC	 	Oklahoma	  	Secretary of State of the State of Oklahoma
	182.	  	Clinton Hospital Corporation	 	Pennsylvania 	  	Secretary of the Commonwealth
	183.	  	Coatesville Hospital Corporation	 	Pennsylvania 	  	Secretary of the Commonwealth
	184.	  	QHG of South Carolina, Inc.	 	South Carolina	  	Secretary of State of the State of South Carolina
	185.	  	QHG of Spartanburg, Inc.	 	South Carolina	  	Secretary of State of the State of South Carolina
	186.	  	Brownsville Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	187.	  	Cleveland Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	188.	  	Dyersburg Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	189.	  	Hospital of Morristown, Inc.	 	Tennessee	  	Secretary of State of the State of Tennessee
	190.	  	Jackson Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	191.	  	Lakeway Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	192.	  	Lexington Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	193.	  	Martin Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	194.	  	McNairy Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	195.	  	Shelbyville Hospital Corporation	 	Tennessee	  	Secretary of State of the State of Tennessee
	196.	  	Big Bend Hospital Corporation	 	Texas	  	Secretary of State of the State of Texas
	197.	  	Big Spring Hospital Corporation	 	Texas	  	Secretary of State of the State of Texas
	198.	  	Granbury Hospital Corporation	 	Texas	  	Secretary of State of the State of Texas
	199.	  	Jourdanton Hospital Corporation	 	Texas	  	Secretary of State of the State of Texas
	200.	  	Weatherford Hospital Corporation	 	Texas	  	Secretary of State of the State of Texas
	201.	  	Weatherford Texas Hospital Company, LLC	 	Texas	  	Secretary of State of the State of Texas
	202.	  	Tooele Hospital Corporation	 	Utah	  	Division of Corporations and Commercial Code
	203.	  	Emporia Hospital Corporation	 	Virginia	  	State Corporation Commission
	204.	  	Franklin Hospital Corporation	 	Virginia	  	State Corporation Commission
	205.	  	Virginia Hospital Company, LLC	 	Virginia	  	State Corporation Commission
	206.	  	Oak Hill Hospital Corporation	 	West Virginia	  	Secretary of State of the State of West Virginia
	207.	  	Evanston Hospital Corporation	 	Wyoming	  	Secretary of State of the State of Wyoming

  
 68 

 HMA Entities: 
  

							
	1.	  	 Fort Smith HMA,
LLC
  
	 	 Arkansas

 
	  	 Secretary of State
of the State of Arkansas
  

	2.	  	 VAN BUREN H.M.A., LLC
	 	Arkansas	  	Secretary of State of the State of Arkansas
	3.	  	 Carolinas JV Holdings General, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	4.	  	 Carolinas JV Holdings, L.P.
	 	Delaware	  	Secretary of State of the State of Delaware
	5.	  	 Central Florida HMA Holdings, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	6.	  	 Central States HMA Holdings, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	7.	  	 Florida HMA Holdings, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	8.	  	 Health Management Associates, Inc.
	 	Delaware	  	Secretary of State of the State of Delaware
	9.	  	 Health Management Associates, LP
	 	Delaware	  	Secretary of State of the State of Delaware
	10.	  	 Health Management General Partner, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	11.	  	 HMA Hospitals Holdings, LP
	 	Delaware	  	Secretary of State of the State of Delaware
	12.   	  	 Lone Star HMA, L.P.
	 	Delaware	  	Secretary of State of the State of Delaware
	13.	  	 Mesquite HMA General, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	14.	  	 Mississippi HMA Holdings I, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	15.	  	 Mississippi HMA Holdings II, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	16.	  	 Southeast HMA Holdings, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	17.	  	 Southwest Florida HMA Holdings, LLC
	 	Delaware	  	Secretary of State of the State of Delaware
	18.	  	 Bartow HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	19.	  	 Brevard HMA Holdings, LLC
	 	Florida	  	Secretary of State of the State of Florida
	20.	  	 Brevard HMA Hospitals, LLC
	 	Florida	  	Secretary of State of the State of Florida
	21.	  	 Citrus HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	22.	  	 HMA Santa Rosa Medical Center, LLC
	 	Florida	  	Secretary of State of the State of Florida
	23.	  	 Hospital Management Associates, LLC
	 	Florida	  	Secretary of State of the State of Florida
	24.	  	 Key West HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	25.	  	 Lehigh HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	26.	  	 Melbourne HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	27.	  	 Naples HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	28.	  	 Port Charlotte HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	29.	  	 Punta Gorda HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	30.	  	 Rockledge HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	31.	  	 Sebastian Hospital, LLC
	 	Florida	  	Secretary of State of the State of Florida
	32.	  	 Sebring Hospital Management Associates,
LLC  
	 	Florida	  	Secretary of State of the State of Florida
	33.	  	 Venice HMA, LLC
	 	Florida	  	Secretary of State of the State of Florida
	34.	  	 Monroe HMA, LLC
	 	Georgia	  	Office of the Clerk of any Superior Court
	35.	  	 Winder HMA, LLC
	 	Georgia	  	Office of the Clerk of any Superior Court
	36.	  	 Amory HMA, LLC
	 	Mississippi	  	Secretary of State of the State of Mississippi

  
 69 

							
	37.	  	 Biloxi H.M.A., LLC
	 	Mississippi	  	Secretary of State of the State of Mississippi
	38.	  	 Brandon HMA, LLC
	 	Mississippi	  	Secretary of State of the State of Mississippi
	39.	  	 Clarksdale HMA, LLC
	 	Mississippi	  	Secretary of State of the State of Mississippi
	40.	  	 Jackson HMA, LLC
	 	Mississippi	  	Secretary of State of the State of Mississippi
	41.	  	 Madison HMA, LLC
	 	Mississippi	  	Secretary of State of the State of Mississippi
	42.	  	 River Oaks Hospital, LLC
	 	Mississippi	  	Secretary of State of the State of Mississippi
	43.	  	 ROH, LLC
	 	Mississippi	  	Secretary of State of the State of Mississippi
	44.	  	 Kennett HMA, LLC
	 	Missouri	  	Secretary of State of the State of Missouri
	45.	  	 Poplar Bluff Regional Medical Center, LLC
	 	Missouri	  	Secretary of State of the State of Missouri
	46.	  	 Hamlet H.M.A., LLC
	 	North Carolina	  	Secretary of State of the State of North Carolina
	47.	  	 Statesville HMA, LLC
	 	North Carolina	  	Secretary of State of the State of North Carolina
	48.	  	 Carlisle HMA, LLC
	 	Pennsylvania	  	Secretary of the Commonwealth
	49.	  	 Chester HMA, LLC
	 	South Carolina	  	Secretary of State of the State of South Carolina
	50.	  	 Campbell County HMA, LLC
	 	Tennessee	  	Secretary of State of the State of Tennessee
	51.   	  	 Cocke County HMA, LLC
	 	Tennessee	  	Secretary of State of the State of Tennessee
	52.	  	 HMA Fentress County General Hospital, LLC
	 	Tennessee	  	Secretary of State of the State of Tennessee
	53.	  	 Jefferson County HMA, LLC
	 	Tennessee	  	Secretary of State of the State of Tennessee
	54.	  	 Knoxville HMA Holdings, LLC
	 	Tennessee	  	Secretary of State of the State of Tennessee
	55.	  	 Metro Knoxville HMA, LLC
	 	Tennessee	  	Secretary of State of the State of Tennessee
	56.	  	 Yakima HMA, LLC
	 	Washington	  	Secretary of State of the State of Washington

  
 70 

 Schedule 6.01 

Existing Indebtedness 
 Please also see
Schedule 1.01(a) 
 CHS Miscellaneous Debt: 

					
	 	 	 	 	        $ amounts in        
    thousands    
	 Fannin RH - Blue Ridge, GA 0102
	 	 Pump station	 	    123    
	 Carolina Surg Cntr - Lancaster, SC 0408
	 	 First Citizens Bank	 	    2410    
	 San Angelo Comm MC - San Angelo, TX 1574
	 		 	    95    
	 Tomball ASC-Tomball, TX  3775
	 	 Const Loan - Woodforest Bk	 	    2885    
	 Tomball ASC-Tomball, TX  3775
	 	 Equip Loan - Woodforest Bk	 	    364    
		 		 	  

		 	 TOTAL	 	    5877    

 CHS Capital Leases: 

							
	 	  	 	  	$ amounts in
thousands	 
	 Hill Regional - Hillsboro, TX 0134
	  	capital lease	  	 	7,383	  
	 Scenic Mountn - Big Spring, TX 0135
	  	capital lease	  	 	0	  
	 Brandywine Hosp - Coatesville, PA 0167
	  	capital lease	  	 	9,315	  
	 Jennersville - West Grove, PA 0170
	  	capital lease	  	 	116	  
	 Southside RMC - Petersburg, VA 0188
	  	capital lease	  	 	6,915	  
	 Chestnut Hill - Philadelphia, PA 0191
	  	capital lease	  	 	241	  
	 Carolina Surg Cntr - Lancaster, SC 0408
	  	capital lease	  	 	534	  
	 Evanston Clinic Corp - Evanston, WY 0659
	  	capital lease	  	 	0	  
	 Village MC Assoc - Coatsville, PA 0767
	  	capital lease	  	 	0	  
	 Deaconess MC - Spokane, WA 1501
	  	capital lease	  	 	5,709	  
	 Wlks-Brr Hosp Co - Wilkes-Barre, PA 1507
	  	capital lease	  	 	141	  
	 Nrthwest Med Cntr - Bentonville, AR 1516
	  	capital lease	  	 	15	  
	 Carolinas Hospital System - Marion      1523
	  	capital lease	  	 	48	  
	 Lutheran Hospital - Ft. Wayne, IN 1525
	  	capital lease	  	 	0	  
	 Memorial Hospital - York, PA 1538
	  	capital lease	  	 	798	  
	 St. Joseph Hosp - Fort Wayne, IN 1545
	  	capital lease	  	 	0	  
	 MCSA, LLC - El Dorado, AR 1548
	  	capital lease	  	 	22	  
	 Northwest MC - Springdale, AR 1550
	  	capital lease	  	 	21	  
	 Dupont Hospital - Ft Wayne, IN 1554
	  	capital lease	  	 	4	  
	 Bluefield RMC - Bluefield, WV  1558
	  	capital lease	  	 	7	  
	 Metro South Med Center-Blue Island, IL
	  	capital lease	  	 	286	  
	 Brownwood RMC - Brownwood, TX 1570
	  	capital lease	  	 	197	  
	 Affinity Hosp, LLC - Birmingham, AL 1583
	  	capital lease	  	 	4,934	  
	 Carlsbad MC - Carlsbad, NM 1589
	  	capital lease	  	 	111	  
	 Carolinas Hosp Sys - Florence, SC 1595
	  	capital lease	  	 	285	  
	 Reg Hosp of Scranton-Scranton, PA  1640
	  	capital lease	  	 	303	  
	 Tyler Mem Hosp-Tunkhannock, PA  1685
	  	capital lease	  	 	22	  
	 Woodward Reg Hosp - Woodward, OK 1712
	  	capital lease	  	 	5,601	  

  
 71 

							
	 Moses Taylor Hospital-Scranton, PA
	  	capital lease	  	 	680   	  
	 Mid Valley Hospital-Peckville, PA
	  	capital lease	  	 	0   	  
	 LMG - BMA - Ft Wayne, IN  6025
	  	capital lease	  	 	9   	  
	 Lutheran Medical Grp - Ft.Wayne, IN 6225
	  	capital lease	  	 	0   	  
	 Brownwood Clinic Ops - Brownwood, TX 6270
	  	capital lease	  	 	23   	  
	 Dcnss Phys Clnc - Oklahoma City, OK 6568
	  	capital lease	  	 	88   	  
	 Moses Taylor Clinic Co-Scranton, PA
	  	capital lease	  	 	68   	  
	 Longview Clinic Ops-Longview, TX 6968
	  	capital lease	  	 	49   	  
	 QHR - Plano, TX 8417
	  	capital lease	  	 	12   	  
		  	TOTAL CAP LEASES	  	 	43,941   	  

 CHS Physician Loans: 

					
	 	  	 	  	$ amounts
  in thousands
	 Fannin RH - Blue Ridge, GA 0102
	  	Physician Loan	  	33
	 Weatherford RMC - Weatherford, TX 0104
	  	Physician Loan	  	32
	 Lakeway RH - Morristown, TN 0116
	  	Physician Loan	  	42
	 Moberly RMC - Moberly, MO 0118
	  	Physician Loan	  	26
	 N Louisiana MC - Ruston, LA 0126
	  	Physician Loan	  	0
	 Hill Regional - Hillsboro, TX 0134
	  	Physician Loan	  	17
	 Porter Hosp - Valparaiso, IN 0137
	  	Physician Loan	  	0
	 Springs Mem - Lancaster, SC 0138
	  	Physician Loan	  	30
	 North Okaloosa - Crestview, FL 0141
	  	Physician Loan	  	88
	 Heartland RMC - Marion, IL 0143
	  	Physician Loan	  	90
	 Watsonville CH - Watsonville, CA 0152
	  	Physician Loan	  	65
	 Fallbrook Hosp - Fallbrook, CA 0153
	  	Physician Loan	  	15
	 Martin General - Williamston, NC 0154
	  	Physician Loan	  	34
	 Berwick HC - Berwick, PA 0155
	  	Physician Loan	  	14
	 W Arizona RMC - Bullhead City, AZ 0163
	  	Physician Loan	  	0
	 S Baldwin RMC - Foley, AL 0164
	  	Physician Loan	  	80
	 Northeast RMC - Kirksville, MO 0166
	  	Physician Loan	  	25
	 Brandywine Hosp - Coatesville, PA 0167
	  	Physician Loan	  	0
	 Easton Hosp - Easton, PA 0169
	  	Physician Loan	  	20
	 Jennersville - West Grove, PA 0170
	  	Physician Loan	  	0
	 Phoenixville - Phoenixville, PA 0177
	  	Physician Loan	  	18
	 Lake Wales MC - Lake Wales, FL 0178
	  	Physician Loan	  	53
	 McKenzie RH - McKenzie, TN 0182
	  	Physician Loan	  	47
	 Volunteer CH - Martin, TN 0184
	  	Physician Loan	  	69
	 Haywood Park - Brownsville, TN 0185
	  	Physician Loan	  	0
	 Pottstown Mem - Pottstown, PA 0187
	  	Physician Loan	  	51
	 Southside RMC - Petersburg, VA 0188
	  	Physician Loan	  	165
	 Laredo MC - Laredo, TX 0189
	  	Physician Loan	  	132
	 Galesburg Cot - Galesburg, IL 0190
	  	Physician Loan	  	0
	 Chestnut Hill - Philadelphia, PA 0191
	  	Physician Loan	  	59

  
 72 

					
	 Heritage MC - Shelbyville, TN 0192
	  	Physician Loan	  	274
	 SkyRidge MC - Cleveland, TN 0193
	  	Physician Loan	  	71
	 DeKalb RMC - Fort Payne, AL 0198
	  	Physician Loan	  	67
	 Clinic Comp, LLC - Pottstown, PA 0787
	  	Physician Loan	  	25
	 Deaconess MC - Spokane, WA 1501
	  	Physician Loan	  	0
	 Wlks-Brr Hosp Co - Wilkes-Barre, PA 1507
	  	Physician Loan	  	88
	 Memorial Hosp - Siloam Springs, AR 1511
	  	Physician Loan	  	27
	 Affinity Med Ctr - Massillion, OH 0153
	  	Physician Loan	  	90
	 Nrthwest Med Cntr - Bentonville, AR 1516
	  	Physician Loan	  	0
	 Cedar Prk RMC (JV) - Cedar Park, TX 1521
	  	Physician Loan	  	8
	 Lutheran Hospital - Ft. Wayne, IN 1525
	  	Physician Loan	  	25
	 Oro Valley Hosp - Oro Valley, AZ 1528
	  	Physician Loan	  	14
	 Augusta Hosp, LLC - Augusta, GA 1536
	  	Physician Loan	  	0
	 Gateway MC - Clarksville, TN 1553
	  	Physician Loan	  	0
	 Dupont Hospital - Ft Wayne, IN 1554
	  	Physician Loan	  	230
	 Kosciusko Comm Hospital - Warsaw, IN
	  	Physician Loan	  	0
	 Bluefield RMC - Bluefield, WV  1558
	  	Physician Loan	  	0
	 Deaconess Hosp - Oklahoma City, OK 1568
	  	Physician Loan	  	0
	 Brownwood RMC - Brownwood, TX 1570
	  	Physician Loan	  	42
	 Flowers Hospital - Dothan, AL 1572
	  	Physician Loan	  	249
	 San Angelo Comm MC - San Angelo, TX 1574
	  	Physician Loan	  	33
	 Affinity Hosp, LLC - Birmingham, AL 1583
	  	Physician Loan	  	67
	 Crestwood Hsp, LLC - Huntsville, AL 1584
	  	Physician Loan	  	195
	 Gadsden RMC - Gadsden, AL 1585
	  	Physician Loan	  	272
	 QHG of Entrprs INC - Enterprise, AL 1590
	  	Physician Loan	  	166
	 Wmn & Chldns Hsp - Lake Charles, LA 1604
	  	Physician Loan	  	0
	 Mry Blck Hlth Sys - Spartanburg, SC 1606
	  	Physician Loan	  	60
	 Detar Hospital - Victoria, TX 1611
	  	Physician Loan	  	211
	 DBA Woodland Hghts MC - Lufkin, TX 1626
	  	Physician Loan	  	14
	 Abilene RMC - Abilene, TX 1628
	  	Physician Loan	  	120
	 Reg Hosp of Scranton-Scranton, PA  1640
	  	Physician Loan	  	72
	 MAT-SU RMC - Palmer, AK 1645
	  	Physician Loan	  	68
	 Trumbull Mem Hosp - Warren, OH  1655
	  	Physician Loan	  	47
	 McKnze-Wllmtte MC - Springfield, OR 1706
	  	Physician Loan	  	0
	 Northwest Hosp - Tucson, AZ 1730
	  	Physician Loan	  	14
	 Moses Taylor Hospital-Scranton, PA
	  	Physician Loan	  	150
	 Greenbrier Vlly MC - Ronceverte, WV 1878
	  	Physician Loan	  	371
	 Vlley Hsp & MC - Spokane Valley, WA 1911
	  	Physician Loan	  	0
	 Surgicare - Lake Charles, LA 3604
	  	Physician Loan	  	26
	 Abilene RMC - Abilene, TX  6328
	  	Physician Loan	  	0
	 Affnty Phys Svrvcs - Birmingham, AL 6583
	  	Physician Loan	  	0
		  	TOTAL PHYSICIAN LOANS	  	4301

 * Debt aggregated by major type per facility. 

  
 73 

       HMA Equipment Leases: 

 

									
	Location	  	Description	 	Amount	 	Lessor	 	End Date
	ANNISTON	  	PACS Storage	 	$139,522.00	 	Agfa	 	4/26/2017
	ANNISTON	  	PACS for Digital Mammography	 	$113,857.00	 	Agfa	 	5/24/2017
	CARLISLE	  	PACS Upgrade	 	$102,213.33	 	Agfa	 	 
	CRYSTAL RIVER	  	PACS Storage	 	$ 122,497.37	 	Agfa	 	11/21/2016
	DALLAS REGIONAL	  	 Cath/Echo Imaging

Software/Equipment
	 	$ 130,439.00	 	Agfa	 	6/20/2016
	GADSDEN	  	Cache	 	$ 133,997.00	 	AGFA	 	9/5/2018
	HARTSVILLE	  	Cache	 	$ 129,988.00	 	AGFA	 	 
	KEY WEST	  	PACS Storage	 	$ 132,284.00	 	Agfa	 	6/20/2017
	LANCASTER REG	  	PACS	 	$ 209,433.00	 	AGFA	 	 
	LANCASTER/ROSE CITY	  	Archive Upgrade EMC	 	$ 132,658.67	 	Agfa	 	2/11/2018
	LEBANON	  	Cache Disk Array	 	$ 122,497.37	 	Agfa	 	8/9/2016
	LEHIGH ACRES	  	MINI-PACS	 	$ 133,111.74	 	Agfa	 	5/31/2013
	LEHIGH ACRES	  	PACS	 	$ 205,819.30	 	Agfa	 	2/23/2014
	MONROE	  	PACS Storage	 	$ 89,466.67	 	Agfa	 	7/11/2016
	NAPLES - PR	  	Multi Cassette Processor	 	$ 137,386.59	 	Agfa	 	7/1/2017
	POPLAR BLUFF	  	CARDIOLOGY PACS SYSTEM	 	$ 304,007.48	 	AGFA	 	3/5/2015
	POPLAR BLUFF	  	Cache	 	$ 139,615.00	 	AGFA	 	4/26/2017
	POPLAR BLUFF	  	PACS	 	$ 240,635.11	 	AGFA	 	 
	PORT CHARLOTTE	  	DIGITAL MAMMOS	 	$ 64,030.00	 	AGFA	 	4/27/2015
	PT CHARLOTTE	  	Archive Upgrade-EMC	 	$ 132,658.67	 	AGFA	 	11/16/2017
	SEBRING	  	MAMMOGRAPHY SYSTEM	 	$ 114,750.00	 	AGFA	 	1/12/2016
	STATESBORO	  	Cache Disk Array	 	$ 151,702.00	 	AGFA	 	4/16/2017
	VENICE	  	PACS Storage	 	$ 129,898.00	 	Agfa	 	5/6/2016
	VENICE - Gulf Coast	  	CR CASSETTE AND PLATE	 	$ 70,941.00	 	AGFA	 	4/16/2015
	WINDER	  	PACS SYSTEM	 	$ 418,613.00	 	AGFA	 	6/2/2014
	WUESTHOFF - ROCKLEDGE	  	PACS Upgrade	 	$ 1,390,574.00	 	AGFA	 	9/9/2016
	WUESTHOFF - ROCKLEDGE	  	IMPAX Archive System	 	$ 323,418.00	 	Agfa	 	9/9/2016
	BROOKSVILLE	  	Cache Disk Array	 	$ 152,180.00	 	Agfa Finance	 	10/13/2016
	WUESTHOFF -MELBOURNE	  	 Nitrogen Generator (Q Trap

Agreement)
	 	$ 232,329.48	 	Applied Biosystems	 	2/28/2013

  
 74 

											
	WUESTHOFF - MELBOURNE	  	Automated System for PCR Testing	  	$ 148,320.00	  	B D Diagnostics	  	4/30/2012
	BARTOW	  	ENT NAVIGATION SYSTEM	  	$ 107,520.00	  	Bank of America	  	2/1/2015
	BARTOW	  	MAKO System	  	$ 937,501.00	  	Bank of America	  	7/1/2015
	BILOXI	  	Makoplasty Robot	  	$ 1,117,080.00	  	Bank of America	  	10/1/2015
	CARLISLE	  	LINEAR ACCELERATOR	  	$ 2,740,267.00	  	Bank of America	  	7/1/2015
	CORP -	  	Mako Surgical Robot (11)	  	$ 845,000.00	  	Bank of America	  	3/30/2016
	CORP -	  	Mako Surgical Robot (11)	  	$ 1,013,000.00	  	Bank of America	  	3/31/2016
	FLOWOOD	  	MAKO ROBOT	  	$ 850,000.00	  	Bank of America	  	12/30/2014
	FLOWOOD	  	Robot Hip Upgrade	  	$ 199,000.00	  	Bank of America	  	1/5/2015
	FORT SMITH	  	Image-Guided Radiotherapy System	  	$ 4,274,233.00	  	Bank of America	  	12/28/2016
	HARTSVILLE	  	HYPERBARIC CHAMBERS	  	$ 231,000.00	  	Bank of America	  	12/23/2014
	HARTSVILLE	  	DEFIBRILLATORS	  	$284,871.84	  	Bank of America	  	5/20/2015
	JACKSON	  	ALLURA XPER FD20 $ Intervent. Pat. Care	  	$ 995,469.00	  	Bank of America	  	 
	LEHIGH ACRES	 	HYPERBARIC CHAMBER	  	$231,000.00	  	Bank of America	  	12/23/2014
	MIDWEST CITY	 	LAPAROSCOPIC ARTHROSCOPIC SYSTEMS	  	$429,404.00	  	Bank of America	  	10/10/2012
	NAPLES - COLLIER	 	ROBOTIC ORTHO SYSTEM	  	$1,044,000.00	  	Bank of America	  	9/16/2016
	POPLAR BLUFF	 	MAKO System	  	$929,500.00	  	Bank of America	  	7/27/2015
	PORT CHARLOTTE	 	MAKO ROBOT	  	$845,000.00	  	Bank of America	  	11/1/2014
	VENICE	 	MAKO ROBOT	  	$850,000.00	  	Bank of America	  	12/30/2014
	WUESTHOFF - MELBOURNE	 	MAKO System	  	$633,750.00	  	Bank of America	  	7/1/2015
	WUESTHOFF - MELBOURNE	 	Mako HIP Application	  	$186,562.50	  	Bank of America	  	7/1/2015
	ANNISTON	 	SPECTRUM PUMPS	  	$567,000.00	  	Baxter	  	12/14/2015
	BARTOW	 	SPECTRUM PUMPS	  	$577,500.00	  	Baxter	  	 
	BILOXI	 	SPECTRUM PUMPS	  	$904,050.00	  	Baxter	  	12/19/2015
	BROOKSVILLE	 	SPECTRUM PUMPS	  	$673,750.00	  	Baxter	  	 
	CHESTER	 	SPECTRUM PUMPS	  	$245,700.00	  	Baxter	  	11/4/2015
	CLARKSDALE	 	SPECTRUM PUMPS	  	$820,050.00	  	Baxter	  	 
	DALLAS REGIONAL	 	SPECTRUM PUMPS	  	$567,000.00	  	Baxter	  	12/22/2015
	DURANT	 	SPECTRUM PUMPS	  	$510,300.00	  	Baxter	  	11/22/2015
	FLOWOOD	 	SPECTRUM PUMPS	  	$1,193,850.00	  	Baxter	  	12/9/2015
	GADSDEN	 	SPECTRUM PUMPS	  	$1,251,250.00	  	Baxter	  	 
	HAINES CITY	 	SPECTRUM PUMPS	  	$945,000.00	  	Baxter	  	11/22/2015

  
 75 

									
	HARTSVILLE	  	SPECTRUM PUMPS	 	$770,000.00	 	Baxter	 	 
	JAMESTOWN	  	SPECTRUM PUMPS	 	$252,000.00	 	Baxter	 	10/27/2015
	KEY WEST	  	SPECTRUM PUMPS	 	$384,300.00	 	Baxter	 	11/22/2015
	KEY WEST	  	SPECTRUM PUMPS	 	$94,500.00	 	Baxter	 	11/22/2015
	LANCASTER Heart o	  	SPECTRUM PUMPS	 	$378,000.00	 	Baxter	 	12/19/2015
	LANCASTER REG	  	SPECTRUM PUMPS	 	$806,400.00	 	Baxter	 	12/19/2015
	Madill	  	Spectrum Wireless Pumps 30	 	$115,500.00	 	Baxter	 	 
	MIDWEST CITY	  	SPECTRUM PUMPS	 	$1,102,500.00	 	Baxter	 	11/4/2015
	MILTON	  	SPECTRUM PUMPS	 	$371,700.00	 	Baxter	 	11/3/2015
	MONROE	  	SPECTRUM PUMPS	 	$305,550.00	 	Baxter	 	12/14/2015
	MONROE	  	15 Wiresless Spectrum Pumps w Battery	 	$57,750.00	 	Baxter	 	 
	MOORESVILLE	  	SPECTRUM PUMPS	 	$648,900.00	 	Baxter	 	11/30/2015
	NAPLES - COLLIER	  	SPECTRUM PUMPS	 	$368,550.00	 	Baxter	 	11/22/2015
	NAPLES - PR	  	SPECTRUM PUMPS	 	$617,250.00	 	Baxter	 	6/30/2015
	NAPLES - PR	  	SPECTRUM PUMPS	 	$63,000.00	 	Baxter	 	12/14/2015
	NATCHEZ	  	SPECTRUM PUMPS	 	$277,200.00	 	Baxter	 	12/2/2015
	NATCHEZ	  	SPECTRUM PUMPS	 	$69,300.00	 	Baxter	 	5/5/2016
	PAINTSVILLE	  	SPECTRUM PUMPS	 	$423,000.00	 	Baxter	 	 
	POPLAR BLUFF	  	SPECTRUM PUMPS	 	$1,102,500.00	 	Baxter	 	10/27/2015
	PORT CHARLOTTE	  	SPECTRUM PUMPS	 	$630,000.00	 	Baxter	 	11/22/2015
	PUNTA GORDA	  	SPECTRUM PUMPS	 	$1,347,500.00	 	Baxter	 	 
	SEBASTIAN	  	SPECTRUM PUMPS	 	$654,500.00	 	Baxter	 	 
	SEBRING	  	SPECTRUM PUMPS	 	$592,900.00	 	Baxter	 	 
	SHANDS LAKE SHORE	  	SPECTRUM PUMPS	 	$441,000.00	 	Baxter	 	11/3/2015
	SHANDS LIVE OAK	  	SPECTRUM PUMPS	 	$141,750.00	 	Baxter	 	11/3/2015
	SHANDS STARKE	  	SPECTRUM PUMPS	 	$157,500.00	 	Baxter	 	11/3/2015
	SPRING HILL	  	SPECTRUM PUMPS	 	$724,500.00	 	Baxter	 	11/4/2015
	ST CLOUD	  	SPECTRUM PUMPS	 	$315,000.00	 	Baxter	 	11/3/2015
	STATESBORO	  	SPECTRUM PUMPS	 	$664,650.00	 	Baxter	 	11/3/2015
	STATESVILLE	  	SPECTRUM PUMPS	 	$463,050.00	 	Baxter	 	12/2/2015
	TOPPENISH	  	SPECTRUM PUMPS	 	$189,000.00	 	Baxter	 	12/14/2015
	VAN BUREN	  	SPECTRUM PUMPS	 	$220,500.00	 	Baxter	 	11/22/2015
	VENICE	  	SPECTRUM PUMPS	 	$913,500.00	 	Baxter	 	12/22/2015
	WILLIAMSON	  	SPECTRUM PUMPS	 	$337,050.00	 	Baxter	 	12/9/2015

  
 76 

									
	WINDER	  	SPECTRUM PUMPS	 	$246,400.00	 	Baxter	 	 
	YAKIMA	  	SPECTRUM PUMPS	 	$945,000.00	 	Baxter	 	12/14/2015
	CANTON	  	SPECTRUM PUMPS	 	$173,250.00	 	Baxter	 	3/2/2016
	VAN BUREN	  	Updated Hematology Analyzer	 	$231,322.95	 	Baytree	 	1/18/2015
	MIDWEST CITY	  	SYSMEX XT-2000 RE	 	$110,300.00	 	Baytree Leasing	 	12/22/2013
	BILOXI	  	CHEMISTRY SYSTEMS	 	$564,865.00	 	Beckman Coulter	 	7/10/2014
	HARTSVILLE	  	Chemistry Analyzer	 	$93,603.00	 	Beckman Coulter	 	2/1/2014
	Knoxville PRMC	  	Coagulation System	 	$129,800.00	 	Beckman Coulter	 	12/21/2013
	Knoxville PRMC	  	Coagulation System	 	$64,900.00	 	Beckman Coulter	 	12/21/2013
	Knoxville PRMC	  	Coagulation System	 	 	 	Beckman Coulter	 	12/22/2013
	PUNTA GORDA	  	HEMATOLOGY ANALYZERS	 	$140,900.00	 	Beckman Coulter	 	3/8/2015
	 WUESTHOFF - MELBOURNE

 
	  	Chemistry Analyzer	 	$ 274,900.80	 	Beckman Coulter	 	10/1/2013
	BARTOW	  	Fusion ENT Navigation System	 	$107,520.00	 	BofA	 	2/2/2015
	JACKSON	  	IMRT LINEAR ACCELERATOR 	 	$2,666,045.00	 	Citicorp Vendor Finance	 	3/29/2011
	LANCASTER REG	  	2 MOBILE XRAY UNITS W 9” C ARM	 	$244,338.00	 	Citicorp Vendor Finance	 	11/29/2012
	LANCASTER REG	  	64 SLICE CT	 	$1,023,437.00	 	Citicorp Vendor Finance	 	6/9/2013
	STATESVILLE	  	MRI PROJECT	 	$1,495,939.00	 	Citicorp Vendor Finance	 	5/25/2014
	JACKSON	  	O ARM IMAGING SYSTEM	 	$937,784.00	 	CoActiv	 	11/7/2011
	BILOXI	  	ENDOSCOPY SYSTEM	 	$400,209.55	 	Court Square	 	1/1/2014
	STATESBORO	  	Computers	 	$94,597.44	 	Court Square Leasing Corp. 	 	9/28/2012
	STATESBORO	  	Printers, Scanners, Copiers	 	$10,231.80	 	Court Square Leasing Corp. 	 	10/28/2013
	Knoxville LaFollette	  	ConMed Equipment	 	$169,999.46	 	Creekridge Capital	 	6/1/2014
	ANNISTON	  	Microscope	 	$102,111.00	 	DLL	 	3/1/2017
	ANNISTON	  	DaVinci Robot	 	$1,866,080.00	 	DLL	 	12/22/2016
	ANNISTON	  	Digital Mammography	 	$283,809.00	 	DLL	 	4/12/2017
	BARTOW	  	DaVinci Robot	 	$1,866,440.00	 	DLL	 	12/22/2016
	BATESVILLE	  	da Vinci Robot	 	$1,289,000.00	 	DLL	 	9/28/2017
	BILOXI	  	Digital Mammography	 	$845,099.00	 	DLL	 	12/20/2015
	BILOXI	  	Zeiss Microscope	 	$162,582.80	 	DLL	 	6/10/2016
	BILOXI	  	FireFly daVinci Upgrade-Accessories	 	$206,050.00	 	DLL	 	8/7/2017
	BILOXI	  	da Vinci Robot	 	$1,390,000.00	 	DLL	 	9/28/2017

  
 77 

									
	BILOXI	  	Two Surgical Sterilizers	 	$80,882.90	 	DLL	 	 
	BILOXI	  	Mamo Unit	 	$151,684.00	 	DLL	 	 
	BILOXI	  	Ventilattors	 	$115,959.16	 	DLL	 	 
	BRANDON	  	Zeiss Microscope	 	$311,492.00	 	DLL	 	 
	BROOKSVILLE/SP HILL	  	Da Vinci Si-e	 	$1,239,460.00	 	DLL	 	12/31/2017
	CANTON	  	Hologic Digital Mammo	 	$313,233.00	 	DLL	 	5/27/2016
	CARLISLE	  	Microscope	 	$288,796.00	 	DLL	 	11/9/2016
	CARLISLE	  	Mammography	 	$185,275.00	 	DLL	 	 
	CHESTER	  	VITEK Workstations and Bench (2)	 	$95,150.00	 	DLL	 	9/28/2017
	CHESTER	  	Hematology Analyzer	 	$105,381.00	 	DLL	 	12/31/2017
	CORP	  	DaVinci Robot	 	$1,790,941.00	 	DLL	 	3/31/2016
	CORP	  	Intuitive Surgical	 	$1,453,500.00	 	DLL	 	5/18/2016
	CORP	  	Intuitive Surgical	 	$1,453,500.00	 	DLL	 	5/18/2016
	CORP	  	Intuitive Surgical	 	$1,602,500.00	 	DLL	 	5/18/2016
	CORP	  	Intuitive Surgical	 	$1,453,500.00	 	DLL	 	5/18/2016
	CORP	  	Intuitive Surgical	 	$1,608,600.00	 	DLL	 	5/18/2016
	CORP	  	Intuitive Surgical	 	$1,602,500.00	 	DLL	 	5/18/2016
	CORP - NAPLES COLLIER	  	Intuitive Surgical	 	$1,033,500.00	 	DLL	 	6/8/2016
	CORPORATE	  	Intuitive Surgical (6)	 	$1,858,906.00	 	DLL	 	3/29/2015
	CORPORATE	  	Intuitive Surgical (6)	 	$1,550,000.00	 	DLL	 	4/1/2015
	CORPORATE	  	Intuitive Surgical (6)	 	$1,575,000.00	 	DLL	 	9/28/2015
	CORPORATE	  	Intuitive Surgical (6)	 	$1,575,000.00	 	DLL	 	9/29/2015
	CORPORATE	  	Intuitive Surgical (6)	 	$1,495,000.00	 	DLL	 	9/29/2015
	CRYSTAL RIVER	  	Hematology Analyzers	 	$124,500.00	 	DLL	 	9/28/2017
	DADE CITY	  	ENT Navigation System	 	$65,000.00	 	DLL	 	6/9/2014
	DALLAS REGIONAL	  	VENTILATORS	 	$96,283.00	 	DLL	 	12/16/2013
	DALLAS/GALLOWAY	  	Lab Analyzers	 	$246,550.00	 	DLL	 	5/29/2018
	DURANT	  	CORE NETWORKING UPGRADE	 	$84,069.00	 	DLL	 	12/11/2012
	FLOWOOD	  	ENT Navigation System	 	$139,200.00	 	DLL	 	9/9/2015
	FLOWOOD	  	Cysto System	 	$300,945.00	 	DLL	 	4/25/2016
	FLOWOOD	  	DaVinci Robot	 	$1,462,220.00	 	DLL	 	6/28/2016
	FLOWOOD	  	Cepheid GeneXpert XVI-12	 	$131,420.00	 	DLL	 	8/22/2017
	FLOWOOD	  	Sysmex Hematology Analyzers	 	$163,237.60	 	DLL	 	9/5/2018
	FLOWOOD EAST	  	ULTRASOUND MACHINE	 	$84,007.00	 	DLL	 	3/20/2013

  
 78 

									
	FLOWOOD EAST	  	DaVinci Robot	 	$1,095,200.00	 	DLL	 	12/22/2015
	FLOWOOD EAST	  	Da Vinci System	 	$1,386,000.00	 	DLL	 	7/28/2016
	FLOWOOD EAST	  	DaVinci Accessories	 	$146,066.00	 	DLL	 	 
	FORT SMITH	  	Navigation System (ENT)	 	$83,576.00	 	DLL	 	7/15/2014
	FORT SMITH	  	Navigation System (Neuro)	 	$246,562.50	 	DLL	 	7/15/2014
	FORT SMITH	  	DaVinci Robot	 	$1,339,789.00	 	DLL	 	3/31/2016
	FORT SMITH	  	DaVinci Robot	 	$1,339,789.00	 	DLL	 	3/31/2016
	FORT SMITH	  	Digital Mammography (2)	 	$488,750.00	 	DLL	 	5/17/2016
	GADSDEN	  	EP Lab	 	$460,399.00	 	DLL	 	1/17/2018
	GADSDEN	  	Covidien Ventilators	 	$251,999.95	 	DLL	 	5/2/2018
	HAINES CITY	  	DaVinci Robot	 	$1,607,400.00	 	DLL	 	7/19/2016
	JACKSON	  	NEURO MICROSCOPE	 	$213,402.00	 	DLL	 	3/31/2014
	JACKSON	  	Navigation System	 	$126,203.90	 	DLL	 	7/15/2014
	JACKSON	  	Volcano s5 Imaging System	 	$117,500.00	 	DLL	 	6/29/2017
	JACKSON	  	Microscope	 	$179,940.05	 	DLL	 	1/17/2018
	JACKSON	  	Cysto Table	 	$299,347.00	 	DLL	 	2/27/2018
	JAMESTOWN	  	TELEMETRY SYSTEM	 	$89,717.00	 	DLL	 	3/18/2013
	KENNETT	  	Digital Mammography	 	$359,625.00	 	DLL	 	7/19/2017
	KEY WEST	  	DaVinci Robot	 	$1,582,400.00	 	DLL	 	7/19/2016
	KNOXVILLE - JEFFERSON 	  	Digital Mammo System; Workstation	 	$374,268.00	 	DLL	 	5/18/2017
	KNOXVILLE - NEWPORT	  	Digital Mammography	 	$217,000.00	 	DLL	 	4/18/2017
	KNOXVILLE - TURKEY CREEK	  	DaVinci Robot	 	$2,011,050.00	 	DLL	 	12/22/2016
	Knoxville North	  	ENT Navigation System	 	$155,759.76	 	DLL	 	5/23/2018
	Knoxville PRMC	  	da Vinci Robotic Surgery System	 	$1,539,000.00	 	DLL	 	8/20/2017
	Knoxville PRMC	  	da Vinci Surgucal System	 	$1,539,000.00	 	DLL	 	 
	Knoxville TCMC	  	Da Vinci System	 	$1,650,000.00	 	DLL	 	1/1/2014
	LANCASTER REG	  	DA VINCI SYSTEM	 	$1,678,350.00	 	DLL	 	9/21/2013
	LANCASTER REG	  	DaVinci Robot	 	$1,339,789.00	 	DLL	 	3/31/2016
	LEBANON	  	Hematology Analyzer	 	$105,090.00	 	DLL	 	3/8/2018
	LIVE OAK	  	Hematology Analyzer	 	$85,560.00	 	DLL	 	4/11/2018
	MIDWEST CITY	  	NEW AGFA/OREX ACL 4 PCKG DELL	 	$54,859.00	 	DLL	 	12/5/2012
	MIDWEST CITY	  	CATH LAB MONITORING SYSTEM	 	$83,243.00	 	DLL	 	12/5/2012
	MIDWEST CITY	  	Analyzers (2)	 	$352,900.00	 	DLL	 	 

  
 79 

									
	MIDWEST CITY	  	Sterilizer	 	$130,929.19	 	DLL	 	 
	MONROE	  	PACS SYSTEM	 	$595,105.00	 	DLL	 	5/29/2013
	MONROE	  	da Vinci	 	$1,596,940.00	 	DLL	 	6/28/2017
	MONROE	  	ForceTriad Electrosurgical Units	 	$86,406.00	 	DLL	 	 
	MOORESVILLE/SURG CTR	  	Medtronic StealthStation S7	 	$238,500.00	 	DLL	 	11/1/2017
	NAPLES - PR	  	Digital Mammograpy	 	$387,558.00	 	DLL	 	3/1/2017
	PAINTSVILLE	  	Ventilators (5)	 	$117,505.00	 	DLL	 	2/23/2017
	PAINTSVILLE	  	Digital Mammography	 	$328,833.00	 	DLL	 	3/22/2017
	POPLAR BLUFF	  	Oasys Monitors	 	$757,085.00	 	DLL	 	10/30/2017
	POPLAR BLUFF	  	Da Vinci SI Robot	 	$999,000.00	 	DLL	 	12/31/2017
	PORT CHARLOTTE	  	Microscope	 	$260,777.00	 	DLL	 	5/15/2016
	Pryor	  	Sterilizer System	 	$95,658.89	 	DLL	 	6/28/2018
	PT CHARLOTTE	  	Sterrad NX Sterilization	 	$100,764.00	 	DLL	 	8/16/2017
	PT CHARLOTTE	  	Da Vinci Robot	 	$1,255,960.00	 	DLL	 	12/31/2017
	PUNTA GORDA/RVERSIDE	  	Chemisty Analyzers	 	$660,000.00	 	DLL	 	12/7/2012
	PUNTA GORDA/RVERSIDE	  	OPMI Pentero Microscope	 	$160,000.00	 	DLL	 	6/27/2018
	SEBASTIAN	  	Intuitive Surgical	 	$1,582,400.00	 	DLL	 	6/28/2016
	SEBRING	  	WASHER/STERILIZER	 	$141,185.00	 	DLL	 	12/21/2012
	SEBRING	  	Radpro Mobile 3 DR	 	$170,200.00	 	DLL	 	6/28/2017
	SEBRING	  	Ultrasound	 	$71,500.00	 	DLL	 	9/7/2017
	SEBRING	  	Telemetry System	 	$357,061.77	 	DLL	 	 
	SPRING HILL	  	REPLACEMENT BEDS	 	$61,598.88	 	DLL	 	5/26/2013
	ST CLOUD	  	da Vinci Robot System	 	$1,197,600.00	 	DLL	 	11/30/2017
	STATESBORO	  	DA VINCI SYSTEM	 	$1,160,000.00	 	DLL	 	9/24/2013
	STATESBORO	  	CHEMISTRY AND IMMUNOLOGY ANALYZER	 	$589,400.00	 	DLL	 	12/11/2013
	STATESBORO	  	Mobile X-Ray	 	$185,000.00	 	DLL	 	5/1/2018
	STATESBORO	  	DA VINCI SYSTEM	 	$1,790,941.00	 	DLL	 	 
	STATESVILLE	  	Da Vinci Si	 	$700,000.00	 	DLL	 	12/31/2017
	TULLAHOMA	  	DR64 UROLOGICAL SYSTEM	 	$287,293.00	 	DLL	 	3/20/2013
	VAN BUREN	  	Digital Mammography	 	$224,392.00	 	DLL	 	3/1/2017
	VENICE	  	ORTORPEDIC SURGERY TABLE	 	$77,569.00	 	DLL	 	3/18/2013
	VENICE	  	DaVinci Robot	 	$1,654,500.00	 	DLL	 	7/1/2015
	VENICE	  	DaVinci Robot	 	$1,726,700.00	 	DLL	 	12/22/2016

  
 80 

									
	WINDER	  	INTELLIVUE TELEMETRY SYSTEM	 	$352,825.00	 	DLL	 	12/11/2012
	YAKIMA	  	INVIVO DYNACAD IMAGING WORKSTA	 	$59,456.00	 	DLL	 	12/5/2012
	YAKIMA	  	BRAINLAB VV PLATFORM UPGRADE	 	$196,198.00	 	DLL	 	6/6/2013
	YAKIMA	  	OR Beds	 	$129,229.16	 	DLL	 	 
	BROOKSVILLE	  	ACCUDOSE CABINETS	 	$65,635.00	 	Farnam Street	 	7/1/2014
	JACKSON	  	ACCUDOSE CABINETS	 	$23,864.00	 	Farnam Street	 	2/1/2014
	AMORY	  	IGS System	 	$123,726.00	 	First American	 	4/11/2015
	ANNISTON	  	Sterilizer	 	$139,520.00	 	First American	 	1/5/2016
	CARLISLE	  	ENT NAVIGATION SYSTEM	 	$113,764.00	 	First American	 	2/4/2013
	CLARKSDALE	  	Microbiology Analyzer	 	$89,475.00	 	First American	 	10/14/2014
	CLARKSDALE	  	Pumps (26)	 	$101,845.00	 	First American	 	 
	CORP	  	IPOD TOUCH	 	$1,775,000.00	 	First American	 	 
	DADE CITY	  	Cardiac Ablation & Recording Equipment	 	$190,100.00	 	First American	 	10/14/2014
	DURANT	  	VERSACARE BEDS	 	$42,167.84	 	First American	 	4/10/2013
	DURANT	  	Ultrasound Vascular Machine	 	$72,120.00	 	First American	 	10/4/2014
	FLOWOOD	  	Pumps (25)	 	$71,125.00	 	First American	 	4/11/2015
	FLOWOOD	  	Sterilizing Equipment	 	$162,667.00	 	First American	 	 
	FLOWOOD	  	Sterilizing Equipment	 	$67,240.00	 	First American	 	 
	FLOWOOD EAST	  	Sterilizer	 	$119,000.00	 	First American	 	 
	FORT SMITH	  	Sterilizers	 	$266,920.00	 	First American	 	9/1/2015
	FORT SMITH	  	Sterilizers	 	$194,253.00	 	First American	 	10/10/2015
	HARTSVILLE	  	SURGICAL LED LIGHTS	 	$151,418.88	 	First American	 	6/8/2013
	HARTSVILLE	  	Sterilizer	 	$155,131.00	 	First American	 	 
	JACKSON	  	PROCEDURAL STRETCHERS	 	$160,637.00	 	First American	 	3/15/2013
	JACKSON	  	12 CRITICAL CARE BEDS	 	$357,146.52	 	First American	 	10/7/2013
	KENNETT	  	LAPAROSCOPIC TOWER	 	$167,150.00	 	First American	 	6/30/2013
	KNOXVILLE - JEFFERSON 	  	Sterilizer	 	$118,960.00	 	First American	 	 
	LANCASTER Heart o	  	Liquid Chemical Sterilant Processor	 	$57,761.62	 	First American	 	 
	LANCASTER REG	  	Sterilizer	 	$59,548.68	 	First American	 	 
	LEBANON	  	Rad Pro 40KW Digital Mobile Unit	 	$162,436.00	 	First American	 	10/1/2014
	MILTON	  	Hospira PCA Pumps	 	$53,072.80	 	First American	 	2/10/2015
	MOORESVILLE	  	LABOR & DELIVERY BEDS	 	$91,781.00	 	First American	 	4/8/2013
	MOORESVILLE	  	2 SURGICAL TABLES	 	$103,082.00	 	First American	 	7/8/2013

  
 81 

									
	POPLAR BLUFF	  	TELEMETRY SYSTEM	 	 $626,233.28	 	First American	 	10/12/2013
	PORT CHARLOTTE	  	3 ICU BEDS	 	 $884,000.00	 	First American	 	4/7/2013
	PUNTA GORDA	  	HD SURGICAL TOWERS	 	 $213,661.17	 	First American	 	11/9/2013
	PUNTA GORDA	  	HD SURGICAL TOWERS	 	 $228,768.98	 	First American	 	 
	SEBRING	  	LAPAROSCOPIC VIDEO TOWERS	 	 $269,939.00	 	First American	 	3/18/2013
	TULLAHOMA	  	PCI Optimization System	 	 $127,036.00	 	First American	 	 
	YAKIMA	  	Beds & OR System	 	 $217,534.56	 	First American	 	 
	BRANDON	  	ULTRASOUND AND DIGITAL RECORD. UNIT	 	 $284,587.00	 	First Premier	 	6/25/2013
	STATESBORO	  	PORTABLE U/S UNIT	 	 $61,980.00	 	First Premier	 	7/20/2013
	AMORY	  	NUCLEAR MEDICINE CAMERA	 	 $271,270.00	 	GE	 	6/30/2013
	AMORY	  	ECHO MACHINE	 	 $154,000.00	 	GE	 	8/30/2013
	AMORY	  	ULTRASOUND	 	 $107,640.00	 	GE	 	6/30/2014
	AMORY	  	Video Processor; Scopes	 	 $65,195.00	 	GE	 	9/15/2016
	AMORY	  	Video Tower	 	 $313,576.80	 	GE	 	 
	ANNISTON	  	DIAGNOSTIC IMAGES	 	 $85,000.00	 	GE	 	9/4/2013
	ANNISTON	  	SIGNA PREEXCITE 1.5T UPGRADE	 	 $675,000.00	 	GE	 	9/30/2014
	ANNISTON	  	C-arm	 	 $283,958.00	 	GE	 	3/17/2015
	ANNISTON	  	R/F Room	 	 $294,673.00	 	GE	 	10/1/2016
	ANNISTON	  	Monitors	 	 $221,205.00	 	GE	 	10/13/2016
	ANNISTON	  	Endoscopic Tower and Scopes	 	 $98,452.88	 	GE	 	7/25/2017
	BARTOW	  	IMAGING EQUIPMENT (Bone Densitometer)	 	$36,995.00	 	GE	 	9/30/2014
	BARTOW	  	IMAGING EQUIPMENT (Logiq Ultrasound)	 	$65,500.00	 	GE	 	10/5/2014
	BARTOW	  	IMAGING EQUIPMENT (Digital  Mammo)	 	 $386,803.00	 	GE	 	10/14/2014
	BARTOW	  	IMAGING EQUIPMENT (ICAD for Mammo)	 	 $45,000.00	 	GE	 	10/14/2014
	Bartow	  	C-Arm	 	 $177,911.75	 	GE	 	12/20/2017
	BATESVILLE	  	Fetal Monitoring System	 	 $288,797.00	 	GE	 	3/21/2017
	BATESVILLE	  	Equipment for ICU (Goldseal DASH Monitors)	 	 $588,736.00	 	GE	 	5/21/2017
	BATESVILLE	  	MR	 	 $375,000.00	 	GE	 	 
	BATESVILLE	  	Logiq E9 Ultrasound	 	 $151,808.00	 	GE	 	 
	BATESVILLE	  	Nuclear Camera	 	 $207,195.10	 	GE	 	 
	Bayfront	  	Laparoscopic Equipment	 	 $236,519.57	 	GE	 	8/8/2018

  
 82 

									
	Bayfront	  	Power Equipment	 	$305,159.22	 	GE	 	 
	BILOXI	  	PATIENT MONITORING SYSTEM	 	$142,948.00	 	GE	 	8/1/2013
	BILOXI	  	PACS	 	$535,000.00	 	GE	 	9/30/2013
	BILOXI	  	DEFIBRILATORS	 	$133,865.00	 	GE	 	3/30/2014
	BILOXI	  	C-Arm	 	$166,452.00	 	GE	 	10/1/2015
	BILOXI	  	PACU Monitors	 	$292,324.88	 	GE	 	10/19/2015
	BILOXI	  	PACU MONITORS	 	$292,324.00	 	GE	 	10/30/2015
	BILOXI	  	Ultrasound	 	$124,697.00	 	GE	 	8/16/2016
	BILOXI	  	Echo Machine	 	$113,130.00	 	GE	 	1/18/2017
	BILOXI	  	Laser	 	$101,150.00	 	GE	 	6/19/2017
	BILOXI	  	Surgical Robot System	 	$1,060,000.00	 	GE	 	9/17/2017
	BILOXI	  	Ultrasound	 	$125,850.00	 	GE	 	12/7/2017
	BILOXI GC SURG CTR	  	GI Scopes	 	$576,482.00	 	GE	 	12/20/2016
	Blackwell	  	C-Arm	 	$111,198.00	 	GE	 	2/7/2017
	Blackwell	  	VOIP PBX Phone System	 	$120,502.34	 	GE	 	8/3/2017
	Blackwell	  	VOIP Schedule 002	 	$21,265.12	 	GE	 	 
	BRANDON	  	CT	 	$648,466.00	 	GE	 	3/19/2013
	BRANDON	  	PACS SYSTEM	 	$372,219.80	 	GE	 	6/24/2013
	BRANDON	  	Bone density equipment	 	$52,900.00	 	GE	 	4/20/2015
	BRANDON	  	BONE DENSITY UNIT	 	$52,900.00	 	GE	 	4/30/2015
	BRANDON	  	C-Arm	 	$177,344.00	 	GE	 	10/1/2016
	BRANDON	  	Monitoring Equipment	 	$101,713.57	 	GE	 	 
	BROOKSVILLE	  	C-ARM 12” PULSERA	 	$152,850.00	 	GE	 	2/14/2013
	BROOKSVILLE	  	DIGITAL MAMMO	 	$551,241.00	 	GE	 	3/22/2015
	BROOKSVILLE	  	Urology Table	 	$190,751.00	 	GE	 	12/15/2015
	BROOKSVILLE/SP HILL	  	Digital Mammo	 	$467,987.32	 	GE	 	3/22/2015
	BROOKSVILLE/SP HILL	  	Arthoscopic Tower System	 	$120,890.93	 	GE	 	 
	CANTON	  	PACS	 	$186,079.88	 	GE	 	12/28/2015
	CANTON	  	Fetal Monitors	 	$106,973.68	 	GE	 	6/24/2016
	CANTON	  	C-Arm	 	$173,950.00	 	GE	 	3/21/2017
	CARLISLE	  	SURGICAL CENTER MISC EQUIPMENT	 	$627,275.00	 	GE	 	9/30/2013
	CARLISLE	  	Phaco equipment	 	$108,840.00	 	GE	 	8/5/2015
	CARLISLE	  	Peds GI Service Video System and Scopes	 	$239,079.00	 	GE	 	12/22/2015

  
 83 

									
	CARLISLE	  	GI Equipment	 	 $290,315.42	 	GE	 	6/9/2016
	CARLISLE	  	Mammography	 	 $387,849.00	 	GE	 	7/11/2017
	CARLISLE	  	C-Arm	 	 $122,000.00	 	GE	 	9/20/2017
	CARLISLE	  	GE CT	 	 $459,957.73	 	GE	 	9/27/2017
	CARLISLE	  	Philips DR	 	 $181,861.60	 	GE	 	9/27/2017
	CARLISLE	  	C-Arm	 	 $122,000.00	 	GE	 	12/17/2017
	CARLISLE	  	Logiq E9 Ultrasound	 	 $154,873.13	 	GE	 	 
	CARLISLE PPM	  	Volusion E6 BT 12 Ultrasound	 	 $69,200.00	 	GE	 	12/31/2017
	CHESTER	  	CT & BUILDOUT	 	 $812,986.00	 	GE	 	3/30/2014
	CHESTER	  	CT WORKSTATION	 	 $36,688.00	 	GE	 	3/30/2014
	CHESTER	  	ANESTHESIA MACHINES	 	 $84,482.00	 	GE	 	3/30/2015
	CLARKSDALE	  	CT SCANNER & ACCESSORY KIT	 	 $1,031,000.00	 	GE	 	12/14/2013
	CLARKSDALE	  	ANESTHESIA MACHINES	 	 $86,455.00	 	GE	 	12/30/2013
	CLARKSDALE	  	ANESTHESIA MACHINES	 	 $78,866.00	 	GE	 	9/20/2015
	CLARKSDALE	  	Digital Mammography	 	 $400,841.00	 	GE	 	10/29/2015
	CLARKSDALE	  	GI Video Equipment	 	 $86,520.72	 	GE	 	6/20/2016
	CLARKSDALE	  	Patient Beds (10)	 	 $273,252.05	 	GE	 	3/21/2017
	Clinton	  	VOIP System Sch 1	 	 $356,184.88	 	GE	 	6/28/2017
	Clinton	  	Mammography	 	 $304,444.00	 	GE	 	3/1/2018
	Clinton	  	VOIP System Sch 2	 	 $62,856.15	 	GE	 	 
	CORP	  	PACS Workstation	 	 $120,947.00	 	GE	 	3/20/2014
	CORP	  	PACS SYSTEM - Shands	 	 $126,418.00	 	GE	 	9/20/2014
	CORP	  	PATIENT FOLDER EQUIPMENT	 	 	 	GE	 	12/14/2014
	CORP	  	CR SYSTEM - Shands	 	 $553,500.00	 	GE	 	9/20/2015
	CORP	  	PATIENT FOLDER EQUIPMENT	 	 $1,957,677.00	 	GE	 	9/30/2015
	CORP	  	PATIENT FOLDER EQUIPMENT	 	$455,097.00	 	GE	 	12/30/2015
	CORP	  	PACS FOR 4 HOSPITALS (Chester)	 	 $916,573.00	 	GE	 	12/30/2015
	CORP	  	PACS FOR 4 HOSPITALS (Jamestown)	 	 	 	GE	 	2/28/2016
	CORP	  	Voice Over Internet Protocol Avaya Telephone Systems (phase 1)	 	 $2,346,501.80	 	GE	 	6/14/2016
	CORP	  	Voice Over Internet Protocol Avaya Telephone Systems (phase 2)	 	 $3,023,004.33	 	GE	 	9/14/2016
	CORP	  	PACS FOR 4 HOSPITALS (Hamlet)	 	 $918,573.00	 	GE	 	 

  
 84 

									
	CORPORATE	  	NUCLEAR CAMERA	 	$271,270.00	 	GE	 	6/30/2013
	CORPORATE	  	HP Equipment	 	$455,097.00	 	GE	 	12/16/2014
	CORPORATE	  	PACS System	 	$918,573.00	 	GE	 	9/28/2015
	CRYSTAL RIVER	  	CT SCANNER	 	$1,027,785.00	 	GE	 	6/30/2012
	CRYSTAL RIVER	  	OEC 9900	 	$364,492.00	 	GE	 	9/23/2015
	CRYSTAL RIVER	  	1188 HD CCU	 	$43,916.80	 	GE	 	9/30/2015
	CRYSTAL RIVER	  	DIGITAL MAMMO	 	$220,784.00	 	GE	 	10/13/2015
	CRYSTAL RIVER	  	ERCP Equipment	 	$139,954.00	 	GE	 	6/23/2016
	CRYSTAL RIVER	  	Cardiac Camera	 	$162,811.00	 	GE	 	 
	DADE CITY	  	DIGITAL MAMMO UNIT	 	$305,745.00	 	GE	 	12/30/2013
	DADE CITY	  	ANESTHESIA MACHINES	 	$448,172.00	 	GE	 	12/15/2014
	DADE CITY	  	Mammography System	 	$156,292.00	 	GE	 	6/20/2016
	DADE CITY	  	IMPAX PACS System	 	$92,297.00	 	GE	 	8/8/2016
	DADE CITY	  	Fetal Monitoring System	 	$112,282.55	 	GE	 	12/28/2016
	DADE CITY	  	BioMerieux Vitek	 	$68,245.00	 	GE	 	3/26/2018
	DADE CITY	  	Telemetry Monitoring	 	$372,377.31	 	GE	 	 
	DALLAS REGIONAL	  	PULSERA MOBILE C-ARM	 	$148,344.07	 	GE	 	8/14/2013
	DALLAS REGIONAL	  	USED ICU BEDS	 	$85,750.00	 	GE	 	7/14/2014
	DALLAS/GALLOWAY	  	BioMerieux Vitek	 	$76,250.00	 	GE	 	2/8/2018
	DURANT	  	VCT SCANNER	 	$1,570,718.72	 	GE	 	11/14/2011
	DURANT	  	CARDIAC CATH LAB	 	$1,107,774.66	 	GE	 	4/30/2012
	DURANT	  	NURSE STATION MONITORS	 	$122,090.00	 	GE	 	4/30/2012
	DURANT	  	SURGICAL MICROSCOPE SYSTEM	 	$79,049.00	 	GE	 	6/30/2013
	DURANT	  	BEDSIDE MONITORS	 	$94,208.00	 	GE	 	12/14/2013
	DURANT	  	DIGITAL MAMMO	 	$323,346.50	 	GE	 	8/14/2014
	DURANT CLINIC	  	ANESTHESIA MACHINES	 	$49,498.00	 	GE	 	6/30/2014
	FLOWOOD	  	64 SLICE CT SCANNER	 	$1,219,354.00	 	GE	 	8/30/2011
	FLOWOOD	  	ANESTHESIA MACHINES	 	$614,212.80	 	GE	 	3/30/2013
	FLOWOOD	  	SOLUTION WARMER	 	$114,500.00	 	GE	 	6/30/2013
	FLOWOOD	  	DEFINIUM 8000 DR EQUIPMENT	 	$391,879.00	 	GE	 	12/30/2013
	FLOWOOD	  	PACS UPGRADE	 	$153,899.00	 	GE	 	12/30/2013
	FLOWOOD	  	RADIOLOGY SYSTEM	 	$114,213.00	 	GE	 	9/15/2014
	FLOWOOD	  	Oasys OR System	 	$192,606.99	 	GE	 	12/28/2014
	FLOWOOD	  	Mizhuo Hana Hip System	 	$70,143.63	 	GE	 	2/3/2015

  
 85 

									
	FLOWOOD	  	Upgrade to MRI	 	 $903,679.00	 	GE	 	9/30/2015
	FLOWOOD	  	Surgical Tables (2)	 	 $116,885.10	 	GE	 	1/13/2016
	FLOWOOD	  	Endoscopy	 	 $203,247.57	 	GE	 	1/24/2016
	FLOWOOD	  	Imaging Equipment (Ultrasound)	 	 $182,647.13	 	GE	 	1/31/2016
	FLOWOOD	  	Anesthesia Machines (2)	 	 $184,312.10	 	GE	 	2/14/2016
	FLOWOOD	  	Imaging Equipment (700 X-Ray)	 	 $161,900.00	 	GE	 	3/25/2016
	FLOWOOD	  	Imaging Equipment (650 X-Ray Rad)	 	 $381,717.05	 	GE	 	3/25/2016
	FLOWOOD	  	Ultrasound Unit	 	 $129,449.09	 	GE	 	7/15/2016
	FLOWOOD	  	Fetal Monitors (11)	 	 $160,938.00	 	GE	 	9/15/2016
	FLOWOOD	  	ASC Macquet Anesthesia	 	 $183,673.92	 	GE	 	10/5/2016
	FLOWOOD	  	Getinge Washer & Sterilizers	 	 $211,325.23	 	GE	 	11/12/2016
	FLOWOOD	  	C-Arm	 	 $129,327.00	 	GE	 	3/21/2017
	FLOWOOD	  	OEC C-Arm	 	 $147,109.50	 	GE	 	12/31/2017
	FLOWOOD	  	AGFA DXG Digitizer/ Reader	 	 $195,028.58	 	GE	 	9/3/2018
	FLOWOOD	  	Monitoring	 	 $195,039.04	 	GE	 	 
	FLOWOOD	  	GI Scopes	 	 $110,779.44	 	GE	 	 
	FLOWOOD EAST	  	HALO SYSTEM	 	 $195,785.00	 	GE	 	8/1/2013
	FLOWOOD EAST	  	DASH 5000 NEONATAL MONITORS	 	 $61,912.50	 	GE	 	1/1/2014
	FLOWOOD EAST	  	ANESTHESIA MACHINES	 	 $78,542.11	 	GE	 	7/30/2014
	FLOWOOD EAST	  	FETAL MONITORING SYSTEM	 	 $95,151.00	 	GE	 	3/22/2015
	FLOWOOD EAST	  	C-Arm	 	 $33,040.00	 	GE	 	11/19/2015
	FLOWOOD EAST	  	Giraffe OmniBed	 	 $41,893.10	 	GE	 	12/21/2015
	FLOWOOD EAST	  	Anesthesia Machine	 	 $77,921.72	 	GE	 	9/15/2016
	FLOWOOD EAST	  	Giraffe Bedded Warmers (9)	 	 $188,965.84	 	GE	 	1/18/2017
	FLOWOOD EAST	  	DIGITAL MAMMO	 	 $1,304,200.00	 	GE	 	 
	FLOWOOD WMNS HOSP	  	Vision Project	 	 $944,243.33	 	GE	 	8/1/2014
	FLOWOOD WMNS HOSP	  	Dash Monitors	 	 $387,329.07	 	GE	 	8/18/2014
	FORT SMITH	  	Patient Room and Waiting Room Furniture	 	$1,118,299.00	 	GE	 	1/25/2016
	FORT SMITH	  	Patient Room and Waiting Room Furniture	 	 $1,019,038.00	 	GE	 	1/30/2016
	FORT SMITH	  	Hematology Analyzer	 	 $116,540.00	 	GE	 	6/20/2016
	FORT SMITH	  	EKG Machine (5)	 	 $63,461.11	 	GE	 	10/1/2016
	FORT SMITH	  	Anesthesia Monitors (10)	 	 $302,127.28	 	GE	 	12/6/2016

  
 86 

									
	FORT SMITH	  	Defibrilators	 	$301,958.43	 	GE	 	12/6/2016
	FORT SMITH	  	Oasys Monitoring	 	$720,640.00	 	GE	 	12/30/2016
	FORT SMITH	  	Telemetry System	 	$861,439.00	 	GE	 	3/13/2017
	FORT SMITH	  	Patient Room and Waiting Room Furniture	 	 	 	GE	 	 
	FT SMITH	  	2 GE Volusion E6 BT 12 Ultrasounds	 	$166,374.98	 	GE	 	6/22/2017
	FT SMITH	  	Cardiac Ultrasounds 3, Image Vault EchoPAC	 	$273,474.00	 	GE	 	12/7/2017
	FT SMITH	  	CT Machine 16	 	$407,490.11	 	GE	 	5/29/2018
	FT SMITH	  	BioMerieux Vitek	 	$87,597.50	 	GE	 	6/24/2018
	FT SMITH	  	Solar & Dash Monitors	 	$395,972.30	 	GE	 	6/26/2018
	FT SMITH	  	Automated Dispensing Medicine Cabinets	 	$625,016.00	 	GE	 	 
	FT SMITH	  	Olympus Scopes 2 Gastroscopes and 2 Colonoscopes	 	$107,548.22	 	GE	 	 
	FT SMITH	  	16 Slice CT	 	$365,213.91	 	GE	 	 
	GADSDEN	  	64 SLICE CT SCANNER	 	$1,049,018.00	 	GE	 	6/30/2011
	GADSDEN	  	GE SIGNA MRI	 	$1,273,675.00	 	GE	 	8/30/2013
	GADSDEN	  	Cardiac Monitors	 	$174,195.00	 	GE	 	12/30/2014
	GADSDEN	  	Digital Mammography	 	$231,116.50	 	GE	 	3/22/2017
	GADSDEN	  	C-Arm	 	$167,144.00	 	GE	 	4/1/2017
	GADSDEN	  	Anesthesia Machines (4)	 	$144,538.00	 	GE	 	4/1/2017
	HAINES CITY	  	16 SLICE CT SCANNER 24 MONTH RENEWAL	 	$802,545.28	 	GE	 	4/14/2012
	HAINES CITY	  	ULTRASOUND	 	$54,642.00	 	GE	 	6/30/2014
	HAINES CITY	  	DIGITAL MAMMO	 	$399,126.00	 	GE	 	3/17/2015
	HAINES CITY	  	PCR Corado Eleva	 	$209,550.00	 	GE	 	7/19/2015
	HAINES CITY	  	ENDOSCOPY MONITORS	 	$86,800.00	 	GE	 	7/21/2015
	HAINES CITY	  	Anesthesia Machines (2)	 	$162,467.27	 	GE	 	9/9/2016
	HAINES CITY	  	Nurse Call System	 	$289,060.00	 	GE	 	12/20/2016
	HAINES CITY	  	Monitor/Telemetry & MIC Equipment 	 	$667,407.27	 	GE	 	6/20/2017
	HAINES CITY	  	Monitor/Telemetry & MIC Equipment 	 	$667,407.27	 	GE	 	6/20/2017
	HAINES CITY	  	BioMerieux Vitek	 	$87,597.50	 	GE	 	2/28/2018
	HARTSVILLE	  	INNOVA 2000 CATH LAB	 	$1,088,541.00	 	GE	 	2/28/2011
	HARTSVILLE	  	64 SLICE CT SCANNER	 	$1,051,172.33	 	GE	 	12/30/2012
	HARTSVILLE	  	GE LIGHTSPEED RT 16 CT	 	$678,562.00	 	GE	 	5/27/2015

  
 87 

									
	HARTSVILLE	  	Cysto System	 	$335,628.00	 	GE	 	3/16/2016
	HARTSVILLE	  	Digital Mammography	 	$444,182.00	 	GE	 	3/30/2016
	HARTSVILLE	  	Digital Mammography (AGFA Imager & J+J Ethicon)	 	$138,955.00	 	GE	 	5/25/2016
	HARTSVILLE	  	Patient Monitors (ER)	 	$238,203.00	 	GE	 	8/23/2017
	HARTSVILLE	  	ICU Beds and IV Poles	 	$141,382.00	 	GE	 	2/27/2018
	HARTSVILLE	  	Cath/Specials Dual Room	 	$963,677.62	 	GE	 	8/22/2018
	HARTSVILLE	  	Anesthesia Machines (2)	 	$111,415.70	 	GE	 	 
	HARTSVILLE	  	Anesthesia Patient Monitors	 	$157,704.37	 	GE	 	 
	JACKSON	  	MRI SYSTEM	 	$1,577,878.00	 	GE	 	5/30/2012
	JACKSON	  	Innova 4100 Cath Lab	 	$1,406,228.00	 	GE	 	3/30/2013
	JACKSON	  	EXAM LIGHT HALOGEN GOOSENECK	 	$16,969.00	 	GE	 	5/4/2013
	JACKSON	  	WHEELCHAIR TRAVELER	 	$39,556.00	 	GE	 	6/15/2013
	JACKSON	  	ANESTHESIA MACHINES	 	$345,152.00	 	GE	 	8/30/2013
	JACKSON	  	GIRAFFE OMNI BED	 	$78,996.00	 	GE	 	9/14/2013
	JACKSON	  	DASH 5000 NEONATAL MONITORS	 	$225,581.00	 	GE	 	9/14/2013
	JACKSON	  	LOGIC 9 ULTRASOUND MACHINE	 	$99,709.00	 	GE	 	9/14/2013
	JACKSON	  	L & D MONITORING SYSTEM	 	$312,213.27	 	GE	 	9/27/2013
	JACKSON	  	PLASMON ADD-ON	 	$141,265.00	 	GE	 	12/30/2013
	JACKSON	  	PACS UPGRADE	 	$864,935.02	 	GE	 	12/30/2013
	JACKSON	  	ENDOSCOPY DASH 5000 MONITORS	 	$89,347.86	 	GE	 	1/15/2014
	JACKSON	  	C-ARM	 	$127,128.00	 	GE	 	10/30/2014
	JACKSON	  	C-ARM	 	$127,128.00	 	GE	 	12/30/2014
	JACKSON	  	C-ARM	 	$125,334.00	 	GE	 	3/23/2015
	JACKSON	  	Endoscopy Video System	 	$637,119.00	 	GE	 	7/1/2015
	JACKSON	  	GE MONITORS	 	$68,333.22	 	GE	 	11/19/2015
	JACKSON	  	Fluroroscopy Unit	 	$405,030.45	 	GE	 	12/21/2015
	JACKSON	  	Dinamaps (31)	 	$85,259.00	 	GE	 	10/1/2016
	JACKSON	  	Video Camera System	 	$426,389.90	 	GE	 	 
	JACKSON	  	Dash Monitoring System	 	$348,562.80	 	GE	 	 
	JACKSON	  	Varian IMRT Linear Accelerator	 	$2,666,045.00	 	GE	 	 
	JACKSON CLINIC	  	VIVID ULTRASOUND	 	$138,163.50	 	GE	 	6/30/2014
	JAMESTOWN	  	USED OFFICE EQUIPMENT	 	$50,200.00	 	GE	 	3/30/2013
	JAMESTOWN	  	Ultrasound Machine	 	$77,486.75	 	GE	 	12/15/2015

  
 88 

									
	JAMESTOWN	  	Radiography System	 	 $73,168.00	 	GE	 	8/24/2017
	JAMESTOWN	  	FETAL MONITORING SYSTEM	 	 $60,941.00	 	GE	 	 
	KENNETT	  	BONE DENSITOMETER	 	 $48,900.00	 	GE	 	8/30/2013
	KENNETT	  	SURGICAL LIGHTS	 	 $97,296.00	 	GE	 	12/14/2013
	KENNETT	  	PATIENT MONITORING SYSTEM	 	 $66,430.00	 	GE	 	6/30/2014
	KENNETT	  	RECOVERY ROOM MONITORS	 	 $64,148.00	 	GE	 	9/30/2014
	KENNETT	  	ADVANCE MONITORS	 	 $57,465.00	 	GE	 	9/30/2014
	KENNETT	  	ANESTHESIA MONITORS	 	 $112,676.36	 	GE	 	3/29/2015
	KEY WEST	  	Fluoroscopy C-Arm	 	 $172,431.00	 	GE	 	8/27/2017
	KNOXVILLE - LAFOLLETTE	  	Cardiovascular Ultrasound	 	 $102,830.00	 	GE	 	12/30/2016
	KNOXVILLE - LAFOLLETTE	  	Ultrasound Imaging System	 	 $103,812.00	 	GE	 	1/18/2017
	KNOXVILLE - PRMC	  	16 Slice CT	 	 $642,706.21	 	GE	 	9/28/2017
	Knoxville Jefferson	  	AW VolumeShare4 and Applications	 	 $78,647.52	 	GE	 	1/30/2013
	Knoxville newport	  	OEC 9900 Elite Digital Mobile C-Arm	 	 	 	GE	 	12/4/2012
	Knoxville newport	  	Logiq S8 Ultrasounds (2)	 	 $209,565.40	 	GE	 	4/29/2018
	Knoxville newport	  	iE33 Ultrasound	 	 $128,053.00	 	GE	 	5/3/2018
	Knoxville PRMC	  	Arthoscopy (Cameras, Scopes, and Accessories)	 	 $437,386.32	 	GE	 	4/25/2013
	Knoxville PRMC	  	Proteus	 	 $89,232.66	 	GE	 	11/30/2015
	Knoxville PRMC	  	Prodigy	 	 $38,390.00	 	GE	 	11/30/2015
	Knoxville PRMC	  	Seno DS	 	 $301,468.82	 	GE	 	11/30/2015
	Knoxville PRMC	  	Logic E9 Ultrasound	 	 $185,215.80	 	GE	 	11/30/2015
	Knoxville PRMC	  	Seno DS	 	$ 301,468.82	 	GE	 	12/1/2015
	Knoxville PRMC	  	Prodigy	 	 $38,390.00	 	GE	 	12/1/2015
	Knoxville PRMC	  	Logic E9 Ultrasound	 	 $185,215.00	 	GE	 	12/1/2015
	Knoxville PRMC	  	Proteus	 	 $89,232.66	 	GE	 	12/1/2015
	Knoxville PRMC	  	OR Tables	 	 $120,077.10	 	GE	 	8/27/2017
	Knoxville PRMC	  	OSI Spinal Table	 	 $110,885.48	 	GE	 	9/19/2017
	Knoxville PRMC	  	Olympus Scopes	 	 $155,094.84	 	GE	 	9/19/2017
	Knoxville PRMC	  	C-Arm	 	 $158,125.50	 	GE	 	12/7/2017
	Knoxville PRMC	  	Anesthesia Machines	 	 $172,233.36	 	GE	 	12/20/2017
	Knoxville PRMC	  	ENT Navigation System	 	 $155,759.76	 	GE	 	3/21/2018
	Knoxville PRMC	  	Axis Table System	 	 $130,958.00	 	GE	 	 
	Knoxville PRMC	  	GE Innova 4100	 	$800,000.00	 	GE	 	 

  
 89 

									
	Knoxville TCMC	  	OEC 9900 Elite Digital C-Arm	 	$218,165.00	 	GE	 	2/21/2013
	Knoxville TCMC	  	Surgical Microscope	 	$336,775.93	 	GE	 	12/7/2017
	Knoxville TCMC	  	Spinal Table	 	$128,813.25	 	GE	 	12/7/2017
	Knoxville TCMC	  	GE Ultrasound	 	$61,046.40	 	GE	 	12/12/2017
	Knoxville TCMC	  	Linear Accelerator	 	$2,223,778.00	 	GE	 	4/25/2018
	Knoxville TCMC	  	Ultrasound	 	$110,720.00	 	GE	 	8/23/2018
	Knoxville TCMC	  	Logiq e9 Ultrasound	 	$133,728.00	 	GE	 	 
	KNOXVILLE TCMC	  	Fluoro Table	 	$356,407.80	 	GE	 	 
	LAKE SHORE	  	Olympus Endoscopy Equipment	 	$218,918.68	 	GE	 	9/28/2017
	LANCASTER HEART	  	Hana Hip-Knee Arthroplasty Table	 	$92,582.45	 	GE	 	10/23/2017
	LANCASTER HEART	  	Spinal Table System	 	$95,949.40	 	GE	 	10/23/2017
	LANCASTER HEART	  	GE Giraffe OmniBeds	 	$113,992.21	 	GE	 	12/7/2017
	LANCASTER HEART	  	Senographe Care Base Digital Memmography & iCAD	 	$247,547.40	 	GE	 	3/25/2018
	LANCASTER HEART	  	BioMerieux Vitek	 	$102,530.00	 	GE	 	 
	LANCASTER Heart o	  	DIGITAL RADIOGRAPHY SYSTEM	 	$445,366.00	 	GE	 	6/1/2013
	LANCASTER Heart o	  	DIGITAL MAMMO EQUIPMENT	 	$473,411.00	 	GE	 	9/30/2014
	LANCASTER Heart o	  	MRI UPGRADE	 	$680,277.00	 	GE	 	9/30/2014
	LANCASTER Heart o	  	PERINATAL ULTRASOUND	 	$117,087.00	 	GE	 	12/14/2014
	LANCASTER Heart o	  	ULTRASOUND SYSTEM	 	$149,570.00	 	GE	 	12/30/2014
	LANCASTER Heart o	  	FETAL MONITORS	 	$83,872.47	 	GE	 	3/3/2015
	LANCASTER Heart o	  	64 SLICE CT UPGRADE	 	$907,000.00	 	GE	 	3/29/2015
	LANCASTER Heart o	  	DIGITAL MAMMOGRAPHY	 	$262,115.40	 	GE	 	6/15/2015
	LANCASTER Heart o	  	Fetal Monitors (6)	 	$94,870.08	 	GE	 	4/24/2016
	LANCASTER Heart o	  	Endoscopy Equipment	 	$380,974.00	 	GE	 	7/26/2016
	LANCASTER Heart o	  	Endo Equipment (HD)	 	$528,963.00	 	GE	 	5/9/2017
	LANCASTER REG	  	STERRAD 100S STERILIZER	 	$120,075.80	 	GE	 	9/3/2015
	LANCASTER REGIONAL	  	Video Arthoscopy System (3)	 	$545,000.00	 	GE	 	7/26/2017
	LANCASTER/ROSE CITY	  	Mammography	 	$187,120.00	 	GE	 	12/20/2017
	LANCASTER/ROSE CITY	  	Senographe Mammo System	 	$178,333.75	 	GE	 	12/31/2017
	LANCASTER/ROSE CITY	  	iCAD / Mammo	 	$22,500.00	 	GE	 	2/8/2018
	LANCASTER/ROSE CITY	  	CT	 	$325,000.00	 	GE	 	 
	LANCASTER/ROSE CITY	  	Linear Accelerator Upgrade	 	$1,466,815.00	 	GE	 	 

  
 90 

									
	LEBANON	  	VCT 64 SLICE CT SCANNER	 	$1,195,274.31	 	GE	 	12/14/2011
	LEBANON	  	DIGITAL MAMMOGRAPHY	 	$404,800.00	 	GE	 	5/28/2013
	LEBANON	  	SURGICAL TABLES (2)	 	$59,337.00	 	GE	 	12/30/2013
	LEBANON	  	ANESTHESIA MACHINES	 	$439,193.00	 	GE	 	6/11/2015
	LEBANON	  	GI HD Equipment	 	$156,470.00	 	GE	 	12/22/2015
	LEBANON	  	Ultrasounds (2)	 	$227,456.00	 	GE	 	9/27/2017
	LEBANON	  	Microscope	 	$131,454.78	 	GE	 	3/20/2018
	LEHIGH	  	Vivid Ultrasound w ECHO	 	$110,300.00	 	GE	 	 
	LEHIGH ACRES	  	C-ARM WITH VASCULAR PACKAGE	 	$159,545.00	 	GE	 	2/25/2015
	LEHIGH ACRES	  	Endobronchial Ultrasound	 	$155,585.00	 	GE	 	5/25/2017
	Marshall County	  	Brightspeed Elite 16 CT	 	$399,976.00	 	GE	 	 
	Mayes County	  	Monitoring System	 	$226,981.45	 	GE	 	6/24/2018
	MIDWEST CITY	  	EQUIPMENT FOR EP CARDIOLOGY	 	$1,434,393.00	 	GE	 	3/13/2013
	MIDWEST CITY	  	BALLOON PUMPS (3)	 	$201,283.00	 	GE	 	7/14/2013
	MIDWEST CITY	  	DIGITAL MAMMOGRAPHY	 	$239,000.00	 	GE	 	12/14/2013
	MIDWEST CITY	  	ULTRASOUND SYSTEM	 	$311,717.00	 	GE	 	12/30/2013
	MIDWEST CITY	  	PACS Upgrade	 	$102,809.88	 	GE	 	8/6/2014
	MIDWEST CITY	  	OB MONITORING SYSTEM	 	$164,129.00	 	GE	 	9/1/2015
	MIDWEST CITY	  	Innova 3100Q Cath Lab Room 3	 	$814,961.00	 	GE	 	12/8/2015
	MIDWEST CITY	  	Innova 3100Q Cath Lab Room 2	 	$904,261.00	 	GE	 	12/30/2015
	MIDWEST CITY	  	Osage Ambulance	 	$125,559.00	 	GE	 	10/31/2017
	MIDWEST CITY	  	LifeNet ECG Cardiac Monitors	 	$487,761.60	 	GE	 	12/7/2017
	MIDWEST CITY	  	Infant Warmers	 	$89,846.92	 	GE	 	12/12/2017
	MIDWEST CITY	  	Radio Equipment and Signage for Osage Ambulance	 	$10,980.13	 	GE	 	12/15/2017
	MIDWEST CITY PPM	  	Portable Echocardiograph Machine	 	$67,987.75	 	GE	 	8/10/2017
	MILTON	  	ECHO MACHINE	 	$116,500.00	 	GE	 	12/14/2013
	MILTON	  	STERILIZATION SYSTEM	 	$99,500.00	 	GE	 	12/30/2013
	MILTON	  	TELEMETRY SYSTEM	 	$216,541.45	 	GE	 	9/30/2014
	MILTON	  	ANESTHESIA MONITORS	 	$96,620.18	 	GE	 	6/17/2015
	MILTON	  	Patient Cardiac Monitors	 	$151,104.15	 	GE	 	9/22/2016
	MILTON	  	Patient Cardiac Monitors (ECG)	 	$287,860.00	 	GE	 	9/30/2016
	MILTON	  	Anesthesia Machine	 	$88,668.14	 	GE	 	1/26/2017

  
 91 

									
	MILTON	  	Ultrasound Machines (2)	 	$234,806.00	 	GE	 	2/13/2017
	MONROE	  	LIGHTSPEED 16 SLICE CT	 	$397,725.73	 	GE	 	12/14/2013
	MONROE	  	Digital Mammography (Ultrasound)	 	$74,025.00	 	GE	 	1/6/2014
	MONROE	  	Definium 8000	 	$384,671.55	 	GE	 	9/14/2014
	MONROE	  	Digital Mammography (Bone Densitometer)	 	$38,250.00	 	GE	 	1/11/2016
	MONROE	  	Digital Mammography	 	$177,070.00	 	GE	 	1/24/2016
	MONROE	  	Digital Mammography	 	$366,583.68	 	GE	 	9/6/2016
	MONROE	  	REPLACEMENT HOSPITAL (Digital Mammo)	 	$5,057,092.00	 	GE	 	9/14/2016
	MONROE	  	Oasys Monitors	 	$267,055.00	 	GE	 	3/1/2017
	MONROE	  	Hill Rom Beds	 	$399,281.29	 	GE	 	5/21/2017
	MONROE	  	Alpha Pro Surgical Tables	 	$140,000.00	 	GE	 	6/19/2017
	MOORESVILLE	  	64 SLICE CT SCANNER	 	$1,131,621.00	 	GE	 	12/30/2013
	MOORESVILLE	  	CT	 	$420,269.00	 	GE	 	3/15/2014
	MOORESVILLE	  	TELEMETRY EQUIPMENT	 	$47,286.00	 	GE	 	9/30/2014
	MOORESVILLE	  	ER MONITORING EQUIPMENT	 	$192,398.00	 	GE	 	3/15/2015
	MOORESVILLE	  	ANESTHESIA MONITORS	 	$63,790.00	 	GE	 	1/1/2016
	MOORESVILLE	  	CARDIAC MONITORS	 	$138,697.00	 	GE	 	4/1/2016
	MOORESVILLE	  	Cysto Room	 	$310,763.00	 	GE	 	5/25/2017
	MOORESVILLE	  	8 MONITORS FOR ASC OR	 	$117,719.00	 	GE	 	 
	MOORESVILLE/SURG CTR	  	Dash Monitors	 	$117,719.36	 	GE	 	9/20/2015
	MOORESVILLE/SURG CTR	  	Telemetry Monitors and Accessories	 	$122,902.68	 	GE	 	9/20/2017
	MOORESVILLE/SURG CTR	  	Monitors/Telemetry Sys	 	$89,609.55	 	GE	 	12/31/2017
	MOORESVILLE/SURG CTR	  	Image Vault	 	$27,925.00	 	GE	 	3/27/2018
	MOORESVILLE/SURG CTR	  	Vivid Ultrasound	 	$119,394.01	 	GE	 	3/27/2018
	MOORESVILLE/SURG CTR	  	Anesthesia Machines and Monitors	 	$290,640.89	 	GE	 	 
	NAPLES - COLLIER	  	Medtronic Fusion Navigation	 	$128,472.00	 	GE	 	12/20/2015
	NAPLES - COLLIER	  	Echo Equipment Vivid E9	 	$175,021.30	 	GE	 	12/28/2015
	NAPLES - PR	  	CARDIO LAB	 	$133,029.00	 	GE	 	12/30/2013
	NAPLES - PR	  	Echo Equipment Vivid E9	 	$353,221.80	 	GE	 	6/22/2016
	NAPLES - PR	  	Nurse Call System; Fire Alarm	 	$1,422,520.00	 	GE	 	12/28/2016
	NAPLES - PR	  	Microscope; Clip Removers; Instrumentation	 	$220,201.15	 	GE	 	2/24/2017

  
 92 

									
	NAPLES - PR	  	RadPRO Mobile Digital Unit	 	 $173,458.00	 	GE	 	3/12/2017
	NAPLES - PR	  	Ultrasound Machine	 	 $149,934.00	 	GE	 	3/21/2017
	NAPLES - PR CLINIC	  	C-Arm; Imaging Table	 	 $144,497.00	 	GE	 	12/15/2015
	NAPLES PINE RIDGE	  	Dr. Kathleen Galatro Equipment	 	 $212,979.20	 	GE	 	3/27/2013
	NATCHEZ	  	ANESTHESIA MACHINES	 	 $408,213.00	 	GE	 	1/1/2014
	NATCHEZ	  	ENDO-UROLOGY PACKAGE	 	 $285,000.00	 	GE	 	6/30/2014
	NATCHEZ	  	PROTEUS RADIOGRAPHIC SYSTEM	 	 $73,757.00	 	GE	 	8/3/2015
	NATCHEZ	  	72-Slice CT	 	 $844,321.00	 	GE	 	3/21/2016
	Osler Medical Group	  	Olympus Cystoscopy System	 	 $107,263.56	 	GE	 	9/20/2017
	PAINTSVILLE	  	GASTROSCOPE & ENDOSCOPE 	 	 $58,891.00	 	GE	 	12/30/2013
	PAINTSVILLE	  	ANESTHESIA MACHINES	 	 $156,042.00	 	GE	 	3/30/2014
	PAINTSVILLE	  	Monitoring System (ER)	 	 $217,013.00	 	GE	 	12/21/2014
	PAINTSVILLE	  	C-ARM	 	 $112,000.00	 	GE	 	2/25/2015
	PAINTSVILLE	  	Boston Scientific Swiss LithoClast System	 	 $51,000.00	 	GE	 	9/16/2017
	PAINTSVILLE	  	Various OR Equipment	 	 $648,665.95	 	GE	 	9/19/2017
	POPLAR BLUFF	  	POST ANESTHESIA CARE UNIT	 	 $144,675.00	 	GE	 	5/30/2013
	POPLAR BLUFF	  	20” FLAT SCREEN TV’S (240)	 	 $209,550.00	 	GE	 	7/7/2013
	POPLAR BLUFF	  	STERRAD STERILIZATION SYSTEM	 	 $221,830.00	 	GE	 	7/7/2013
	POPLAR BLUFF	  	ULTRASOUND	 	 $54,800.00	 	GE	 	9/1/2013
	POPLAR BLUFF	  	CHEMISTRY ANALYZER	 	 $105,000.00	 	GE	 	12/30/2013
	POPLAR BLUFF	  	Intravascular Ultrasound Machine	 	 $168,267.00	 	GE	 	1/31/2016
	POPLAR BLUFF	  	64-Slice CT	 	 $1,330,154.00	 	GE	 	6/1/2016
	POPLAR BLUFF	  	 64-Slice CT (Medrad Injector &

Abbot iStat)
	 	$1,148,131.00	 	GE	 	6/14/2016
	POPLAR BLUFF	  	Nuclear Medicine Camera	 	 $315,809.73	 	GE	 	6/20/2016
	POPLAR BLUFF	  	64-Slice CT (AW server)	 	 	 	GE	 	6/30/2016
	POPLAR BLUFF	  	Radiology Equipment	 	 $504,779.00	 	GE	 	10/1/2016
	POPLAR BLUFF	  	Generator Cautry Units	 	 $78,440.00	 	GE	 	7/23/2017
	POPLAR BLUFF	  	Monitors	 	 $2,063,773.27	 	GE	 	11/14/2017
	POPLAR BLUFF	  	GE Monitoring Equipment	 	 $625,899.66	 	GE	 	11/30/2017
	POPLAR BLUFF	  	Surgical Table	 	 $423,974.00	 	GE	 	12/17/2017
	POPLAR BLUFF	  	Aespire Anesthesia Monitors	 	 $93,311.83	 	GE	 	12/31/2017
	POPLAR BLUFF	  	Endoscopy Scopes	 	 $819,036.13	 	GE	 	2/8/2018
	POPLAR BLUFF	  	C Arm #3	 	 $142,107.00	 	GE	 	2/8/2018

  
 93 

									
	POPLAR BLUFF	  	C Arm #2	 	$181,549.50	 	GE	 	2/8/2018
	POPLAR BLUFF	  	Endoscopic Ultrasound	 	$145,450.09	 	GE	 	2/28/2018
	POPLAR BLUFF	  	C Arm #1	 	$134,687.00	 	GE	 	3/21/2018
	POPLAR BLUFF	  	STERRAD NX STERILIZATION SYSTEM	 	$48,003.00	 	GE	 	 
	POPLAR BLUFF	  	Linear Accelerator	 	$3,583,739.00	 	GE	 	 
	PORT CHARLOTTE	  	VIDEO TOWER WITH 2 CAMERA HEADS	 	$87,521.73	 	GE	 	6/30/2013
	PORT CHARLOTTE	  	DIGITAL MOBILE C-ARM	 	$194,000.00	 	GE	 	5/14/2014
	PORT CHARLOTTE	  	DIGITAL MAMMOS	 	$615,042.04	 	GE	 	1/1/2015
	PORT CHARLOTTE	  	Cardiac Tower (Karl Storz)	 	$202,774.58	 	GE	 	1/27/2017
	PORT CHARLOTTE	  	 Cardiac Tower (GE Aespire

Anesthesia)
	 	$150,557.46	 	GE	 	1/27/2017
	PORT CHARLOTTE	  	Cardiac Tower (Omega)	 	$734,234.97	 	GE	 	1/27/2017
	PORT CHARLOTTE	  	Cardiac Tower (Mindray)	 	$700,556.83	 	GE	 	1/27/2017
	PORT CHARLOTTE	  	Cardiac Tower (Rad Pro Cannon)	 	$147,640.00	 	GE	 	1/27/2017
	PORT CHARLOTTE	  	Cardiac Tower	 	 	 	GE	 	 
	Pryor	  	VOIP System Sch 2	 	$37,918.71	 	GE	 	4/20/2017
	Pryor	  	MRI Upgrade	 	$828,812.85	 	GE	 	6/27/2017
	Pryor	  	VOIP System	 	$214,872.71	 	GE	 	6/28/2017
	Pryor	  	Optima CT 660 (32 Slice CT)	 	$515,172.65	 	GE	 	2/20/2018
	PUNTA GORDA	  	C-ARM	 	$143,188.20	 	GE	 	8/30/2013
	PUNTA GORDA	  	C-ARM	 	$123,690.00	 	GE	 	10/30/2014
	PUNTA GORDA	  	Digital Mammography	 	$367,255.00	 	GE	 	6/20/2017
	PUNTA GORDA/RVERSIDE	  	Spinal Table	 	$104,235.04	 	GE	 	12/7/2017
	ROCKLEDGE	  	Surgical Robot System	 	$1,060,000.00	 	GE	 	9/17/2017
	ROCKLEDGE	  	DR Portable X-Ray Machine	 	$149,500.00	 	GE	 	6/10/2018
	SEBASTIAN	  	ICU BEDS	 	$88,101.00	 	GE	 	9/14/2013
	SEBASTIAN	  	VASCULAR C-ARM	 	$262,027.00	 	GE	 	10/27/2014
	SEBASTIAN	  	 PATIENT MONITORING

SYSTEM / NURSING STATIONS 
	 	$520,138.00	 	GE	 	12/7/2014
	SEBASTIAN	  	EKG MACHINE	 	$12,565.00	 	GE	 	12/8/2014
	SEBASTIAN	  	Defibrillators	 	$62,000.00	 	GE	 	10/14/2015
	SEBASTIAN	  	Cath Lab	 	$1,150,688.76	 	GE	 	4/19/2017
	SEBASTIAN	  	Image Vault	 	$52,790.00	 	GE	 	7/21/2017
	SEBASTIAN	  	HP SAS Storage	 	$   8,139.31	 	GE	 	9/21/2017
	SEBASTIAN	  	Mako Robot	 	$1,060,000.00	 	GE	 	12/28/2017

  
 94 

									
	SEBASTIAN	  	Radiography & Fluroscopy	 	 $406,950.00	 	GE	 	3/21/2018
	SEBASTIAN	  	Innova System	 	 $971,726.60	 	GE	 	5/3/2018
	SEBASTIAN	  	BioMerieux Vitek	 	 $54,336.60	 	GE	 	6/24/2018
	SEBASTIAN	  	Mindray Monitoring	 	 $214,994.99	 	GE	 	6/26/2018
	SEBASTIAN	  	Echo System	 	$266,698.32	 	GE	 	 
	SEBRING	  	ULTRASOUND MACHINE	 	 $120,050.00	 	GE	 	12/14/2014
	SEBRING	  	ANESTHESIA MACHINES	 	 $111,000.00	 	GE	 	3/24/2015
	SEBRING	  	ECHO MACHINE	 	 $235,875.00	 	GE	 	3/24/2015
	SEBRING	  	MOBILE C-ARM	 	 $212,861.00	 	GE	 	5/15/2015
	SEBRING	  	ENDCOSCOPIC SYSTEM	 	 $205,000.00	 	GE	 	1/1/2016
	SEBRING	  	DIGITAL MAMMO	 	 $438,846.51	 	GE	 	5/17/2016
	SEBRING	  	OEC C-Arm	 	 $272,168.70	 	GE	 	5/21/2018
	SEBRING CLINIC	  	XRAY MACHINE	 	 $220,849.00	 	GE	 	2/28/2014
	Seminole	  	MindRay Patient Monitoring System 	 	 $181,299.47	 	GE	 	3/29/2018
	SHANDS LIVE OAK	  	Ultrasound	 	 $171,552.00	 	GE	 	12/15/2016
	SHANDS LIVE OAK	  	Infinia Nuclear Camera	 	 $373,579.71	 	GE	 	3/21/2017
	SPRING HILL	  	CATH LAB MONITORING	 	 $124,652.00	 	GE	 	11/14/2013
	SPRING HILL	  	MRI	 	 $1,126,699.75	 	GE	 	12/30/2013
	SPRING HILL	  	DIGITAL MAMMO	 	 $550,487.00	 	GE	 	12/14/2014
	SPRING HILL	  	ULTRASOUND	 	 $138,600.00	 	GE	 	7/1/2015
	SPRING HILL	  	Telemetry System (2 North)	 	 $122,820.00	 	GE	 	11/26/2015
	SPRING HILL	  	Surgical Towers (2)	 	 $183,563.00	 	GE	 	2/3/2016
	SPRING HILL	  	SPECIAL PROCEDURES ROOM	 	$798,943.00	 	GE	 	6/1/2016
	SPRING HILL	  	SPECIAL PROCEDURES ROOM (Solar Monitors)	 	 $37,476.00	 	GE	 	6/1/2016
	SPRING HILL	  	Urology Room Upgrade	 	 $371,311.00	 	GE	 	3/1/2017
	ST CLOUD	  	CT SCANNER	 	 $1,234,467.26	 	GE	 	10/14/2011
	ST CLOUD	  	 PATIENT MONITORING

SYSTEM
	 	 $203,839.00	 	GE	 	1/1/2014
	ST CLOUD	  	DIGITAL MAMMO	 	 $397,389.00	 	GE	 	9/15/2015
	ST CLOUD CLINIC	  	Ultrasound Machine	 	 $59,048.00	 	GE	 	10/25/2015
	STARKE	  	Ultrasound	 	 $187,411.00	 	GE	 	6/19/2017
	STATESBORO	  	VCT SCANNER	 	 $1,135,336.30	 	GE	 	3/30/2012
	STATESBORO	  	16 SLICE CT SCANNER	 	 $824,711.00	 	GE	 	6/24/2012
	STATESBORO	  	ICU MONITORS	 	 $285,156.00	 	GE	 	1/30/2013
	STATESBORO	  	CARDIAC CATH LAB REPLACEMENT	 	 $1,334,724.00	 	GE	 	2/14/2013

  
 95 

									
	STATESBORO	  	BEDS	 	$277,262.00	 	GE	 	11/30/2013
	STATESBORO	  	DIGITAL C-ARM	 	$138,770.00	 	GE	 	2/14/2014
	STATESBORO	  	C-ARM	 	$143,352.00	 	GE	 	12/23/2014
	STATESBORO	  	CARDIAC CATH LAB	 	$931,579.19	 	GE	 	5/15/2015
	STATESBORO	  	ANALYZERS	 	$285,380.00	 	GE	 	1/21/2016
	STATESBORO	  	 REPLACEMENT ECHO

MACHINE
	 	$139,967.00	 	GE	 	6/28/2016
	STATESBORO	  	St Jude EP Equipment	 	$617,899.00	 	GE	 	9/2/2016
	STATESBORO	  	Boston Scientific EP Equipment	 	$30,000.00	 	GE	 	9/2/2016
	STATESBORO	  	Mizuhosi Table	 	$102,907.35	 	GE	 	9/20/2017
	STATESBORO	  	Ultrasound	 	$153,324.00	 	GE	 	10/2/2017
	STATESBORO	  	Olympus EUS System	 	$484,866.74	 	GE	 	11/12/2017
	STATESBORO	  	OEC 9900 C-Arm	 	$178,687.50	 	GE	 	3/26/2018
	STATESBORO	  	Signa 1.5 EchSpeed System	 	$907,000.00	 	GE	 	 
	STATESBORO	  	Buildout Signa EchoSpeed	 	$217,442.00	 	GE	 	 
	STATESVILLE	  	ACCUDOSE CABINETS	 	$69,376.00	 	GE	 	6/14/2013
	STATESVILLE	  	PROTEUS RAD ROOM	 	$77,517.00	 	GE	 	12/14/2013
	STATESVILLE	  	Med Rad Dual Injector	 	$33,785.00	 	GE	 	6/1/2014
	STATESVILLE	  	CATH LAB WITH PCI	 	$986,611.94	 	GE	 	5/15/2015
	STATESVILLE	  	MedRad Dual Injector	 	$33,785.00	 	GE	 	5/20/2015
	STATESVILLE	  	Med Rad Provis Injector	 	$18,463.75	 	GE	 	6/1/2015
	STATESVILLE	  	DATASCOPE BALLOON PUMP 	 	$46,624.75	 	GE	 	6/1/2015
	STATESVILLE	  	ANGIOJET INJECTOR	 	$38,000.00	 	GE	 	6/1/2015
	STATESVILLE	  	SIGNATURE ANALYZER	 	$13,000.00	 	GE	 	6/1/2015
	STATESVILLE	  	AVOXIMETER	 	$   4,999.00	 	GE	 	6/1/2015
	STATESVILLE	  	SONOSITE ULTRASOUND	 	$28,077.20	 	GE	 	6/1/2015
	STATESVILLE	  	AGFA imager	 	$34,503.00	 	GE	 	7/1/2015
	STATESVILLE	  	64 SLICE CT	 	$962,701.96	 	GE	 	7/1/2015
	STATESVILLE	  	C-Arm	 	$145,503.00	 	GE	 	12/7/2017
	STATESVILLE	  	C-Arm - Original Agmt with CER 
	 	$168,644.25	 	GE	 	 
	TOPPENISH	  	MAMMOGRAPHY SYSTEM	 	$74,165.00	 	GE	 	2/28/2013
	TOPPENISH	  	C-ARM	 	$144,584.00	 	GE	 	9/1/2013
	TOPPENISH	  	Ultrasound Machine	 	$133,952.00	 	GE	 	3/15/2016
	TOPPENISH	  	Acute Care Patient Beds	 	$74,348.02	 	GE	 	3/29/2018

  
 96 

									
	TULLAHOMA	  	CT SCANNER	 	$1,018,752.20	 	GE	 	6/30/2011
	TULLAHOMA	  	BAXTER IV PUMPS	 	$250,635.00	 	GE	 	7/14/2013
	TULLAHOMA	  	EKG MONITOR	 	$13,764.50	 	GE	 	12/30/2013
	TULLAHOMA	  	TOWER BUILDOUT - DASH MONITORS	 	$49,161.21	 	GE	 	3/30/2014
	TULLAHOMA	  	TOWER BUILDOUT - DINAMAP  & CIC MONITORS	 	$84,306.91	 	GE	 	6/30/2014
	TULLAHOMA	  	PACS Storage System Upgrade	 	$586,502.00	 	GE	 	10/1/2015
	TULLAHOMA	  	OR Expansion (Truevision Microsurgery System)	 	$201,500.00	 	GE	 	12/1/2015
	TULLAHOMA	  	OR Expansion (Aisys Anesthesia)	 	$171,918.66	 	GE	 	1/1/2016
	TULLAHOMA	  	OR Expansion (Steris Tables)	 	$81,072.35	 	GE	 	3/1/2016
	TULLAHOMA	  	Patient Monitoring System (ICU)	 	$121,606.08	 	GE	 	3/16/2016
	TULLAHOMA	  	 OR Expansion (Steris Surgical

System)
	 	$350,509.28	 	GE	 	4/15/2016
	TULLAHOMA	  	OR Expansion (DASH Monitors)	 	$54,336.35	 	GE	 	5/15/2016
	TULLAHOMA	  	C-Arm	 	$194,539.00	 	GE	 	10/1/2016
	TULLAHOMA	  	PACS Workstation	 	$72,251.20	 	GE	 	12/7/2017
	TULLAHOMA	  	EKG Carts	 	$53,693.20	 	GE	 	3/21/2018
	TULLAHOMA	  	Pumps	 	$130,175.00	 	GE	 	5/29/2018
	TULLAHOMA	  	BioMerieux Vitek	 	$81,250.00	 	GE	 	6/28/2018
	TULLAHOMA	  	Image Vault	 	$11,977.00	 	GE	 	 
	TULLAHOMA	  	HL7	 	$22,558.38	 	GE	 	 
	TULLAHOMA	  	Vivid Ultrasound	 	$193,390.50	 	GE	 	 
	VAN BUREN	  	ARTHROSCOPY TOWER & EQUIPMENT	 	$177,167.00	 	GE	 	8/30/2013
	VAN BUREN	  	Endoscopic Equipment	 	$140,527.33	 	GE	 	8/27/2017
	VENICE	  	STERILIZER - WASHER	 	$143,035.00	 	GE	 	9/14/2013
	VENICE	  	Workstations	 	$66,768.00	 	GE	 	3/17/2014
	VENICE	  	Pro Telemetry	 	$379,000.00	 	GE	 	2/15/2015
	VENICE	  	MACLAB WORKSTATIONS	 	$105,205.22	 	GE	 	6/17/2015
	VENICE	  	Urology Surgical Equipment	 	$152,182.34	 	GE	 	8/27/2017
	VENICE	  	Navigation System	 	$455,189.08	 	GE	 	11/5/2017
	VENICE	  	EP Service Line Equipment	 	$169,967.60	 	GE	 	12/20/2017
	WILLIAMSON	  	ECHO MACHINE	 	$118,295.00	 	GE	 	1/5/2015
	WILLIAMSON	  	Endoscopy System	 	$348,328.00	 	GE	 	12/1/2015
	WILLIAMSON	  	Cardiac Monitoring System	 	$191,477.39	 	GE	 	9/22/2016
	WINDER	  	C-Arm	 	$189,423.00	 	GE	 	9/20/2017

  
 97 

									
	WUESTHOFF - MELBOURNE	  	Endoscopy System	 	$374,674.00	 	GE	 	2/14/2016
	WUESTHOFF - MELBOURNE	  	ICU Conversion Project (Hill Rom  Beds)	 	$204,444.00	 	GE	 	1/1/2017
	WUESTHOFF - MELBOURNE	  	Fetal Monitors	 	$130,806.96	 	GE	 	3/21/2017
	WUESTHOFF - ROCKLEDGE	  	Endoscopic Ultrasound System	 	$603,844.00	 	GE	 	1/17/2017
	WUESTHOFF - ROCKLEDGE	  	Dinamap Monitors	 	$   5,346.30	 	GE	 	3/19/2017
	WUESTHOFF - ROCKLEDGE	  	Telemetry System	 	$162,487.19	 	GE	 	3/19/2017
	YAKIMA	  	DIAMOND MAMMO SYSTEM	 	$73,495.50	 	GE	 	3/30/2013
	YAKIMA	  	MACLAB AND PACS	 	$565,385.99	 	GE	 	5/23/2014
	YAKIMA	  	SURGERY WASHER	 	$80,998.00	 	GE	 	8/16/2014
	YAKIMA	  	DASH 4000 MONITORS	 	$78,239.02	 	GE	 	6/15/2015
	YAKIMA	  	Cath Lab	 	$517,841.69	 	GE	 	5/23/2016
	YAKIMA	  	Carrot Flat Panel Display	 	$128,002.00	 	GE	 	6/1/2016
	YAKIMA	  	VENTILATORS	 	$116,638.60	 	GE	 	9/29/2016
	YAKIMA	  	Getinge Pump	 	$147,373.00	 	GE	 	3/2/2017
	YAKIMA	  	Biosense Webster CARTO/ St Jude  Medical Lab System	 	$599,000.00	 	GE	 	9/19/2017
	YAKIMA	  	GE Innova	 	$892,302.69	 	GE	 	9/19/2017
	YAKIMA	  	Acute Care Beds	 	$210,109.83	 	GE	 	3/26/2018
	YAKIMA	  	Monitor and Video Cart	 	$18,830.50	 	GE	 	6/27/2018
	YAKIMA	  	Balloon Pumps	 	$172,196.75	 	GE	 	 
	YAKIMA	  	Mammography System	 	$346,697.00	 	GE	 	 
	YAKIMA	  	Nuclear Camera	 	$376,647.70	 	GE	 	 
	YAKIMA	  	Vivid Ultrasound	 	$174,776.80	 	GE	 	 
	MILTON	  	64 SLICE CT SCANNER	 	$1,514,872.00	 	GE/CitiCorp	 	6/30/2013
	NAPLES - PR	  	ROBOTIC ORTHO SYSTEM	 	$895,000.00	 	Health Capital	 	10/9/2012
	JAMESTOWN	  	CO2 LASER	 	$120,250.00	 	 Heartland Business

Credit
	 	11/12/2012
	AMORY	  	DIGITAL MAMMO	 	$537,000.00	 	Highland Capital	 	5/1/2014
	STATESVILLE	  	DIGITAL MAMMOGRAPHY	 	$376,300.00	 	Highland Capital	 	8/12/2014
	TULLAHOMA	  	DIGITAL MAMMOGRAPHY	 	$411,411.00	 	Highland Capital	 	3/4/2014
	CORP	  	IBM DISASTER RECOVERY MAINFRAME	 	$68,030.00	 	IBM	 	12/13/2011
	CORP	  	DISASTER RECOVERY MAINFRAME	 	$68,030.00	 	IBM	 	12/31/2011

  
 98 

									
	CORP	  	IBM Storage device	 	$186,800.00	 	IBM	 	3/25/2012
	CORP	  	IBM CORE XEION	 	$19,585.00	 	IBM	 	9/28/2012
	CORP	  	IBM/AS400 9406-520 SERVER	 	$299,647.00	 	IBM	 	3/30/2013
	CORP	  	LAB INFO SYSTEM	 	$344,623.00	 	IBM	 	4/2/2013
	CORP	  	RAID ADAPTER SUPPLEMENTAL EQUIPMENT 	 	$22,477.00	 	IBM	 	5/25/2013
	CORP	  	PHARMACY SYSTEM UPDATE	 	$199,733.00	 	IBM	 	6/4/2013
	CORP	  	DISASTER RECOVERY MAINFRAME	 	$253,943.00	 	IBM	 	7/7/2013
	CORP	  	INTERFACE BOX FOR PATIENT  FOLDER	 	$95,303.00	 	IBM	 	7/27/2013
	CORP	  	AS/400 SYSTEM	 	$72,463.00	 	IBM	 	8/14/2013
	CORP	  	AS 400	 	$72,463.00	 	IBM	 	8/18/2013
	CORP	  	IBM POWER 750 EXPRESS	 	$92,961.00	 	IBM	 	8/31/2013
	CORP	  	SOFTLAB SYSTEM	 	$92,961.00	 	IBM	 	9/1/2013
	CORP	  	LAB INFO SYSTEM	 	$104,680.16	 	IBM	 	9/12/2013
	CORP	  	IBM CORE XEION	 	$229,340.00	 	IBM	 	12/7/2013
	CORP	  	LIS SERVER REPLACEMENTS	 	$16,518.00	 	IBM	 	5/7/2014
	CORP	  	IBM System Z10	 	$210,348.00	 	IBM	 	5/7/2014
	CORP	  	IBM Eclipse	 	$47,969.00	 	IBM	 	5/7/2014
	CORP	  	IBM Eclipse	 	$132,028.00	 	IBM	 	5/7/2014
	CORP	  	IBM Storage device enclosure	 	$78,786.00	 	IBM	 	5/7/2014
	CORP	  	AS/400 SYSTEM (10)	 	$286,374.00	 	IBM	 	5/31/2014
	CORPORATE	  	Mainframe (Atlanta)	 	$419,614.00	 	IBM	 	 
	CORP	  	10 AS/400 Servers	 	$247,511.00	 	IBM Credit	 	 
	Bayfront	  	StealthStation	 	$569,000.00	 	ICSE	 	8/15/2016
	BILOXI	  	R & F Room	 	$477,740.47	 	ICSE	 	10/14/2014
	BILOXI ASC	  	Recorder; Stirrups; Glidescope	 	$52,895.00	 	ICSE	 	9/14/2014
	BILOXI ASC	  	Sterilizer	 	$44,011.00	 	ICSE	 	2/15/2015
	BRANDON	  	Imaging Table	 	$113,797.00	 	ICSE	 	9/14/2014
	BRANDON CLINIC	  	X Ray Machine; Buildout	 	$87,445.00	 	ICSE	 	6/14/2014
	CANTON	  	DaVinci	 	$1,551,607.00	 	ICSE	 	4/15/2015
	CARLISLE	  	Instrumentation/Equipment	 	$118,196.60	 	ICSE	 	9/14/2014
	CARLISLE	  	Coagulation Analyzers	 	$78,440.00	 	ICSE	 	2/15/2015
	CHESTER	  	Eye Laser	 	$93,000.00	 	ICSE	 	6/14/2014
	CHESTER	  	Telemetry System	 	$114,034.89	 	ICSE	 	6/14/2014

  
 99 

									
	CHESTER	  	Sterilizers	 	$154,119.90	 	ICSE	 	10/14/2014
	DADE CITY	  	Patient Monitoring System	 	$153,926.64	 	ICSE	 	1/1/2016
	DADE CITY	  	AccuDose Equipment	 	$196,700.00	 	ICSE	 	7/15/2016
	DALLAS REGIONAL	  	Sterilizer	 	$164,482.00	 	ICSE	 	1/15/2015
	DALLAS REGIONAL	  	Sterilizer	 	$82,186.00	 	ICSE	 	 
	DALLAS/GALLOWAY	  	AccuDose Equipment	 	$336,855.00	 	ICSE	 	9/15/2016
	FLOWOOD	  	DaVinci	 	$1,767,077.00	 	ICSE	 	4/15/2015
	FLOWOOD	  	DaVinci Robot	 	$1,390,000.00	 	ICSE	 	 
	FLOWOOD EAST	  	Patient Room Furniture	 	$135,233.00	 	ICSE	 	7/15/2015
	FORT SMITH	  	Cysto Table	 	$314,308.00	 	ICSE	 	3/14/2015
	GADSDEN	  	Fluorescence Imaging Upgrade	 	$125,000.00	 	ICSE	 	 
	HARTSVILLE	  	AccuDose Equipment	 	$423,626.00	 	ICSE	 	7/15/2016
	 HARTSVILLE MED

GRP LLC
	  	Phone System	 	$56,575.80	 	ICSE	 	4/15/2016
	JACKSON	  	 Heart/Lung Perfusion System (2);

Pump Controller (2)
	 	$395,897.00	 	ICSE	 	6/15/2015
	JACKSON	  	Archive Servers for PACS Sys	 	$290,627.25	 	ICSE	 	10/15/2015
	Knoxville PRMC	  	
Cardiac Mapping System -ICSE

Lease
	 	$179,774.00	 	ICSE	 	10/15/2015
	Knoxville PRMC	  	Allura Xper FD20	 	$784,589.20	 	ICSE	 	6/15/2016
	LANCASTER HEART	  	Opus II System	 	$257,000.00	 	ICSE	 	9/15/2015
	LANCASTER HEART	  	Sterrad Sterilizers	 	$163,331.88	 	ICSE	 	8/15/2016
	 LANCASTER/ROSE

CITY
	  	AccuDose Equipment	 	$387,532.00	 	ICSE	 	10/15/2016
	LEBANON	  	Force Triad Energy Platforms	 	$168,366.00	 	ICSE	 	 
	MIDWEST CITY	  	Stress Test Unit (3)	 	$72,134.10	 	ICSE	 	6/14/2014
	MIDWEST CITY	  	Tables (2)	 	$94,743.00	 	ICSE	 	9/14/2014
	MIDWEST CITY	  	da Vinci Upgrade - ICSE	 	$125,350.00	 	ICSE	 	10/15/2015
	MOORESVILLE	  	ADVANTA BED SYSTEM	 	$85,570.00	 	ICSE	 	9/14/2014
	MOORESVILLE/SURG CTR	  	AccuDose Equipment	 	$355,212.00	 	ICSE	 	10/15/2016
	NAPLES - COLLIER	  	PACS Hardware; Voice Recognition  System	 	$511,867.00	 	ICSE	 	6/15/2015
	NATCHEZ	  	Sonic Cleaner	 	$75,976.00	 	ICSE	 	7/14/2014
	POPLAR BLUFF	  	CDW IT Equipment	 	$1,427,984.25	 	ICSE	 	6/15/2015
	POPLAR BLUFF	  	Furniture	 	$2,065,365.54	 	ICSE	 	7/15/2015
	POPLAR BLUFF	  	TVs	 	$199,247.74	 	ICSE	 	12/1/2015
	POPLAR BLUFF	  	IT Monitors	 	$151,135.89	 	ICSE	 	12/1/2015

  
 100 

									
	PT CHARLOTTE	  	AcuDose Auxiliary Cabinet	 	$201,266.00	 	ICSE	 	11/15/2015
	PUNTA GORDA	  	Portable Digital Radiology	 	$159,924.00	 	ICSE	 	12/15/2014
	PUNTA GORDA/RVERSIDE	  	AccuDose Equipment	 	$303,806.00	 	ICSE	 	8/15/2016
	SEBASTIAN	  	Endobronchial Ultrasound	 	$155,644.00	 	ICSE	 	5/15/2015
	SEBASTIAN	  	AccuDose Equipment	 	$119,790.00	 	ICSE	 	6/15/2016
	SEBRING	  	Telemetry Monitors	 	$102,309.92	 	ICSE	 	10/14/2014
	SEBRING	  	AccuDose Equipment	 	$109,212.00	 	ICSE	 	9/15/2016
	SPRING HILL	  	Central Monitoring System (ER)	 	$185,944.00	 	ICSE	 	5/15/2015
	ST CLOUD CLINIC	  	Urodynamic System	 	$32,195.00	 	ICSE	 	6/14/2014
	STATESBORO	  	AccuDose Equipment	 	$409,260.02	 	ICSE	 	5/15/2016
	VENICE	  	Sterilizers (5)	 	$102,103.00	 	ICSE	 	12/15/2014
	DURANT	  	URINALYSIS EQUIPMENT	 	$111,500.00	 	IRIS	 	12/7/2013
	BROOKSVILLE	  	MRI Upgrade (8 Channel Coils)	 	$378,290.00	 	ISCE	 	6/15/2015
	Knoxville PRMC	  	DaVinci upgrade	 	$241,650.00	 	ISCE	 	6/15/2015
	ANNISTON	  	Endoscopy Tower	 	$122,362.00	 	Karl Storz	 	2/7/2017
	DALLAS REGIONAL	  	Endo Cameras	 	$120,908.00	 	Karl Storz	 	 
	JACKSON	  	HD VIDEO UPGRADE	 	$244,282.00	 	Karl Storz	 	8/30/2012
	MONROE	  	Laparoscopic Video Equipment	 	$375,000.04	 	Karl Storz	 	4/30/2017
	POPLAR BLUFF	  	ENDOSCOPY EQUIPMENT	 	$80,332.00	 	Karl Storz	 	7/31/2012
	POPLAR BLUFF	  	Video Equipment	 	$459,232.20	 	Karl Storz	 	9/21/2017
	POPLAR BLUFF	  	Endscopy Equipment	 	$210,443.14	 	Karl Storz	 	12/17/2017
	POPLAR BLUFF	  	Urologic Equipment	 	$331,548.32	 	Karl Storz	 	 
	STATESBORO	  	Endoscopic System OR	 	$424,088.30	 	Karl Storz	 	11/8/2017
	WILLIAMSON	  	Surgical Video Tower; Equipment	 	$110,848.00	 	Karl Storz	 	9/22/2014
	WUESTHOFF - MELBOURNE	  	Central Imaging & Data Archiving  System	 	$96,930.00	 	Karl Storz	 	7/15/2016
	NAPLES - COLLIER	  	OR HD Video Upgrade	 	$260,241.00	 	Karl Storz/Wells Fargo	 	11/22/2013
	VENICE	  	UROLOGY CYSTOSCOPY EQUIPMENT	 	$323,992.77	 	Karl Storz/Wells Fargo	 	9/1/2013
	VENICE	  	TOWERS (3)	 	$188,062.00	 	Karl Storz/Wells Fargo	 	 
	VENICE	  	ARTHROSCOPY CAMERAS	 	$91,971.00	 	Karl Storz/Wells Fargo	 	 
	NAPLES PINE RIDGE	  	Konica Minolta Copier	 	$   4,280.98	 	Konica Minolta	 	1/20/2014
	BILOXI	  	Coagulation Instruments (2)	 	$139,100.00	 	LaSalle	 	6/1/2017
	FLOWOOD	  	ER CENTRAL MONITORING SYSTEM	 	$105,666.00	 	LaSalle	 	11/30/2014
	FLOWOOD	  	 PATIENT MONITORING

SYSTEM
	 	$128,828.00	 	LaSalle	 	5/1/2015

  
 101 

									
	SEBRING	  	PATIENT ICU MONITORING SYSTEM	 	 $227,141.00	 	LaSalle	 	1/1/2015
	SEBRING	  	PACU MONITORS	 	 $87,002.51	 	LaSalle	 	4/1/2015
	BARTOW	  	Echo Ultrasound Machine	 	 $77,671.00	 	Macquarie	 	8/14/2014
	Knoxville PRMC	  	Solargen 2100s CV Therapy Console 	 	 $330,000.00	 	Macquarie Equipment Finance	 	2/23/2012
	BRANDON	  	Accudose	 	 $23,771.00	 	Marquette	 	2/11/2014
	BRANDON	  	McKesson Accudose	 	$71,499.00	 	Marquette	 	12/12/2014
	BRANDON	  	Hill-Rom Total Care Beds	 	$142,943.25	 	Marquette	 	5/26/2015
	CANTON	  	Accudose	 	 $41,108.00	 	Marquette	 	8/9/2014
	VENICE	  	Accudose	 	$129,731.00	 	Marquette	 	5/1/2014
	BILOXI	  	Bio Rad Evolis Instrument	 	 $65,534.00	 	Marquette Equipment Finance	 	10/13/2014
	BILOXI ASC	  	Endoscopic Insufflator	 	 $8,624.00	 	Marquette Equipment Finance	 	1/1/2014
	BILOXI ASC	  	Ansthesia Machines (2)	 	 $42,800.00	 	Marquette Equipment Finance	 	2/9/2014
	BILOXI ASC	  	Scope Washer	 	 $58,655.00	 	Marquette Equipment Finance	 	2/9/2014
	BRANDON	  	ACCUDOSE CABINETS	 	 $23,771.00	 	Marquette Equipment Finance	 	2/11/2014
	BRANDON	  	Create 15-Bed Burn Unit	 	 $2,505,721.00	 	Marquette Equipment Finance	 	5/25/2015
	CLARKSDALE	  	Sterilizer	 	 $131,013.00	 	Marquette Equipment Finance	 	5/24/2015
	CRYSTAL RIVER	  	ACCUDOSE EQUIPMENT	 	 $47,635.00	 	Marquette Equipment Finance	 	11/17/2014
	CRYSTAL RIVER	  	Sterilizers (3)	 	 $224,831.00	 	Marquette Equipment Finance	 	10/19/2015
	DADE CITY	  	BRANCH EXCHANGE SYSTEM	 	 $443,342.00	 	Marquette Equipment Finance	 	9/23/2013
	DALLAS REGIONAL	  	DIGITAL MAMMO	 	 $224,000.00	 	Marquette Equipment Finance	 	3/5/2015
	DURANT	  	ACCUDOSE	 	 $29,833.00	 	Marquette Equipment Finance	 	7/13/2014
	FLOWOOD	  	ELECTRIC CAUTERY UNITS	 	 $169,587.50	 	Marquette Equipment Finance	 	8/17/2014
	FLOWOOD CLINIC	  	Laser	 	 $135,000.00	 	Marquette Equipment Finance	 	10/26/2013
	FLOWOOD EAST	  	Birthing Beds (7)	 	 $112,212.00	 	Marquette Equipment Finance	 	4/8/2015
	FORT SMITH	  	DIALYSIS MACHINES	 	 $103,200.00	 	Marquette Equipment Finance	 	8/27/2013
	GADSDEN	  	PERFUSION PUMP	 	 $81,399.00	 	Marquette Equipment Finance	 	11/5/2013

  
 102 

									
	JACKSON	  	SURGICAL TABLES	 	$88,926.00	 	Marquette Equipment Finance	 	1/25/2015
	JACKSON	  	MINI C-ARM	 	$57,650.00	 	Marquette Equipment Finance	 	1/25/2015
	JACKSON	  	Defib Monitors (7)	 	$139,066.00	 	Marquette Equipment Finance	 	5/23/2015
	KEY WEST	  	ACCUDOSE CABINETS AND TOWER	 	$53,697.00	 	Marquette Equipment Finance	 	5/24/2014
	KEY WEST	  	DIGITAL MAMMO	 	$500,800.00	 	Marquette Equipment Finance	 	3/5/2015
	LANCASTER CLINIC	  	Digital Strobe System	 	$102,720.00	 	Marquette Equipment Finance	 	10/24/2015
	LANCASTER Heart o	  	ACCUDOSE EQUIPMENT	 	$41,771.00	 	Marquette Equipment Finance	 	12/31/2013
	LEBANON	  	ICU RENOVATION	 	$160,463.00	 	Marquette Equipment Finance	 	8/16/2014
	MIDWEST CITY	  	ACCUDOSE TOWER & MAIN	 	$226,564.00	 	Marquette Equipment Finance	 	7/1/2014
	MONROE	  	ACCUDOSE CABINETS	 	$47,728.00	 	Marquette Equipment Finance	 	2/11/2014
	MOORESVILLE	  	POWER DRILLS & SAWS	 	$231,898.00	 	Marquette Equipment Finance	 	8/16/2014
	MOORESVILLE	  	DIGITAL MAMMO	 	$236,000.00	 	Marquette Equipment Finance	 	5/24/2015
	POPLAR BLUFF	  	Defibrillators (28)	 	$222,932.00	 	Marquette Equipment Finance	 	8/1/2015
	PORT CHARLOTTE	  	Ortho Equipment	 	$116,433.00	 	Marquette Equipment Finance	 	6/13/2015
	SEBASTIAN	  	ULTRASOUND	 	$137,840.00	 	Marquette Equipment Finance	 	4/16/2013
	SEBASTIAN	  	Dispensers	 	$190,924.00	 	Marquette Equipment Finance	 	12/22/2014
	SEBRING	  	Acudose Medication Tower	 	$29,726.00	 	Marquette Equipment Finance	 	8/1/2014
	SPRING HILL	  	Accudose Tower and Cabinet	 	$31,772.00	 	Marquette Equipment Finance	 	8/1/2014
	ST CLOUD	  	GI Equipment	 	$180,901.00	 	Marquette Equipment Finance	 	5/23/2015
	STATESBORO	  	REPLACEMENT STERIS UNITS 	 	$124,983.35	 	Marquette Equipment Finance	 	11/8/2014
	VENICE	  	CVICU - PUMPS	 	$105,864.00	 	Marquette Equipment Finance	 	12/1/2013
	VENICE	  	ACCUDOSE	 	$35,073.00	 	Marquette Equipment Finance	 	12/24/2013
	VENICE	  	ACCUDOSE	 	$26,484.00	 	Marquette Equipment Finance	 	3/31/2014
	WINDER	  	DIGITAL MAMMOGRAPHY	 	$95,328.00	 	Marquette Equipment Finance	 	4/1/2013

  
 103 

									
	WINDER	  	Acudose	 	$25,935.00	 	Marquette Equipment Finance	 	10/24/2014
	WINDER	  	DIGITAL MAMMOGRAPHY	 	$353,695.00	 	Marquette Equipment Finance	 	2/15/2015
	STATESBORO	  	 ADDITIONAL ENDOSCOPY

SUITE
	 	$447,226.14	 	Marquette Equipment Finance/TC	 	9/8/2014
	DADE CITY	  	VENTILATORS	 	$122,833.00	 	Med One	 	12/11/2014
	DADE CITY	  	CATH LAB	 	$916,174.00	 	Med One	 	3/25/2015
	DALLAS REGIONAL	  	NUCLEAR CAMERA	 	$262,570.00	 	Med One	 	12/4/2014
	FLOWOOD	  	VIDEO EQUIPMENT	 	$158,800.00	 	Med One	 	10/27/2012
	FLOWOOD	  	VISION PROJECT - STRYKER	 	$396,248.00	 	Med One	 	7/29/2013
	FLOWOOD	  	VIDEO EQUIPMENT	 	$158,400.00	 	Med One	 	11/20/2013
	FLOWOOD	  	DA VINCI SYSTEM	 	$1,390,000.00	 	Med One	 	4/14/2014
	FLOWOOD	  	MICROSCOPE	 	$239,397.00	 	Med One	 	5/12/2014
	FLOWOOD EAST	  	GAMMA CAMERA	 	$277,363.44	 	Med One	 	3/23/2015
	HARTSVILLE	  	BRONCHOSCOPE UPGRADE	 	$175,081.00	 	Med One	 	7/8/2015
	LEBANON	  	NUCLEAR CAMERA	 	$310,238.00	 	Med One	 	12/14/2014
	LEBANON	  	ECHO MACHINE	 	$136,939.00	 	Med One	 	3/17/2015
	LEHIGH ACRES	  	MED/SURG BEDS	 	$206,484.00	 	Med One	 	3/13/2014
	MELBOURNE	  	Smiths Medical Pumps	 	$106,240.00	 	Med One	 	 
	MOORESVILLE	  	ULTRASOUND	 	$67,950.00	 	Med One	 	4/8/2014
	ROCKLEDGE	  	Smiths Medical Pumps	 	$199,010.00	 	Med One	 	 
	SEBASTIAN	  	MED SURGE AND BARIATRIC BEDS	 	$213,367.90	 	Med One	 	4/14/2014
	VENICE	  	C-ARM	 	$99,561.00	 	Med One	 	2/24/2015
	VENICE	  	ANGIOGRAPHY SUITE	 	$1,550,298.00	 	Med One	 	6/10/2015
	WINDER	  	ER MONITORING EQUIPMENT	 	$104,446.00	 	Med One	 	2/17/2015
	YAKIMA	  	ENDOSCOPY	 	$569,521.00	 	Med One	 	11/8/2013
	SEBASTIAN	  	COPIERS	 	$126,063.00	 	Minolta	 	1/29/2013
	STATESBORO	  	Credit Card Machine	 	 	 	Northern Leasing Systems, Inc.	 	1/23/2013
	BROOKSVILLE	  	ENDOSCOPIC ULTRASOUND	 	$231,384.00	 	Olympus	 	3/30/2014
	CARLISLE	  	OR Rooms HD Upgrade	 	$933,878.68	 	Olympus	 	 
	DALLAS/GALLOWAY	  	GI Scopes	 	$223,302.42	 	Olympus	 	 
	GADSDEN	  	PEDIATRIC COLON SCOPES	 	$57,148.00	 	Olympus	 	7/26/2015
	JACKSON	  	Endoscopic Ultrasound	 	$162,596.53	 	Olympus	 	 
	 KNOXVILLE

JEFFERSON
	  	GI Lab Scopes	 	$172,162.45	 	Olympus	 	 

  
 104 

									
	Knoxville TCMC	  	Olympus Video Scopes	 	 $419,334.79	 	Olympus	 	12/31/2013
	LANCASTER REG	  	ENDOSCOPY EQUIPMENT	 	 $464,148.00	 	OLYMPUS	 	10/10/2015
	MILTON	  	ENDOSCOPY SYSTEM	 	 $492,578.00	 	Olympus	 	12/8/2013
	PAINTSVILLE	  	OR SCOPE REPLACEMENT	 	 $251,616.00	 	Olympus	 	1/20/2014
	PUNTA GORDA	  	ENDO-SCOPES	 	 $94,027.00	 	Olympus	 	10/8/2014
	SEBASTIAN	  	HD ENDOSCOPY UPGRADED WORKSTATION	 	 $342,122.42	 	Olympus	 	7/31/2013
	SEBRING	  	ENDOSCOPIC VIDEO SYSTEM	 	 $958,164.00	 	Olympus	 	11/30/2014
	TULLAHOMA	  	VIDEO TOWERS	 	 $323,367.65	 	Olympus	 	8/25/2013
	VAN BUREN	  	COLONSCOPES	 	 $53,521.00	 	Olympus	 	12/24/2013
	WINDER	  	Endoscopes	 	 $140,047.85	 	Olympus	 	 
	AMORY	  	BUCKY DIAGNOSTIC AND MOBILE X-RAY	 	 $81,720.00	 	Philips	 	7/26/2014
	AMORY	  	C-Arm	 	 $149,432.00	 	Philips	 	6/7/2016
	ANNISTON	  	HEMATOLOGY ANALYZER	 	 $187,920.00	 	Philips	 	9/18/2013
	ANNISTON	  	Cardiac Monitoring System, Telemetry Units	 	 $514,344.72	 	Philips	 	12/17/2017
	BARTOW	  	IE33 ULTRASOUND MACHINE	 	 $199,350.00	 	Philips	 	4/20/2015
	BARTOW	  	iE33 Ultrasound System	 	 $162,500.00	 	Philips	 	4/21/2015
	BARTOW	  	CENTRAL MONITOR STATION  UPGRADE	 	 $133,147.00	 	Philips	 	8/30/2015
	BARTOW	  	Intellivue Monitors	 	 $133,146.80	 	Philips	 	8/31/2015
	BARTOW	  	40-Slice CT	 	 $471,800.00	 	Philips	 	 
	BRANDON	  	MICROSCOPE	 	 $74,000.00	 	Philips	 	5/6/2013
	BRANDON CLINIC	  	Digital X Ray Unit	 	 $96,665.00	 	Philips	 	11/15/2015
	BROOKSVILLE	  	64 SLICE CT SCANNER	 	 $863,809.58	 	Philips	 	7/22/2013
	BROOKSVILLE	  	DIAGNOSTIC IMAGING DIGITAL ECHO	 	 $160,196.00	 	Philips	 	12/12/2013
	BROOKSVILLE	  	ED AND SDS PATIENT MONITORS	 	 $75,423.10	 	Philips	 	4/8/2014
	BROOKSVILLE	  	DIAGNOSTIC IMAGING UPS	 	 $140,394.00	 	Philips	 	4/8/2014
	BROOKSVILLE	  	Telemetry System	 	 $96,921.00	 	Philips	 	3/10/2016
	BROOKSVILLE	  	Nuclear Medicine Camera	 	 $292,351.00	 	Philips	 	7/22/2016
	CANTON	  	Mindray Equipment	 	 $280,052.00	 	Philips	 	3/22/2017
	CARLISLE	  	LARYNGOSCOPE EQUIPMENT	 	 $69,335.00	 	Philips	 	11/14/2012
	CARLISLE	  	GAMMA CAMERA	 	$341,764.00	 	Philips	 	4/8/2013
	CARLISLE	  	ENDO CAMERA S AND SCOPES 	 	 $138,548.00	 	Philips	 	5/18/2013
	CARLISLE	  	 BRIGHTVIEW NUCLEAR

CAMERA
	 	 $323,780.00	 	Philips	 	12/30/2013

  
 105 

									
	CARLISLE	  	Cardio Physiomonitoring System	 	$119,958.00	 	Philips	 	2/22/2018
	CHESTER	  	VIVID CARDIO ULTRASOUND SYSTEM	 	$130,990.00	 	Philips	 	1/20/2014
	CLARKSDALE	  	ICU BEDSIDE MONITORS	 	$164,542.00	 	Philips	 	3/9/2015
	CLARKSDALE	  	Mobile C-Arm	 	$174,742.00	 	Philips	 	6/29/2016
	CLARKSDALE	  	Ultrasound System (2)	 	$318,434.00	 	Philips	 	7/11/2016
	CLARKSDALE	  	Telemetry Equipment	 	$182,118.00	 	Philips	 	9/29/2016
	CRYSTAL RIVER	  	VITEK2 COMPACT 30 FOR MICROBIO	 	$58,381.00	 	Philips	 	11/14/2012
	CRYSTAL RIVER	  	ULTRASOUND EQUIPMENT	 	$92,760.00	 	Philips	 	8/1/2013
	CRYSTAL RIVER	  	EKG MACHINES	 	$86,490.00	 	Philips	 	10/26/2014
	CRYSTAL RIVER	  	CARDIAC CATHERITZATION & MONITORS	 	$879,457.00	 	Philips	 	7/30/2015
	CRYSTAL RIVER	  	C-Arm	 	$130,732.00	 	Philips	 	3/22/2017
	DADE CITY	  	NUCLEAR CAMERA	 	$334,464.00	 	Philips	 	7/9/2015
	DADE CITY	  	Ultrasound Machine	 	$132,345.00	 	Philips	 	7/27/2016
	DADE CITY	  	16-Slice CT; Injector	 	$292,221.00	 	Philips	 	12/1/2016
	DALLAS REGIONAL	  	Telemetry System	 	$1,002,055.00	 	Philips	 	12/16/2016
	DALLAS WOMAN’S	  	ENT EQUIPMENT	 	$197,779.00	 	Philips	 	3/30/2015
	DURANT	  	 SURGERY MONITORS FOR

PACU
	 	$184,857.00	 	Philips	 	6/30/2014
	DURANT	  	Surgery Monitors	 	$184,857.00	 	Philips	 	10/1/2015
	DURANT	  	Telemetry Units	 	$290,512.00	 	Philips	 	2/22/2016
	DURANT	  	Fetal Monitors	 	$129,303.00	 	Philips	 	3/28/2016
	DURANT	  	C-Arm	 	$120,250.00	 	Philips	 	4/30/2017
	FLOWOOD	  	OPMI PENTERO MICROSCOPE	 	$267,505.00	 	Philips	 	12/5/2012
	FLOWOOD	  	SINGLE PLANE VASCULAR LAB	 	$748,445.00	 	Philips	 	8/7/2014
	FLOWOOD	  	160-Slice CT	 	$1,367,618.00	 	Philips	 	4/1/2016
	FLOWOOD	  	Hemodynamics System	 	$153,221.00	 	Philips	 	3/28/2017
	FORT SMITH	  	Interventional Radiology Lab	 	$2,209,527.00	 	Philips	 	10/28/2015
	FORT SMITH	  	PET CT	 	$1,989,206.00	 	Philips	 	11/17/2016
	FORT SMITH	  	Multi Eleva with Flat Detector	 	$686,333.00	 	Philips	 	9/28/2017
	HAINES CITY	  	VASCULAR /THORACIC INSTRUMENTS	 	$211,962.62	 	Philips	 	8/12/2014
	HAINES CITY	  	CATH LAB	 	$1,228,713.00	 	Philips	 	4/8/2015
	HAINES CITY	  	TELEMETRY SYSTEM	 	$175,325.56	 	Philips	 	11/2/2015
	HAINES CITY	  	64 Slice CT	 	$891,156.95	 	Philips	 	6/12/2016
	HAINES CITY	  	Telemetry System (ER)	 	$365,758.00	 	Philips	 	8/1/2016

  
 106 

									
	KENNETT	  	ULTRASOUND SYSTEM	 	$116,258.00	 	Philips	 	8/24/2014
	KENNETT	  	64-Slice CT	 	$748,422.00	 	Philips	 	 
	KEY WEST	  	CARDIAC CATHERITZATION	 	$1,450,227.00	 	Philips	 	12/8/2013
	KEY WEST	  	 PATIENT MONITORING

SYSTEM
	 	$143,441.16	 	Philips	 	11/23/2014
	KEY WEST	  	 PATIENT MONITORING

SYSTEM
	 	$87,885.00	 	Philips	 	7/9/2015
	KEY WEST	  	Patient Monitoring System	 	$286,402.00	 	Philips	 	7/29/2016
	 KNOXVILLE -

JEFFERSON
	  	Ultrasound	 	$136,089.00	 	Philips	 	1/27/2017
	KNOXVILLE - PRMC	  	Ultrasound	 	$288,998.00	 	Philips	 	3/28/2012
	Knoxville Jefferson	  	iE33 Ultrasound	 	$139,889.00	 	Philips	 	8/22/2017
	Knoxville LaFollette	  	C-Arm	 	$247,000.00	 	Philips	 	 
	LANCASTER HEART	  	Philips Wall Monitors	 	$101,880.00	 	Philips	 	1/31/2018
	LANCASTER Heart o	  	Telemetry System	 	$153,784.00	 	Philips	 	4/15/2016
	LANCASTER Heart o	  	Echo Machine	 	$231,271.00	 	Philips	 	11/17/2016
	LANCASTER REG	  	Cath Lab Sch 3	 	$98,334.83	 	Philips	 	11/1/2015
	LANCASTER REG	  	Cardiac Cath Lab Sch 1	 	$1,218,101.89	 	Philips	 	4/21/2016
	LANCASTER REG	  	Cath Lab Sch 2	 	$551,919.20	 	Philips	 	5/27/2016
	LANCASTER REG	  	Replacement Telemetry System	 	$147,396.63	 	Philips	 	7/29/2016
	LANCASTER REG	  	Cath Lab Sch 8	 	$85,677.60	 	Philips	 	8/1/2016
	LANCASTER REG	  	R/F Unit	 	$489,143.00	 	Philips	 	12/1/2016
	 LANCASTER

REGIONAL
	  	Echo Machines (2)	 	$389,464.00	 	Philips	 	3/13/2017
	 LANCASTER/ROSE

CITY
	  	Rad Room	 	$391,049.00	 	Philips	 	8/8/2017
	 LANCASTER/ROSE

CITY
	  	Ultrasound	 	$100,485.00	 	Philips	 	9/24/2017
	LEBANON	  	CATH LAB - 24 MONTH RENEWAL	 	$325,000.00	 	Philips	 	8/30/2011
	LEBANON	  	16 SLICE CT - 24 MONTH RENEWAL	 	$250,000.00	 	Philips	 	12/14/2011
	LEBANON	  	C-Arm	 	$121,077.00	 	Philips	 	1/4/2016
	LEBANON	  	Rad Room	 	$86,848.00	 	Philips	 	6/7/2016
	LEBANON	  	Rad Room Diagnostic Ceiling	 	$177,396.00	 	Philips	 	7/29/2016
	LEBANON	  	Rad/Fluro Room	 	$399,183.00	 	Philips	 	7/29/2016
	LEBANON	  	Fetal Monitors (8); Thick Clients	 	$369,509.00	 	Philips	 	 
	LEHIGH ACRES	  	PT MONITOR/TELE SYSTEM	 	$472,871.00	 	Philips	 	1/21/2013
	LEHIGH ACRES	  	16 SLICE CT SCANNER	 	$529,122.00	 	Philips	 	9/18/2013

  
 107 

									
	MIDWEST CITY	  	 Philips EKG database & EKG

system
	 	$231,227.00	 	Philips	 	3/23/2014
	MIDWEST CITY	  	IE33 ULTRASOUND MACHINE 	 	$207,090.00	 	Philips	 	4/16/2014
	MIDWEST CITY	  	 Telemetry & PCU Monitoring

System
	 	$1,843,497.00	 	Philips	 	5/29/2017
	MIDWEST CLINIC	  	X-RAY AND PACS EQUIPMENT 	 	$176,607.00	 	Philips	 	4/8/2013
	MILTON	  	C-ARM	 	$111,063.00	 	Philips	 	6/7/2015
	MILTON	  	C-Arm	 	$142,340.00	 	Philips	 	3/14/2016
	MILTON	  	MRI	 	$1,189,843.00	 	Philips	 	4/1/2016
	MILTON	  	Angio Suite	 	$987,329.85	 	Philips	 	9/19/2016
	MONROE	  	40-Slice CT	 	$427,635.00	 	Philips	 	2/22/2016
	MONROE	  	Telemetry System	 	$134,110.00	 	Philips	 	4/21/2016
	MONROE	  	Ultrasound	 	$43,942.00	 	Philips	 	12/12/2016
	MONROE	  	16 Slice CT	 	$497,282.00	 	Philips	 	3/22/2017
	MONROE	  	Nuclear	 	$250,522.00	 	Philips	 	3/22/2017
	MONROE	  	X-Ray	 	$419,061.00	 	Philips	 	3/22/2017
	MONROE	  	Defibs	 	$101,280.00	 	Philips	 	3/22/2017
	MONROE	  	C-Arm	 	$135,153.00	 	Philips	 	3/22/2017
	MONROE	  	Monitoring	 	$1,122,091.00	 	Philips	 	3/22/2017
	MONROE	  	MRI	 	$760,000.00	 	Philips	 	4/21/2017
	MOORESVILLE	  	DIGITAL XRAY	 	$131,701.10	 	Philips	 	4/20/2014
	MOORESVILLE	  	C-Arm	 	$83,788.00	 	Philips	 	9/19/2016
	NAPLES - PR	  	CARDIAC CATH LAB	 	$1,150,336.00	 	Philips	 	1/14/2015
	NAPLES - PR	  	Patient Monitoring System (ER)	 	$342,249.00	 	Philips	 	8/29/2016
	NAPLES - PR	  	Ultrasound Machine	 	$160,572.00	 	Philips	 	1/23/2017
	NAPLES - PR	  	Patient Monitoring System	 	$677,152.26	 	Philips	 	3/1/2017
	NAPLES - PR	  	Defibrillators (16)	 	$163,333.00	 	Philips	 	3/28/2017
	NAPLES PINE RIDGE	  	CX50 POC Ultrasound	 	$71,792.00	 	Philips	 	12/6/2017
	NATCHEZ	  	HeartStart MRx Monitor/Defib	 	$125,382.00	 	Philips	 	7/20/2017
	NATCHEZ	  	iE33 Ultrasound	 	$176,778.00	 	Philips	 	8/28/2017
	NATCHEZ	  	Telemetry System	 	$349,714.00	 	Philips	 	 
	NATCHEZ	  	Cardiac Monitoring System	 	$142,895.11	 	Philips	 	 
	PAINTSVILLE	  	PACS	 	$335,674.00	 	Philips	 	7/18/2013
	PAINTSVILLE	  	CARDIAC ECHO EQUIPMENT	 	$256,868.00	 	Philips	 	1/27/2015
	PAINTSVILLE	  	Ultrasound and Table	 	$224,621.00	 	Philips	 	3/27/2018
	POPLAR BLUFF	  	RADIOLOGY SYSTEM	 	$1,318,681.00	 	Philips	 	12/29/2013

  
 108 

									
	POPLAR BLUFF	  	Ultrasound Machine	  	 $167,546.00	  	Philips	  	1/11/2016
	POPLAR BLUFF	  	Digital Diagnostic (1)	  	 $241,686.00	  	Philips	  	12/17/2017
	POPLAR BLUFF	  	Allura FD20 Cath Lab	  	 $1,287,592.00	  	Philips	  	12/17/2017
	POPLAR BLUFF	  	UPS	  	 $105,035.00	  	Philips	  	12/17/2017
	POPLAR BLUFF	  	Easy Diagnostic Eleva	  	 $375,059.00	  	Philips	  	12/17/2017
	POPLAR BLUFF	  	Digital Diagnostic (2)	  	 $334,225.00	  	Philips	  	12/17/2017
	POPLAR BLUFF	  	Brilliance 16 CT	  	 $328,288.00	  	Philips	  	12/17/2017
	POPLAR BLUFF	  	FD20 Hybrid	  	 $1,448,862.00	  	Philips	  	12/17/2017
	POPLAR BLUFF	  	Mobile Diagnostic (2)	  	 $181,448.00	  	Philips	  	1/4/2018
	POPLAR BLUFF	  	Ventilators	  	 $176,397.00	  	Philips	  	1/29/2018
	POPLAR BLUFF	  	Xper Flex Cardio	  	 $162,923.00	  	Philips	  	3/21/2018
	POPLAR BLUFF	  	CV Upgrades Inter	  	 $273,459.00	  	Philips	  	3/21/2018
	POPLAR BLUFF	  	CV Upgrades FD20	  	 $170,317.00	  	Philips	  	3/21/2018
	POPLAR BLUFF CLINIC	  	Ultrasound System	  	 $197,947.00	  	Philips	  	3/23/2017
	PORT CHARLOTTE	  	MRI	  	 $930,985.00	  	Philips	  	2/23/2014
	PORT CHARLOTTE	  	5 DEFIBRILLATORS	  	 $107,987.62	  	Philips	  	6/1/2014
	PORT CHARLOTTE	  	ECG Management System	  	 $97,314.00	  	Philips	  	2/1/2017
	PORT CHARLOTTE	  	Cardiac Tower	  	 $2,302,277.71	  	Philips	  	2/1/2017
	PORT CHARLOTTE	  	Cath Lab	  	 $1,240,062.00	  	Philips	  	5/24/2017
	PUNTA GORDA	  	CARD CATH LAB ALLURA XPERFD10	  	 $1,080,858.00	  	Philips	  	5/30/2013
	PUNTA GORDA/RVERSIDE	  	Philips Ultrasound System IE 33	  	 $149,613.00	  	Philips	  	6/28/2017
	SEBASTIAN	  	UROVIEW 2800 UROLOGICAL TABLE	  	 $222,686.00	  	Philips	  	4/8/2013
	SEBRING	  	CENTER FOR VASCULAR CARE	  	 $604,244.00	  	Philips	  	6/23/2013
	SEBRING	  	CT	  	 $401,193.00	  	Philips	  	1/18/2015
	SEBRING	  	ECG	  	 $105,122.00	  	Philips	  	5/5/2015
	SEBRING	  	OB Tracevue System	  	 $471,681.00	  	Philips	  	2/15/2016
	SEBRING	  	Cath Lab	  	 $1,023,159.00	  	Philips	  	5/30/2018
	SHANDS LAKE SHORE	  	Cardiac Monitors	  	 $249,328.00	  	Philips	  	2/15/2016
	SHANDS LAKE SHORE	  	40 Slice CT; MRI	  	 $1,093,427.00	  	Philips	  	2/22/2016
	SHANDS LAKE SHORE	  	OB TraceVue & Fetal Monitors	  	 $236,466.00	  	Philips	  	8/29/2016
	SHANDS LAKE SHORE	  	Telemetry System	  	 $258,549.32	  	Philips	  	 

  
 112 

									
	SPRING HILL	  	DIAGNOSTIC IMAGING DIGITAL ECHO	 	 $160,196.00	 	Philips	 	12/16/2013
	SPRING HILL	  	16-Slice CT	 	 $374,204.00	 	Philips	 	7/1/2016
	ST CLOUD	  	C-ARM	 	 $148,244.00	 	Philips	 	9/24/2013
	ST CLOUD	  	Cardiology Ultrasound Units (2)	 	 $307,191.00	 	Philips	 	6/24/2016
	ST CLOUD	  	Tracemaster	 	 $160,807.42	 	Philips	 	 
	ST CLOUD	  	Allura Cath Lab	 	 $1,125,899.00	 	Philips	 	 
	ST CLOUD	  	Xper Flex Cardio	 	 $137,195.20	 	Philips	 	 
	STARKE	  	Pulsera C-Arm	 	 $147,521.00	 	Philips	 	8/7/2017
	STATESBORO	  	Intellivue monitoring system	 	 $133,021.00	 	Philips	 	6/30/2014
	STATESBORO	  	Patient Monitors	 	 $150,772.00	 	Philips	 	10/1/2014
	STATESBORO	  	PACU MONITORS	 	 $150,418.25	 	Philips	 	9/24/2015
	STATESBORO	  	CCU RENOVATION & MONITORS	 	 $348,854.85	 	Philips	 	12/3/2015
	STATESBORO	  	Telemetry System	 	 $564,171.00	 	Philips	 	5/29/2018
	STATESBORO	  	Vascular Room	 	 $1,400,925.00	 	Philips	 	5/30/2018
	STATESBORO	  	CT Flex 32	 	 $420,000.00	 	Philips	 	5/30/2018
	STATESVILLE	  	GE 9800 DIGITAL MOBILE C ARM	 	 $147,259.00	 	Philips	 	3/17/2013
	STATESVILLE	  	DIAGNOSTIC RADIOLOGY ROOM	 	 $145,261.00	 	Philips	 	7/23/2013
	STATESVILLE	  	ECHOVASCULAR PACKAGE	 	 $186,527.00	 	Philips	 	9/18/2013
	STATESVILLE	  	Telemetry System	 	 $318,821.76	 	Philips	 	6/28/2018
	STATESVILLE	  	Fetal Monitors	 	 $158,482.00	 	Philips	 	6/28/2018
	STATESVILLE	  	Equipment for Chest Pain Accreditation	 	 $308,977.00	 	Philips	 	 
	TULLAHOMA	  	PANTERA MICROSCOPE	 	 $283,764.00	 	Philips	 	12/5/2012
	TULLAHOMA	  	Cath Lab	 	 $1,001,278.00	 	Philips	 	6/15/2016
	TULLAHOMA	  	MRI	 	 $1,376,082.00	 	Philips	 	4/30/2017
	VAN BUREN	  	RAD/FLOURO Room	 	 $332,424.00	 	Philips	 	9/24/2013
	VAN BUREN	  	TELEMETRY MONITORING SYSTEM	 	 $299,559.00	 	Philips	 	9/14/2014
	VAN BUREN	  	CT UPGRADE	 	 $559,234.05	 	Philips	 	1/11/2016
	VAN BUREN	  	PACS & CR	 	 $308,801.00	 	Philips	 	4/24/2017
	VAN BUREN	  	Mobile Diagnostics with DR	 	 $168,352.00	 	Philips	 	8/29/2018
	VENICE	  	Echo Carts Ultrsound	 	 $313,000.00	 	Philips	 	5/1/2014
	VENICE	  	C-ARM	 	 $157,298.00	 	Philips	 	8/27/2014
	VENICE	  	IE33 ULTRASOUND MACHINE  	 	 $371,870.00	 	Philips	 	6/14/2015

  
 113 

									
	VENICE	  	Vital Signs Monitors Sensor System	 	 $47,100.00	 	Philips	 	9/15/2015
	VENICE	  	CVICU - PATIENT MONITORS    	 	 $362,525.00	 	Philips	 	12/27/2015
	VENICE	  	Patient Monitoring System	 	 $304,611.00	 	Philips	 	9/21/2016
	VENICE	  	Patient Monitoring System	 	 $466,390.00	 	Philips	 	9/23/2016
	VENICE	  	Telemetry Monitors	 	 $159,989.69	 	Philips	 	 
	WILLIAMSON	  	CARDIAC CAT LAB	 	 $1,175,643.00	 	Philips	 	10/26/2014
	WILLIAMSON	  	NUCLEAR CAMERA	 	 $288,203.00	 	Philips	 	10/26/2014
	WILLIAMSON	  	PACS EQUIPMENT	 	 $241,697.40	 	Philips	 	12/6/2016
	WUESTHOFF - MELBOURNE	  	4D Ultrasound System	 	 $278,928.00	 	Philips	 	3/22/2017
	YAKIMA	  	HEMATOLOGY ANALYZER	 	 $160,684.00	 	Philips	 	6/23/2013
	YAKIMA	  	C-ARM	 	 $143,537.52	 	Philips	 	12/19/2013
	YAKIMA	  	TELEMETRY MONITORING SYSTEM	 	 $328,144.00	 	Philips	 	10/11/2016
	Knoxville North	  	ECHO Ultrasound System	 	 $197,847.00	 	Philips`	 	3/28/2018
	STATESBORO	  	Radiography System	 	 $94,358.00	 	Physicians Solutions, LLC  	 	12/30/2012
	LEBANON	  	PHONE SYSTEM	 	 $637,977.00	 	Relational	 	1/30/2013
	CANTON	  	DA VINCI SURGICAL SYSTEM (from Jackson)	 	 $1,731,870.00	 	Relational/Macquarie	 	1/1/2014
	BRANDON	  	MRI + BUILDING + BUILDOUT	 	 $1,258,737.00	 	SCG/GE	 	12/30/2013
	HARTSVILLE	  	DIGITAL C-ARM	 	 $153,260.00	 	SCG/GE	 	12/30/2013
	AMORY	  	Stratus CS/UPS & Advia Centaur CPw/ Workbench	 	 $92,847.58	 	Siemens	 	1/29/2018
	AMORY	  	Lithotripter, Table & Accessories	 	 $256,649.00	 	Siemens	 	2/27/2018
	ANNISTON	  	ANESTHESIA MACHINES	 	 $108,506.00	 	Siemens	 	9/21/2013
	ANNISTON	  	CADD-Solis Pumps	 	 $35,470.00	 	Siemens	 	1/31/2018
	BARTOW	  	Anesthesia Machine	 	 $104,711.00	 	Siemens	 	9/9/2016
	BARTOW	  	Anesthesia Machines (3)	 	 $344,526.00	 	Siemens	 	10/28/2016
	BARTOW	  	Chemisty Equipment	 	 $326,136.00	 	Siemens	 	1/19/2017
	Bayfront	  	MRI Manetom Aera	 	 $1,735,888.00	 	Siemens	 	 
	BILOXI	  	MICROSCAN EQUIPMENT	 	 $92,000.00	 	Siemens	 	3/3/2014
	BILOXI	  	Pumps PCS & Syringe	 	 $147,375.00	 	Siemens	 	 
	BRANDON	  	3 Mindray Central Station	 	 $233,507.11	 	Siemens	 	7/27/2016
	BRANDON	  	10 Beds	 	 $106,776.80	 	Siemens	 	8/23/2016
	BRANDON	  	Chemisty Equipment	 	 $251,450.00	 	Siemens	 	6/28/2017
	BROOKSVILLE	  	MAKO Robot	 	 $845,000.00	 	Siemens	 	12/21/2016
	CANTON	  	Draeger Ventilators	 	 $230,079.01	 	Siemens	 	7/19/2016

  
 114 

									
	CHESTER	  	ACUSON S2000 ULTRASOUND SYSTEM	 	 $179,995.00	 	Siemens	 	12/4/2013
	CHESTER	  	Chemistry Analyzer	 	 $57,000.00	 	Siemens	 	5/1/2018
	CLARKSDALE	  	Nuclear Medicine Camera	 	 $179,850.00	 	Siemens	 	 
	CORP -	  	Mako Surgical Robot (11)	 	 $1,013,000.00	 	Siemens	 	6/24/2016
	CORP -	  	Mako Surgical Robot (11)	 	 $1,013,000.00	 	Siemens	 	8/23/2016
	CORP -	  	Mako Surgical Robot (11)	 	 $1,013,000.00	 	Siemens	 	5/12/2016
	CORP -	  	Mako Surgical Robot (11)	 	 $1,013,000.00	 	Siemens	 	6/17/2016
	CORP -	  	Mako Surgical Robot (11)	 	 $1,013,000.00	 	Siemens	 	8/29/2016
	CORP -	  	Mako Surgical Robot (11)	 	 $1,013,000.00	 	Siemens	 	9/23/2016
	CORP -	  	Mako Surgical Robot (11)	 	 $1,013,000.00	 	Siemens	 	9/30/2016
	CORP -	  	Mako Surgical Robot (11)	 	 $1,013,000.00	 	Siemens	 	12/21/2016
	CRYSTAL RIVER	  	ANESTHESIA MACHINES	 	 $497,357.00	 	Siemens	 	12/1/2013
	CRYSTAL RIVER	  	Chemistry Analyzers & Centaur CP  	 	 $319,800.00	 	Siemens	 	5/14/2018
	DADE CITY	  	ANGIOPLASTY	 	 $528,552.00	 	Siemens	 	5/26/2014
	FLOWOOD	  	Ortho Camera System	 	 $231,333.28	 	Siemens	 	7/22/2016
	FLOWOOD	  	Infant Ventillator (5)	 	 $147,208.00	 	Siemens	 	12/16/2016
	FLOWOOD	  	Chemisty Equipment	 	 $434,350.00	 	Siemens	 	7/13/2017
	FLOWOOD EAST	  	Laparosopic Scopes; Camera Heads	 	 $99,821.00	 	Siemens	 	8/9/2016
	FLOWOOD EAST	  	Infant Ventilators (2)	 	 $55,240.91	 	Siemens	 	1/13/2017
	FLOWOOD EAST	  	Chemisty Equipment	 	 $91,485.00	 	Siemens	 	 
	FT SMITH	  	Chemistry Automation	 	 $1,367,887.00	 	Siemens	 	7/13/2017
	HARTSVILLE	  	PCA - MedFusion Syringe Pumps	 	 $164,700.00	 	Siemens	 	4/25/2018
	JACKSON	  	Washers (2)	 	 $95,237.90	 	Siemens	 	3/22/2017
	JACKSON	  	Chemistry Analyzer	 	 $487,426.00	 	Siemens	 	3/22/2017
	JACKSON	  	Syringe and PCA Pumps	 	 $232,300.00	 	Siemens	 	 
	KENNETT	  	Chemistry Analyzers	 	 $235,000.00	 	Siemens	 	 
	KEY WEST	  	Ventilators (3)	 	 $66,654.21	 	Siemens	 	7/18/2016
	KEY WEST	  	Video Systems for GI	 	 $312,522.61	 	Siemens	 	5/18/2017
	KEY WEST	  	30 CADD Pumps & 12 MedFusion	 	 $186,450.00	 	Siemens	 	 
	KNOXVILLE - TURKEY CREEK	  	MAKO	 	 $1,106,703.00	 	Siemens	 	12/22/2016
	Knoxville Jefferson	  	Dimension EXL Analyzer	 	 $275,550.00	 	Siemens	 	 
	Knoxville LaFollette	  	EXL Analyzer	 	 $275,550.00	 	Siemens	 	 
	Knoxville newport	  	EXL Analyzers	 	 $276,550.00	 	Siemens	 	 
	Knoxville PRMC	  	BCS XP Coagulation Analyzers	 	$129,000.00	 	Siemens	 	7/21/2015

  
 115 

									
	Knoxville PRMC	  	BCS XP System	 	$119,614.00	 	Siemens	 	8/26/2015
	Knoxville TCMC	  	CADD Solis Pumps (50)	 	 $173,750.00	 	Siemens	 	6/28/2018
	Knoxville TCMC	  	Chemistry Lab Equipment	 	 $436,750.00	 	Siemens	 	 
	LANCASTER HEART	  	Cadd Solis Pump/Medfusion Syringe Pump	 	 $189,730.00	 	Siemens	 	10/16/2017
	LANCASTER Heart o	  	Anesthesia Machines (7)	 	 $559,527.00	 	Siemens	 	3/17/2016
	LANCASTER REG	  	16 SLICE CT	 	 $425,228.00	 	Siemens	 	7/24/2014
	LANCASTER REG	  	NUCLEAR CAMERA	 	 $198,543.00	 	Siemens	 	1/28/2015
	LANCASTER REG	  	CONCERTO MR	 	 $109,200.00	 	Siemens	 	 
	LANCASTER REG	  	CONCERTO MR	 	 $90,000.00	 	Siemens	 	 
	LANCASTER/ROSE CITY	  	Cadd-Solis Pumps (20)	 	 $94,100.00	 	Siemens	 	8/30/2018
	LEBANON	  	STEREOTACTIC BREAST BIOPSY SYSTEM	 	 $148,974.00	 	Siemens	 	2/10/2015
	LEHIGH ACRES	  	ANESTHESIA MACHINES	 	 $225,273.71	 	Siemens	 	8/18/2013
	MIDWEST CITY	  	Pumps 20 CADD	 	 $89,550.00	 	Siemens	 	2/5/2018
	MIDWEST CITY	  	Seimens 1.5T MRI System	 	 $2,039,574.40	 	Siemens	 	6/28/2018
	MILTON	  	UROLOGY SYSTEM TABLE	 	 $307,897.00	 	Siemens	 	12/17/2014
	MILTON	  	Chemistry Analyzer	 	 $121,500.00	 	Siemens	 	7/16/2017
	MILTON	  	Dimension ExL Chemistry Analyzers (2)	 	 $250,000.00	 	Siemens	 	9/7/2017
	MONROE	  	Anesthesia Infusion Pumps	 	 $18,550.00	 	Siemens	 	4/25/2018
	MONROE	  	CADD Solis Pumps	 	 $42,025.00	 	Siemens	 	6/28/2018
	MOORESVILLE/SURG CTR	  	Mindray DCV-7 Ultrasound	 	 $94,600.00	 	Siemens	 	7/19/2017
	NAPLES - PR	  	C-ARM	 	 $259,026.00	 	Siemens	 	3/3/2015
	NAPLES - PR	  	MRI Equipment	 	 $1,800,429.00	 	Siemens	 	6/6/2017
	NAPLES - PR	  	Biplane Equipment	 	 $1,805,402.00	 	Siemens	 	6/22/2017
	NAPLES - PR	  	Digital Mammography	 	 $373,557.00	 	Siemens	 	 
	NATCHEZ	  	STEREOTACTIC BREAST BIOPSY SYSTEM	 	 $149,037.00	 	Siemens	 	8/18/2015
	POPLAR BLUFF	  	Chemistry Dimension EXL Analyzer	 	 $250,000.00	 	Siemens	 	1/29/2018
	SEBASTIAN	  	Chemistry Analyzers	 	 $250,000.00	 	Siemens	 	8/16/2017
	SHANDS LAKE SHORE	  	MAKO Robot	 	 $1,082,175.00	 	Siemens	 	12/28/2016
	SHANDS STARKE	  	Laparoscope & Tower	 	 $107,070.00	 	Siemens	 	8/9/2016
	ST CLOUD	  	Ortho/Spine Equipment	 	 $431,706.00	 	Siemens	 	3/14/2016
	ST CLOUD	  	Dimmension Chemistry Analyzers  	 	 $250,000.00	 	Siemens	 	10/26/2017
	ST CLOUD	  	Siemens E-Cam	 	 $159,500.00	 	Siemens	 	6/6/2018

  
 116 

									
	STATESBORO	  	ANESTHESIA MACHINES	 	 $455,090.00	 	Siemens	 	2/18/2013
	STATESBORO	  	VENTILATORS	 	 $103,929.60	 	Siemens	 	2/8/2014
	STATESBORO	  	Medfusion Pumps	 	 $62,200.00	 	Siemens	 	2/11/2018
	STATESBORO	  	Ambulatory Infusion Pumps 29	 	 $113,930.00	 	Siemens	 	2/11/2018
	STATESVILLE	  	Nuclear Medicine Camera	 	 $389,910.00	 	Siemens	 	 
	VENICE	  	CVICU - VENTILATORS	 	 $43,847.80	 	Siemens	 	5/1/2016
	VENICE	  	Siemens Diagnostics Vista	 	 $585,000.00	 	Siemens	 	10/24/2016
	VENICE	  	Diagnostics Advia Centaur	 	 $69,800.00	 	Siemens	 	12/20/2016
	WINDER	  	Mizuho OSI Jackson Table	 	 $76,923.56	 	Siemens	 	3/13/2016
	WUESTHOFF -MELBOURNE	  	64-Slice CT	 	 $979,617.00	 	Siemens	 	10/26/2016
	YAKIMA	  	MR & INVIVO COILS	 	 $1,469,057.00	 	Siemens	 	1/29/2014
	YAKIMA	  	Ultrasound	 	 $177,807.00	 	Siemens	 	8/22/2017
	YAKIMA	  	Ultrasound and Softward Maintenance  	 	$177,807.00	 	Siemens	 	11/8/2017
	YAKIMA	  	Blood Gas Analyzer	 	 $58,485.00	 	Siemens	 	 
	LEBANON	  	ARTHROSCOPY TOWERS (3)	 	 $293,519.00	 	Smith & Nephew	 	5/23/2013
	CARLISLE	  	OPEN MRI	 	 $1,450,000.00	 	SMT Leasing	 	4/30/2014
	STATESBORO	  	ECG, Ultrasound, Computer, Furniture	 	 	 	Sterling National Bank	 	5/1/2014
	AMORY	  	BEDS	 	 $64,564.63	 	Stryker	 	4/30/2014
	ANNISTON	  	NAVIGATION SYSTEM	 	 $131,902.56	 	Stryker	 	4/30/2013
	BARTOW	  	Laparoscopic Tower	 	$82,401.01	 	Stryker	 	9/24/2016
	BILOXI	  	ENDOSCOPY SYSTEM	 	 $170,221.20	 	Stryker	 	3/30/2012
	BILOXI	  	Ortho Drills/Saws	 	 $213,909.00	 	Stryker	 	5/25/2016
	BILOXI GC SURG CTR	  	Stretchers	 	 $30,732.00	 	Stryker	 	 
	Blackwell	  	HD Laparoscopic Tower	 	 $125,930.12	 	Stryker	 	6/28/2018
	BRANDON	  	Endoscopy	 	 $213,668.48	 	Stryker	 	6/1/2014
	BRANDON	  	Beds (16)	 	 $97,018.00	 	Stryker	 	 
	CANTON	  	Hospital Beds	 	 $484,879.56	 	Stryker	 	2/15/2016
	CANTON	  	Ortho Equipment	 	 $105,166.00	 	Stryker	 	4/26/2016
	CARLISLE	  	LARGE POWER SYSTEM	 	 $146,698.00	 	Stryker	 	4/14/2014
	CARLISLE	  	Surgical Power Tools	 	 $146,698.30	 	Stryker	 	4/15/2014
	CARLISLE	  	Surgical Power Tools	 	 $73,211.25	 	Stryker	 	6/15/2014
	CLARKSDALE	  	LAP VIDEO EQUIPMENT	 	 $167,687.00	 	Stryker	 	8/15/2012
	CLARKSDALE	  	Hospital Furniture	 	 $147,450.84	 	Stryker	 	 

  
 117 

									
	CRYSTAL RIVER	  	ARTHROSCOPY SCOPES & CAMERAS	 	 $105,969.98	 	Stryker	 	2/8/2013
	CRYSTAL RIVER	  	DRILLS	 	 $67,434.00	 	Stryker	 	5/1/2013
	DALLAS REGIONAL	  	Surgical Equipment	 	 $207,056.00	 	Stryker	 	 
	FLOWOOD	  	SURGICAL SAWS & DRILLS	 	 $217,674.00	 	Stryker	 	5/28/2013
	FLOWOOD	  	ENDOSCOPY EQUIPMENT	 	 $128,000.00	 	Stryker	 	6/1/2014
	FLOWOOD	  	STRETCHERS	 	 $82,109.00	 	Stryker	 	8/9/2015
	FLOWOOD	  	Endoscopy Equipment	 	 $201,425.78	 	Stryker	 	12/16/2015
	FLOWOOD	  	OR Saw & Drills	 	 $232,400.17	 	Stryker	 	10/25/2016
	FLOWOOD	  	Neuro/Spine/ENT Power Tools and Accessories	 	 $451,980.16	 	Stryker	 	9/9/2018
	FLOWOOD	  	Hospital Beds	 	 $182,944.97	 	Stryker	 	9/10/2018
	FLOWOOD EAST	  	Tower	 	 $98,842.00	 	Stryker	 	11/2/2015
	FLOWOOD EAST	  	Surgical Video Tower	 	 $98,841.76	 	Stryker	 	2/29/2016
	FLOWOOD EAST	  	Video Towers	 	 $121,005.00	 	Stryker	 	11/4/2016
	FLOWOOD EAST	  	Patient Beds (28)	 	 $200,113.00	 	Stryker	 	3/28/2017
	FORT SMITH	  	REMB Power System	 	 $177,478.00	 	Stryker	 	8/26/2013
	FT SMITH	  	Power Tools and Accessories	 	 $252,063.06	 	Stryker	 	 
	GADSDEN	  	Video Tower and Laparoscope System  	 	 $303,361.00	 	Stryker	 	6/20/2015
	HAINES CITY	  	VASCULAR /THORACIC INSTRUMENTS	 	 $25,999.00	 	Stryker	 	7/24/2012
	HAINES CITY	  	OR EQUIPMENT	 	 $140,372.97	 	Stryker	 	8/7/2012
	HAINES CITY	  	Beds, Mattressess, Stretchers	 	 $296,015.46	 	Stryker	 	11/17/2016
	HARTSVILLE	  	HD Video Equipment	 	 $221,764.00	 	Stryker	 	 
	JACKSON	  	Video Equipment	 	 $97,556.74	 	Stryker	 	2/28/2018
	KEY WEST	  	TOWERS	 	 $612,597.00	 	Stryker	 	11/30/2012
	KEY WEST	  	OR ORTHOPEDIC EQUIPMENT	 	 $81,915.00	 	Stryker	 	3/14/2013
	KEY WEST	  	OR ORTHOPEDIC EQUIPMENT	 	 $267,979.41	 	Stryker	 	10/8/2013
	KEY WEST	  	Power Tools & Accessories	 	 $359,687.00	 	Stryker	 	8/9/2014
	Knoxville North	  	Patient Room Furniture	 	 $231,533.85	 	Stryker	 	11/27/2017
	Knoxville PRMC	  	Ortho Power Equipment	 	 $485,681.94	 	Stryker	 	10/31/2012
	Knoxville TCMC	  	HD Camera System	 	 $433,108.62	 	Stryker	 	1/1/2013
	Knoxville TCMC	  	Navigation Producs	 	 $317,238.17	 	Stryker	 	2/28/2017
	Knoxville TCMC	  	Surgical Power Tools	 	 $268,714.88	 	Stryker	 	1/14/2018
	Knoxville TCMC	  	Endoscopy / Communications Equipment	 	 $2,420,344.10	 	Stryker	 	6/28/2018
	LANCASTER REG	  	NEURO/ORTHO DRILLS	 	 $69,143.00	 	Stryker	 	5/30/2012

  
 118 

									
	LEHIGH ACRES	  	PATIENT BEDS & FURNITURE	 	 $331,792.50	 	Stryker	 	6/19/2013
	LEHIGH ACRES	  	ICU BEDS	 	 $142,500.00	 	Stryker	 	7/30/2013
	Mayes County	  	Endo Equipment	 	 $169,470.92	 	Stryker	 	 
	Mayes County	  	Communication Equipment (Video Upgrade)	 	 $74,255.23	 	Stryker	 	 
	MIDWEST CITY	  	Power Equipment	 	 $308,428.82	 	Stryker	 	8/31/2014
	MILTON	  	VIDEO TOWERS	 	 $185,922.26	 	Stryker	 	6/30/2012
	MILTON	  	VIDEO CART	 	 $192,285.60	 	Stryker	 	3/30/2013
	MILTON	  	Bone Drill for Ortho	 	 $52,758.00	 	Stryker	 	11/14/2013
	MONROE	  	Stryker Equipment	 	 $49,942.45	 	Stryker	 	3/1/2013
	MONROE	  	HIGH DEF VIDEO ARTROSCOPY SYSTEM	 	 $254,436.64	 	Stryker	 	4/30/2013
	MONROE	  	HIGH DEF VIDEO ARTROSCOPY SYSTEM	 	 $45,530.00	 	Stryker	 	5/8/2013
	MOORESVILLE	  	ENDOSCOPY EQUIPMENT	 	 $164,000.00	 	Stryker	 	12/30/2013
	MOORESVILLE	  	PATIENT ROOM FURNITURE	 	 $166,640.00	 	Stryker	 	4/30/2014
	MOORESVILLE/SURG CTR	  	Laparoscopic Equipment	 	 $312,837.84	 	Stryker	 	10/8/2017
	NAPLES - PR	  	Ortho Equipment	 	 $138,523.00	 	Stryker	 	8/12/2014
	NAPLES - PR	  	ICU Beds (8)	 	 $306,509.00	 	Stryker	 	3/28/2017
	NATCHEZ	  	Orthopedic System-Battery Powered Equipment	 	 $139,542.00	 	Stryker	 	2/28/2015
	NATCHEZ	  	Endoscopy Products & Accessories        	 	 $174,122.60	 	Stryker	 	5/1/2018
	POPLAR BLUFF	  	Surgical Towers (2)	 	 $107,879.00	 	Stryker	 	2/15/2015
	POPLAR BLUFF	  	Beds & Stretchers	 	 $1,405,930.42	 	Stryker	 	3/27/2018
	PORT CHARLOTTE	  	Cardiac Tower	 	 $347,419.30	 	Stryker	 	1/27/2017
	PUNTA GORDA	  	ORTHO POWER	 	 $109,925.00	 	Stryker	 	12/30/2012
	PUNTA GORDA	  	Neptune System	 	 $77,868.00	 	Stryker	 	4/30/2015
	SEBASTIAN	  	Drill System	 	 $107,244.00	 	Stryker	 	9/29/2013
	SEBASTIAN	  	BEDS	 	 $93,032.00	 	Stryker	 	12/3/2013
	SEBASTIAN	  	Hospital Furniture	 	$54,678.48	 	Stryker	 	1/10/2015
	SEBASTIAN	  	Hospital Beds	 	 $517,588.00	 	Stryker	 	9/9/2015
	SEBASTIAN	  	HD Towers	 	 $485,249.94	 	Stryker	 	 
	SEBRING	  	BEDS	 	 $162,062.00	 	Stryker	 	12/30/2013
	SEBRING	  	Ortho Equipment	 	 $185,088.00	 	Stryker	 	7/11/2015
	SPRING HILL	  	BEDS	 	 $80,000.00	 	Stryker	 	 
	STATESBORO	  	ARTHROSCOPY TOWER	 	 $100,983.30	 	Stryker	 	11/30/2012
	STATESBORO	  	Beds (45)	 	 $347,415.00	 	Stryker	 	5/25/2017

  
 119 

									
	STATESBORO	  	Hospital Stretchers	 	 $82,143.18	 	Stryker	 	9/7/2017
	STATESBORO	  	Orthopedic Power Tools	 	 $378,519.00	 	Stryker	 	 
	STATESVILLE	  	Ortho Drll Systems (3)	 	 $258,074.72	 	Stryker	 	4/12/2016
	TOPPENISH	  	Stryker Equipment	 	 $121,131.15	 	Stryker	 	12/19/2012
	TOPPENISH	  	Endoscopy Tower	 	 $151,458.28	 	Stryker	 	 
	TULLAHOMA	  	BEDS & FURNITURE - BUILDOUT	 	 $160,985.20	 	Stryker	 	5/30/2014
	VENICE	  	CRITICAL CARE BEDS	 	 $201,311.00	 	Stryker	 	6/30/2013
	VENICE	  	8 CRITICAL CARE BEDS	 	 $207,285.00	 	Stryker	 	2/1/2014
	VENICE	  	Beds (49), Overbed Tables (49), Stretchers (12)	 	 $359,642.95	 	Stryker	 	9/27/2015
	VENICE	  	CVICU - BEDS	 	 $191,600.00	 	Stryker	 	10/7/2015
	VENICE	  	Beds & Equipment (3 South)	 	 $578,051.64	 	Stryker	 	 
	WINDER	  	Surgical ENT Navigation System	 	 $125,717.37	 	Stryker	 	2/21/2017
	WUESTHOFF - ROCKLEDGE	  	Drill Systems	 	 $127,233.00	 	Stryker	 	1/20/2014
	WUESTHOFF - ROCKLEDGE	  	Endoscopy Video Equipment	 	 $219,356.00	 	Stryker	 	8/8/2015
	WUESTHOFF - ROCKLEDGE	  	Beds (59)	 	 $393,974.00	 	Stryker	 	12/23/2015
	WUESTHOFF - ROCKLEDGE	  	Hospital Beds	 	 $123,975.00	 	Stryker	 	2/6/2017
	YAKIMA	  	Ortho Power Equipment	 	 $277,322.93	 	Stryker	 	3/25/2014
	GADSDEN	  	CAMERA CONTROL UNIT	 	 $270,500.00	 	Stryker / Med One	 	12/14/2013
	Clinton	  	Stryker	 	 $127,170.54	 	Styker	 	6/11/2018
	STATESBORO	  	EMR Software System	 	 $62,235.00	 	Summit Vendor Finance	 	1/5/2014
	MONROE	  	FETAL MONITORING SYSTEM	 	 $218,164.00	 	Synovus	 	9/24/2013
	MONROE	  	ENDOSCOPY SYSTEM	 	 $284,218.00	 	Synovus	 	11/30/2013
	JACKSON	  	HEMATOLOGY INSTRUMENT  	 	 $182,500.00	 	Sysmex	 	6/1/2015
	CANTON	  	CT	 	 $484,130.00	 	Toshiba	 	11/26/2013
	JACKSON	  	LARGE BORE MRI	 	 $1,866,092.00	 	Toshiba	 	3/25/2015
	KEY WEST	  	64-Slice CT	 	 $1,220,904.00	 	Toshiba	 	4/12/2016
	MILTON	  	16 SLICE CT	 	 $413,729.00	 	Toshiba	 	2/18/2014
	WILLIAMSON	  	CT	 	 $351,479.00	 	Toshiba	 	3/5/2014
	WILLIAMSON	  	Ultrasound	 	 $124,861.00	 	Toshiba	 	11/21/2017
	YAKIMA	  	Ultrasound System	 	 $157,738.00	 	Toshiba	 	7/4/2015
	ANNISTON	  	VITEX 2 COMPACT 60 & CART	 	 $71,197.00	 	US Bank	 	1/27/2014
	FLOWOOD	  	ZIMMER CAS NAVIGATION	 	 $393,500.00	 	US Bank	 	11/12/2013

  
 120 

									
	GADSDEN	  	GENEXPERT XVI	 	 $80,897.00	 	US Bank	 	9/21/2013
	PORT CHARLOTTE	  	VITEK 2 XL MICROBIOLOGY INSTRUMENT	 	 $114,413.00	 	US Bank	 	1/27/2014
	PUNTA GORDA	  	GENERATORS	 	 $17,060.00	 	US Bank	 	11/17/2013
	YAKIMA	  	GENERATORS	 	 $34,121.00	 	US Bank	 	12/22/2013
	FLOWOOD	  	BRAINLAB	 	$201,509.00	 	US Express	 	11/3/2013
	WUESTHOFF - ROCKLEDGE	  	IVUS Unit for Cath Lab	 	 $120,000.00	 	Volcano	 	6/30/2012
	PORT CHARLOTTE	  	Orthopedic Tower	 	 $240,000.00	 	Wells Fargo	 	12/13/2013
	AMORY	  	Ortho Equipment	 	 $250,302.00	 	Winthrop	 	2/1/2016
	AMORY	  	OR Lights	 	 $101,183.00	 	Winthrop	 	3/1/2016
	AMORY PPM	  	Horiba Medical Instruments	 	 $88,335.00	 	Winthrop	 	10/12/2016
	BARTOW	  	Hematology Analyzer	 	 $66,400.00	 	Winthrop	 	3/6/2018
	BARTOW	  	ACL TOP CTS System	 	 $52,600.00	 	Winthrop	 	 
	BILOXI	  	Main Pharmacy Cabinet	 	 $22,130.00	 	Winthrop	 	 
	BROOKSVILLE/SP HILL	  	Blood Bank Analyzer-Workstation	 	 $63,400.00	 	Winthrop	 	2/8/2017
	CANTON	  	Sysmex Analyzers	 	 $69,400.00	 	Winthrop	 	6/9/2015
	CANTON	  	Accudose Rx System	 	 $128,891.00	 	Winthrop	 	6/9/2015
	CANTON	  	Brainlab Equipment	 	 $212,088.00	 	Winthrop	 	10/18/2016
	CARLISLE	  	Acudose Cabinet	 	 $24,621.00	 	Winthrop	 	12/22/2014
	CARLISLE	  	Sterilizers (2)	 	 $68,794.56	 	Winthrop	 	3/29/2015
	CARLISLE	  	AcuDose Cabinet	 	 $16,717.00	 	Winthrop	 	12/31/2016
	CRYSTAL RIVER	  	Surgical Table	 	 $130,438.00	 	Winthrop	 	8/4/2015
	DURANT	  	Surgical Eye Microscopes	 	 $106,122.00	 	Winthrop	 	5/23/2016
	FLOWOOD	  	Telescopes and Cysto Sheaths	 	 $77,340.00	 	Winthrop	 	7/25/2016
	HAINES CITY	  	Accudose Machine	 	 $29,833.00	 	Winthrop	 	12/8/2014
	HAINES CITY	  	Acudose Medication Tower	 	 $13,403.00	 	Winthrop	 	9/2/2015
	HAINES CITY	  	Accudose	 	 $140,169.00	 	Winthrop	 	11/26/2016
	HAINES CITY	  	Histology Equipment	 	 $131,637.26	 	Winthrop	 	 
	HARTSVILLE	  	Hematology Analyzer	 	 $81,100.00	 	Winthrop	 	12/31/2016
	JACKSON	  	McKesson EMR	 	 $3,712,337.00	 	Winthrop	 	9/1/2013
	JACKSON	  	Acudose Cabinet	 	 $56,576.00	 	Winthrop	 	5/24/2015
	JACKSON	  	Acudose Cabinet	 	 $22,727.00	 	Winthrop	 	6/30/2015
	KEY WEST	  	Analyzer	 	 $70,793.00	 	Winthrop	 	12/12/2015
	KNOXVILLE-JEFFERSON	  	Ortho Table System	 	 $113,978.98	 	Winthrop	 	4/6/2016

  
 121 

									
	KNOXVILLE - NORTH	  	Hematology Analyzer	 	 $109,453.00	 	Winthrop	 	4/1/2016
	KNOXVILLE - PRMC	  	Ultrasound Imaging System	 	 $151,715.00	 	Winthrop	 	3/1/2016
	KNOXVILLE JEFFERSON	  	Sterilizer	 	 $96,004.88	 	Winthrop	 	7/12/2017
	Knoxville TCMC	  	Integra CUSA EXCEL & Ultrasonic Tissue Ablation System	 	 $119,764.00	 	Winthrop	 	3/6/2017
	LANCASTER/ROSE CITY	  	Hill Rom Spo2rt Bed System ICU	 	 $85,555.00	 	Winthrop	 	12/3/2016
	LEBANON	  	Acudose Cabinet	 	 $26,771.00	 	Winthrop	 	2/11/2015
	LEBANON	  	Acudose Cabinet	 	 $20,149.00	 	Winthrop	 	 
	LEHIGH	  	Ultrasounds (2)	 	 $149,620.00	 	Winthrop	 	9/26/2017
	LEHIGH ACRES	  	Gastroscopes; Colonoscopes	 	 $144,514.00	 	Winthrop	 	1/17/2015
	MIDWEST CITY	  	Hil-Rom Bed Systems	 	 $1,046,382.00	 	Winthrop	 	9/28/2017
	MONROE	  	Acudose Cabinet; (5) Towers	 	 $45,863.00	 	Winthrop	 	2/26/2017
	NAPLES - PR	  	Acudose System	 	 $32,870.00	 	Winthrop	 	4/16/2016
	NATCHEZ	  	Orthopedic Arthoscopy Equipment	 	 $145,093.00	 	Winthrop	 	3/7/2015
	NATCHEZ	  	Sterilizer	 	 $136,602.00	 	Winthrop	 	8/3/2015
	OSLER MEDICAL GROUP	  	Lab Equipment	 	 $263,500.00	 	Winthrop	 	8/30/2018
	POPLAR BLUFF	  	AcuDose Cabinets	 	 $348,770.00	 	Winthrop	 	1/31/2018
	POPLAR BLUFF	  	Volcano Imaging System - Ultrasound	 	 $67,500.00	 	Winthrop	 	 
	POPLAR BLUFF	  	Acudose (Rehab)	 	 $47,654.00	 	Winthrop	 	 
	Pryor	  	Telemedicine Robot	 	 $101,416.00	 	Winthrop	 	6/3/2016
	Pryor	  	Accudose Medication Equipment	 	 $179,795.00	 	Winthrop	 	 
	SEBASTIAN	  	Sterilizer (2)	 	 $163,831.00	 	Winthrop	 	3/28/2017
	SEBRING	  	ACCUDOSE	 	 $42,635.00	 	Winthrop	 	4/1/2015
	SHANDS LAKE SHORE	  	ACUDOSE CABINETS	 	 $357,392.00	 	Winthrop	 	12/1/2014
	SHANDS LIVE OAK	  	ACUDOSE CABINETS	 	 $120,976.00	 	Winthrop	 	8/18/2014
	SHANDS STARKE	  	ACUDOSE CABINETS	 	 $126,945.00	 	Winthrop	 	8/18/2014
	ST CLOUD	  	Patient Monitoring System (8)	 	 $113,415.00	 	Winthrop	 	2/1/2016
	STATESBORO	  	AcuDose Main Cabinet and Tower	 	 $22,811.00	 	Winthrop	 	 
	STATESVILLE	  	Acudose System	 	 $126,909.00	 	Winthrop	 	4/1/2015
	STATESVILLE	  	Renovation for Geri Psych (Dispensers)    	 	 $36,636.00	 	Winthrop	 	12/2/2015
	STATESVILLE	  	2 UniCel DxC 600 PRO Instruments	 	 $285,568.00	 	Winthrop	 	12/20/2017
	STATESVILLE	  	Hematology Analyzer	 	 $100,350.00	 	Winthrop	 	2/28/2018

  
 122 

									
	STATESVILLE	  	Hill-Rom Beds	 	 $123,591.00	 	Winthrop	 	6/25/2018
	STATESVILLE	  	Hill-Rom Beds	 	 $172,484.00	 	Winthrop	 	6/25/2018
	STATESVILLE	  	Hill-Rom Beds	 	 $243,426.00	 	Winthrop	 	6/25/2018
	TOPPENISH	  	Hematology Analyzer	 	 $66,400.00	 	Winthrop	 	 
	VENICE	  	CVICU - MCKESSON DISPENSER	 	 $53,697.00	 	Winthrop	 	5/23/2015
	WILLIAMSON	  	Hematology System	 	 $80,342.00	 	Winthrop	 	3/28/2015
	WINDER	  	Digital X Ray	 	 $155,339.00	 	Winthrop	 	9/1/2015
	WUESTHOFF - MELBOURNE	  	IVUS System	 	$145,236.00	 	Winthrop	 	5/4/2016
	WUESTHOFF - ROCKLEDGE	  	Various	 	$943,955.00	 	Winthrop	 	5/17/2012
	YAKIMA	  	Brain Lab	 	 $204,033.00	 	Winthrop	 	3/19/2016
	YAKIMA	  	Chemistry Equipment	 	 $132,800.00	 	Winthrop	 	 
	CARLISLE	  	Ultrasound	 	 $93,607.20	 	 	 	10/23/2017
	CORP	  	IBM	 	 $83,315.00	 	 	 	6/25/2012
	CORP	  	HP PATIENT FOLDER EQUIPMENT	 	 $455,097.00	 	 	 	 
	CORP	  	Intuitive Surgical (13)	 	 $1,386,000.00	 	 	 	 
	CORP	  	Intuitive Surgical (13)	 	 $63,500.00	 	 	 	 
	DADE CITY	  	Acudose	 	 $20,728.00	 	 	 	 
	DADE CITY	  	PCI Program Equipment	 	 $488,504.00	 	 	 	 
	DALLAS REGIONAL	  	INNOVA CATH LAB	 	 $119,000.00	 	 	 	 
	DURANT	  	ULTRASONIC WOUND TREATMENT    	 	 $70,291.00	 	 	 	 
	DURANT	  	NUCLEAR MEDICINE CAMERA	 	 $302,196.00	 	 	 	 
	DURANT	  	CENTRAL MONITOR W/9 BEDSIDE	 	 $217,111.00	 	 	 	 
	DURANT	  	Sterilizers (3)	 	 $173,924.00	 	 	 	 
	FLOWOOD	  	LOGIC 9 ULTRASOUND UNIT	 	 $219,777.00	 	 	 	 
	FLOWOOD	  	VISION PROJECT - GE	 	 $1,253,800.33	 	 	 	 
	FT SMITH	  	Advia Chemistry Equip	 	$1,367,867.00	 	 	 	1/17/2018
	GADSDEN	  	Integrated ivus with FFR 2 room system	 	 $135,000.00	 	 	 	 
	HAINES CITY	  	Sterilzers (5)	 	 $405,383.48	 	 	 	 
	JACKSON	  	Anesthesia Machine- Monitoring System	 	 $98,653.74	 	 	 	12/3/2017
	JACKSON	  	HYPERBARIC CHAMBERS	 	 $157,000.00	 	 	 	 
	JACKSON	  	DATA CENTER BUILDOUT	 	 $299,288.00	 	 	 	 
	JACKSON	  	FURNITURE	 	 $95,282.00	 	 	 	 

  
 123 

									
	KNOXVILLE-PRMC	  	BrainLab; 16-Slice CT	 	 $1,695,995.00	 	 	 	7/15/2015
	MIDWEST CITY	  	Lease Buy Out (Centricity for Cath Lab)	 	 $95,774.00	 	 	 	 
	MIDWEST CLINIC	  	Dr. Norred Equipment Lease	 	 $188,000.00	 	 	 	10/15/2015
	MILTON	  	Anesthesia Machine	 	 $98,222.00	 	 	 	 
	MONROE	  	Build Out 4th OR (Anesthesia Machine)	 	 $266,045.00	 	 	 	 
	MOORESVILLE	  	BEDSIDE MONITORING FOR CCU  	 	 $301,027.00	 	 	 	 
	NAPLES COLLIER	  	Chemistry Dimension EXL Analyzer	 	$250,000.00	 	 	 	5/9/2018
	NATCHEZ	  	LH 750 HEMATOLOGY SYSTEM	 	 $195,000.00	 	 	 	4/16/2015
	POPLAR BLUFF	  	Hip Upgrade	 	 $183,104.00	 	 	 	 
	PORT CHARLOTTE	  	120 GENERAL BEDS	 	 $814,578.00	 	 	 	 
	PORT CHARLOTTE	  	DIGITAL MAMMOS	 	 $317,150.00	 	 	 	 
	PT CHARLOTTE	  	Database Storage; Archive upgrade	 	 $162,856.67	 	 	 	 
	PUNTA GORDA	  	XCELERA ECHO MACHINE	 	 $254,472.00	 	 	 	 
	PUNTA GORDA	  	64 SLICE CT	 	 $928,328.00	 	 	 	 
	SEBASTIAN	  	Ultrasound/Tee Probe	 	 $205,809.25	 	 	 	9/21/2017
	SEBASTIAN	  	Infusion pumps	 	 $132,800.00	 	 	 	 
	SEBASTIAN	  	BP monitors	 	 $36,162.00	 	 	 	 
	SEBRING	  	GENERATORS	 	 $34,121.00	 	 	 	 
	SEBRING	  	PHYSIOLOGICAL MONITOR	 	 $25,000.00	 	 	 	 
	STATESBORO	  	Bronchoscopy Equipment	 	 $309,418.02	 	 	 	12/5/2017
	STATESBORO	  	DIGITAL MAMMO	 	 $487,950.00	 	 	 	 
	VENICE	  	WSGE WORKSTATIONS	 	 $66,768.00	 	 	 	 
	WUESTHOFF - MELBOURNE	  	Sterilizer	 	 $121,276.00	 	 	 	1/15/2015
	WUESTHOFF - MELBOURNE	  	Acuson Sequoia Echo System	 	 $161,000.00	 	 	 	 
	YAKIMA	  	Sterilizer	 	 $89,317.00	 	 	 	2/15/2015
	YAKIMA	  	ACHIEVA 1.5T MRI	 	 $1,874,478.00	 	 	 	 

  
 124 

 Schedule 6.05(b) 

Certain Syndication Transactions 
  

	1.	Wesley Health System LLC (Hattiesburg, MS) 

	1.	Piney Woods Healthcare System, L.P. (Lufkin, TAX) (second offering) 

	2.	McKenzie-Willamette Regional Medical Center Associates, LLC (Springfield, OR) (supplemental offering) 

	3.	NOV Holdings, LLC (Tucson, AZ - 2 hospitals) 

	4.	Kay County Oklahoma Hospital Company, LLC (Ponca City, OK) 

	5.	Petersburg Hospital Company, LLC (Petersburg, VA) 

	6.	Laredo-Texas Hospital Company, LLC (Laredo, TX) (second offering) 

	7.	Northwest Indiana Health System, LLC (Valpraiso, IN) 

	8.	National Healthcare of Mt. Vernon, Inc. (Crossroads Community) 

	9.	Coatesville, PA 

	10.	Westgrove, PA 

	11.	Easton, PA 

	12.	Salem, NJ 

	13.	Abilene, TX 

	14.	Las Cruces, NM 

	15.	Victoria, TX 

	16.	Ft. Wayne, IN (Lutheran) 

	17.	Metro Health Cascade (Grand Rapis, MI). 

	18.	Munroe Regional Health System (Ocala, FL). 

  
 126 

 Schedule 6.07 

Certain Affiliate Transactions 

None. 

  
 127 

 EXHIBIT A 
  

FORM OF 
 CHS/COMMUNITY HEALTH
SYSTEMS, INC. 
 ADMINISTRATIVE QUESTIONNAIRE 

Please accurately complete the following information and return via Fax to the attention of Agency Administration at Credit Suisse AG as soon
as possible, at Fax No. (212) 322-2291. 
  

LENDER LEGAL NAME TO APPEAR IN DOCUMENTATION: 

GENERAL INFORMATION - DOMESTIC LENDING OFFICE: 

Institution Name: 

			
	  
	  	

  

			
	Street Address:  	 	  

  

			
	City, State, Zip Code:  	 	  

 GENERAL INFORMATION - EURODOLLAR LENDING OFFICE: 

 

			
	Institution Name:  	 	  

  

			
	Street Address:  	 	  

  

			
	City, State, Zip Code:  	 	  

 POST-CLOSING, ONGOING CREDIT CONTACTS/NOTIFICATION METHODS: 

CREDIT CONTACTS: 
  

			
	Primary Contact: 	 	  

  

			
	Street Address:  	 	  

  

			
	City, State, Zip Code:  	 	  

  

			
	Phone Number:  	 	  

  

			
	Fax Number:  	 	  

 
  

			
	Backup Contact: 	 	  

  

			
	Street Address:  	 	  

  

			
	City, State, Zip Code:  	 	  

  

			
	Phone Number:  	 	  

  

			
	Fax Number:  	 	  

 
 125
 
  

 TAX WITHHOLDING: 

 

									
	United States Person	  		  	        Y    	  	        N	  	
	(as defined in Section 7701(a)(30) of the Code)            	  		  		  	
	  
 Enclose Form W-8 or W-9, as applicable
	  		  		  	

  

					
	Tax ID Number  	 	  
	 	

  
 POST-CLOSING, ONGOING ADMIN. CONTACTS /
NOTIFICATION METHODS: 
 ADMINISTRATIVE CONTACTS - BORROWINGS, PAYDOWNS, FEES, ETC. 

 

			
	Contact:  	 	  

  

			
	Street Address:  	 	  

  

			
	City, State, Zip Code:  	 	  

  

			
	Phone Number:  	 	  

  

			
	Fax Number:  	 	  

  
 PAYMENT INSTRUCTIONS: 

 

			
	Name of Bank to which funds are to be transferred:  	 	  

  
  

 

			
	Routing Transit/ABA number of Bank to which funds are to be transferred:  	 	  

  

			
	Name of Account, if applicable:  	 	  

  

			
	Account Number:  	 	  

  

			
	Additional information:  	 	  

  
  

  

MAILINGS: 
 Please specify the
person to whom the Borrower should send financial and compliance information received subsequent to the closing (if different from primary credit contact): 
  

			
	Name:  	 	  

 
 126
 
  

			
	Street Address:  	 	  

  

			
	City, State, Zip Code:  	 	  

 It is very important that all the above information be accurately completed and that this questionnaire
be returned to the person specified in the introductory paragraph of this questionnaire as soon as possible. If there is someone other than yourself who should receive this questionnaire, please notify us of that person’s name and Fax number
and we will Fax a copy of the questionnaire. If you have any questions about this form, please call Agency Administration at Credit Suisse AG. 

 EXHIBIT B 

FORM OF 
 ASSIGNMENT AND
ACCEPTANCE 
 Reference is made to the Credit Agreement dated as of July 25, 2007, as amended and restated as of
November 5, 2010, as further amended and restated as of February 2, 2012, and as further amended and restated as of January 27, 2014 (as further amended, restated, supplemented or otherwise modified from time to time, the
“Credit Agreement”), among CHS/Community Health Systems, Inc., a Delaware corporation (the “Borrower”), Community Health Systems, Inc., a Delaware corporation (“Parent”), the
Lenders (as defined in Article I of the Credit Agreement), and Credit Suisse AG, as administrative agent (in such capacity, the “Administrative Agent”) and as collateral agent for the Lenders. Terms defined in the Credit
Agreement are used herein with the same meanings. 
 1.   The Assignor hereby sells and assigns, without
recourse, to the Assignee, and the Assignee hereby purchases and assumes, without recourse, from the Assignor, effective as of the Effective Date set forth below (but not prior to the registration of the information contained herein in the Register
pursuant to Section 9.04(d) of the Credit Agreement), the interests set forth below (the “Assigned Interest”) in the Assignor’s rights and obligations under the Credit Agreement and the other Loan Documents,
including, without limitation, the amounts and percentages set forth below of (i) the Commitments of the Assignor on the Effective Date and (ii) the Loans owing to the Assignor which are outstanding on the Effective Date. Each of the
Assignor and the Assignee hereby makes and agrees to be bound by all the representations, warranties and agreements set forth in Section 9.04(c) of the Credit Agreement, a copy of which has been received by each such party. From and after the
Effective Date (i) the Assignee shall be a party to and be bound by the provisions of the Credit Agreement and, to the extent of the interests assigned by this Assignment and Acceptance, have the rights and obligations of a Lender thereunder
and under the Loan Documents and (ii) the Assignor shall, to the extent of the interests assigned by this Assignment and Acceptance, relinquish its rights and be released from its obligations under the Credit Agreement. 

2.   This Assignment and Acceptance is being delivered to the Administrative Agent together with (i) if
the Assignee is organized under the laws of a jurisdiction outside the United States, any forms referred to in Section 2.20(e) of the Credit Agreement, duly completed and executed by such Assignee, (ii) if the Assignee is not already a
Lender under the Credit Agreement, a completed Administrative Questionnaire and (iii) unless waived or reduced in the sole discretion of the Administrative Agent, a processing and recordation fee of $3,500.1 
  
  

1 Only one such fee shall be payable in the case of concurrent assignments to persons
that, after giving effect to such assignments, will be Related Funds. 

 
 2
 
  

 3.   This Assignment and Acceptance shall be governed by and
construed in accordance with the laws of the State of New York. 
 Date of Assignment: 

Legal Name of Assignor (“Assignor”): 

Legal Name of Assignee (“Assignee”): 

Assignee’s Address for Notices: 
 Effective Date of
Assignment (“Effective Date”): 
  

					
	
Class of   

Loans/Commitments   

Assigned   
	 	 Principal Amount 

Assigned 
	 	 Percentage of
Loans/Commitments
 of the applicable Class Assigned

(set forth, to at least 8 decimals, as

a percentage of the aggregate
 Loans
and Commitments, of the
 applicable Class, of all Lenders)

	 	 	$	 	%
	 	 	$	 	%

  
  

[Remainder of Page Intentionally Left Blank] 

 
 3
 
  

Accepted                      
   
  

			
	 CREDIT SUISSE AG, as Administrative

Agent[, Swingline Lender and Issuing Bank],2      
  

	     by:	 	
		 	  

		 	  Name:
		 	  Title:
		
		 	  

		 	  Name:
		 	  Title:
	
	 [CHS/COMMUNITY HEALTH SYTEMS,

INC.],

	     by:	 	
		 	  

		 	  Name:
		 	  Title: ]3
	
	 [COMMUNITY HEALTH SYSTEMS,

INC.],

	     by:	 	
		 	  

		 	  Name:
		 	  Title: ]4

  
  
  

 
 2 Consent of Swingline Lender and Issuing Bank only required in the case of an assignment of a Revolving Credit Commitment. 

3 Consent of the Borrower is only required in the case of an assignment of
a Revolving Credit Commitment; provided, that the consent of the Borrower shall not be required for any assignment (a) made to another Lender, an Affiliate of a Lender or a Related Fund of a Lender or (b) after the occurrence and
during the continuance of any Event of Default. 

 
 4
 
  

					
	 The terms set forth above are

hereby agreed to:
  
	 	
	
                          
      , as Assignor,
  
 by:

	  
	 	
		 	Name:	 	
		 	Title:	 	
	  

                          
          , as Assignee,
  

by:

	  
	 	
		 	Name:	 	
		 	Title:	 	

 EXHIBIT C 
  

FORM OF 
 BORROWING REQUEST 

Credit Suisse AG, as Administrative Agent for 

     the Lenders referred to below, 

Eleven Madison Avenue 
 New York, New York 10010 

Attention: Agency Group 
 [DATE]1 
 Ladies and Gentlemen: 

The undersigned, CHS/Community Health Systems, Inc., a Delaware corporation, (the “Borrower”), refers
to the Credit Agreement dated as of July 25, 2007, as amended and restated as of November 5, 2010, as further amended and restated as of February 2, 2011, and as further amended and restated as of January 27, 2014 (as
further amended, restated, supplemented or otherwise modified from time to time, the “Credit Agreement”), among the Borrower, Community Health Systems, Inc., a Delaware corporation, the lenders from time to time party thereto
(the “Lenders”) and Credit Suisse AG, as administrative agent (in such capacity, the “Administrative Agent”) and collateral agent for the Lenders. Capitalized terms used herein and not otherwise
defined herein shall have the meanings assigned to such terms in the Credit Agreement. The Borrower hereby gives the Administrative Agent notice pursuant to Section 2.03 of the Credit Agreement that it requests a Borrowing under the Credit
Agreement, and in connection therewith sets forth below the terms on which such Borrowing is requested to be made: 
  

							
	(A)	  	Type of Borrowing2                	  	  
	  	
				
	(B)	  	Date of Borrowing3	  	  
	  	

							
				
	(C)	  	Account Number and Location	  	  
	  	
				
	(D)	  	Principal Amount of Borrowing          	  	  
	  	
				
	(E)	  	Interest Period4	  	  
	  	

  
  

1 The Administrative Agent must be notified irrevocably by telephone
(a) in the case of a Eurodollar Borrowing, not later than 12:00 (noon) (New York City time), three Business Days before a proposed Borrowing and (b) in the case of an ABR Borrowing, not later than 11:00 a.m. (New York City time), on
the day of a proposed Borrowing, in each case to be confirmed promptly by hand delivery or fax of a Borrowing Request to the Administrative Agent. 

2 Specify whether such Borrowing is to be a Term Borrowing or a Revolving
Credit Borrowing, and whether such Borrowing is to be a Eurodollar Borrowing or an ABR Borrowing. 
 3 Date of Borrowing must be a Business Day. 
 4 If such Borrowing is to be a Eurodollar Borrowing, specify the Interest Period with respect thereto. 

 
 2
 
  

 The Borrower shall indemnify each Lender against any loss or expense that
such Lender may sustain or incur as a consequence of (a) any event, other than a default by such Lender in the performance of its obligations hereunder, which results in (i) such Lender receiving or being deemed to receive any amount on
account of the principal of any Eurodollar Loan prior to the end of the Interest Period in effect therefor, (ii) the conversion of any Eurodollar Loan to an ABR Loan, or the conversion of the Interest Period with respect to any Eurodollar Loan,
in each case other than on the last day of the Interest Period in effect therefor, or (iii) any Eurodollar Loan to be made by such Lender (including any Eurodollar Loan to be made pursuant to a conversion or continuation of such Loan) not being
made after notice of such Loan shall have been given by the Borrower hereunder (any of the events referred to in this paragraph being called a “Breakage Event”) or (b) any default in the making of any payment or
prepayment of any Eurodollar Loan required to be made hereunder. In the case of any Breakage Event, such loss shall include an amount equal to the excess, as reasonably determined by such Lender, of (i) its cost of obtaining funds for the
Eurodollar Loan that is the subject of such Breakage Event for the period from the date of such Breakage Event to the last day of the Interest Period in effect (or that would have been in effect) for such Loan over (ii) the amount of interest
likely to be realized by such Lender in redeploying the funds released or not utilized by reason of such Breakage Event for such period. A certificate of any Lender setting forth any amount or amounts which such Lender is entitled to receive
pursuant to this paragraph shall be delivered to the Borrower and shall be conclusive absent manifest error. 
 The Borrower
hereby represents and warrants to the Administrative Agent and the Lenders that, on the date of this Borrowing Request and on the date of the related Borrowing, the conditions to lending specified in paragraphs (b) and (c) of
Section 4.01 of the Credit Agreement have been satisfied. 
  
  

 

			
	 CHS/COMMUNITY HEALTH SYSTEMS,    

INC.,
  

	     by	 	
		 	  

		 	  Name:
		 	  Title:

 EXHIBIT D 
  

 
  
  

 
  
  

 
  
  

 
 MORTGAGE, ASSIGNMENT OF LEASES AND RENTS, SECURITY AGREEMENT 

AND FINANCING STATEMENT 
 From 

[NAME OF MORTGAGOR] 
 To 

CREDIT SUISSE AG 
  

 
  

 
 Dated:
                 , 20[l]

  Premises: [City], [State] 

                       
   County 
  
  

 
  

 
  

 

 THIS MORTGAGE, ASSIGNMENT OF LEASES AND RENTS, SECURITY AGREEMENT AND FINANCING
STATEMENT dated as of                     , 20[•] (this “Mortgage”), by
[        ], a [      ] corporation, having an office at [      ] (the “Mortgagor”), to and for the benefit of CREDIT SUISSE
AG, a bank organized under the laws of Switzerland, having an office at Eleven Madison Avenue, New York, New York 10010 (the “Mortgagee”) as Collateral Agent for the Secured Parties (as such terms are defined
below). 
 WITNESSETH THAT: 

Reference is made to (i) the Credit Agreement dated as of July 25, 2007, as amended and restated as of November 5, 2010, as
further amended and restated as of February 2, 2012 and as further amended and restated as of January 27, 2014 (as further amended, restated, amended and restated, supplemented or otherwise modified from time to time, the
“Credit Agreement”), among CHS/Community Health Systems, Inc., a Delaware corporation (the “Borrower”), Community Health Systems, Inc., a Delaware corporation (“Parent”), the
lenders from time to time party thereto (the “Lenders”) and Credit Suisse AG as administrative agent (the “Administrative Agent”) for the Lenders, collateral agent (the “Collateral
Agent”) for the Secured Parties, and issuing bank (the “Issuing Bank”) with respect to any letters of credit (the “Letters of Credit”) issued pursuant to the terms of the Credit Agreement,
(ii) the Guarantee and Collateral Agreement dated as of July 25, 2007, as amended and restated as of November 5, 2010, as further amended pursuant to the Amendment No. 1 and Reaffirmation Agreement dated as of August 17,
2012 (as further amended, restated, amended and restated, supplemented or otherwise modified from time to time, the “Guarantee and Collateral Agreement”) among Parent, the Borrower, the Subsidiaries identified therein and the
Collateral Agent, (iii) the Underwriting Agreement dated as of August 8, 2012 (as amended, restated, supplemented or otherwise modified from time to time, the “Underwriting Agreement”) among the Borrower, the
Guarantors party thereto and Credit Suisse Securities (USA) LLC, as representative of the underwriters specified therein (the “Underwriters”), (iv) the Indenture dated as of August 17, 2012 (as amended, restated,
supplemented or otherwise modified from time to time, the “2012 Indenture”), among the Borrower, the Guarantors party thereto, the Collateral Agent and Regions Bank, as trustee (the “2012 Indenture
Trustee”), (v) the Indenture dated as of January 27, 2014 (as amended, restated, supplemented or otherwise modified from time to time, the “2014 Indenture” and, together with the 2012 Indenture, the
“Indentures”), among the Borrower, the Guarantors party thereto, the Collateral Agent and Regions Bank, as trustee (the “2014 Indenture Trustee” and, together with the 2012 Indenture Trustee, the
“Indenture Trustees”), (v) that certain designation certificate dated as of August 17, 2012 delivered to the Collateral Agent pursuant to Section 7.09(c) of the Guarantee and Collateral Agreement (the
“2012 Designation Certificate”), (vi) that certain designation certificate dated as of January 27, 2014 delivered to the Collateral Agent pursuant to Section 7.09(c) of the Guarantee and Collateral Agreement
(the “2014 Designation Certificate”), (vii) the First Lien Intercreditor Agreement dated as of August 17, 2012 among Credit Suisse AG, as the Collateral Agent and the Authorized Representative (as such term is
defined therein) under the Credit Agreement, Regions Bank, in its capacity as 2014 Indenture Trustee under the Initial Additional Agreement (as such term is defined therein), as the Initial Additional

 
Authorized Representative (as such term is defined therein), and each additional Authorized Representative (as such term is defined therein) from time to time party thereto (the
“Intercreditor Agreement”) and (viii) the Joinder Agreement to the First Lien Intercreditor Agreement (the “Joinder Agreement”) dated as of January 27, 2014 delivered by the 2014 Indenture
Trustee to the Collateral Agent . Capitalized terms used but not defined herein have the meanings given to them in the Credit Agreement and the Guarantee and Collateral Agreement. 

In the Credit Agreement, (i) the Lenders have agreed to make term loans (the “Term Loans”) and revolving loans
(the “Revolving Loans”, together with Term Loans and Revolving Loans, the “Loans”) to the Borrower and (ii) the Issuing Bank has issued or agreed to issue from time to time Letters of Credit for
the account of the Borrower, in each case pursuant to, upon the terms, and subject to the conditions specified in, the Credit Agreement. Amounts paid in respect of Term Loans may not be reborrowed. Subject to the terms of the Credit Agreement,
Borrower may borrow, prepay and reborrow Revolving Loans. 
 Pursuant to the terms of the 2012 Indenture and Underwriting Agreement, the
Underwriters have purchased $1,600,000,000 aggregate principal amount of 5.125% Senior Secured Notes due 2018 of the Borrower (the “2018 Notes”) on the terms and subject to the conditions set forth in the Underwriting
Agreement. 
 In accordance with the 2012 Designation Certificate, the 2018 Notes and related obligations thereunder are secured on a
pari passu basis with all other obligations secured under the Guarantee and Collateral Agreement and, in accordance with the provisions of subsection 7.09(c) of the Guarantee and Collateral Agreement, among other things, the Collateral
Agent has been appointed and authorized to act on behalf and for the benefit of the Initial Additional Secured Parties (as such term is defined in the Intercreditor Agreement) under the Indenture. 

Pursuant to the terms of the 2014 Indenture, the [  ] have purchased $1,705,000,000 aggregate principal amount of [  ]%
Senior Secured Notes due 2021 of the Borrower (the “2021 Notes”) on the terms and subject to the conditions set forth in the 2014 Indenture. 

In accordance with the 2014 Designation Certificate, the 2021 Notes and related obligations thereunder are secured on a pari passu basis
with all other obligations secured under the Guarantee and Collateral Agreement and, in accordance with the provisions of subsection 7.09(c) of the Guarantee and Collateral Agreement, among other things, the Collateral Agent has been appointed
and authorized to act on behalf and for the benefit of the Additional Secured Parties (as such term is defined in the Intercreditor Agreement) under the Indenture. 

Mortgagor is a wholly-owned direct or indirect Subsidiary of the Borrower and will derive substantial benefit from the making of the Loans by
the Lenders, the issuance of the Letters of Credit by the Issuing Bank and from the purchase of the Notes by the Underwriters. In order to induce the Lenders to make Loans, the Issuing Bank to issue Letters of Credit, the Underwriters to purchase
the Notes and the Indenture Trustees to enter 

 
into the Indentures, the Mortgagor has agreed to guarantee, among other things, the due and punctual payment and performance of all of the obligations of the Borrower under the Credit Agreement
and the Indenture pursuant to the terms of the Guarantee and Collateral Agreement. 
 The obligations of the Lenders to make Loans and of
the Issuing Bank to issue Letters of Credit are conditioned upon, among other things, the execution and delivery by the Mortgagor of this Mortgage in the form hereof to secure the Obligations. 

As used in this Mortgage, the term “Secured Parties” shall mean (a)(i) the Lenders, (ii) the Administrative Agent,
(iii) the Collateral Agent, (iv) any Issuing Bank, (v) each counterparty to any Hedging Agreement or Cash Management Agreement with a Loan Party that either (A) is in effect on the Closing Date if such counterparty is the
Administrative Agent, a Lender or an Affiliate of the Administrative Agent or a Lender as of the Closing Date or (B) is entered into after the Closing Date if such counterparty is the Administrative Agent, a Lender or an Affiliate of the
Administrative Agent or a Lender at the time such Hedging Agreement or Cash Management Agreement is entered into, (vi) the beneficiaries of each indemnification obligation undertaken by any Loan Party under any Loan Document, and (vii) the
successors and assigns of each of the foregoing and (b)(i) the holders of any Pari Passu Debt Obligations and (ii) any Pari Passu Representative with respect thereto. 

Pursuant to the requirements of the Credit Agreement, the Mortgagor is granting this Mortgage to create a lien on and a security interest in
the Mortgaged Property (as hereinafter defined) to secure the performance and payment by the Mortgagor of the Obligations. The Credit Agreement also requires the granting by other Loan Parties of mortgages, deeds of trust and/or deeds to secure debt
(the “Other Mortgages”) that create liens on and security interests in certain real and personal property other than the Mortgaged Property to secure the performance of the Obligations. 

Granting Clauses 
 NOW,
THEREFORE, IN CONSIDERATION OF the foregoing and in order to secure the due and punctual payment and performance of the Obligations for the benefit of the Secured Parties, Mortgagor hereby grants, conveys, mortgages, assigns and pledges to the
Mortgagee, a mortgage lien on and a security interest in, all the following described property (the “Mortgaged Property”) whether now owned or held or hereafter acquired: 

(1) the land more particularly described on Exhibit A hereto (the “Land”), together with all
rights appurtenant thereto, including the easements over certain other adjoining land granted by any easement agreements, covenant or restrictive agreements and all air rights, mineral rights, water rights, oil and gas rights and development rights,
if any, relating thereto, and also together with all of the other easements, rights, privileges, interests, hereditaments and appurtenances thereunto belonging or in any way appertaining and all of the estate, right, title, interest, claim or demand
whatsoever of Mortgagor therein and in the streets and ways adjacent thereto, either in law or in equity, in possession or expectancy, now or hereafter acquired (the “Premises”); 

 (2) all buildings, improvements, structures, paving, parking areas, walkways
and landscaping now or hereafter erected or located upon the Land, and all fixtures of every kind and type affixed to the Premises or attached to or forming part of any structures, buildings or improvements and replacements thereof now or hereafter
erected or located upon the Land (the “Improvements”); 
 (3) all apparatus, movable
appliances, building materials, equipment, fittings, furnishings, furniture, machinery and other articles of tangible personal property of every kind and nature, and replacements thereof, now or at any time hereafter placed upon or used in any way
in connection with the use, enjoyment, occupancy or operation of the Improvements or the Premises, including all of Mortgagor’s books and records relating thereto and including all pumps, tanks, goods, machinery, tools, equipment, lifts
(including fire sprinklers and alarm systems, fire prevention or control systems, cleaning rigs, air conditioning, heating, boilers, refrigerating, electronic monitoring, water, loading, unloading, lighting, power, sanitation, waste removal,
entertainment, communications, computers, recreational, window or structural, maintenance, truck or car repair and all other equipment of every kind), restaurant, bar and all other indoor or outdoor furniture (including tables, chairs, booths,
serving stands, planters, desks, sofas, racks, shelves, lockers and cabinets), bar equipment, glasses, cutlery, uniforms, linens, memorabilia and other decorative items, furnishings, appliances, supplies, inventory, rugs, carpets and other floor
coverings, draperies, drapery rods and brackets, awnings, venetian blinds, partitions, chandeliers and other lighting fixtures, freezers, refrigerators, walk-in coolers, signs (indoor and outdoor), computer systems, cash registers and inventory
control systems, and all other apparatus, equipment, furniture, furnishings, and articles used in connection with the use or operation of the Improvements or the Premises, it being understood that the enumeration of any specific articles of property
shall in no way result in or be held to exclude any items of property not specifically mentioned (the property referred to in this subparagraph (3), the “Personal Property”); 

(4) all general intangibles owned by Mortgagor and relating to design, development, operation, management and use of the
Premises or the Improvements, all certificates of occupancy, zoning variances, building, use or other permits, approvals, authorizations and consents obtained from and all materials prepared for filing or filed with any governmental agency in
connection with the development, use, operation or management of the Premises and Improvements, all construction, service, engineering, consulting, leasing, architectural and other similar contracts concerning the design, construction, management,
operation, occupancy and/or use of the Premises and Improvements, all architectural drawings, plans, specifications, soil tests, feasibility studies, appraisals, environmental studies, engineering reports and similar materials relating to any
portion of or all of the Premises and Improvements, and all payment and performance bonds or warranties or guarantees relating to the Premises or the Improvements, all to the extent assignable (the “Permits, Plans and
Warranties”); 
 (5) all now or hereafter existing leases or licenses (under which Mortgagor is landlord
or licensor) and subleases (under which Mortgagor is sublandlord), 

 
concession, management, mineral or other agreements of a similar kind that permit the use or occupancy of the Premises or the Improvements for any purpose in return for any payment, or the
extraction or taking of any gas, oil, water or other minerals from the Premises in return for payment of any fee, rent or royalty (collectively, “Leases”), and all agreements or contracts for the sale or other disposition of
all or any part of the Premises or the Improvements, now or hereafter entered into by Mortgagor, together with all charges, fees, income, issues, profits, receipts, rents, revenues or royalties payable thereunder (“Rents”);

 (6) all real estate tax refunds and all proceeds of the conversion, voluntary or involuntary, of any of the
Mortgaged Property into cash or liquidated claims (“Proceeds”), including Proceeds of insurance maintained by the Mortgagor and condemnation awards, any awards that may become due by reason of the taking by eminent domain or
any transfer in lieu thereof of the whole or any part of the Premises or Improvements or any rights appurtenant thereto, and any awards for change of grade of streets, together with any and all moneys now or hereafter on deposit for the payment of
real estate taxes, assessments or common area charges levied against the Mortgaged Property, unearned premiums on policies of fire and other insurance maintained by the Mortgagor covering any interest in the Mortgaged Property or required by the
Credit Agreement; and 
 (7) all extensions, improvements, betterments, renewals, substitutes and replacements of and
all additions and appurtenances to, the Land, the Premises, the Improvements, the Personal Property, the Permits, Plans and Warranties and the Leases, hereinafter acquired by or released to the Mortgagor or constructed, assembled or placed by the
Mortgagor on the Land, the Premises or the Improvements, and all conversions of the security constituted thereby, immediately upon such acquisition, release, construction, assembling, placement or conversion, as the case may be, and in each such
case, without any further mortgage, deed of trust, conveyance, assignment or other act by the Mortgagor, all of which shall become subject to the lien of this Mortgage as fully and completely, and with the same effect, as though now owned by the
Mortgagor and specifically described herein. 
 TO HAVE AND TO HOLD the Mortgaged Property unto the Mortgagee, its successors and assigns,
for the ratable benefit of the Secured Parties, forever, subject only to the Liens set forth in Section 6.02 of the Credit Agreement, including, for the avoidance of uncertainty, those Liens set forth in Sections 6.02(h), (i) and
(l) of the Credit Agreement and to satisfaction and release as provided in Section 3.04 hereof. 
 The Obligations hereby secured,
if not earlier accelerated, have a maturity date of (i) January 27, 2019 as to the Revolving Loans and the 2019 Term A Loans, (iii) January 27, 2021 as to the 2021 Term D Loans, (iv) January 25, 2017 as to the 2017 Term
E Loans, (v) August 25, 2018 as to the 2018 Notes and (vi) [  ], 2021 as to the 2021 Notes. 

 ARTICLE I 

Representations, Warranties and Covenants of Mortgagor 

Mortgagor agrees, covenants, represents and/or warrants as follows: 

SECTION 1.01.  Title, Mortgage Lien.  (a)  Mortgagor has good and marketable fee simple title to the
Mortgaged Property, subject only to the Liens set forth in Section 6.02 of the Credit Agreement, including, for the avoidance of uncertainty, those Liens set forth in Sections 6.02(h), (i) and (l) of the Credit Agreement. 

(b)  The execution and delivery of this Mortgage is within Mortgagor’s corporate powers and has been duly authorized by all
necessary corporate and, if required, stockholder action. This Mortgage has been duly executed and delivered by Mortgagor and constitutes a legal, valid and binding obligation of Mortgagor, enforceable in accordance with its terms, subject to
applicable bankruptcy, insolvency, reorganization, moratorium or other laws affecting creditors’ rights generally and subject to general principles of equity, regardless of whether considered in a proceeding in equity or at law. 

(c)  The execution, delivery and recordation of this Mortgage (i) do not require any consent or approval of, registration or
filing with, or any other action by, any Governmental Authority, except such as have been obtained or made and are in full force and effect and except filings necessary to perfect the lien of this Mortgage, (ii) will not violate any applicable
law or regulation or the charter, by-laws or other organizational documents of Mortgagor or any order of any Governmental Authority, (iii) will not violate or result in a default under any indenture, agreement or other instrument binding upon
Mortgagor or its assets, or give rise to a right thereunder to require any payment to be made by Mortgagor, and (iv) will not result in the creation or imposition of any Lien on any asset of Mortgagor, except the lien of this Mortgage. 

(d)  This Mortgage and the Uniform Commercial Code Financing Statements described in Section 1.09 of this Mortgage, when duly
recorded in the public records will create a valid, perfected and enforceable lien upon and security interest in all of the Mortgaged Property. 

(e)  Mortgagor will forever warrant and defend its title to the Mortgaged Property, the rights of Mortgagee therein under this
Mortgage and the validity and priority of the lien of this Mortgage thereon against the claims of all persons and parties except those having rights under the Liens set forth in Section 6.02 of the Credit Agreement to the extent of those
rights. 
 SECTION 1.02.  Credit Agreement.  This Mortgage is given pursuant to the Credit Agreement. Mortgagor
expressly covenants and agrees to pay when due, and to timely perform, and to cause the other Loan Parties to pay when due, and to timely perform, the Obligations in accordance with their terms. 

SECTION 1.03.  Payment of Taxes, and Other Obligations.  (a)  Mortgagor will pay and discharge from time
to time prior to the time when the same shall become delinquent, and before any interest or penalty accrues thereon or attaches thereto, all Taxes and other 

 
obligations with respect to the Mortgaged Property or any part thereof or upon the Rents from the Mortgaged Property or arising in respect of the occupancy, use or possession thereof in
accordance with, and to the extent required by, the Credit Agreement and/or any equivalent provision of the Indentures. 
 (b)  In
the event of the passage of any state, Federal, municipal or other governmental law, order, rule or regulation subsequent to the date hereof (i) deducting from the value of real property for the purpose of taxation any lien or encumbrance
thereon or in any manner changing or modifying the laws now in force governing the taxation of this Mortgage or debts secured by mortgages or deeds of trust (other than laws governing income, franchise and similar taxes generally) or the manner of
collecting taxes thereon and (ii) imposing a tax to be paid by Mortgagee, either directly or indirectly, on this Mortgage or any of the Secured Credit Documents, or requiring an amount of taxes to be withheld or deducted therefrom, Mortgagor
will promptly (x) notify Mortgagee of such event, (y) enter into such further instruments as Mortgagee may determine are reasonably necessary or desirable to obligate Mortgagor to make any additional payments necessary to put the Lenders
and Secured Parties in the same financial position they would have been if such law, order, rule or regulation had not been passed and (z) make such additional payments to Mortgagee for the benefit of the Lenders and Secured Parties. 

SECTION 1.04.  Maintenance of Mortgaged Property.  Mortgagor will maintain the Improvements and the Personal
Property in the manner required by the Credit Agreement. 
 SECTION 1.05.  Insurance.  Mortgagor will keep or
cause to be kept the Improvements and Personal Property insured against such risks, and in the manner, described in Section 4.03(l) of the Guarantee and Collateral Agreement and shall purchase such additional insurance as may be required from
time to time pursuant to Section 5.02 of the Credit Agreement. Federal Emergency Management Agency Standard Flood Hazard Determination Forms will be purchased by Mortgagor for each Mortgaged Property on which Improvements are located. If any
portion of Improvements constituting part of the Mortgaged Property is located in an area identified as a special flood hazard area by Federal Emergency Management Agency or other applicable agency, Mortgagor will purchase flood insurance in an
amount reasonably satisfactory to Mortgagee, but in no event less than the maximum limit of coverage available under the National Flood Insurance Act of 1968, as amended. 

SECTION 1.06.  Casualty Condemnation/Eminent Domain.  Mortgagor shall give Mortgagee prompt written notice of any
casualty or other damage to the Mortgaged Property or any proceeding for the taking of the Mortgaged Property or any portion thereof or interest therein under power of eminent domain or by condemnation or any similar proceeding in accordance with,
and to the extent required by, the Credit Agreement. Any Net Cash Proceeds received by or on behalf of the Mortgagor in respect of any such casualty, damage or taking shall constitute trust funds held by the Mortgagor for the benefit of the Secured
Parties to be applied to repair, restore or replace the Mortgaged Property or, if a prepayment event shall occur with respect to any such Net Cash Proceeds, to be applied in accordance with the Credit Agreement and/or any equivalent provision of the
Indentures. 

 SECTION 1.07.  Assignment of Leases and
Rents.  (a)  Mortgagor hereby irrevocably and absolutely grants, transfers and assigns all of its right title and interest in all Leases, together with any and all extensions and renewals thereof for purposes of securing and
discharging the performance by Mortgagor of the Obligations. Mortgagor has not assigned or executed any assignment of, and will not assign or execute any assignment of, any Leases or the Rents payable thereunder to anyone other than Mortgagee. 

(b)  Except for those Leases set forth in Section 6.02(l) of the Credit Agreement, all Leases shall be subordinate to the lien
of this Mortgage. Except for those Leases set forth in Section 6.02(l) of the Credit Agreement, Mortgagor will not enter into, modify or amend any Lease if such Lease, as entered into, modified or amended, will not be subordinate to the lien of
this Mortgage. 
 (c)  Subject to Section 1.07(d), Mortgagor has assigned and transferred to Mortgagee all of
Mortgagor’s right, title and interest in and to the Rents now or hereafter arising from each Lease heretofore or hereafter made or agreed to by Mortgagor, it being intended that this assignment establish, subject to Section 1.07(d), an
absolute transfer and assignment of all Rents and all Leases to Mortgagee and not merely to grant a security interest therein. Subject to Section 1.07(d), Mortgagee may in Mortgagor’s name and stead (with or without first taking possession
of any of the Mortgaged Property personally or by receiver as provided herein) operate the Mortgaged Property and rent, lease or let all or any portion of any of the Mortgaged Property to any party or parties at such rental and upon such terms as
Mortgagee shall, in its sole discretion, determine, and may collect and have the benefit of all of said Rents arising from or accruing at any time thereafter or that may thereafter become due under any Lease. 

(d)  So long as an Event of Default shall not have occurred and be continuing, Mortgagee will not exercise any of its rights under
Section 1.07(c), and Mortgagor shall receive and collect the Rents accruing under any Lease; but after the happening and during the continuance of any Event of Default, Mortgagee may, at its option, receive and collect all Rents and enter upon
the Premises and Improvements through its officers, agents, employees or attorneys for such purpose and for the operation and maintenance thereof. Mortgagor hereby irrevocably authorizes and directs each tenant, if any, and each successor, if any,
to the interest of any tenant under any Lease, respectively, to rely upon any notice of an Event of Default sent by Mortgagee to any such tenant or any of such tenant’s successors in interest, and thereafter to pay Rents to Mortgagee without
any obligation or right to inquire as to whether an Event of Default actually exists and even if some notice to the contrary is received from the Mortgagor, who shall have no right or claim against any such tenant or successor in interest for any
such Rents so paid to Mortgagee. Each tenant or any of such tenant’s successors in interest from whom Mortgagee or any officer, agent, attorney or employee of Mortgagee shall have collected any Rents, shall be authorized to pay Rents to
Mortgagor only after such tenant or any of their successors in interest shall have received written notice from Mortgagee (such notice to promptly be sent by Mortgagee once an Event of Default is no longer occurring) that the Event of Default is no
longer continuing, unless and until a further notice of an Event of Default is given by Mortgagee to such tenant or any of its successors in interest. 

 (e)  Mortgagee will not become a mortgagee in possession so long as it does not enter
or take actual possession of the Mortgaged Property. In addition, Mortgagee shall not be responsible or liable for performing any of the obligations of the landlord under any Lease, for any waste by any tenant, or others, for any dangerous or
defective conditions of any of the Mortgaged Property, for negligence in the management, upkeep, repair or control of any of the Mortgaged Property or any other act or omission by any other person. 

(f)  Mortgagor shall furnish to Mortgagee, within 30 days after a request by Mortgagee to do so, a written statement containing
the names of all tenants, subtenants and concessionaires of the Premises or Improvements, the terms of any Lease, the space occupied and the rentals and/or other amounts payable thereunder. 

SECTION 1.08.  Restrictions on Transfers and Encumbrances.  Mortgagor shall not directly or indirectly sell,
convey, divest, alienate, assign, lease, sublease, license, mortgage, pledge, encumber or otherwise transfer, create, consent to or suffer the creation of any lien, charge or other form of encumbrance upon any interest in or any part of the
Mortgaged Property (other than resulting from a condemnation), or engage in any common, cooperative, joint, time-sharing or other congregate ownership of all or part thereof, except in each case in accordance with and to the extent permitted by the
Credit Agreement and/or any equivalent provision of the Indentures; provided, that Mortgagor may, in the ordinary course of business and in accordance with reasonable commercial standards, enter into easement or covenant agreements that
relate to and/or benefit the operation of the Mortgaged Property and that do not materially and adversely affect the value, use or operation of the Mortgaged Property. If any of the foregoing transfers or encumbrances results in an event requiring
prepayment of the Loans in accordance with the terms of the Credit Agreement, any Net Cash Proceeds received by or on behalf of the Mortgagor in respect thereof shall constitute trust funds to be held by the Mortgagor for the benefit of the Secured
Parties and applied in accordance with the Credit Agreement and/or any equivalent provision of the Indentures. 
 SECTION
1.09.  Security Agreement.  This Mortgage is both a mortgage of real property and a grant of a security interest in personal property, and shall constitute and serve as a “Security Agreement” within
the meaning of the uniform commercial code as adopted in the state wherein the Premises are located (“UCC”). Mortgagor has hereby granted unto Mortgagee a security interest in and to all the Mortgaged Property described in
this Mortgage that is not real property, and simultaneously with the recording of this Mortgage, Mortgagor has filed or will file UCC financing statements, and will file continuation statements prior to the lapse thereof, at the appropriate offices
in the jurisdiction of formation of the Mortgagor to perfect the security interest granted by this Mortgage in all the Mortgaged Property that is not real property. Mortgagor hereby appoints Mortgagee as its true and lawful attorney-in-fact and
agent, for Mortgagor and in its name, place and stead, in any and all capacities, to execute any document and to file the same in the appropriate offices (to the extent it may lawfully do so), and to perform each and every act and thing reasonably
requisite and necessary to be done to perfect the security interest contemplated by the preceding sentence. Mortgagee shall have all rights with respect to the part of the Mortgaged Property that is the subject of a security interest afforded by the
UCC in addition to, but not in limitation of, the other rights afforded Mortgagee hereunder and under the Guarantee and Collateral Agreement. 

 SECTION 1.10.  Filing and Recording.  Mortgagor will cause this
Mortgage, the UCC financing statements referred to in Section 1.09, any other security instrument creating a security interest in or evidencing the lien hereof upon the Mortgaged Property and each UCC continuation statement and instrument of
further assurance to be filed, registered or recorded and, if necessary, refiled, rerecorded and reregistered, in such manner and in such places as may be required by any present or future law in order to publish notice of and fully to perfect the
lien hereof upon, and the security interest of Mortgagee in, the Mortgaged Property until this Mortgage is terminated and released in full in accordance with Section 3.04 hereof. Mortgagor will pay all filing, registration and recording fees,
all Federal, state, county and municipal recording, documentary or intangible taxes and other taxes, duties, imposts, assessments and charges, and all reasonable expenses incidental to or arising out of or in connection with the execution, delivery
and recording of this Mortgage, UCC continuation statements any mortgage supplemental hereto, any security instrument with respect to the Personal Property, Permits, Plans and Warranties and Proceeds or any instrument of further assurance. 

SECTION 1.11.  Further Assurances.  Upon reasonable demand by Mortgagee, Mortgagor will, at the cost of Mortgagor
and without expense to Mortgagee, do, execute, acknowledge and deliver all such further acts, deeds, conveyances, mortgages, assignments, notices of assignment, transfers and assurances as Mortgagee shall from time to time reasonably require for the
better assuring, conveying, assigning, transferring and confirming unto Mortgagee the property and rights hereby conveyed or assigned or intended now or hereafter so to be, or which Mortgagor may be or may hereafter become bound to convey or assign
to Mortgagee, or for carrying out the intention or facilitating the performance of the terms of this Mortgage, or for filing, registering or recording this Mortgage, and on demand, Mortgagor will also execute and deliver and hereby appoints
Mortgagee as its true and lawful attorney-in-fact and agent, for Mortgagor and in its name, place and stead, in any and all capacities, to execute and file to the extent it may lawfully do so, one or more financing statements, chattel mortgages or
comparable security instruments reasonably requested by Mortgagee to evidence more effectively the lien hereof upon the Personal Property and to perform each and every act and thing requisite and necessary to be done to accomplish the same. 

SECTION 1.12.  Additions to Mortgaged Property.  All right, title and interest of Mortgagor in and to all
extensions, improvements, betterments, renewals, substitutions and replacements of, and all additions and appurtenances to, the Mortgaged Property hereafter acquired by or released to Mortgagor or constructed, assembled or placed by Mortgagor upon
the Premises or the Improvements, and all conversions of the security constituted thereby, immediately upon such acquisition, release, construction, assembling, placement or conversion, as the case may be, and in each such case without any further
mortgage, conveyance, assignment or other act by Mortgagor, shall become subject to the lien and security interest of this Mortgage as fully and completely and with the same effect as though now owned by Mortgagor and specifically described in the
grant of the Mortgaged Property above, but at any and all times Mortgagor will execute and deliver to Mortgagee any and all such further assurances, mortgages, conveyances or assignments thereof as Mortgagee may reasonably require for the purpose of
expressly and specifically subjecting the same to the lien and security interest of this Mortgage. 

 SECTION 1.13.  No Claims Against Mortgagee.  Nothing contained in this
Mortgage shall constitute any consent or request by Mortgagee, express or implied, for the performance of any labor or services or the furnishing of any materials or other property in respect of the Mortgaged Property or any part thereof, nor as
giving Mortgagor any right, power or authority to contract for or permit the performance of any labor or services or the furnishing of any materials or other property in such fashion as would permit the making of any claim against Mortgagee in
respect thereof. 
 SECTION 1.14.  Fixture Filing.  (a)  Certain portions of the Mortgaged Property are
or will become “fixtures” (as that term is defined in the UCC) on the Land, and this Mortgage, upon being filed for record in the real estate records of the county wherein such fixtures are situated, shall operate also as a financing
statement filed as a fixture filing in accordance with the applicable provisions of said UCC upon such portions of the Mortgaged Property that are or become fixtures. 

(b)  The real property to which the fixtures relate is described in Exhibit A attached hereto. The record owner of the real property
described in Exhibit A attached hereto is Mortgagor. The name, type of organization and jurisdiction of organization of the debtor for purposes of this financing statement are the name, type of organization and jurisdiction of organization of the
Mortgagor set forth in the first paragraph of this Mortgage, and the name of the secured party for purposes of this financing statement is the name of the Mortgagee set forth in the first paragraph of this Mortgage. The mailing address of the
Mortgagor/debtor is the address of the Mortgagor set forth in the first paragraph of this Mortgage. The mailing address of the Mortgagee/secured party from which information concerning the security interest hereunder may be obtained is the address
of the Mortgagee set forth in the first paragraph of this Mortgage. Mortgagor’s organizational identification number is
[                        ]. 

ARTICLE II 
 Defaults and Remedies

 SECTION 2.01.  Events of Default.  Any Event of Default under the Credit Agreement (as such term is defined
therein) or an Indenture (as such term is defined therein) shall constitute an Event of Default under this Mortgage. 
 SECTION
2.02.  Demand for Payment.  If an Event of Default shall occur and be continuing, then, upon written demand of Mortgagee, Mortgagor will pay to Mortgagee all amounts due hereunder and under any Secured Credit Document and
such further amount as shall be sufficient to cover the out-of-pocket costs and expenses of collection, including attorneys’ fees, disbursements and expenses incurred by Mortgagee, and Mortgagee shall be entitled and empowered to institute an
action or proceedings at law or in equity for the collection of the sums so due and unpaid, to prosecute any such action or proceedings to judgment or final decree, to enforce any such judgment or final decree against Mortgagor and to collect, in
any manner provided by law, all moneys adjudged or decreed to be payable. 

 SECTION 2.03.  Rights To Take Possession, Operate and Apply
Revenues.  (a)  If an Event of Default shall occur and be continuing, Mortgagor shall, upon demand of Mortgagee, forthwith surrender to Mortgagee actual possession of the Mortgaged Property and, if and to the extent not
prohibited by applicable law, Mortgagee itself, or by such officers or agents as it may appoint, may then enter and take possession of all the Mortgaged Property without the appointment of a receiver or an application therefor, exclude Mortgagor and
its agents and employees wholly therefrom, and have access to the books, papers and accounts of Mortgagor. 
 (b)  If Mortgagor
shall for any reason fail to surrender or deliver the Mortgaged Property or any part thereof after such demand by Mortgagee, Mortgagee may to the extent not prohibited by applicable law, obtain a judgment or decree conferring upon Mortgagee the
right to immediate possession or requiring Mortgagor to deliver immediate possession of the Mortgaged Property to Mortgagee, to the entry of which judgment or decree Mortgagor hereby specifically consents. Mortgagor will pay to Mortgagee, upon
demand, all reasonable expenses of obtaining such judgment or decree, including reasonable compensation to Mortgagee’s attorneys and agents with interest thereon at the rate per annum applicable to overdue amounts under the Credit Agreement as
provided in Section 2.07 of the Credit Agreement (the “Interest Rate”); and all such expenses and compensation shall, until paid, be secured by this Mortgage. 

(c)  Upon every such entry or taking of possession, Mortgagee may, to the extent not prohibited by applicable law, hold, store, use,
operate, manage and control the Mortgaged Property, conduct the business thereof and, from time to time, (i) make all necessary and proper maintenance, repairs, renewals, replacements, additions, betterments and improvements thereto and
thereon, (ii) purchase or otherwise acquire additional fixtures, personalty and other property that are reasonably necessary for the operation of the business, (iii) insure or keep the Mortgaged Property insured, (iv) manage and
operate the Mortgaged Property and exercise all the rights and powers of Mortgagor to the same extent as Mortgagor could in its own name or otherwise with respect to the same, or (v) enter into any and all agreements with respect to the
exercise by others of any of the powers herein granted Mortgagee, all as may from time to time be directed or determined by Mortgagee to reasonably be in its best interest and Mortgagor hereby appoints Mortgagee as its true and lawful
attorney-in-fact and agent, for Mortgagor and in its name, place and stead, in any and all capacities, to perform any of the foregoing acts. Mortgagee may collect and receive all the Rents, issues, profits and revenues from the Mortgaged Property,
including those past due as well as those accruing thereafter, and, after deducting (i) all out-of-pocket expenses of taking, holding, managing and operating the Mortgaged Property (including compensation for the services of all persons
employed for such purposes), (ii) the out-of-pocket costs of all such maintenance, repairs, renewals, replacements, additions, betterments, improvements, purchases and acquisitions, (iii) the costs of insurance, (iv) such taxes,
assessments and other similar charges as Mortgagee may at its option pay, (v) other proper charges upon the Mortgaged Property or any part thereof and (vi) the compensation, expenses and disbursements of the attorneys and agents of
Mortgagee, Mortgagee shall apply the remainder of the moneys and proceeds so received first to the payment of the Mortgagee for the satisfaction of the Obligations, and second, if there is any surplus, to Mortgagor, subject to the entitlement of
others thereto under applicable law. 

 (d)  Whenever, before any sale of the Mortgaged Property under Section 2.06, all
Obligations that are then due shall have been paid and all Events of Default fully cured, Mortgagee will surrender possession of the Mortgaged Property back to Mortgagor, its successors or assigns. The same right of taking possession shall, however,
arise again if any subsequent Event of Default shall occur and be continuing. 
 SECTION 2.04.  Right To Cure Mortgagor’s
Failure to Perform.  Should Mortgagor fail in the payment, performance or observance of any term, covenant or condition required by this Mortgage or the Secured Credit Document (with respect to the Mortgaged Property), Mortgagee may
pay, perform or observe the same, and all payments made or costs or expenses incurred by Mortgagee in connection therewith shall be secured hereby and shall be, without demand, immediately repaid by Mortgagor to Mortgagee with interest thereon at
the Interest Rate. Mortgagee shall be the judge using reasonable discretion of the necessity for any such actions and of the amounts to be paid. Mortgagee is hereby empowered to enter and to authorize others to enter upon the Premises or the
Improvements or any part thereof for the purpose of performing or observing any such defaulted term, covenant or condition without having any obligation to so perform or observe and without thereby becoming liable to Mortgagor, to any person in
possession holding under Mortgagor or to any other person; provided, however, that except in the case of an emergency, Mortgagee will provide reasonable advance notice of such entry, such entry shall be conducted in a reasonable manner and Mortgagee
shall use reasonable efforts to endeavor to minimize the amount of disturbance to the Mortgagor’s possession of the Mortgaged Property. 

SECTION 2.05.  Right to a Receiver.  If an Event of Default shall occur and be continuing, Mortgagee, upon
application to a court of competent jurisdiction, shall be entitled as a matter of right to the appointment of a receiver to take possession of and to operate the Mortgaged Property and to collect and apply the Rents. The receiver shall have all of
the rights and powers permitted under the laws of the state wherein the Mortgaged Property is located. Mortgagor shall pay to Mortgagee upon demand all reasonable out-of-pocket expenses, including receiver’s fees, reasonable attorney’s
fees and disbursements, costs and agent’s compensation incurred pursuant to the provisions of this Section 2.05; and all such expenses shall be secured by this Mortgage and shall be, without demand, immediately repaid by Mortgagor to
Mortgagee with interest thereon at the Interest Rate. 
 SECTION 2.06.  Foreclosure and Sale.  (a)  If
an Event of Default shall occur and be continuing, Mortgagee may elect to sell the Mortgaged Property or any part of the Mortgaged Property by exercise of the power of foreclosure or of sale granted to Mortgagee by applicable law or this Mortgage.
In such case, Mortgagee may commence a civil action to foreclose this Mortgage, or it may proceed and sell the Mortgaged Property to satisfy any Obligation. Mortgagee or an officer appointed by a judgment of foreclosure to sell the Mortgaged
Property, may sell all or such parts of the Mortgaged Property as may be chosen by Mortgagee at the time and place of sale fixed by it in a notice of sale, either as a whole or in separate lots, parcels or items as Mortgagee shall deem expedient,
and in such order as it may determine, at public auction to the highest bidder. Mortgagee or an officer appointed by a judgment of foreclosure to sell the Mortgaged Property may postpone any foreclosure or other sale of all or any portion of the
Mortgaged Property by public announcement at such time and place of sale, and from time to time thereafter may postpone such sale by public 

 
announcement or subsequently noticed sale. Without further notice, Mortgagee or an officer appointed to sell the Mortgaged Property may make such sale at the time fixed by the last postponement,
or may, in its discretion, give a new notice of sale. Any person, including Mortgagor or Mortgagee or any designee or affiliate thereof, may purchase at such sale. 

(b)  The Mortgaged Property may be sold subject to unpaid taxes and the Liens set forth in Section 6.02 of the Credit
Agreement, and, after deducting all costs, fees and out-of-pocket expenses of Mortgagee (including costs of evidence of title in connection with the sale), Mortgagee or an officer that makes any sale shall apply the proceeds of sale in the manner
set forth in Section 2.08. 
 (c)  Any foreclosure or other sale of less than the whole of the Mortgaged Property or any
defective or irregular sale made hereunder shall not exhaust the power of foreclosure or of sale provided for herein; and subsequent sales may be made hereunder until the Obligations have been satisfied, or the entirety of the Mortgaged Property has
been sold. 
 (d)  If an Event of Default shall occur and be continuing, Mortgagee may instead of, or in addition to, exercising
the rights described in Section 2.06(a) above and either with or without entry or taking possession as herein permitted, proceed by a suit or suits in law or in equity or by any other appropriate proceeding or remedy (i) to specifically
enforce payment of some or all of the Obligations, or the performance of any term, covenant, condition or agreement of this Mortgage or any other Loan Document or any other right, or (ii) to pursue any other remedy available to Mortgagee, all
as Mortgagee shall determine most effectual for such purposes. 
 SECTION 2.07.  Other
Remedies.  (a)  In case an Event of Default shall occur and be continuing, Mortgagee may also exercise, to the extent not prohibited by law, any or all of the remedies available to a secured party under the UCC. 

(b)  In connection with a sale of the Mortgaged Property or any Personal Property and the application of the proceeds of sale as
provided in Section 2.08, Mortgagee shall be entitled to enforce payment of and to receive up to the principal amount of the Obligations, plus all other charges, payments and costs due under this Mortgage, and to recover a deficiency judgment
for any portion of the aggregate principal amount of the Obligations remaining unpaid, with interest. 
 SECTION
2.08.  Application of Sale Proceeds and Rents.  After any foreclosure sale of all or any of the Mortgaged Property, Mortgagee shall receive and apply the proceeds of the sale together with any Rents that may have been
collected and any other sums that then may be held by Mortgagee under this Mortgage as follows: 
 FIRST, to the payment of
all out-of-pocket costs and expenses incurred by the Administrative Agent or the Mortgagee (in their respective capacities as such hereunder or under any other Secured Credit Document) in connection with such collection, sale, foreclosure or
realization or otherwise in connection with this Mortgage, any other Secured Credit Document or any of the Obligations, including all court costs and the fees and expenses of its agents and legal counsel, the

 
repayment of all advances made by the Administrative Agent and/or the Mortgagee hereunder or under any other Secured Credit Document, as applicable, on behalf of any Mortgagor and any other
out-of-pocket costs or expenses incurred in connection with the exercise of any right or remedy hereunder or under any other Secured Credit Document; 

SECOND, to the payment in full of Unfunded Advances/Participations (the amounts so applied to be distributed between or among
the Administrative Agent and any Issuing Bank pro rata in accordance with the amounts of Unfunded Advances/Participations owed to them on the date of any such distribution); 

THIRD, to the payment in full of all other Obligations (the amounts so applied to be distributed among the Secured Parties pro
rata in accordance with the amounts of the Obligations owed to them on the date of any such distribution); 
 FOURTH, to the
Mortgagor, its successors or assigns, or as a court of competent jurisdiction may otherwise direct. 
 The Mortgagee shall have absolute discretion as to
the time of application of any such proceeds, moneys or balances in accordance with this Mortgage. Upon any sale of the Mortgaged Property by the Mortgagee (including pursuant to a power of sale granted by statute or under a judicial proceeding),
the receipt of the Mortgagee or of the officer making the sale shall be a sufficient discharge to the purchaser or purchasers of the Mortgaged Property so sold and such purchaser or purchasers shall not be obligated to see to the application of any
part of the purchase money paid over to the Mortgagee or such officer or be answerable in any way for the misapplication thereof. 
 SECTION
2.09.  Mortgagor as Tenant Holding Over.  If Mortgagor remains in possession of any of the Mortgaged Property after any foreclosure sale by Mortgagee, at Mortgagee’s election Mortgagor shall be deemed a tenant holding
over and shall forthwith surrender possession to the purchaser or purchasers at such sale or be summarily dispossessed or evicted according to provisions of law applicable to tenants holding over. 

SECTION 2.10.  Waiver of Appraisement, Valuation, Stay, Extension and Redemption Laws.  Mortgagor waives, to the
extent not prohibited by law, (i) the benefit of all laws now existing or that hereafter may be enacted (x) providing for any appraisement or valuation of any portion of the Mortgaged Property and/or (y) in any way extending the time
for the enforcement or the collection of amounts due under any of the Obligations or creating or extending a period of redemption from any sale made in collecting said debt or any other amounts due Mortgagee, (ii) any right to at any time
insist upon, plead, claim or take the benefit or advantage of any law now or hereafter in force providing for any homestead exemption, stay, statute of limitations, extension or redemption, or sale of the Mortgaged Property as separate tracts, units
or estates or as a single parcel in the event of foreclosure or notice of deficiency, and (iii) all rights of redemption, valuation, appraisement, stay of execution, notice of election to mature or declare due the whole of or each of the
Obligations and marshaling in the event of foreclosure of this Mortgage. 

 SECTION 2.11.  Discontinuance of Proceedings.  In case Mortgagee shall
proceed to enforce any right, power or remedy under this Mortgage by foreclosure, entry or otherwise, and such proceedings shall be discontinued or abandoned for any reason, or shall be determined adversely to Mortgagee, then and in every such case
Mortgagor and Mortgagee shall be restored to their former positions and rights hereunder, and all rights, powers and remedies of Mortgagee shall continue as if no such proceeding had been taken. 

SECTION 2.12.  Suits To Protect the Mortgaged Property.  Mortgagee shall have power (a) to institute and
maintain suits and proceedings to prevent any impairment of the Mortgaged Property by any acts that may be unlawful or in violation of this Mortgage, (b) to preserve or protect its interest in the Mortgaged Property and in the Rents arising
therefrom and (c) to restrain the enforcement of or compliance with any legislation or other governmental enactment, rule or order that may be unconstitutional or otherwise invalid if the enforcement of or compliance with such enactment, rule
or order would impair the security or be prejudicial to the interest of Mortgagee hereunder. 
 SECTION 2.13.  Filing Proofs of
Claim.  In case of any receivership, insolvency, bankruptcy, reorganization, arrangement, adjustment, composition or other proceedings affecting Mortgagor, Mortgagee shall, to the extent permitted by law, be entitled to file such
proofs of claim and other documents as may be necessary or advisable in order to have the claims of Mortgagee allowed in such proceedings for the Obligations secured by this Mortgage at the date of the institution of such proceedings and for any
interest accrued, late charges and additional interest or other amounts due or that may become due and payable hereunder after such date. 

SECTION 2.14.  Possession by Mortgagee.  Notwithstanding the appointment of any receiver, liquidator or trustee of
Mortgagor, any of its property or the Mortgaged Property, Mortgagee shall be entitled, to the extent not prohibited by law, to remain in possession and control of all parts of the Mortgaged Property now or hereafter granted under this Mortgage to
Mortgagee in accordance with the terms hereof and applicable law. 
 SECTION 2.15.  Waiver.  (a)  No
delay or failure by Mortgagee to exercise any right, power or remedy accruing upon any breach or Event of Default shall exhaust or impair any such right, power or remedy or be construed to be a waiver of any such breach or Event of Default or
acquiescence therein; and every right, power and remedy given by this Mortgage to Mortgagee may be exercised from time to time and as often as may be deemed expedient by Mortgagee. No consent or waiver by Mortgagee to or of any breach or Event of
Default by Mortgagor in the performance of the Obligations shall be deemed or construed to be a consent or waiver to or of any other breach or Event of Default in the performance of the same or of any other Obligations by Mortgagor hereunder. No
failure on the part of Mortgagee to complain of any act or failure to act or to declare an Event of Default, irrespective of how long such failure continues, shall constitute a waiver by Mortgagee of its rights hereunder or impair any rights, powers
or remedies consequent on any future Event of Default by Mortgagor. 
 (b)  Even if Mortgagee (i) grants some forbearance or
an extension of time for the payment of any sums secured hereby, (ii) takes other or additional security for the payment 

 
of any sums secured hereby, (iii) waives or does not exercise some right granted herein or under the Secured Credit Documents, (iv) releases a part of the Mortgaged Property from this
Mortgage, (v) agrees to change some of the terms, covenants, conditions or agreements of any of the Secured Credit Documents, (vi) consents to the filing of a map, plat or replat affecting the Premises, (vii) consents to the granting
of an easement or other right affecting the Premises or (viii) makes or consents to an agreement subordinating Mortgagee’s lien on the Mortgaged Property hereunder; no such act or omission shall preclude Mortgagee from exercising any other
right, power or privilege herein granted or intended to be granted in the event of any breach or Event of Default then made or of any subsequent default; nor, except as otherwise expressly provided in an instrument executed by Mortgagee, shall this
Mortgage be altered thereby. In the event of the sale or transfer by operation of law or otherwise of all or part of the Mortgaged Property, Mortgagee is hereby authorized and empowered to deal with any vendee or transferee with reference to the
Mortgaged Property secured hereby, or with reference to any of the terms, covenants, conditions or agreements hereof, as fully and to the same extent as it might deal with the original parties hereto and without in any way releasing or discharging
any liabilities, obligations or undertakings. 
 SECTION 2.16.  Waiver of Trial by Jury.  To the fullest extent
permitted by applicable law, Mortgagor and Mortgagee each hereby irrevocably and unconditionally waive trial by jury in any action, claim, suit or proceeding relating to this Mortgage and for any counterclaim brought therein. Mortgagor hereby waives
all rights to interpose any counterclaim in any suit brought by Mortgagee hereunder and all rights to have any such suit consolidated with any separate suit, action or proceeding. 

SECTION 2.17.  Remedies Cumulative.  No right, power or remedy conferred upon or reserved to Mortgagee by this
Mortgage is intended to be exclusive of any other right, power or remedy, and each and every such right, power and remedy shall be cumulative and concurrent and in addition to any other right, power and remedy given hereunder or now or hereafter
existing at law or in equity or by statute. 
 ARTICLE III 

Miscellaneous 
 SECTION
3.01.  Partial Invalidity.  In the event any one or more of the provisions contained in this Mortgage shall for any reason be held to be invalid, illegal or unenforceable in any respect, such validity, illegality or
unenforceability shall, at the option of Mortgagee, not affect any other provision of this Mortgage, and this Mortgage shall be construed as if such invalid, illegal or unenforceable provision had never been contained herein or therein. 

SECTION 3.02.  Notices.  All notices and communications hereunder shall be in writing and given to Mortgagor in
accordance with the terms of the Credit Agreement at the address set forth on the first page of this Mortgage and to the Mortgagee as provided in the Credit Agreement and the Indentures. 

 SECTION 3.03.  Successors and Assigns.  All of the grants, covenants,
terms, provisions and conditions herein shall run with the Premises and the Improvements and shall apply to, bind and inure to, the benefit of the permitted successors and assigns of Mortgagor and the successors and assigns of Mortgagee. 

SECTION 3.04.  Satisfaction and Cancelation.  (a)  The conveyance to Mortgagee of the Mortgaged Property
as security created and consummated by this Mortgage shall terminate and be null and void when all the Obligations have been indefeasibly paid in full and the Lenders have no further commitment to lend under the Credit Agreement, the aggregate L/C
Exposure has been reduced to zero, the Issuing Bank has no further obligation to issue Letters of Credit under the Credit Agreement and the satisfaction and discharge requirements set forth in the Indentures have been satisfied. 

(b)  Mortgagor shall automatically be released from its obligations hereunder upon the consummation of (i) any transaction
permitted by the Credit Agreement as a result of which Mortgagor ceases to be a Subsidiary or (ii) any Permitted Receivables Transaction or a Permitted Securitization Transaction consummated after the date hereof as a result of which Mortgagor
becomes a Permitted Syndication Subsidiary or Securitization Subsidiary. 
 (c)  Upon any sale or other transfer by Mortgagor of
any Collateral that is permitted under the Credit Agreement to any person that is not the Borrower or a Guarantor, or, upon the effectiveness of any written consent to the release of the Security Interest granted hereby in any Collateral pursuant to
Section 9.09 of the Credit Agreement, the Security Interest in such Collateral shall be automatically released; provided that, upon the consummation after the date hereof of any Permitted Receivables Transaction or a Permitted
Securitization Transaction, the Security Interest in the Equity Interests of the Subsidiary that is the subject of such Permitted Receivables Transaction or a Permitted Securitization Transaction, as the case may be, shall be automatically released
to the extent the pledge of the Equity Interests in such Subsidiary is prohibited by any applicable Contractual Obligation or requirement of law. 

(d)  In connection with any termination or release pursuant to paragraph (a), (b) or (c) above, the Mortgagee shall
promptly execute and deliver to Mortgagor, at Mortgagor’s expense, a release of this Mortgage and all Uniform Commercial Code termination statements and similar documents that Mortgagor shall reasonably request to evidence such termination or
release. Any execution and delivery of documents pursuant to this Section 3.04 shall be without recourse to or representation or warranty by the Mortgagee or any Secured Party. Without limiting the provisions of Section 7.06 of the
Guarantee and Collateral Agreement, the Borrower shall reimburse the Mortgagee upon demand for all reasonable out of pocket expenses, including the fees, charges and expenses of counsel, incurred by it in connection with any action contemplated by
this Section 3.04. 
 SECTION 3.05.  Definitions.  As used in this Mortgage, the singular shall include the
plural as the context requires and the following words and phrases shall have the following meanings: (a) “including” shall mean “including but not limited to”; (b) “provisions” shall mean “provisions,
terms, covenants and/or conditions”; (c) “lien” shall mean “lien, charge, encumbrance, security interest, mortgage or deed of trust”; (d) “obligation” shall mean

 
“obligation, duty, covenant and/or condition”; and (e) “any of the Mortgaged Property” shall mean “the Mortgaged Property or any part thereof or interest
therein”. Any act that Mortgagee is permitted to perform hereunder may be performed at any time and from time to time by Mortgagee or any person or entity designated by Mortgagee. Any act that is prohibited to Mortgagor hereunder is also
prohibited to all lessees of any of the Mortgaged Property. Each appointment of Mortgagee as attorney-in-fact for Mortgagor under the Mortgage is irrevocable, with power of substitution and coupled with an interest. Subject to the applicable
provisions hereof, Mortgagee has the right to refuse to grant its consent, approval or acceptance or to indicate its satisfaction, in its sole discretion, whenever such consent, approval, acceptance or satisfaction is required hereunder. 

SECTION 3.06.  Multisite Real Estate Transaction.  Mortgagor acknowledges that this Mortgage is one of a number of
Other Mortgages and Security Documents that secure the Obligations. Mortgagor agrees that the lien of this Mortgage shall be absolute and unconditional and shall not in any manner be affected or impaired by any acts or omissions whatsoever of
Mortgagee, and without limiting the generality of the foregoing, the lien hereof shall not be impaired by any acceptance by the Mortgagee of any security for or guarantees of any of the Obligations hereby secured, or by any failure, neglect or
omission on the part of Mortgagee to realize upon or protect any Obligation or indebtedness hereby secured or any collateral security therefor including the Other Mortgages and other Security Documents. The lien hereof shall not in any manner be
impaired or affected by any release (except as to the property released), sale, pledge, surrender, compromise, settlement, renewal, extension, indulgence, alteration, changing, modification or disposition of any of the Obligations secured or of any
of the collateral security therefor, including the Other Mortgages and other Security Documents or of any guarantee thereof, and Mortgagee may at its discretion foreclose, exercise any power of sale, or exercise any other remedy available to it
under any or all of the Other Mortgages and other Security Documents without first exercising or enforcing any of its rights and remedies hereunder. Such exercise of Mortgagee’s rights and remedies under any or all of the Other Mortgages and
other Security Documents shall not in any manner impair the indebtedness hereby secured or the lien of this Mortgage and any exercise of the rights or remedies of Mortgagee hereunder shall not impair the lien of any of the Other Mortgages and other
Security Documents or any of Mortgagee’s rights and remedies thereunder. Mortgagor specifically consents and agrees that Mortgagee may exercise its rights and remedies hereunder and under the Other Mortgages and other Security Documents
separately or concurrently and in any order that it may deem appropriate and waives any rights of subrogation. 
 SECTION
3.07.  No Oral Modification.  This Mortgage may not be changed or terminated orally. Any agreement made by Mortgagor and Mortgagee after the date of this Mortgage relating to this Mortgage shall be superior to the rights
of the holder of any intervening or subordinate Mortgage, lien or encumbrance. 

 ARTICLE IV 

Particular Provisions 
 This
Mortgage is subject to the following provisions relating to the particular laws of the state wherein the Premises are located: 
 SECTION
4.01.  Applicable Law; Certain Particular Provisions.  This Mortgage shall be governed by and construed in accordance with the internal law of the state where the Mortgaged Property is located, except that Mortgagor
expressly acknowledges that by their terms, the Credit Agreement and other Loan Documents (aside from those Other Mortgages to be recorded outside New York) shall be governed by the internal law of the State of New York, without regard to
principles of conflict of law. Mortgagor and Mortgagee agree to submit to jurisdiction and the laying of venue for any suit on this Mortgage in the state where the Mortgaged Property is located. The terms and provisions set forth in Appendix A
attached hereto are hereby incorporated by reference as though fully set forth herein. In the event of any conflict between the terms and provisions contained in the body of this Mortgage and the terms and provisions set forth in Appendix A,
the terms and provisions set forth in Appendix A shall govern and control. 

 IN WITNESS WHEREOF, this Mortgage has been duly executed and delivered to Mortgagee by Mortgagor
on the date of the acknowledgment attached hereto. 
  

											
		 		 	 [NAME OF MORTGAGOR], a [            ]

corporation,

					
		 		 		 	by	  	
		 		 		 		  	  

		 		 		 		  	  Name:	  	[Rachel A. Seifert]
		 		 		 		  	  Title:	  	[Senior Vice President and Secretary]

  

					
	Attest:
		
	by:	 	

					
		 	  

		 	Name:	 	
		 	Title:	 	

 [Corporate Seal] 

 [ADD LOCAL FORM OF ACKNOWLEDGMENT] 

 Exhibit A 

to Mortgage 
 Description of the
Land 

 Appendix A 

to Mortgage 
 Local Law
Provisions 
 1.  Notwithstanding anything else contained in this Mortgage, (i) the maximum principal debt or obligation
which is, or under any contingency may be secured at the date of execution hereof or any time thereafter by this Mortgage is $[8,230,000,000] (the “Secured Amount”), (ii) this Mortgage shall also secure amounts other than the
principal debt or obligation to the extent permitted by the Tax Law without payment of additional recording tax and (iii) so long as the aggregate amount of the Obligations exceeds the Secured Amount, any payments and repayments of the
Obligations shall not be deemed to be applied against, or to reduce, the Secured Amount.1 

2.  [Other relevant local law provisions to be provided by local counsel.] 

 
  
  

 
  

1 Applicable only in mortgage tax states.EX-10.3

 Exhibit 10.3 

EXECUTION COPY 

CONTINGENT VALUE RIGHTS AGREEMENT 

by and between 

COMMUNITY HEALTH SYSTEMS, INC. 

and 
 AMERICAN STOCK
TRANSFER & TRUST COMPANY, LLC 
 Dated as of January 27, 2014 

 TABLE OF CONTENTS 

 

							
	 	  	 	  	Page	 
	 ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION
	  	 	1	  
	 SECTION 1.1
	  	Definitions	  	 	1	  
	 SECTION 1.2
	  	Compliance and Opinions	  	 	7	  
	 SECTION 1.3
	  	Form of Documents Delivered to Trustee	  	 	8	  
	 SECTION 1.4
	  	Acts of Holders	  	 	8	  
	 SECTION 1.5
	  	Notices, etc., to Trustee and Company	  	 	9	  
	 SECTION 1.6
	  	Notice to Holders; Waiver	  	 	10	  
	 SECTION 1.7
	  	Conflict with the Trust Indenture Act	  	 	10	  
	 SECTION 1.8
	  	Effect of Headings and Table of Contents	  	 	10	  
	 SECTION 1.9
	  	Benefits of Agreement	  	 	10	  
	 SECTION 1.10
	  	Governing Law; Jurisdiction; Venue; Waiver of Jury Trial	  	 	10	  
	 SECTION 1.11
	  	Legal Holidays	  	 	12	  
	 SECTION 1.12
	  	Separability Clause	  	 	12	  
	 SECTION 1.13
	  	No Recourse Against Others	  	 	12	  
	 SECTION 1.14
	  	Counterparts	  	 	12	  
	 SECTION 1.15
	  	Acceptance of Trust	  	 	12	  
	 SECTION 1.16
	  	Termination	  	 	12	  
		
	 ARTICLE 2 SECURITY FORMS
	  	 	13	  
	 SECTION 2.1
	  	Forms Generally	  	 	13	  
		
	 ARTICLE 3 THE SECURITIES
	  	 	13	  
	 SECTION 3.1
	  	Title and Payment Terms	  	 	13	  
	 SECTION 3.2
	  	Registrable Form	  	 	15	  
	 SECTION 3.3
	  	Execution, Authentication, Delivery and Dating	  	 	15	  
	 SECTION 3.4
	  	Intentionally Omitted	  	 	16	  
	 SECTION 3.5
	  	Registration, Registration of Transfer and Exchange	  	 	16	  
	 SECTION 3.6
	  	Mutilated, Destroyed, Lost and Stolen Securities	  	 	17	  
	 SECTION 3.7
	  	Payments with Respect to CVR Certificates	  	 	17	  
	 SECTION 3.8
	  	Persons Deemed Owners	  	 	17	  
	 SECTION 3.9
	  	Cancellation	  	 	17	  
	 SECTION 3.10
	  	CUSIP Numbers	  	 	18	  
		
	 ARTICLE 4 THE TRUSTEE
	  	 	18	  
	 SECTION 4.1
	  	Certain Duties and Responsibilities	  	 	18	  
	 SECTION 4.2
	  	Certain Rights of Trustee	  	 	19	  
	 SECTION 4.3
	  	Notice of Breach	  	 	20	  
	 SECTION 4.4
	  	Not Responsible for Recitals or Issuance of Securities	  	 	21	  
	 SECTION 4.5
	  	May Hold Securities	  	 	21	  
	 SECTION 4.6
	  	Money Held in Trust	  	 	21	  
	 SECTION 4.7
	  	Compensation and Reimbursement	  	 	21	  

  
 i 

							
	 	  	 	  	Page	 
	 SECTION 4.8
	  	Disqualification; Conflicting Interests	  	 	22	  
	 SECTION 4.9
	  	Corporate Trustee Required; Eligibility	  	 	22	  
	 SECTION 4.10
	  	Resignation and Removal; Appointment of Successor	  	 	22	  
	 SECTION 4.11
	  	Acceptance of Appointment of Successor	  	 	24	  
	 SECTION 4.12
	  	Merger, Conversion, Consolidation or Succession to Business	  	 	24	  
	 SECTION 4.13
	  	Preferential Collection of Claims Against Company	  	 	24	  
		
	 ARTICLE 5 HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY
	  	 	24	  
	 SECTION 5.1
	  	Company to Furnish Trustee with Names and Addresses of Holders	  	 	24	  
	 SECTION 5.2
	  	Preservation of Information; Communications to Holders	  	 	25	  
	 SECTION 5.3
	  	Reports by Trustee	  	 	25	  
	 SECTION 5.4
	  	Reports by Company	  	 	25	  
		
	 ARTICLE 6 AMENDMENTS
	  	 	26	  
	 SECTION 6.1
	  	Amendments without Consent of Holders	  	 	26	  
	 SECTION 6.2
	  	Amendments with Consent of Holders	  	 	27	  
	 SECTION 6.3
	  	Execution of Amendments	  	 	27	  
	 SECTION 6.4
	  	Effect of Amendments; Notice to Holders	  	 	28	  
	 SECTION 6.5
	  	Conformity with Trust Indenture Act	  	 	28	  
	 SECTION 6.6
	  	Reference in Securities to Amendments	  	 	28	  
		
	 ARTICLE 7 COVENANTS
	  	 	28	  
	 SECTION 7.1
	  	Payment of Amounts, if any, to Holders	  	 	28	  
	 SECTION 7.2
	  	Maintenance of Office or Agency	  	 	28	  
	 SECTION 7.3
	  	Money for Security Payments to Be Held in Trust	  	 	29	  
	 SECTION 7.4
	  	Certain Purchases and Sales	  	 	30	  
	 SECTION 7.5
	  	Books and Records	  	 	30	  
	 SECTION 7.6
	  	Listing of CVRs	  	 	30	  
	 SECTION 7.7
	  	Existing Litigation	  	 	30	  
	 SECTION 7.8
	  	Notice of Breach	  	 	30	  
	 SECTION 7.9
	  	Non-Use of Name	  	 	30	  
		
	 ARTICLE 8 REMEDIES OF THE TRUSTEE AND HOLDERS IN THE EVENT OF BREACH
	  	 	31	  
	 SECTION 8.1
	  	Breach Defined; Waiver of Breach	  	 	31	  
	 SECTION 8.2
	  	Collection by the Trustee; the Trustee May Prove Payment Obligations	  	 	32	  
	 SECTION 8.3
	  	Application of Proceeds	  	 	33	  
	 SECTION 8.4
	  	Suits for Enforcement	  	 	34	  
	 SECTION 8.5
	  	Restoration of Rights on Abandonment of Proceedings	  	 	34	  
	 SECTION 8.6
	  	Limitations on Suits by Holders	  	 	34	  
	 SECTION 8.7
	  	Unconditional Right of Holders to Receive Payment	  	 	35	  
	 SECTION 8.8
	  	Powers and Remedies Cumulative; Delay or Omission Not Waiver of Breach	  	 	35	  
	 SECTION 8.9
	  	Control by Holders	  	 	35	  

  
 ii 

							
	 	  	 	  	Page	 
	 SECTION 8.10
	  	Waiver of Past Breaches	  	 	36	  
	 SECTION 8.11
	  	The Trustee to Give Notice of Breach, But May Withhold in Certain Circumstances	  	 	36	  
	 SECTION 8.12
	  	Right of Court to Require Filing of Undertaking to Pay Costs	  	 	36	  
		
	 ARTICLE 9 CONSOLIDATION, MERGER, SALE OR CONVEYANCE
	  	 	37	  
	 SECTION 9.1
	  	Successor Person Substituted	  	 	37	  
	 SECTION 9.2
	  	Opinion of Counsel to the Trustee	  	 	38	  
	 SECTION 9.3
	  	Successors	  	 	38	  
		
	 ARTICLE 10 SUBORDINATION
	  	 	38	  
	 SECTION 10.1
	  	Agreement to Subordinate	  	 	38	  
	 SECTION 10.2
	  	Liquidation; Dissolution; Bankruptcy	  	 	38	  
	 SECTION 10.3
	  	When Distribution Must be Paid Over	  	 	39	  
	 SECTION 10.4
	  	Notice by the Company	  	 	39	  
	 SECTION 10.5
	  	Subrogation	  	 	39	  
	 SECTION 10.6
	  	Relative Rights	  	 	40	  
	 SECTION 10.7
	  	Subordination May Not be Impaired by the Company	  	 	40	  
	 SECTION 10.8
	  	Distribution or Notice to the Representative	  	 	40	  
	 SECTION 10.9
	  	Rights of the Trustee	  	 	40	  
	 SECTION 10.10
	  	Authorization to Effect Subordination	  	 	41	  
	 SECTION 10.11
	  	Amendments	  	 	41	  
	 SECTION 10.12
	  	Subordination Language to be Included in the Securities	  	 	41	  

 Annex A — Form of CVR Certificate 

Note: This table of contents shall not, for any purpose, be deemed to be a part of this CVR Agreement. 

  
 iii 

 Reconciliation and tie between Trust Indenture Act of 1939 and Contingent Value Rights Agreement,
dated as of January 27, 2014. 
  

					
	 Trust Indenture Act Section
	  	Agreement Section
	 Section 310
	 	 (a)(1)
	  	4.9
		 	 (a)(2)
	  	4.9
		 	 (a)(3)
	  	Not Applicable
		 	 (a)(4)
	  	Not Applicable
		 	 (a)(5)
	  	4.9
		 	 (b)
	  	4.8, 4.10
	 Section 311
	 	 (a)
	  	4.13
		 	 (b)
	  	4.13
	 Section 312
	 	 (a)
	  	5.1, 5.2(a)
		 	 (b)
	  	5.2(b)
		 	 (c)
	  	5.2(c)
	 Section 313
	 	 (a)
	  	5.3(a)
		 	 (b)
	  	5.3(a)
		 	 (c)
	  	5.3(a)
		 	 (d)
	  	5.3(b)
	 Section 314
	 	 (a)
	  	5.4
		 	 (b)
	  	Not Applicable
		 	 (c)(1)
	  	1.2(a)
		 	 (c)(2)
	  	1.2(a)
		 	 (c)(3)
	  	Not Applicable
		 	 (d)
	  	Not Applicable
		 	 (e)
	  	1.2(b)
	 Section 315
	 	 (a)
	  	4.1(a), 4.1(b)
		 	 (b)
	  	8.11
		 	 (c)
	  	4.1(a)
		 	 (d)
	  	4.1(c)
		 	 (d)(1)
	  	4.1(a), 4.1(b)
		 	 (d)(2)
	  	4.1(c)(ii)
		 	 (d)(3)
	  	4.1(c)(iii)
		 	 (e)
	  	8.12
	 Section 316
	 	 (a)(last sentence)
	  	1.1 (Definition of “Outstanding”)
		 	 (a)(1)(A)
	  	8.9
		 	 (a)(1)(B)
	  	8.10
		 	 (a)(2)
	  	Not Applicable
		 	 (b)
	  	8.7
		 	 (c)
	  	Not Applicable
	 Section 317
	 	 (a)(1)
	  	8.2
		 	 (a)(2)
	  	8.2
		 	 (b)
	  	7.3
	 Section 318
	 	 (a)
	  	1.7

 Note: This reconciliation table shall not, for any purpose, be deemed to be a part of this CVR Agreement. 

  
 iv 

 THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of January 27, 2014 (this “CVR
Agreement”), by and between Community Health Systems, Inc., a Delaware corporation (the “Company”), and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as trustee (the
“Trustee”), in favor of each person who from time to time holds one or more Contingent Value Rights (the “Securities” or “CVRs” and, each individually, a “Security” or a
“CVR”) to receive cash payments in the amounts and subject to the terms and conditions set forth herein. 
 W
I T N E S S E T H: 
 WHEREAS, this CVR Agreement is entered into
pursuant to the Agreement and Plan of Merger, dated as of July 29, 2013 (the “Merger Agreement”), by and among the Company, FWCT-2 Acquisition Corporation, a Delaware corporation and a wholly owned Subsidiary of the Company
(“Merger Sub”), and Health Management Associates, Inc., a Delaware corporation (“HMA”); 
 WHEREAS,
pursuant to the Merger Agreement, Merger Sub shall merge with and into HMA (the “Merger”), with HMA being the surviving corporation in the Merger and becoming a wholly owned Subsidiary of the Company; 

WHEREAS, the CVRs shall be issued in accordance with and pursuant to the terms of the Merger Agreement; and 

WHEREAS, a registration statement on Form S-4 (No. 333-191339) (the “Registration Statement”) with respect to the CVRs has
been prepared and filed by the Company with the Commission (as defined below) and has become effective in accordance with the Securities Act of 1933, as amended (the “Securities Act”). 

NOW, THEREFORE, in consideration of the foregoing premises and the consummation of the transactions contemplated by the Merger Agreement, it
is covenanted and agreed, for the equal and proportionate benefit of all Holders of the Securities, as follows: 
 ARTICLE 1 

DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 

SECTION 1.1 Definitions. For all purposes of this CVR Agreement, except as otherwise expressly provided or unless the context otherwise
requires: 
 (a) the terms defined in this ARTICLE 1 have the meanings assigned to them in this Article, and include the plural as well as
the singular; 
 (b) all accounting terms used herein and not expressly defined herein shall, except as otherwise noted, have the meanings
assigned to such terms in accordance with applicable Accounting Standards, where “Accounting Standards” means generally accepted accounting principles in the United States, consistently applied; 

 (c) all capitalized terms used in this CVR Agreement without definition shall have the respective
meanings ascribed to them in the Merger Agreement; 
 (d) all other terms used herein which are defined in the Trust Indenture Act (as
defined herein), either directly or by reference therein, have the respective meanings assigned to them therein; and 
 (e) the words
“herein,” “hereof” and “hereunder” and other words of similar import refer to this CVR Agreement as a whole and not to any particular Article, Section or other subdivision. 

“Act” shall have the meaning set forth in SECTION 1.4 of this CVR Agreement. 

“Acting Holders” means, at the time of determination, Holders of at least thirty percent (30%) of the Outstanding
Securities. 
 “Affiliate” of any specified Person means any other Person directly or indirectly controlling or controlled
by or under direct or indirect common control with such specified Person. For the purposes of this definition, “control” when used with respect to any specified Person means the power to direct the management and policies of such Person,
directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; and the terms “controlling” and “controlled” have meanings correlative to the foregoing. 

“Board of Directors” means the board of directors of the Company or any other body performing similar functions, or any duly
authorized committee of that board. 
 “Board Resolution” means a copy of a resolution certified by the Chairman of the
Board of Directors, the Chief Executive Officer or the Secretary to the Board of Directors, to have been duly adopted by the Board of Directors and to be in full force and effect on the date of such certification, and delivered to the Trustee. 

“Breach” shall have the meaning set forth in SECTION 8.1 of this CVR Agreement. 

“Breach Interest Rate” means a per annum rate equal to the prime rate of interest quoted by Bloomberg, or a similar reputable
data source, plus three percent (3%), calculated daily on the basis of a three hundred sixty-five (365) day year or, if lower, the highest rate permitted under applicable Law. 

“Business Day” means any day (other than a Saturday or a Sunday) on which banking institutions in The City of New York, New
York are not authorized or obligated by Law or executive order to close and, if the CVRs are listed on a national securities exchange, electronic trading network or other suitable trading platform, such exchange, electronic network or other trading
platform is open for trading. 
 “Code” means the Internal Revenue Code of 1986, as amended. 

“Commission” means the Securities and Exchange Commission, as from time to time constituted, created under the Exchange Act,
or if at any time after the execution of this instrument such Commission is not existing and performing the duties now assigned to it under the Trust Indenture Act, then the body performing such duties at such time. 

  
 2 

 “Company” means the Person named as the “Company” in the first
paragraph of this CVR Agreement, until a successor Person shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter “Company” shall mean such successor Person. 

“Company Group” means the Company and its Subsidiaries. 

“Company Request” or “Company Order” means a written request or order signed in the name of the Company by
the chairman of the Board of Directors, the Chief Executive Officer, a president or any vice president, the General Counsel, or any other person duly authorized to act on behalf of the Company for such purpose or for any general purpose, and
delivered to the Trustee. 
 “Corporate Trust Office” means the office of the Trustee at which at any particular time its
corporate trust business shall be principally administered, which office at the date of execution of this CVR Agreement is located at 6201 15th Avenue, Brooklyn, New York 11219. 

“CVRs” shall have the meaning set forth in the Preamble of this CVR Agreement. 

“CVR Agreement” means this instrument as originally executed and as it may from time to time be supplemented or amended
pursuant to the applicable provisions hereof. 
 “CVR Certificate” means, with respect to any certificated CVRs, a
certificate representing any such CVRs and, with respect to any uncertificated CVRs, a book-entry account statement relating to the ownership of any such CVRs. 

“CVR Payment Amount” means $1.00 in cash per CVR; provided, however, that if the aggregate amount of Losses as
of the Payment Event Date exceeds $18,000,000 (the “Deductible”), the CVR Payment Amount shall be reduced by an amount equal to the quotient obtained by dividing: (a) the product of (i) all Losses in excess of the
Deductible and (ii) 90%; by (b) the number of Outstanding Securities on the Payment Event Date; provided, that the CVR Payment Amount shall not be reduced to an amount below zero. All payments of the CVR Payment Amount shall be made
without interest thereon and less any applicable withholding of Taxes. In no event shall the Company be obligated to pay the CVR Payment Amount on more than one occasion. 

“CVR Payment Date” means the date on which the CVR Payment Amount is payable by the Paying Agent to the Holders, which date
shall be established pursuant to SECTION 3.1(e). 
 “DOJ” means the U.S. Department of Justice. 

“Exchange Act” means the Securities Exchange Act of 1934, as amended. 

“Existing Litigation” means any litigation, investigation (whether formal or informal, including subpoenas), or other action
or proceeding involving the HHS-OIG, the DOJ, the Commission or any other Governmental Entity, relating to whether HMA or any of its Affiliates violated any Law, and any civil litigation or other action or proceeding, including any shareholder or
derivative action or proceeding, arising out of or relating to the foregoing, in each 

  
 3 

 
case existing on or prior to the date of the Merger Agreement; provided that Existing Litigation shall not include any such litigation, investigation or other action or proceeding involving only
individuals or entities other than HMA unless HMA is required to indemnify Losses incurred by such individuals or entities. For the avoidance of doubt, for purposes of this definition, the Company and its Subsidiaries shall not be considered
Affiliates of HMA. 
 “Final Resolution” means (i) receipt of written confirmation from each applicable Governmental
Entity that it has closed its investigation into HMA with respect to the Existing Litigation; or (ii) resolution of the Existing Litigation pursuant to a written settlement agreement, consent decree or other final non-appealable judgment by a
court of competent jurisdiction. 
 “Governmental Entity” means any domestic (federal or state), or foreign court,
commission, governmental body, regulatory or administrative agency or other political subdivision thereof. 
 “HHS-OIG”
means the U.S. Department of Health and Human Services Office of Inspector General. 
 “HMA” shall have the meaning set
forth in the Recitals of this CVR Agreement. 
 “Holder” means a Person in whose name a Security is registered in the
Security Register. 
 “Junior Obligations” shall have the meaning set forth in SECTION 10.1. 

“Law” means any foreign, federal, state, local or municipal laws, rules, judgments, orders, regulations, statutes,
ordinances, codes, decisions, injunctions, decrees, international treaties and conventions or requirements of any Governmental Entity. 

“Losses” means the amount of all losses, damages, costs, fees and expenses (including, without limitation, attorneys’
fees and expenses), and all fines, penalties, settlement amounts, indemnification obligations and other liabilities, in each case arising out of or relating to the Existing Litigation that are paid by the Company or any of its Affiliates (including
HMA) prior to the Payment Event Date; provided that Losses shall not include (i) the costs associated with any change to HMA’s policies, procedures or practices, or (ii) the loss of any (A) licenses or (B) rights and
privileges to participate in government sponsored programs even if required under a settlement agreement, consent decree or other final non-appealable judgment by a court of competent jurisdiction; provided that in each case, the amount of any
Losses shall be net of any amounts actually recovered by the Company or any of its wholly owned Subsidiaries under insurance policies. 

“Majority Holders” means, at the time of determination, Holders of at least a majority of the Outstanding Securities. 

“Merger” shall have the meaning set forth in the Recitals of this CVR Agreement. 

“Merger Agreement” shall have the meaning set forth in the Recitals of this CVR Agreement. 

  
 4 

 “Merger Sub” shall have the meaning set forth in the Recitals of this CVR
Agreement. 
 “NASDAQ” shall have the meaning set forth in SECTION 7.6. 

“NYSE” shall have the meaning set forth in SECTION 7.6. 

“Officer’s Certificate” when used with respect to the Company means a certificate signed by the Chief Executive Officer,
a president or any vice president, the Chief Financial Officer or any other person duly authorized to act on behalf of the Company for such purpose or for any general purpose. 

“Opinion of Counsel” means a written opinion of counsel, who may be counsel for the Company. 

“Outstanding” when used with respect to Securities (“Outstanding Securities”) means, as of the date of
determination, all Securities theretofore authenticated and delivered under this CVR Agreement, except: (a) Securities theretofore cancelled by the Trustee or delivered to the Trustee for cancellation and (b) Securities in exchange for or
in lieu of which other Securities have been authenticated and delivered pursuant to this CVR Agreement, other than any such Securities in respect of which there shall have been presented to the Trustee proof satisfactory to it that such Securities
are held by a bona fide purchaser in whose hands the Securities are valid obligations of the Company; provided, however, that in determining whether the Holders of the requisite Outstanding Securities have given any request, demand, authorization,
direction, consent, waiver or other action hereunder, Securities owned by the Company or any Affiliate of the Company, whether held as treasury securities or otherwise, shall be disregarded and deemed not to be Outstanding, except that for the
purposes of determining whether the Trustee shall be protected in relying on any such request, demand, authorization, direction, consent, waiver or other action, only Securities that a Responsible Officer of the Trustee actually knows are so owned
shall be so disregarded (but the Trustee need not confirm or investigate the accuracy of mathematical calculations or other facts stated in such request, demand, authorization, direction, consent, waiver or other action). 

“Party” shall mean the Trustee and the Company, as applicable. 

“Paying Agent” means any Person authorized by the Company to pay the amount determined pursuant to SECTION 3.1, if any, on
any Securities on behalf of the Company. 
 “Payment Certificate” has the meaning set forth in SECTION 3.1(c). 

“Payment Event Date” means the date on which Final Resolution occurs. 

“Person” means any individual, corporation, partnership, joint venture, association, jointstock company, trust, limited
liability company, unincorporated organization or government or any agency or political subdivision thereof. 
 “Permitted Junior
Securities” shall have the meaning set forth in SECTION 10.2(a). 

  
 5 

 “Registration Statement” shall have the meaning set forth in the Recitals of
this CVR Agreement. 
 “Responsible Officer” when used with respect to the Trustee means any officer assigned to the
Corporate Trust Office and also means, with respect to any particular corporate trust matter, any other officer of the Trustee to whom such matter is referred because of his or her knowledge of and familiarity with the particular subject. 

“Securities” shall have the meaning set forth in the Preamble of this CVR Agreement. 

“Securities Act” shall have the meaning set forth in the Recitals of this CVR Agreement. 

“Security Register” shall have the meaning set forth in SECTION 3.5(a) of this CVR Agreement. 

“Security Registrar” shall have the meaning set forth in SECTION 3.5(a) of this CVR Agreement. 

“Senior Obligations” means (a) the principal of, and premium (if any) and interest (including, without limitation, any
interest accruing subsequent to the filing of a petition of bankruptcy at the rate provided for in the documentation with respect thereto, whether or not such interest is an allowed claim under applicable Law) on, the following existing or future
obligations of the Company, and all other amounts owing thereon: (i) with respect to borrowed money, (ii) evidenced by notes, debentures, bonds or other similar debt instruments, (iii) with respect to the net obligations owed under
interest rate swaps or similar agreements or currency exchange transactions, (iv) reimbursement obligations in respect of letters of credit and similar obligations, (v) in respect of capital leases, or (vi) guarantees in respect of
obligations referred to in clauses (i) through (v) above; unless, in any case, the instrument creating or evidencing the same or pursuant to which the same is outstanding provides that such obligations are pari passu to or
subordinate in right of payment to the Securities and (b) any Losses. 
 Notwithstanding the foregoing, “Senior Obligations”
shall not include: 
 (a) Junior Obligations; 

(b) trade debt incurred in the ordinary course of business; 

(c) any intercompany indebtedness between the Company and any of its Subsidiaries or Affiliates; 

(d) indebtedness of the Company that is subordinated in right of payment to Senior Obligations; 

(e) indebtedness or other obligations of the Company that by its terms ranks equal or junior in right of payment to the Junior Obligations;

 (f) indebtedness of the Company that, by operation of Law, is subordinate to any general unsecured obligations of the Company; 

  
 6 

 (g) indebtedness evidenced by any guarantee of indebtedness ranking equal or junior in right of
payment to the Junior Obligations; 
 (h) indebtedness consisting of the deferred purchase price for property or services, including earn-out
and milestone payments and contingent value rights; or 
 (i) indebtedness that is contractually non-recourse to the general credit of the
Company. 
 “Series A Contingent Value Rights” shall have the meaning set forth in SECTION 3.1(b) of this CVR Agreement.

 “Subsidiary” means, with respect to any Person, any corporation, limited liability company, association, partnership or
other business entity of which more than fifty percent (50%) of the total voting power of shares of Voting Securities is at the time owned or controlled, directly or indirectly, by: (a) such Person; (b) such Person and one or more
Subsidiaries of such Person; or (c) one or more Subsidiaries of such Person. 
 “Tax” means any U.S. federal, state or
local tax, assessment, levy or other governmental charge of any kind, including any income, profits, gross receipts, license, payroll, employment, severance, stamp, occupation, premium, windfall profits, environmental, customs duty, capital stock,
franchise, sales, social security, unemployment, disability, use, property, withholding, excise, transfer, registration, production, value added, alternative minimum, occupancy, estimated or any other tax of any kind whatsoever, whether disputed or
not, together with any interest, penalty or addition thereto. 
 “Tax Return” means any return, report, declaration, claim
or other statement (including attached schedules) relating to Taxes. 
 “Trust Indenture Act” means the Trust Indenture Act
of 1939, as amended from time to time. 
 “Trustee” means the Person named as the “Trustee” in the first
paragraph of this CVR Agreement, until a successor Trustee shall have become such pursuant to the applicable provisions of this CVR Agreement, and thereafter “Trustee” shall mean such successor Trustee. 

“Voting Securities” means securities or other interests having voting power, or the right, to elect or appoint directors, or
any Persons performing similar functions, irrespective of whether or not stock or other interests of any other class or classes shall have or might have voting power or any right by reason of the happening of any contingency. 

SECTION 1.2 Compliance and Opinions. 

(a) Upon any application or request by the Company to the Trustee to take any action under any provision of this CVR Agreement, the Company
shall furnish to the Trustee an Officer’s Certificate stating that, in the opinion of the signor, all conditions precedent, if any, provided for in this CVR Agreement relating to the proposed action have been complied with and an Opinion of
Counsel stating, subject to customary exceptions, that in the opinion of such 

  
 7 

 
counsel all such conditions precedent, if any, have been complied with, except that, in the case of any such application or request as to which the furnishing of such documents is specifically
required by any provision of this CVR Agreement relating to such particular application or request, no additional certificate or opinion need be furnished. 

(b) Every certificate or opinion with respect to compliance with a condition or covenant provided for in this CVR Agreement shall include:
(i) a statement that each individual signing such certificate or opinion has read such covenant or condition and the definitions herein relating thereto; (ii) a brief statement as to the nature and scope of the examination or investigation
upon which the statements or opinions contained in such certificate or opinion are based; (iii) a statement that, in the opinion of each such individual, he or she has made such examination or investigation as is necessary to enable him or her
to express an informed opinion as to whether or not such covenant or condition has been complied with; and (iv) a statement as to whether, in the opinion of each such individual, such condition or covenant has been complied with. 

SECTION 1.3 Form of Documents Delivered to Trustee. 

(a) In any case where several matters are required to be certified by, or covered by an opinion of, any specified Person, it is not necessary
that all such matters be certified by, or covered by the opinion of, only one such Person, or that they be so certified or covered by only one document, but one such Person may certify or give an opinion with respect to some matters and one or more
other such Persons as to other matters, and any such Person may certify or give an opinion as to such matters in one or several documents. 

(b) Any certificate or opinion of an officer of the Company may be based, insofar as it relates to legal matters, upon a certificate or opinion
of, or representations by, counsel. Any such certificate or Opinion of Counsel may be based, insofar as it relates to factual matters, upon a certificate or opinion of, or representations by, an officer or officers of the Company stating that the
information with respect to such factual matters is in the possession of the Company. 
 (c) Any certificate, statement or opinion of an
officer of the Company or of counsel may be based, insofar as it relates to accounting matters, upon a certificate or opinion of or representations by an accountant or firm of accountants in the employ of the Company. Any certificate or opinion of
any independent firm of public accountants filed with the Trustee shall contain a statement that such firm is independent. 
 (d) Where any
Person is required to make, give or execute two or more applications, requests, consents, certificates, statements, opinions or other instruments under this CVR Agreement, they may, but need not, be consolidated and form one instrument. 

SECTION 1.4 Acts of Holders. 

(a) Any request, demand, authorization, direction, notice, consent, waiver or other action provided by this CVR Agreement to be given or taken
by Holders may be embodied in and evidenced by one or more instruments of substantially similar tenor signed by such Holders in person or by an agent duly appointed in writing; and, except as herein otherwise expressly provided, such action shall
become effective when such instrument or instruments are delivered 

  
 8 

 
to the Trustee and, where it is hereby expressly required, to the Company. Such instrument or instruments (and the action embodied therein and evidenced thereby) are herein sometimes referred to
as the “Act” of the Holders signing such instrument or instruments. Proof of execution of any such instrument or of a writing appointing any such agent shall be sufficient for any purpose of this CVR Agreement and (subject to
SECTION 4.1) conclusive in favor of the Trustee and the Company, if made in the manner provided in this SECTION 1.4. The Company may set a record date for purposes of determining the identity of Holders entitled to vote or consent to any action by
vote or consent authorized or permitted under this CVR Agreement, which date shall be no greater than ninety (90) days and no less than ten (10) days prior to the date of such vote or consent to any action by vote or consent authorized or
permitted under this CVR Agreement. If not previously set by the Company, (i) the record date for determining the Holders entitled to vote at a meeting of the Holders shall be the date preceding the date notice of such meeting is mailed to the
Holders, or if notice is not given, on the day next preceding the day such meeting is held, and (ii) the record date for determining the Holders entitled to consent to any action in writing without a meeting shall be the first date on which a
signed written consent setting forth the action taken or proposed to be taken is delivered to the Company. If a record date is fixed, those Persons who were Holders of Securities at such record date (or their duly designated proxies), and only those
Persons, shall be entitled to take such action by vote or consent or, except with respect to clause (d) below, to revoke any vote or consent previously given, whether or not such Persons continue to be Holders after such record date. No such
vote or consent shall be valid or effective for more than one hundred twenty (120) days after such record date. 
 (b) The fact and
date of the execution by any Person of any such instrument or writing may be proved in any reasonable manner which the Trustee deems sufficient. 

(c) The ownership of Securities shall be proved by the Security Register. Neither the Company nor the Trustee nor any agent of the Company or
the Trustee shall be affected by any notice to the contrary. 
 (d) At any time prior to (but not after) the evidencing to the Trustee, as
provided in this SECTION 1.4, of the taking of any action by the Holders of the Securities specified in this CVR Agreement in connection with such action, any Holder of a Security the serial number of which is shown by the evidence to be included
among the serial numbers of the Securities the Holders of which have consented to such action may, by filing written notice at the Corporate Trust Office and upon proof of holding as provided in this SECTION 1.4, revoke such action so far as
concerns such Security. Any request, demand, authorization, direction, notice, consent, waiver or other action by the Holder of any Security shall bind every future Holder of the same Security or the Holder of every Security issued upon the
registration of transfer thereof or in exchange therefor or in lieu thereof, in respect of anything done, suffered or omitted to be done by the Trustee, any Paying Agent or the Company in reliance thereon, whether or not notation of such action is
made upon such Security. 
 SECTION 1.5 Notices, etc., to Trustee and Company. Any request, demand, authorization, direction, notice,
consent, waiver or Act of Holders or other document provided or permitted by this CVR Agreement to be made upon, given or furnished to, or filed with: 

(a) the Trustee by any Holder or by the Company shall be sufficient for every purpose hereunder if made, given, furnished or filed, in writing,
to or with the Trustee at its Corporate Trust Office; or 

  
 9 

 (b) the Company by the Trustee or by any Holder shall be sufficient for every purpose hereunder
if in writing and mailed, first-class postage prepaid, to the Company addressed to it at Community Health Systems, Inc., 4000 Meridian Blvd., Franklin, Tennessee 37067, Attention: General Counsel, or at any other address previously furnished in
writing to the Trustee by the Company. 
 SECTION 1.6 Notice to Holders; Waiver. 

(a) Where this CVR Agreement provides for notice to Holders of any event, such notice shall be sufficiently given (unless otherwise herein
expressly provided) if in writing and mailed, first-class postage prepaid, to each Holder affected by such event, at the Holder’s address as it appears in the Security Register, not later than the latest date, and not earlier than the earliest
date, prescribed for the giving of such notice. In any case where notice to Holders is given by mail, neither the failure to mail such notice, nor any defect in any notice so mailed, to any particular Holder shall affect the sufficiency of such
notice with respect to other Holders. Where this CVR Agreement provides for notice in any manner, such notice may be waived in writing by the Person entitled to receive such notice, either before or after the event, and such waiver shall be the
equivalent of such notice. Waivers of notice by Holders shall be filed with the Trustee, but such filing shall not be a condition precedent to the validity of any action taken in reliance upon such waiver. 

(b) In case by reason of the suspension of regular mail service or by reason of any other cause, it shall be impracticable to mail notice of
any event as required by any provision of this CVR Agreement, then any method of giving such notice as shall be satisfactory to the Trustee shall be deemed to be a sufficient giving of such notice. 

SECTION 1.7 Conflict with the Trust Indenture Act. If any provision hereof limits, qualifies or conflicts with another provision hereof
which is required to be included in this CVR Agreement by any of the provisions of the Trust Indenture Act, such required provision shall control. 

SECTION 1.8 Effect of Headings and Table of Contents. The Article and Section headings herein and the Table of Contents are for
convenience only and shall not affect the construction hereof. 
 SECTION 1.9 Benefits of Agreement. Nothing in this CVR Agreement or
in the Securities, express or implied, shall give to any Person (other than the Parties hereto and their successors and permitted assigns and, solely in accordance with the express terms of this CVR Agreement and subject to SECTIONS 1.13, 3.1(g) and
8.6, the Holders) any benefit or any legal or equitable right, remedy or claim under this CVR Agreement or under any covenant or provision herein contained. 

SECTION 1.10 Governing Law; Jurisdiction; Venue; Waiver of Jury Trial. 

  
 10 

 (a) THIS CVR AGREEMENT AND ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY
BE BASED UPON, ARISE OUT OF OR RELATE TO THIS CVR AGREEMENT, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS CVR AGREEMENT (INCLUDING ANY CLAIM OR CAUSE OF ACTION BASED UPON, ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN
OR IN CONNECTION WITH THIS CVR AGREEMENT OR AS AN INDUCEMENT TO ENTER INTO THIS CVR AGREEMENT) OR THE SECURITIES, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, INCLUDING, WITHOUT LIMITATION, SECTIONS 5-1401
AND 5-1402 OF THE NEW YORK GENERAL OBLIGATIONS LAW WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. 
 (b) EACH OF THE COMPANY, THE
TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY NEW YORK STATE COURT SITTING IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK OR ANY FEDERAL COURT SITTING IN
THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN RESPECT OF ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS CVR AGREEMENT, OR THE NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS
CVR AGREEMENT (INCLUDING ANY CLAIM OR CAUSE OF ACTION BASED UPON, ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN OR IN CONNECTION WITH THIS CVR AGREEMENT OR AS AN INDUCEMENT TO ENTER INTO THIS CVR AGREEMENT), OR THE SECURITIES,
AND IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE AFORESAID COURTS. EACH OF THE COMPANY AND THE TRUSTEE AGREES THAT PROCESS MAY BE SERVED UPON THEM IN ANY MANNER AUTHORIZED BY THE
LAWS OF THE STATE OF NEW YORK FOR SUCH PERSONS. EACH OF THE COMPANY AND THE TRUSTEE HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT, BY WAY OF MOTION, AS A DEFENSE, COUNTERCLAIM OR OTHERWISE, IN ANY ACTION OR PROCEEDING WITH RESPECT TO THIS CVR
AGREEMENT (A) ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF THE ABOVE-NAMED COURTS FOR ANY REASON OTHER THAN THE FAILURE TO SERVE PROCESS IN ACCORDANCE WITH THIS SECTION 1.10, (B) THAT IT OR ITS PROPERTY IS EXEMPT OR
IMMUNE FROM JURISDICTION OF ANY SUCH COURT OR FROM ANY LEGAL PROCESS COMMENCED IN SUCH COURTS (WHETHER THROUGH SERVICE OF NOTICE, ATTACHMENT PRIOR TO JUDGMENT, ATTACHMENT IN AID OF EXECUTION OF JUDGMENT, EXECUTION OF JUDGMENT OR OTHERWISE), AND
(C) TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW THAT (I) THE SUIT, ACTION OR PROCEEDING IN SUCH COURT IS BROUGHT IN AN INCONVENIENT FORUM, (II) THE VENUE OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER AND (III) THIS CVR AGREEMENT, OR
THE SUBJECT MATTER HEREOF, MAY NOT BE ENFORCED IN OR BY SUCH COURTS. 

  
 11 

 (c) EACH OF THE COMPANY, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF THE
SECURITIES, HEREBY AGREES THAT ANY CONTROVERSY WHICH MAY ARISE UNDER THIS CVR AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH SUCH PERSON HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT SUCH PERSON MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS CVR AGREEMENT OR THE SUBJECT MATTER HEREOF. 

(d) EACH OF THE COMPANY, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF THE SECURITIES, HEREBY AGREES THAT NOTWITHSTANDING
ANYTHING TO THE CONTRARY HEREIN, IN NO EVENT SHALL THE COMPANY BE RESPONSIBLE TO THE TRUSTEE OR ANY HOLDER FOR ANY CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES. 

SECTION 1.11 Legal Holidays. In the event that the CVR Payment Date shall not be a Business Day, then (notwithstanding any provision of
this CVR Agreement or the Securities to the contrary) payment on the Securities need not be made on such date, but may be made, without the accrual of any interest thereon, on the next succeeding Business Day with the same force and effect as if
made on the CVR Payment Date. 
 SECTION 1.12 Separability Clause. In the event any provision in this CVR Agreement or in the CVRs
shall be invalid, illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby. 

SECTION 1.13 No Recourse Against Others. A past or present director, officer or employee, as such, of the Company or an Affiliate of
the Company or the Trustee shall not have any liability for any obligations of the Company or the Trustee under the Securities or this CVR Agreement or for any claim based on, in respect of or by reason of such obligations or their creation. By
accepting a Security, each Holder waives and releases all such liability. The waiver and release are part of the consideration for the issue of the Securities. 

SECTION 1.14 Counterparts. This CVR Agreement shall be signed in any number of counterparts with the same effect as if the signatures
to each counterpart were upon a single instrument, and all such counterparts together shall be deemed an original of this CVR Agreement. 

SECTION 1.15 Acceptance of Trust. American Stock Transfer & Trust Company, LLC, the Trustee named herein, hereby accepts the
trusts in this CVR Agreement declared and provided, upon the terms and conditions set forth herein. 
 SECTION 1.16 Termination. This
CVR Agreement shall terminate and be of no further force or effect, and the parties hereto shall have no liability hereunder, at 5:00 p.m., New York City time, on the CVR Payment Date; provided, that the obligations of the Parties to this CVR
Agreement set forth in Section 4.7 and the obligation of the Company to pay the CVR Payment Amount that is due in accordance with the terms of this CVR Agreement shall survive termination of this CVR Agreement in accordance with its terms, and
provided further that no termination of this CVR Agreement shall be deemed to affect the rights of the parties set forth in ARTICLE 8 of this CVR Agreement to bring suit in the case of a Breach occurring prior to such CVR Payment Date. 

  
 12 

 ARTICLE 2 

SECURITY FORMS 
 SECTION
2.1 Forms Generally. 
 (a) Any Securities that are certificated and the Trustee’s certificate of authentication shall be in the
forms set forth in Annex A, attached hereto and incorporated herein by this reference, with such appropriate insertions, omissions, substitutions and other variations as are required or permitted by this CVR Agreement and may have such
letters, numbers or other marks of identification and such legends or endorsements placed thereon as may be required to comply with the rules of any securities exchange or as may be required by Law or any rule or regulation pursuant thereto, all as
may be determined by the officers executing such Securities, as evidenced by their execution of the Securities. Any portion of the text of any Security may be set forth on the reverse thereof, with an appropriate reference thereto on the face of the
Security. 
 (b) The Securities shall be typewritten, printed, lithographed or engraved on steel engraved borders or produced by any
combination of these methods or may be produced in any other manner permitted by the rules of any securities exchange on which the Securities may be listed, all as determined by the officers executing such Securities, as evidenced by their execution
of such Securities. 
 ARTICLE 3 

THE SECURITIES 
 SECTION
3.1 Title and Payment Terms. 
 (a) The aggregate number of CVRs in respect of which CVR Certificates may be authenticated and
delivered under this CVR Agreement is limited to a number equal to 264,544,053, except for Securities authenticated and delivered upon registration of transfer of, or in exchange for, or in lieu of, other Securities pursuant to SECTION 3.4, 3.5, 3.6
or 6.6. From and after the Effective Time, the Company shall not be permitted to issue any CVRs, except as provided and in accordance with the terms and conditions of the Merger Agreement or as otherwise expressly permitted by this CVR Agreement.

 (b) The Securities shall be known and designated as the “Series A Contingent Value Rights” of the Company. 

(c) Promptly following the Payment Event Date, but in no event later than thirty (30) days after such date, the Company shall deliver to
the Trustee and provide notice to the Holders of a certificate (the “Payment Certificate”) setting forth in reasonable detail the Company’s calculation of the CVR Payment Amount. 

  
 13 

 (d) All determinations with respect to the calculation of the CVR Payment Amount shall be
reasonably made by the Company in good faith, and such determinations shall be binding on the Holders absent manifest error; provided that (i) the Company may and, at the written request of the Trustee, shall, at the Company’s sole cost
and expense, reasonably select an independent third-party financial, accounting, valuation, appraisal or other advisor (an “Independent Advisor”) to assist it in calculating the amount of the CVR Payment Amount. The Company shall be
entitled to conclusively rely on the reports of any Independent Advisor for purposes of making its determination hereunder and all such calculations of the Independent Advisor shall be binding on the Holders absent manifest error. In the event that
a Final Resolution involves a settlement which includes claims that are not included in the Existing Litigation, the Company or the Independent Advisor, as the case may be, will calculate in good faith the amount of Losses that are properly
attributed to the Existing Litigation, on the one hand, and such other claims, on the other hand. 
 (e) If the CVR Payment Amount reflected
on the Payment Certificate is greater than zero, the Company shall establish a CVR Payment Date that is not later than sixty (60) days after the Payment Event Date. On or prior to the CVR Payment Date, the Company shall cause an amount in cash
equal to the CVR Payment Amount multiplied by the number of Outstanding Securities to be delivered to the Paying Agent. On the CVR Payment Date, the Paying Agent shall (in accordance with such exchange procedures as the Paying Agent and the Company
may reasonably agree and subject to SECTION 7.1) pay to each Holder as of the CVR Payment Date an amount in cash equal to the CVR Payment Amount multiplied by the number of CVRs held by such Holder, as reflected in the Security Register. 

(f) The Holders of the CVR Certificates, by acceptance thereof, agree that no joint venture, partnership or other fiduciary relationship is
created hereby or by the Securities. 
 (g) Other than in the case of interest on amounts due and payable after the occurrence of a Breach,
no interest or dividends shall accrue on any amounts payable in respect of the CVRs. 
 (h) Except to the extent any portion of any CVR
Payment Amount is required to be treated as interest pursuant to applicable Law, the Parties hereto agree to treat the CVRs issued pursuant to this CVR Agreement in connection with the Merger Agreement for all Tax purposes as consideration for the
shares of Company Common Stock, Company Stock Options, Company Restricted Stock Awards, Company Deferred Stock Awards and Company Performance Cash Awards, and none of the Parties hereto will take any position to the contrary on any Tax Return or for
other Tax purposes except as required by applicable Law. Except to the extent otherwise required pursuant to a “determination” within the meaning of Section 1313(a) of the Code, the Company shall determine the portion of any CVR
Payment Amount required to be treated as interest for U.S. federal income tax purposes pursuant to Section 483 of the Code and the Treasury Regulations promulgated thereunder. 

(i) The Holder of any CVR or CVR Certificate is not, and shall not, by virtue thereof, be entitled to any rights of a holder of any Voting
Securities or other equity security or other ownership interest of the Company, in any constituent company to the Merger or in any of such companies’ Affiliates or other subsidiaries, either at Law or in equity, and the rights of the Holders
are limited to those contractual rights expressed in this CVR Agreement. 

  
 14 

 (j) Except as provided in this CVR Agreement, none of the Company or any of its Affiliates shall
have any right to set off any amounts owed or claimed to be owed by any Holder to any of them against such Holder’s Securities or any CVR Payment Amount or other amount payable to such Holder in respect of such Securities. 

(k) In the event that (i) all of the CVR Certificates not previously cancelled shall have become due and payable pursuant to the terms
hereof, (ii) all disputes with respect to amounts payable to the Holders brought pursuant to the terms and conditions of this CVR Agreement have been resolved, and (iii) the Company has paid or caused to be paid or deposited with the
Trustee all amounts payable to the Holders under this CVR Agreement, then this CVR Agreement shall cease to be of further effect and shall be deemed satisfied and discharged. Notwithstanding the satisfaction and discharge of this CVR Agreement, the
obligations of the Company under SECTION 4.7(c) shall survive. 
 (l) The Company and the Paying Agent shall be entitled to deduct and
withhold from any amount payable pursuant to this CVR Agreement such amounts as they reasonably determine are required to be deducted and withheld under applicable Tax law. Amounts withheld pursuant to this SECTION 3.1(l) and timely paid to the
appropriate Tax authority shall be treated for all purposes of this CVR Agreement as having been paid to the Person in respect of which such deduction and withholding was made. 

SECTION 3.2 Registrable Form. The Securities shall be issuable only in registered form. 

SECTION 3.3 Execution, Authentication, Delivery and Dating. 

(a) The Securities shall be executed on behalf of the Company by its Chief Executive Officer or any other person duly authorized to act on
behalf of the Company for such purpose or any general purpose, but need not be attested. The signature of any of these persons on the Securities may be manual or facsimile. 

(b) Securities bearing the manual or facsimile signatures of individuals who were, at the time of execution, the proper officers of the Company
shall bind the Company, notwithstanding that such individuals or any of them have ceased to hold such offices prior to the authentication and delivery of such Securities or did not hold such offices at the date of such Securities. 

(c) At any time and from time to time after the execution and delivery of this CVR Agreement, the Company may deliver Securities executed by
the Company to the Trustee for authentication, together with a Company Order for the authentication and delivery of such Securities; and the Trustee, in accordance with such Company Order, shall authenticate and deliver such Securities as provided
in this CVR Agreement and not otherwise. 
 (d) Each Security shall be dated the date of its authentication. 

  
 15 

 (e) No Security shall be entitled to any benefit under this CVR Agreement or be valid or
obligatory for any purpose unless there appears on such Security a certificate of authentication substantially in the form provided for herein duly executed by the Trustee, by manual or facsimile signature of an authorized officer, and such
certificate upon any Security shall be conclusive evidence, and the only evidence, that such Security has been duly authenticated and delivered hereunder and that the Holder is entitled to the benefits of this CVR Agreement. 

SECTION 3.4 Intentionally Omitted. 

SECTION 3.5 Registration, Registration of Transfer and Exchange. 

(a) The Company shall cause to be kept at the office of the Trustee a register (the register maintained in such office and in any other office
or agency designated pursuant to SECTION 7.2 being herein sometimes referred to as the “Security Register”) in which, subject to such reasonable regulations as it may prescribe, the Company shall provide for the registration of
Securities and of transfers of Securities. The Trustee is hereby initially appointed “Security Registrar” for the purpose of registering Securities and transfers of Securities as herein provided. 

(b) Upon surrender for registration of transfer of any Security at the office or agency of the Company designated pursuant to SECTION 7.2, the
Company shall execute, and the Trustee shall authenticate and deliver, in the name of the designated transferee or transferees, one or more new CVR Certificates representing the same aggregate number of CVRs represented by the CVR Certificate so
surrendered that are to be transferred and the Company shall execute and the Trustee shall authenticate and deliver, in the name of the transferor, one or more new CVR Certificates representing the aggregate number of CVRs represented by such CVR
Certificate that are not to be transferred. 
 (c) At the option of the Holder, CVR Certificates may be exchanged for other CVR Certificates
that represent in the aggregate the same number of CVRs as the CVR Certificates surrendered at such office or agency. Whenever any CVR Certificates are so surrendered for exchange, the Company shall execute, and the Trustee shall authenticate and
deliver, the CVR Certificates which the Holder making the exchange is entitled to receive. 
 (d) All Securities issued upon any registration
of transfer or exchange of Securities shall be the valid obligations of the Company, evidencing the same rights, and entitled to the same benefits under this CVR Agreement, as the Securities surrendered upon such registration of transfer or
exchange. 
 (e) Every Security presented or surrendered for registration of transfer or for exchange shall (if so required by the Company or
the Security Registrar) be accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar, duly executed by the Holder thereof or his attorney duly authorized in writing. 

(f) No service charge shall be made for any registration of transfer or exchange of Securities, but the Company may require payment of a sum
sufficient to cover any documentary, stamp or similar tax or other similar governmental charge payable in connection with any registration of transfer or exchange of Securities, other than exchanges pursuant to SECTIONS 3.4, 3.6 or 6.6 not involving
any transfer. 

  
 16 

 SECTION 3.6 Mutilated, Destroyed, Lost and Stolen Securities. 

(a) If (i) any mutilated Security is surrendered to the Trustee, or (ii) the Company and the Trustee receive evidence to their
satisfaction of the destruction, loss or theft of any Security, and there is delivered to the Company and the Trustee an affidavit of loss and such security or indemnity as may be required by them to save each of them harmless in respect of such
Security, then, in the absence of notice to the Company or the Trustee that such Security has been acquired by a bona fide purchaser, the Company shall execute and, upon delivery of a Company Order, the Trustee shall authenticate and deliver, in
exchange for any such mutilated Security or in lieu of any such destroyed, lost or stolen Security, a new CVR Certificate of like tenor and amount of CVRs, bearing a number not contemporaneously outstanding. 

(b) In case any such mutilated, destroyed, lost or stolen Security has become or is to become finally due and payable within fifteen
(15) days, the Company in its discretion may, instead of issuing a new CVR Certificate, pay to the Holder of such Security on the CVR Payment Date all amounts due and payable with respect thereto. 

(c) Every new Security issued pursuant to this SECTION 3.6 in lieu of any destroyed, lost or stolen Security shall constitute an original
additional contractual obligation of the Company, whether or not the destroyed, lost or stolen Security shall be at any time enforceable by anyone, and shall be entitled to all benefits of this CVR Agreement equally and proportionately with any and
all other Securities duly issued hereunder. 
 (d) The provisions of this SECTION 3.6 are exclusive and shall preclude (to the extent lawful)
all other rights and remedies with respect to the replacement or payment of mutilated, destroyed, lost or stolen Securities. 
 SECTION 3.7
Payments with Respect to CVR Certificates. Payment of any amounts pursuant to the CVRs shall be made in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts. The
Company may, at its option, pay such amounts by wire transfer or check payable in such money. 
 SECTION 3.8 Persons Deemed Owners.
Prior to the time of due presentment for registration of transfer, the Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name any Security is registered as the owner of such Security for the purpose of
receiving payment on such Security and for all other purposes whatsoever, whether or not such Security be overdue, and neither the Company, the Trustee nor any agent of the Company or the Trustee shall be affected by notice to the contrary. 

SECTION 3.9 Cancellation. All Securities surrendered for payment, registration of transfer or exchange shall, if surrendered to any
Person other than the Trustee, be delivered to the Trustee and shall be promptly cancelled by it. The Company shall promptly deliver to the Trustee for cancellation any Securities previously authenticated and delivered hereunder which the Company
has acquired in any manner whatsoever, and all Securities so delivered shall be promptly cancelled by the Trustee. No Securities shall be authenticated in lieu of or in exchange for any Securities cancelled as provided in this SECTION 3.9, except as
expressly permitted by this CVR Agreement. All cancelled Securities held by the Trustee shall be destroyed and a certificate of destruction shall be issued by the Trustee to the Company, unless otherwise directed by a Company Order. 

  
 17 

 SECTION 3.10 CUSIP Numbers. The Company in issuing the Securities may use
“CUSIP” numbers (if then generally in use), and, if so, the Trustee shall use “CUSIP” numbers in any notice provided for in this CVR Agreement as a convenience to Holders; provided, that any such notice may state that no
representation is made as to the correctness of such numbers either as printed on the Securities or as contained in any such notice and that reliance may be placed only on the other identification numbers printed on the Securities, and any such
notice shall not be affected by any defect in or omission of such numbers. The Company shall promptly notify the Trustee in writing of any change in the “CUSIP” numbers. 

ARTICLE 4 
 THE TRUSTEE

 SECTION 4.1 Certain Duties and Responsibilities. 

(a) With respect to the Holders, the Trustee, prior to the occurrence of a Breach (as defined in SECTION 8.1) with respect to the Securities
and after the curing or waiving of all Breaches which may have occurred, undertakes to perform such duties and only such duties as are specifically set forth in this CVR Agreement and no implied covenants shall be read into this CVR Agreement
against the Trustee. In case a Breach with respect to the Securities has occurred (which has not been cured or waived), the Trustee shall exercise such of the rights and powers vested in it by this CVR Agreement, and use the same degree of care and
skill in their exercise, as a reasonably prudent person would exercise or use under the circumstances in the conduct of his or her own affairs. 

(b) In the absence of bad faith on its part, prior to the occurrence of a Breach and after the curing or waiving of all such Breaches which may
have occurred, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or opinions furnished to the Trustee which conform to the requirements of this CVR
Agreement; but in the case of any such certificates or opinions which by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall be under a duty to examine the same to determine whether or not they conform to
the requirements of this CVR Agreement. 
 (c) No provision of this CVR Agreement shall be construed to relieve the Trustee from liability
for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that (i) this Subsection (c) shall not be construed to limit the effect of Subsections (a) and (b) of this SECTION 4.1;
(ii) the Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it shall be proved that the Trustee was negligent in ascertaining the pertinent facts; and (iii) the Trustee shall not be
liable with respect to any action taken or omitted to be taken by it in good faith in accordance with the direction of the Holders pursuant to SECTION 8.9 relating to the time, method and place of conducting any proceeding for any remedy available
to the Trustee, or exercising any trust or power conferred upon the Trustee, under this CVR Agreement. 

  
 18 

 (d) Whether or not therein expressly so provided, every provision of this CVR Agreement relating
to the conduct or affecting the liability of or affording protection to the Trustee shall be subject to the provisions of this SECTION 4.1. 

SECTION 4.2 Certain Rights of Trustee. Subject to the provisions of SECTION 4.1, including without limitation, the duty of care that
the Trustee is required to exercise upon the occurrence of a Breach: 
 (a) the Trustee may rely and shall be protected in acting or
refraining from acting upon any resolution, certificate, statement, instrument, opinion, report, notice, request, direction, consent, order, bond, debenture, note, other evidence of indebtedness or other paper or document reasonably believed by it
to be genuine and to have been signed or presented by the proper party or parties and the Trustee need not investigate any fact or matter stated in the document; 

(b) any request or direction or order of the Company mentioned herein shall be sufficiently evidenced by a Company Request or Company Order and
any resolution of the Board of Directors may be sufficiently evidenced by a Board Resolution and the Trustee shall not be liable for any action it takes or omits to take in good faith reliance thereon; 

(c) whenever in the administration of this CVR Agreement the Trustee shall deem it desirable that a matter be proved or established prior to
taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically prescribed) may, in the absence of bad faith on its part, rely upon an Officer’s Certificate and the Trustee shall not be liable for
any action it takes or omits to take in good faith reliance thereon or an Opinion of Counsel; 
 (d) the Trustee may consult with counsel and
the written advice of such counsel or any Opinion of Counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with such advice or Opinion of
Counsel; 
 (e) the Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this CVR Agreement at the
request or direction of any of the Holders pursuant to this CVR Agreement, unless such Holders shall have offered to the Trustee reasonable security or indemnity against the costs, expenses and liabilities which might be incurred by it in compliance
with such request or direction; 
 (f) the Trustee shall not be bound to make any investigation into the facts or matters stated in any
resolution, certificate, statement, instrument, opinion, report, notice, request, consent, order, approval, appraisal, bond, debenture, note, coupon, security, or other paper or document, but the Trustee in its discretion may make such further
inquiry or investigation into such facts or matters as it may see fit, and if the Trustee shall determine to make such further inquiry or investigation, it shall be entitled to examine the books, records and premises of the Company, personally or by
agent or attorney, as necessary for such inquiry or investigation at the sole cost of the Company and shall incur no liability of any kind by reason of such inquiry or investigation other than as a result of Trustee’s gross negligence or
willful misconduct; 

  
 19 

 (g) the Trustee may execute any of the trusts or powers hereunder or perform any duties hereunder
either directly or by or through agents or attorneys and the Trustee shall not be responsible for any misconduct or negligence on the part of any agent or attorney appointed with due care by it hereunder; 

(h) the Trustee shall not be liable for any action taken, suffered or omitted to be taken by it in good faith and believed by it to be
authorized or within the discretion or rights or powers conferred upon it by this CVR Agreement; 
 (i) the rights, privileges, protections,
immunities and benefits given to the Trustee, including, without limitation, its right to be indemnified, are extended to, and shall be enforceable by, the Paying Agent, the Security Registrar, the Trustee in each of its capacities hereunder, and
each agent, custodian and other Person employed to act hereunder; 
 (j) in no event shall the Trustee be responsible or liable for special,
indirect, or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action; 

(k) certain of the Trustee’s duties hereunder may be performed by the Paying Agent or Security Registrar; 

(l) the Trustee shall not be deemed to have notice of any Breach or other breach under this CVR Agreement unless a Responsible Officer of the
Trustee has actual knowledge thereof or unless written notice thereof has been received by such Responsible Officer at the offices of the Trustee and such notice references the Securities and this CVR Agreement and the fact that such notice
constitutes notification of a Breach or other breach under this CVR Agreement; 
 (m) the Trustee shall not be required to give any bond or
surety in respect of the performance of its powers and duties hereunder; 
 (n) the permissive rights of the Trustee enumerated in this CVR
Agreement shall not be construed as duties hereunder; and 
 (o) in no event shall the Trustee be responsible or liable for any failure or
delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including, without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military
disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities or communications services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted
practices in the banking industry to resume performance as soon as practicable under the circumstances. 
 SECTION 4.3 Notice of
Breach. If a breach occurs hereunder with respect to the Securities, the Trustee shall give the Holders notice of any such breach actually known to it as and to the extent applicable and provided by the Trust Indenture Act; provided,
however, that in the case of any breach of the character specified in SECTION 8.1(b) with respect to the Securities, no notice to Holders shall be given until at least ninety (90) days after the occurrence thereof. For the purpose of
this SECTION 4.3, the term “breach” means any event that is, or after notice or lapse of time or both would become, a Breach with respect to the Securities. 

  
 20 

 SECTION 4.4 Not Responsible for Recitals or Issuance of Securities. The Trustee shall not
be accountable for the Company’s use of the Securities. The recitals contained herein and in the Securities, except the Trustee’s certificates of authentication, shall be taken as the statements of the Company, and the Trustee assumes no
responsibility for their correctness. The Trustee makes no representations as to the validity or sufficiency of this CVR Agreement or of the Securities. 

SECTION 4.5 May Hold Securities. The Trustee, any Paying Agent, Security Registrar or any other agent of the Company, in its individual
or any other capacity, may become the owner or pledgee of Securities, and, subject to SECTIONS 4.8 and 4.13, may otherwise deal with the Company with the same rights it would have if it were not Trustee, Paying Agent, Security Registrar or such
other agent. 
 SECTION 4.6 Money Held in Trust. Except as expressly provided in this CVR Agreement, money held by the Trustee in
trust hereunder need not be segregated from other funds except to the extent required by Law. The Trustee shall be under no liability for interest on any money received by it hereunder, except as otherwise agreed by the Trustee in writing with the
Company. 
 SECTION 4.7 Compensation and Reimbursement. The Company agrees: 

(a) to pay to the Trustee from time to time reasonable compensation for all services rendered by it hereunder in such amount as the Company and
the Trustee shall agree from time to time (which compensation shall not be limited by any provision of Law in regard to the compensation of a trustee of an express trust); 

(b) except as otherwise expressly provided herein, to reimburse the Trustee upon its request for all reasonable expenses, disbursements and
advances incurred or made by the Trustee in accordance with any provision of this CVR Agreement (including the reasonable compensation and the reasonable expenses and disbursements of its agents and counsel), except any such expense, disbursement or
advance as may be attributable to the Trustee’s negligence, bad faith or willful misconduct; and 
 (c) to indemnify the Trustee and any
predecessor Trustee and each of their respective agents, officers, directors and employees for, and to hold them harmless against, any loss, liability or expense (including attorneys’ fees and expenses) incurred without negligence or bad faith
on its part, arising out of or in connection with the acceptance or administration of this trust and the performance of its duties hereunder, including the reasonable costs and expenses of defending itself against any claim or liability in
connection with the exercise or performance of any of its powers or duties hereunder. The Company’s payment obligations pursuant to this SECTION 4.7 shall survive the termination of this CVR Agreement. When the Trustee incurs expenses after the
occurrence of a Breach specified in SECTION 8.1(c) or 8.1(d) with respect to the Company, the expenses are intended to constitute expenses of administration under bankruptcy Laws. 

  
 21 

 SECTION 4.8 Disqualification; Conflicting Interests. 

(a) If applicable, to the extent that the Trustee or the Company determines that the Trustee has a conflicting interest within the meaning of
the Trust Indenture Act, the Trustee shall immediately notify the Company of such conflict and, within ninety (90) days after ascertaining that it has such conflicting interest, either eliminate such conflicting interest or resign to the extent
and in the manner provided by, and subject to the provisions of, the Trust Indenture Act and this CVR Agreement. The Company shall take prompt steps to have a successor appointed in the manner provided in this CVR Agreement. 

(b) In the event the Trustee shall fail to comply with the foregoing subsection 4.8(a), the Trustee shall, within ten (10) days of the
expiration of such ninety (90) day period, transmit a notice of such failure to the Holders in the manner and to the extent provided in the Trust Indenture Act and this CVR Agreement. 

(c) In the event the Trustee shall fail to comply with the foregoing subsection 4.8(a) after written request therefor by the Company or any
Holder, any Holder of any Security who has been a bona fide Holder for at least six (6) months may on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the removal of such Trustee and the
appointment of a successor Trustee. 
 SECTION 4.9 Corporate Trustee Required; Eligibility. There shall at all times be a Trustee
hereunder which satisfies the applicable requirements of Sections 310(a)(1) and (5) of the Trust Indenture Act and has a combined capital and surplus of at least fifty million dollars ($50,000,000). If such corporation publishes reports of
condition at least annually, pursuant to Law or to the requirements of a supervising or examining authority, then for the purposes of this SECTION 4.9, the combined capital and surplus of such corporation shall be deemed to be its combined capital
and surplus as set forth in its most recent report of condition so published. If at any time the Trustee shall cease to be eligible in accordance with the provisions of this SECTION 4.9, it shall resign immediately in the manner and with the effect
hereinafter specified in this ARTICLE 4. 
 SECTION 4.10 Resignation and Removal; Appointment of Successor. 

(a) No resignation or removal of the Trustee and no appointment of a successor Trustee pursuant to this ARTICLE 4 shall become effective until
the acceptance of appointment by the successor Trustee under SECTION 4.11. 
 (b) The Trustee, or any trustee or trustees hereafter
appointed, may resign at any time by giving written notice thereof to the Company. If an instrument of acceptance by a successor Trustee shall not have been delivered to the Trustee within thirty (30) days after the giving of such notice of
resignation, the resigning Trustee may petition any court of competent jurisdiction for the appointment of a successor Trustee. 
 (c) The
Trustee may be removed at any time by a demand in writing by the Majority Holders delivered to the Trustee and to the Company. 

  
 22 

 (d) If at any time: 

(i) the Trustee shall fail to comply with SECTION 4.8 after written request therefor by the Company or by any Holder who has been a bona fide
Holder of a Security for at least six (6) months; or 
 (ii) the Trustee shall cease to be eligible under SECTION 4.9 and shall fail to
resign after written request therefor by the Company or by any such Holder; or 
 (iii) the Trustee shall become incapable of acting or shall
be adjudged a bankrupt or insolvent, or a receiver of the Trustee or of its property shall be appointed, or any public officer shall take charge or control of the Trustee or of its property or affairs for the purpose of rehabilitation, conservation
or liquidation, then, in any case, (A) the Company, by a Board Resolution or action of the Chief Executive Officer, may remove the Trustee, or (B) the Holder of any Security who has been a bona fide Holder of a Security for at least six
(6) months may, on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the removal of the Trustee and the appointment of a successor Trustee. 

(e) If the Trustee shall resign, be removed or become incapable of acting, or if a vacancy shall occur in the office of Trustee for any cause,
the Company, by a Board Resolution and/or action of the Chief Executive Officer, shall promptly appoint a successor Trustee. If, within one (1) year after any removal by the Majority Holders, a successor Trustee shall be appointed by act of the
Majority Holders delivered to the Company and the retiring Trustee the successor Trustee so appointed shall, forthwith upon its acceptance of such appointment in accordance with SECTION 4.11, become the successor Trustee and supersede the successor
Trustee appointed by the Company. If no successor Trustee shall have been so appointed by the Company or the Holders of the Securities and accepted appointment within sixty (60) days after the retiring Trustee tenders its resignation or is
removed, the retiring Trustee may, or, the Holder of any Security who has been a bona fide Holder for at least six (6) months may on behalf of himself and all others similarly situated, petition any court of competent jurisdiction for the
appointment of a successor Trustee. If any Trustee is removed with or without cause, all fees and expenses (including the reasonable fees and expenses of counsel) of such Trustee incurred prior to such removal in performing its duties hereunder
shall be paid to such Trustee. 
 (f) The Company shall give notice of each resignation and each removal of the Trustee and each appointment
of a successor Trustee by mailing written notice of such event by first-class mail, postage prepaid, to the Holders of Securities as their names and addresses appear in the Security Register. Each notice shall include the name of the successor
Trustee and the address of its Corporate Trust Office. If the Company fails to send such notice within ten (10) days after acceptance of appointment by a successor Trustee, it shall not be a breach hereunder but the successor Trustee shall
cause the notice to be mailed at the expense of the Company. 

  
 23 

 SECTION 4.11 Acceptance of Appointment of Successor. 

(a) Every successor Trustee appointed hereunder shall execute, acknowledge and deliver to the Company and to the retiring Trustee an instrument
accepting such appointment, and thereupon the resignation or removal of the retiring Trustee shall become effective and such successor Trustee, without any further act, deed or conveyance, shall become vested with all the rights, powers, trusts and
duties of the retiring Trustee; but, upon request of the Company or the successor Trustee, such retiring Trustee shall, upon payment of its charges, execute and deliver an instrument transferring to such successor Trustee all the rights, powers and
trusts of the retiring Trustee, and shall duly assign, transfer and deliver to such successor Trustee all property and money held by such retiring Trustee hereunder. Upon request of any such successor Trustee, the Company shall execute any and all
instruments for more fully and certainly vesting in and confirming to such successor Trustee all such rights, powers and trusts. 
 (b) No
successor Trustee shall accept its appointment unless at the time of such acceptance such successor Trustee shall be qualified and eligible under this ARTICLE 4. 

SECTION 4.12 Merger, Conversion, Consolidation or Succession to Business. Any corporation into which the Trustee may be merged or
converted or with which it may be consolidated, or any corporation resulting from any merger, conversion or consolidation to which the Trustee shall be a party, or any corporation succeeding to all or substantially all of the corporate trust
business of the Trustee, by sale or otherwise shall be the successor of the Trustee hereunder, provided such corporation shall be otherwise qualified and eligible under this ARTICLE 4, without the execution or filing of any paper or any
further act on the part of any of the Parties hereto. In case any Securities shall have been authenticated, but not delivered, by the Trustee then in office, any successor by merger, conversion, sale or consolidation to such authenticating Trustee
may adopt such authentication and deliver the Securities so authenticated with the same effect as if such successor Trustee had itself authenticated such Securities; and such certificate shall have the full force which it is anywhere in the
Securities or in this CVR Agreement provided that the certificate of the Trustee shall have; provided that the right to adopt the certificate of authentication of any predecessor Trustee shall apply only to its successor or successors by
merger, conversion or consolidation. 
 SECTION 4.13 Preferential Collection of Claims Against Company. If and when the Trustee shall
be or shall become a creditor, directly or indirectly, secured or unsecured, of the Company (or any other obligor upon the Securities), excluding any creditor relationship set forth in Section 311(b) of the Trust Indenture Act, if applicable,
the Trustee shall be subject to the applicable provisions of the Trust Indenture Act regarding the collection of claims against the Company (or any such other obligor). 

ARTICLE 5 

HOLDERS’ LISTS AND REPORTS BY THE TRUSTEE AND COMPANY 

SECTION 5.1 Company to Furnish Trustee with Names and Addresses of Holders. The Company shall furnish or cause to be furnished to the
Trustee (a) promptly after the issuance of the Securities, and semi-annually thereafter, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a recent date, and (b) at such times as
the Trustee may request in writing, within thirty (30) days after receipt by the Company of any such request, a list, in such form as the Trustee may reasonably require, of the names and addresses of the Holders as of a date not more than
fifteen (15) days prior to the time such list is furnished; provided, however, that if and so long as the Trustee shall be the Security Registrar, no such list need be furnished. 

  
 24 

 SECTION 5.2 Preservation of Information; Communications to Holders. 

(a) The Trustee shall preserve, in as current a form as is reasonably practicable, the names and addresses of the Holders contained in the most
recent list furnished to the Trustee as provided in SECTION 5.1 and the names and addresses of Holders received by the Trustee in its capacity as Security Registrar. The Trustee may destroy any list furnished to it as provided in SECTION 5.1 upon
receipt of a new list so furnished. 
 (b) The rights of the Holders to communicate with other Holders with respect to their rights under
this CVR Agreement and the corresponding rights and privileges of the Trustee shall be as provided by Section 312(b)(2) of the Trust Indenture Act, if applicable. 

(c) Every Holder of Securities, by receiving and holding the same, agrees with the Company and the Trustee that neither the Company nor the
Trustee shall be deemed to be in violation of Law or held accountable by reason of the disclosure of any such information as to the names and addresses of the Holders made pursuant to the Trust Indenture Act (if applicable) regardless of the source
from which such information was derived. 
 SECTION 5.3 Reports by Trustee. 

(a) Within sixty (60) days after December 31 of each year commencing with the December 31 following the date of this CVR
Agreement, the Trustee shall transmit to all Holders such reports concerning the Trustee and its actions under this CVR Agreement as may be required pursuant to the Trust Indenture Act to the extent and in the manner provided pursuant thereto. The
Trustee shall also comply with Section 313(b)(2) of the Trust Indenture Act, if applicable. The Trustee shall also transmit by mail all reports as required by Section 313(c) of the Trust Indenture Act, if applicable. 

(b) A copy of each such report shall, at the time of such transmission to the Holders, be filed by the Trustee with each stock exchange, if
any, upon which the Securities are listed, with the Commission and also with the Company. The Company shall promptly notify the Trustee when the Securities are listed on any stock exchange. 

SECTION 5.4 Reports by Company. 

(a) The Company shall: (a) file with the Trustee, (i) within fifteen (15) days after the Company files the same with the
Commission, copies of the annual reports filed on Form 10-K and quarterly reports filed on Form 10-Q and of the information, documents and other reports (or copies of such portions of any of the foregoing as the Commission may from time to time by
rules and regulations prescribe) which the Company is required to file with the Commission, pursuant to Section 13 or Section 15(d) of the Exchange Act (such annual and quarterly reports and required information, documents and other
reports, together the “Exchange Act Documents”), (ii) if the Company does not file such annual reports on Form 10-K or quarterly reports on Form 10-Q with the Commission, within forty-five (45) days after the end of first three
fiscal quarters of each fiscal year, quarterly information, and, within ninety (90) days after 

  
 25 

 
each fiscal year, annual financial information, in each case calculated in accordance with Accounting Standards applied consistently with the application of such standards in either the
Company’s prior quarterly reports on Form 10-Q or annual reports on Form 10-K, as applicable, and (iii) copies of any quarterly financial information or earnings reports made public by the Company or made available on the Company’s
website, within fifteen (15) days after such information or reports are furnished or otherwise made public or available; (b) file with the Trustee such additional information, documents and reports with respect to compliance by the Company
with the conditions and covenants of this CVR Agreement as may be required from time to time by the rules and regulations of the Commission; and (c) make available to the Holders on the Company’s website as of an even date with the filing
of such materials with the Trustee, the information, documents and reports required to be filed by the Company pursuant to subsections (a) or (b) of this SECTION 5.4. If the Company has timely electronically filed with the
Commission’s Next-Generation EDGAR system (or any successor system) the reports described above, the Company shall be deemed to have satisfied the requirements of this Section 5.4. 

ARTICLE 6 
 AMENDMENTS

 SECTION 6.1 Amendments without Consent of Holders. Without the consent of any Holders, the Company and the Trustee, at any
time and from time to time, may enter into one or more amendments hereto or to the Securities, for any of the following purposes: 
 (a) to
convey, transfer, assign, mortgage or pledge to the Trustee as security for the Securities any property or assets; 
 (b) to evidence the
succession of another Person to the Company, and the assumption by any such successor of the covenants of the Company herein and in the Securities; 

(c) to add to the covenants of the Company such further covenants, restrictions, conditions or provisions as the Board of Directors and/or the
Chief Executive Officer of the Company and the Trustee shall consider to be for the protection of the Holders of Securities, and to make the occurrence, or the occurrence and continuance, of a breach of any such additional covenants, restrictions,
conditions or provisions a Breach permitting the enforcement of all or any of the several remedies provided in this CVR Agreement as herein set forth; provided, that in respect of any such additional covenant, restriction, condition or
provision, such amendment may provide for a particular period of grace after breach (which period may be shorter or longer than that allowed in the case of other breaches) or may provide for an immediate enforcement upon such a Breach or may limit
the remedies available to the Trustee upon such a Breach or may limit the right of the Acting Holders to waive such a Breach; 
 (d) to cure
any ambiguity, or to correct or supplement any provision herein or in the Securities which may be defective or inconsistent with any other provision herein; provided that such amendment shall not adversely affect the interests of the Holders;

  
 26 

 (e) to make any other provisions with respect to matters or questions arising under this CVR
Agreement; provided that such provisions shall not adversely affect the interests of the Holders; 
 (f) to make any amendments or
changes necessary to comply or maintain compliance with the Trust Indenture Act, if applicable; or 
 (g) to make any change that does not
adversely affect the interests of the Holders. 
 Promptly following any amendment of this CVR Agreement or the Securities in accordance
with this SECTION 6.1, the Trustee shall notify the Holders of the Securities of such amendment; provided that any failure so to notify the Holders shall not affect the validity of such amendment. 

SECTION 6.2 Amendments with Consent of Holders. With the consent of the Majority Holders, by Act of said Holders delivered to the
Company and the Trustee (including, without limitation, consents obtained in connection with a purchase of, or tender offer or exchange offer for, the Securities), the Company (when authorized by a Board Resolution and/or the Chief Executive
Officer) and the Trustee may enter into one or more amendments hereto or to the Securities for the purpose of adding any provisions to or changing in any manner or eliminating any of the provisions of this CVR Agreement or to the Securities or of
modifying in any manner the rights of the Holders under this CVR Agreement or to the Securities; provided, however, that no such amendment shall, without the consent of the Holder of each Outstanding Security affected thereby: 

(a) modify in a manner adverse to the Holders { ) any provision contained herein with respect to the termination of this CVR Agreement or the
Securities, (ii) the time for payment or amount of any CVR Payment Amount, or otherwise extend the time for payment of the Securities or reduce the amounts payable in respect of the Securities or modify any other payment term or CVR Payment
Date; 
 (b) reduce the number of CVRs; or 

(c) modify any of the provisions of this SECTION 6.2, except to increase the percentage of Holders from whom consent is required or to provide
that certain other provisions of this CVR Agreement cannot be modified or waived without the consent of the Holder of each Security affected thereby. 

SECTION 6.3 Execution of Amendments. In executing any amendment permitted by this ARTICLE 6, the Trustee (subject to SECTION 4.1) shall
be fully protected in relying upon an Opinion of Counsel stating that the execution of such amendment is authorized or permitted by this CVR Agreement. The Trustee shall execute any amendment authorized pursuant to this ARTICLE 6 if the amendment
does not adversely affect the Trustee’s own rights, duties or immunities under this CVR Agreement or otherwise. Otherwise, the Trustee may, but need not, execute such amendment. 

  
 27 

 SECTION 6.4 Effect of Amendments; Notice to Holders. 

(a) Upon the execution of any amendment under this ARTICLE 6, this CVR Agreement and the Securities shall be modified in accordance therewith,
and such amendment shall form a part of this CVR Agreement and the Securities for all purposes; and every Holder of Securities theretofore or thereafter authenticated and delivered hereunder shall be bound thereby. 

(b) Promptly after the execution by the Company and the Trustee of any amendment pursuant to the provisions of this ARTICLE 6, the Company
shall mail a notice thereof by first-class mail to the Holders of Securities at their addresses as they shall appear on the Security Register, setting forth in general terms the substance of such amendment. Any failure of the Company to mail such
notice, or any defect therein, shall not, however, in any way impair or affect the validity of any such amendment. 
 SECTION 6.5
Conformity with Trust Indenture Act. Every amendment executed pursuant to this ARTICLE 6 shall conform to the applicable requirements of the Trust Indenture Act, if any. 

SECTION 6.6 Reference in Securities to Amendments. If an amendment changes the terms of a Security, the Trustee may require the Holder
of the Security to deliver it to the Trustee. Securities authenticated and delivered after the execution of any amendment pursuant to this ARTICLE 6 may, and shall if required by the Trustee, bear a notation in form approved by the Trustee as to any
matter provided for in such amendment. If the Company shall so determine, new Securities so modified as to conform, in the opinion of the Trustee on the one hand and the Board of Directors and/or the Chief Executive Officer on the other hand, to any
such amendment may be prepared and executed by the Company and authenticated and delivered by the Trustee in exchange for Outstanding Securities. Failure to make the appropriate notation or to issue a new Security shall not affect the validity of
such amendment. 
 ARTICLE 7 

COVENANTS 
 SECTION 7.1
Payment of Amounts, if any, to Holders. The Company shall duly and punctually pay or cause to be paid the amounts, if any, on the Securities in accordance with the terms of the Securities and this CVR Agreement. Such amounts shall be
considered paid on the CVR Payment Date if on such date the Trustee or the Paying Agent holds in accordance with this CVR Agreement money sufficient to pay all such amounts then due. 

SECTION 7.2 Maintenance of Office or Agency. 

(a) As long as any of the Securities remain Outstanding, the Company shall maintain in the Borough of Manhattan, The City of New York an office
or agency (i) where Securities may be presented or surrendered for payment, (ii) where Securities may be surrendered for registration of transfer or exchange and (iii) where notices and demands to or upon the Company in respect of the
Securities and this CVR Agreement may be served. The Corporate Trust Office shall be such office or agency of the Company, unless the Company shall designate and maintain some other office or agency for one or more of such purposes. The Company or
any of its 

  
 28 

 
Subsidiaries may act as Paying Agent, registrar or transfer agent; provided that such Person shall take appropriate actions to avoid the commingling of funds. The Company shall give prompt
written notice to the Trustee of any change in the location of any such office or agency. If at any time the Company shall fail to furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or
served at the Corporate Trust Office of the Trustee, and the Company hereby appoints the Trustee as its agent to receive all such presentations, surrenders, notices and demands. 

(b) The Company may from time to time designate one or more other offices or agencies (in the City of New York) where the Securities may be
presented or surrendered for any or all such purposes, and may from time to time rescind such designation; provided, however, that no such designation or rescission shall in any manner relieve the Company of its obligation to maintain
an office or agency in the Borough of Manhattan, The City of New York for such purposes. The Company shall give prompt written notice to the Trustee of any such designation or rescission and any change in the location of any such office or agency.

 SECTION 7.3 Money for Security Payments to Be Held in Trust. 

(a) If the Company or any of its Subsidiaries shall at any time act as the Paying Agent, it shall, on or before the CVR Payment Date, as the
case may be, segregate and hold in trust for the benefit of the Holders all sums held by such Paying Agent for payment on the Securities until such sums shall be paid to the Holders as herein provided, and shall promptly notify the Trustee of any
failure of the Company to make payment on the Securities. 
 (b) Whenever the Company shall have one or more Paying Agents for the
Securities, it shall, on or before a CVR Payment Date, deposit with a Paying Agent a sum in same day funds sufficient to pay the amount, if any, so becoming due; such sum to be held in trust for the benefit of the Persons entitled to such amount,
and (unless such Paying Agent is the Trustee) the Company shall promptly notify the Trustee of such action or any failure so to act. 
 (c)
The Company shall cause each Paying Agent other than the Trustee to execute and deliver to the Trustee an instrument in which such Paying Agent shall agree with the Trustee, subject to the provisions of this SECTION 7.3, that (i) such Paying
Agent shall hold all sums held by it for the payment of any amount payable on Securities in trust for the benefit of the Persons entitled thereto until such sums shall be paid to such Persons or otherwise disposed of as herein provided and shall
notify the Trustee of the sums so held and (ii) that it shall give the Trustee notice of any failure by the Company (or by any other obligor on the Securities) to make any payment on the Securities when the same shall be due and payable. 

(d) Any money deposited with the Trustee or any Paying Agent, or then held by the Company, in trust for the payment on any Security and
remaining unclaimed for one (1) year after the CVR Payment Date shall be paid to the Company on Company Request, or (if then held by the Company) shall be discharged from such trust; and the Holder of such Security shall thereafter, as an
unsecured general creditor, look only to the Company for payment thereof, and all liability of the Trustee or such Paying Agent with respect to such trust money shall thereupon cease. 

  
 29 

 SECTION 7.4 Certain Purchases and Sales. The Company or any of its Subsidiaries or
Affiliates may at any time acquire in open market transactions, private transactions or otherwise, some or all of the Securities; provided that prior to any acquisition of any Securities, the Company must publicly disclose the amount of Securities
which it has been authorized to acquire and the Company must report in its quarterly reports the amount of Securities it has been authorized to acquire as well as the amount of Securities it has acquired as of the end of such quarterly period
reported in such quarterly report. 
 SECTION 7.5 Books and Records. The Company shall keep, and shall cause its Subsidiaries to keep
records in sufficient detail to enable the amounts payable under this CVR Agreement to be determined for a period ending on the CVR Payment Date. 

SECTION 7.6 Listing of CVRs. The Company hereby covenants and agrees it shall use its reasonable best efforts to maintain a listing for
trading on the New York Stock Exchange (“NYSE”) or NASDAQ Capital Market (“NASDAQ”), or if unable to be listed on the NYSE or NASDAQ, on another national securities exchange, the OTC Markets Group (f/k/a Pink
Sheets) or the OTC Bulletin Board, as designated by the Company, for so long as any CVRs remain Outstanding. 
 SECTION 7.7 Existing
Litigation. The Company shall be entitled to fully control the management and disposition of any Existing Litigation, including with respect to the defense, negotiation or settlement thereof, and all decisions relating thereto. In addition, the
Company shall keep the Trustee and Holders reasonably informed, on a timely basis and in no event less than on a quarterly basis, with respect to the status of the Existing Litigation (including the reports, documents and other information described
in Section 5.4); provided that so long as Parent is a person subject to the reporting requirements of Section 13(a) or 15(d) of the Exchange Act, the foregoing requirements shall be deemed satisfied by satisfying the applicable disclosure
requirements of Part I, Item 3 “Legal Proceedings” in Parent’s annual report on Form 10-K and Part II, Item 1 “Legal Proceedings” in Parent’s quarterly reports on Form 10-Q. Solely for purposes of this
Section 7.7, “Existing Litigation” shall not include any such litigation, investigation or other proceeding involving individuals or entities other than HMA even if HMA is required to indemnify Losses incurred by such individuals or
entities or Losses arising out of any such litigation, investigation or other proceeding that occurs after the date of the Merger Agreement. 

SECTION 7.8 Notice of Breach. The Company shall file with the Trustee written notice of the occurrence of any Breach or other breach
under this CVR Agreement within five (5) Business Days of its becoming aware of any such Breach or other breach. 
 SECTION 7.9
Non-Use of Name. Neither the Trustee nor the Holders shall use the name, trademark, trade name or logo of the Company, its Affiliates, or their respective employees in any publicity or news release relating to this CVR Agreement or its
subject matter, without the prior express written permission of the Company. 

  
 30 

 ARTICLE 8 

REMEDIES OF THE TRUSTEE AND HOLDERS IN THE EVENT OF BREACH 

SECTION 8.1 Breach Defined; Waiver of Breach. “Breach” with respect to the Securities, means each one of the following
events which shall have occurred and be continuing (whatever the reason for such Breach and whether it shall be voluntary or involuntary or be effected by operation of Law or pursuant to any judgment, decree or order of any court or any order, rule
or regulation of any administrative or governmental body): 
 (a) failure to pay all or any part of any CVR Payment Amount after a period of
ten (10) Business Days after such CVR Payment Amount shall become due and payable on the CVR Payment Date or otherwise; 
 (b) material
breach in the performance, or breach in any material respect, of any covenant or warranty of the Company in respect of the Securities (other than a covenant or warranty in respect of the Securities, a breach in whose performance or other breach is
specifically dealt with elsewhere in this SECTION 8.1), and continuance of such breach for a period of ninety (90) days after there has been given, by registered or certified mail, to the Company by the Trustee or to the Company and the Trustee
by the Acting Holders, a written notice specifying such breach and requiring it to be remedied and stating that such notice is a “Notice of Breach” hereunder; 

(c) a court of competent jurisdiction shall enter a decree or order for relief in respect of the Company in an involuntary case under any
applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or shall appoint a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) for the Company or for any substantial part of its
property or ordering the winding up or liquidation of its affairs, and such decree or order shall remain unstayed and in effect for a period of ninety (90) consecutive days; or 

(d) the Company shall commence a voluntary case under any applicable bankruptcy, insolvency or other similar Law now or hereafter in effect, or
consent to the entry of an order for relief in an involuntary case under any such Law, or consent to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee or sequestrator (or similar official) of the Company
or for any substantial part of its property, or make any general assignment for the benefit of creditors. 
 Except where authorization
and/or appearance of each of the Holders is required by applicable Law, if a Breach described above occurs and is continuing, then either the Trustee may, by notice in writing to the Company, or the Trustee shall, upon the written request of the
Acting Holders by notice in writing to the Company and to the Trustee, bring suit to protect the rights of the Holders, including to obtain payment for any amounts then due and payable; which amounts shall bear interest at the Breach Interest Rate
from the date such amounts were due and payable until payment is made to the Trustee. 

  
 31 

 The foregoing provisions, however, are subject to the condition that if, at any time after the
Trustee shall have begun such suit, and before any judgment or decree for the payment of the moneys due shall have been obtained or entered as hereinafter provided, the Company shall pay or shall deposit with the Trustee a sum sufficient to pay all
amounts which shall have become due and payable (with interest upon such overdue amount at the Breach Interest Rate to the date of such payment or deposit) and such amount as shall be sufficient to cover reasonable compensation to the Trustee, its
agents, attorneys and counsel, and all other expenses and liabilities incurred and all advances made, by the Trustee, and if any and all Breaches under this CVR Agreement shall have been cured, waived or otherwise remedied as provided herein, then
and in every such case the Acting Holders, by written notice to the Company and to the Trustee, may waive all breaches with respect to the Securities, but no such waiver or rescission and annulment shall extend to or shall affect any subsequent
breach or shall impair any right consequent thereof. 
 SECTION 8.2 Collection by the Trustee; the Trustee May Prove Payment
Obligations. The Company covenants that in the case of any failure to pay all or any part of the Securities when the same shall have become due and payable, then upon demand of the Trustee, the Company shall pay to the Trustee for the benefit of
the Holders of the Securities the whole amount that then shall have become due and payable on all Securities (with interest from the date due and payable to the date of such payment upon the overdue amount at the Breach Interest Rate); and in
addition thereto, such further amount as shall be sufficient to cover the costs and expenses of collection, including reasonable compensation to the Trustee and each predecessor Trustee, their respective agents, attorneys and counsel, and any
expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence or bad faith. 

The Trustee may in its discretion proceed to protect and enforce its rights and the rights of the Holders by such appropriate judicial
proceedings as the Trustee shall deem most effectual to protect and enforce any such rights, whether for the specific enforcement of any covenant or agreement in this CVR Agreement or in aid of the exercise of any power granted herein, or to enforce
any other remedy. 
 In case the Company shall fail forthwith to pay such amounts upon such demand, the Trustee, in its own name and as
trustee of an express trust, shall be entitled and empowered to institute any action or proceedings at Law or in equity for the collection of the sums so due and unpaid, and may prosecute any such action or proceedings to judgment or final decree,
and may enforce any such judgment or final decree against the Company or other obligor upon such Securities and collect in the manner provided by Law out of the property of the Company or other obligor upon such Securities, wherever situated, the
moneys adjudged or decreed to be payable. 
 In any judicial proceedings relative to the Company or other obligor upon the Securities,
irrespective of whether any amount is then due and payable with respect to the Securities, the Trustee is authorized: 
 (a) to file and
prove a claim or claims for the whole amount owing and unpaid in respect of the Securities, and to file such other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for reasonable
compensation to the Trustee and each predecessor Trustee, and their respective agents, attorneys 

  
 32 

 
and counsel, and for reimbursement of all expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of negligence or bad faith) and
of the Holders allowed in any judicial proceedings relative to the Company or other obligor upon the Securities, or to their respective property; 

(b) unless prohibited by and only to the extent required by applicable Law, to vote on behalf of the Holders in any election of a trustee or a
standby trustee in arrangement, reorganization, liquidation or other bankruptcy or insolvency proceedings or Person performing similar functions in comparable proceedings; and 

(c) to collect and receive any moneys or other property payable or deliverable on any such claims, and to distribute all amounts received with
respect to the claims of the Holders and of the Trustee on their behalf; and any trustee, receiver, or liquidator, custodian or other similar official is hereby authorized by each of the Holders to make payments to the Trustee, and, in the event
that the Trustee shall consent to the making of payments directly to the Holders, to pay to the Trustee such amounts as shall be sufficient to cover reasonable compensation to the Trustee, each predecessor Trustee and their respective agents,
attorneys and counsel, and all other expenses and liabilities incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence or bad faith, and all other amounts due to the Trustee or any
predecessor Trustee pursuant to SECTION 4.7. To the extent that such payment of reasonable compensation, expenses, disbursements, advances and other amounts out of the estate in any such proceedings shall be denied for any reason, payment of the
same shall be secured by a lien on, and shall be paid out of, any and all distributions, dividends, moneys, securities and other property which the Holders may be entitled to receive in such proceedings, whether in liquidation or under any plan of
reorganization or safeguard arrangement or otherwise. 
 Nothing herein contained shall be deemed to authorize the Trustee to authorize or
consent to or vote for or accept or adopt on behalf of any Holder any plan of reorganization, safeguard arrangement, adjustment or composition affecting the Securities, or the rights of any Holder thereof, or to authorize the Trustee to vote in
respect of the claim of any Holder in any such proceeding except, as aforesaid, to vote for the election of a trustee in bankruptcy or similar person. 

All rights of action and of asserting claims under this CVR Agreement, or under any of the Securities, may be enforced by the Trustee without
the possession of any of the Securities or the production thereof and any trial or other proceedings instituted by the Trustee shall be brought in its own name as trustee of an express trust, and any recovery of judgment, subject to the payment of
the expenses, disbursements and compensation of the Trustee, each predecessor Trustee and their respective agents and attorneys, shall be for the ratable benefit of the Holders. 

In any proceedings brought by the Trustee (and also any proceedings involving the interpretation of any provision of this CVR Agreement to
which the Trustee shall be a party) the Trustee shall be held to represent all the Holders, and it shall not be necessary to make any Holders of such Securities parties to any such proceedings (unless required by applicable Law). 

  
 33 

 SECTION 8.3 Application of Proceeds. Any monies collected by the Trustee pursuant to this
ARTICLE 8 in respect of any Securities shall be applied in the following order at the date or dates fixed by the Trustee upon presentation of the several Securities in respect of which monies have been collected and stamping (or otherwise noting)
thereon the payment in exchange for the presented Securities if only partially paid or upon surrender thereof if fully paid: 
 FIRST:
To the payment of costs and expenses in respect of which monies have been collected, including reasonable compensation to the Trustee and each predecessor Trustee and their respective agents and attorneys and of all expenses and liabilities
incurred, and all advances made, by the Trustee and each predecessor Trustee, except as a result of its negligence or willful misconduct, and all other amounts due to the Trustee or any predecessor Trustee pursuant to SECTION 4.7; 

SECOND: To the payment of the whole amount then owing and unpaid upon all the Securities, with interest at the Breach Interest Rate on
all such amounts, and, in case such monies shall be insufficient to pay in full the whole amount so due and unpaid upon the Securities, then to the payment of such amounts without preference or priority of any security over any other Security,
ratably to the aggregate of such amounts due and payable; and 
 THIRD: To the payment of the remainder, if any, to the Company or any
other Person lawfully entitled thereto. 
 SECTION 8.4 Suits for Enforcement. In case a Breach has occurred, has not been waived and
is continuing, the Trustee may in its discretion (subject to SECTION 1.10) proceed to protect and enforce the rights vested in it by this CVR Agreement by such appropriate judicial proceedings as the Trustee shall deem most effectual to protect and
enforce any of such rights (unless authorization and/or appearance of each of the Holders is required by applicable Law), either at Law or in equity or in bankruptcy or otherwise, whether for the specific enforcement of any covenant or agreement
contained in this CVR Agreement or in aid of the exercise of any power granted in this CVR Agreement or to enforce any other legal or equitable right vested in the Trustee by this CVR Agreement or by Law. 

SECTION 8.5 Restoration of Rights on Abandonment of Praoceedings. In case the Trustee or any Holder shall have proceeded to enforce any
right under this CVR Agreement and such proceedings shall have been discontinued or abandoned for any reason, or shall have been determined adversely to the Trustee or to such Holder, then and in every such case the Company and the Trustee and the
Holders shall be restored respectively to their former positions and rights hereunder, and all rights, remedies and powers of the Company, the Trustee and the Holders shall continue as though no such proceedings had been taken. 

SECTION 8.6 Limitations on Suits by Holders. Subject to the rights of the Holders under Section 8.7, no Holder of any Security
shall have any right by virtue or by availing itself of any provision of this CVR Agreement to institute any action or proceeding at Law or in equity or in bankruptcy or otherwise upon or under or with respect to this CVR Agreement, or for the
appointment of a trustee, receiver, liquidator, custodian or other similar official or for any other remedy hereunder, unless such Holder previously shall have given to the Trustee written notice of breach and of the continuance thereof, as
hereinbefore provided, and unless also the Acting Holders shall have made written request upon the Trustee to institute such action or proceedings 

  
 34 

 
in its own name as trustee hereunder and shall have offered to the Trustee such reasonable indemnity as it may require against the costs, expenses and liabilities to be incurred therein or
thereby, and the Trustee for thirty (30) days after its receipt of such notice and request shall have failed to institute any such action or proceeding and no direction inconsistent with such written request shall have been given to the Trustee
pursuant to SECTION 8.9; it being understood and intended, and being expressly covenanted by the taker and Holder of every Security with every other taker and Holder and the Trustee, that no one or more Holders of Securities shall have any right in
any manner whatever by virtue or by availing itself of any provision of this CVR Agreement to effect, disturb or prejudice the rights of any other such Holder of Securities, or to obtain or seek to obtain priority over or preference to any other
such Holder or to enforce any right under this CVR Agreement, except in the manner herein provided and for the equal, ratable and common benefit of all Holders of Securities. For the protection and enforcement of the provisions of this
Section 8.6, each and every Holder and the Trustee shall be entitled to such relief as can be given either at Law or in equity. 

SECTION 8.7 Unconditional Right of Holders to Receive Payment. Notwithstanding any other provision in this CVR Agreement and any
provision of any Security, the right of any Holder of any Security to receive payment of the amounts payable in respect of such Security on or after the respective due dates expressed in such Security, or to institute suit for the enforcement of any
such payment on or after such respective dates, shall not be impaired or affected without the consent of such Holder. 
 SECTION 8.8
Powers and Remedies Cumulative; Delay or Omission Not Waiver of Breach. 
 (a) Except as provided in SECTION 8.6, no right or remedy
herein conferred upon or reserved to the Trustee or to the Holders is intended to be exclusive of any other right or remedy, and every right and remedy shall, to the extent permitted by Law, be cumulative and in addition to every other right and
remedy given hereunder or now or hereafter existing at Law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other appropriate right
or remedy. 
 (b) No delay or omission of the Trustee or of any Holder to exercise any right or power accruing upon any Breach occurring and
continuing as aforesaid shall impair any such right or power or shall be construed to be a waiver of any such Breach or an acquiescence therein; and, subject to SECTION 8.6, every power and remedy given by this CVR Agreement or by Law to the Trustee
or to the Holders may be exercised from time to time, and as often as shall be deemed expedient, by the Trustee or by the Holders. 

SECTION 8.9 Control by Holders. 

(a) The Majority Holders shall have the right to direct the time, method and place of conducting any proceeding for any remedy available to the
Trustee, or exercising any power conferred on the Trustee with respect to the Securities by this CVR Agreement; provided that such direction shall not be otherwise than in accordance with Law and the provisions of this CVR Agreement; and
provided further that (subject to the provisions of SECTION 4.1) the Trustee shall have the right to decline to follow any such direction if the Trustee, being advised 

  
 35 

 
by counsel, shall determine that the action or proceeding so directed may not lawfully be taken or if the Trustee in good faith by its board of directors, the executive committee, or a committee
of directors or Responsible Officers of the Trustee shall determine that the action or proceedings so directed would involve the Trustee in personal liability or if the Trustee in good faith shall so determine that the actions or forbearances
specified in or pursuant to such direction would be unduly prejudicial to the interests of Holders of the Securities not joining in the giving of said direction. 

(b) Nothing in this CVR Agreement shall impair the right of the Trustee in its discretion to take any action deemed proper by the Trustee and
which is not inconsistent with such direction or directions by Holders. 
 SECTION 8.10 Waiver of Past Breaches. 

(a) In the case of a breach or a Breach specified in clause (b), (c) or (d) of SECTION 8.1, the Majority Holders may waive any such
Breach, and its consequences except a breach in respect of a covenant or provisions hereof which cannot be modified or amended without the consent of the Holder of each Security affected. In the case of any such waiver, the Company, the Trustee and
the Holders of the Securities shall be restored to their former positions and rights hereunder, respectively; but no such waiver shall extend to any subsequent or other breach or impair any right consequent thereon. 

(b) Upon any such waiver, such breach shall cease to exist and be deemed to have been cured and not to have occurred, and any Breach arising
therefrom shall be deemed to have been cured, and not to have occurred for every purpose of this CVR Agreement; but no such waiver shall extend to any subsequent or other Breach or other breach of any kind or impair any right consequent thereon.

 SECTION 8.11 The Trustee to Give Notice of Breach, But May Withhold in Certain Circumstances. The Trustee shall transmit to the
Holders, as the names and addresses of such Holders appear on the Security Register (as provided under Section 313(c) of the Trust Indenture Act, if applicable), notice by mail of all breaches which have occurred and are known to the Trustee, such
notice to be transmitted within ninety (90) days after the occurrence thereof, unless such breaches shall have been cured before the giving of such notice (the term “breach” for the purposes of this SECTION 8.11 being hereby defined
to mean any event or condition which is, or with notice or lapse of time or both would become, a Breach); provided that, except in the case of a failure to pay the amounts payable in respect of any of the Securities, the Trustee shall be
protected in withholding such notice if and so long as the board of directors, the executive committee, or a trust committee of directors or trustees and/or Responsible Officers of the Trustee in good faith reasonably determines that the withholding
of such notice is in the best interests of the Holders. 
 SECTION 8.12 Right of Court to Require Filing of Undertaking to Pay Costs.
All Parties to this CVR Agreement agree, and each Holder of any Security by his acceptance thereof shall be deemed to have agreed, that any court may in its discretion require, in any suit for the enforcement of any right or remedy under this CVR
Agreement or in any suit against the Trustee for any action taken, suffered or omitted by it as the Trustee, the filing by any party litigant in 

  
 36 

 
such suit of an undertaking to pay the costs of such suit, and that such court may in its discretion assess reasonable costs, including attorneys’ fees, against any party litigant in such
suit, having due regard to the merits and good faith of the claims or defenses made by such party litigant; but the provisions of this SECTION 8.12 shall not apply to any suit instituted by the Trustee, to any suit instituted by any Holder or group
of Holders holding in the aggregate more than ten percent (10%) of the Outstanding Securities or to any suit instituted by any Holder for the enforcement of the payment of any Security on or after the due date expressed in such Security. 

ARTICLE 9 

CONSOLIDATION, MERGER, SALE OR CONVEYANCE 

SECTION 9.1 Successor Person Substituted. 

(a) The Company covenants that it shall not merge or consolidate with or into any other Person (other than a wholly-owned subsidiary of the
Company), split-off, or sell or convey all or substantially all of its assets to any Person (including in connection with a spin-off transaction), unless (i) the Company shall be the continuing Person, or the successor Person or the Person
which acquires by sale or conveyance all or substantially all the assets of the Company shall be a Person organized under the Laws of the United States of America or any State thereof and shall expressly assume by an instrument supplemental hereto,
executed and delivered to the Trustee, in form satisfactory to the Trustee, the due and punctual payment of the Securities, according to their tenor, and the due and punctual performance and observance of all of the covenants and conditions of this
CVR Agreement to be performed or observed by the Company, including, without limitation, the provisions concerning governing law and consent to jurisdiction set forth in Section 1.10 hereof, and (ii) the Company, or such successor Person,
as the case may be, shall not, immediately after such merger or consolidation, split-off, or such sale or conveyance, be in breach in the performance of any such covenant or condition. 

(b) In case of any such consolidation, merger, split-off, spin-off, sale or conveyance, and following such an assumption by the successor
Person, such successor Person shall succeed to and be substituted for the Company with the same effect as if it had been named herein. Such successor Person may cause to be signed, and may issue either in its own name or in the name of the Company
prior to such succession any or all of the Securities issuable hereunder which theretofore shall not have been signed by the Company and delivered to the Trustee; and, upon the order of such successor Person instead of the Company and subject to all
the terms, conditions and limitations in this CVR Agreement prescribed, the Trustee shall authenticate and shall deliver any Securities which previously shall have been signed and delivered to the Trustee for authentication, and any Securities which
such successor Person thereafter shall cause to be signed and delivered to the Trustee for that purpose. All of the Securities so issued shall in all respects have the same legal rank and benefit under this CVR Agreement as the Securities
theretofore or thereafter issued in accordance with the terms of this CVR Agreement as though all of such Securities had been issued at the date of the execution hereof. 

(c) In case of any such consolidation, merger, sale or conveyance, such changes in phraseology and form (but not in substance) may be made in
the Securities thereafter to be issued as may be appropriate. 

  
 37 

 (d) In the event of any such sale, transfer or conveyance (other than a conveyance by way of
lease) the Company or any Person which shall theretofore have become such in the manner described in this ARTICLE 9 shall be discharged from all obligations and covenants under this CVR Agreement and the Securities and may be liquidated and
dissolved. 
 SECTION 9.2 Opinion of Counsel to the Trustee. The Trustee, subject to the provisions of Sections 4.1 and 4.2, shall
receive an Officer’s Certificate and Opinion of Counsel, prepared in accordance with Sections 1.2 and 1.3, as conclusive evidence that any such consolidation, merger, sale or conveyance, and any such assumption, and any such liquidation or
dissolution, complies with the applicable provisions of this CVR Agreement, and if a supplemental agreement is required in connection with such transaction, such supplemental agreement complies with this ARTICLE 9 and that there has been compliance
with all conditions precedent herein provided for or relating to such transaction. 
 SECTION 9.3 Successors. All covenants,
provisions and agreements in this CVR Agreement by or for the benefit of the Company, the Trustee or the Holders shall bind and inure to the benefit of their respective successors, assigns, heirs and personal representatives, whether so expressed or
not. Neither this CVR Agreement nor any of the rights, interests or obligations hereunder shall be assigned, in whole or in part, by any of the Parties without the prior written consent of each other Party. Notwithstanding the foregoing, the Company
may assign this CVR Agreement without the prior written consent of the other Parties to this CVR Agreement to one or more of its direct or indirect Subsidiaries, provided, however, that in the event of any such assignment the Company
shall remain subject to its obligations and covenants hereunder, including, but not limited to, its obligation to make any payments under the CVRs (including the CVR Payment Amount). 

ARTICLE 10 

SUBORDINATION 
 SECTION
10.1 Agreement to Subordinate. The Company agrees, and each Holder by accepting a Security hereunder agrees, that all payments under the CVRs, all other obligations under this CVR Agreement and the Securities and any rights or claims relating
thereto (collectively, the “Junior Obligations”) are subordinated in right of payment, to the extent and in the manner provided in this ARTICLE 10 to the prior payment in full in money or money’s worth of all Senior Obligations
of the Company (whether outstanding on the date hereof or hereafter created, incurred, assumed or guaranteed), and that the subordination is for the benefit of the holders of such Senior Obligations. 

SECTION 10.2 Liquidation; Dissolution; Bankruptcy. Upon any distribution to creditors of the Company in a liquidation or dissolution of
the Company or in a bankruptcy, reorganization, insolvency, receivership or similar proceeding relating to the Company or its property, in an assignment for the benefit of creditors or any marshaling of the Company’s assets and liabilities:

 (a) holders of Senior Obligations will be entitled to receive payment in full in money or money’s worth of all Senior Obligations of
the Company (including interest after the 

  
 38 

 
commencement of any bankruptcy proceeding at the rate specified in the applicable Senior Obligation, whether or not permitted under such bankruptcy proceedings) before the Holders will be
entitled to receive any payment of any kind with respect to the Junior Obligations (other than securities of the Company or debt of the Company that is subordinated to the Senior Obligations on terms at least as favorable to holders of Senior
Obligations as this ARTICLE 10 (“Permitted Junior Securities”)); and 
 (b) until all Senior Obligations of the Company (as
provided in clause (a) above) are paid in full in money or money’s worth, any distribution to which Holders would be entitled but for this ARTICLE 10 (other than Permitted Junior Securities) will be made to holders of Senior Obligations of
the Company, as their interests may appear. 
 SECTION 10.3 When Distribution Must be Paid Over. 

(a) In the event that the Trustee or any Holder receives any payment of any Junior Obligations (other than Permitted Junior Securities) at a
time when the Trustee or such Holder has actual knowledge that such payment is prohibited by this ARTICLE 10, such payment will be held by the Trustee or such Holder, in trust for the benefit of, and will be paid forthwith over and delivered, upon
written request, to, the holders of Senior Obligations of the Company as their interests may appear or their representative under the agreement, indenture or other document (if any) pursuant to which such Senior Obligations may have been issued, as
their respective interests may appear, for application to the payment of all such Senior Obligations remaining unpaid to the extent necessary to pay such Senior Obligations in full in accordance with their terms, after giving effect to any
concurrent payment or distribution to or for the holders of Senior Obligations. 
 (b) With respect to the holders of Senior Obligations, the
Trustee undertakes to perform only those obligations on the part of the Trustee as are specifically set forth in this ARTICLE 10, and no implied covenants or obligations with respect to the holders of Senior Obligations will be read into this CVR
Agreement against the Trustee. The Trustee will not be deemed to owe any fiduciary duty to the holders of Senior Obligations, and will not be liable to any such holders if the Trustee pays over or distributes to or on behalf of Holders or the
Company or any other Person money or assets to which any holders of Senior Obligations are then entitled by virtue of this ARTICLE 10, except if such payment is made as a result of the willful misconduct or negligence of the Trustee. 

SECTION 10.4 Notice by the Company. The Company will promptly notify the Trustee of any facts known to the Company that would cause a
payment of any Junior Obligations to violate this ARTICLE 10, but failure to give such notice will not affect the subordination of the Junior Obligations to the Senior Obligations as provided in this ARTICLE 10. 

SECTION 10.5 Subrogation. After all Senior Obligations are paid in full in money or money’s worth and until the Junior Obligations
are paid in full, Holders will be subrogated to the rights of holders of Senior Obligations to receive distributions applicable to Senior Obligations to the extent that distributions otherwise payable to the Holders have been applied to the payment
of Senior Obligations. The Holders by accepting the Securities acknowledge that to the extent that the Senior Obligations are determined to be unenforceable, or the Senior Obligations are subordinated to other obligations of the Company, such
subrogation rights may be impaired. 

  
 39 

 SECTION 10.6 Relative Rights. This ARTICLE 10 defines the relative rights of Holders and
holders of Senior Obligations. Nothing in this CVR Agreement will: 
 (a) impair, as between the Company and Holders, the obligations of the
Company under this CVR Agreement and the Securities; 
 (b) affect the relative rights of Holders and creditors of the Company other than
their rights in relation to holders of Senior Obligations; or 
 (c) prevent the Trustee or any Holder from exercising its available remedies
upon a Breach, subject to the rights of holders of Senior Obligations to receive distributions and payments otherwise payable to Holders under this ARTICLE 10. 

If the Company fails because of this ARTICLE 10 to pay any amounts due in respect of the Securities on a due date in violation of SECTION 3.1(e), the failure
is still a Breach. 
 SECTION 10.7 Subordination May Not be Impaired by the Company. No right of any holder of Senior Obligations to
enforce the subordination of the Junior Obligations may be impaired by any act or failure to act by the Company or any Holder or by the failure of the Company or any Holder to comply with this CVR Agreement. 

SECTION 10.8 Distribution or Notice to the Representative. Whenever a distribution is to be made or a notice given to holders of Senior
Obligations, the distribution may be made and the notice given to their representative in accordance with the terms of the instrument or other agreement governing such Senior Obligations. Upon any payment or distribution of assets of the Company
referred to in this ARTICLE 10, the Trustee and the Holders will be entitled to rely upon any order or decree made by any court of competent jurisdiction or upon any certificate of such representative or of the liquidating trustee or agent or other
Person making any distribution to the Trustee or to the Holders for the purpose of ascertaining the Persons entitled to participate in such distribution, the holders of the Senior Obligations and other obligations of the Company, the amount thereof
or payable thereon, the amount or amounts paid or distributed thereon and all other facts pertinent thereto or to this ARTICLE 10. 

SECTION 10.9 Rights of the Trustee. Notwithstanding the provisions of this ARTICLE 10 or any other provision of this CVR Agreement, the
Trustee will not be charged with knowledge of the existence of any facts that would prohibit the making of any payment or distribution by the Trustee, and the Trustee may continue to make payments on the Securities, unless the Trustee has received
at its address for notice specified in SECTION 1.5 at least five (5) Business Days prior to the date of such payment written notice of facts that would cause the payment of any Junior Obligations to violate this ARTICLE 10. Only the Company or
a representative of Senior Obligations may give the notice. Nothing in this ARTICLE 10 will impair the claims of, or payments to, the Trustee under or pursuant to SECTION 4.7 hereof. The Trustee in its individual or any other capacity may hold
Senior Obligations with the same rights it would have if it were not the Trustee. 

  
 40 

 SECTION 10.10 Authorization to Effect Subordination. Each Holder, by the Holder’s
acceptance of the Securities, authorizes and directs the Trustee on such Holder’s behalf to take such action as may be necessary or appropriate to effectuate the subordination as provided in this ARTICLE 10, and appoints the Trustee to act as
such Holder’s attorney-in-fact for any and all such purposes. If the Trustee (or any other Person acting on behalf of and at the direction of the Majority Holders) does not file a proper proof of claim or proof of debt in the form required in
any proceeding referred to in SECTION 8.2 hereof at least thirty (30) days before the expiration of the time to file such claim, the representatives of the Senior Obligations are hereby authorized to file an appropriate claim for and on behalf
of the Holders of the Securities. 
 SECTION 10.11 Amendments. The provisions of this ARTICLE 10 are expressly made for the benefit
of the holders from time to time of the Senior Obligations, and may not be amended or modified without the written consent of the representatives of the holders of all Senior Obligations. 

SECTION 10.12 Subordination Language to be Included in the Securities. Each Security shall contain a subordination provision which will
be substantially in the following form: 
 “The Securities of this series are subordinated in right of payment, in
the manner and to the extent set forth in the CVR Agreement, to the prior payment in full of all Senior Obligations of the Company (as defined in the CVR Agreement). Each Holder by accepting a Security agrees to such subordination and authorizes the
Trustee to give it effect.” 

  
 41 

 IN WITNESS WHEREOF, the Parties hereto have caused this CVR Agreement to be duly executed, all as
of the day and year first above written. 
  

					
	COMMUNITY HEALTH SYSTEMS, INC.
		
	By:	 	/s/ Rachel A. Seifert
		 	Name:	 	Rachel A. Seifert
		 	Title:	 	Executive Vice President and Secretary

  

					
	 AMERICAN STOCK TRANSFER & TRUST COMPANY, LLC,

as the Trustee

		
	By:	 	/s/ John D. Baker
		 	Name:	 	John D. Baker
		 	Title:	 	Senior Vice President

  
 42 

 ANNEX A 

THE SECURITIES OF THIS SERIES ARE SUBORDINATED IN RIGHT OF PAYMENT, IN THE MANNER AND TO THE EXTENT SET FORTH IN THE CVR AGREEMENT, TO THE
PRIOR PAYMENT IN FULL OF ALL SENIOR OBLIGATIONS OF THE COMPANY (AS DEFINED IN THE CVR AGREEMENT). EACH HOLDER BY ACCEPTING A SECURITY AGREES TO SUCH SUBORDINATION AND AUTHORIZES THE TRUSTEE TO GIVE IT EFFECT. 

COMMUNITY HEALTH SYSTEMS, INC. 
 No.
             Certificate for                  Contingent Value Rights 

This certifies that [            ], or registered assigns (the
“Holder”), is the registered holder of the number of Contingent Value Rights (“CVRs” or “Securities”) set forth above. Each CVR entitles the Holder, subject to the provisions contained herein and in
the CVR Agreement referred to on the reverse hereof, to payments from Community Health Systems, Inc., a Delaware corporation (the “Company”), in the amounts and in the forms determined pursuant to the provisions set forth on the
reverse hereof and as more fully described in the CVR Agreement referred to on the reverse hereof. Such payments shall be made on a CVR Payment Date, as defined in the CVR Agreement referred to on the reverse hereof. 

Payment of any amounts pursuant to this CVR Certificate shall be made only to the registered Holder (as defined in the CVR Agreement) of this
CVR Certificate. Such payment shall be made in the Borough of Manhattan, The City of New York, New York, or at any other office or agency maintained by the Company outside of the City of New York, New York for such purpose, in such coin or currency
of the United States of America as at the time is legal tender for the payment of public and private debts; provided, however, the Company may pay such amounts by wire transfer or check payable in such money. American Stock
Transfer & Trust Company, LLC has been initially appointed as Paying Agent at its office or agency in the Borough of Brooklyn, The City of New York, New York. 

Reference is hereby made to the further provisions of this CVR Certificate set forth on the reverse hereof, which further provisions shall for
all purposes have the same effect as if set forth at this place. 
 Unless the certificate of authentication hereon has been duly executed
by the Trustee referred to on the reverse hereof by manual signature, this CVR Certificate shall not be entitled to any benefit under the CVR Agreement, or be valid or obligatory for any purpose. 

  
 A-1 

 IN WITNESS WHEREOF, the Company has caused this instrument to be duly executed. 

 

					
	COMMUNITY HEALTH SYSTEMS, INC.
			
	By:	 	 	 	 
		 	Name:	 	
		 	Title:	 	

  

			
	Dated:
		
	Attest:	 	 
		 	Authorized Signature

  
 A-2 

 [Form of Reverse of CVR Certificate] 

1. This CVR Certificate is issued under and in accordance with the Contingent Value Rights Agreement, dated as of January 27, 2014 (the
“CVR Agreement”), by and between the Company and American Stock Transfer & Trust Company, LLC, a New York limited liability trust company, as trustee (the “Trustee,” which term includes any successor
Trustee under the CVR Agreement), and is subject to the terms and provisions contained in the CVR Agreement, to all of which terms and provisions the Holder of this CVR Certificate consents by acceptance hereof. The CVR Agreement is hereby
incorporated herein by reference and made a part hereof. Reference is hereby made to the CVR Agreement for a full statement of the respective rights, limitations of rights, duties, obligations and immunities thereunder of the Company, the Trustee
and the Holders of the CVRs. All capitalized terms used in this CVR Certificate without definition shall have the respective meanings ascribed to them in the CVR Agreement. Copies of the CVR Agreement can be obtained by contacting the Trustee. 

2. In the event of any conflict between this CVR Certificate and the CVR Agreement, the CVR Agreement shall govern and prevail. 

3. Subject to the terms and conditions of the CVR Agreement, on the CVR Payment Date, the Company shall pay to the Trustee, for the benefit of
the Holder hereof as of the applicable record date, for each CVR represented hereby, the CVR Payment Amount. 
 4. Payment of any amounts
pursuant to the CVRs, if any, shall be payable by the Company in such coin or currency of the United States of America as at the time is legal tender for the payment of public and private debts; provided, however, the Company may pay
such amounts by its check or wire transfer payable in such money. American Stock Transfer & Trust Company, LLC has been initially appointed as Paying Agent at its office or agency in the Borough of Brooklyn, The City of New York. 

5. If a Breach occurs and is continuing, either the Trustee may or the Acting Holders, by notice in writing to the Company and to the Trustee
shall, bring suit in accordance with the terms and conditions of the CVR Agreement to protect the rights of the Holders, including to obtain payment of all amounts then due and payable, with interest at the Breach Interest Rate from the date of the
Breach through the date payment is made or duly provided for. 
 6. No reference herein to the CVR Agreement and no provision of this CVR
Certificate or of the CVR Agreement shall alter or impair the obligation of the Company, which is absolute and unconditional, to pay any amounts determined pursuant to the terms hereof and of the CVR Agreement at the times, place and amount, and in
the manner, herein prescribed. 
 7. As provided in the CVR Agreement and subject to certain limitations therein set forth, the transfer of
the CVRs represented by this CVR Certificate is registrable on the Security Register, upon surrender of this CVR Certificate for registration of transfer at the office or agency of the Company maintained for such purpose in the Borough of Manhattan,
The City of New York, accompanied by a written instrument of transfer in form satisfactory to the Company and the Security Registrar duly executed by the Holder hereof or his attorney duly authorized in writing, and thereupon one or more new CVR
Certificates, for the same amount of CVRs, shall 

  
 A-3 

 
be issued to the designated transferee or transferees. The Company hereby initially designates the office of American Stock Transfer & Trust Company, LLC at 6201 15th Avenue, Brooklyn, New York 11219 as the office for registration of transfer of this CVR Certificate. 

8. As provided in the CVR Agreement and subject to certain limitations therein set forth, this CVR Certificate is exchangeable for one or more
CVR Certificates representing the same number of CVRs as represented by this CVR Certificate as requested by the Holder surrendering the same. 

9. No service charge shall be made for any registration of transfer or exchange of CVRs, but the Company may require payment of a sum
sufficient to cover any documentary, stamp or similar tax or other similar governmental charge payable in connection with any registration of transfer or exchange of Securities, other than exchanges pursuant to Sections 3.4, 3.6 or 6.6 of the CVR
Agreement not involving any transfer. 
 10. Prior to the time of due presentment of this CVR Certificate for registration of transfer, the
Company, the Trustee and any agent of the Company or the Trustee may treat the Person in whose name this CVR Certificate is registered as the owner hereof for all purposes, and neither the Company, the Trustee nor any agent shall be affected by
notice to the contrary. 
 11. Neither the Company nor the Trustee has any duty or obligation to the Holder of this CVR Certificate, except
as expressly set forth herein or in the CVR Agreement. 
 12. As provided in the CVR Agreement and subject to certain limitations therein
set forth, the rights of the Holder of this CVR Certificate shall terminate on the CVR Payment Date. 
 13. Governing Law; Jurisdiction;
Venue; Waiver of Jury Trial. THIS CVR CERTIFICATE AND THE CVR AGREEMENT AND ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY BE BASED UPON, ARISE OUT OF OR RELATE TO THIS CVR CERTIFICATE AND THE CVR AGREEMENT, OR THE
NEGOTIATION, EXECUTION OR PERFORMANCE OF THIS CVR CERTIFICATE AND THE CVR AGREEMENT (INCLUDING ANY CLAIM OR CAUSE OF ACTION BASED UPON, ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN OR IN CONNECTION WITH THIS CVR CERTIFICATE
AND THE CVR AGREEMENT OR AS AN INDUCEMENT TO ACCEPT THIS CVR CERTIFICATE) OR THE SECURITIES, SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, INCLUDING, WITHOUT LIMITATION, SECTIONS 5-1401 AND 5-1402 OF THE
NEW YORK GENERAL OBLIGATIONS LAW WITHOUT REGARD TO THE CONFLICT OF LAWS PRINCIPLES THEREOF. EACH OF THE COMPANY, THE TRUSTEE AND EACH OF THE HOLDERS BY THEIR ACCEPTANCE OF THE SECURITIES, HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF
ANY NEW YORK STATE COURT SITTING IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK OR ANY FEDERAL COURT SITTING IN THE BOROUGH OF MANHATTAN IN THE CITY OF NEW YORK IN RESPECT OF ALL CLAIMS OR CAUSES OF ACTION (WHETHER IN CONTRACT OR TORT) THAT MAY
BE BASED UPON, ARISE OUT OF OR RELATE TO THIS CVR CERTIFICATE AND THE CVR AGREEMENT, OR THE NEGOTIATION, EXECUTION OR 

  
 A-4 

 
PERFORMANCE OF THIS CVR CERTIFICATE AND THE CVR AGREEMENT (INCLUDING ANY CLAIM OR CAUSE OF ACTION BASED UPON, ARISING OUT OF OR RELATED TO ANY REPRESENTATION OR WARRANTY MADE IN OR IN CONNECTION
WITH THIS CVR CERTIFICATE AND THE CVR AGREEMENT OR AS AN INDUCEMENT TO ACCEPT THIS CVR CERTIFICATE), OR THE SECURITIES, AND IRREVOCABLY ACCEPTS FOR ITSELF AND IN RESPECT OF ITS PROPERTY, GENERALLY AND UNCONDITIONALLY, JURISDICTION OF THE AFORESAID
COURTS. ANY CONTROVERSY WHICH MAY ARISE UNDER THE CVR AGREEMENT IS LIKELY TO INVOLVE COMPLICATED AND DIFFICULT ISSUES, AND THEREFORE EACH OF THE HOLDERS BY ACCEPTANCE OF THIS CVR CERTIFICATE HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES ANY RIGHT
SUCH PERSON MAY HAVE TO A TRIAL BY JURY IN RESPECT OF ANY LITIGATION DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THE CVR AGREEMENT OR THE SUBJECT MATTER THEREOF. NOTWITHSTANDING ANYTHING TO THE CONTRARY CONTAINED IN THIS CVR AGREEMENT, IN
NO EVENT SHALL THE COMPANY BE RESPONSIBLE TO ANY HOLDER FOR ANY CONSEQUENTIAL, SPECIAL OR PUNITIVE DAMAGES. 

  
 A-5 

 TRUSTEE’S CERTIFICATE OF AUTHENTICATION 

This is one of the CVR Certificates referred to in the within-mentioned CVR Agreement. 

 

			
	 American Stock Transfer & Trust Company, LLC,

as the Trustee

		
	By:	 	 
		 	Authorized Signatory

 Dated: 

  
 A-6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00225-of-00352.parquet"}]]